<?xml version="1.0" encoding="UTF-8"?>
<Record
    xmlns="http://pubchem.ncbi.nlm.nih.gov/pug_view"
    xmlns:xs="http://www.w3.org/2001/XMLSchema-instance"
    xs:schemaLocation="http://pubchem.ncbi.nlm.nih.gov/pug_view https://pubchem.ncbi.nlm.nih.gov/pug_view/pug_view.xsd"
>
  <RecordType>CID</RecordType>
  <RecordNumber>938</RecordNumber>
  <RecordTitle>Nicotinic acid</RecordTitle>
  <Section>
    <TOCHeading>Structures</TOCHeading>
    <Description>Structure depictions and information for 2D, 3D, and crystal related</Description>
    <Section>
      <TOCHeading>2D Structure</TOCHeading>
      <Description>A two-dimensional representation of the compound</Description>
      <DisplayControls>
        <MoveToTop>true</MoveToTop>
      </DisplayControls>
      <Information>
        <ReferenceNumber>77</ReferenceNumber>
        <Value>
          <Boolean>true</Boolean>
        </Value>
      </Information>
    </Section>
    <Section>
      <TOCHeading>3D Conformer</TOCHeading>
      <Description>A three-dimensional representation of the compound. The 3D structure is not experimentally determined, but computed by PubChem. More detailed information on this conformer model is described in the PubChem3D thematic series published in the Journal of Cheminformatics.</Description>
      <DisplayControls>
        <MoveToTop>true</MoveToTop>
      </DisplayControls>
      <Information>
        <ReferenceNumber>77</ReferenceNumber>
        <Description>Nicotinic acid</Description>
        <Value>
          <Number>938</Number>
        </Value>
      </Information>
    </Section>
  </Section>
  <Section>
    <TOCHeading>Chemical Safety</TOCHeading>
    <Description>Launch the Laboratory Chemical Safety Summary datasheet, and link to the safety and hazard section</Description>
    <DisplayControls>
      <HideThisSection>true</HideThisSection>
      <MoveToTop>true</MoveToTop>
    </DisplayControls>
    <Information>
      <ReferenceNumber>77</ReferenceNumber>
      <Name>Chemical Safety</Name>
      <Value>
        <StringWithMarkup>
          <String>          </String>
          <Markup>
            <Start>0</Start>
            <Length>1</Length>
            <URL>https://pubchem.ncbi.nlm.nih.gov/images/ghs/GHS07.svg</URL>
            <Type>Icon</Type>
            <Extra>Irritant</Extra>
          </Markup>
        </StringWithMarkup>
      </Value>
    </Information>
  </Section>
  <Section>
    <TOCHeading>Names and Identifiers</TOCHeading>
    <Description>Record identifiers, synonyms, chemical names, descriptors, etc.</Description>
    <Section>
      <TOCHeading>Record Description</TOCHeading>
      <Description>Summary Information</Description>
      <DisplayControls>
        <HideThisSection>true</HideThisSection>
        <MoveToTop>true</MoveToTop>
      </DisplayControls>
      <Information>
        <ReferenceNumber>1</ReferenceNumber>
        <Name>Record Description</Name>
        <Description>Physical Description</Description>
        <Reference>National Toxicology Program, Institute of Environmental Health Sciences, National Institutes of Health (NTP). 1992. National Toxicology Program Chemical Repository Database. Research Triangle Park, North Carolina: NTP.</Reference>
        <Value>
          <StringWithMarkup>
            <String>NICOTINIC ACID is an odorless white crystalline powder with a feebly acid taste. pH (saturated aqueous solution) 2.7. pH (1.3% solution) 3-3.5. (NTP, 1992)</String>
            <Markup>
              <Start>0</Start>
              <Length>14</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/NICOTINIC%20ACID</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
          </StringWithMarkup>
        </Value>
      </Information>
      <Information>
        <ReferenceNumber>2</ReferenceNumber>
        <Name>Record Description</Name>
        <Description>Ontology Summary</Description>
        <Value>
          <StringWithMarkup>
            <String>Nicotinic acid is a pyridinemonocarboxylic acid that is pyridine in which the hydrogen at position 3 is replaced by a carboxy group. It has a role as an antidote, an antilipemic drug, a vasodilator agent, a metabolite, a B vitamin, an EC 3.5.1.19 (nicotinamidase) inhibitor, an Escherichia coli metabolite and a mouse metabolite. It is a pyridinemonocarboxylic acid and a pyridine alkaloid. It is a conjugate acid of a nicotinate.</String>
            <Markup>
              <Start>0</Start>
              <Length>14</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/Nicotinic%20acid</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>56</Start>
              <Length>8</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/pyridine</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-1049</Extra>
            </Markup>
            <Markup>
              <Start>78</Start>
              <Length>8</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/element/Hydrogen</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>Element-Hydrogen</Extra>
            </Markup>
            <Markup>
              <Start>419</Start>
              <Length>10</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/nicotinate</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-937</Extra>
            </Markup>
          </StringWithMarkup>
        </Value>
      </Information>
      <Information>
        <ReferenceNumber>17</ReferenceNumber>
        <Name>Record Description</Name>
        <Value>
          <StringWithMarkup>
            <String>A water-soluble vitamin of the B complex occurring in various animal and plant tissues. It is required by the body for the formation of coenzymes NAD and NADP. It has pellagra-curative, vasodilating, and antilipemic properties.</String>
            <Markup>
              <Start>2</Start>
              <Length>5</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/water</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-962</Extra>
            </Markup>
            <Markup>
              <Start>146</Start>
              <Length>3</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/NAD</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-5893</Extra>
            </Markup>
            <Markup>
              <Start>154</Start>
              <Length>4</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/NADP</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-2734411</Extra>
            </Markup>
          </StringWithMarkup>
        </Value>
      </Information>
      <Information>
        <ReferenceNumber>30</ReferenceNumber>
        <Name>Record Description</Name>
        <Description>FDA Pharmacology Summary</Description>
        <Value>
          <StringWithMarkup>
            <String>Niacin is a Nicotinic Acid. The chemical classification of niacin is Nicotinic Acids.</String>
            <Markup>
              <Start>0</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/Niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>12</Start>
              <Length>14</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/Nicotinic%20Acid</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>59</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
          </StringWithMarkup>
        </Value>
      </Information>
      <Information>
        <ReferenceNumber>33</ReferenceNumber>
        <Name>Record Description</Name>
        <Description>Metabolite Description</Description>
        <Value>
          <StringWithMarkup>
            <String>Nicotinic acid, also known as niacin or vitamin B3, is a water-soluble vitamin whose derivatives such as NADH, NAD, NAD+, and NADP play essential roles in energy metabolism in the living cell and DNA repair. The designation vitamin B3 also includes the amide form, nicotinamide or niacinamide. Severe lack of niacin causes the deficiency disease pellagra, whereas a mild deficiency slows down the metabolism decreasing cold tolerance. The recommended daily allowance of niacin is 2-12 mg a day for children, 14 mg a day for women, 16 mg a day for men, and 18 mg a day for pregnant or breast-feeding women. It is found in various animal and plant tissues and has pellagra-curative, vasodilating, and antilipemic properties. The liver can synthesize niacin from the essential amino acid tryptophan (see below), but the synthesis is extremely slow and requires vitamin B6; 60 mg of tryptophan are required to make one milligram of niacin. Bacteria in the gut may also perform the conversion but are inefficient.</String>
            <Markup>
              <Start>0</Start>
              <Length>14</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/Nicotinic%20acid</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>30</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>40</Start>
              <Length>10</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/vitamin%20B3</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>57</Start>
              <Length>5</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/water</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-962</Extra>
            </Markup>
            <Markup>
              <Start>105</Start>
              <Length>4</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/NADH</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-439153</Extra>
            </Markup>
            <Markup>
              <Start>111</Start>
              <Length>3</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/NAD</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-5893</Extra>
            </Markup>
            <Markup>
              <Start>116</Start>
              <Length>4</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/NAD%2B</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-5893</Extra>
            </Markup>
            <Markup>
              <Start>126</Start>
              <Length>4</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/NADP</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-2734411</Extra>
            </Markup>
            <Markup>
              <Start>224</Start>
              <Length>10</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/vitamin%20B3</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>265</Start>
              <Length>12</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/nicotinamide</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-936</Extra>
            </Markup>
            <Markup>
              <Start>281</Start>
              <Length>11</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacinamide</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-936</Extra>
            </Markup>
            <Markup>
              <Start>309</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>470</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>748</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>785</Start>
              <Length>10</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/tryptophan</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-6305</Extra>
            </Markup>
            <Markup>
              <Start>858</Start>
              <Length>10</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/vitamin%20B6</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>multiple-CIDs</Extra>
            </Markup>
            <Markup>
              <Start>879</Start>
              <Length>10</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/tryptophan</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-6305</Extra>
            </Markup>
            <Markup>
              <Start>928</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
          </StringWithMarkup>
        </Value>
      </Information>
      <Information>
        <ReferenceNumber>35</ReferenceNumber>
        <Name>Record Description</Name>
        <Description>LiverTox Summary</Description>
        <Value>
          <StringWithMarkup>
            <String>Niacin, also known as nicotinic acid and vitamin B3, is a water soluble, essential B vitamin which, when given in high doses, is effective in lowering low density lipoprotein (LDL) cholesterol and raising high density lipoprotein (HDL) cholesterol, which makes this agent of unique value in the therapy of dyslipidemia. Niacin can cause mild-to-moderate serum aminotransferase elevations and high doses and certain formulations of niacin have been linked to clinically apparent, acute liver injury which can be severe as well as fatal.</String>
            <Markup>
              <Start>0</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/Niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>22</Start>
              <Length>14</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/nicotinic%20acid</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>41</Start>
              <Length>10</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/vitamin%20B3</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>58</Start>
              <Length>5</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/water</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-962</Extra>
            </Markup>
            <Markup>
              <Start>181</Start>
              <Length>11</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/cholesterol</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-5997</Extra>
            </Markup>
            <Markup>
              <Start>236</Start>
              <Length>11</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/cholesterol</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-5997</Extra>
            </Markup>
            <Markup>
              <Start>320</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/Niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>431</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
          </StringWithMarkup>
        </Value>
      </Information>
      <Information>
        <ReferenceNumber>41</ReferenceNumber>
        <Name>Record Description</Name>
        <Description>Pharmacology</Description>
        <Value>
          <StringWithMarkup>
            <String>Niacin is a water-soluble vitamin belonging to the vitamin B family, which occurs in many animal and plant tissues, with antihyperlipidemic activity. Niacin is converted to its active form niacinamide, which is a component of the coenzymes nicotinamide adenine dinucleotide (NAD) and its phosphate form, NADP. These coenzymes play an important role in tissue respiration and in glycogen, lipid, amino acid, protein, and purine metabolism. Although the exact mechanism of action by which niacin lowers cholesterol is not fully understood, it may act by inhibiting the synthesis of very low density lipoproteins (VLDL), inhibiting the release of free fatty acids from adipose tissue, increasing lipoprotein lipase activity, and reducing the hepatic synthesis of VLDL-C and LDL-C.</String>
            <Markup>
              <Start>0</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/Niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>12</Start>
              <Length>5</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/water</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-962</Extra>
            </Markup>
            <Markup>
              <Start>150</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/Niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>189</Start>
              <Length>11</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacinamide</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-936</Extra>
            </Markup>
            <Markup>
              <Start>240</Start>
              <Length>33</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/nicotinamide%20adenine%20dinucleotide</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-15938971</Extra>
            </Markup>
            <Markup>
              <Start>275</Start>
              <Length>3</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/NAD</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-5893</Extra>
            </Markup>
            <Markup>
              <Start>288</Start>
              <Length>9</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/phosphate</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-1061</Extra>
            </Markup>
            <Markup>
              <Start>304</Start>
              <Length>4</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/NADP</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-2734411</Extra>
            </Markup>
            <Markup>
              <Start>378</Start>
              <Length>8</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/glycogen</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-439177</Extra>
            </Markup>
            <Markup>
              <Start>420</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/purine</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-1044</Extra>
            </Markup>
            <Markup>
              <Start>487</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>501</Start>
              <Length>11</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/cholesterol</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-5997</Extra>
            </Markup>
          </StringWithMarkup>
        </Value>
      </Information>
      <Information>
        <ReferenceNumber>76</ReferenceNumber>
        <Value>
          <StringWithMarkup>
            <String>A water-soluble vitamin of the B complex occurring in various animal and plant tissues. It is required by the body for the formation of coenzymes NAD and NADP. It has PELLAGRA-curative, vasodilating, and antilipemic properties.</String>
          </StringWithMarkup>
        </Value>
      </Information>
    </Section>
    <Section>
      <TOCHeading>Computed Descriptors</TOCHeading>
      <Description>Descriptors generated from chemical structure input</Description>
      <Section>
        <TOCHeading>IUPAC Name</TOCHeading>
        <Description>Chemical name computed from chemical structure that uses International Union of Pure and Applied Chemistry (IUPAC) nomenclature standards.</Description>
        <URL>http://old.iupac.org/publications/books/seriestitles/nomenclature.html</URL>
        <Information>
          <ReferenceNumber>77</ReferenceNumber>
          <Value>
            <StringWithMarkup>
              <String>pyridine-3-carboxylic acid</String>
            </StringWithMarkup>
          </Value>
        </Information>
      </Section>
      <Section>
        <TOCHeading>InChI</TOCHeading>
        <Description>International Chemical Identifier (InChI) computed from chemical structure using the International Union of Pure and Applied Chemistry (IUPAC) standard.</Description>
        <URL>http://www.iupac.org/home/publications/e-resources/inchi.html</URL>
        <Information>
          <ReferenceNumber>77</ReferenceNumber>
          <Value>
            <StringWithMarkup>
              <String>InChI=1S/C6H5NO2/c8-6(9)5-2-1-3-7-4-5/h1-4H,(H,8,9)</String>
            </StringWithMarkup>
          </Value>
        </Information>
      </Section>
      <Section>
        <TOCHeading>InChI Key</TOCHeading>
        <Description>International Chemical Identifier hash (InChIKey) computed from chemical structure using the International Union of Pure and Applied Chemistry (IUPAC) standard.</Description>
        <URL>http://www.iupac.org/home/publications/e-resources/inchi.html</URL>
        <Information>
          <ReferenceNumber>77</ReferenceNumber>
          <Value>
            <StringWithMarkup>
              <String>PVNIIMVLHYAWGP-UHFFFAOYSA-N</String>
            </StringWithMarkup>
          </Value>
        </Information>
      </Section>
      <Section>
        <TOCHeading>Canonical SMILES</TOCHeading>
        <Description>Simplified Molecular-Input Line-Entry System (SMILES) computed from chemical structure devoid of isotopic and stereochemical information.</Description>
        <URL>http://www.daylight.com/dayhtml/doc/theory/theory.smiles.html</URL>
        <Information>
          <ReferenceNumber>77</ReferenceNumber>
          <Value>
            <StringWithMarkup>
              <String>C1=CC(=CN=C1)C(=O)O</String>
            </StringWithMarkup>
          </Value>
        </Information>
      </Section>
    </Section>
    <Section>
      <TOCHeading>Molecular Formula</TOCHeading>
      <Description>A chemical formula is a way of expressing information about the proportions of atoms that constitute a particular chemical compound, using a single line of chemical element symbols and numbers. PubChem uses the Hill system whereby the number of carbon atoms in a molecule is indicated first, the number of hydrogen atoms second, and then the number of all other chemical elements in alphabetical order. When the formula contains no carbon, all the elements, including hydrogen, are listed alphabetically. Sources other than PubChem may include a variant of the formula that is more structural or natural to chemists, for example &quot;H2SO4&quot; for sulfuric acid, rather than the Hill version &quot;H2O4S.&quot;</Description>
      <DisplayControls>
        <MoveToTop>true</MoveToTop>
      </DisplayControls>
      <Information>
        <ReferenceNumber>34</ReferenceNumber>
        <Name>Molecular Formula</Name>
        <Value>
          <StringWithMarkup>
            <String>C6H5NO2</String>
          </StringWithMarkup>
          <StringWithMarkup>
            <String>HOOC5H4N</String>
          </StringWithMarkup>
        </Value>
      </Information>
      <Information>
        <ReferenceNumber>75</ReferenceNumber>
        <Name>Molecular Formula</Name>
        <Value>
          <StringWithMarkup>
            <String>C5H4NCOOH</String>
          </StringWithMarkup>
        </Value>
      </Information>
      <Information>
        <ReferenceNumber>77</ReferenceNumber>
        <Value>
          <StringWithMarkup>
            <String>C6H5NO2</String>
          </StringWithMarkup>
        </Value>
      </Information>
    </Section>
    <Section>
      <TOCHeading>Other Identifiers</TOCHeading>
      <Description>Important identifiers assigned to this chemical substance by authoritative organizations</Description>
      <Section>
        <TOCHeading>CAS</TOCHeading>
        <Description>A proprietary registry number assigned by the Chemical Abstracts Service (CAS) division of the American Chemical Society (ACS) often used to help describe chemical ingredients.</Description>
        <URL>http://en.wikipedia.org/wiki/CAS_Registry_Number</URL>
        <Information>
          <ReferenceNumber>3</ReferenceNumber>
          <Value>
            <StringWithMarkup>
              <String>59-67-6</String>
            </StringWithMarkup>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>3</ReferenceNumber>
          <Name>Related CAS</Name>
          <Value>
            <StringWithMarkup>
              <String>10361-13-4 (iron(2+) salt)</String>
              <Markup>
                <Start>0</Start>
                <Length>10</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/10361-13-4</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-82583</Extra>
              </Markup>
              <Markup>
                <Start>12</Start>
                <Length>8</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/iron%282%2B%29</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-27284</Extra>
              </Markup>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>16518-17-5 (potassium salt)</String>
              <Markup>
                <Start>0</Start>
                <Length>10</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/16518-17-5</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-23668574</Extra>
              </Markup>
              <Markup>
                <Start>12</Start>
                <Length>9</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/element/Potassium</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>Element-Potassium</Extra>
              </Markup>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>1976-28-9 (aluminum salt)</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>28029-53-0 (cobalt(2+) salt)</String>
              <Markup>
                <Start>0</Start>
                <Length>10</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/28029-53-0</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-119797</Extra>
              </Markup>
              <Markup>
                <Start>12</Start>
                <Length>10</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/cobalt%282%2B%29</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-104729</Extra>
              </Markup>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>28029-54-1 (manganese(2+) salt)</String>
              <Markup>
                <Start>0</Start>
                <Length>10</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/28029-54-1</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-119798</Extra>
              </Markup>
              <Markup>
                <Start>12</Start>
                <Length>13</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/manganese%282%2B%29</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-27854</Extra>
              </Markup>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>36321-41-2 (ammonium salt)</String>
              <Markup>
                <Start>0</Start>
                <Length>10</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/36321-41-2</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-14678929</Extra>
              </Markup>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>3789-96-6 (tartrate)</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>53890-72-5 (lithium salt)</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>54-86-4 (hydrochloride salt)</String>
              <Markup>
                <Start>0</Start>
                <Length>7</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/54-86-4</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-23687810</Extra>
              </Markup>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>636-79-3 (hydrochloride)</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>7069-06-9 (magnesium salt)</String>
              <Markup>
                <Start>0</Start>
                <Length>9</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/7069-06-9</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-23472</Extra>
              </Markup>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>823-77-8 (calcium salt)</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>99148-57-9 (tosylate)</String>
            </StringWithMarkup>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>3</ReferenceNumber>
          <Name>Other CAS</Name>
          <Value>
            <StringWithMarkup>
              <String>123574-58-3</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>1580002-26-1</String>
            </StringWithMarkup>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>17</ReferenceNumber>
          <Name>CAS</Name>
          <Value>
            <StringWithMarkup>
              <String>59-67-6</String>
            </StringWithMarkup>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>18</ReferenceNumber>
          <Name>CAS</Name>
          <Value>
            <StringWithMarkup>
              <String>59-67-6</String>
            </StringWithMarkup>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>19</ReferenceNumber>
          <Name>CAS</Name>
          <Value>
            <StringWithMarkup>
              <String>59-67-6</String>
            </StringWithMarkup>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>20</ReferenceNumber>
          <Value>
            <StringWithMarkup>
              <String>59-67-6</String>
            </StringWithMarkup>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>21</ReferenceNumber>
          <Name>CAS</Name>
          <Value>
            <StringWithMarkup>
              <String>59-67-6</String>
            </StringWithMarkup>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>24</ReferenceNumber>
          <Name>CAS</Name>
          <Value>
            <StringWithMarkup>
              <String>59-67-6</String>
            </StringWithMarkup>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>33</ReferenceNumber>
          <Name>CAS</Name>
          <Value>
            <StringWithMarkup>
              <String>59-67-6</String>
            </StringWithMarkup>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>34</ReferenceNumber>
          <Name>CAS</Name>
          <Value>
            <StringWithMarkup>
              <String>59-67-6</String>
            </StringWithMarkup>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>72</ReferenceNumber>
          <Value>
            <StringWithMarkup>
              <String>59-67-6</String>
            </StringWithMarkup>
          </Value>
        </Information>
      </Section>
      <Section>
        <TOCHeading>EC Number</TOCHeading>
        <Description>A seven-digit regulatory identifier currently assigned by the European Chemicals Agency (ECHA) known as a European Community (EC) number.  It is sometimes referred to as an EINECS, ELINCS, or NLP number, which are subsets of an EC number.</Description>
        <URL>http://en.wikipedia.org/wiki/European_Community_number</URL>
        <Information>
          <ReferenceNumber>24</ReferenceNumber>
          <Name>EC Number</Name>
          <URL>https://echa.europa.eu/substance-information/-/substanceinfo/100.000.401</URL>
          <Value>
            <StringWithMarkup>
              <String>200-441-0</String>
            </StringWithMarkup>
          </Value>
        </Information>
      </Section>
      <Section>
        <TOCHeading>ICSC Number</TOCHeading>
        <Description>An identifier assigned by the International Labour Organization (ILO) known as an International Chemical Safety Card number.</Description>
        <URL>http://www.ilo.org/safework/info/publications/WCMS_113134/lang--en/index.htm</URL>
        <Information>
          <ReferenceNumber>34</ReferenceNumber>
          <Name>ICSC Number</Name>
          <URL>http://www.ilo.org/dyn/icsc/showcard.display?p_card_id=1702</URL>
          <Value>
            <StringWithMarkup>
              <String>1702</String>
            </StringWithMarkup>
          </Value>
        </Information>
      </Section>
      <Section>
        <TOCHeading>NSC Number</TOCHeading>
        <Description>The NSC number is a numeric identifier for substances submitted to the National Cancer Institute (NCI) for testing and evaluation. It is a registration number for the Developmental Therapeutics Program (DTP) repository. NSC stands for National Service Center.</Description>
        <Information>
          <ReferenceNumber>18</ReferenceNumber>
          <Name>NSC Number</Name>
          <URL>https://dtp.cancer.gov/dtpstandard/servlet/dwindex?searchtype=NSC&amp;outputformat=html&amp;searchlist=757241</URL>
          <Value>
            <StringWithMarkup>
              <String>757241</String>
            </StringWithMarkup>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>19</ReferenceNumber>
          <Name>NSC Number</Name>
          <URL>https://dtp.cancer.gov/dtpstandard/servlet/dwindex?searchtype=NSC&amp;outputformat=html&amp;searchlist=169454</URL>
          <Value>
            <StringWithMarkup>
              <String>169454</String>
            </StringWithMarkup>
          </Value>
        </Information>
      </Section>
      <Section>
        <TOCHeading>RTECS Number</TOCHeading>
        <Description>An identifier of the Registry of Toxic Effects of Chemical Substances (RTECS) database of toxicity information.</Description>
        <URL>http://www.cdc.gov/niosh/rtecs/</URL>
        <Information>
          <ReferenceNumber>72</ReferenceNumber>
          <URL>https://www.cdc.gov/niosh-rtecs/QT802C8.html</URL>
          <Value>
            <StringWithMarkup>
              <String>QT0525000</String>
            </StringWithMarkup>
          </Value>
        </Information>
      </Section>
      <Section>
        <TOCHeading>UNII</TOCHeading>
        <Description>A non-proprietary registry number assigned by the U.S. Food and Drug Administration (FDA) known as an UNique Ingredient Identifier (UNII) code.</Description>
        <URL>http://www.fda.gov/ForIndustry/DataStandards/SubstanceRegistrationSystem-UniqueIngredientIdentifierUNII/</URL>
        <Information>
          <ReferenceNumber>31</ReferenceNumber>
          <Name>UNII</Name>
          <Value>
            <StringWithMarkup>
              <String>2679MF687A</String>
            </StringWithMarkup>
          </Value>
        </Information>
      </Section>
      <Section>
        <TOCHeading>Wikipedia</TOCHeading>
        <Description>Links to Wikipedia or wikidata for this record.</Description>
        <Information>
          <ReferenceNumber>75</ReferenceNumber>
          <Name>Wikipedia</Name>
          <URL>https://en.wikipedia.org/wiki/Niacin</URL>
          <Value>
            <StringWithMarkup>
              <String>Niacin</String>
            </StringWithMarkup>
          </Value>
        </Information>
      </Section>
    </Section>
    <Section>
      <TOCHeading>Synonyms</TOCHeading>
      <Description>Alternative names for this PubChem Compound record.  A compound can have many different names.  For example, acetone (CH3C(=O)CH3) is also known as propanone, propan-2-one, or dimethyl ketone.  The brand name of a product is commonly used to indicate the primary chemical ingredient(s) in the product (e.g., Tylenol, a common pain killer, is often used for acetaminophen, its active ingredient).  Another example of common synonyms is record identifiers used in different data collections, such as Chemical Abstract Service (CAS) registry numbers, FDA UNII (Unique Ingredient Identifiers), and many others.  All these various names and identifiers that designate this compound are organized under the Synonyms section.</Description>
      <Section>
        <TOCHeading>MeSH Entry Terms</TOCHeading>
        <Description>Medical Subject Heading (MeSH) names or identifiers matching this PubChem Compound record.  The matching between the MeSH and compound records is performed by name matching (i.e., identical common names).</Description>
        <DisplayControls>
          <ListType>Columns</ListType>
        </DisplayControls>
        <Information>
          <ReferenceNumber>76</ReferenceNumber>
          <Value>
            <StringWithMarkup>
              <String>3 Pyridinecarboxylic Acid</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>3-Pyridinecarboxylic Acid</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Aluminum Salt, Niacin</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Enduracin</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Hydrochloride, Niacin</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Induracin</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Lithium Nicotinate</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Niacin</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Niacin Aluminum Salt</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Niacin Ammonium Salt</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Niacin Calcium Salt</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Niacin Cobalt (2+) Salt</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Niacin Copper (2+) Salt</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Niacin Hydrochloride</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Niacin Iron (2+) Salt</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Niacin Lithium Salt</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Niacin Lithium Salt, Hemihydrate</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Niacin Magnesium Salt</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Niacin Manganese (2+) Salt</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Niacin Potassium Salt</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Niacin Sodium Salt</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Niacin Tartrate</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Niacin Tosylate</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Niacin Zinc Salt</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Nicamin</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Nico 400</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Nico-400</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Nico400</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Nicobid</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Nicocap</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Nicolar</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Nicotinate</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Nicotinate, Lithium</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Nicotinic Acid</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Potassium Salt, Niacin</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Sodium Salt, Niacin</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Tartrate, Niacin</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Tosylate, Niacin</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Wampocap</String>
            </StringWithMarkup>
          </Value>
        </Information>
      </Section>
      <Section>
        <TOCHeading>Depositor-Supplied Synonyms</TOCHeading>
        <Description>Chemical names provided by individual data contributors. Synonyms of Substances corresponding to a PubChem Compound record are combined. Some contributed names may be considered erroneous and filtered out. The link on each synonym shows which depositors provided that particular synonym for this structure.</Description>
        <DisplayControls>
          <ListType>Columns</ListType>
          <MoveToTop>true</MoveToTop>
        </DisplayControls>
        <Information>
          <ReferenceNumber>77</ReferenceNumber>
          <Value>
            <StringWithMarkup>
              <String>nicotinic acid</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>niacin</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>59-67-6</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Pyridine-3-carboxylic acid</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>3-pyridinecarboxylic acid</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>vitamin B3</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>3-Carboxypyridine</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>wampocap</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Acidum nicotinicum</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Apelagrin</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Pellagrin</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Akotin</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Daskil</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Efacin</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Pelonin</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Linic</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>nicamin</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>nicobid</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>nicocap</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>nicolar</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Enduracin</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Nicodelmine</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Niconacid</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Nicotinipca</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Pellagramin</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Direktan</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Niaspan</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Nicacid</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Nicangin</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Peviton</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Bionic</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Diacin</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Nicyl</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Nyclin</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Niac</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Vitaplex N</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Davitamon PP</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Nico-Span</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Tega-Span</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Nicocidin</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Nicocrisina</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Niconazid</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Nicoside</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Nicotamin</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Nicotene</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Nicovasan</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Nicovasen</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Nipellen</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>SK-Niacin</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Naotin</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Nicodan</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Nicodon</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Niconat</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Nicosan 3</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Nicosyl</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Nicotil</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Tinic</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>3-Carboxylpyridine</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Nicotine acid</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Niacor</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>nicotinate</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Slo-niacin</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Acide nicotinique</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>NICO</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Nicotinsaure</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Nico-400</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>3-Picolinic acid</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Pyridine-beta-carboxylic acid</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Nicagin</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Caswell No. 598</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>PP Factor</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Kyselina nikotinova</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>P.P. factor</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Pellagra preventive factor</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>S115</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>anti-Pellagra vitamin</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Nicotinsaure [German]</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Acido nicotinico</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>3-Pyridylcarboxylic acid</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>m-Pyridinecarboxylic acid</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Niacin [USAN]</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Kyselina nikotinova [Czech]</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>niacine</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>CCRIS 1902</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Pyridine-carboxylique-3</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>EPA Pesticide Chemical Code 056701</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Acide nicotinique [INN-French]</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Acido nicotinico [INN-Spanish]</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Acidum nicotinicum [INN-Latin]</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>HSDB 3134</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Pyridine-carboxylique-3 [French]</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>AI3-18994</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Pyridinecarboxylic acid, 3-</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>MFCD00006391</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Niacin [USP]</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>SR 4390</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>BRN 0109591</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>UNII-2679MF687A</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>EINECS 200-441-0</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>NIASPAN TITRATION STARTER PACK</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>NAH</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>CHEMBL573</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>beta-pyridinecarboxylic acid</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>NSC 169454</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>C6H5NO2</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>MLS000069603</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Pyridine-.beta.-carboxylic acid</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>CHEBI:15940</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>PVNIIMVLHYAWGP-UHFFFAOYSA-N</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Niacin (USP)</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>2679MF687A</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>P.P. factor-pellagra preventive factor</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>CAS-59-67-6</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>NCGC00016268-02</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>SMR000059024</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>DSSTox_CID_932</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Nicotinic acid, 99.5%</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>[5, 6-3H]-niacin</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>DSSTox_RID_75875</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>DSSTox_GSID_20932</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Induracin</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>NIO</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Niacin (nicotinic acid)</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>SR-01000722017</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>pellagra</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Nikotinsaeure</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>AC-907/25014105</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Ncotnc acd</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Nicotinic acid, specified according to the requirements of Ph. Eur</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>preventative factor</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>antipellagra vitamin</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Niaspan (TN)</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>3PyrCOOH</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>[3H]nicotinic acid</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Niacor (TN)</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Nicotinic Acid,(S)</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>PubChem2594</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Pyridylcarboxylic Acid</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>[3H]-Nicotinic acid</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Niacin(Nicotinic-acid)</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Nicotinic acid [INN]</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Spectrum_001063</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>3-Pyridinecarboxylicacid</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Nicotinic acid, Ph Eur</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>5-pyridinecarboxylic acid</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Opera_ID_1346</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Prestwick0_000881</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Prestwick1_000881</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Prestwick2_000881</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Prestwick3_000881</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Pyridine-3-carbonic acid</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Spectrum2_000006</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Spectrum3_000515</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Spectrum4_000965</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Spectrum5_001287</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>3-Pyridyl carboxylic acid</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Nicotinic acid-d3(major)</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>ACMC-1AS6M</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>WLN: T6NJ CVQ</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>3-pyridine carboxylic acid</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>bmse000104</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Nicotinic acid, &gt;=98%</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>EC 200-441-0</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>AC1L1AD5</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>SCHEMBL1433</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Nicotinic acid [INN:BAN]</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Oprea1_514398</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>BSPBio_000662</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>BSPBio_002069</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>KBioGR_001309</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>KBioSS_001543</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>5-22-02-00057 (Beilstein Handbook Reference)</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>KSC236Q9T</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>BIDD:GT0644</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>DivK1c_000695</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Nicotinic acid (JP17/INN)</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>SPECTRUM1500430</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>.beta.-Pyridinecarboxylic acid</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>SPBio_000011</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>SPBio_002881</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>AC1Q73P3</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>BPBio1_000730</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>GTPL1588</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>GTPL1594</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>ZINC1795</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>DTXSID1020932</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>BDBM23515</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>HMS502C17</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>KBio1_000695</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>KBio2_001543</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>KBio2_004111</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>KBio2_006679</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>KBio3_001569</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>ABT-919</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>NINDS_000695</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>HMS1570B04</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>HMS1920P17</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>HMS2091H22</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>HMS2097B04</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>HMS2236A05</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>HMS3259K21</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>HMS3371E07</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>HMS3655K08</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>HMS3714B04</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Pharmakon1600-01500430</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Nicotinic acid, analytical standard</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>BCP16301</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>HY-B0143</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>STR00112</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Tox21_110337</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Tox21_201420</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Tox21_302904</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>ANW-75276</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>BBL037343</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>CCG-38340</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>FC1287</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Nicotinic acid, for synthesis, 99%</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>NSC169454</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>NSC757241</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>s1744</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>SBB004279</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>STK301803</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>AKOS000118980</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Nicotinic acid, &gt;=99.5% (HPLC)</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Tox21_110337_1</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>AM81316</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>CS-1946</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>DB00627</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>EBD2198325</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>LS-2334</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>MCULE-3788394698</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>NC00524</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Nicotinic Acid 1.0 mg/ml in Methanol</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>NSC-169454</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>NSC-757241</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>PS-4255</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>RP00705</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>SDCCGMLS-0066610.P001</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>IDI1_000695</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>NCGC00016268-01</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>NCGC00016268-03</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>NCGC00016268-04</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>NCGC00016268-05</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>NCGC00016268-08</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>NCGC00016268-09</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>NCGC00094734-01</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>NCGC00094734-02</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>NCGC00256537-01</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>NCGC00258971-01</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>AC-22484</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>AJ-08093</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>AK-46486</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>AN-23622</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>BP-21419</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>CPD000059024</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>NCI60_001041</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Nicotinic acid, NIST(R) SRM(R) 148</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Nicotinic acid, plant cell culture tested</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>SAM002554917</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>SC-05611</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>ST097540</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>SY011111</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>SBI-0051456.P003</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>AB1002056</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>DB-007765</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Nicotinic Acid [Matrix for MALDI-TOF/MS]</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>ST2413625</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>TR-032523</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>AB00052050</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>FT-0082580</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>FT-0600004</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>N0082</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>N1103</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Nicotinic acid, purum, &gt;=99.0% (HPLC)</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>SW197229-3</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>MFCD00006391 (98%)</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>C00253</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>D00049</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>M-5918</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Nicotinic acid, SAJ special grade, &gt;=99.5%</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>11054-EP2269610A2</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>11054-EP2269990A1</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>11054-EP2270002A1</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>11054-EP2270014A1</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>11054-EP2272825A2</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>11054-EP2272834A1</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>11054-EP2272848A1</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>11054-EP2274983A1</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>11054-EP2275401A1</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>11054-EP2277848A1</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>11054-EP2280001A1</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>11054-EP2289510A1</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>11054-EP2292228A1</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>11054-EP2292610A1</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>11054-EP2295406A1</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>11054-EP2295409A1</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>11054-EP2295424A1</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>11054-EP2298742A1</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>11054-EP2298772A1</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>11054-EP2298776A1</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>11054-EP2298779A1</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>11054-EP2301923A1</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>11054-EP2301929A1</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>11054-EP2301935A1</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>11054-EP2301937A1</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>11054-EP2305651A1</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>11054-EP2305674A1</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>11054-EP2308838A1</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>11054-EP2308839A1</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>11054-EP2308848A1</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>11054-EP2308854A1</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>11054-EP2308858A1</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>11054-EP2308874A1</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>11054-EP2311808A1</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>11054-EP2311816A1</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>11054-EP2311817A1</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>11054-EP2311829A1</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>11054-EP2311830A1</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>11054-EP2314588A1</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>11054-EP2316457A1</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>11054-EP2316458A1</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>11054-EP2316825A1</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>11054-EP2316826A1</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>11054-EP2316827A1</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>11054-EP2316828A1</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>AB00052050-13</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>AB00052050_14</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>AB00052050_15</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Nicotinic acid, meets USP testing specifications</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>L001199</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Nicotinic acid, Vetec(TM) reagent grade, &gt;=98%</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>I02-0699</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>J-523605</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>SR-01000722017-2</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>SR-01000722017-3</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>SR-01000722017-4</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>I14-92791</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Z56755709</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>3DDB011E-F3A6-45B6-A2D2-77B2A6E8936E</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>F2191-0082</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Niacin, United States Pharmacopeia (USP) Reference Standard</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Nicotinic acid, certified reference material, TraceCERT(R)</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Nicotinic acid, European Pharmacopoeia (EP) Reference Standard</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Nicotinic acid, matrix substance for MALDI-MS, &gt;=99.5% (HPLC)</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>InChI=1/C6H5NO2/c8-6(9)5-2-1-3-7-4-5/h1-4H,(H,8,9</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Nicotinic acid, for inorganic trace analysis, &gt;=99.999% (metals basis)</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Niacin (Nicotinic Acid), Pharmaceutical Secondary Standard; Certified Reference Material</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>123574-58-3</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>3-Picolinic acid; Niacin; Pellagra preventive factor; Pyridine-3-carboxylic acid; Vitamin B3</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Nicotinic acid (Vitamin B3) solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Nicotinic acid, BioReagent, suitable for cell culture, suitable for insect cell culture, suitable for plant cell culture, &gt;=98%</String>
            </StringWithMarkup>
          </Value>
        </Information>
      </Section>
      <Section>
        <TOCHeading>Removed Synonyms</TOCHeading>
        <Description>Potentially erroneous chemical names and identifiers provided by PubChem Substance records for the same chemical structure that were removed by name/structure consistency filtering.</Description>
        <DisplayControls>
          <HideThisSection>true</HideThisSection>
        </DisplayControls>
        <Information>
          <ReferenceNumber>77</ReferenceNumber>
          <Value>
            <StringWithMarkup>
              <String>Nicorol</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>niacinamide</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Nicovel</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Vitamin B</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>nicotinamide</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Niacotinamide</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Nicotililamido</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Nicotinamidum</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Nicotinicacid</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Nicotylamidum</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>vitamin PP</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Aminicotin</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Amixicotyn</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Enduramide</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Nicamindon</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Nicosylamide</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Nicotamide</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Nicotilamide</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Nicotinamid</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Nicotinamida</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Nicotylamide</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Nicovitina</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Nikotinamid</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Niocinamide</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Amnicotin</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Endobion</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Hansamid</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Mediatric</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Niacevit</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Nicamina</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Nicobion</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Nicofort</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Nicomidol</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Nicovitol</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Nicozymin</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Niozymin</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Savacotyl</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Advicor</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Benicot</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Dipegyl</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Niamide</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Nicasir</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Nicogen</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Nicotol</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Nicovit</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Nikasan</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Nikazan</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Papulex</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Pelmine</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Nicota</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Pelmin</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Simcor</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>nipecotic acid</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Nicotinsaureamid</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Nicotinic amide</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Lithium nicotinate</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Nicotine amide</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Delonin amide</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Pelonin amide</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>niacin magnesium</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>niacin potassium</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Niacin Tartrate</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Niacin Tosylate</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Niko-tamin</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Nicotinsaeureamid</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Nikotinsaeureamid</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Factor pp</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Nandervit-N</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>?-Picolinsaure</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Vi-Nicotyl</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Austrovit PP</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>beta-Picolinsaure</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Inovitan PP</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Witamina PP</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Tartrate, Niacin</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Tosylate, Niacin</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Niavit PP</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>PP-Faktor</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Niacin Zinc Salt</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Nicosan 2</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Amide PP</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Vitamin H1</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Niacinamide (TN)</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Niacin Sodium Salt</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>3-Carbamoylpyridine</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Niacin hydrochloride</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Nicotine acid amide</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>B3, Vitamin</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Niacin-Vitamin B3</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Nicotinamide (TN)</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Nicotinate, Lithium</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Vitamin B 3</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Niacin Calcium Salt</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Niacin Lithium Salt</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Niacinamide (USP)</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>3-Pyridylcarboxylate</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Nicotinic acid amide</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Niacin (TN)</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Vitamin B3 (Niacin)</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>3-pyridinecarboxylate</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>B 3, Vitamin</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Niacin Aluminum Salt</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Niacin Ammonium Salt</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Vitamin B (VAN)</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>3 Pyridinecarboxamide</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>3-Pyridinecarboxamide</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Niacinamide [USAN]</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Sodium Salt, Niacin</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Hydrochloride, Niacin</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Niacin Magnesium Salt</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Niacin Potassium Salt</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Aluminum Salt, Niacin</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>pyridine-3-carboxamide</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>beta-Pyridinecarboxamide</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Nico400</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Niacinamide Astra Brand</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Niacinamide Merck Brand</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Potassium Salt, Niacin</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Amid kyseliny nikotinove</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Nico 400</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>m-(Aminocarbonyl)pyridine</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Nicotinsaureamid Jenapharm</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>3 Pyridinecarboxylic Acid</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Nicotinsaureamid [German]</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Nicotinamide-carbonyl-14C</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Nicotinic acid; (Niacin)</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Niacin Iron (2+) Salt</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Nicotinamide (Niacinamide)</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Nikotinsaeureamid [German]</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Astra Brand of Niacinamide</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>D06NVJ</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Jenapharm, Nicotinsaureamid</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Merck Brand of Niacinamide</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Niacinamide Jenapharm Brand</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Nicotinamidum [INN-Latin]</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Niacin Cobalt (2+) Salt</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Niacin Copper (2+) Salt</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Nicotinamida [INN-Spanish]</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Nicotinamide (JP15/INN)</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Nicotinic acid;  (Niacin)</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Niacinamide Pharmagenix Brand</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Niacin Manganese (2+) Salt</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>PYRIDINECARBOXYLIC ACID</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Jenapharm Brand of Niacinamide</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Nicotinic acid, 99% 250g</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>3-Pyridinecarboxylic acid amide</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>CID938</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Pharmagenix Brand of Niacinamide</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Niacin Lithium Salt, Hemihydrate</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Pyridine-3-carboxylic acid amide</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Amid kyseliny nikotinove [Czech]</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Nicotinamide, niacin, vitamin B3</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>C6-H5-N-O2</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>ACN-049546</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Nicotinic Acid 99.5% extra pure 25gm</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Nicotinic acid, 99% - 100G 100g</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Nicotinic acid, 99.5% - 100G 100g</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>B1987</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Niacinamide, Nicotinic acid amide, Nicotinamide</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>D009525</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>354527-69-8</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>54-86-4</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>na</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>36321-41-2</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>7477-10-3</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>8054-81-7</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>98-92-0</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>99148-57-9</String>
            </StringWithMarkup>
          </Value>
        </Information>
      </Section>
    </Section>
    <Section>
      <TOCHeading>Create Date</TOCHeading>
      <Description>Date the compound record was initially added to PubChem</Description>
      <DisplayControls>
        <HideThisSection>true</HideThisSection>
        <MoveToTop>true</MoveToTop>
      </DisplayControls>
      <Information>
        <ReferenceNumber>77</ReferenceNumber>
        <Value>
          <DateISO8601>2004-09-16</DateISO8601>
        </Value>
      </Information>
    </Section>
    <Section>
      <TOCHeading>Modify Date</TOCHeading>
      <Description>Date this record was last updated in PubChem</Description>
      <DisplayControls>
        <HideThisSection>true</HideThisSection>
        <MoveToTop>true</MoveToTop>
      </DisplayControls>
      <Information>
        <ReferenceNumber>77</ReferenceNumber>
        <Value>
          <DateISO8601>2019-06-15</DateISO8601>
        </Value>
      </Information>
    </Section>
  </Section>
  <Section>
    <TOCHeading>Chemical and Physical Properties</TOCHeading>
    <Description>Chemical and physical properties such as melting point, molecular weight, etc.</Description>
    <Section>
      <TOCHeading>Computed Properties</TOCHeading>
      <Description>Properties computed automatically from the given chemical structure</Description>
      <DisplayControls>
        <CreateTable>
          <FromInformationIn>Subsections</FromInformationIn>
          <NumberOfColumns>2</NumberOfColumns>
          <ColumnHeadings>Property Name</ColumnHeadings>
          <ColumnHeadings>Property Value</ColumnHeadings>
          <ColumnContents>Name</ColumnContents>
          <ColumnContents>Value</ColumnContents>
        </CreateTable>
      </DisplayControls>
      <Section>
        <TOCHeading>Molecular Weight</TOCHeading>
        <Description>Molecular weight or molecular mass refers to the mass of a molecule. It is calculated as the sum of the mass of each constituent atom multiplied by the number of atoms of that element in the molecular formula.</Description>
        <DisplayControls>
          <MoveToTop>true</MoveToTop>
        </DisplayControls>
        <Information>
          <ReferenceNumber>77</ReferenceNumber>
          <Value>
            <Number>123.111</Number>
            <Unit>g/mol</Unit>
          </Value>
        </Information>
      </Section>
      <Section>
        <TOCHeading>XLogP3</TOCHeading>
        <Description>Computed Octanol/Water Partition Coefficient</Description>
        <Information>
          <ReferenceNumber>77</ReferenceNumber>
          <Value>
            <Number>0.4</Number>
          </Value>
        </Information>
      </Section>
      <Section>
        <TOCHeading>Hydrogen Bond Donor Count</TOCHeading>
        <Description>Hydrogen Bond Donor count</Description>
        <Information>
          <ReferenceNumber>77</ReferenceNumber>
          <Value>
            <Number>1</Number>
          </Value>
        </Information>
      </Section>
      <Section>
        <TOCHeading>Hydrogen Bond Acceptor Count</TOCHeading>
        <Description>Hydrogen Bond Acceptor count</Description>
        <Information>
          <ReferenceNumber>77</ReferenceNumber>
          <Value>
            <Number>3</Number>
          </Value>
        </Information>
      </Section>
      <Section>
        <TOCHeading>Rotatable Bond Count</TOCHeading>
        <Description>Rotatable bond is defined as any single non-ring bond, bounded to nonterminal heavy (i.e., non-hydrogen) atom.</Description>
        <Information>
          <ReferenceNumber>77</ReferenceNumber>
          <Value>
            <Number>1</Number>
          </Value>
        </Information>
      </Section>
      <Section>
        <TOCHeading>Exact Mass</TOCHeading>
        <Description>The exact mass of an isotopic species is obtained by summing the masses of the individual isotopes of the molecule.</Description>
        <Information>
          <ReferenceNumber>77</ReferenceNumber>
          <Value>
            <Number>123.032</Number>
            <Unit>g/mol</Unit>
          </Value>
        </Information>
      </Section>
      <Section>
        <TOCHeading>Monoisotopic Mass</TOCHeading>
        <Description>The monoisotopic mass is the sum of the masses of the atoms in a molecule using the unbound, ground-state, rest mass of the principal (most abundant) isotope for each element instead of the isotopic average mass.</Description>
        <Information>
          <ReferenceNumber>77</ReferenceNumber>
          <Value>
            <Number>123.032</Number>
            <Unit>g/mol</Unit>
          </Value>
        </Information>
      </Section>
      <Section>
        <TOCHeading>Topological Polar Surface Area</TOCHeading>
        <Description>The topological polar surface area (TPSA) of a molecule is defined as the surface sum over all polar atoms in a molecule. </Description>
        <Information>
          <ReferenceNumber>77</ReferenceNumber>
          <Value>
            <Number>50.2</Number>
            <Unit>A^2</Unit>
          </Value>
        </Information>
      </Section>
      <Section>
        <TOCHeading>Heavy Atom Count</TOCHeading>
        <Description>A heavy atom is defined as any atom except hydrogen in a chemical structure.</Description>
        <Information>
          <ReferenceNumber>77</ReferenceNumber>
          <Value>
            <Number>9</Number>
          </Value>
        </Information>
      </Section>
      <Section>
        <TOCHeading>Formal Charge</TOCHeading>
        <Description>Formal charge is the difference between the number of valence electrons of each atom and the number of electrons the atom is associated with. Formal charge assumes any shared electrons are equally shared between the two bonded atoms.</Description>
        <Information>
          <ReferenceNumber>77</ReferenceNumber>
          <Value>
            <Number>0</Number>
          </Value>
        </Information>
      </Section>
      <Section>
        <TOCHeading>Complexity</TOCHeading>
        <Description>The complexity rating of a compound is a rough estimate of how complicated a structure is, seen from both the point of view of the elements contained and the displayed structural features including symmetry. This complexity rating is computed using the Bertz/Hendrickson/Ihlenfeldt formula.</Description>
        <Information>
          <ReferenceNumber>77</ReferenceNumber>
          <Value>
            <Number>114</Number>
          </Value>
        </Information>
      </Section>
      <Section>
        <TOCHeading>Isotope Atom Count</TOCHeading>
        <Description>Isotopte Atom Count is the number of isotopes that are not most abundant for the corresponding chemical elements.  Isotopes are variants of a chemical element which differ in neutron number.  For example, among three isotopes of carbon (i.e., C-12, C-13, and C-14), the isotope atom count considers the C-13 and C-14 atoms, because C-12 is the most abundant isotope of carbon.</Description>
        <Information>
          <ReferenceNumber>77</ReferenceNumber>
          <Value>
            <Number>0</Number>
          </Value>
        </Information>
      </Section>
      <Section>
        <TOCHeading>Defined Atom Stereocenter Count</TOCHeading>
        <Description>An atom stereocenter, also known as a chiral center, is an atom that is attached to four different types of atoms (or groups of atoms) in the tetrahedral arrangement. It can have either (R)- or (S)- configurations.  Some compounds, such as racemic mixtures, have an undefined atom stereocenter, whose (R/S)-configuration is not specifically defined.</Description>
        <Information>
          <ReferenceNumber>77</ReferenceNumber>
          <Value>
            <Number>0</Number>
          </Value>
        </Information>
      </Section>
      <Section>
        <TOCHeading>Undefined Atom Stereocenter Count</TOCHeading>
        <Description>An atom stereocenter, also known as a chiral center, is an atom that is attached to four different types of atoms (or groups of atoms) in the tetrahedral arrangement. It can have either (R)- or (S)- configurations.  Some compounds, such as racemic mixtures, have an undefined atom stereocenter, whose (R/S)-configuration is not specifically defined.</Description>
        <Information>
          <ReferenceNumber>77</ReferenceNumber>
          <Value>
            <Number>0</Number>
          </Value>
        </Information>
      </Section>
      <Section>
        <TOCHeading>Defined Bond Stereocenter Count</TOCHeading>
        <Description>A bond stereocenter is a non-rotatable bond around which two atoms can have different arrangement (as in cis- and trans-forms of butene around its double bond).  Some compounds have an undefined bond stereocenter, whose stereochemistry is not specifically defined.</Description>
        <Information>
          <ReferenceNumber>77</ReferenceNumber>
          <Value>
            <Number>0</Number>
          </Value>
        </Information>
      </Section>
      <Section>
        <TOCHeading>Undefined Bond Stereocenter Count</TOCHeading>
        <Description>A bond stereocenter is a non-rotatable bond around which two atoms can have different arrangement (as in cis- and trans-forms of butene around its double bond).  Some compounds have an undefined bond stereocenter, whose stereochemistry is not specifically defined.</Description>
        <Information>
          <ReferenceNumber>77</ReferenceNumber>
          <Value>
            <Number>0</Number>
          </Value>
        </Information>
      </Section>
      <Section>
        <TOCHeading>Covalently-Bonded Unit Count</TOCHeading>
        <Description>Covalently-Bonded Unit Count </Description>
        <Information>
          <ReferenceNumber>77</ReferenceNumber>
          <Value>
            <Number>1</Number>
          </Value>
        </Information>
      </Section>
      <Section>
        <TOCHeading>Compound Is Canonicalized</TOCHeading>
        <Description>Compound is canonicalized</Description>
        <Information>
          <ReferenceNumber>77</ReferenceNumber>
          <Value>
            <StringWithMarkup>
              <String>Yes</String>
            </StringWithMarkup>
          </Value>
        </Information>
      </Section>
    </Section>
    <Section>
      <TOCHeading>Experimental Properties</TOCHeading>
      <Description>Properties determined experimentally (See also Safety and Hazard Properties section for more information if available)</Description>
      <Section>
        <TOCHeading>Physical Description</TOCHeading>
        <Description>Physical description refers to the appearance or features of a given chemical compound including color, odor, state, taste and more in general</Description>
        <Information>
          <ReferenceNumber>1</ReferenceNumber>
          <Name>Physical Description</Name>
          <Reference>National Toxicology Program, Institute of Environmental Health Sciences, National Institutes of Health (NTP). 1992. National Toxicology Program Chemical Repository Database. Research Triangle Park, North Carolina: NTP.</Reference>
          <Value>
            <StringWithMarkup>
              <String>NICOTINIC ACID is an odorless white crystalline powder with a feebly acid taste. pH (saturated aqueous solution) 2.7. pH (1.3% solution) 3-3.5. (NTP, 1992)</String>
              <Markup>
                <Start>0</Start>
                <Length>14</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/NICOTINIC%20ACID</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
            </StringWithMarkup>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>20</ReferenceNumber>
          <Value>
            <StringWithMarkup>
              <String>OtherSolid</String>
            </StringWithMarkup>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>33</ReferenceNumber>
          <Name>Physical Description</Name>
          <Value>
            <StringWithMarkup>
              <String>Solid</String>
            </StringWithMarkup>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>34</ReferenceNumber>
          <Name>Physical Description</Name>
          <Value>
            <StringWithMarkup>
              <String>WHITE CRYSTALS OR CRYSTALLINE POWDER.</String>
            </StringWithMarkup>
          </Value>
        </Information>
      </Section>
      <Section>
        <TOCHeading>Color/Form</TOCHeading>
        <Description>Physical description - color</Description>
        <Information>
          <ReferenceNumber>32</ReferenceNumber>
          <Description>**PEER REVIEWED**</Description>
          <Reference>O&apos;Neil, M.J. (ed.). The Merck Index - An Encyclopedia of Chemicals, Drugs, and Biologicals. Cambridge, UK:  Royal Society of Chemistry, 2013., p. 1214</Reference>
          <Value>
            <StringWithMarkup>
              <String>Needles from alcohol or water</String>
              <Markup>
                <Start>24</Start>
                <Length>5</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/water</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-962</Extra>
              </Markup>
            </StringWithMarkup>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>32</ReferenceNumber>
          <Description>**PEER REVIEWED**</Description>
          <Reference>Larranaga, M.D., Lewis, R.J. Sr., Lewis, R.A.; Hawley&apos;s Condensed Chemical Dictionary 16th  Edition. John Wiley &amp; Sons, Inc. Hoboken, NJ 2016., p. 966</Reference>
          <Value>
            <StringWithMarkup>
              <String>Colorless needles</String>
            </StringWithMarkup>
          </Value>
        </Information>
      </Section>
      <Section>
        <TOCHeading>Odor</TOCHeading>
        <Description>Physical description - odor</Description>
        <Information>
          <ReferenceNumber>32</ReferenceNumber>
          <Description>**PEER REVIEWED**</Description>
          <Reference>Larranaga, M.D., Lewis, R.J. Sr., Lewis, R.A.; Hawley&apos;s Condensed Chemical Dictionary 16th  Edition. John Wiley &amp; Sons, Inc. Hoboken, NJ 2016., p. 966</Reference>
          <Value>
            <StringWithMarkup>
              <String>Odorless</String>
            </StringWithMarkup>
          </Value>
        </Information>
      </Section>
      <Section>
        <TOCHeading>Taste</TOCHeading>
        <Description>Physical description - taste</Description>
        <Information>
          <ReferenceNumber>32</ReferenceNumber>
          <Description>**PEER REVIEWED**</Description>
          <Reference>Larranaga, M.D., Lewis, R.J. Sr., Lewis, R.A.; Hawley&apos;s Condensed Chemical Dictionary 16th  Edition. John Wiley &amp; Sons, Inc. Hoboken, NJ 2016., p. 966</Reference>
          <Value>
            <StringWithMarkup>
              <String>Sour taste</String>
            </StringWithMarkup>
          </Value>
        </Information>
      </Section>
      <Section>
        <TOCHeading>Boiling Point</TOCHeading>
        <Description>The boiling point of a substance is the temperature at which the vapor pressure of the liquid equals the pressure surrounding the liquid and the liquid changes into a vapor</Description>
        <Information>
          <ReferenceNumber>1</ReferenceNumber>
          <Name>Boiling Point</Name>
          <Reference>National Toxicology Program, Institute of Environmental Health Sciences, National Institutes of Health (NTP). 1992. National Toxicology Program Chemical Repository Database. Research Triangle Park, North Carolina: NTP.</Reference>
          <Value>
            <StringWithMarkup>
              <String>Sublimes (NTP, 1992)</String>
            </StringWithMarkup>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>32</ReferenceNumber>
          <Description>**PEER REVIEWED**</Description>
          <Reference>Haynes, W.M. (ed.). CRC Handbook of Chemistry and Physics. 95th Edition. CRC Press LLC, Boca Raton: FL 2014-2015, p. 3-474</Reference>
          <Value>
            <StringWithMarkup>
              <String>Sublimes</String>
            </StringWithMarkup>
          </Value>
        </Information>
      </Section>
      <Section>
        <TOCHeading>Melting Point</TOCHeading>
        <Description>The melting point is the temperature at which a substance changes state from solid to liquid at atmospheric pressure. When considered as the temperature of the reverse change, from liquid to solid, it is referred to as the freezing point.</Description>
        <Information>
          <ReferenceNumber>1</ReferenceNumber>
          <Name>Melting Point</Name>
          <Reference>National Toxicology Program, Institute of Environmental Health Sciences, National Institutes of Health (NTP). 1992. National Toxicology Program Chemical Repository Database. Research Triangle Park, North Carolina: NTP.</Reference>
          <Value>
            <StringWithMarkup>
              <String>457  F (NTP, 1992)</String>
            </StringWithMarkup>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>17</ReferenceNumber>
          <Name>Melting Point</Name>
          <Reference>PhysProp</Reference>
          <Value>
            <Number>236.6</Number>
            <Unit>C</Unit>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>21</ReferenceNumber>
          <Name>Melting Point</Name>
          <Value>
            <StringWithMarkup>
              <String>236.6C</String>
            </StringWithMarkup>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>32</ReferenceNumber>
          <Description>**PEER REVIEWED**</Description>
          <Reference>Haynes, W.M. (ed.). CRC Handbook of Chemistry and Physics. 95th Edition. CRC Press LLC, Boca Raton: FL 2014-2015, p. 3-474</Reference>
          <Value>
            <StringWithMarkup>
              <String>237 deg C</String>
            </StringWithMarkup>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>33</ReferenceNumber>
          <Name>Melting Point</Name>
          <Value>
            <StringWithMarkup>
              <String>236.6C</String>
            </StringWithMarkup>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>34</ReferenceNumber>
          <Name>Melting Point</Name>
          <Value>
            <StringWithMarkup>
              <String>236.6 C</String>
            </StringWithMarkup>
          </Value>
        </Information>
      </Section>
      <Section>
        <TOCHeading>Flash Point</TOCHeading>
        <Description>The flash point (of a volatile material) is the lowest temperature at which it can vaporize to form an ignitable mixture in air</Description>
        <Information>
          <ReferenceNumber>32</ReferenceNumber>
          <Description>**PEER REVIEWED**</Description>
          <Reference>Sigma-Aldrich; Safety Data Sheet for Nicotinic acid. Product Number: N4126, Version 4.11 (Revision Date 09/22/2017). Available from, as of July 18, 2018: http://www.sigmaaldrich.com/safety-center.html</Reference>
          <Value>
            <StringWithMarkup>
              <String>193 deg C (379 deg F) - closed cup</String>
            </StringWithMarkup>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>34</ReferenceNumber>
          <Name>Flash Point</Name>
          <Value>
            <StringWithMarkup>
              <String>193 C c.c.</String>
            </StringWithMarkup>
          </Value>
        </Information>
      </Section>
      <Section>
        <TOCHeading>Solubility</TOCHeading>
        <Description>The solubility of a substance is the amount of that substance that will dissolve in a given amount of solvent. The default solvent is water, if not indicated.</Description>
        <Information>
          <ReferenceNumber>1</ReferenceNumber>
          <Name>Solubility</Name>
          <Reference>National Toxicology Program, Institute of Environmental Health Sciences, National Institutes of Health (NTP). 1992. National Toxicology Program Chemical Repository Database. Research Triangle Park, North Carolina: NTP.</Reference>
          <Value>
            <StringWithMarkup>
              <String>10 to 50 mg/mL at 63 F (NTP, 1992)</String>
            </StringWithMarkup>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>17</ReferenceNumber>
          <Name>Water Solubility</Name>
          <Reference>YALKOWSKY,SH &amp; DANNENFELSER,RM (1992)</Reference>
          <Value>
            <Number>18000</Number>
            <Unit>mg/L (at 25 C)</Unit>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>21</ReferenceNumber>
          <Name>Water Solubility</Name>
          <Reference>YALKOWSKY,SH &amp; HE,Y (2003)</Reference>
          <Value>
            <StringWithMarkup>
              <String>0.15 M</String>
            </StringWithMarkup>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>32</ReferenceNumber>
          <Description>**PEER REVIEWED**</Description>
          <Reference>Yalkowsky, S.H., He, Yan, Jain, P. Handbook of Aqueous Solubility Data Second Edition. CRC Press, Boca Raton, FL 2010, p. 227</Reference>
          <Value>
            <StringWithMarkup>
              <String>In water, 1.8X10+4 mg/L at 20 deg C</String>
              <Markup>
                <Start>3</Start>
                <Length>5</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/water</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-962</Extra>
              </Markup>
            </StringWithMarkup>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>32</ReferenceNumber>
          <Description>**PEER REVIEWED**</Description>
          <Reference>Haynes, W.M. (ed.). CRC Handbook of Chemistry and Physics. 95th Edition. CRC Press LLC, Boca Raton: FL 2014-2015, p. 3-474</Reference>
          <Value>
            <StringWithMarkup>
              <String>Slightly soluble in water</String>
            </StringWithMarkup>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>32</ReferenceNumber>
          <Description>**PEER REVIEWED**</Description>
          <Reference>Haynes, W.M. (ed.). CRC Handbook of Chemistry and Physics. 95th Edition. CRC Press LLC, Boca Raton: FL 2014-2015, p. 3-474</Reference>
          <Value>
            <StringWithMarkup>
              <String>Slightly soluble in ethanol, ethyl ether</String>
              <Markup>
                <Start>20</Start>
                <Length>7</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/ethanol</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-702</Extra>
              </Markup>
              <Markup>
                <Start>29</Start>
                <Length>11</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/ethyl%20ether</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-3283</Extra>
              </Markup>
            </StringWithMarkup>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>32</ReferenceNumber>
          <Description>**PEER REVIEWED**</Description>
          <Reference>Larranaga, M.D., Lewis, R.J. Sr., Lewis, R.A.; Hawley&apos;s Condensed Chemical Dictionary 16th  Edition. John Wiley &amp; Sons, Inc. Hoboken, NJ 2016., p. 966</Reference>
          <Value>
            <StringWithMarkup>
              <String>Soluble in alcohol, insoluble in most lipid solvents</String>
            </StringWithMarkup>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>33</ReferenceNumber>
          <Name>Solubility</Name>
          <Value>
            <StringWithMarkup>
              <String>18.0 mg/mL</String>
            </StringWithMarkup>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>34</ReferenceNumber>
          <Name>Solubility</Name>
          <Value>
            <StringWithMarkup>
              <String>Solubility in water, g/100ml at 20 C: 1.8 (moderate)</String>
              <Markup>
                <Start>14</Start>
                <Length>5</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/water</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-962</Extra>
              </Markup>
            </StringWithMarkup>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>52</ReferenceNumber>
          <Name>Solubility</Name>
          <Value>
            <StringWithMarkup>
              <String>&gt;18.5 [ug/mL]</String>
            </StringWithMarkup>
          </Value>
        </Information>
      </Section>
      <Section>
        <TOCHeading>Density</TOCHeading>
        <Description>The density of a substance is its mass per unit volume.</Description>
        <Information>
          <ReferenceNumber>1</ReferenceNumber>
          <Name>Density</Name>
          <Reference>National Toxicology Program, Institute of Environmental Health Sciences, National Institutes of Health (NTP). 1992. National Toxicology Program Chemical Repository Database. Research Triangle Park, North Carolina: NTP.</Reference>
          <Value>
            <StringWithMarkup>
              <String>1.473 (NTP, 1992)</String>
            </StringWithMarkup>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>32</ReferenceNumber>
          <Description>**PEER REVIEWED**</Description>
          <Reference>Haynes, W.M. (ed.). CRC Handbook of Chemistry and Physics. 95th Edition. CRC Press LLC, Boca Raton: FL 2014-2015, p. 3-474</Reference>
          <Value>
            <StringWithMarkup>
              <String>1.473 g/cu cm at 25 deg C</String>
            </StringWithMarkup>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>34</ReferenceNumber>
          <Name>Density</Name>
          <Value>
            <StringWithMarkup>
              <String>1.5 g/cm</String>
            </StringWithMarkup>
          </Value>
        </Information>
      </Section>
      <Section>
        <TOCHeading>Vapor Pressure</TOCHeading>
        <Description>Vapor pressure is the pressure of a vapor in thermodynamic equilibrium with its condensed phases in a closed system.</Description>
        <Information>
          <ReferenceNumber>32</ReferenceNumber>
          <Description>**PEER REVIEWED**</Description>
          <Reference>US EPA; Estimation Program Interface (EPI) Suite. Ver. 4.11. Nov, 2012. Available from, as of June 18, 2018: http://www2.epa.gov/tsca-screening-tools</Reference>
          <Value>
            <StringWithMarkup>
              <String>9.36X10-5 mm Hg at 25 deg C (est)</String>
            </StringWithMarkup>
          </Value>
        </Information>
      </Section>
      <Section>
        <TOCHeading>Octanol/Water Partition Coefficient</TOCHeading>
        <Description>Octanol/Water Partition Coefficient, used as a measure of molecular lipophilicity</Description>
        <Information>
          <ReferenceNumber>17</ReferenceNumber>
          <Name>LogP</Name>
          <Reference>SANGSTER (1993)</Reference>
          <Value>
            <Number>0.36</Number>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>21</ReferenceNumber>
          <Name>Octanol/Water Partition Coefficient</Name>
          <Reference>SANGSTER (1993)</Reference>
          <Value>
            <StringWithMarkup>
              <String>0.36 (LogP)</String>
            </StringWithMarkup>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>32</ReferenceNumber>
          <Description>**PEER REVIEWED**</Description>
          <Reference>Sangster J; LOGKOW Databank. Sangster Research Lab., Montreal, Quebec, Canada (1993)</Reference>
          <Value>
            <StringWithMarkup>
              <String>log Kow = 0.36</String>
            </StringWithMarkup>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>33</ReferenceNumber>
          <Name>LogP</Name>
          <Reference>SANGSTER (1993)</Reference>
          <Value>
            <StringWithMarkup>
              <String>0.36</String>
            </StringWithMarkup>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>34</ReferenceNumber>
          <Name>LogP</Name>
          <Value>
            <StringWithMarkup>
              <String>-2.43</String>
            </StringWithMarkup>
          </Value>
        </Information>
      </Section>
      <Section>
        <TOCHeading>LogS</TOCHeading>
        <Description>the base-10 logarithm of the aqueous solubility of a compound</Description>
        <Information>
          <ReferenceNumber>17</ReferenceNumber>
          <Name>LogS</Name>
          <Reference>ADME Research, USCD</Reference>
          <Value>
            <Number>-0.84</Number>
          </Value>
        </Information>
      </Section>
      <Section>
        <TOCHeading>Stability/Shelf Life</TOCHeading>
        <Description>Tendency of a material to resist change or decomposition due to internal reaction, or due to the action of air, heat, light, pressure, etc. (See also Stability and Reactivity section under Safety and Hazards)</Description>
        <Information>
          <ReferenceNumber>32</ReferenceNumber>
          <Description>**PEER REVIEWED**</Description>
          <Reference>Sigma-Aldrich; Safety Data Sheet for Nicotinic acid. Product Number: N4126, Version 4.11 (Revision Date 09/22/2017). Available from, as of July 18, 2018: http://www.sigmaaldrich.com/safety-center.html</Reference>
          <Value>
            <StringWithMarkup>
              <String>Stable under recommended storage conditions.</String>
            </StringWithMarkup>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>32</ReferenceNumber>
          <Description>**PEER REVIEWED**</Description>
          <Reference>O&apos;Neil, M.J. (ed.). The Merck Index - An Encyclopedia of Chemicals, Drugs, and Biologicals. Cambridge, UK:  Royal Society of Chemistry, 2013., p. 1214</Reference>
          <Value>
            <StringWithMarkup>
              <String>Nonhygroscopic and stable in air.</String>
            </StringWithMarkup>
          </Value>
        </Information>
      </Section>
      <Section>
        <TOCHeading>Autoignition Temperature</TOCHeading>
        <Description>The lowest temperature at which the substance will spontaneously ignite in a normal atmosphere without an external source of ignition</Description>
        <Information>
          <ReferenceNumber>34</ReferenceNumber>
          <Name>Auto-Ignition</Name>
          <Value>
            <StringWithMarkup>
              <String>580 C</String>
            </StringWithMarkup>
          </Value>
        </Information>
      </Section>
      <Section>
        <TOCHeading>Decomposition</TOCHeading>
        <Description>The decomposition temperature of a substance is the temperature at which the substance chemically decomposes</Description>
        <Information>
          <ReferenceNumber>32</ReferenceNumber>
          <Description>**PEER REVIEWED**</Description>
          <Reference>Sigma-Aldrich; Safety Data Sheet for Nicotinic acid. Product Number: N4126, Version 4.11 (Revision Date 09/22/2017). Available from, as of July 18, 2018: http://www.sigmaaldrich.com/safety-center.html</Reference>
          <Value>
            <StringWithMarkup>
              <String>Hazardous decomposition products formed under fire conditions - Carbon oxides, nitrogen oxides (NOx).</String>
            </StringWithMarkup>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>32</ReferenceNumber>
          <Description>**PEER REVIEWED**</Description>
          <Reference>Lewis, R.J. Sr. (ed) Sax&apos;s Dangerous Properties of Industrial Materials. 11th Edition. Wiley-Interscience, Wiley &amp; Sons, Inc. Hoboken, NJ. 2004., p. 2623</Reference>
          <Value>
            <StringWithMarkup>
              <String>When heated to decomposition it emits toxic fumes of /nitrogen oxides/.</String>
            </StringWithMarkup>
          </Value>
        </Information>
      </Section>
      <Section>
        <TOCHeading>pH</TOCHeading>
        <Description>pH is a measure of the acidity or basicity of an aqueous solution.</Description>
        <Information>
          <ReferenceNumber>32</ReferenceNumber>
          <Description>**PEER REVIEWED**</Description>
          <Reference>O&apos;Neil, M.J. (ed.). The Merck Index - An Encyclopedia of Chemicals, Drugs, and Biologicals. Cambridge, UK:  Royal Society of Chemistry, 2013., p. 1214</Reference>
          <Value>
            <StringWithMarkup>
              <String>pH = 2.7 (saturated aq soln)</String>
            </StringWithMarkup>
          </Value>
        </Information>
      </Section>
      <Section>
        <TOCHeading>pKa</TOCHeading>
        <Description>The negative logarithm of the acid dissociation constant</Description>
        <Information>
          <ReferenceNumber>17</ReferenceNumber>
          <Name>pKa</Name>
          <Reference>DEAN,JA (1985)</Reference>
          <Value>
            <Number>4.75</Number>
            <Unit>(at 25 C)</Unit>
          </Value>
        </Information>
      </Section>
      <Section>
        <TOCHeading>Dissociation Constants</TOCHeading>
        <Description>A specific type of equilibrium constant that measures the propensity of a larger object to separate (dissociate) reversibly into smaller components, as when a complex falls apart into its component molecules, or when a salt splits up into its component ions.</Description>
        <Information>
          <ReferenceNumber>32</ReferenceNumber>
          <Description>**PEER REVIEWED**</Description>
          <Reference>Dean JA; Lange&apos;s Handbook of Chemistry 13th ed. NY: McGraw-Hill Book Co. p. 5-39 (1985)</Reference>
          <Value>
            <StringWithMarkup>
              <String>pKa = 4.75 at 25 deg C</String>
            </StringWithMarkup>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>32</ReferenceNumber>
          <Description>**PEER REVIEWED**</Description>
          <Reference>van Arnum SD; Niacin, Nicotinamide, and Nicotinic Acid. Kirk-Othmer Encyclopedia of Chemical Technology. (1999-2018). New York, NY: John Wiley &amp; Sons. Online Posting Date: 4 Dec 2000</Reference>
          <Value>
            <StringWithMarkup>
              <String>kb1 = 1.50X10-5; kb2 = 1.04X10-12 (in water at 20 deg C)</String>
              <Markup>
                <Start>38</Start>
                <Length>5</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/water</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-962</Extra>
              </Markup>
            </StringWithMarkup>
          </Value>
        </Information>
      </Section>
      <Section>
        <TOCHeading>Kovats Retention Index</TOCHeading>
        <Description>Kovats (gas phase) retention index.</Description>
        <URL>http://en.wikipedia.org/wiki/Kovats_retention_index</URL>
        <DisplayControls>
          <CreateTable>
            <FromInformationIn>ThisSection</FromInformationIn>
            <NumberOfColumns>2</NumberOfColumns>
            <ColumnContents>Name</ColumnContents>
            <ColumnContents>Value</ColumnContents>
          </CreateTable>
          <ListType>CommaSeparated</ListType>
        </DisplayControls>
        <Information>
          <ReferenceNumber>49</ReferenceNumber>
          <Name>Standard non-polar</Name>
          <Value>
            <Number>1335</Number>
            <Number>1340</Number>
            <Number>1335</Number>
          </Value>
        </Information>
      </Section>
      <Section>
        <TOCHeading>Other Experimental Properties</TOCHeading>
        <Description>Additional property information.</Description>
        <Information>
          <ReferenceNumber>32</ReferenceNumber>
          <Description>**PEER REVIEWED**</Description>
          <Reference>O&apos;Neil, M.J. (ed.). The Merck Index - An Encyclopedia of Chemicals, Drugs, and Biologicals. Cambridge, UK:  Royal Society of Chemistry, 2013., p. 1214</Reference>
          <Value>
            <StringWithMarkup>
              <String>Nonhygroscopic; sublimes without decomposition</String>
            </StringWithMarkup>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>32</ReferenceNumber>
          <Description>**PEER REVIEWED**</Description>
          <Reference>Larranaga, M.D., Lewis, R.J. Sr., Lewis, R.A.; Hawley&apos;s Condensed Chemical Dictionary 16th  Edition. John Wiley &amp; Sons, Inc. Hoboken, NJ 2016., p. 966</Reference>
          <Value>
            <StringWithMarkup>
              <String>Stable to heat and oxidation</String>
            </StringWithMarkup>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>32</ReferenceNumber>
          <Description>**PEER REVIEWED**</Description>
          <Reference>O&apos;Neil, M.J. (ed.). The Merck Index - An Encyclopedia of Chemicals, Drugs, and Biologicals. Cambridge, UK:  Royal Society of Chemistry, 2013., p. 1214</Reference>
          <Value>
            <StringWithMarkup>
              <String>Mol wt: 154.10. White crystals or crystalline powder; stable in air. On gram dissolves in approx 1.4 mL water, in approx 60 mL alcohol, in 10 mL glycerol. Insoluble in ether. pH of aqueous solution: approx 7. /Nicotinic acid, sodium salt sesquihydrate/</String>
              <Markup>
                <Start>104</Start>
                <Length>5</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/water</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-962</Extra>
              </Markup>
              <Markup>
                <Start>145</Start>
                <Length>8</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/glycerol</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-753</Extra>
              </Markup>
              <Markup>
                <Start>210</Start>
                <Length>27</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/Nicotinic%20acid%2C%20sodium%20salt</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-23687810</Extra>
              </Markup>
            </StringWithMarkup>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>32</ReferenceNumber>
          <Description>**PEER REVIEWED**</Description>
          <Reference>O&apos;Neil, M.J. (ed.). The Merck Index - An Encyclopedia of Chemicals, Drugs, and Biologicals. Cambridge, UK:  Royal Society of Chemistry, 2013., p. 1288</Reference>
          <Value>
            <StringWithMarkup>
              <String>Mol wt: 139.11. Needles; MP: 254-255 deg C. Slightly soluble in cold water, more soluble in hot water, hot glacial acetic acid, hot methanol, less soluble in ethanol. Insoluble in light petroleum, benzene, chloroform. UV max (0.1N H2SO4): 220, 260 nm (epsilon 22400, 10200) /Nicotinic acid, 1-oxide/</String>
              <Markup>
                <Start>69</Start>
                <Length>5</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/water</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-962</Extra>
              </Markup>
              <Markup>
                <Start>96</Start>
                <Length>5</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/water</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-962</Extra>
              </Markup>
              <Markup>
                <Start>115</Start>
                <Length>11</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/acetic%20acid</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-176</Extra>
              </Markup>
              <Markup>
                <Start>132</Start>
                <Length>8</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/methanol</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-887</Extra>
              </Markup>
              <Markup>
                <Start>158</Start>
                <Length>7</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/ethanol</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-702</Extra>
              </Markup>
              <Markup>
                <Start>197</Start>
                <Length>7</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/benzene</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-241</Extra>
              </Markup>
              <Markup>
                <Start>206</Start>
                <Length>10</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/chloroform</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-6212</Extra>
              </Markup>
              <Markup>
                <Start>275</Start>
                <Length>14</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/Nicotinic%20acid</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
            </StringWithMarkup>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>32</ReferenceNumber>
          <Description>**PEER REVIEWED**</Description>
          <Reference>US EPA; Estimation Program Interface (EPI) Suite. Ver. 4.11. Nov, 2012. Available from, as of June 18, 2018: http://www2.epa.gov/tsca-screening-tools</Reference>
          <Value>
            <StringWithMarkup>
              <String>Henry&apos;s Law constant = 5.11X10-11 atm-cu m/mol at 25 deg C (est)</String>
            </StringWithMarkup>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>32</ReferenceNumber>
          <Description>**PEER REVIEWED**</Description>
          <Reference>Atkinson R; Environ Toxicol Chem 7: 435-62 (1988)</Reference>
          <Value>
            <StringWithMarkup>
              <String>Hydroxyl radical reaction rate constant = 1.72X10-13 cu cm/molec-sec at 25 deg C (est)</String>
              <Markup>
                <Start>0</Start>
                <Length>8</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/Hydroxyl</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-961</Extra>
              </Markup>
            </StringWithMarkup>
          </Value>
        </Information>
      </Section>
    </Section>
  </Section>
  <Section>
    <TOCHeading>Spectral Information</TOCHeading>
    <Description>Spectral data for chemical compounds</Description>
    <Section>
      <TOCHeading>1D NMR Spectra</TOCHeading>
      <Description>1D NMR Spectra data or Linking.</Description>
      <DisplayControls>
        <CreateTable>
          <FromInformationIn>ThisSection</FromInformationIn>
          <NumberOfColumns>2</NumberOfColumns>
          <ColumnContents>Name</ColumnContents>
          <ColumnContents>Value</ColumnContents>
        </CreateTable>
        <ShowAtMost>2</ShowAtMost>
      </DisplayControls>
      <Information>
        <ReferenceNumber>32</ReferenceNumber>
        <Description>**PEER REVIEWED**</Description>
        <Reference>Lide, D.R., G.W.A. Milne (eds.). Handbook of Data on Organic Compounds. Volume I. 3rd ed. CRC Press, Inc. Boca Raton ,FL. 1994., p. V5: 4688</Reference>
        <Value>
          <StringWithMarkup>
            <String>1H NMR: 14671 (Sadtler Research Laboratories Spectral Collection)</String>
          </StringWithMarkup>
        </Value>
      </Information>
      <Information>
        <ReferenceNumber>50</ReferenceNumber>
        <Name>1D NMR Spectra</Name>
        <Value>
          <StringWithMarkup>
            <String>NMRShiftDB Link</String>
            <Markup>
              <Start>0</Start>
              <Length>15</Length>
              <URL>http://nmrshiftdb.nmr.uni-koeln.de//portal/js_pane/P-Results/nmrshiftdbaction/showDetailsFromHome/molNumber/20027733</URL>
            </Markup>
          </StringWithMarkup>
        </Value>
      </Information>
      <Section>
        <TOCHeading>1H NMR Spectra</TOCHeading>
        <Description>Hydrogen-1 NMR (also Proton NMR) is the application of nuclear magnetic resonance in NMR spectroscopy with respect to hydrogen-1 nuclei within the molecules of a substance, in order to determine the structure of its molecules.</Description>
        <DisplayControls>
          <CreateTable>
            <FromInformationIn>ThisSection</FromInformationIn>
            <NumberOfColumns>2</NumberOfColumns>
            <ColumnContents>Name</ColumnContents>
            <ColumnContents>Value</ColumnContents>
          </CreateTable>
          <ShowAtMost>2</ShowAtMost>
        </DisplayControls>
        <Information>
          <ReferenceNumber>33</ReferenceNumber>
          <Name>1H NMR Spectra</Name>
          <Value>
            <StringWithMarkup>
              <String>1D NMR Spectrum 1716 - 1H NMR Spectrum (HMDB0001488)</String>
              <Markup>
                <Start>0</Start>
                <Length>52</Length>
                <URL>http://www.hmdb.ca/spectra/nmr_one_d/1716</URL>
              </Markup>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>1D NMR Spectrum 2514 - 1H NMR Spectrum (HMDB0001488)</String>
              <Markup>
                <Start>0</Start>
                <Length>52</Length>
                <URL>http://www.hmdb.ca/spectra/nmr_one_d/2514</URL>
              </Markup>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>1D NMR Spectrum 4801 - 1H NMR Spectrum (HMDB0001488)</String>
              <Markup>
                <Start>0</Start>
                <Length>52</Length>
                <URL>http://www.hmdb.ca/spectra/nmr_one_d/4801</URL>
              </Markup>
            </StringWithMarkup>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>56</ReferenceNumber>
          <Name>Copyright</Name>
          <Value>
            <StringWithMarkup>
              <String>Copyright  2006-2018 Bio-Rad Laboratories, Inc.  Portions provided by BioMagResBank(BMRB) and the Board of Regents of the University of Wisconsin System.   All Rights Reserved.</String>
            </StringWithMarkup>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>56</ReferenceNumber>
          <Name>Thumbnail</Name>
          <URL>https://spectrabase.com/spectrum/4pPSBsn6fDW</URL>
          <Value>
            <ExternalDataURL>https://pubchem.ncbi.nlm.nih.gov/rest/pug_view/data/key/4975084_1</ExternalDataURL>
            <MimeType>image/png</MimeType>
          </Value>
        </Information>
      </Section>
      <Section>
        <TOCHeading>13C NMR Spectra</TOCHeading>
        <Description>Carbon-13 NMR (13C NMR or CMR) is the application of nuclear magnetic resonance (NMR) spectroscopy to carbon isotope 13.</Description>
        <DisplayControls>
          <CreateTable>
            <FromInformationIn>ThisSection</FromInformationIn>
            <NumberOfColumns>2</NumberOfColumns>
            <ColumnContents>Name</ColumnContents>
            <ColumnContents>Value</ColumnContents>
          </CreateTable>
          <ShowAtMost>2</ShowAtMost>
        </DisplayControls>
        <Information>
          <ReferenceNumber>33</ReferenceNumber>
          <Name>13C NMR Spectra</Name>
          <Value>
            <StringWithMarkup>
              <String>1D NMR Spectrum 3213 - 13C NMR Spectrum (HMDB0001488)</String>
              <Markup>
                <Start>0</Start>
                <Length>53</Length>
                <URL>http://www.hmdb.ca/spectra/nmr_one_d/3213</URL>
              </Markup>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>1D NMR Spectrum 4802 - 13C NMR Spectrum (HMDB0001488)</String>
              <Markup>
                <Start>0</Start>
                <Length>53</Length>
                <URL>http://www.hmdb.ca/spectra/nmr_one_d/4802</URL>
              </Markup>
            </StringWithMarkup>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>55</ReferenceNumber>
          <Name>Copyright</Name>
          <Value>
            <StringWithMarkup>
              <String>Copyright  2006-2018 Bio-Rad Laboratories, Inc.  Portions provided by BioMagResBank(BMRB) and the Board of Regents of the University of Wisconsin System.   All Rights Reserved.</String>
            </StringWithMarkup>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>55</ReferenceNumber>
          <Name>Thumbnail</Name>
          <URL>https://spectrabase.com/spectrum/5lXbMRxggfO</URL>
          <Value>
            <ExternalDataURL>https://pubchem.ncbi.nlm.nih.gov/rest/pug_view/data/key/4975083_1</ExternalDataURL>
            <MimeType>image/png</MimeType>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>57</ReferenceNumber>
          <Name>Source of Sample</Name>
          <Value>
            <StringWithMarkup>
              <String>MCB Manufacturing Chemists, Norwood, Ohio</String>
            </StringWithMarkup>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>57</ReferenceNumber>
          <Name>Copyright</Name>
          <Value>
            <StringWithMarkup>
              <String>Copyright  1980, 1981-2018  Bio-Rad Laboratories, Inc.  All Rights Reserved.</String>
            </StringWithMarkup>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>57</ReferenceNumber>
          <Name>Thumbnail</Name>
          <URL>https://spectrabase.com/spectrum/2lFSfwK1NW1</URL>
          <Value>
            <ExternalDataURL>https://pubchem.ncbi.nlm.nih.gov/rest/pug_view/data/key/4975085_1</ExternalDataURL>
            <MimeType>image/png</MimeType>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>68</ReferenceNumber>
          <Name>Copyright</Name>
          <Value>
            <StringWithMarkup>
              <String>Copyright  2016  W. Robien, Inst. of Org. Chem., Univ. of Vienna.  All Rights Reserved.</String>
            </StringWithMarkup>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>68</ReferenceNumber>
          <Name>Thumbnail</Name>
          <URL>https://spectrabase.com/spectrum/Fmfuqd2wBn7</URL>
          <Value>
            <ExternalDataURL>https://pubchem.ncbi.nlm.nih.gov/rest/pug_view/data/key/4975096_1</ExternalDataURL>
            <MimeType>image/png</MimeType>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>69</ReferenceNumber>
          <Name>Copyright</Name>
          <Value>
            <StringWithMarkup>
              <String>Copyright  2016  W. Robien, Inst. of Org. Chem., Univ. of Vienna.  All Rights Reserved.</String>
            </StringWithMarkup>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>69</ReferenceNumber>
          <Name>Thumbnail</Name>
          <URL>https://spectrabase.com/spectrum/KtJDzp9xTk2</URL>
          <Value>
            <ExternalDataURL>https://pubchem.ncbi.nlm.nih.gov/rest/pug_view/data/key/4975097_1</ExternalDataURL>
            <MimeType>image/png</MimeType>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>70</ReferenceNumber>
          <Name>Copyright</Name>
          <Value>
            <StringWithMarkup>
              <String>Copyright  2016  W. Robien, Inst. of Org. Chem., Univ. of Vienna.  All Rights Reserved.</String>
            </StringWithMarkup>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>70</ReferenceNumber>
          <Name>Thumbnail</Name>
          <URL>https://spectrabase.com/spectrum/AX2TKE0S8e2</URL>
          <Value>
            <ExternalDataURL>https://pubchem.ncbi.nlm.nih.gov/rest/pug_view/data/key/4975098_1</ExternalDataURL>
            <MimeType>image/png</MimeType>
          </Value>
        </Information>
      </Section>
      <Section>
        <TOCHeading>15N NMR Spectra</TOCHeading>
        <Description>Nitrogen-15 NMR or 15N NMR is the application of nuclear magnetic resonance (NMR) spectroscopy to nitrogen isotope 15.</Description>
        <DisplayControls>
          <CreateTable>
            <FromInformationIn>ThisSection</FromInformationIn>
            <NumberOfColumns>2</NumberOfColumns>
            <ColumnContents>Name</ColumnContents>
            <ColumnContents>Value</ColumnContents>
          </CreateTable>
          <ShowAtMost>2</ShowAtMost>
        </DisplayControls>
        <Information>
          <ReferenceNumber>58</ReferenceNumber>
          <Name>Copyright</Name>
          <Value>
            <StringWithMarkup>
              <String>Copyright  2016 W. Robien, Inst. of Org. Chem., Univ. of Vienna.  All Rights Reserved.</String>
            </StringWithMarkup>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>58</ReferenceNumber>
          <Name>Thumbnail</Name>
          <URL>https://spectrabase.com/spectrum/5YFtP9lfmIT</URL>
          <Value>
            <ExternalDataURL>https://pubchem.ncbi.nlm.nih.gov/rest/pug_view/data/key/4975086_1</ExternalDataURL>
            <MimeType>image/png</MimeType>
          </Value>
        </Information>
      </Section>
      <Section>
        <TOCHeading>17O NMR Spectra</TOCHeading>
        <Description>Oxygen-17 NMR or 17O NMR is the application of nuclear magnetic resonance (NMR) spectroscopy to oxygen isotope 17.</Description>
        <DisplayControls>
          <CreateTable>
            <FromInformationIn>ThisSection</FromInformationIn>
            <NumberOfColumns>2</NumberOfColumns>
            <ColumnContents>Name</ColumnContents>
            <ColumnContents>Value</ColumnContents>
          </CreateTable>
          <ShowAtMost>2</ShowAtMost>
        </DisplayControls>
        <Information>
          <ReferenceNumber>59</ReferenceNumber>
          <Name>Copyright</Name>
          <Value>
            <StringWithMarkup>
              <String>Copyright  2016 W. Robien, Inst. of Org. Chem., Univ. of Vienna.  All Rights Reserved.</String>
            </StringWithMarkup>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>59</ReferenceNumber>
          <Name>Thumbnail</Name>
          <URL>https://spectrabase.com/spectrum/FH3fYG9Mp3R</URL>
          <Value>
            <ExternalDataURL>https://pubchem.ncbi.nlm.nih.gov/rest/pug_view/data/key/4975087_1</ExternalDataURL>
            <MimeType>image/png</MimeType>
          </Value>
        </Information>
      </Section>
    </Section>
    <Section>
      <TOCHeading>2D NMR Spectra</TOCHeading>
      <Description>NMR data or links for 2D NMR spectra. Two-dimensional nuclear magnetic resonance spectroscopy (2D NMR) is a set of nuclear magnetic resonance spectroscopy (NMR) methods which give data plotted in a space defined by two frequency axes. 2D NMR includes correlation spectroscopy (COSY), J-spectroscopy, exchange spectroscopy (EXSY), and nuclear Overhauser effect spectroscopy (NOESY).</Description>
      <DisplayControls>
        <CreateTable>
          <FromInformationIn>ThisSection</FromInformationIn>
          <NumberOfColumns>2</NumberOfColumns>
          <ColumnContents>Name</ColumnContents>
          <ColumnContents>Value</ColumnContents>
        </CreateTable>
        <ShowAtMost>2</ShowAtMost>
      </DisplayControls>
      <Section>
        <TOCHeading>1H-1H NMR Spectra</TOCHeading>
        <Description>1H-1H 2D NMR data or linking information.</Description>
        <DisplayControls>
          <CreateTable>
            <FromInformationIn>ThisSection</FromInformationIn>
            <NumberOfColumns>2</NumberOfColumns>
            <ColumnContents>Name</ColumnContents>
            <ColumnContents>Value</ColumnContents>
          </CreateTable>
          <ShowAtMost>2</ShowAtMost>
        </DisplayControls>
        <Information>
          <ReferenceNumber>33</ReferenceNumber>
          <Name>1H-1H NMR Spectra</Name>
          <Value>
            <StringWithMarkup>
              <String>2D NMR Spectrum 1075 - [1H,1H] 2D NMR Spectrum (HMDB0001488)</String>
              <Markup>
                <Start>0</Start>
                <Length>60</Length>
                <URL>http://www.hmdb.ca/spectra/nmr_two_d/1075</URL>
              </Markup>
            </StringWithMarkup>
          </Value>
        </Information>
      </Section>
      <Section>
        <TOCHeading>1H-13C NMR Spectra</TOCHeading>
        <Description>1H-13C 2D NMR data or linking information.</Description>
        <DisplayControls>
          <CreateTable>
            <FromInformationIn>ThisSection</FromInformationIn>
            <NumberOfColumns>2</NumberOfColumns>
            <ColumnContents>Name</ColumnContents>
            <ColumnContents>Value</ColumnContents>
          </CreateTable>
          <ShowAtMost>2</ShowAtMost>
        </DisplayControls>
        <Information>
          <ReferenceNumber>33</ReferenceNumber>
          <Name>1H-13C NMR Spectra</Name>
          <Value>
            <StringWithMarkup>
              <String>2D NMR Spectrum 1656 - [1H,13C] 2D NMR Spectrum (HMDB0001488)</String>
              <Markup>
                <Start>0</Start>
                <Length>61</Length>
                <URL>http://www.hmdb.ca/spectra/nmr_two_d/1656</URL>
              </Markup>
            </StringWithMarkup>
          </Value>
        </Information>
      </Section>
    </Section>
    <Section>
      <TOCHeading>Mass Spectrometry</TOCHeading>
      <Description>Mass spectrometry (MS or mass spec) is a technique to determine molecular structure through ionization and fragmentation of the parent compound into smaller components.</Description>
      <DisplayControls>
        <CreateTable>
          <FromInformationIn>ThisSection</FromInformationIn>
          <NumberOfColumns>2</NumberOfColumns>
          <ColumnContents>Name</ColumnContents>
          <ColumnContents>Value</ColumnContents>
        </CreateTable>
        <ShowAtMost>2</ShowAtMost>
      </DisplayControls>
      <Information>
        <ReferenceNumber>32</ReferenceNumber>
        <Description>**PEER REVIEWED**</Description>
        <Reference>Lide, D.R., G.W.A. Milne (eds.). Handbook of Data on Organic Compounds. Volume I. 3rd ed. CRC Press, Inc. Boca Raton ,FL. 1994., p. V5: 4688</Reference>
        <Value>
          <StringWithMarkup>
            <String>MASS: 40521 (NIST/EPA/MSDC Mass Spectral database, 1990 version); 203 (National Bureau of Standards)</String>
            <Markup>
              <Start>22</Start>
              <Length>4</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/MSDC</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-131526</Extra>
            </Markup>
          </StringWithMarkup>
        </Value>
      </Information>
      <Information>
        <ReferenceNumber>32</ReferenceNumber>
        <Description>**PEER REVIEWED**</Description>
        <Reference>Pfleger, K., H. Maurer and A. Weber. Mass Spectral and GC Data of Drugs, Poisons and their Metabolites. Parts I and II. Mass Spectra Indexes. Weinheim, Federal Republic of Germany. 1985., p. 181</Reference>
        <Value>
          <StringWithMarkup>
            <String>Intense mass spectral peaks: 78 m/z, 106 m/z, 137 m/z</String>
          </StringWithMarkup>
        </Value>
      </Information>
      <Information>
        <ReferenceNumber>36</ReferenceNumber>
        <Name>MoNA ID</Name>
        <URL>http://mona.fiehnlab.ucdavis.edu/spectra/display/FiehnHILIC000611</URL>
        <Value>
          <StringWithMarkup>
            <String>FiehnHILIC000611</String>
          </StringWithMarkup>
        </Value>
      </Information>
      <Information>
        <ReferenceNumber>36</ReferenceNumber>
        <Name>MS Category</Name>
        <Value>
          <StringWithMarkup>
            <String>Experimental</String>
          </StringWithMarkup>
        </Value>
      </Information>
      <Information>
        <ReferenceNumber>36</ReferenceNumber>
        <Name>MS Type</Name>
        <Value>
          <StringWithMarkup>
            <String>Chromatography identified as LC-MS</String>
          </StringWithMarkup>
        </Value>
      </Information>
      <Information>
        <ReferenceNumber>36</ReferenceNumber>
        <Name>MS Level</Name>
        <Value>
          <StringWithMarkup>
            <String>MS2</String>
          </StringWithMarkup>
        </Value>
      </Information>
      <Information>
        <ReferenceNumber>36</ReferenceNumber>
        <Name>Precursor Type</Name>
        <Value>
          <StringWithMarkup>
            <String>[M+H]+</String>
          </StringWithMarkup>
        </Value>
      </Information>
      <Information>
        <ReferenceNumber>36</ReferenceNumber>
        <Name>precursor m/z</Name>
        <Value>
          <StringWithMarkup>
            <String>124.0394</String>
          </StringWithMarkup>
        </Value>
      </Information>
      <Information>
        <ReferenceNumber>36</ReferenceNumber>
        <Name>Instrument</Name>
        <Value>
          <StringWithMarkup>
            <String>Thermo Q Exactive HF</String>
          </StringWithMarkup>
        </Value>
      </Information>
      <Information>
        <ReferenceNumber>36</ReferenceNumber>
        <Name>Instrument Type</Name>
        <Value>
          <StringWithMarkup>
            <String>LC-ESI-QFT</String>
          </StringWithMarkup>
        </Value>
      </Information>
      <Information>
        <ReferenceNumber>36</ReferenceNumber>
        <Name>Ionization Mode</Name>
        <Value>
          <StringWithMarkup>
            <String>positive</String>
          </StringWithMarkup>
        </Value>
      </Information>
      <Information>
        <ReferenceNumber>36</ReferenceNumber>
        <Name>Collision Energy</Name>
        <Value>
          <StringWithMarkup>
            <String>HCD (NCE 20-30-40%)</String>
          </StringWithMarkup>
        </Value>
      </Information>
      <Information>
        <ReferenceNumber>36</ReferenceNumber>
        <Name>Splash</Name>
        <URL>http://mona.fiehnlab.ucdavis.edu/spectra/browse?query=splash.splash%3D%3D%22splash10-00di-1900000000-fc5c19517205f8c5f10c%22</URL>
        <Value>
          <StringWithMarkup>
            <String>splash10-00di-1900000000-fc5c19517205f8c5f10c</String>
          </StringWithMarkup>
        </Value>
      </Information>
      <Information>
        <ReferenceNumber>36</ReferenceNumber>
        <Name>Thumbnail</Name>
        <URL>http://mona.fiehnlab.ucdavis.edu/spectra/display/FiehnHILIC000611</URL>
        <Value>
          <ExternalDataURL>https://pubchem.ncbi.nlm.nih.gov/rest/pug_view/data/key/3412666_1</ExternalDataURL>
          <MimeType>image/png</MimeType>
        </Value>
      </Information>
      <Information>
        <ReferenceNumber>36</ReferenceNumber>
        <Name>Submitter</Name>
        <Value>
          <StringWithMarkup>
            <String>Megan Showalter, University of California, Davis</String>
          </StringWithMarkup>
        </Value>
      </Information>
      <Information>
        <ReferenceNumber>37</ReferenceNumber>
        <Name>MoNA ID</Name>
        <URL>http://mona.fiehnlab.ucdavis.edu/spectra/display/MoNA003051</URL>
        <Value>
          <StringWithMarkup>
            <String>MoNA003051</String>
          </StringWithMarkup>
        </Value>
      </Information>
      <Information>
        <ReferenceNumber>37</ReferenceNumber>
        <Name>MS Category</Name>
        <Value>
          <StringWithMarkup>
            <String>Experimental</String>
          </StringWithMarkup>
        </Value>
      </Information>
      <Information>
        <ReferenceNumber>37</ReferenceNumber>
        <Name>Precursor Type</Name>
        <Value>
          <StringWithMarkup>
            <String>[M+H]+</String>
          </StringWithMarkup>
        </Value>
      </Information>
      <Information>
        <ReferenceNumber>37</ReferenceNumber>
        <Name>precursor m/z</Name>
        <Value>
          <StringWithMarkup>
            <String>124.039306640625</String>
          </StringWithMarkup>
        </Value>
      </Information>
      <Information>
        <ReferenceNumber>37</ReferenceNumber>
        <Name>Instrument</Name>
        <Value>
          <StringWithMarkup>
            <String>Agilent 6550 iFunnel</String>
          </StringWithMarkup>
        </Value>
      </Information>
      <Information>
        <ReferenceNumber>37</ReferenceNumber>
        <Name>Ionization Mode</Name>
        <Value>
          <StringWithMarkup>
            <String>positive</String>
          </StringWithMarkup>
        </Value>
      </Information>
      <Information>
        <ReferenceNumber>37</ReferenceNumber>
        <Name>Splash</Name>
        <URL>http://mona.fiehnlab.ucdavis.edu/spectra/browse?query=splash.splash%3D%3D%22splash10-00di-0900000000-d8d5a47ca3f86ce5e0d5%22</URL>
        <Value>
          <StringWithMarkup>
            <String>splash10-00di-0900000000-d8d5a47ca3f86ce5e0d5</String>
          </StringWithMarkup>
        </Value>
      </Information>
      <Information>
        <ReferenceNumber>37</ReferenceNumber>
        <Name>Thumbnail</Name>
        <URL>http://mona.fiehnlab.ucdavis.edu/spectra/display/MoNA003051</URL>
        <Value>
          <ExternalDataURL>https://pubchem.ncbi.nlm.nih.gov/rest/pug_view/data/key/7676788_1</ExternalDataURL>
          <MimeType>image/png</MimeType>
        </Value>
      </Information>
      <Information>
        <ReferenceNumber>37</ReferenceNumber>
        <Name>Submitter</Name>
        <Value>
          <StringWithMarkup>
            <String>romanas chaleckis, gunma university</String>
          </StringWithMarkup>
        </Value>
      </Information>
      <Information>
        <ReferenceNumber>38</ReferenceNumber>
        <Name>MoNA ID</Name>
        <URL>http://mona.fiehnlab.ucdavis.edu/spectra/display/MoNA003052</URL>
        <Value>
          <StringWithMarkup>
            <String>MoNA003052</String>
          </StringWithMarkup>
        </Value>
      </Information>
      <Information>
        <ReferenceNumber>38</ReferenceNumber>
        <Name>MS Category</Name>
        <Value>
          <StringWithMarkup>
            <String>Experimental</String>
          </StringWithMarkup>
        </Value>
      </Information>
      <Information>
        <ReferenceNumber>38</ReferenceNumber>
        <Name>Precursor Type</Name>
        <Value>
          <StringWithMarkup>
            <String>[M+H]+</String>
          </StringWithMarkup>
        </Value>
      </Information>
      <Information>
        <ReferenceNumber>38</ReferenceNumber>
        <Name>precursor m/z</Name>
        <Value>
          <StringWithMarkup>
            <String>124.039306640625</String>
          </StringWithMarkup>
        </Value>
      </Information>
      <Information>
        <ReferenceNumber>38</ReferenceNumber>
        <Name>Instrument</Name>
        <Value>
          <StringWithMarkup>
            <String>Agilent 6550 iFunnel</String>
          </StringWithMarkup>
        </Value>
      </Information>
      <Information>
        <ReferenceNumber>38</ReferenceNumber>
        <Name>Ionization Mode</Name>
        <Value>
          <StringWithMarkup>
            <String>positive</String>
          </StringWithMarkup>
        </Value>
      </Information>
      <Information>
        <ReferenceNumber>38</ReferenceNumber>
        <Name>Splash</Name>
        <URL>http://mona.fiehnlab.ucdavis.edu/spectra/browse?query=splash.splash%3D%3D%22splash10-00gi-9400000000-99a76949db523f311fa8%22</URL>
        <Value>
          <StringWithMarkup>
            <String>splash10-00gi-9400000000-99a76949db523f311fa8</String>
          </StringWithMarkup>
        </Value>
      </Information>
      <Information>
        <ReferenceNumber>38</ReferenceNumber>
        <Name>Thumbnail</Name>
        <URL>http://mona.fiehnlab.ucdavis.edu/spectra/display/MoNA003052</URL>
        <Value>
          <ExternalDataURL>https://pubchem.ncbi.nlm.nih.gov/rest/pug_view/data/key/7676789_1</ExternalDataURL>
          <MimeType>image/png</MimeType>
        </Value>
      </Information>
      <Information>
        <ReferenceNumber>38</ReferenceNumber>
        <Name>Submitter</Name>
        <Value>
          <StringWithMarkup>
            <String>romanas chaleckis, gunma university</String>
          </StringWithMarkup>
        </Value>
      </Information>
      <Information>
        <ReferenceNumber>39</ReferenceNumber>
        <Name>MoNA ID</Name>
        <URL>http://mona.fiehnlab.ucdavis.edu/spectra/display/MoNA003053</URL>
        <Value>
          <StringWithMarkup>
            <String>MoNA003053</String>
          </StringWithMarkup>
        </Value>
      </Information>
      <Information>
        <ReferenceNumber>39</ReferenceNumber>
        <Name>MS Category</Name>
        <Value>
          <StringWithMarkup>
            <String>Experimental</String>
          </StringWithMarkup>
        </Value>
      </Information>
      <Information>
        <ReferenceNumber>39</ReferenceNumber>
        <Name>Precursor Type</Name>
        <Value>
          <StringWithMarkup>
            <String>[M+H]+</String>
          </StringWithMarkup>
        </Value>
      </Information>
      <Information>
        <ReferenceNumber>39</ReferenceNumber>
        <Name>precursor m/z</Name>
        <Value>
          <StringWithMarkup>
            <String>124.039306640625</String>
          </StringWithMarkup>
        </Value>
      </Information>
      <Information>
        <ReferenceNumber>39</ReferenceNumber>
        <Name>Instrument</Name>
        <Value>
          <StringWithMarkup>
            <String>Agilent 6550 iFunnel</String>
          </StringWithMarkup>
        </Value>
      </Information>
      <Information>
        <ReferenceNumber>39</ReferenceNumber>
        <Name>Ionization Mode</Name>
        <Value>
          <StringWithMarkup>
            <String>positive</String>
          </StringWithMarkup>
        </Value>
      </Information>
      <Information>
        <ReferenceNumber>39</ReferenceNumber>
        <Name>Splash</Name>
        <URL>http://mona.fiehnlab.ucdavis.edu/spectra/browse?query=splash.splash%3D%3D%22splash10-0059-9000000000-4adb2169176c20395674%22</URL>
        <Value>
          <StringWithMarkup>
            <String>splash10-0059-9000000000-4adb2169176c20395674</String>
          </StringWithMarkup>
        </Value>
      </Information>
      <Information>
        <ReferenceNumber>39</ReferenceNumber>
        <Name>Thumbnail</Name>
        <URL>http://mona.fiehnlab.ucdavis.edu/spectra/display/MoNA003053</URL>
        <Value>
          <ExternalDataURL>https://pubchem.ncbi.nlm.nih.gov/rest/pug_view/data/key/7676790_1</ExternalDataURL>
          <MimeType>image/png</MimeType>
        </Value>
      </Information>
      <Information>
        <ReferenceNumber>39</ReferenceNumber>
        <Name>Submitter</Name>
        <Value>
          <StringWithMarkup>
            <String>romanas chaleckis, gunma university</String>
          </StringWithMarkup>
        </Value>
      </Information>
      <Information>
        <ReferenceNumber>40</ReferenceNumber>
        <Name>MoNA ID</Name>
        <URL>http://mona.fiehnlab.ucdavis.edu/spectra/display/MoNA003054</URL>
        <Value>
          <StringWithMarkup>
            <String>MoNA003054</String>
          </StringWithMarkup>
        </Value>
      </Information>
      <Information>
        <ReferenceNumber>40</ReferenceNumber>
        <Name>MS Category</Name>
        <Value>
          <StringWithMarkup>
            <String>Experimental</String>
          </StringWithMarkup>
        </Value>
      </Information>
      <Information>
        <ReferenceNumber>40</ReferenceNumber>
        <Name>Precursor Type</Name>
        <Value>
          <StringWithMarkup>
            <String>[M+H]+</String>
          </StringWithMarkup>
        </Value>
      </Information>
      <Information>
        <ReferenceNumber>40</ReferenceNumber>
        <Name>precursor m/z</Name>
        <Value>
          <StringWithMarkup>
            <String>124.039306640625</String>
          </StringWithMarkup>
        </Value>
      </Information>
      <Information>
        <ReferenceNumber>40</ReferenceNumber>
        <Name>Instrument</Name>
        <Value>
          <StringWithMarkup>
            <String>Agilent 6550 iFunnel</String>
          </StringWithMarkup>
        </Value>
      </Information>
      <Information>
        <ReferenceNumber>40</ReferenceNumber>
        <Name>Ionization Mode</Name>
        <Value>
          <StringWithMarkup>
            <String>positive</String>
          </StringWithMarkup>
        </Value>
      </Information>
      <Information>
        <ReferenceNumber>40</ReferenceNumber>
        <Name>Splash</Name>
        <URL>http://mona.fiehnlab.ucdavis.edu/spectra/browse?query=splash.splash%3D%3D%22splash10-0ufr-9000000000-024d4ac2c4fe3b9ded27%22</URL>
        <Value>
          <StringWithMarkup>
            <String>splash10-0ufr-9000000000-024d4ac2c4fe3b9ded27</String>
          </StringWithMarkup>
        </Value>
      </Information>
      <Information>
        <ReferenceNumber>40</ReferenceNumber>
        <Name>Thumbnail</Name>
        <URL>http://mona.fiehnlab.ucdavis.edu/spectra/display/MoNA003054</URL>
        <Value>
          <ExternalDataURL>https://pubchem.ncbi.nlm.nih.gov/rest/pug_view/data/key/7676791_1</ExternalDataURL>
          <MimeType>image/png</MimeType>
        </Value>
      </Information>
      <Information>
        <ReferenceNumber>40</ReferenceNumber>
        <Name>Submitter</Name>
        <Value>
          <StringWithMarkup>
            <String>romanas chaleckis, gunma university</String>
          </StringWithMarkup>
        </Value>
      </Information>
      <Information>
        <ReferenceNumber>53</ReferenceNumber>
        <Name>Source of Spectrum</Name>
        <Value>
          <StringWithMarkup>
            <String>Mass Spectrometry Committee of the Toxicology Section of the American Academy of Forensic Sciences</String>
          </StringWithMarkup>
        </Value>
      </Information>
      <Information>
        <ReferenceNumber>53</ReferenceNumber>
        <Name>Copyright</Name>
        <Value>
          <StringWithMarkup>
            <String>Copyright  2012-2018  Bio-Rad Laboratories, Inc. Portions provided by AAFS, Toxicology Section. All Rights Reserved.</String>
          </StringWithMarkup>
        </Value>
      </Information>
      <Information>
        <ReferenceNumber>53</ReferenceNumber>
        <Name>Thumbnail</Name>
        <URL>https://spectrabase.com/spectrum/Asz28UwMTPG</URL>
        <Value>
          <ExternalDataURL>https://pubchem.ncbi.nlm.nih.gov/rest/pug_view/data/key/4975081_1</ExternalDataURL>
          <MimeType>image/png</MimeType>
        </Value>
      </Information>
      <Section>
        <TOCHeading>GC-MS</TOCHeading>
        <Description>Data from GC-MS experiments.</Description>
        <DisplayControls>
          <CreateTable>
            <FromInformationIn>ThisSection</FromInformationIn>
            <NumberOfColumns>2</NumberOfColumns>
            <ColumnContents>Name</ColumnContents>
            <ColumnContents>Value</ColumnContents>
          </CreateTable>
          <ListType>Columns</ListType>
          <ShowAtMost>2</ShowAtMost>
        </DisplayControls>
        <Information>
          <ReferenceNumber>33</ReferenceNumber>
          <Name>GC-MS</Name>
          <Value>
            <StringWithMarkup>
              <String>GC-MS Spectrum 754</String>
              <Markup>
                <Start>0</Start>
                <Length>18</Length>
                <URL>http://www.hmdb.ca/spectra/c_ms/754</URL>
              </Markup>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>GC-MS Spectrum 755</String>
              <Markup>
                <Start>0</Start>
                <Length>18</Length>
                <URL>http://www.hmdb.ca/spectra/c_ms/755</URL>
              </Markup>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>GC-MS Spectrum 756</String>
              <Markup>
                <Start>0</Start>
                <Length>18</Length>
                <URL>http://www.hmdb.ca/spectra/c_ms/756</URL>
              </Markup>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>GC-MS Spectrum 757</String>
              <Markup>
                <Start>0</Start>
                <Length>18</Length>
                <URL>http://www.hmdb.ca/spectra/c_ms/757</URL>
              </Markup>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>GC-MS Spectrum 1037</String>
              <Markup>
                <Start>0</Start>
                <Length>19</Length>
                <URL>http://www.hmdb.ca/spectra/c_ms/1037</URL>
              </Markup>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>GC-MS Spectrum 2756</String>
              <Markup>
                <Start>0</Start>
                <Length>19</Length>
                <URL>http://www.hmdb.ca/spectra/c_ms/2756</URL>
              </Markup>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>GC-MS Spectrum 27987</String>
              <Markup>
                <Start>0</Start>
                <Length>20</Length>
                <URL>http://www.hmdb.ca/spectra/c_ms/27987</URL>
              </Markup>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>GC-MS Spectrum 30223</String>
              <Markup>
                <Start>0</Start>
                <Length>20</Length>
                <URL>http://www.hmdb.ca/spectra/c_ms/30223</URL>
              </Markup>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>GC-MS Spectrum 30321</String>
              <Markup>
                <Start>0</Start>
                <Length>20</Length>
                <URL>http://www.hmdb.ca/spectra/c_ms/30321</URL>
              </Markup>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>GC-MS Spectrum 30648</String>
              <Markup>
                <Start>0</Start>
                <Length>20</Length>
                <URL>http://www.hmdb.ca/spectra/c_ms/30648</URL>
              </Markup>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>GC-MS Spectrum 30893</String>
              <Markup>
                <Start>0</Start>
                <Length>20</Length>
                <URL>http://www.hmdb.ca/spectra/c_ms/30893</URL>
              </Markup>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>GC-MS Spectrum 31339</String>
              <Markup>
                <Start>0</Start>
                <Length>20</Length>
                <URL>http://www.hmdb.ca/spectra/c_ms/31339</URL>
              </Markup>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>GC-MS Spectrum 32373</String>
              <Markup>
                <Start>0</Start>
                <Length>20</Length>
                <URL>http://www.hmdb.ca/spectra/c_ms/32373</URL>
              </Markup>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>GC-MS Spectrum 38091</String>
              <Markup>
                <Start>0</Start>
                <Length>20</Length>
                <URL>http://www.hmdb.ca/spectra/c_ms/38091</URL>
              </Markup>
            </StringWithMarkup>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>43</ReferenceNumber>
          <Name>NIST Number</Name>
          <Value>
            <Number>233225</Number>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>43</ReferenceNumber>
          <Name>Library</Name>
          <Value>
            <StringWithMarkup>
              <String>Main library</String>
            </StringWithMarkup>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>43</ReferenceNumber>
          <Name>Total Peaks</Name>
          <Value>
            <Number>54</Number>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>43</ReferenceNumber>
          <Name>m/z Top Peak</Name>
          <Value>
            <Number>123</Number>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>43</ReferenceNumber>
          <Name>m/z 2nd Highest</Name>
          <Value>
            <Number>105</Number>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>43</ReferenceNumber>
          <Name>m/z 3rd Highest</Name>
          <Value>
            <Number>78</Number>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>43</ReferenceNumber>
          <Name>Thumbnail</Name>
          <Value>
            <ExternalDataURL>https://pubchem.ncbi.nlm.nih.gov/rest/pug_view/data/key/112097_1</ExternalDataURL>
            <MimeType>image/png</MimeType>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>44</ReferenceNumber>
          <Name>NIST Number</Name>
          <Value>
            <Number>312948</Number>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>44</ReferenceNumber>
          <Name>Library</Name>
          <Value>
            <StringWithMarkup>
              <String>Replicate library</String>
            </StringWithMarkup>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>44</ReferenceNumber>
          <Name>Total Peaks</Name>
          <Value>
            <Number>32</Number>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>44</ReferenceNumber>
          <Name>m/z Top Peak</Name>
          <Value>
            <Number>123</Number>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>44</ReferenceNumber>
          <Name>m/z 2nd Highest</Name>
          <Value>
            <Number>78</Number>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>44</ReferenceNumber>
          <Name>m/z 3rd Highest</Name>
          <Value>
            <Number>105</Number>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>44</ReferenceNumber>
          <Name>Thumbnail</Name>
          <Value>
            <ExternalDataURL>https://pubchem.ncbi.nlm.nih.gov/rest/pug_view/data/key/267348_1</ExternalDataURL>
            <MimeType>image/png</MimeType>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>45</ReferenceNumber>
          <Name>NIST Number</Name>
          <Value>
            <Number>155087</Number>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>45</ReferenceNumber>
          <Name>Library</Name>
          <Value>
            <StringWithMarkup>
              <String>Replicate library</String>
            </StringWithMarkup>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>45</ReferenceNumber>
          <Name>Total Peaks</Name>
          <Value>
            <Number>77</Number>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>45</ReferenceNumber>
          <Name>m/z Top Peak</Name>
          <Value>
            <Number>123</Number>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>45</ReferenceNumber>
          <Name>m/z 2nd Highest</Name>
          <Value>
            <Number>105</Number>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>45</ReferenceNumber>
          <Name>m/z 3rd Highest</Name>
          <Value>
            <Number>78</Number>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>45</ReferenceNumber>
          <Name>Thumbnail</Name>
          <Value>
            <ExternalDataURL>https://pubchem.ncbi.nlm.nih.gov/rest/pug_view/data/key/267427_1</ExternalDataURL>
            <MimeType>image/png</MimeType>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>46</ReferenceNumber>
          <Name>NIST Number</Name>
          <Value>
            <Number>291061</Number>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>46</ReferenceNumber>
          <Name>Library</Name>
          <Value>
            <StringWithMarkup>
              <String>Replicate library</String>
            </StringWithMarkup>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>46</ReferenceNumber>
          <Name>Total Peaks</Name>
          <Value>
            <Number>43</Number>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>46</ReferenceNumber>
          <Name>m/z Top Peak</Name>
          <Value>
            <Number>123</Number>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>46</ReferenceNumber>
          <Name>m/z 2nd Highest</Name>
          <Value>
            <Number>105</Number>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>46</ReferenceNumber>
          <Name>m/z 3rd Highest</Name>
          <Value>
            <Number>78</Number>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>46</ReferenceNumber>
          <Name>Thumbnail</Name>
          <Value>
            <ExternalDataURL>https://pubchem.ncbi.nlm.nih.gov/rest/pug_view/data/key/267428_1</ExternalDataURL>
            <MimeType>image/png</MimeType>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>47</ReferenceNumber>
          <Name>NIST Number</Name>
          <Value>
            <Number>379751</Number>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>47</ReferenceNumber>
          <Name>Library</Name>
          <Value>
            <StringWithMarkup>
              <String>Replicate library</String>
            </StringWithMarkup>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>47</ReferenceNumber>
          <Name>Total Peaks</Name>
          <Value>
            <Number>15</Number>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>47</ReferenceNumber>
          <Name>m/z Top Peak</Name>
          <Value>
            <Number>123</Number>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>47</ReferenceNumber>
          <Name>m/z 2nd Highest</Name>
          <Value>
            <Number>105</Number>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>47</ReferenceNumber>
          <Name>m/z 3rd Highest</Name>
          <Value>
            <Number>78</Number>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>47</ReferenceNumber>
          <Name>Thumbnail</Name>
          <Value>
            <ExternalDataURL>https://pubchem.ncbi.nlm.nih.gov/rest/pug_view/data/key/267429_1</ExternalDataURL>
            <MimeType>image/png</MimeType>
          </Value>
        </Information>
      </Section>
      <Section>
        <TOCHeading>MS-MS</TOCHeading>
        <Description>Data from MS-MS experiments.</Description>
        <DisplayControls>
          <CreateTable>
            <FromInformationIn>ThisSection</FromInformationIn>
            <NumberOfColumns>2</NumberOfColumns>
            <ColumnContents>Name</ColumnContents>
            <ColumnContents>Value</ColumnContents>
          </CreateTable>
          <ListType>Columns</ListType>
          <ShowAtMost>2</ShowAtMost>
        </DisplayControls>
        <Information>
          <ReferenceNumber>33</ReferenceNumber>
          <Name>MS-MS</Name>
          <Value>
            <StringWithMarkup>
              <String>MS-MS Spectrum 1604</String>
              <Markup>
                <Start>0</Start>
                <Length>19</Length>
                <URL>http://www.hmdb.ca/spectra/ms_ms/1604</URL>
              </Markup>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>MS-MS Spectrum 1605</String>
              <Markup>
                <Start>0</Start>
                <Length>19</Length>
                <URL>http://www.hmdb.ca/spectra/ms_ms/1605</URL>
              </Markup>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>MS-MS Spectrum 1606</String>
              <Markup>
                <Start>0</Start>
                <Length>19</Length>
                <URL>http://www.hmdb.ca/spectra/ms_ms/1606</URL>
              </Markup>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>MS-MS Spectrum 5336</String>
              <Markup>
                <Start>0</Start>
                <Length>19</Length>
                <URL>http://www.hmdb.ca/spectra/ms_ms/5336</URL>
              </Markup>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>MS-MS Spectrum 5337</String>
              <Markup>
                <Start>0</Start>
                <Length>19</Length>
                <URL>http://www.hmdb.ca/spectra/ms_ms/5337</URL>
              </Markup>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>MS-MS Spectrum 5338</String>
              <Markup>
                <Start>0</Start>
                <Length>19</Length>
                <URL>http://www.hmdb.ca/spectra/ms_ms/5338</URL>
              </Markup>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>MS-MS Spectrum 5339</String>
              <Markup>
                <Start>0</Start>
                <Length>19</Length>
                <URL>http://www.hmdb.ca/spectra/ms_ms/5339</URL>
              </Markup>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>MS-MS Spectrum 5340</String>
              <Markup>
                <Start>0</Start>
                <Length>19</Length>
                <URL>http://www.hmdb.ca/spectra/ms_ms/5340</URL>
              </Markup>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>MS-MS Spectrum 5341</String>
              <Markup>
                <Start>0</Start>
                <Length>19</Length>
                <URL>http://www.hmdb.ca/spectra/ms_ms/5341</URL>
              </Markup>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>MS-MS Spectrum 5342</String>
              <Markup>
                <Start>0</Start>
                <Length>19</Length>
                <URL>http://www.hmdb.ca/spectra/ms_ms/5342</URL>
              </Markup>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>MS-MS Spectrum 5343</String>
              <Markup>
                <Start>0</Start>
                <Length>19</Length>
                <URL>http://www.hmdb.ca/spectra/ms_ms/5343</URL>
              </Markup>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>MS-MS Spectrum 5344</String>
              <Markup>
                <Start>0</Start>
                <Length>19</Length>
                <URL>http://www.hmdb.ca/spectra/ms_ms/5344</URL>
              </Markup>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>MS-MS Spectrum 5345</String>
              <Markup>
                <Start>0</Start>
                <Length>19</Length>
                <URL>http://www.hmdb.ca/spectra/ms_ms/5345</URL>
              </Markup>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>MS-MS Spectrum 5346</String>
              <Markup>
                <Start>0</Start>
                <Length>19</Length>
                <URL>http://www.hmdb.ca/spectra/ms_ms/5346</URL>
              </Markup>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>MS-MS Spectrum 5351</String>
              <Markup>
                <Start>0</Start>
                <Length>19</Length>
                <URL>http://www.hmdb.ca/spectra/ms_ms/5351</URL>
              </Markup>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>MS-MS Spectrum 5352</String>
              <Markup>
                <Start>0</Start>
                <Length>19</Length>
                <URL>http://www.hmdb.ca/spectra/ms_ms/5352</URL>
              </Markup>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>MS-MS Spectrum 5353</String>
              <Markup>
                <Start>0</Start>
                <Length>19</Length>
                <URL>http://www.hmdb.ca/spectra/ms_ms/5353</URL>
              </Markup>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>MS-MS Spectrum 178800</String>
              <Markup>
                <Start>0</Start>
                <Length>21</Length>
                <URL>http://www.hmdb.ca/spectra/ms_ms/178800</URL>
              </Markup>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>MS-MS Spectrum 178801</String>
              <Markup>
                <Start>0</Start>
                <Length>21</Length>
                <URL>http://www.hmdb.ca/spectra/ms_ms/178801</URL>
              </Markup>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>MS-MS Spectrum 178802</String>
              <Markup>
                <Start>0</Start>
                <Length>21</Length>
                <URL>http://www.hmdb.ca/spectra/ms_ms/178802</URL>
              </Markup>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>MS-MS Spectrum 181119</String>
              <Markup>
                <Start>0</Start>
                <Length>21</Length>
                <URL>http://www.hmdb.ca/spectra/ms_ms/181119</URL>
              </Markup>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>MS-MS Spectrum 181120</String>
              <Markup>
                <Start>0</Start>
                <Length>21</Length>
                <URL>http://www.hmdb.ca/spectra/ms_ms/181120</URL>
              </Markup>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>MS-MS Spectrum 181121</String>
              <Markup>
                <Start>0</Start>
                <Length>21</Length>
                <URL>http://www.hmdb.ca/spectra/ms_ms/181121</URL>
              </Markup>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>MS-MS Spectrum 438191</String>
              <Markup>
                <Start>0</Start>
                <Length>21</Length>
                <URL>http://www.hmdb.ca/spectra/ms_ms/438191</URL>
              </Markup>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>MS-MS Spectrum 438192</String>
              <Markup>
                <Start>0</Start>
                <Length>21</Length>
                <URL>http://www.hmdb.ca/spectra/ms_ms/438192</URL>
              </Markup>
            </StringWithMarkup>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>48</ReferenceNumber>
          <Name>NIST Number</Name>
          <Value>
            <Number>1052366</Number>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>48</ReferenceNumber>
          <Name>Instrument Type</Name>
          <Value>
            <StringWithMarkup>
              <String>IT/ion trap</String>
            </StringWithMarkup>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>48</ReferenceNumber>
          <Name>Collision Energy</Name>
          <Value>
            <Number>0</Number>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>48</ReferenceNumber>
          <Name>Spectrum Type</Name>
          <Value>
            <StringWithMarkup>
              <String>MS2</String>
            </StringWithMarkup>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>48</ReferenceNumber>
          <Name>Precursor Type</Name>
          <Value>
            <StringWithMarkup>
              <String>[M+H]+</String>
            </StringWithMarkup>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>48</ReferenceNumber>
          <Name>Precursor m/z</Name>
          <Value>
            <Number>124.0393</Number>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>48</ReferenceNumber>
          <Name>Total Peaks</Name>
          <Value>
            <Number>2</Number>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>48</ReferenceNumber>
          <Name>m/z Top Peak</Name>
          <Value>
            <Number>106.1</Number>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>48</ReferenceNumber>
          <Name>m/z 2nd Highest</Name>
          <Value>
            <Number>80</Number>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>48</ReferenceNumber>
          <Name>m/z 3rd Highest</Name>
          <Value>
            <Number>0</Number>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>48</ReferenceNumber>
          <Name>Thumbnail</Name>
          <Value>
            <ExternalDataURL>https://pubchem.ncbi.nlm.nih.gov/rest/pug_view/data/key/287055_1</ExternalDataURL>
            <MimeType>image/png</MimeType>
          </Value>
        </Information>
      </Section>
      <Section>
        <TOCHeading>EI-MS</TOCHeading>
        <Description>Linking to EI-MS spectrum.</Description>
        <DisplayControls>
          <CreateTable>
            <FromInformationIn>ThisSection</FromInformationIn>
            <NumberOfColumns>2</NumberOfColumns>
            <ColumnContents>Name</ColumnContents>
            <ColumnContents>Value</ColumnContents>
          </CreateTable>
          <ShowAtMost>2</ShowAtMost>
        </DisplayControls>
        <Information>
          <ReferenceNumber>33</ReferenceNumber>
          <Name>EI-MS</Name>
          <Value>
            <StringWithMarkup>
              <String>EI-MS Spectrum 446</String>
              <Markup>
                <Start>0</Start>
                <Length>18</Length>
                <URL>http://www.hmdb.ca/spectra/ei_ms/446</URL>
              </Markup>
            </StringWithMarkup>
          </Value>
        </Information>
      </Section>
    </Section>
    <Section>
      <TOCHeading>UV Spectra</TOCHeading>
      <Description>Ultraviolet (UV) spectroscopy refers to absorption spectroscopy or reflectance spectroscopy in the ultraviolet spectral region.</Description>
      <Information>
        <ReferenceNumber>32</ReferenceNumber>
        <Description>**PEER REVIEWED**</Description>
        <Reference>O&apos;Neil, M.J. (ed.). The Merck Index - An Encyclopedia of Chemicals, Drugs, and Biologicals. Cambridge, UK:  Royal Society of Chemistry, 2013., p. 1214</Reference>
        <Value>
          <StringWithMarkup>
            <String>Max absorption: 263 nm</String>
          </StringWithMarkup>
        </Value>
      </Information>
      <Information>
        <ReferenceNumber>32</ReferenceNumber>
        <Description>**PEER REVIEWED**</Description>
        <Reference>Lide, D.R., G.W.A. Milne (eds.). Handbook of Data on Organic Compounds. Volume I. 3rd ed. CRC Press, Inc. Boca Raton ,FL. 1994., p. V5: 4688</Reference>
        <Value>
          <StringWithMarkup>
            <String>UV: 161 (Sadtler Research Laboratories Prism Collection)</String>
          </StringWithMarkup>
        </Value>
      </Information>
      <Section>
        <TOCHeading>UV-VIS Spectra</TOCHeading>
        <Description>Ultraviolet-visible (UV) or ultraviolet-visible (UV-Vis or UV/Vis) spectrophotometry refers to absorption spectroscopy or reflectance spectroscopy in the ultraviolet-visible spectral region.</Description>
        <DisplayControls>
          <CreateTable>
            <FromInformationIn>ThisSection</FromInformationIn>
            <NumberOfColumns>2</NumberOfColumns>
            <ColumnContents>Name</ColumnContents>
            <ColumnContents>Value</ColumnContents>
          </CreateTable>
          <ShowAtMost>2</ShowAtMost>
        </DisplayControls>
        <Information>
          <ReferenceNumber>62</ReferenceNumber>
          <Name>Copyright</Name>
          <Value>
            <StringWithMarkup>
              <String>Copyright  2008-2018 Bio-Rad Laboratories, Inc.  All Rights Reserved.</String>
            </StringWithMarkup>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>62</ReferenceNumber>
          <Name>Thumbnail</Name>
          <URL>https://spectrabase.com/spectrum/GHMJC1lPBOh</URL>
          <Value>
            <ExternalDataURL>https://pubchem.ncbi.nlm.nih.gov/rest/pug_view/data/key/4975090_1</ExternalDataURL>
            <MimeType>image/png</MimeType>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>63</ReferenceNumber>
          <Name>Copyright</Name>
          <Value>
            <StringWithMarkup>
              <String>Copyright  2008-2018 Bio-Rad Laboratories, Inc.  All Rights Reserved.</String>
            </StringWithMarkup>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>63</ReferenceNumber>
          <Name>Thumbnail</Name>
          <URL>https://spectrabase.com/spectrum/2mpWyETltKW</URL>
          <Value>
            <ExternalDataURL>https://pubchem.ncbi.nlm.nih.gov/rest/pug_view/data/key/4975091_1</ExternalDataURL>
            <MimeType>image/png</MimeType>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>64</ReferenceNumber>
          <Name>Copyright</Name>
          <Value>
            <StringWithMarkup>
              <String>Copyright  2008-2018 Bio-Rad Laboratories, Inc.  All Rights Reserved.</String>
            </StringWithMarkup>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>64</ReferenceNumber>
          <Name>Thumbnail</Name>
          <URL>https://spectrabase.com/spectrum/F5JN1HlmoE3</URL>
          <Value>
            <ExternalDataURL>https://pubchem.ncbi.nlm.nih.gov/rest/pug_view/data/key/4975092_1</ExternalDataURL>
            <MimeType>image/png</MimeType>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>65</ReferenceNumber>
          <Name>Copyright</Name>
          <Value>
            <StringWithMarkup>
              <String>Copyright  2008-2018 Bio-Rad Laboratories, Inc.  All Rights Reserved.</String>
            </StringWithMarkup>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>65</ReferenceNumber>
          <Name>Thumbnail</Name>
          <URL>https://spectrabase.com/spectrum/L92EDJNff43</URL>
          <Value>
            <ExternalDataURL>https://pubchem.ncbi.nlm.nih.gov/rest/pug_view/data/key/4975093_1</ExternalDataURL>
            <MimeType>image/png</MimeType>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>66</ReferenceNumber>
          <Name>Copyright</Name>
          <Value>
            <StringWithMarkup>
              <String>Copyright  2008-2018 Bio-Rad Laboratories, Inc.  All Rights Reserved.</String>
            </StringWithMarkup>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>66</ReferenceNumber>
          <Name>Thumbnail</Name>
          <URL>https://spectrabase.com/spectrum/CrzRcEWgKJG</URL>
          <Value>
            <ExternalDataURL>https://pubchem.ncbi.nlm.nih.gov/rest/pug_view/data/key/4975094_1</ExternalDataURL>
            <MimeType>image/png</MimeType>
          </Value>
        </Information>
      </Section>
    </Section>
    <Section>
      <TOCHeading>IR Spectra</TOCHeading>
      <Description>Infrared spectroscopy (IR spectroscopy) is the spectroscopy that deals with the infrared region of the electromagnetic spectrum.</Description>
      <DisplayControls>
        <CreateTable>
          <FromInformationIn>ThisSection</FromInformationIn>
          <NumberOfColumns>2</NumberOfColumns>
          <ColumnContents>Name</ColumnContents>
          <ColumnContents>Value</ColumnContents>
        </CreateTable>
        <ShowAtMost>2</ShowAtMost>
      </DisplayControls>
      <Information>
        <ReferenceNumber>32</ReferenceNumber>
        <Description>**PEER REVIEWED**</Description>
        <Reference>Lide, D.R., G.W.A. Milne (eds.). Handbook of Data on Organic Compounds. Volume I. 3rd ed. CRC Press, Inc. Boca Raton ,FL. 1994., p. V5: 4688</Reference>
        <Value>
          <StringWithMarkup>
            <String>IR: 5076 (Coblentz Society Spectral Collection)</String>
          </StringWithMarkup>
        </Value>
      </Information>
      <Section>
        <TOCHeading>FTIR Spectra</TOCHeading>
        <Description>FTIR spectral data</Description>
        <DisplayControls>
          <CreateTable>
            <FromInformationIn>ThisSection</FromInformationIn>
            <NumberOfColumns>2</NumberOfColumns>
            <ColumnContents>Name</ColumnContents>
            <ColumnContents>Value</ColumnContents>
          </CreateTable>
          <ShowAtMost>2</ShowAtMost>
        </DisplayControls>
        <Information>
          <ReferenceNumber>61</ReferenceNumber>
          <Name>Technique</Name>
          <Value>
            <StringWithMarkup>
              <String>KBr WAFER</String>
            </StringWithMarkup>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>61</ReferenceNumber>
          <Name>Source of Sample</Name>
          <Value>
            <StringWithMarkup>
              <String>Hoffmann-La Roche, Inc., Nutley, New Jersey</String>
            </StringWithMarkup>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>61</ReferenceNumber>
          <Name>Copyright</Name>
          <Value>
            <StringWithMarkup>
              <String>Copyright  1980, 1981-2018  Bio-Rad Laboratories, Inc.  All Rights Reserved.</String>
            </StringWithMarkup>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>61</ReferenceNumber>
          <Name>Thumbnail</Name>
          <URL>https://spectrabase.com/spectrum/D9KI1cPezdt</URL>
          <Value>
            <ExternalDataURL>https://pubchem.ncbi.nlm.nih.gov/rest/pug_view/data/key/4975089_1</ExternalDataURL>
            <MimeType>image/png</MimeType>
          </Value>
        </Information>
      </Section>
      <Section>
        <TOCHeading>ATR-IR Spectra</TOCHeading>
        <Description>ATR-IR spectral data</Description>
        <DisplayControls>
          <CreateTable>
            <FromInformationIn>ThisSection</FromInformationIn>
            <NumberOfColumns>2</NumberOfColumns>
            <ColumnContents>Name</ColumnContents>
            <ColumnContents>Value</ColumnContents>
          </CreateTable>
          <ShowAtMost>2</ShowAtMost>
        </DisplayControls>
        <Information>
          <ReferenceNumber>54</ReferenceNumber>
          <Name>Instrument Name</Name>
          <Value>
            <StringWithMarkup>
              <String>Bio-Rad FTS</String>
            </StringWithMarkup>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>54</ReferenceNumber>
          <Name>Technique</Name>
          <Value>
            <StringWithMarkup>
              <String>ATR-Neat (DuraSamplIR II)</String>
            </StringWithMarkup>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>54</ReferenceNumber>
          <Name>Source of Spectrum</Name>
          <Value>
            <StringWithMarkup>
              <String>Forensic Spectral Research</String>
            </StringWithMarkup>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>54</ReferenceNumber>
          <Name>Source of Sample</Name>
          <Value>
            <StringWithMarkup>
              <String>Supelco, Sigma-Aldrich Inc.</String>
            </StringWithMarkup>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>54</ReferenceNumber>
          <Name>Catalog Number</Name>
          <Value>
            <StringWithMarkup>
              <String>47864</String>
            </StringWithMarkup>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>54</ReferenceNumber>
          <Name>Lot Number</Name>
          <Value>
            <StringWithMarkup>
              <String>LB60597</String>
            </StringWithMarkup>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>54</ReferenceNumber>
          <Name>Copyright</Name>
          <Value>
            <StringWithMarkup>
              <String>Copyright  2009-2018 Bio-Rad Laboratories, Inc.  All Rights Reserved.</String>
            </StringWithMarkup>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>54</ReferenceNumber>
          <Name>Thumbnail</Name>
          <URL>https://spectrabase.com/spectrum/BkKtRe7AAEX</URL>
          <Value>
            <ExternalDataURL>https://pubchem.ncbi.nlm.nih.gov/rest/pug_view/data/key/4975082_1</ExternalDataURL>
            <MimeType>image/png</MimeType>
          </Value>
        </Information>
      </Section>
      <Section>
        <TOCHeading>Vapor Phase IR Spectra</TOCHeading>
        <Description>Vapor Phase IR spectral data</Description>
        <DisplayControls>
          <CreateTable>
            <FromInformationIn>ThisSection</FromInformationIn>
            <NumberOfColumns>2</NumberOfColumns>
            <ColumnContents>Name</ColumnContents>
            <ColumnContents>Value</ColumnContents>
          </CreateTable>
          <ShowAtMost>2</ShowAtMost>
        </DisplayControls>
        <Information>
          <ReferenceNumber>67</ReferenceNumber>
          <Name>Instrument Name</Name>
          <Value>
            <StringWithMarkup>
              <String>DIGILAB FTS-14</String>
            </StringWithMarkup>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>67</ReferenceNumber>
          <Name>Technique</Name>
          <Value>
            <StringWithMarkup>
              <String>Vapor Phase</String>
            </StringWithMarkup>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>67</ReferenceNumber>
          <Name>Copyright</Name>
          <Value>
            <StringWithMarkup>
              <String>Copyright  1980, 1981-2018  Bio-Rad Laboratories, Inc.  All Rights Reserved.</String>
            </StringWithMarkup>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>67</ReferenceNumber>
          <Name>Thumbnail</Name>
          <URL>https://spectrabase.com/spectrum/2fOTglO1ij3</URL>
          <Value>
            <ExternalDataURL>https://pubchem.ncbi.nlm.nih.gov/rest/pug_view/data/key/4975095_1</ExternalDataURL>
            <MimeType>image/png</MimeType>
          </Value>
        </Information>
      </Section>
    </Section>
    <Section>
      <TOCHeading>Raman Spectra</TOCHeading>
      <Description>Raman spectroscopy is a spectroscopic technique used to observe vibrational, rotational, and other low-frequency modes in a system.</Description>
      <DisplayControls>
        <CreateTable>
          <FromInformationIn>ThisSection</FromInformationIn>
          <NumberOfColumns>2</NumberOfColumns>
          <ColumnContents>Name</ColumnContents>
          <ColumnContents>Value</ColumnContents>
        </CreateTable>
        <ShowAtMost>2</ShowAtMost>
      </DisplayControls>
      <Information>
        <ReferenceNumber>60</ReferenceNumber>
        <Name>Technique</Name>
        <Value>
          <StringWithMarkup>
            <String>FT-Raman</String>
          </StringWithMarkup>
        </Value>
      </Information>
      <Information>
        <ReferenceNumber>60</ReferenceNumber>
        <Name>Source of Spectrum</Name>
        <Value>
          <StringWithMarkup>
            <String>Forensic Spectral Research</String>
          </StringWithMarkup>
        </Value>
      </Information>
      <Information>
        <ReferenceNumber>60</ReferenceNumber>
        <Name>Source of Sample</Name>
        <Value>
          <StringWithMarkup>
            <String>Supelco, Sigma-Aldrich</String>
          </StringWithMarkup>
        </Value>
      </Information>
      <Information>
        <ReferenceNumber>60</ReferenceNumber>
        <Name>Catalog Number</Name>
        <Value>
          <StringWithMarkup>
            <String>47864</String>
          </StringWithMarkup>
        </Value>
      </Information>
      <Information>
        <ReferenceNumber>60</ReferenceNumber>
        <Name>Lot Number</Name>
        <Value>
          <StringWithMarkup>
            <String>LB60597</String>
          </StringWithMarkup>
        </Value>
      </Information>
      <Information>
        <ReferenceNumber>60</ReferenceNumber>
        <Name>Copyright</Name>
        <Value>
          <StringWithMarkup>
            <String>Copyright  2012-2018 Bio-Rad Laboratories, Inc.  All Rights Reserved.</String>
          </StringWithMarkup>
        </Value>
      </Information>
      <Information>
        <ReferenceNumber>60</ReferenceNumber>
        <Name>Thumbnail</Name>
        <URL>https://spectrabase.com/spectrum/CZoaeS2tVAc</URL>
        <Value>
          <ExternalDataURL>https://pubchem.ncbi.nlm.nih.gov/rest/pug_view/data/key/4975088_1</ExternalDataURL>
          <MimeType>image/png</MimeType>
        </Value>
      </Information>
    </Section>
    <Section>
      <TOCHeading>Other Spectra</TOCHeading>
      <Description>Other spectra include fluorescence, emission, etc.</Description>
      <Information>
        <ReferenceNumber>32</ReferenceNumber>
        <Description>**PEER REVIEWED**</Description>
        <Reference>Weast, R.C. (ed.). Handbook of Chemistry and Physics. 60th ed. Boca Raton, Florida: CRC Press Inc., 1979., p. C-474</Reference>
        <Value>
          <StringWithMarkup>
            <String>SADTLER REFERENCE NUMBER: 434 (IR, PRISM); 120 (IR, GRATING)</String>
          </StringWithMarkup>
        </Value>
      </Information>
    </Section>
  </Section>
  <Section>
    <TOCHeading>Related Records</TOCHeading>
    <Description>Related compounds/substances information based on the similar structure, annotations, etc.</Description>
    <Section>
      <TOCHeading>Related Compounds with Annotation</TOCHeading>
      <Description>The subset of compounds that are related to the one currently displayed AND that have biomedical annotations.</Description>
      <Information>
        <ReferenceNumber>77</ReferenceNumber>
        <Value>
          <Boolean>true</Boolean>
        </Value>
      </Information>
    </Section>
    <Section>
      <TOCHeading>Related Compounds</TOCHeading>
      <Description>Compound records closely associated to this record.</Description>
      <DisplayControls>
        <CreateTable>
          <FromInformationIn>ThisSection</FromInformationIn>
          <NumberOfColumns>2</NumberOfColumns>
          <ColumnContents>Name</ColumnContents>
          <ColumnContents>Value</ColumnContents>
        </CreateTable>
        <ShowAtMost>1</ShowAtMost>
      </DisplayControls>
      <Information>
        <ReferenceNumber>77</ReferenceNumber>
        <Name>Same Connectivity Count</Name>
        <URL>https://www.ncbi.nlm.nih.gov/pccompound?cmd=Link&amp;LinkName=pccompound_pccompound_sameconnectivity_pulldown&amp;from_uid=938</URL>
        <Value>
          <Number>14</Number>
        </Value>
      </Information>
      <Information>
        <ReferenceNumber>77</ReferenceNumber>
        <Name>Same Parent, Connectivity Count</Name>
        <URL>https://www.ncbi.nlm.nih.gov/pccompound?cmd=Link&amp;LinkName=pccompound_pccompound_parent_connectivity_pulldown&amp;from_uid=938</URL>
        <Value>
          <Number>160</Number>
        </Value>
      </Information>
      <Information>
        <ReferenceNumber>77</ReferenceNumber>
        <Name>Same Parent, Exact Count</Name>
        <URL>https://www.ncbi.nlm.nih.gov/pccompound?cmd=Link&amp;LinkName=pccompound_pccompound_parent_pulldown&amp;from_uid=938</URL>
        <Value>
          <Number>147</Number>
        </Value>
      </Information>
      <Information>
        <ReferenceNumber>77</ReferenceNumber>
        <Name>Mixtures, Components, and Neutralized Forms Count</Name>
        <URL>https://www.ncbi.nlm.nih.gov/pccompound?cmd=Link&amp;LinkName=pccompound_pccompound_mixture&amp;from_uid=938</URL>
        <Value>
          <Number>691</Number>
        </Value>
      </Information>
      <Information>
        <ReferenceNumber>77</ReferenceNumber>
        <Name>Similar Compounds Count</Name>
        <URL>https://www.ncbi.nlm.nih.gov/pccompound?cmd=Link&amp;LinkName=pccompound_pccompound&amp;from_uid=938</URL>
        <Value>
          <Number>1102</Number>
        </Value>
      </Information>
      <Information>
        <ReferenceNumber>77</ReferenceNumber>
        <Name>Similar Conformers Count</Name>
        <URL>https://www.ncbi.nlm.nih.gov/pccompound?cmd=Link&amp;LinkName=pccompound_pccompound_3d&amp;from_uid=938</URL>
        <Value>
          <Number>13345</Number>
        </Value>
      </Information>
    </Section>
    <Section>
      <TOCHeading>Substances</TOCHeading>
      <Description>Substance records linked to this compound.</Description>
      <Section>
        <TOCHeading>Related Substances</TOCHeading>
        <Description>Substances identical or nearly identical to this record.</Description>
        <URL>https://pubchemdocs.ncbi.nlm.nih.gov/substances</URL>
        <DisplayControls>
          <CreateTable>
            <FromInformationIn>ThisSection</FromInformationIn>
            <NumberOfColumns>2</NumberOfColumns>
            <ColumnContents>Name</ColumnContents>
            <ColumnContents>Value</ColumnContents>
          </CreateTable>
          <ShowAtMost>1</ShowAtMost>
        </DisplayControls>
        <Information>
          <ReferenceNumber>77</ReferenceNumber>
          <Name>All Count</Name>
          <URL>https://www.ncbi.nlm.nih.gov/pcsubstance/?term=938[CompoundID]</URL>
          <Value>
            <Number>2159</Number>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>77</ReferenceNumber>
          <Name>Same Count</Name>
          <URL>https://www.ncbi.nlm.nih.gov/pcsubstance/?term=938[StandardizedCID]</URL>
          <Value>
            <Number>388</Number>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>77</ReferenceNumber>
          <Name>Mixture Count</Name>
          <URL>https://www.ncbi.nlm.nih.gov/pcsubstance/?term=938[ComponentCID]</URL>
          <Value>
            <Number>1771</Number>
          </Value>
        </Information>
      </Section>
      <Section>
        <TOCHeading>Substances by Category</TOCHeading>
        <Description>Substance category according to the depositors. Substance Categorization Classification - The subheaders in this section of a PubChem Compound record reflect the various categories of depositors that have submitted corresponding PubChem Substance records. This allows you to quickly find the corresponding PubChem Substance records that are likely to contain a given type of information, such as Chemical Reactions.</Description>
        <URL>https://pubchemdocs.ncbi.nlm.nih.gov/substances</URL>
        <Information>
          <ReferenceNumber>77</ReferenceNumber>
          <Value>
            <StringWithMarkup>
              <String>Chemical Vendors</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Curation Efforts</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Governmental Organizations</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Journal Publishers</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Legacy Depositors</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>NIH Initiatives</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Research and Development</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Subscription Services</String>
            </StringWithMarkup>
          </Value>
        </Information>
      </Section>
    </Section>
    <Section>
      <TOCHeading>Entrez Crosslinks</TOCHeading>
      <Description>Cross-references to associated records in other Entrez databases such as PubMed, Gene, Protein, etc.</Description>
      <DisplayControls>
        <CreateTable>
          <FromInformationIn>ThisSection</FromInformationIn>
          <NumberOfColumns>2</NumberOfColumns>
          <ColumnContents>Name</ColumnContents>
          <ColumnContents>Value</ColumnContents>
        </CreateTable>
        <ShowAtMost>1</ShowAtMost>
      </DisplayControls>
      <Information>
        <ReferenceNumber>77</ReferenceNumber>
        <Name>PubMed Count</Name>
        <URL>https://www.ncbi.nlm.nih.gov/sites/entrez?LinkName=pccompound_pubmed&amp;db=pccompound&amp;cmd=Link&amp;from_uid=938</URL>
        <Value>
          <Number>3663</Number>
        </Value>
      </Information>
      <Information>
        <ReferenceNumber>77</ReferenceNumber>
        <Name>Protein Structures Count</Name>
        <URL>https://www.ncbi.nlm.nih.gov/sites/entrez?LinkName=pccompound_structure&amp;db=pccompound&amp;cmd=Link&amp;from_uid=938</URL>
        <Value>
          <Number>32</Number>
        </Value>
      </Information>
      <Information>
        <ReferenceNumber>77</ReferenceNumber>
        <Name>Taxonomy Count</Name>
        <URL>https://www.ncbi.nlm.nih.gov/sites/entrez?LinkName=pccompound_taxonomy&amp;db=pccompound&amp;cmd=Link&amp;from_uid=938</URL>
        <Value>
          <Number>6</Number>
        </Value>
      </Information>
      <Information>
        <ReferenceNumber>77</ReferenceNumber>
        <Name>OMIM Count</Name>
        <URL>https://www.ncbi.nlm.nih.gov/sites/entrez?LinkName=pccompound_omim&amp;db=pccompound&amp;cmd=Link&amp;from_uid=938</URL>
        <Value>
          <Number>32</Number>
        </Value>
      </Information>
      <Information>
        <ReferenceNumber>77</ReferenceNumber>
        <Name>Gene Count</Name>
        <URL>https://www.ncbi.nlm.nih.gov/sites/entrez?LinkName=pccompound_gene&amp;db=pccompound&amp;cmd=Link&amp;from_uid=938</URL>
        <Value>
          <Number>182</Number>
        </Value>
      </Information>
    </Section>
    <Section>
      <TOCHeading>NCBI LinkOut</TOCHeading>
      <Description>LinkOut is a service that allows one to link directly from NCBI databases to a wide range of information and services beyond NCBI systems.</Description>
      <URL>https://www.ncbi.nlm.nih.gov/projects/linkout</URL>
      <Information>
        <ReferenceNumber>100</ReferenceNumber>
        <Value>
          <Boolean>true</Boolean>
        </Value>
      </Information>
    </Section>
  </Section>
  <Section>
    <TOCHeading>Chemical Vendors</TOCHeading>
    <Description>A list of chemical vendors that sell this compound.  Each vendor may have multiple products containing the same chemical, but different in various aspects, such as amount and purity.  For each product, the external identifier used to locate the product on the vendor&apos;s website is provided under the Purcharsable Chemical column, and clicking this identifier directs you to the vendor&apos;s website.  The information on the product provided by the vendor to PubChem can be accessed at the Summary page of the corresponding PubChem Substance ID (SID).  Note that the order of chemical vendors on the list is randomized, and that PubChem do not endorse any of the vendors.</Description>
    <Information>
      <ReferenceNumber>77</ReferenceNumber>
      <Value>
        <Boolean>true</Boolean>
      </Value>
    </Information>
  </Section>
  <Section>
    <TOCHeading>Drug and Medication Information</TOCHeading>
    <Description>Drug and medication information from multiple sources.</Description>
    <Section>
      <TOCHeading>Drug Indication</TOCHeading>
      <Description>Drug Indication information from various sources.</Description>
      <DisplayControls>
        <ShowAtMost>3</ShowAtMost>
      </DisplayControls>
      <Information>
        <ReferenceNumber>17</ReferenceNumber>
        <Name>Drug Indication</Name>
        <Value>
          <StringWithMarkup>
            <String>For the treatment of type IV and V hyperlipidemia. It is indicated as ajunctive therapy.</String>
          </StringWithMarkup>
        </Value>
      </Information>
      <Information>
        <ReferenceNumber>17</ReferenceNumber>
        <Name>Drug Indication</Name>
        <URL>http://s3-us-west-2.amazonaws.com/drugbank/fda_labels/DB00627.pdf?1265922796</URL>
        <Value>
          <StringWithMarkup>
            <String>FDA Label</String>
          </StringWithMarkup>
        </Value>
      </Information>
      <Information>
        <ReferenceNumber>25</ReferenceNumber>
        <Name>Drug Indication</Name>
        <Value>
          <StringWithMarkup>
            <String>Hypercholesterolaemia</String>
          </StringWithMarkup>
        </Value>
      </Information>
      <Information>
        <ReferenceNumber>26</ReferenceNumber>
        <Name>Drug Indication</Name>
        <Value>
          <StringWithMarkup>
            <String>Hypercholesterolaemia</String>
          </StringWithMarkup>
        </Value>
      </Information>
      <Information>
        <ReferenceNumber>27</ReferenceNumber>
        <Name>Drug Indication</Name>
        <Value>
          <StringWithMarkup>
            <String>Hypercholesterolaemia</String>
          </StringWithMarkup>
        </Value>
      </Information>
    </Section>
    <Section>
      <TOCHeading>LiverTox Summary</TOCHeading>
      <Description>This section provides an overview of drug induced liver injury, diagnostic criteria, assessment of causality and severity, descriptions of different clinical patterns (phenotypes), information on management and treatment, and standardized nomenclature.  The role of liver biopsy and major histological patterns of drug induced liver disease are also given.</Description>
      <URL>https://livertox.nlm.nih.gov/aboutus.html</URL>
      <Information>
        <ReferenceNumber>35</ReferenceNumber>
        <Name>LiverTox Summary</Name>
        <Value>
          <StringWithMarkup>
            <String>Niacin, also known as nicotinic acid and vitamin B3, is a water soluble, essential B vitamin which, when given in high doses, is effective in lowering low density lipoprotein (LDL) cholesterol and raising high density lipoprotein (HDL) cholesterol, which makes this agent of unique value in the therapy of dyslipidemia. Niacin can cause mild-to-moderate serum aminotransferase elevations and high doses and certain formulations of niacin have been linked to clinically apparent, acute liver injury which can be severe as well as fatal.</String>
            <Markup>
              <Start>0</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/Niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>22</Start>
              <Length>14</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/nicotinic%20acid</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>41</Start>
              <Length>10</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/vitamin%20B3</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>58</Start>
              <Length>5</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/water</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-962</Extra>
            </Markup>
            <Markup>
              <Start>181</Start>
              <Length>11</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/cholesterol</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-5997</Extra>
            </Markup>
            <Markup>
              <Start>236</Start>
              <Length>11</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/cholesterol</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-5997</Extra>
            </Markup>
            <Markup>
              <Start>320</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/Niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>431</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
          </StringWithMarkup>
        </Value>
      </Information>
    </Section>
    <Section>
      <TOCHeading>Drug Classes</TOCHeading>
      <Description>Drug classes information from various sources.</Description>
      <Information>
        <ReferenceNumber>35</ReferenceNumber>
        <Name>Drug Classes</Name>
        <Value>
          <StringWithMarkup>
            <String>Antilipemic Agents; Vitamins</String>
          </StringWithMarkup>
        </Value>
      </Information>
    </Section>
    <Section>
      <TOCHeading>FDA Orange Book</TOCHeading>
      <Description>The Orange Book identifies drug products approved on the basis of safety and effectiveness by the Food and Drug Administration (FDA) under the Federal Food, Drug, and Cosmetic Act.</Description>
      <URL>https://www.fda.gov/Drugs/DevelopmentApprovalProcess/ucm079068.htm</URL>
      <Information>
        <ReferenceNumber>29</ReferenceNumber>
        <Name>FDA Orange Book</Name>
        <Value>
          <ExternalTableName>fdaorangebook</ExternalTableName>
          <ExternalTableNumRows>52</ExternalTableNumRows>
        </Value>
      </Information>
    </Section>
    <Section>
      <TOCHeading>Drug Labels for Ingredients</TOCHeading>
      <Description>This section contains the drug label information for given drug ingredients (compounds) from DailyMed.  DailyMed provides trustworthy information about marketed drugs in the United States. DailyMed is the official provider of FDA label information (package inserts).</Description>
      <URL>https://dailymed.nlm.nih.gov/dailymed/</URL>
      <DisplayControls>
        <CreateTable>
          <FromInformationIn>Subsections</FromInformationIn>
          <NumberOfColumns>2</NumberOfColumns>
          <ColumnContents>Name</ColumnContents>
          <ColumnContents>Value</ColumnContents>
        </CreateTable>
        <ShowAtMost>2</ShowAtMost>
      </DisplayControls>
      <Section>
        <TOCHeading>Label Title</TOCHeading>
        <Description>The drug title on the given label.</Description>
        <Information>
          <ReferenceNumber>6</ReferenceNumber>
          <Name>Label Information</Name>
          <URL>https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&amp;query=NIACIN</URL>
          <Value>
            <StringWithMarkup>
              <String>Total 146 labels</String>
            </StringWithMarkup>
          </Value>
        </Information>
      </Section>
      <Section>
        <TOCHeading>Label Ingredient</TOCHeading>
        <Description>The drug ingredient in the given label.</Description>
        <Information>
          <ReferenceNumber>6</ReferenceNumber>
          <Name>Drug Ingredient</Name>
          <Value>
            <StringWithMarkup>
              <String>NIACIN</String>
            </StringWithMarkup>
          </Value>
        </Information>
      </Section>
      <Section>
        <TOCHeading>NDC Code(s)</TOCHeading>
        <Description>The related NDC code(s) for the drug.</Description>
        <Information>
          <ReferenceNumber>6</ReferenceNumber>
          <Name>NDC Code(s)</Name>
          <Value>
            <StringWithMarkup>
              <String>0074-3074-03, 0074-3074-07, 0074-3074-30, 0074-3074-90, 0074-3079-30, 0074-3079-90, 0074-3080-30, 0074-3080-90, 0074-3265-90, 0074-3274-90 ... total 287.</String>
            </StringWithMarkup>
          </Value>
        </Information>
      </Section>
      <Section>
        <TOCHeading>Packager</TOCHeading>
        <Description>The manufacture company.</Description>
        <Information>
          <ReferenceNumber>6</ReferenceNumber>
          <Name>Packagers</Name>
          <Value>
            <StringWithMarkup>
              <String>7T Pharma LLC; A-S Medication Solutions; AMELLA PHARMA, LLC; AbbVie Inc.; American Health Packaging; Amneal Pharmaceuticals of New York, LLC; Artesa Labs, LLC; Aurobindo Pharma Limited; AvPAK; Avondale Pharmaceuticals, LLC ... total 76.</String>
            </StringWithMarkup>
          </Value>
        </Information>
      </Section>
    </Section>
    <Section>
      <TOCHeading>Clinical Trials</TOCHeading>
      <Description>Clinical trials are research studies performed in people that are aimed at evaluating a medical, surgical, or behavioral intervention. They are the primary way that researchers find out if a new treatment, like a new drug or diet or medical device (for example, a pacemaker) is safe and effective in people.</Description>
      <Section>
        <TOCHeading>ClinicalTrials.gov</TOCHeading>
        <Description>The brief clinical trials summary from the ClinicalTrials.gov at the U.S. National Library of Medicine.</Description>
        <URL>https://clinicaltrials.gov/</URL>
        <Information>
          <ReferenceNumber>5</ReferenceNumber>
          <Name>ClinicalTrials.gov</Name>
          <Value>
            <ExternalTableName>clinicaltrials</ExternalTableName>
            <ExternalTableNumRows>59</ExternalTableNumRows>
          </Value>
        </Information>
      </Section>
      <Section>
        <TOCHeading>EU Clinical Trials Register</TOCHeading>
        <Description>The clinical trials summary from the EU Clinical Trials Register.</Description>
        <URL>https://www.clinicaltrialsregister.eu/</URL>
        <Information>
          <ReferenceNumber>22</ReferenceNumber>
          <Name>EU Clinical Trials Register</Name>
          <Value>
            <ExternalTableName>clinicaltrials_eu</ExternalTableName>
            <ExternalTableNumRows>95</ExternalTableNumRows>
          </Value>
        </Information>
      </Section>
      <Section>
        <TOCHeading>NIPH Clinical Trials Search of Japan</TOCHeading>
        <Description>The brief clinical trials summary from the NIPH Clinical Trials Search of Japan.</Description>
        <URL>https://rctportal.niph.go.jp/en/</URL>
        <Information>
          <ReferenceNumber>42</ReferenceNumber>
          <Name>NIPH Clinical Trials Search of Japan</Name>
          <Value>
            <ExternalTableName>clinicaltrials_jp</ExternalTableName>
            <ExternalTableNumRows>1</ExternalTableNumRows>
          </Value>
        </Information>
      </Section>
    </Section>
    <Section>
      <TOCHeading>European Medicines Agency (EMA)</TOCHeading>
      <Description>Drug and medicines information from the European Medicines Agency (EMA)</Description>
      <URL>https://www.ema.europa.eu/en/medicines</URL>
      <DisplayControls>
        <CreateTable>
          <FromInformationIn>ThisSection</FromInformationIn>
          <NumberOfColumns>2</NumberOfColumns>
          <ColumnContents>Name</ColumnContents>
          <ColumnContents>Value</ColumnContents>
        </CreateTable>
        <ShowAtMost>2</ShowAtMost>
      </DisplayControls>
      <Information>
        <ReferenceNumber>25</ReferenceNumber>
        <Name>Active Substance</Name>
        <Value>
          <StringWithMarkup>
            <String>Nicotinic acid, simvastatin and laropiprant</String>
            <Markup>
              <Start>0</Start>
              <Length>14</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/Nicotinic%20acid</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>16</Start>
              <Length>11</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/simvastatin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-54454</Extra>
            </Markup>
            <Markup>
              <Start>32</Start>
              <Length>11</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/laropiprant</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-9867642</Extra>
            </Markup>
          </StringWithMarkup>
        </Value>
      </Information>
      <Information>
        <ReferenceNumber>25</ReferenceNumber>
        <Name>Category</Name>
        <Value>
          <StringWithMarkup>
            <String>Human, EU pediatric investigation plans</String>
          </StringWithMarkup>
        </Value>
      </Information>
      <Information>
        <ReferenceNumber>25</ReferenceNumber>
        <Name>Therapeutic Area</Name>
        <Value>
          <StringWithMarkup>
            <String>Endocrinology, -gynacology-fertility-metabolism</String>
          </StringWithMarkup>
        </Value>
      </Information>
      <Information>
        <ReferenceNumber>25</ReferenceNumber>
        <Name>Indication/Condition</Name>
        <Value>
          <StringWithMarkup>
            <String>Hypercholesterolaemia</String>
          </StringWithMarkup>
        </Value>
      </Information>
      <Information>
        <ReferenceNumber>25</ReferenceNumber>
        <Name>Decision Type</Name>
        <Value>
          <StringWithMarkup>
            <String>W: decision granting a waiver in all age groups for all conditions/indications</String>
          </StringWithMarkup>
        </Value>
      </Information>
      <Information>
        <ReferenceNumber>25</ReferenceNumber>
        <Name>Decision Date</Name>
        <Value>
          <StringWithMarkup>
            <String>2008-08-20</String>
          </StringWithMarkup>
        </Value>
      </Information>
      <Information>
        <ReferenceNumber>26</ReferenceNumber>
        <Name>Active Substance</Name>
        <Value>
          <StringWithMarkup>
            <String>Nicotinic acid, simvastatin and laropiprant</String>
            <Markup>
              <Start>0</Start>
              <Length>14</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/Nicotinic%20acid</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>16</Start>
              <Length>11</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/simvastatin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-54454</Extra>
            </Markup>
            <Markup>
              <Start>32</Start>
              <Length>11</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/laropiprant</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-9867642</Extra>
            </Markup>
          </StringWithMarkup>
        </Value>
      </Information>
      <Information>
        <ReferenceNumber>26</ReferenceNumber>
        <Name>Category</Name>
        <Value>
          <StringWithMarkup>
            <String>Human, EU pediatric investigation plans</String>
          </StringWithMarkup>
        </Value>
      </Information>
      <Information>
        <ReferenceNumber>26</ReferenceNumber>
        <Name>Therapeutic Area</Name>
        <Value>
          <StringWithMarkup>
            <String>Endocrinology, -gynacology-fertility-metabolism</String>
          </StringWithMarkup>
        </Value>
      </Information>
      <Information>
        <ReferenceNumber>26</ReferenceNumber>
        <Name>Indication/Condition</Name>
        <Value>
          <StringWithMarkup>
            <String>Hypercholesterolaemia</String>
          </StringWithMarkup>
        </Value>
      </Information>
      <Information>
        <ReferenceNumber>26</ReferenceNumber>
        <Name>Decision Type</Name>
        <Value>
          <StringWithMarkup>
            <String>W: decision granting a waiver in all age groups for all conditions/indications</String>
          </StringWithMarkup>
        </Value>
      </Information>
      <Information>
        <ReferenceNumber>26</ReferenceNumber>
        <Name>Decision Date</Name>
        <Value>
          <StringWithMarkup>
            <String>2008-08-20</String>
          </StringWithMarkup>
        </Value>
      </Information>
      <Information>
        <ReferenceNumber>27</ReferenceNumber>
        <Name>Active Substance</Name>
        <Value>
          <StringWithMarkup>
            <String>Nicotinic acid, simvastatin and laropiprant</String>
            <Markup>
              <Start>0</Start>
              <Length>14</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/Nicotinic%20acid</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>16</Start>
              <Length>11</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/simvastatin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-54454</Extra>
            </Markup>
            <Markup>
              <Start>32</Start>
              <Length>11</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/laropiprant</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-9867642</Extra>
            </Markup>
          </StringWithMarkup>
        </Value>
      </Information>
      <Information>
        <ReferenceNumber>27</ReferenceNumber>
        <Name>Category</Name>
        <Value>
          <StringWithMarkup>
            <String>Human, EU pediatric investigation plans</String>
          </StringWithMarkup>
        </Value>
      </Information>
      <Information>
        <ReferenceNumber>27</ReferenceNumber>
        <Name>Therapeutic Area</Name>
        <Value>
          <StringWithMarkup>
            <String>Endocrinology, -gynacology-fertility-metabolism</String>
          </StringWithMarkup>
        </Value>
      </Information>
      <Information>
        <ReferenceNumber>27</ReferenceNumber>
        <Name>Indication/Condition</Name>
        <Value>
          <StringWithMarkup>
            <String>Hypercholesterolaemia</String>
          </StringWithMarkup>
        </Value>
      </Information>
      <Information>
        <ReferenceNumber>27</ReferenceNumber>
        <Name>Decision Type</Name>
        <Value>
          <StringWithMarkup>
            <String>W: decision granting a waiver in all age groups for all conditions/indications</String>
          </StringWithMarkup>
        </Value>
      </Information>
      <Information>
        <ReferenceNumber>27</ReferenceNumber>
        <Name>Decision Date</Name>
        <Value>
          <StringWithMarkup>
            <String>2008-08-20</String>
          </StringWithMarkup>
        </Value>
      </Information>
    </Section>
    <Section>
      <TOCHeading>Therapeutic Uses</TOCHeading>
      <Description>Therapeutic Uses information from HSDB</Description>
      <Information>
        <ReferenceNumber>32</ReferenceNumber>
        <Description>**PEER REVIEWED**</Description>
        <Reference>National Library of Medicine&apos;s Medical Subject Headings. Citalopram. Online file (MeSH, 2018). Available from, as of February 2, 2018: https://meshb.nlm.nih.gov/search</Reference>
        <Value>
          <StringWithMarkup>
            <String>Hypolipidemic Agents, Vasodilator Agents, Vitamin B Complex</String>
          </StringWithMarkup>
        </Value>
      </Information>
      <Information>
        <ReferenceNumber>32</ReferenceNumber>
        <Description>**PEER REVIEWED**</Description>
        <Reference>NIH/NLM; ClinicalTrials.Gov. Available from, as of February 2, 2018: https://clinicaltrials.gov/</Reference>
        <Value>
          <StringWithMarkup>
            <String>/CLINICAL TRIALS/ ClinicalTrials.gov is a registry and results database of publicly and privately supported clinical studies of human participants conducted around the world. The Web site is maintained by the National Library of Medicine (NLM) and the National Institutes of Health (NIH). Each ClinicalTrials.gov record presents summary information about a study protocol and includes the following: Disease or condition; Intervention (for example, the medical product, behavior, or procedure being studied); Title, description, and design of the study; Requirements for participation (eligibility criteria); Locations where the study is being conducted; Contact information for the study locations; and Links to relevant information on other health Web sites, such as NLM&apos;s MedlinePlus for patient health information and PubMed for citations and abstracts for scholarly articles in the field of medicine. Niacin included in the database.</String>
            <Markup>
              <Start>906</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/Niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
          </StringWithMarkup>
        </Value>
      </Information>
      <Information>
        <ReferenceNumber>32</ReferenceNumber>
        <Description>**PEER REVIEWED**</Description>
        <Reference>American Society of Health-System Pharmacists 2017; Drug Information 2017. Bethesda, MD. 2017, p. 1936</Reference>
        <Value>
          <StringWithMarkup>
            <String>Niacin is used as an adjunct to dietary therapy in patients with a history of myocardial infarction (MI) and hypercholesterolemia to reduce the risk of recurrent nonfatal MI. Extended-release niacin in fixed combination with lovastatin is used in patients for whom treatment with both extended-release niacin and lovastatin is appropriate. /Included in US product label/</String>
            <Markup>
              <Start>0</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/Niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>192</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>225</Start>
              <Length>10</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/lovastatin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-53232</Extra>
            </Markup>
            <Markup>
              <Start>302</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>313</Start>
              <Length>10</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/lovastatin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-53232</Extra>
            </Markup>
          </StringWithMarkup>
        </Value>
      </Information>
      <Information>
        <ReferenceNumber>32</ReferenceNumber>
        <Description>**PEER REVIEWED**</Description>
        <Reference>American Society of Health-System Pharmacists 2017; Drug Information 2017. Bethesda, MD. 2017, p. 1936</Reference>
        <Value>
          <StringWithMarkup>
            <String>Niacin, in combination with a bile acid sequestrant, also is used to slow the progression or promote regression of atherosclerosis in patients with clinical evidence of coronary heart disease who have elevated cholesterol concentrations. Extended-release niacin in fixed combination with lovastatin is used in patients for whom treatment with both extended-release niacin and lovastatin is appropriate. /Included in US product label/</String>
            <Markup>
              <Start>0</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/Niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>210</Start>
              <Length>11</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/cholesterol</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-5997</Extra>
            </Markup>
            <Markup>
              <Start>255</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>288</Start>
              <Length>10</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/lovastatin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-53232</Extra>
            </Markup>
            <Markup>
              <Start>365</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>376</Start>
              <Length>10</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/lovastatin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-53232</Extra>
            </Markup>
          </StringWithMarkup>
        </Value>
      </Information>
      <Information>
        <ReferenceNumber>32</ReferenceNumber>
        <Description>**PEER REVIEWED**</Description>
        <Reference>American Society of Health-System Pharmacists 2017; Drug Information 2017. Bethesda, MD. 2017, p. 1936</Reference>
        <Value>
          <StringWithMarkup>
            <String>Niacin is used as an adjunct to dietary therapy to decrease elevated serum total and LDL-cholesterol, apo B, and triglyceride concentrations, and to increase HDL-cholesterol concentrations in the treatment of primary hypercholesterolemia and mixed dyslipidemia, including heterozygous familial hypercholesterolemia and other causes of hypercholesterolemia (e.g., polygenic hypercholesterolemia). Niacin, in combination with a bile acid sequestrant, is used as an adjunct to dietary therapy to decrease elevated serum total and LDL-cholesterol concentrations in patients with primary hypercholesterolemia in whom a regimen of diet with or without pharmacologic therapies has not resulted in normal serum cholesterol concentrations. Extended-release niacin in combination with lovastatin is used in the treatment of primary hypercholesterolemia (heterozygous familial and nonfamilial) and mixed dyslipidemia in adults receiving lovastatin who require further reductions in triglyceride or increases in HDL-cholesterol concentrations or in patients receiving niacin who require further reductions in LDL-cholesterol concentrations. When such combination therapy is appropriate, the fixed-combination preparation containing extended-release niacin and lovastatin may be used. /Included in US product label/</String>
            <Markup>
              <Start>0</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/Niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>89</Start>
              <Length>11</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/cholesterol</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-5997</Extra>
            </Markup>
            <Markup>
              <Start>162</Start>
              <Length>11</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/cholesterol</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-5997</Extra>
            </Markup>
            <Markup>
              <Start>396</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/Niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>531</Start>
              <Length>11</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/cholesterol</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-5997</Extra>
            </Markup>
            <Markup>
              <Start>703</Start>
              <Length>11</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/cholesterol</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-5997</Extra>
            </Markup>
            <Markup>
              <Start>748</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>775</Start>
              <Length>10</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/lovastatin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-53232</Extra>
            </Markup>
            <Markup>
              <Start>926</Start>
              <Length>10</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/lovastatin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-53232</Extra>
            </Markup>
            <Markup>
              <Start>1004</Start>
              <Length>11</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/cholesterol</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-5997</Extra>
            </Markup>
            <Markup>
              <Start>1056</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>1101</Start>
              <Length>11</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/cholesterol</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-5997</Extra>
            </Markup>
            <Markup>
              <Start>1237</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>1248</Start>
              <Length>10</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/lovastatin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-53232</Extra>
            </Markup>
          </StringWithMarkup>
        </Value>
      </Information>
      <Information>
        <ReferenceNumber>32</ReferenceNumber>
        <Description>**PEER REVIEWED**</Description>
        <Reference>American Society of Health-System Pharmacists 2017; Drug Information 2017. Bethesda, MD. 2017, p. 1937</Reference>
        <Value>
          <StringWithMarkup>
            <String>Niacin is used as adjunctive therapy in the management of severe hypertriglyceridemia in patients at risk of developing pancreatitis (typically those with serum triglyceride concentrations exceeding 2000 mg/dL and elevated concentrations of VLDL-cholesterol and fasting chylomicrons) who do not respond adequately to dietary management. The drug also may be used in patients with triglyceride concentrations of 1000-2000 mg/dL who have a history of pancreatitis or of recurrent abdominal pain typical of pancreatitis. /Included in US product label/</String>
            <Markup>
              <Start>0</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/Niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>246</Start>
              <Length>11</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/cholesterol</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-5997</Extra>
            </Markup>
          </StringWithMarkup>
        </Value>
      </Information>
      <Information>
        <ReferenceNumber>32</ReferenceNumber>
        <Description>**PEER REVIEWED**</Description>
        <Reference>American Society of Health-System Pharmacists 2017; Drug Information 2017. Bethesda, MD. 2017, p. 1937</Reference>
        <Value>
          <StringWithMarkup>
            <String>Niacin is recommended for use in high-risk patients with isolated low HDL-cholesterol concentrations in whom drug therapy is deemed appropriate. ... Niacin also is used as an adjunct to dietary therapy for the treatment of patients with primary dysbetalipoproteinemia who do not respond adequately to diet. /NOT included in US product label/</String>
            <Markup>
              <Start>0</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/Niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>74</Start>
              <Length>11</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/cholesterol</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-5997</Extra>
            </Markup>
            <Markup>
              <Start>149</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/Niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
          </StringWithMarkup>
        </Value>
      </Information>
      <Information>
        <ReferenceNumber>32</ReferenceNumber>
        <Description>**PEER REVIEWED**</Description>
        <Reference>American Society of Health-System Pharmacists 2017; Drug Information 2017. Bethesda, MD. 2017</Reference>
        <Value>
          <StringWithMarkup>
            <String>Niacin and niacinamide are used to prevent niacin deficiency and to treat pellagra. Some clinicians prefer niacinamide for the treatment of pellagra because it lacks vasodilating effects. Pellagra may result from dietary deficiency, isoniazid therapy, or from decreased conversion of tryptophan to niacin in Hartnup disease or carcinoid tumors.</String>
            <Markup>
              <Start>0</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/Niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>11</Start>
              <Length>11</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacinamide</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-936</Extra>
            </Markup>
            <Markup>
              <Start>43</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>107</Start>
              <Length>11</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacinamide</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-936</Extra>
            </Markup>
            <Markup>
              <Start>233</Start>
              <Length>9</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/isoniazid</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-3767</Extra>
            </Markup>
            <Markup>
              <Start>284</Start>
              <Length>10</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/tryptophan</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-6305</Extra>
            </Markup>
            <Markup>
              <Start>298</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
          </StringWithMarkup>
        </Value>
      </Information>
      <Information>
        <ReferenceNumber>32</ReferenceNumber>
        <Description>**PEER REVIEWED**</Description>
        <Reference>American Society of Health-System Pharmacists 2017; Drug Information 2017. Bethesda, MD. 2017</Reference>
        <Value>
          <StringWithMarkup>
            <String>/EXPL THER/ Although niacin and niacinamide have not been shown by well-controlled trials to have therapeutic value, the drugs have been used for the management of schizophrenic disorder, drug-induced hallucinations, chronic brain syndrome, hyperkinesis, unipolar depression, motion sickness, alcohol dependence, livedoid vasculitis, acne, and leprosy.</String>
            <Markup>
              <Start>21</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>32</Start>
              <Length>11</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacinamide</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-936</Extra>
            </Markup>
          </StringWithMarkup>
        </Value>
      </Information>
      <Information>
        <ReferenceNumber>32</ReferenceNumber>
        <Description>**PEER REVIEWED**</Description>
        <Reference>Bays HE et al; Vasc Health Risk Manag 11: 165-72 (2015)</Reference>
        <Value>
          <StringWithMarkup>
            <String>The degree of glycemic control in patients with type 2 diabetes mellitus (T2DM) may alter lipid levels and may alter the efficacy of lipid-modifying agents. /The study objective was to/ evaluate the lipid-modifying efficacy of extended-release niacin/laropiprant (ERN/LRPT) in subgroups of patients with T2DM with better or poorer glycemic control. /This was a/ post hoc analysis of clinical trial data from patients with T2DM who were randomized 4:3 to double-blind ERN/LRPT or placebo (n=796), examining the lipid-modifying effects of ERN/LRPT in patients with glycosylated hemoglobin or fasting plasma glucose levels above and below median baseline levels. At Week 12 of treatment, ERN/LRPT significantly improved low-density lipoprotein cholesterol, high-density lipoprotein cholesterol (HDL-C), non-high-density lipoprotein cholesterol, triglycerides, and lipoprotein (a), compared with placebo, with equal efficacy in patients above or below median baseline glycemic control. Compared with placebo, over 36 weeks of treatment more patients treated with ERN/LRPT had worsening of their diabetes and required intensification of antihyperglycemic medication, irrespective of baseline glycemic control. Incidences of other adverse experiences were generally low in all treatment groups. The lipid-modifying effects of ERN/LRPT are independent of the degree of baseline glycemic control in patients with T2DM. PubMed Abstract Full text: PMC4348131</String>
            <Markup>
              <Start>1411</Start>
              <Length>15</Length>
              <URL>http://www.ncbi.nlm.nih.gov/pubmed/25750540?dopt=Abstract</URL>
            </Markup>
            <Markup>
              <Start>1438</Start>
              <Length>10</Length>
              <URL>https://www.ncbi.nlm.nih.gov/pmc/?term=PMC4348131</URL>
            </Markup>
            <Markup>
              <Start>244</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>251</Start>
              <Length>11</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/laropiprant</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-9867642</Extra>
            </Markup>
            <Markup>
              <Start>605</Start>
              <Length>7</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/glucose</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-5793</Extra>
            </Markup>
            <Markup>
              <Start>741</Start>
              <Length>11</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/cholesterol</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-5997</Extra>
            </Markup>
            <Markup>
              <Start>779</Start>
              <Length>11</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/cholesterol</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-5997</Extra>
            </Markup>
            <Markup>
              <Start>829</Start>
              <Length>11</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/cholesterol</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-5997</Extra>
            </Markup>
          </StringWithMarkup>
        </Value>
      </Information>
      <Information>
        <ReferenceNumber>32</ReferenceNumber>
        <Description>**PEER REVIEWED**</Description>
        <Reference>Pearl RG, Raffin TA; Pharmacol 27 (4): 219-22 (1983)</Reference>
        <Value>
          <StringWithMarkup>
            <String>Niacin at concentrations of 0.1-10 mM resulted in a dose-dependent reduction of oxygen toxicity in a mouse alveolar macrophage model. These concentrations of niacin did not affect alveolar macrophage function under normoxic conditions. Our results are consistent with observations from other groups that niacin reduces oxygen toxicity in bacteria and paraquat toxicity in bacteria and rats. The mechanism by which niacin reduces oxygen toxicity may involve the ability of niacin to function as an alternate substrate for nicotinamide-adenine dinucleotide synthesis. Niacin may have clinical value in the prevention of oxygen toxicity.</String>
            <Markup>
              <Start>0</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/Niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>80</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/element/Oxygen</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>Element-Oxygen</Extra>
            </Markup>
            <Markup>
              <Start>158</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>304</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>319</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/element/Oxygen</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>Element-Oxygen</Extra>
            </Markup>
            <Markup>
              <Start>351</Start>
              <Length>8</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/paraquat</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-15939</Extra>
            </Markup>
            <Markup>
              <Start>414</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>429</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/element/Oxygen</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>Element-Oxygen</Extra>
            </Markup>
            <Markup>
              <Start>472</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>521</Start>
              <Length>33</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/nicotinamide-adenine%20dinucleotide</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-15938971</Extra>
            </Markup>
            <Markup>
              <Start>566</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/Niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>618</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/element/Oxygen</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>Element-Oxygen</Extra>
            </Markup>
          </StringWithMarkup>
        </Value>
      </Information>
      <Information>
        <ReferenceNumber>32</ReferenceNumber>
        <Description>**PEER REVIEWED**</Description>
        <Reference>Canner PL; J Am Coll Cardiol 8 (6): 1245-55 (1986)</Reference>
        <Value>
          <StringWithMarkup>
            <String>The Coronary Drug project was conducted between 1966 and 1975 to assess the long-term efficacy and safety of five lipid-influencing drugs in 8,341 men aged 30 to 64 years with electrocardiogram-documented previous myocardial infarction. The two estrogen regimens and dextrothyroxine were discontinued early because of adverse effects. No evidence of efficacy was found for the clofibrate treatment. Niacin treatment showed modest benefit in decreasing definite nonfatal recurrent myocardial infarction but did not decrease total mortality. With a mean follow-up of 15 years, nearly 9 years after termination of the trial, mortality from all causes in each of the drug groups, except for niacin, was similar to that in the placebo group. Mortality in the niacin group was 11% lower than in the placebo group (52.0 verus 58.2%; p= 0.0004). This late benefit of niacin, occurring after discontinuation of the drug, may be a result of a translation into a mortality benefit over subsequent years of the early favorable effect of niacin in decreasing nonfatal reinfarction or a result of the cholesterol-lowering effect of niacin, or both. PubMed Abstract</String>
            <Markup>
              <Start>1135</Start>
              <Length>15</Length>
              <URL>http://www.ncbi.nlm.nih.gov/pubmed/3782631?dopt=Abstract</URL>
            </Markup>
            <Markup>
              <Start>267</Start>
              <Length>15</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/dextrothyroxine</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-8730</Extra>
            </Markup>
            <Markup>
              <Start>377</Start>
              <Length>10</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/clofibrate</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-2796</Extra>
            </Markup>
            <Markup>
              <Start>399</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/Niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>687</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>754</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>859</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>1025</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>1087</Start>
              <Length>11</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/cholesterol</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-5997</Extra>
            </Markup>
            <Markup>
              <Start>1118</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
          </StringWithMarkup>
        </Value>
      </Information>
      <Information>
        <ReferenceNumber>32</ReferenceNumber>
        <Description>**PEER REVIEWED**</Description>
        <Reference>Inculet RI et al; J Parenter Enter Nutr 11 (May-Jun): 243-49 (1987)</Reference>
        <Value>
          <StringWithMarkup>
            <String>Forty-three cancer patients were maintained on oral diet with no parenteral vitamins, total parenteral nutrition with 5 mL MVI concentrate (multiple vitamins) or total parenteral nutrition with 10 mL vitamins and serum; red blood cell and urinary levels of water soluble vitamins were assessed weekly. The majority of patients in all groups had normal vitamin levels with no evidence of vitamin deficiency or toxicity. Thiamine, riboflavin, pyridoxine and niacin levels were less than the normal range in 4-40% of patients, although patients receiving 10 mL doses were partially improved. Niacin deficiency was most prevalent, occurring in 40% of patients. It was concluded that increased daily amounts of B-complex vitamins are warranted in cancer patients on total parenteral nutrition.</String>
            <Markup>
              <Start>257</Start>
              <Length>5</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/water</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-962</Extra>
            </Markup>
            <Markup>
              <Start>419</Start>
              <Length>8</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/Thiamine</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-1130</Extra>
            </Markup>
            <Markup>
              <Start>429</Start>
              <Length>10</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/riboflavin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-493570</Extra>
            </Markup>
            <Markup>
              <Start>441</Start>
              <Length>10</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/pyridoxine</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-1054</Extra>
            </Markup>
            <Markup>
              <Start>456</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>589</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/Niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
          </StringWithMarkup>
        </Value>
      </Information>
      <Information>
        <ReferenceNumber>32</ReferenceNumber>
        <Description>**PEER REVIEWED**</Description>
        <Reference>Illingworth DR et al; Lancet 1 (Feb 7): 296-97 (1981)</Reference>
        <Value>
          <StringWithMarkup>
            <String>Thirteen patients with heterozygous familial hypercholesterolemia were treated with: a low cholesterol, fat restricted diet; diet and colestipol hydrochloride (Colestid) 10 to 15 g daily; and diet, colestipol hydrochloride and nicotinic acid (niacin) 750 mg to 8 g/day orally. Concentrations of plasma cholesterol decreased from 415 +/- 69 mg/dL on diet alone; to 327 +/- 54 mg/dL on colestipol; and fell to 246 +/- mg/dL on the combined drug regimen. Plasma concentrations of low density lipoprotein cholesterol declined 24% on colestipol; the subsequent addition of nicotinic acid resulted in a further 31% fall so that value on the combined drug regimen were 47% below those seen on diet alone. High density lipoprotein cholesterol levels were similar on both the diet (40 mg/dL) and colestipol (43 mg/dL) treatment periods but increased to 53 mg/dL on the combined drug regimen. Treatment resulted in significant decreases in the low density lipoprotein:high density lipoprotein ratio which fell from 8.4 on diet to 3.3 on the colestipol plus nicotinic acid regimen. In most patients with heterozygous familial hypercholesterolemia combined use of colestipol hydrochloride and nicotinic acid affords the opportunity to maintain a normal lipid profile. Prolonged use of this regimen may reduce the incidence of premature coronary atherosclerosis which naturally occurs in these patients. PubMed Abstract</String>
            <Markup>
              <Start>1391</Start>
              <Length>15</Length>
              <URL>http://www.ncbi.nlm.nih.gov/pubmed/6109940?dopt=Abstract</URL>
            </Markup>
            <Markup>
              <Start>91</Start>
              <Length>11</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/cholesterol</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-5997</Extra>
            </Markup>
            <Markup>
              <Start>134</Start>
              <Length>24</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/colestipol%20hydrochloride</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-3084661</Extra>
            </Markup>
            <Markup>
              <Start>160</Start>
              <Length>8</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/Colestid</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-3084661</Extra>
            </Markup>
            <Markup>
              <Start>198</Start>
              <Length>24</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/colestipol%20hydrochloride</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-3084661</Extra>
            </Markup>
            <Markup>
              <Start>227</Start>
              <Length>14</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/nicotinic%20acid</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>243</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>302</Start>
              <Length>11</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/cholesterol</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-5997</Extra>
            </Markup>
            <Markup>
              <Start>384</Start>
              <Length>10</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/colestipol</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-62816</Extra>
            </Markup>
            <Markup>
              <Start>501</Start>
              <Length>11</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/cholesterol</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-5997</Extra>
            </Markup>
            <Markup>
              <Start>529</Start>
              <Length>10</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/colestipol</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-62816</Extra>
            </Markup>
            <Markup>
              <Start>568</Start>
              <Length>14</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/nicotinic%20acid</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>723</Start>
              <Length>11</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/cholesterol</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-5997</Extra>
            </Markup>
            <Markup>
              <Start>787</Start>
              <Length>10</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/colestipol</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-62816</Extra>
            </Markup>
            <Markup>
              <Start>1031</Start>
              <Length>10</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/colestipol</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-62816</Extra>
            </Markup>
            <Markup>
              <Start>1047</Start>
              <Length>14</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/nicotinic%20acid</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>1152</Start>
              <Length>24</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/colestipol%20hydrochloride</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-3084661</Extra>
            </Markup>
            <Markup>
              <Start>1181</Start>
              <Length>14</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/nicotinic%20acid</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
          </StringWithMarkup>
        </Value>
      </Information>
      <Information>
        <ReferenceNumber>32</ReferenceNumber>
        <Description>**PEER REVIEWED**</Description>
        <Reference>Wu BJ et al; Arterioscler Thromb Vasc Biol 30 (5): 968-75 (2010)</Reference>
        <Value>
          <StringWithMarkup>
            <String>/EXPL THER/ /The study objective was/ to determine if niacin can confer cardiovascular benefit by inhibiting vascular inflammation and improving endothelial function independent of changes in plasma lipid and lipoprotein levels. New Zealand white rabbits received normal chow or chow supplemented with 0.6% or 1.2% (wt/wt) niacin. This regimen had no effect on plasma cholesterol, triglyceride, or high-density lipoprotein levels. Acute vascular inflammation and endothelial dysfunction were induced in the animals with a periarterial carotid collar. At the 24-hour postcollar implantation, the endothelial expression of vascular cell adhesion molecule-1, intercellular adhesion molecule-1, and monocyte chemotactic protein-1 was markedly decreased in the niacin-supplemented animals compared with controls. Niacin also inhibited intima-media neutrophil recruitment and myeloperoxidase accumulation, enhanced endothelial-dependent vasorelaxation and cyclic guanosine monophosphate production, increased vascular reduced glutathione content, and protected against hypochlorous acid-induced endothelial dysfunction and tumor necrosis factor alpha-induced vascular inflammation. Previous human intervention studies have demonstrated that niacin inhibits coronary artery disease. This benefit is thought to be because of its ability to reduce low-density lipoprotein and plasma triglyceride levels and increase high-density lipoprotein levels. The present study showed that niacin inhibits vascular inflammation and protects against endothelial dysfunction independent of these changes in plasma lipid levels. PubMed Abstract</String>
            <Markup>
              <Start>1606</Start>
              <Length>15</Length>
              <URL>http://www.ncbi.nlm.nih.gov/pubmed/20167660?dopt=Abstract</URL>
            </Markup>
            <Markup>
              <Start>54</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>323</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>368</Start>
              <Length>11</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/cholesterol</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-5997</Extra>
            </Markup>
            <Markup>
              <Start>756</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>808</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/Niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>1063</Start>
              <Length>17</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/hypochlorous%20acid</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-24341</Extra>
            </Markup>
            <Markup>
              <Start>1235</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>1470</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
          </StringWithMarkup>
        </Value>
      </Information>
      <Information>
        <ReferenceNumber>32</ReferenceNumber>
        <Description>**PEER REVIEWED**</Description>
        <Reference>Kotsia AP et al; J Invasive Cardiol 27 (10): E204-10 (2015)</Reference>
        <Value>
          <StringWithMarkup>
            <String>/EXPL THER/ Intermediate saphenous vein graft (SVG) lesions have high rates of progression. The purpose of this study was to examine the impact of extended-release niacin (ER-niacin) vs placebo on intermediate SVG lesions. Patients with intermediate (30%-60% diameter stenosis) SVG lesions were randomized to ER-niacin vs placebo for 12 months. Quantitative coronary angiography (QCA), intravascular ultrasonography (IVUS), and optical coherence tomography (OCT) were performed at baseline and at 12 months. The primary endpoint was change in percent atheroma volume (deltaPAV). Enrollment was planned for 138 patients for 90% power to detect &gt;/=2.5% difference in the primary endpoint of deltaPAV, but stopped early after publication of two negative outcome trials of ER-niacin, with enrolled patients completing the 12-month trial protocol. Thirty-eight patients were randomized to niacin (n = 19) or placebo (n = 19), yielding power of 47% to detect the primary planned treatment effect of 2.5 +/- 4.0% difference in deltaPAV. Between baseline and 12-month follow-up, no significant difference was found between study groups in deltaPAV (-1.31 +/- 6.05% vs 1.05 +/- 17.8%; P=0.60). By OCT, the ER-niacin vs placebo group had less plaque rupture within the intermediate SVG lesion (0.0% vs 36.0%; P=0.01). Administration of ER-niacin did not significantly impact intermediate SVG disease, with the notable limitation of compromised statistical power due to early termination of enrollment. PubMed Abstract</String>
            <Markup>
              <Start>1492</Start>
              <Length>15</Length>
              <URL>http://www.ncbi.nlm.nih.gov/pubmed/26429851?dopt=Abstract</URL>
            </Markup>
            <Markup>
              <Start>164</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>175</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>312</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>772</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>884</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>1200</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>1329</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
          </StringWithMarkup>
        </Value>
      </Information>
      <Information>
        <ReferenceNumber>32</ReferenceNumber>
        <Description>**PEER REVIEWED**</Description>
        <Reference>Scoffone HM et al; Am J Cardiol 112 (9): 1499-504 (2013)</Reference>
        <Value>
          <StringWithMarkup>
            <String>/EXPL THER/ Through bound apolipoprotein A-I (apoA-I), high-density lipoprotein cholesterol (HDL-C) activates endothelial nitric oxide synthase, inducing vasodilation. Because patients with sickle cell disease (SCD) have low apoA-I and endothelial dysfunction, we conducted a randomized, double-blinded, placebo-controlled trial to test whether extended-release niacin (niacin-ER) increases apoA-I-containing HDL-C and improves vascular function in SCD. Twenty-seven patients with SCD with levels of HDL-C &lt;39 mg/dL or apoA-I &lt;99 mg/dL were randomized to 12 weeks of niacin-ER, increased in 500-mg increments to a maximum of 1,500 mg/day, or placebo. The primary outcome was the absolute change in HDL-C level after 12 weeks, with endothelial function assessed before and at the end of treatment. Niacin-ER-treated patients trended to greater increase in HDL-C level compared with placebo treatment at 12 weeks (5.1 +/- 7.7 vs 0.9 +/- 3.8 mg/dL, 1-tailed p = 0.07), associated with significantly greater improvements in the ratios of low-density lipoprotein to HDL-C levels (1.24 vs 1.95, p = 0.003) and apolipoprotein B to apoA-I levels (0.46 vs 0.58, p = 0.03) compared with placebo-treated patients. No improvements were detected in 3 independent vascular physiology assays of endothelial function. Thus, the relatively small changes in HDL-C levels achieved by the dose of niacin-ER used in our study are not associated with improved vascular function in patients with SCD with initially low levels of apoA-I or HDL-C. PubMed Abstract Full text: PMC4196719</String>
            <Markup>
              <Start>1523</Start>
              <Length>15</Length>
              <URL>http://www.ncbi.nlm.nih.gov/pubmed/24035168?dopt=Abstract</URL>
            </Markup>
            <Markup>
              <Start>1550</Start>
              <Length>10</Length>
              <URL>https://www.ncbi.nlm.nih.gov/pmc/?term=PMC4196719</URL>
            </Markup>
            <Markup>
              <Start>80</Start>
              <Length>11</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/cholesterol</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-5997</Extra>
            </Markup>
            <Markup>
              <Start>122</Start>
              <Length>12</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/nitric%20oxide</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-145068</Extra>
            </Markup>
            <Markup>
              <Start>362</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>370</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
          </StringWithMarkup>
        </Value>
      </Information>
      <Information>
        <ReferenceNumber>32</ReferenceNumber>
        <Description>**PEER REVIEWED**</Description>
        <Reference>Li Q et al; Alcohol Clin Exp Res 38 (7): 1982-92 (2014)</Reference>
        <Value>
          <StringWithMarkup>
            <String>/EXPL THER/ Alcohol abuse frequently causes niacin deficiency in association with the development of alcoholic liver disease. The objective of the present study was to determine whether dietary nicotinic acid (NA) deficiency exaggerates and whether dietary NA supplementation alleviates alcohol-induced fatty liver. Male Sprague-Dawley rats were pair-fed with 4 isocaloric liquid diets: control, ethanol (EtOH), EtOH with dietary NA deficiency, and EtOH with dietary NA supplementation, respectively, for 8 weeks. The control and EtOH diets contained normal levels of NA (7.5 mg/l). Dietary NA deficiency (0 mg NA/L) was achieved by removing NA from the vitamin mix, while NA was added to the liquid diet at 750 mg/L for dietary NA supplementation. Chronic EtOH feeding induced significant lipid accumulation in the liver, which was not worsened by dietary NA deficiency, but was ameliorated by dietary NA supplementation. Liver total NAD, NAD(+), and NADH levels were remarkably higher in the NA supplemented group than the NA deficient or EtOH alone groups. Dietary NA supplementation to EtOH-fed rats increased the protein levels of hepatic cytochrome P450 4A1 (CYP4A1) and acyl-coenzyme A oxidase 1 without affecting their mRNA levels. Interestingly, we found dietary NA supplementation reduced the ubiquitination level of CYP4A1. In addition, hepatic fatty acid synthase expression was reduced, while the serum beta-hydroxybutyrate and adiponectin concentrations were significantly elevated by dietary NA supplementation. Moreover, dietary NA supplementation modulated EtOH-perturbed liver and serum metabolite profiles. These results demonstrate that alcoholic fatty liver was not exaggerated by dietary NA deficiency, but was ameliorated by dietary NA supplementation. Increased hepatic fatty acid oxidation and decreased hepatic de novo lipogenesis contribute to the effects of dietary NA supplementation. PubMed Abstract Full text: PMC5742865</String>
            <Markup>
              <Start>1914</Start>
              <Length>15</Length>
              <URL>http://www.ncbi.nlm.nih.gov/pubmed/24848081?dopt=Abstract</URL>
            </Markup>
            <Markup>
              <Start>1941</Start>
              <Length>10</Length>
              <URL>https://www.ncbi.nlm.nih.gov/pmc/?term=PMC5742865</URL>
            </Markup>
            <Markup>
              <Start>44</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>194</Start>
              <Length>14</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/nicotinic%20acid</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>396</Start>
              <Length>7</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/ethanol</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-702</Extra>
            </Markup>
            <Markup>
              <Start>935</Start>
              <Length>3</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/NAD</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-5893</Extra>
            </Markup>
            <Markup>
              <Start>940</Start>
              <Length>3</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/NAD</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-5893</Extra>
            </Markup>
            <Markup>
              <Start>952</Start>
              <Length>4</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/NADH</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-439153</Extra>
            </Markup>
            <Markup>
              <Start>1416</Start>
              <Length>20</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/beta-hydroxybutyrate</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-3541112</Extra>
            </Markup>
          </StringWithMarkup>
        </Value>
      </Information>
      <Information>
        <ReferenceNumber>32</ReferenceNumber>
        <Description>**PEER REVIEWED**</Description>
        <Reference>Dou X et al; J Nutr Biochem 24 (8): 1520-8 (2013)</Reference>
        <Value>
          <StringWithMarkup>
            <String>/EXPL THER/ Oxidative stress plays a pathological role in the development of alcoholic liver disease. In this study, we investigated the effects of nicotinic acid (NA) supplementation on H2O2-induced cell death in hepatocytes and alcohol-induced liver injury in mice. Hepatocytes were exposed to H2O2 (0-0.4 mM) for 16 hr after a 2-hr pretreatment with NA (0-100 uM). Cell viability, intracellular glutathione and total NAD contents were determined. In animal experiments, male C57BL/6 mice were exposed to Lieber-De Carli liquid diet [+/- ethanol with/without NA supplementation (0.5%, w/v) for 4 weeks]. Nicotinic acid phosphoribosyltransferase (NaPRT) is the first enzyme participated in the NA metabolism, converting NA to nicotinic acid mononucleotide (NaMN). In NaPRT-expressing Hep3B cells, H2O2-induced cell death was attenuated by NA, whereas in NaPRT-lost HepG2 cells, only NaMN conferred protective effect, suggesting that NA metabolism is required for its protective action against H2O2. In Hep3B cells, NA supplementation prevented H2O2-induced declines in intracellular total NAD and GSH/GSSG ratios. Further mechanistic investigations revealed that conservation of Akt activity contributed to NA&apos;s protective effect against H2O2-induced cell death. In alcohol-fed mice, NA supplementation attenuated liver injury induced by chronic alcohol exposure, which was associated with alleviated hepatic lipid peroxidation and increased liver GSH concentrations. In conclusion, our findings indicate that exogenous NA supplementation may be an ideal choice for the treatment of liver diseases that involve oxidative stress. PubMed Abstract Full text: PMC3679291</String>
            <Markup>
              <Start>1630</Start>
              <Length>15</Length>
              <URL>http://www.ncbi.nlm.nih.gov/pubmed/23465591?dopt=Abstract</URL>
            </Markup>
            <Markup>
              <Start>1657</Start>
              <Length>10</Length>
              <URL>https://www.ncbi.nlm.nih.gov/pmc/?term=PMC3679291</URL>
            </Markup>
            <Markup>
              <Start>148</Start>
              <Length>14</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/nicotinic%20acid</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>398</Start>
              <Length>11</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/glutathione</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-124886</Extra>
            </Markup>
            <Markup>
              <Start>420</Start>
              <Length>3</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/NAD</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-5893</Extra>
            </Markup>
            <Markup>
              <Start>540</Start>
              <Length>7</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/ethanol</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-702</Extra>
            </Markup>
            <Markup>
              <Start>606</Start>
              <Length>14</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/Nicotinic%20acid</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>727</Start>
              <Length>29</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/nicotinic%20acid%20mononucleotide</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-5288991</Extra>
            </Markup>
            <Markup>
              <Start>758</Start>
              <Length>4</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/NaMN</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-5288991</Extra>
            </Markup>
            <Markup>
              <Start>884</Start>
              <Length>4</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/NaMN</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-5288991</Extra>
            </Markup>
            <Markup>
              <Start>1090</Start>
              <Length>3</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/NAD</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-5893</Extra>
            </Markup>
            <Markup>
              <Start>1098</Start>
              <Length>3</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/GSH</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-124886</Extra>
            </Markup>
            <Markup>
              <Start>1102</Start>
              <Length>4</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/GSSG</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-65359</Extra>
            </Markup>
            <Markup>
              <Start>1449</Start>
              <Length>3</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/GSH</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-124886</Extra>
            </Markup>
          </StringWithMarkup>
        </Value>
      </Information>
      <Information>
        <ReferenceNumber>32</ReferenceNumber>
        <Description>**PEER REVIEWED**</Description>
        <Reference>Zhang J et al; Neurobiol Dis 32 (2): 273-80 (2008)</Reference>
        <Value>
          <StringWithMarkup>
            <String>/EXPL THER/ We investigated the treatment of experimental autoimmune encephalomyelitis (EAE) in mice with Niaspan, an agent used to elevate high-density lipoprotein (HDL). EAE mice were treated with Niaspan starting on the immunization or clinical onset day. Neurological functional recovery was significantly increased in the Niaspan treated mice (100 mg/kg bw) compared to the controls. Inflammatory infiltrates were significantly reduced in the Niaspan treatment group compared to the EAE controls. HDL level, intact myelin area, newly formed oligodendrocytes, regenerating axons, gene and protein levels of sonic hedgehog (Shh)/Gli1 were significantly increased in the Niaspan treated mice compared to EAE controls. These data indicate that Niaspan treatment improved functional recovery after EAE, possibly, via reducing inflammatory infiltrates and demyelination areas, and stimulating oligodendrogenesis and axonal regeneration. Niaspan-mediated activation of Shh/Gli1 pathway may promote functional recovery post-EAE. PubMed Abstract Full text: PMC2593648</String>
            <Markup>
              <Start>1026</Start>
              <Length>15</Length>
              <URL>http://www.ncbi.nlm.nih.gov/pubmed/18778774?dopt=Abstract</URL>
            </Markup>
            <Markup>
              <Start>1053</Start>
              <Length>10</Length>
              <URL>https://www.ncbi.nlm.nih.gov/pmc/?term=PMC2593648</URL>
            </Markup>
            <Markup>
              <Start>106</Start>
              <Length>7</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/Niaspan</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>199</Start>
              <Length>7</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/Niaspan</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>327</Start>
              <Length>7</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/Niaspan</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>448</Start>
              <Length>7</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/Niaspan</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>673</Start>
              <Length>7</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/Niaspan</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>745</Start>
              <Length>7</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/Niaspan</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>936</Start>
              <Length>7</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/Niaspan</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
          </StringWithMarkup>
        </Value>
      </Information>
      <Information>
        <ReferenceNumber>32</ReferenceNumber>
        <Description>**PEER REVIEWED**</Description>
        <Reference>Kuhnast S et al; PLoS One 8 (6): e66467 (2013)</Reference>
        <Value>
          <StringWithMarkup>
            <String>/EXPL THER/ Niacin potently lowers triglycerides, mildly decreases LDL-cholesterol, and largely increases HDL-cholesterol. Despite evidence for an atheroprotective effect of niacin from previous small clinical studies, the large outcome trials, AIM-HIGH and HPS2-THRIVE did not reveal additional beneficial effects of niacin (alone or in combination with laropiprant) on top of statin treatment. We aimed to address this apparent discrepancy by investigating the effects of niacin without and with simvastatin on atherosclerosis development and determine the underlying mechanisms, in APOE*3Leiden.CETP mice, a model for familial dysbetalipoproteinemia (FD). Mice were fed a western-type diet containing cholesterol without or with niacin (120 mg/kg/day), simvastatin (36 mg/kg/day) or their combination for 18 weeks. Similarly as in FD patients, niacin reduced total cholesterol by -39% and triglycerides by -50%, (both P&lt;0.001). Simvastatin and the combination reduced total cholesterol (-30%; -55%, P&lt;0.001) where the combination revealed a greater reduction compared to simvastatin (-36%, P&lt;0.001). Niacin decreased total cholesterol and triglycerides primarily by increasing VLDL clearance. Niacin increased HDL-cholesterol (+28%, P&lt;0.01) and mildly increased reverse cholesterol transport. All treatments reduced monocyte adhesion to the endothelium (-46%; -47%, P&lt;0.01; -53%, P&lt;0.001), atherosclerotic lesion area (-78%; -49%, P&lt;0.01; -87%, P&lt;0.001) and severity. Compared to simvastatin, the combination increased plaque stability index [(SMC+collagen)/macrophages] (3-fold, P&lt;0.01). Niacin and the combination reduced T cells in the aortic root (-71%, P&lt;0.01; -81%, P&lt;0.001). Lesion area was strongly predicted by nonHDL-cholesterol (R(2)=0.69, P&lt;0.001) and to a much lesser extent by HDL-cholesterol (R(2)=0.20, P&lt;0.001). Niacin decreases atherosclerosis development mainly by reducing nonHDL-cholesterol with modest HDL-cholesterol-raising and additional anti-inflammatory effects. The additive effect of niacin on top of simvastatin is mostly dependent on its nonHDL-cholesterol-lowering capacities. These data suggest that clinical beneficial effects of niacin are largely dependent on its ability to lower LDL-cholesterol on top of concomitant lipid-lowering therapy. PubMed Abstract Full text: PMC3686722</String>
            <Markup>
              <Start>2282</Start>
              <Length>15</Length>
              <URL>http://www.ncbi.nlm.nih.gov/pubmed/23840481?dopt=Abstract</URL>
            </Markup>
            <Markup>
              <Start>2309</Start>
              <Length>10</Length>
              <URL>https://www.ncbi.nlm.nih.gov/pmc/?term=PMC3686722</URL>
            </Markup>
            <Markup>
              <Start>12</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/Niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>71</Start>
              <Length>11</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/cholesterol</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-5997</Extra>
            </Markup>
            <Markup>
              <Start>110</Start>
              <Length>11</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/cholesterol</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-5997</Extra>
            </Markup>
            <Markup>
              <Start>174</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>318</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>355</Start>
              <Length>11</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/laropiprant</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-9867642</Extra>
            </Markup>
            <Markup>
              <Start>474</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>498</Start>
              <Length>11</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/simvastatin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-54454</Extra>
            </Markup>
            <Markup>
              <Start>704</Start>
              <Length>11</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/cholesterol</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-5997</Extra>
            </Markup>
            <Markup>
              <Start>732</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>756</Start>
              <Length>11</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/simvastatin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-54454</Extra>
            </Markup>
            <Markup>
              <Start>847</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>868</Start>
              <Length>11</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/cholesterol</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-5997</Extra>
            </Markup>
          </StringWithMarkup>
        </Value>
      </Information>
      <Information>
        <ReferenceNumber>32</ReferenceNumber>
        <Description>**PEER REVIEWED**</Description>
        <Reference>Le NA et al; J Am Heart Assoc 2 (4): e000037 (2013)</Reference>
        <Value>
          <StringWithMarkup>
            <String>/EXPL THER/ Combination therapy with ezetimibe/simvastatin (E/S) and extended-release niacin (N) has been reported to be safe and efficacious in concomitantly reducing low-density lipoprotein cholesterol and increasing high-density lipoprotein cholesterol in hyperlipidemic patients at high risk for atherosclerotic cardiovascular events. This analysis evaluated the effect of E/S coadministered with N on low-density lipoprotein particle number (LDL-P) and high-density lipoprotein particle number (HDL-P) as assessed by nuclear magnetic resonance (NMR) spectroscopy in patients with type IIa or IIb hyperlipidemia. This was an analysis of a previously reported 24-week randomized, double-blind study in type IIa/IIb hyperlipidemic patients randomized to treatment with E/S (10/20 mg/day)+N (titrated to 2 g/day) or N (titrated to 2 g/day) or E/S (10/20 mg/day). Samples from a subset of patients (577 of 1220) were available for post hoc analysis of LDL-P and HDL-P by NMR spectroscopy. Increases in HDL-P (+16.2%) and decreases in LDL-P (-47.7%) were significantly greater with E/S+N compared with N (+9.8% for HDL-P and -21.5% for LDL-P) and E/S (+12.8% for HDL-P and -36.8% for LDL-P). In tertile analyses, those with the lowest baseline HDL-P had the greatest percent increase in HDL-P (N, 18.4/7.9/2.1; E/S, 19.3/12.2/5.3; and E/S+N, 26.9/13.8/6.9; all P&lt;0.001). Individuals in the highest tertile of LDL-P had the greatest percent reduction in LDL-P (N, 18.3/23.1/24.6; E/S, 29.7/38.3/41.8; and E/S+N, 44.3/49.0/50.5; all P&lt;0.001). These results suggest that E/S+N improves lipoprotein particle number, consistent with its lipid-modifying benefits in type IIa or IIb hyperlipidemia patients and may exert the greatest effect in those with high LDL-P and low HDL-P at baseline. PubMed Abstract Full text: PMC3828803</String>
            <Markup>
              <Start>1785</Start>
              <Length>15</Length>
              <URL>http://www.ncbi.nlm.nih.gov/pubmed/23926117?dopt=Abstract</URL>
            </Markup>
            <Markup>
              <Start>1812</Start>
              <Length>10</Length>
              <URL>https://www.ncbi.nlm.nih.gov/pmc/?term=PMC3828803</URL>
            </Markup>
            <Markup>
              <Start>37</Start>
              <Length>21</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/ezetimibe%2Fsimvastatin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-9832423</Extra>
            </Markup>
            <Markup>
              <Start>86</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>192</Start>
              <Length>11</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/cholesterol</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-5997</Extra>
            </Markup>
            <Markup>
              <Start>244</Start>
              <Length>11</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/cholesterol</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-5997</Extra>
            </Markup>
          </StringWithMarkup>
        </Value>
      </Information>
      <Information>
        <ReferenceNumber>32</ReferenceNumber>
        <Description>**PEER REVIEWED**</Description>
        <Reference>Weitberg AB; Mutat Res 216 (4): 197-201 (1989)</Reference>
        <Value>
          <StringWithMarkup>
            <String>/EXPL THER/ The ability of nicotinic acid to protect human lymphocytes in vivo against oxygen radical-induced DNA strand breakage was tested. NAD+ concentrations rose progressively in lymphocytes to nearly 5 times baseline levels in human volunteers ingesting nicotinic acid (100 mg/day) for 8 weeks. Strand breaks decreased proportionately to NAD+ concentrations over this time period in lymphocytes exposed to oxygen radicals. After 8 weeks of supplementation with nicotinic acid, radical-treated lymphocytes incubated for 24 hr evidenced significantly less DNA damage compared to controls. PubMed Abstract</String>
            <Markup>
              <Start>593</Start>
              <Length>15</Length>
              <URL>http://www.ncbi.nlm.nih.gov/pubmed/2761560?dopt=Abstract</URL>
            </Markup>
            <Markup>
              <Start>27</Start>
              <Length>14</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/nicotinic%20acid</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>87</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/element/Oxygen</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>Element-Oxygen</Extra>
            </Markup>
            <Markup>
              <Start>142</Start>
              <Length>4</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/NAD%2B</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-5893</Extra>
            </Markup>
            <Markup>
              <Start>260</Start>
              <Length>14</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/nicotinic%20acid</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>344</Start>
              <Length>4</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/NAD%2B</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-5893</Extra>
            </Markup>
            <Markup>
              <Start>412</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/element/Oxygen</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>Element-Oxygen</Extra>
            </Markup>
            <Markup>
              <Start>467</Start>
              <Length>14</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/nicotinic%20acid</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
          </StringWithMarkup>
        </Value>
      </Information>
      <Information>
        <ReferenceNumber>32</ReferenceNumber>
        <Description>**PEER REVIEWED**</Description>
        <Reference>Souza SA et al; Hawaii Med J 69 (5): 122-5 (2010)</Reference>
        <Value>
          <StringWithMarkup>
            <String>//EXPL THER/ /The study objective was/ to determine the safety and tolerability of extended release niacin (ERN) in HIV-infected patients. This was a pilot, open-label, 36 week study evaluating the safety and tolerability of ERN in HIV-infected patients with hypertriglyceridemia. Subjects with cardiovascular disease, diabetes or liver disease were excluded. Subjects with persistent elevation of triglyceride (TG) &gt; 200 after 8 weeks on American Heart Association Step One and Two Diets were started on ERN 500 mg once daily, with continuation of the diet and exercise recommendations until the end of the study. ERN was increased by 500 mg every 4 weeks, to a maximum of 1500 mg/day, depending on subject tolerability. Safety and tolerability of ERN were assessed. Ten subjects enrolled received ERN. Dose titration and maintenance to 1500 mg/day were achieved in all 10 subjects. No subject required dose adjustment. Mild flushing was experienced in 8 subjects. Asymptomatic hypophosphotemia was noted in 4 subjects; all resolved with oral phosphate supplementation. Median TG was reduced by 254 mg/dL (p &lt; 0.05). Non-significant changes were noted in liver enzymes, HDL, LDL, and total cholesterol. Fasting insulin and glucose levels did not change with treatment. In this pilot study ERN was well-tolerated and resulted in reduction of TG. Although the results of this study are promising, the study is limited in the small number of subjects. Further investigation is warranted. PubMed Abstract Full text: PMC3111654</String>
            <Markup>
              <Start>1486</Start>
              <Length>15</Length>
              <URL>http://www.ncbi.nlm.nih.gov/pubmed/20533755?dopt=Abstract</URL>
            </Markup>
            <Markup>
              <Start>1513</Start>
              <Length>10</Length>
              <URL>https://www.ncbi.nlm.nih.gov/pmc/?term=PMC3111654</URL>
            </Markup>
            <Markup>
              <Start>100</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>1044</Start>
              <Length>9</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/phosphate</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-1061</Extra>
            </Markup>
          </StringWithMarkup>
        </Value>
      </Information>
      <Information>
        <ReferenceNumber>32</ReferenceNumber>
        <Description>**PEER REVIEWED**</Description>
        <Reference>AIM-HIGH Investigators et al; N Engl J Med 365 (24): 2255-67 (2011)</Reference>
        <Value>
          <StringWithMarkup>
            <String>/EXPL THER/ In patients with established cardiovascular disease, residual cardiovascular risk persists despite the achievement of target low-density lipoprotein (LDL) cholesterol levels with statin therapy. It is unclear whether extended-release niacin added to simvastatin to raise low levels of high-density lipoprotein (HDL) cholesterol is superior to simvastatin alone in reducing such residual risk. We randomly assigned eligible patients to receive extended-release niacin, 1500 to 2000 mg per day, or matching placebo. All patients received simvastatin, 40 to 80 mg per day, plus ezetimibe, 10 mg per day, if needed, to maintain an LDL cholesterol level of 40 to 80 mg per deciliter (1.03 to 2.07 mmol per liter). The primary end point was the first event of the composite of death from coronary heart disease, nonfatal myocardial infarction, ischemic stroke, hospitalization for an acute coronary syndrome, or symptom-driven coronary or cerebral revascularization. A total of 3414 patients were randomly assigned to receive niacin (1718) or placebo (1696). The trial was stopped after a mean follow-up period of 3 years owing to a lack of efficacy. At 2 years, niacin therapy had significantly increased the median HDL cholesterol level from 35 mg per deciliter (0.91 mmol per liter) to 42 mg per deciliter (1.08 mmol per liter), lowered the triglyceride level from 164 mg per deciliter (1.85 mmol per liter) to 122 mg per deciliter (1.38 mmol per liter), and lowered the LDL cholesterol level from 74 mg per deciliter (1.91 mmol per liter) to 62 mg per deciliter (1.60 mmol per liter). The primary end point occurred in 282 patients in the niacin group (16.4%) and in 274 patients in the placebo group (16.2%) (hazard ratio, 1.02; 95% confidence interval, 0.87 to 1.21; P=0.79 by the log-rank test). Among patients with atherosclerotic cardiovascular disease and LDL cholesterol levels of less than 70 mg per deciliter (1.81 mmol per liter), there was no incremental clinical benefit from the addition of niacin to statin therapy during a 36-month follow-up period, despite significant improvements in HDL cholesterol and triglyceride levels. PubMed Abstract</String>
            <Markup>
              <Start>2152</Start>
              <Length>15</Length>
              <URL>http://www.ncbi.nlm.nih.gov/pubmed/22085343?dopt=Abstract</URL>
            </Markup>
            <Markup>
              <Start>167</Start>
              <Length>11</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/cholesterol</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-5997</Extra>
            </Markup>
            <Markup>
              <Start>246</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>262</Start>
              <Length>11</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/simvastatin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-54454</Extra>
            </Markup>
            <Markup>
              <Start>328</Start>
              <Length>11</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/cholesterol</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-5997</Extra>
            </Markup>
            <Markup>
              <Start>355</Start>
              <Length>11</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/simvastatin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-54454</Extra>
            </Markup>
            <Markup>
              <Start>472</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>548</Start>
              <Length>11</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/simvastatin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-54454</Extra>
            </Markup>
            <Markup>
              <Start>587</Start>
              <Length>9</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/ezetimibe</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-150311</Extra>
            </Markup>
            <Markup>
              <Start>643</Start>
              <Length>11</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/cholesterol</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-5997</Extra>
            </Markup>
            <Markup>
              <Start>1032</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>1169</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>1227</Start>
              <Length>11</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/cholesterol</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-5997</Extra>
            </Markup>
            <Markup>
              <Start>1484</Start>
              <Length>11</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/cholesterol</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-5997</Extra>
            </Markup>
            <Markup>
              <Start>1649</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>1876</Start>
              <Length>11</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/cholesterol</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-5997</Extra>
            </Markup>
            <Markup>
              <Start>2014</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>2115</Start>
              <Length>11</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/cholesterol</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-5997</Extra>
            </Markup>
          </StringWithMarkup>
        </Value>
      </Information>
      <Information>
        <ReferenceNumber>32</ReferenceNumber>
        <Description>**PEER REVIEWED**</Description>
        <Reference>McNamara MJ et al; Trials 16: 530 (2015)</Reference>
        <Value>
          <StringWithMarkup>
            <String>/EXPL THER/ Niacin induces the release of vasodilating prostaglandins, for which receptors are present within the pulmonary arterial circulation. We hypothesized that immediate-release niacin would reduce right ventricular systolic pressure in patients with pulmonary hypertension in a randomized, double-blinded, single-dose provocation study. We recruited inpatient subjects with a Doppler echocardiogram showing a peak tricuspid regurgitation (TR) jet velocity of 2.7 m/sec or greater, and who were free of known pulmonary vascular disease. Subjects were randomized in a 1:2:2 ratio to receive a single dose of either placebo, niacin 100 mg or niacin 500 mg, respectively. TR jet velocities were measured immediately before, and 1 hour post dose, corresponding to peak niacin absorption and prostaglandin release. The primary endpoint was the change in mean TR jet velocity measured over ten successive cardiac cycles. The baseline mean estimated right ventricular systolic pressure (RVSP) for all 49 subjects (25 male) was 51.9 +/- 12.1 mm Hg. The primary endpoint of mean change in TR jet velocity was 0.016 +/- 0.065 m/s in the placebo group, compared to -0.017 +/- 0.065 m/sec with niacin 100 mg, and -0.063 +/- 0.038 m/sec with niacin 500 mg (P=0.63). The change in maximum estimated RVSP across the three drug groups was 0.2 +/- 1.6 mm Hg, -1.3 +/- 1.8 mm Hg and -2.2 +/- 1.2 mm Hg (P=0.62). In exploratory pairwise analysis in the high-dose niacin group (500 mg), the reduction in mean RVSP was from 50.9 +/- 9.4 mm Hg to 48.7 +/- 10.0 mm Hg (P=0.09). A single dose of immediate-release niacin (100 mg or 500 mg) had no significant effect on RVSP 1 hour post administration. A nonsignificant dose-dependent trend for a modest reduction in RVSP, most notable in the 500 mg group, was noted. PubMed Abstract Full text: PMC4654874</String>
            <Markup>
              <Start>1800</Start>
              <Length>15</Length>
              <URL>http://www.ncbi.nlm.nih.gov/pubmed/26590128?dopt=Abstract</URL>
            </Markup>
            <Markup>
              <Start>1827</Start>
              <Length>10</Length>
              <URL>https://www.ncbi.nlm.nih.gov/pmc/?term=PMC4654874</URL>
            </Markup>
            <Markup>
              <Start>12</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/Niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>185</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>630</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>647</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>772</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>1189</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>1236</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>1451</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>1597</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
          </StringWithMarkup>
        </Value>
      </Information>
      <Information>
        <ReferenceNumber>32</ReferenceNumber>
        <Description>**PEER REVIEWED**</Description>
        <Reference>Gehring W; J Cosmet Dermatol 3 (2): 88-93 (2004)</Reference>
        <Value>
          <StringWithMarkup>
            <String>Nicotinic acid (also generally known as niacin) and niacinamide (also known as nicotinamide) are similarly effective as a vitamin because they can be converted into each other within the organism. The blanket term vitamin B(3) is used for both. Niacinamide is a component of important coenzymes involved in hydrogen transfer. Here, the two codehydrogenases, nicotinamide adenine dinucleotide (NAD) and nicotinamide adenine dinucleotide phosphate (NADP) are of central importance. Topical application of niacinamide has a stabilizing effect on epidermal barrier function, seen as a reduction in transepidermal water loss and an improvement in the moisture content of the horny layer. Niacinamide leads to an increase in protein synthesis (e.g. keratin), has a stimulating effect on ceramide synthesis, speeds up the differentiation of keratinocytes, and raises intracellular NADP levels. In aging skin, topical application of niacinamide improves the surface structure, smoothes out wrinkles and inhibits photocarcinogenesis. It is possible to demonstrate anti-inflammatory effects in acne, rosacea and nitrogen mustard-induced irritation. Because of its verifiable beneficial effects, niacinamide would be a suitable component in cosmetic products for use in disorders of epidermal barrier function, for aging skin, for improving pigmentary disorders and for use on skin prone to acne. PubMed Abstract</String>
            <Markup>
              <Start>1386</Start>
              <Length>15</Length>
              <URL>http://www.ncbi.nlm.nih.gov/pubmed/17147561?dopt=Abstract</URL>
            </Markup>
            <Markup>
              <Start>0</Start>
              <Length>14</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/Nicotinic%20acid</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>40</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>52</Start>
              <Length>11</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacinamide</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-936</Extra>
            </Markup>
            <Markup>
              <Start>79</Start>
              <Length>12</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/nicotinamide</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-936</Extra>
            </Markup>
            <Markup>
              <Start>245</Start>
              <Length>11</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/Niacinamide</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-936</Extra>
            </Markup>
            <Markup>
              <Start>307</Start>
              <Length>8</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/element/Hydrogen</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>Element-Hydrogen</Extra>
            </Markup>
            <Markup>
              <Start>358</Start>
              <Length>33</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/nicotinamide%20adenine%20dinucleotide</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-15938971</Extra>
            </Markup>
            <Markup>
              <Start>393</Start>
              <Length>3</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/NAD</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-5893</Extra>
            </Markup>
            <Markup>
              <Start>402</Start>
              <Length>43</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/nicotinamide%20adenine%20dinucleotide%20phosphate</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-42609791</Extra>
            </Markup>
            <Markup>
              <Start>447</Start>
              <Length>4</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/NADP</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-2734411</Extra>
            </Markup>
            <Markup>
              <Start>503</Start>
              <Length>11</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacinamide</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-936</Extra>
            </Markup>
            <Markup>
              <Start>609</Start>
              <Length>5</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/water</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-962</Extra>
            </Markup>
            <Markup>
              <Start>874</Start>
              <Length>4</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/NADP</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-2734411</Extra>
            </Markup>
            <Markup>
              <Start>925</Start>
              <Length>11</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacinamide</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-936</Extra>
            </Markup>
            <Markup>
              <Start>1185</Start>
              <Length>11</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacinamide</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-936</Extra>
            </Markup>
          </StringWithMarkup>
        </Value>
      </Information>
      <Information>
        <ReferenceNumber>32</ReferenceNumber>
        <Description>**PEER REVIEWED**</Description>
        <Reference>Sampathkumar K et al; Int Urol Nephrol 38 (1): 171-4 (2006)</Reference>
        <Value>
          <StringWithMarkup>
            <String>/EXPL THER/ ... A prospective study /examined whether nicotinic acid/ reduces serum phosphorus levels in hemodialysis patients. METHODS: Patients who were on maintenance hemodialysis were enrolled in to the study if their predialysis serum phosphorus was more than 6 mg/dL. During the pre-trial run in period of 1 week all phosphate binders were stopped. A single dose of extended release nicotinic acid (375 mg) tablet was given with meal. Repeat measurements of serum calcium, phosphorus and alkaline phosphatase were carried out after 8 weeks. Then the drug was stopped in a subgroup of patients and serum phosphorus remeasured after 2 weeks. There were 34 patients with varied etiological spectrum of end stage renal disease. They were on hemodialysis for a mean period of 8.7 months. Serum phosphorus levels changed significantly from a pre treatment level of 7.7 +/- 1.5 mg/dL to post treatment level of 5.6 +/- 1 mg/dL (p &lt; 0.001). There was no significant variance across age groups, sex, disease categories and dialysis duration. The calcium level increased from 8.1 +/- 1.0 to 8.5 +/- 1.0 mg/dL (p &lt; 0.015). The serum alkaline phosphatase level decreased significantly from 107 +/- 66 IU/L to 82 +/- 46 IU/L (p &lt; 0.001 ). There was a significant reduction of calcium phosphate product from 63.1 + 15.1 sq mg to 48.7 +/- 10.9 sq mg2/sq dL (p &lt; 0.001). Oral nicotinic acid was well tolerated. Mild pruritus was encountered in 2 patients. Oral nicotinic acid may emerge as a safe, low cost yet powerful agent for phosphorus control in dialysis patients. PubMed Abstract</String>
            <Markup>
              <Start>1561</Start>
              <Length>15</Length>
              <URL>http://www.ncbi.nlm.nih.gov/pubmed/16502077?dopt=Abstract</URL>
            </Markup>
            <Markup>
              <Start>54</Start>
              <Length>14</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/nicotinic%20acid</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>84</Start>
              <Length>10</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/element/Phosphorus</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>Element-Phosphorus</Extra>
            </Markup>
            <Markup>
              <Start>240</Start>
              <Length>10</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/element/Phosphorus</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>Element-Phosphorus</Extra>
            </Markup>
            <Markup>
              <Start>323</Start>
              <Length>9</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/phosphate</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-1061</Extra>
            </Markup>
            <Markup>
              <Start>389</Start>
              <Length>14</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/nicotinic%20acid</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>470</Start>
              <Length>7</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/element/Calcium</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>Element-Calcium</Extra>
            </Markup>
            <Markup>
              <Start>479</Start>
              <Length>10</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/element/Phosphorus</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>Element-Phosphorus</Extra>
            </Markup>
            <Markup>
              <Start>609</Start>
              <Length>10</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/element/Phosphorus</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>Element-Phosphorus</Extra>
            </Markup>
            <Markup>
              <Start>795</Start>
              <Length>10</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/element/Phosphorus</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>Element-Phosphorus</Extra>
            </Markup>
          </StringWithMarkup>
        </Value>
      </Information>
      <Information>
        <ReferenceNumber>32</ReferenceNumber>
        <Description>**PEER REVIEWED**</Description>
        <Reference>Aschemann M et al; Arch Anim Nutr 66 (4): 303-18 (2012)</Reference>
        <Value>
          <StringWithMarkup>
            <String>/EXPL THER/ /VET/ The aim of the present experiment was to ascertain if a daily niacin supplementation of 6 g/cow to lactating dairy cow diets can compensate for the decrease in rumen microbial fermentation due to a negative rumen nitrogen balance (RNB). A total of nine ruminally and duodenally fistulated lactating multiparous German Holstein cows was used. The diets consisted of 10 kg dry matter (DM) maize silage and 7 kg DM concentrate and differed as follows: (i) Diet RNB- (n = 6) with energy and utilizable crude protein (CP) at the duodenum (uCP) according to the average requirement of the animals, but with a negative RNB (-0.41 g N/MJ metabolizable energy [ME]); (ii) Diet RNB0 (n = 7) with energy, uCP, and RNB (0.08 g N/MJ ME) according to the average requirement of the animals; and (iii) Diet NA (nicotinic acid; n = 5), which was the same diet as RNB-, but supplemented with 6 g niacin/d. The negative RNB affected the rumen fermentation pattern and reduced ammonia content in rumen fluid and the daily duodenal flows of microbial CP (MP) and uCP. Niacin supplementation increased the apparent ruminal digestibility of neutral detergent fiber. The efficiency of microbial protein synthesis per unit of rumen degradable CP was higher, whereby the amount of MP reaching the duodenum was unaffected by niacin supplementation. The number of protozoa in rumen fluid was higher in NA treatment. The results indicated a more efficient use of rumen degradable N due to changes in the microbial population in the rumen when niacin was supplemented to diets deficient in RNB for lactating dairy cows. PubMed Abstract</String>
            <Markup>
              <Start>1609</Start>
              <Length>15</Length>
              <URL>http://www.ncbi.nlm.nih.gov/pubmed/22924176?dopt=Abstract</URL>
            </Markup>
            <Markup>
              <Start>80</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>231</Start>
              <Length>8</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/element/Nitrogen</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>Element-Nitrogen</Extra>
            </Markup>
            <Markup>
              <Start>814</Start>
              <Length>14</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/nicotinic%20acid</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>897</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>1066</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/Niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>1317</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>1533</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
          </StringWithMarkup>
        </Value>
      </Information>
      <Information>
        <ReferenceNumber>32</ReferenceNumber>
        <Description>**PEER REVIEWED**</Description>
        <Reference>O&apos;Neil, M.J. (ed.). The Merck Index - An Encyclopedia of Chemicals, Drugs, and Biologicals. Cambridge, UK:  Royal Society of Chemistry, 2013., p. 1215</Reference>
        <Value>
          <StringWithMarkup>
            <String>VET: Vitamin (enzyme cofactor)</String>
          </StringWithMarkup>
        </Value>
      </Information>
      <Information>
        <ReferenceNumber>32</ReferenceNumber>
        <Description>**PEER REVIEWED**</Description>
        <Reference>Muller LD et al; J Dairy Sci 69 (5): 1416-20 (1986)</Reference>
        <Value>
          <StringWithMarkup>
            <String>VET: Five herds with 240 cows were used to determine the response to feeding 6 g/d of supplemental niacin during the summer months. Diets consisted of corn silage, hay crop silage, hay, or pasture as the forage and concentrate. Cows in each herd were paired by lactation number and stage of lactation and randomly assigned to either a control or niacin group and fed niacin once daily for 84 d (July 3 to September 25). Cows averaged 143 d postpartum with a total of 121 and 119 cows on control and niacin groups. Using milk weight and composition prior to initiating the trial as a covariate, least squares means for all cows for control and niacin were milk, 24.5, 25.4 kg/d; milk fat, 3.72, 3.70%; milk fat, .91, .94 kg/d; milk protein, 3.35, 3.34%; and fat-corrected milk, 23.5, 24.3, kg/d. Yields of milk and fat-corrected milk were significantly higher for niacin-supplemented cows. Cows in first lactation and second lactation and greater had a similar response to niacin. Cows producing greater than 34 kg milk produced 2.4 kg more milk with supplemental niacin. Results indicate that feeding 6 g/d supplemental niacin during the summer increased yield of milk and fat-corrected milk but had no effect on milk composition. PubMed Abstract</String>
            <Markup>
              <Start>1231</Start>
              <Length>15</Length>
              <URL>http://www.ncbi.nlm.nih.gov/pubmed/3722550?dopt=Abstract</URL>
            </Markup>
            <Markup>
              <Start>99</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>346</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>367</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>499</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>643</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>863</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>972</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>1063</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>1120</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
          </StringWithMarkup>
        </Value>
      </Information>
    </Section>
    <Section>
      <TOCHeading>Drug Warnings</TOCHeading>
      <Description>Drug Warning information from HSDB</Description>
      <Information>
        <ReferenceNumber>32</ReferenceNumber>
        <Description>**PEER REVIEWED**</Description>
        <Reference>American Society of Health-System Pharmacists 2017; Drug Information 2017. Bethesda, MD. 2017, p. 1937</Reference>
        <Value>
          <StringWithMarkup>
            <String>Concomitant administration of niacin with alcohol, hot drinks, or spicy foods may increase the risk of flushing or pruritus; these beverages or foods should be avoided at the time of drug ingestion.</String>
            <Markup>
              <Start>30</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
          </StringWithMarkup>
        </Value>
      </Information>
      <Information>
        <ReferenceNumber>32</ReferenceNumber>
        <Description>**PEER REVIEWED**</Description>
        <Reference>American Society of Health-System Pharmacists 2017; Drug Information 2017. Bethesda, MD. 2017, p. 1939</Reference>
        <Value>
          <StringWithMarkup>
            <String>Decreased glucose tolerance has been reported in patients receiving niacin in controlled clinical trials. Therefore, the manufacturers and many clinicians suggest that patients with (or those at risk of developing) diabetes mellitus be observed closely. The ACC/AHA cholesterol management guideline recommends that fasting blood glucose concentrations or glycosylated hemoglobin (hemoglobin A1c, HbA1c) be obtained before initiation of therapy, following an increase in niacin dosage, and periodically (e.g., every 6 months) thereafter. If niacin is used in diabetic or potentially diabetic patients, dosages of niacin and/or antidiabetic agents should be adjusted appropriately. Niacin should be discontinued if hyperglycemia persists.</String>
            <Markup>
              <Start>10</Start>
              <Length>7</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/glucose</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-5793</Extra>
            </Markup>
            <Markup>
              <Start>68</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>266</Start>
              <Length>11</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/cholesterol</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-5997</Extra>
            </Markup>
            <Markup>
              <Start>329</Start>
              <Length>7</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/glucose</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-5793</Extra>
            </Markup>
            <Markup>
              <Start>470</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>540</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>612</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>680</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/Niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
          </StringWithMarkup>
        </Value>
      </Information>
      <Information>
        <ReferenceNumber>32</ReferenceNumber>
        <Description>**PEER REVIEWED**</Description>
        <Reference>American Society of Health-System Pharmacists 2017; Drug Information 2017. Bethesda, MD. 2017, p. 1939</Reference>
        <Value>
          <StringWithMarkup>
            <String>Niacin should be used with caution in patients with unstable angina, acute myocardial infarction (MI), or coronary heart disease (CHD), particularly when these patients also are receiving vasoactive drugs such as nitrates, calcium-channel blockers, or adrenergic blocking agents. Since niacin therapy has been associated with small, but statistically significant, increases in prothrombin time (PT), the drug, alone or in fixed combination with lovastatin, should be used with caution in patients undergoing surgery. PT and platelet count should be monitored closely in patients receiving niacin concomitantly with anticoagulants.</String>
            <Markup>
              <Start>0</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/Niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>223</Start>
              <Length>7</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/element/Calcium</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>Element-Calcium</Extra>
            </Markup>
            <Markup>
              <Start>286</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>445</Start>
              <Length>10</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/lovastatin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-53232</Extra>
            </Markup>
            <Markup>
              <Start>589</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
          </StringWithMarkup>
        </Value>
      </Information>
      <Information>
        <ReferenceNumber>32</ReferenceNumber>
        <Description>**PEER REVIEWED**</Description>
        <Reference>American Society of Health-System Pharmacists 2017; Drug Information 2017. Bethesda, MD. 2017, p. 1939</Reference>
        <Value>
          <StringWithMarkup>
            <String>Because hyperuricemia has been reported with niacin therapy, the drug should be used with caution in patients predisposed to gout. The ACC/AHA cholesterol management guideline recommends that uric acid concentrations be obtained before initiation of therapy, following an increase in niacin dosage, and periodically (e.g., every 6 months) thereafter. Niacin should be discontinued if acute gout occurs.</String>
            <Markup>
              <Start>45</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>143</Start>
              <Length>11</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/cholesterol</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-5997</Extra>
            </Markup>
            <Markup>
              <Start>192</Start>
              <Length>9</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/uric%20acid</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-1175</Extra>
            </Markup>
            <Markup>
              <Start>284</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>351</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/Niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
          </StringWithMarkup>
        </Value>
      </Information>
      <Information>
        <ReferenceNumber>32</ReferenceNumber>
        <Description>**PEER REVIEWED**</Description>
        <Reference>American Society of Health-System Pharmacists 2017; Drug Information 2017. Bethesda, MD. 2017, p. 1939</Reference>
        <Value>
          <StringWithMarkup>
            <String>Use of niacin has been associated with reductions in phosphorus concentrations; therefore, phosphorus concentrations should be monitored periodically in patients at risk for developing hypophosphatemia.</String>
            <Markup>
              <Start>7</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>53</Start>
              <Length>10</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/element/Phosphorus</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>Element-Phosphorus</Extra>
            </Markup>
            <Markup>
              <Start>91</Start>
              <Length>10</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/element/Phosphorus</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>Element-Phosphorus</Extra>
            </Markup>
          </StringWithMarkup>
        </Value>
      </Information>
      <Information>
        <ReferenceNumber>32</ReferenceNumber>
        <Description>**PEER REVIEWED**</Description>
        <Reference>American Society of Health-System Pharmacists 2017; Drug Information 2017. Bethesda, MD. 2017, p. 1939</Reference>
        <Value>
          <StringWithMarkup>
            <String>Since data in patients with renal or hepatic impairment currently are lacking, the manufacturers state that niacin should be used with caution in these patients.</String>
            <Markup>
              <Start>108</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
          </StringWithMarkup>
        </Value>
      </Information>
      <Information>
        <ReferenceNumber>32</ReferenceNumber>
        <Description>**PEER REVIEWED**</Description>
        <Reference>American Society of Health-System Pharmacists 2017; Drug Information 2017. Bethesda, MD. 2017, p. 1939</Reference>
        <Value>
          <StringWithMarkup>
            <String>Niacin is contraindicated in patients with hypersensitivity to any component of the drug formulations. The drug also is contraindicated in patients with active liver disease or unexplained persistent elevations of serum transaminases, active peptic ulcer disease, or arterial bleeding.</String>
            <Markup>
              <Start>0</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/Niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
          </StringWithMarkup>
        </Value>
      </Information>
      <Information>
        <ReferenceNumber>32</ReferenceNumber>
        <Description>**PEER REVIEWED**</Description>
        <Reference>American Society of Health-System Pharmacists 2017; Drug Information 2017. Bethesda, MD. 2017, p. 1939-40</Reference>
        <Value>
          <StringWithMarkup>
            <String>Animal reproduction studies have not been performed with niacin, and it is also not known whether the drug (at antilipemic dosages) can cause fetal harm or affect reproduction capacity when administered to pregnant women. Niacin should not be used in women who are or may become pregnant or in nursing women unless the possible benefits outweigh the potential risks. Currently, most experts recommend that hyperlipoproteinemias in pregnant women be managed with dietary measures; consultation with a lipid specialist may be indicated for pregnant women with severe forms of hyperlipidemia. If the patient becomes pregnant while receiving niacin for primary hypercholesterolemia, the drug should be discontinued. If the patient being treated with niacin for hypertriglyceridemia or mixed dyslipidemia becomes pregnant, the benefits and risks of continued therapy should be assessed on an individual basis.</String>
            <Markup>
              <Start>57</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>222</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/Niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>638</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>746</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
          </StringWithMarkup>
        </Value>
      </Information>
      <Information>
        <ReferenceNumber>32</ReferenceNumber>
        <Description>**PEER REVIEWED**</Description>
        <Reference>American Society of Health-System Pharmacists 2017; Drug Information 2017. Bethesda, MD. 2017, p. 1940</Reference>
        <Value>
          <StringWithMarkup>
            <String>Niacin is distributed in human milk. Because of the potential for serious adverse effects in nursing infants, a decision should be made whether to discontinue nursing or the drug, taking into account the importance of the drug to the woman.</String>
            <Markup>
              <Start>0</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/Niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
          </StringWithMarkup>
        </Value>
      </Information>
      <Information>
        <ReferenceNumber>32</ReferenceNumber>
        <Description>**PEER REVIEWED**</Description>
        <Reference>American Society of Health-System Pharmacists 2017; Drug Information 2017. Bethesda, MD. 2017, p. 1940</Reference>
        <Value>
          <StringWithMarkup>
            <String>The risk of developing myopathy and rhabdomyolysis is increased in patients receiving niacin (particularly at antilipemic dosages [exceeding 1 g daily]) concomitantly with statins. ... Myopathy or rhabdomyolysis has occurred in some patients receiving certain statins concomitantly with antilipemic dosages of niacin. However, some manufacturers state that no cases of rhabdomyolysis were reported in 124 patients receiving extended-release niacin (Niaspan) concomitantly with various statins; rhabdomyolysis also was not reported in 1079 patients receiving extended-release niacin in fixed combination with lovastatin (Advicor) for up to 2 years. Other severe adverse effects, including disturbances in glycemic control requiring hospitalization, development of diabetes mellitus, adverse GI effects, myopathy, gout, rash, skin ulceration, infection, and bleeding, have been reported in patients with established cardiovascular disease following concomitant use of extended-release niacin with statin-based therapy. ... Therefore, the potential benefits (e.g., further alterations in lipid concentrations) of concomitant use of antilipemic dosages of niacin with statins should be weighed carefully against the possible risks of severe adverse effects, and caution is advised if such concomitant therapy is employed. The manufacturer of atorvastatin states that lower initial and maintenance dosages of this statin should be considered during concomitant therapy with antilipemic dosages of niacin, and patients should be carefully monitored for manifestations of muscle pain, tenderness, or weakness, particularly during the initial months of therapy and following an increase in dosage of either drug. The manufacturers of fluvastatin, pitavastatin, and pravastatin state that dosage reduction of these statins should be considered when used concomitantly with antilipemic dosages of niacin.</String>
            <Markup>
              <Start>86</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>310</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>441</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>449</Start>
              <Length>7</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/Niaspan</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>575</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>608</Start>
              <Length>10</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/lovastatin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-53232</Extra>
            </Markup>
            <Markup>
              <Start>620</Start>
              <Length>7</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/Advicor</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-151176</Extra>
            </Markup>
            <Markup>
              <Start>983</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>1152</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>1338</Start>
              <Length>12</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/atorvastatin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-60823</Extra>
            </Markup>
            <Markup>
              <Start>1492</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>1726</Start>
              <Length>11</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/fluvastatin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-446155</Extra>
            </Markup>
            <Markup>
              <Start>1739</Start>
              <Length>12</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/pitavastatin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-5282452</Extra>
            </Markup>
            <Markup>
              <Start>1757</Start>
              <Length>11</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/pravastatin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-54687</Extra>
            </Markup>
            <Markup>
              <Start>1887</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
          </StringWithMarkup>
        </Value>
      </Information>
      <Information>
        <ReferenceNumber>32</ReferenceNumber>
        <Description>**PEER REVIEWED**</Description>
        <Reference>American Society of Health-System Pharmacists 2017; Drug Information 2017. Bethesda, MD. 2017</Reference>
        <Value>
          <StringWithMarkup>
            <String>Liver function should be determined periodically (especially early in the course of therapy) in patients receiving long-term niacin or niacinamide therapy in dosages that greatly exceed the physiologic requirement. Large doses of niacin should be used with caution in patients with coronary artery disease, since an increased incidence of atrial and other cardiac arrhythmias has been reported in one study in patients who received the drug to lower serum lipid concentrations.</String>
            <Markup>
              <Start>125</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>135</Start>
              <Length>11</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacinamide</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-936</Extra>
            </Markup>
            <Markup>
              <Start>230</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
          </StringWithMarkup>
        </Value>
      </Information>
      <Information>
        <ReferenceNumber>32</ReferenceNumber>
        <Description>**PEER REVIEWED**</Description>
        <Reference>American Society of Health-System Pharmacists 2017; Drug Information 2017. Bethesda, MD. 2017, p. 1940</Reference>
        <Value>
          <StringWithMarkup>
            <String>Limited data indicate that cholestyramine or colestipol resin may decrease the bioavailability of niacin, as 10-30 or 98% of the dose of niacin binds to cholestyramine or colestipol, respectively, following concomitant administration. Therefore, some manufacturers recommend that cholestyramine or colestipol and niacin be administered at least 4-6 hours apart.</String>
            <Markup>
              <Start>27</Start>
              <Length>14</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/cholestyramine</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-70695641</Extra>
            </Markup>
            <Markup>
              <Start>45</Start>
              <Length>10</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/colestipol</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-62816</Extra>
            </Markup>
            <Markup>
              <Start>98</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>137</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>153</Start>
              <Length>14</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/cholestyramine</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-70695641</Extra>
            </Markup>
            <Markup>
              <Start>171</Start>
              <Length>10</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/colestipol</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-62816</Extra>
            </Markup>
            <Markup>
              <Start>280</Start>
              <Length>14</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/cholestyramine</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-70695641</Extra>
            </Markup>
            <Markup>
              <Start>298</Start>
              <Length>10</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/colestipol</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-62816</Extra>
            </Markup>
            <Markup>
              <Start>313</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
          </StringWithMarkup>
        </Value>
      </Information>
      <Information>
        <ReferenceNumber>32</ReferenceNumber>
        <Description>**PEER REVIEWED**</Description>
        <Reference>American Society of Health-System Pharmacists 2017; Drug Information 2017. Bethesda, MD. 2017, p. 1940</Reference>
        <Value>
          <StringWithMarkup>
            <String>Increased prothrombin time (PT) and decreased platelet count have been reported in patients receiving niacin. Therefore, niacin should be used with caution in patients receiving concomitant anticoagulant therapy; PT and platelet count should be monitored closely in such patients.</String>
            <Markup>
              <Start>102</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>121</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
          </StringWithMarkup>
        </Value>
      </Information>
      <Information>
        <ReferenceNumber>32</ReferenceNumber>
        <Description>**PEER REVIEWED**</Description>
        <Reference>American Society of Health-System Pharmacists 2017; Drug Information 2017. Bethesda, MD. 2017</Reference>
        <Value>
          <StringWithMarkup>
            <String>Small oral doses of niacin or niacinamide are usually nontoxic. However, following larger doses of niacin, such as those used to treat pellagra and other disorders, flushing (especially of the face and neck), pruritus, sensation of burning, stinging or tingling of the skin, nausea, bloating, flatulence, hunger pains, vomiting, heartburn, diarrhea, increased sebaceous gland activity, hypotension, dizziness, tachycardia, syncope (perhaps psychogenic), vasovagal attacks, headache, and blurred vision have occurred. Within 2 weeks after initiating long-term, high-dose, oral niacin therapy, the flushing and skin sensations, increased sebaceous gland activity, and increased GI motility disappear in most patients. Some clinicians suggest that initiating therapy with low doses and then gradually increasing the dose will lessen these transient adverse effects; however, this is controversial. When high dosages are used, some manufacturers recommend the use of extended-release preparations to lessen adverse effects; however, there is no evidence that these preparations offer an advantage over conventional dosage forms.</String>
            <Markup>
              <Start>20</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>30</Start>
              <Length>11</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacinamide</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-936</Extra>
            </Markup>
            <Markup>
              <Start>99</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>576</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
          </StringWithMarkup>
        </Value>
      </Information>
      <Information>
        <ReferenceNumber>32</ReferenceNumber>
        <Description>**PEER REVIEWED**</Description>
        <Reference>American Society of Health-System Pharmacists 2017; Drug Information 2017. Bethesda, MD. 2017</Reference>
        <Value>
          <StringWithMarkup>
            <String>During long-term use of large doses of niacin, rash, hyperpigmentation sometimes resembling acanthosis nigricans, dry skin, xerostomia, hyperuricemia occasionally precipitating gout, activation of peptic ulcer, toxic amblyopia, blurred vision, proptosis, loss of central vision secondary to an atypical form of cystoid macular edema, nervousness, panic, hyperglycemia and abnormal glucose tolerance, and glycosuria have occurred.</String>
            <Markup>
              <Start>39</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>381</Start>
              <Length>7</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/glucose</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-5793</Extra>
            </Markup>
          </StringWithMarkup>
        </Value>
      </Information>
      <Information>
        <ReferenceNumber>32</ReferenceNumber>
        <Description>**PEER REVIEWED**</Description>
        <Reference>American Society of Health-System Pharmacists 2017; Drug Information 2017. Bethesda, MD. 2017</Reference>
        <Value>
          <StringWithMarkup>
            <String>Large doses of niacin or niacinamide should be administered with caution to patients with gallbladder disease or a history of jaundice or liver disease, diabetes mellitus, gout, peptic ulcer, or allergy.  Niacin and niacinamide are contraindicated in patients with liver disease, active peptic ulcer, or hypersensitivity to the drugs. Niacin is also contraindicated in patients with arterial hemorrhaging or severe hypotension.</String>
            <Markup>
              <Start>15</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>25</Start>
              <Length>11</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacinamide</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-936</Extra>
            </Markup>
            <Markup>
              <Start>205</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/Niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>216</Start>
              <Length>11</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacinamide</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-936</Extra>
            </Markup>
            <Markup>
              <Start>335</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/Niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
          </StringWithMarkup>
        </Value>
      </Information>
      <Information>
        <ReferenceNumber>32</ReferenceNumber>
        <Description>**PEER REVIEWED**</Description>
        <Reference>American Society of Health-System Pharmacists 2017; Drug Information 2017. Bethesda, MD. 2017, p. 1936</Reference>
        <Value>
          <StringWithMarkup>
            <String>Niacin preparations available as dietary supplements should not be used interchangeably with prescription-only niacin preparations.</String>
            <Markup>
              <Start>0</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/Niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>111</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
          </StringWithMarkup>
        </Value>
      </Information>
      <Information>
        <ReferenceNumber>32</ReferenceNumber>
        <Description>**PEER REVIEWED**</Description>
        <Reference>American Society of Health-System Pharmacists 2017; Drug Information 2017. Bethesda, MD. 2017, p. 1937</Reference>
        <Value>
          <StringWithMarkup>
            <String>Niacin, alone or in fixed combination with lovastatin, should be used with caution in patients with renal or hepatic impairment. In addition, the drug also should be used with caution in patients who consume substantial amounts of alcohol and/or who have a history of liver disease; such patients should be closely monitored. Use of niacin is contraindicated in patients with active liver disease or unexplained, persistent increases in serum aminotransferase concentrations.</String>
            <Markup>
              <Start>0</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/Niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>43</Start>
              <Length>10</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/lovastatin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-53232</Extra>
            </Markup>
            <Markup>
              <Start>333</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
          </StringWithMarkup>
        </Value>
      </Information>
      <Information>
        <ReferenceNumber>32</ReferenceNumber>
        <Description>**PEER REVIEWED**</Description>
        <Reference>American Society of Health-System Pharmacists 2017; Drug Information 2017. Bethesda, MD. 2017, p. 1939</Reference>
        <Value>
          <StringWithMarkup>
            <String>Rhabdomyolysis has been reported rarely in patients receiving niacin concomitantly with statins. Patients receiving niacin therapy, alone or in fixed combination with lovastatin, should be carefully monitored for signs and symptoms of muscle pain, tenderness, or weakness, especially early in the course of therapy or during upward titration of either drug. The manufacturers state that periodic monitoring of serum CK (CPK) and potassium concentrations should be considered in patients exhibiting such symptoms; however, there is no assurance that such monitoring will prevent the occurrence of severe myopathy.</String>
            <Markup>
              <Start>62</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>116</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>167</Start>
              <Length>10</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/lovastatin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-53232</Extra>
            </Markup>
            <Markup>
              <Start>429</Start>
              <Length>9</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/element/Potassium</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>Element-Potassium</Extra>
            </Markup>
          </StringWithMarkup>
        </Value>
      </Information>
      <Information>
        <ReferenceNumber>32</ReferenceNumber>
        <Description>**PEER REVIEWED**</Description>
        <Reference>American Society of Health-System Pharmacists 2017; Drug Information 2017. Bethesda, MD. 2017, p. 1939</Reference>
        <Value>
          <StringWithMarkup>
            <String>Niacin preparations available as dietary supplements are not labeled by the US Food and Drug Administration (FDA) for the prevention of cardiovascular events or management of dyslipidemias. Such dietary supplements may contain widely varying amounts of niacin, and the American Heart Association (AHA) states that dietary supplement niacin preparations should not be used for cholesterol lowering or as substitutes for prescription-only niacin preparations because of the potential for serious adverse effects.</String>
            <Markup>
              <Start>0</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/Niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>253</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>333</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>376</Start>
              <Length>11</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/cholesterol</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-5997</Extra>
            </Markup>
            <Markup>
              <Start>437</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
          </StringWithMarkup>
        </Value>
      </Information>
      <Information>
        <ReferenceNumber>32</ReferenceNumber>
        <Description>**PEER REVIEWED**</Description>
        <Reference>American Society of Health-System Pharmacists 2017; Drug Information 2017. Bethesda, MD. 2017, p. 1939</Reference>
        <Value>
          <StringWithMarkup>
            <String>Other adverse effects of niacin include toxic amblyopia, blurred vision, dry eyes, dyspnea, proptosis, loss of central vision secondary to an atypical form of cystoid macular edema, pain, rhinitis, decreased platelet count, increased prothrombin time (PT), impotence, and increased amylase concentrations. ... Brief activation of fibrinolysis has been reported following IV administration of niacin.</String>
            <Markup>
              <Start>25</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>392</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
          </StringWithMarkup>
        </Value>
      </Information>
      <Information>
        <ReferenceNumber>32</ReferenceNumber>
        <Description>**PEER REVIEWED**</Description>
        <Reference>American Society of Health-System Pharmacists 2017; Drug Information 2017. Bethesda, MD. 2017, p. 1939</Reference>
        <Value>
          <StringWithMarkup>
            <String>Headache is the most common adverse nervous system effect of niacin, occurring in about 4-11% of patients in controlled studies. Asthenia, dizziness, fatigue, insomnia, leg cramps, migraine, myasthenia, nervousness, and paresthesia also have been reported with niacin therapy.</String>
            <Markup>
              <Start>61</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>261</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
          </StringWithMarkup>
        </Value>
      </Information>
      <Information>
        <ReferenceNumber>32</ReferenceNumber>
        <Description>**PEER REVIEWED**</Description>
        <Reference>American Society of Health-System Pharmacists 2017; Drug Information 2017. Bethesda, MD. 2017</Reference>
        <Value>
          <StringWithMarkup>
            <String>Blood glucose concentration should be monitored periodically in patients receiving niacin or niacinamide, especially early in the course of therapy. Dosage requirements for antidiabetic agents (e.g., insulin, oral sulfonylureas) may change in diabetic patients.</String>
            <Markup>
              <Start>6</Start>
              <Length>7</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/glucose</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-5793</Extra>
            </Markup>
            <Markup>
              <Start>83</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>93</Start>
              <Length>11</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacinamide</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-936</Extra>
            </Markup>
          </StringWithMarkup>
        </Value>
      </Information>
      <Information>
        <ReferenceNumber>32</ReferenceNumber>
        <Description>**PEER REVIEWED**</Description>
        <Reference>American Society of Health-System Pharmacists 2017; Drug Information 2017. Bethesda, MD. 2017, p. 1938-9</Reference>
        <Value>
          <StringWithMarkup>
            <String>Decreased glucose tolerance has been reported in patients receiving niacin in controlled clinical trials. In one study in patients with type 2 diabetes mellitus, antilipemic therapy with niacin (1.5 g 3 times daily) for 8 weeks resulted in a mean increase in blood glucose concentrations of 16% and glycosylated hemoglobin concentrations of 21%, and the induction of marked glycosuria in some patients. However, it has been suggested that such increases in blood glucose concentrations may reflect short-term effects from rapid institution of antilipemic dosages of niacin. ... Hyperuricemia and gout also have been reported in patients receiving niacin in controlled clinical studies. Reductions in phosphorus concentrations have been reported in patients receiving niacin alone or in fixed combination with lovastatin.</String>
            <Markup>
              <Start>10</Start>
              <Length>7</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/glucose</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-5793</Extra>
            </Markup>
            <Markup>
              <Start>68</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>187</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>265</Start>
              <Length>7</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/glucose</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-5793</Extra>
            </Markup>
            <Markup>
              <Start>463</Start>
              <Length>7</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/glucose</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-5793</Extra>
            </Markup>
            <Markup>
              <Start>566</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>647</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>700</Start>
              <Length>10</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/element/Phosphorus</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>Element-Phosphorus</Extra>
            </Markup>
            <Markup>
              <Start>767</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>809</Start>
              <Length>10</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/lovastatin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-53232</Extra>
            </Markup>
          </StringWithMarkup>
        </Value>
      </Information>
      <Information>
        <ReferenceNumber>32</ReferenceNumber>
        <Description>**PEER REVIEWED**</Description>
        <Reference>American Society of Health-System Pharmacists 2017; Drug Information 2017. Bethesda, MD. 2017, p. 1938</Reference>
        <Value>
          <StringWithMarkup>
            <String>Pruritus and rash are the most common dermatologic reactions of niacin, occurring in up to 12% of patients receiving the drug in controlled clinical trials. Hyperpigmentation, acanthosis nigricans, urticaria, dry skin, and sweating, also have been reported with niacin therapy. Hypersensitivity reactions (e.g., anaphylaxis, angioedema, urticaria, flushing, dyspnea, tongue edema, laryngeal edema, facial edema, peripheral edema, laryngismus, vesiculobullous rash) have been reported rarely with niacin therapy. Anaphylactic shock has been reported following IV administration of niacin.</String>
            <Markup>
              <Start>64</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>262</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>496</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>580</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
          </StringWithMarkup>
        </Value>
      </Information>
      <Information>
        <ReferenceNumber>32</ReferenceNumber>
        <Description>**PEER REVIEWED**</Description>
        <Reference>American Society of Health-System Pharmacists 2017; Drug Information 2017. Bethesda, MD. 2017, p. 1938</Reference>
        <Value>
          <StringWithMarkup>
            <String>Elevations in serum creatine kinase (CK, creatine phosphokinase, CPK), myalgia, myopathy, and rhabdomyolysis have been reported in patients receiving niacin alone or combined with other antilipemic agents (e.g., gemfibrozil, various statins), including reports of myopathy and/or rhabdomyolysis in patients receiving niacin (in antilipemic dosages of 1 g daily or higher) in combination with lovastatin. In clinical studies, no cases of rhabdomyolysis but one suspected case of myopathy have been reported in 1079 patients receiving extended-release niacin (up to 2 g daily) in combination with lovastatin (up to 40 mg daily) for up to 2 years.</String>
            <Markup>
              <Start>20</Start>
              <Length>8</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/creatine</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-586</Extra>
            </Markup>
            <Markup>
              <Start>41</Start>
              <Length>8</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/creatine</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-586</Extra>
            </Markup>
            <Markup>
              <Start>150</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>212</Start>
              <Length>11</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/gemfibrozil</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-3463</Extra>
            </Markup>
            <Markup>
              <Start>317</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>392</Start>
              <Length>10</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/lovastatin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-53232</Extra>
            </Markup>
            <Markup>
              <Start>550</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>595</Start>
              <Length>10</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/lovastatin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-53232</Extra>
            </Markup>
          </StringWithMarkup>
        </Value>
      </Information>
      <Information>
        <ReferenceNumber>32</ReferenceNumber>
        <Description>**PEER REVIEWED**</Description>
        <Reference>American Society of Health-System Pharmacists 2017; Drug Information 2017. Bethesda, MD. 2017, p. 1938</Reference>
        <Value>
          <StringWithMarkup>
            <String>Abnormal liver function test results (including increased serum bilirubin, AST [SGOT], ALT [SGPT], and LDH concentrations), jaundice, and chronic liver damage have occurred during niacin therapy. Reversible increases in serum aminotransferase concentrations to more than 3 times the upper limit of normal occurred in approximately 1% of those who received extended-release niacin in fixed combination with lovastatin; such increases have been reported in up to 52% of patients receiving sustained-release preparations of niacin. Elevations in serum aminotransferase concentrations appear to be dose related and usually return slowly to pretreatment values following discontinuance of niacin. ... Hypoalbuminemia, cholelithiasis, jaundice, hepatitis, and hepatic failure have also been reported in patients receiving niacin therapy.</String>
            <Markup>
              <Start>64</Start>
              <Length>9</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/bilirubin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-5280352</Extra>
            </Markup>
            <Markup>
              <Start>180</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>373</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>406</Start>
              <Length>10</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/lovastatin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-53232</Extra>
            </Markup>
            <Markup>
              <Start>521</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>684</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>816</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
          </StringWithMarkup>
        </Value>
      </Information>
      <Information>
        <ReferenceNumber>32</ReferenceNumber>
        <Description>**PEER REVIEWED**</Description>
        <Reference>American Society of Health-System Pharmacists 2017; Drug Information 2017. Bethesda, MD. 2017, p. 1938</Reference>
        <Value>
          <StringWithMarkup>
            <String>The most frequent adverse GI effects of niacin are diarrhea, nausea, and vomiting, which occurred in about 6-11, 2-10, and 2-8%, respectively, of patients receiving the drug, alone or in fixed combination with lovastatin, in controlled clinical trials. Abdominal pain and dyspepsia occurred in about 2-6% of patients receiving the drug in controlled clinical trials.Constipation, flatulence, eructation, anorexia, heartburn, activation of peptic ulcers, and/or peptic ulceration have been reported in patients receiving niacin therapy; bloating, hunger pains, or xerostomia also has been reported. A metallic taste in the mouth has been reported following IV administration of niacin (an IV preparation of niacin currently is not commercially available in the US).</String>
            <Markup>
              <Start>40</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>210</Start>
              <Length>10</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/lovastatin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-53232</Extra>
            </Markup>
            <Markup>
              <Start>520</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>677</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>706</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
          </StringWithMarkup>
        </Value>
      </Information>
      <Information>
        <ReferenceNumber>32</ReferenceNumber>
        <Description>**PEER REVIEWED**</Description>
        <Reference>American Society of Health-System Pharmacists 2017; Drug Information 2017. Bethesda, MD. 2017, p. 1938</Reference>
        <Value>
          <StringWithMarkup>
            <String>Other cardiovascular adverse effects, including atrial fibrillation and other cardiac arrhythmias, hypotension, orthostasis, vasovagal attacks, and generalized edema, ... have been reported with niacin therapy.</String>
            <Markup>
              <Start>195</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
          </StringWithMarkup>
        </Value>
      </Information>
      <Information>
        <ReferenceNumber>32</ReferenceNumber>
        <Description>**PEER REVIEWED**</Description>
        <Reference>American Society of Health-System Pharmacists 2017; Drug Information 2017. Bethesda, MD. 2017, p. 1938</Reference>
        <Value>
          <StringWithMarkup>
            <String>Flushing (i.e., warmth, redness, itching, and/or tingling) reportedly occurs in approximately 53-91% of patients who received niacin, alone or in fixed combination with lovastatin, in controlled clinical trials. Although the incidence of flushing appears to be similar among patients treated with immediate- or extended-release niacin, fewer episodes of flushing were reported by patients who received the extended-release preparation (Niaspan) (1.88 versus 8.56 episodes per patient). In controlled clinical trials, approximately 6 or 8% of patients receiving extended-release niacin (Niaspan) or extended-release niacin in fixed combination with lovastatin discontinued the drug because of flushing, respectively. Flushing usually occurs within 20 minutes or 2-4 hours after administration of immediate-release (e.g., Niacor) or extended-release (Niaspan) niacin, respectively, and generally persists for 0.5-1.5 hours; flushing usually subsides after several weeks of consistent niacin use. Flushing episodes often may be accompanied by symptoms of dizziness, tachycardia, palpitations, shortness of breath, sweating, chills, and/or edema, that rarely may result in syncope. A sensation of burning, stinging or tingling of the skin, increased sebaceous gland activity, nausea, bloating, flatulence, hunger pains, vomiting, heartburn, and diarrhea also have occurred. Within 2-6 weeks after initiating chronic oral high-dose niacin therapy, the flushing and skin sensations, increased sebaceous gland activity, and increased GI motility disappear in most patients.</String>
            <Markup>
              <Start>126</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>169</Start>
              <Length>10</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/lovastatin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-53232</Extra>
            </Markup>
            <Markup>
              <Start>328</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>436</Start>
              <Length>7</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/Niaspan</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>578</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>586</Start>
              <Length>7</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/Niaspan</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>615</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>648</Start>
              <Length>10</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/lovastatin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-53232</Extra>
            </Markup>
            <Markup>
              <Start>820</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/Niacor</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>849</Start>
              <Length>7</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/Niaspan</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>858</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>982</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>1427</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
          </StringWithMarkup>
        </Value>
      </Information>
      <Information>
        <ReferenceNumber>32</ReferenceNumber>
        <Description>**PEER REVIEWED**</Description>
        <Reference>Young, L.Y., M.A. Koda-Kimble (eds.). Applied Therapeutics. The Clinical Use of Drugs. 6th ed. Vancouver, WA., Applied Therapeutics, Inc. 1995., p. 9-15</Reference>
        <Value>
          <StringWithMarkup>
            <String>Doses should be taken with food to minimize GI side effects.</String>
          </StringWithMarkup>
        </Value>
      </Information>
      <Information>
        <ReferenceNumber>32</ReferenceNumber>
        <Description>**PEER REVIEWED**</Description>
        <Reference>Lang JR; ASHP Midyear Clin Meeting 24: 257 (1989)</Reference>
        <Value>
          <StringWithMarkup>
            <String>One of the most significant adverse reactions of nicotinic acid (niacin) is the hepatotoxicity seen in dosages exceeding 3 g/day. In this report a 36 year old male was being followed for type IIa hyperlipoproteinemia and was put on a low fat, low cholesterol diet, cholestyramine resin, and quick-release nicotinic acid at 1.5 g/day. Because of side effects, the patient was switched to a sustained-release product and the dosage was gradually increased to 3 g/day. After six weeks of therapy, the patient began feeling lethargic, weak, and complained of flu-like symptoms. Laboratory values revealed a serum glutamic-oxaloacetic transaminase of  IU and a serum glutamate pyruvate transaminase of 465 IU. The sustained-release product was suspected as the cause, and the patient was re-challenged with quick-release nicotinic acid at 3 g/day. There were no apparent adverse reactions after six months of therapy. Nicotinic acid is being promoted as a medication free from serious adverse reactions and is available over-the-counter in tablets as large as 750 mg. From this report it is apparent that high dose nicotinic acid is not free from serious adverse reactions. Hepatoxicity has been associated with the sustained-release nicotinic acid formulations, and the time course of this report supports that nicotinic acid should not be considered an innocuous over-the-counter drug, and should only be administered in large doses cautiously with liver enzymes monitored accordingly.</String>
            <Markup>
              <Start>49</Start>
              <Length>14</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/nicotinic%20acid</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>65</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>247</Start>
              <Length>11</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/cholesterol</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-5997</Extra>
            </Markup>
            <Markup>
              <Start>305</Start>
              <Length>14</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/nicotinic%20acid</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>662</Start>
              <Length>9</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/glutamate</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-4525487</Extra>
            </Markup>
            <Markup>
              <Start>672</Start>
              <Length>8</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/pyruvate</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-107735</Extra>
            </Markup>
            <Markup>
              <Start>816</Start>
              <Length>14</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/nicotinic%20acid</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>913</Start>
              <Length>14</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/Nicotinic%20acid</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>1110</Start>
              <Length>14</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/nicotinic%20acid</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>1229</Start>
              <Length>14</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/nicotinic%20acid</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>1307</Start>
              <Length>14</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/nicotinic%20acid</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
          </StringWithMarkup>
        </Value>
      </Information>
      <Information>
        <ReferenceNumber>32</ReferenceNumber>
        <Description>**PEER REVIEWED**</Description>
        <Reference>Garg A, Grundy SM; JAMA 264 (Aug 8): 723-26 (1990)</Reference>
        <Value>
          <StringWithMarkup>
            <String>A randomized, cross-over study of the therapy of hyperlipidemia was conducted in 13 patients with non-insulin dependent diabetes mellitus who were treated with niacin (nicotinic acid), 1.5 g 3 times daily for 8 wk, and placebo for the same period. Compared with the control period, niacin therapy reduced the plasma total cholesterol level by 24%, plasma triglyceride level by 45%, very-low density lipoprotein cholesterol level by 15%, and it increased the high-density lipoproptein cholesterol level by 34%. However, niacin therapy resulted in the deterioration of glycemic control, as evidenced by a 16% increase in mean plasma glucose concentrations, a 21% increase in glycosylated hemoglobin levels, and the induction of marked glycosuria in some patients. Furthermore, a consistent increase in plasma uric acid levels was observed. It was concluded that, despite improvement in lipid and lipoprotein concentrations, because of worsening hyperglycemia and the development of hyperuricemia, niacin must be used with caution in patients with non-insulin dependent diabetes mellitus with dyslipidemia. PubMed Abstract</String>
            <Markup>
              <Start>1104</Start>
              <Length>15</Length>
              <URL>http://www.ncbi.nlm.nih.gov/pubmed/2374275?dopt=Abstract</URL>
            </Markup>
            <Markup>
              <Start>160</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>168</Start>
              <Length>14</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/nicotinic%20acid</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>282</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>322</Start>
              <Length>11</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/cholesterol</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-5997</Extra>
            </Markup>
            <Markup>
              <Start>411</Start>
              <Length>11</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/cholesterol</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-5997</Extra>
            </Markup>
            <Markup>
              <Start>484</Start>
              <Length>11</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/cholesterol</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-5997</Extra>
            </Markup>
            <Markup>
              <Start>519</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>631</Start>
              <Length>7</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/glucose</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-5793</Extra>
            </Markup>
            <Markup>
              <Start>807</Start>
              <Length>9</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/uric%20acid</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-1175</Extra>
            </Markup>
            <Markup>
              <Start>995</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
          </StringWithMarkup>
        </Value>
      </Information>
    </Section>
    <Section>
      <TOCHeading>Maximum Drug Dose</TOCHeading>
      <Description>Maximum Drug Dose information from HSDB</Description>
      <Information>
        <ReferenceNumber>32</ReferenceNumber>
        <Description>**PEER REVIEWED**</Description>
        <Reference>Young, L.Y., M.A. Koda-Kimble (eds.). Applied Therapeutics. The Clinical Use of Drugs. 6th ed. Vancouver, WA., Applied Therapeutics, Inc. 1995., p. 9-16</Reference>
        <Value>
          <StringWithMarkup>
            <String>1500 mg BID /From table/</String>
          </StringWithMarkup>
        </Value>
      </Information>
    </Section>
  </Section>
  <Section>
    <TOCHeading>Food Additives and Ingredients</TOCHeading>
    <Description>This section provides information and links related to food additives, flavorings, food coloring agents.</Description>
    <Section>
      <TOCHeading>FDA Substances Added to Food</TOCHeading>
      <Description>The FDA Substances Added to Food (formerly EAFUS - Everything Added to Food in the United States) includes the ingredients regulated by the U.S. Food and Drug Administration.</Description>
      <URL>https://www.accessdata.fda.gov/scripts/fdcc/?set=FoodSubstances</URL>
      <DisplayControls>
        <CreateTable>
          <FromInformationIn>ThisSection</FromInformationIn>
          <NumberOfColumns>2</NumberOfColumns>
          <ColumnContents>Name</ColumnContents>
          <ColumnContents>Value</ColumnContents>
        </CreateTable>
      </DisplayControls>
      <Information>
        <ReferenceNumber>28</ReferenceNumber>
        <Name>Substance</Name>
        <URL>https://www.accessdata.fda.gov/scripts/fdcc/?set=FoodSubstances&amp;id=NIACIN</URL>
        <Value>
          <StringWithMarkup>
            <String>NIACIN</String>
          </StringWithMarkup>
        </Value>
      </Information>
      <Information>
        <ReferenceNumber>28</ReferenceNumber>
        <Name>Used for (Technical Effect)</Name>
        <Value>
          <StringWithMarkup>
            <String>NUTRIENT SUPPLEMENT</String>
          </StringWithMarkup>
        </Value>
      </Information>
      <Information>
        <ReferenceNumber>28</ReferenceNumber>
        <Name>Document Number (21 CFR)</Name>
        <Value>
          <StringWithMarkup>
            <String>184.1530</String>
            <Markup>
              <Start>0</Start>
              <Length>8</Length>
              <URL>https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfCFR/CFRSearch.cfm?fr=184.1530</URL>
            </Markup>
          </StringWithMarkup>
        </Value>
      </Information>
    </Section>
  </Section>
  <Section>
    <TOCHeading>Pharmacology and Biochemistry</TOCHeading>
    <Description>Pharmacology and biochemistry information related to this record</Description>
    <Section>
      <TOCHeading>Pharmacology</TOCHeading>
      <Description>Pharmacology information related to this record</Description>
      <Information>
        <ReferenceNumber>17</ReferenceNumber>
        <Name>Pharmacology</Name>
        <Value>
          <StringWithMarkup>
            <String>Niacin and niacinamide are indicated for prevention and treatment of vitamin B3 deficiency states. Vitamin B3 (Niacin) also acts to reduce LDL cholesterol, triglycerides, and HDL cholesterol. The magnitude of individual lipid and lipoprotein responses may be influenced by the severity and type of underlying lipid abnormality. The increase in total HDL is associated with a shift in the distribution of HDL subfractions (as defined by ultra-centrifugation) with an increase in the HDL2:HDL3 ratio and an increase in apolipoprotein A-I content. Vitamin B3 (Niacin) treatment also decreases the serum levels of apolipoprotein B-100 (apo B), the major protein component of the VLDL (very low-density lipoprotein) and LDL fractions, and of lipoprotein-a, a variant form of LDL independently associated with coronary risk.</String>
            <Markup>
              <Start>0</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/Niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>11</Start>
              <Length>11</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacinamide</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-936</Extra>
            </Markup>
            <Markup>
              <Start>69</Start>
              <Length>10</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/vitamin%20B3</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>99</Start>
              <Length>10</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/Vitamin%20B3</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>111</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/Niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>143</Start>
              <Length>11</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/cholesterol</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-5997</Extra>
            </Markup>
            <Markup>
              <Start>179</Start>
              <Length>11</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/cholesterol</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-5997</Extra>
            </Markup>
            <Markup>
              <Start>545</Start>
              <Length>10</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/Vitamin%20B3</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>557</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/Niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
          </StringWithMarkup>
        </Value>
      </Information>
      <Information>
        <ReferenceNumber>41</ReferenceNumber>
        <Name>Pharmacology</Name>
        <Value>
          <StringWithMarkup>
            <String>Niacin is a water-soluble vitamin belonging to the vitamin B family, which occurs in many animal and plant tissues, with antihyperlipidemic activity. Niacin is converted to its active form niacinamide, which is a component of the coenzymes nicotinamide adenine dinucleotide (NAD) and its phosphate form, NADP. These coenzymes play an important role in tissue respiration and in glycogen, lipid, amino acid, protein, and purine metabolism. Although the exact mechanism of action by which niacin lowers cholesterol is not fully understood, it may act by inhibiting the synthesis of very low density lipoproteins (VLDL), inhibiting the release of free fatty acids from adipose tissue, increasing lipoprotein lipase activity, and reducing the hepatic synthesis of VLDL-C and LDL-C.</String>
            <Markup>
              <Start>0</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/Niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>12</Start>
              <Length>5</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/water</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-962</Extra>
            </Markup>
            <Markup>
              <Start>150</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/Niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>189</Start>
              <Length>11</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacinamide</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-936</Extra>
            </Markup>
            <Markup>
              <Start>240</Start>
              <Length>33</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/nicotinamide%20adenine%20dinucleotide</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-15938971</Extra>
            </Markup>
            <Markup>
              <Start>275</Start>
              <Length>3</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/NAD</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-5893</Extra>
            </Markup>
            <Markup>
              <Start>288</Start>
              <Length>9</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/phosphate</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-1061</Extra>
            </Markup>
            <Markup>
              <Start>304</Start>
              <Length>4</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/NADP</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-2734411</Extra>
            </Markup>
            <Markup>
              <Start>378</Start>
              <Length>8</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/glycogen</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-439177</Extra>
            </Markup>
            <Markup>
              <Start>420</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/purine</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-1044</Extra>
            </Markup>
            <Markup>
              <Start>487</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>501</Start>
              <Length>11</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/cholesterol</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-5997</Extra>
            </Markup>
          </StringWithMarkup>
        </Value>
      </Information>
    </Section>
    <Section>
      <TOCHeading>MeSH Pharmacological Classification</TOCHeading>
      <Description>Pharmacological action classes that provided by MeSH</Description>
      <Information>
        <ReferenceNumber>97</ReferenceNumber>
        <Name>Vasodilator Agents</Name>
        <Value>
          <StringWithMarkup>
            <String>Drugs used to cause dilation of the blood vessels. (See all compounds classified as Vasodilator Agents.)</String>
            <Markup>
              <Start>56</Start>
              <Length>46</Length>
              <URL>https://www.ncbi.nlm.nih.gov/sites/entrez?Db=pccompound&amp;DbFrom=mesh&amp;Cmd=Link&amp;LinkName=mesh_pccompound&amp;IdsFromResult=68014665</URL>
            </Markup>
          </StringWithMarkup>
        </Value>
      </Information>
      <Information>
        <ReferenceNumber>98</ReferenceNumber>
        <Name>Hypolipidemic Agents</Name>
        <Value>
          <StringWithMarkup>
            <String>Substances that lower the levels of certain LIPIDS in the BLOOD. They are used to treat HYPERLIPIDEMIAS. (See all compounds classified as Hypolipidemic Agents.)</String>
            <Markup>
              <Start>110</Start>
              <Length>48</Length>
              <URL>https://www.ncbi.nlm.nih.gov/sites/entrez?Db=pccompound&amp;DbFrom=mesh&amp;Cmd=Link&amp;LinkName=mesh_pccompound&amp;IdsFromResult=68000960</URL>
            </Markup>
          </StringWithMarkup>
        </Value>
      </Information>
      <Information>
        <ReferenceNumber>99</ReferenceNumber>
        <Name>Vitamin B Complex</Name>
        <Value>
          <StringWithMarkup>
            <String>A group of water-soluble vitamins, some of which are COENZYMES. (See all compounds classified as Vitamin B Complex.)</String>
            <Markup>
              <Start>69</Start>
              <Length>45</Length>
              <URL>https://www.ncbi.nlm.nih.gov/sites/entrez?Db=pccompound&amp;DbFrom=mesh&amp;Cmd=Link&amp;LinkName=mesh_pccompound&amp;IdsFromResult=68014803</URL>
            </Markup>
          </StringWithMarkup>
        </Value>
      </Information>
    </Section>
    <Section>
      <TOCHeading>FDA Pharmacological Classification</TOCHeading>
      <Description>Pharmacological classes codes are from the National Drug File Reference Terminology (NDF-RT) maintained by the Department of Veterans Affairs. Click the class link to see all drugs information under the class from DailyMed</Description>
      <Section>
        <TOCHeading>FDA Pharmacology Summary</TOCHeading>
        <Description>Descriptive text summarizing FDA&apos;s pharmacological annotation for a given UNII.</Description>
        <Information>
          <ReferenceNumber>30</ReferenceNumber>
          <Name>FDA Pharmacology Summary</Name>
          <Value>
            <StringWithMarkup>
              <String>Niacin is a Nicotinic Acid. The chemical classification of niacin is Nicotinic Acids.</String>
              <Markup>
                <Start>0</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/Niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>12</Start>
                <Length>14</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/Nicotinic%20Acid</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>59</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
            </StringWithMarkup>
          </Value>
        </Information>
      </Section>
      <Section>
        <TOCHeading>Active Moiety</TOCHeading>
        <Description>Active ingredient name</Description>
        <Information>
          <ReferenceNumber>30</ReferenceNumber>
          <Name>Active Moiety</Name>
          <Value>
            <StringWithMarkup>
              <String>NIACIN</String>
            </StringWithMarkup>
          </Value>
        </Information>
      </Section>
      <Section>
        <TOCHeading>FDA UNII</TOCHeading>
        <Description>UNII to the record</Description>
        <Information>
          <ReferenceNumber>30</ReferenceNumber>
          <Name>FDA UNII</Name>
          <Value>
            <StringWithMarkup>
              <String>2679MF687A</String>
            </StringWithMarkup>
          </Value>
        </Information>
      </Section>
      <Section>
        <TOCHeading>Pharmacological Classes</TOCHeading>
        <Description>FDA pharm classes</Description>
        <DisplayControls>
          <CreateTable>
            <FromInformationIn>ThisSection</FromInformationIn>
            <NumberOfColumns>2</NumberOfColumns>
            <ColumnContents>Name</ColumnContents>
            <ColumnContents>Value</ColumnContents>
          </CreateTable>
        </DisplayControls>
        <Information>
          <ReferenceNumber>30</ReferenceNumber>
          <Name>Established Pharmacologic Class [EPC]</Name>
          <Value>
            <StringWithMarkup>
              <String>Nicotinic Acid</String>
            </StringWithMarkup>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>30</ReferenceNumber>
          <Name>Chemical/Ingredient structural concept [Chemical/Ingredient]</Name>
          <Value>
            <StringWithMarkup>
              <String>Nicotinic Acids</String>
            </StringWithMarkup>
          </Value>
        </Information>
      </Section>
    </Section>
    <Section>
      <TOCHeading>ATC Code</TOCHeading>
      <Description>The Anatomical Therapeutic Chemical (ATC) Classification System is used for the classification of drugs. This pharmaceutical coding system divides drugs into different groups according to the organ or system on which they act and/or their therapeutic and chemical characteristics. Each bottom-level ATC code stands for a pharmaceutically used substance, or a combination of substances, in a single indication (or use). This means that one drug can have more than one code: acetylsalicylic acid (aspirin), for example, has A01AD05 as a drug for local oral treatment, B01AC06 as a platelet inhibitor, and N02BA01 as an analgesic and antipyretic. On the other hand, several different brands share the same code if they have the same active substance and indications.</Description>
      <URL>http://www.whocc.no/atc/</URL>
      <Information>
        <ReferenceNumber>74</ReferenceNumber>
        <Name>ATC Code</Name>
        <Value>
          <StringWithMarkup>
            <String>C - Cardiovascular system</String>
            <Markup>
              <Start>0</Start>
              <Length>1</Length>
              <URL>https://www.whocc.no/atc_ddd_index/?code=C</URL>
            </Markup>
          </StringWithMarkup>
          <StringWithMarkup>
            <String>C04 - Peripheral vasodilators</String>
            <Markup>
              <Start>0</Start>
              <Length>3</Length>
              <URL>https://www.whocc.no/atc_ddd_index/?code=C04</URL>
            </Markup>
          </StringWithMarkup>
          <StringWithMarkup>
            <String>C04A - Peripheral vasodilators</String>
            <Markup>
              <Start>0</Start>
              <Length>4</Length>
              <URL>https://www.whocc.no/atc_ddd_index/?code=C04A</URL>
            </Markup>
          </StringWithMarkup>
          <StringWithMarkup>
            <String>C04AC - Nicotinic acid and derivatives</String>
            <Markup>
              <Start>0</Start>
              <Length>5</Length>
              <URL>https://www.whocc.no/atc_ddd_index/?code=C04AC</URL>
            </Markup>
            <Markup>
              <Start>8</Start>
              <Length>14</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/Nicotinic%20acid</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
          </StringWithMarkup>
          <StringWithMarkup>
            <String>C04AC01 - Nicotinic acid</String>
            <Markup>
              <Start>0</Start>
              <Length>7</Length>
              <URL>https://www.whocc.no/atc_ddd_index/?code=C04AC01</URL>
            </Markup>
          </StringWithMarkup>
        </Value>
      </Information>
      <Information>
        <ReferenceNumber>74</ReferenceNumber>
        <Name>ATC Code</Name>
        <Value>
          <StringWithMarkup>
            <String>C - Cardiovascular system</String>
            <Markup>
              <Start>0</Start>
              <Length>1</Length>
              <URL>https://www.whocc.no/atc_ddd_index/?code=C</URL>
            </Markup>
          </StringWithMarkup>
          <StringWithMarkup>
            <String>C10 - Lipid modifying agents</String>
            <Markup>
              <Start>0</Start>
              <Length>3</Length>
              <URL>https://www.whocc.no/atc_ddd_index/?code=C10</URL>
            </Markup>
          </StringWithMarkup>
          <StringWithMarkup>
            <String>C10A - Lipid modifying agents, plain</String>
            <Markup>
              <Start>0</Start>
              <Length>4</Length>
              <URL>https://www.whocc.no/atc_ddd_index/?code=C10A</URL>
            </Markup>
            <Markup>
              <Start>0</Start>
              <Length>4</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/C10A</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-41625</Extra>
            </Markup>
          </StringWithMarkup>
          <StringWithMarkup>
            <String>C10AD - Nicotinic acid and derivatives</String>
            <Markup>
              <Start>0</Start>
              <Length>5</Length>
              <URL>https://www.whocc.no/atc_ddd_index/?code=C10AD</URL>
            </Markup>
            <Markup>
              <Start>8</Start>
              <Length>14</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/Nicotinic%20acid</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
          </StringWithMarkup>
          <StringWithMarkup>
            <String>C10AD02 - Nicotinic acid</String>
            <Markup>
              <Start>0</Start>
              <Length>7</Length>
              <URL>https://www.whocc.no/atc_ddd_index/?code=C10AD02</URL>
            </Markup>
          </StringWithMarkup>
        </Value>
      </Information>
    </Section>
    <Section>
      <TOCHeading>Bionecessity</TOCHeading>
      <Description>Bionecessity information related to the record</Description>
      <Information>
        <ReferenceNumber>32</ReferenceNumber>
        <Description>**PEER REVIEWED**</Description>
        <Reference>Kahn, C.M (ed.).;  The Merck Veterinary Manual 10th  Edition. Merck &amp; Co. Whitehouse Station NJ. 2010, p. 2079</Reference>
        <Value>
          <StringWithMarkup>
            <String>VET: Pigs deficient in niacin have inflammatory lesions of the digestive tract and exhibit diarrhea, weight loss, rough skin and coat, and dermatitis on the ears. Intestinal conditions can be due to niacin deficiency or bacterial infection. Deficient pigs respond readily to niacin therapy and, although not a cure for infectious enteritis, adequate dietary niacin probably allows the pig to maintain its resistance to bacterial invasion.</String>
            <Markup>
              <Start>23</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>199</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>275</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>358</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
          </StringWithMarkup>
        </Value>
      </Information>
      <Information>
        <ReferenceNumber>32</ReferenceNumber>
        <Description>**PEER REVIEWED**</Description>
        <Reference>Kahn, C.M (ed.).;  The Merck Veterinary Manual 10th  Edition. Merck &amp; Co. Whitehouse Station NJ. 2010, p. 2537</Reference>
        <Value>
          <StringWithMarkup>
            <String>VET: Niacin deficiency /in poultry/ is characterized by severe metabolic disorders in the skin and digestive organs. The first signs are usually loss of appetite, retarded growth, general weakness, and diarrhea. There is conflicting evidence as to whether broilers respond, in terms of growth and feed utilization, to niacin supplementation. However, it has been clearly established that chicks do have a requirement for niacin. Deficiency produces an enlargement of the tibiotarsal joint, bowing of the legs, poor feathering, and dermatitis on the head and feet.</String>
            <Markup>
              <Start>5</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/Niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>318</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>421</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
          </StringWithMarkup>
        </Value>
      </Information>
      <Information>
        <ReferenceNumber>32</ReferenceNumber>
        <Description>**PEER REVIEWED**</Description>
        <Reference>Kahn, C.M (ed.).;  The Merck Veterinary Manual 10th  Edition. Merck &amp; Co. Whitehouse Station NJ. 2010, p. 2537</Reference>
        <Value>
          <StringWithMarkup>
            <String>VET: Niacin deficiency in chicks can also result in &quot;black tongue.&quot; At approximately 2 wk of age, the tongue, oral cavity, and esophagus become distinctly inflamed. In the niacin-deficient hen, weight loss, reduced egg production, and a marked decrease in hatchability can result. Turkeys, ducks, pheasants, and goslings are much more severely affected by niacin deficiency than are chickens. Their apparently higher requirements are likely related to their less efficient conversion of tryptophan to niacin. Ducks and turkeys with a niacin deficiency show a severe bowing of the legs and an enlargement of the hock joint. The main difference between the leg seen in niacin deficiency and perosis seen in manganese and choline deficiency is that with niacin deficiency the Achilles tendon seldom slips from its condyles.</String>
            <Markup>
              <Start>5</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/Niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>172</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>356</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>487</Start>
              <Length>10</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/tryptophan</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-6305</Extra>
            </Markup>
            <Markup>
              <Start>501</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>534</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>667</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>705</Start>
              <Length>9</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/element/Manganese</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>Element-Manganese</Extra>
            </Markup>
            <Markup>
              <Start>719</Start>
              <Length>7</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/choline</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-305</Extra>
            </Markup>
            <Markup>
              <Start>751</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
          </StringWithMarkup>
        </Value>
      </Information>
      <Information>
        <ReferenceNumber>32</ReferenceNumber>
        <Description>**PEER REVIEWED**</Description>
        <Reference>Coates, P.M., Blackman, M.R., Cragg, G.M., Levine, M., Moss, J., White, J.D. (Ed), Encyclopedia of Dietary Supplements. Marcel Dekker, New York, NY, p. 483 (2005)</Reference>
        <Value>
          <StringWithMarkup>
            <String>As a precursor of pyridine nucleotides (nicotinamide adenine dinucleotide (NAD) and nicotinamide adenine dinucleotide phosphate (NADP), niacin participates in the function of numerous enzymatic pathways, which are critical for normal cell metabolism, involving, for example redox reactions and those that consume NAD.</String>
            <Markup>
              <Start>40</Start>
              <Length>33</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/nicotinamide%20adenine%20dinucleotide</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-15938971</Extra>
            </Markup>
            <Markup>
              <Start>75</Start>
              <Length>3</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/NAD</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-5893</Extra>
            </Markup>
            <Markup>
              <Start>84</Start>
              <Length>43</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/nicotinamide%20adenine%20dinucleotide%20phosphate</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-42609791</Extra>
            </Markup>
            <Markup>
              <Start>129</Start>
              <Length>4</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/NADP</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-2734411</Extra>
            </Markup>
            <Markup>
              <Start>136</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>313</Start>
              <Length>3</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/NAD</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-5893</Extra>
            </Markup>
          </StringWithMarkup>
        </Value>
      </Information>
      <Information>
        <ReferenceNumber>32</ReferenceNumber>
        <Description>**PEER REVIEWED**</Description>
        <Reference>Coates, P.M., Blackman, M.R., Cragg, G.M., Levine, M., Moss, J., White, J.D. (Ed), Encyclopedia of Dietary Supplements. Marcel Dekker, New York, NY, p. 483 (2005)</Reference>
        <Value>
          <StringWithMarkup>
            <String>A deficiency of this vitamin causes pellagra, a disease characterized by dermatitis, diarrhea, and dementia that is endemic today in parts of India and China, and may result in death in severe cases.</String>
          </StringWithMarkup>
        </Value>
      </Information>
      <Information>
        <ReferenceNumber>32</ReferenceNumber>
        <Description>**PEER REVIEWED**</Description>
        <Reference>Kirkland JB; Subcell Biochem 56: 21-36 (2012)</Reference>
        <Value>
          <StringWithMarkup>
            <String>Niacin deficiency causes dramatic genomic instability in bone marrow cells in an in vivo rat model. The end result is seen in the increased incidence of sister chromatid exchanges, micronuclei, chromosomal aberrations and the eventual development of nitrosourea-induced leukemias. From a mechanistic perspective, niacin deficiency delays excision repair and causes double strand break accumulation, which in turn favor chromosome breaks and translocations. Niacin deficiency also impairs cell cycle arrest and apoptosis in response to DNA damage, which combine to encourage the survival of cells with leukemogenic potential. Niacin deficiency also enhances the level of oxidant damage found in cellular proteins and DNA, but not through depression of GSH levels. Pharmacological supplementation of niacin decreases the development of nitrosourea-induced leukemias, while short term effects of high niacin intake include a large increase in cellular NAD+ and poly(ADP-ribose) content and enhanced apoptosis. These results are important to cancer patients, which tend to be niacin deficient, are exposed to large doses of genotoxic drugs, and suffer short-term bone marrow suppression and long-term development of secondary leukemias. The data from our rat model suggest that niacin supplementation of cancer patients may decrease the severity of short and long-term side effects, and may also improve tumor cell killing through activation of poly(ADP-ribose)-dependent apoptosis pathways. PubMed Abstract</String>
            <Markup>
              <Start>1488</Start>
              <Length>15</Length>
              <URL>http://www.ncbi.nlm.nih.gov/pubmed/22116692?dopt=Abstract</URL>
            </Markup>
            <Markup>
              <Start>0</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/Niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>250</Start>
              <Length>11</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/nitrosourea</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-105035</Extra>
            </Markup>
            <Markup>
              <Start>313</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>457</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/Niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>625</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/Niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>751</Start>
              <Length>3</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/GSH</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-124886</Extra>
            </Markup>
            <Markup>
              <Start>798</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>834</Start>
              <Length>11</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/nitrosourea</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-105035</Extra>
            </Markup>
            <Markup>
              <Start>898</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>949</Start>
              <Length>4</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/NAD%2B</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-5893</Extra>
            </Markup>
            <Markup>
              <Start>1072</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>1274</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
          </StringWithMarkup>
        </Value>
      </Information>
      <Information>
        <ReferenceNumber>32</ReferenceNumber>
        <Description>**PEER REVIEWED**</Description>
        <Reference>Dart, R.C. (ed). Medical Toxicology. Third Edition, Lippincott Williams &amp; Wilkins. Philadelphia, PA. 2004., p. 1022</Reference>
        <Value>
          <StringWithMarkup>
            <String>Niacin deficiency causes pellagra, which is characterized by dermatitis, diarrhea, and dementia. Other symptoms include irritability, loss of appetite, weakness, and dizziness. Niacin deficiency is rare in the United States but may still be seen in alcoholics, dietary cultists, and patients with malabsorption syndrome.</String>
            <Markup>
              <Start>0</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/Niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>177</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/Niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
          </StringWithMarkup>
        </Value>
      </Information>
    </Section>
    <Section>
      <TOCHeading>Absorption, Distribution and Excretion</TOCHeading>
      <Information>
        <ReferenceNumber>17</ReferenceNumber>
        <Name>Absorption</Name>
        <Value>
          <StringWithMarkup>
            <String>Both nicotinic acid and nicotinamide are efficiently absorbed from the stomach and small intestine.</String>
            <Markup>
              <Start>5</Start>
              <Length>14</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/nicotinic%20acid</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>24</Start>
              <Length>12</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/nicotinamide</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-936</Extra>
            </Markup>
          </StringWithMarkup>
        </Value>
      </Information>
      <Information>
        <ReferenceNumber>32</ReferenceNumber>
        <Description>**PEER REVIEWED**</Description>
        <Reference>American Society of Health-System Pharmacists 2017; Drug Information 2017. Bethesda, MD. 2017, p. 1940</Reference>
        <Value>
          <StringWithMarkup>
            <String>/MILK/ Niacin is distributed in human milk.</String>
            <Markup>
              <Start>7</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/Niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
          </StringWithMarkup>
        </Value>
      </Information>
      <Information>
        <ReferenceNumber>32</ReferenceNumber>
        <Description>**PEER REVIEWED**</Description>
        <Reference>American Society of Health-System Pharmacists 2017; Drug Information 2017. Bethesda, MD. 2017, p. 1941</Reference>
        <Value>
          <StringWithMarkup>
            <String>Niacin is rapidly and extensively (60-76% of dose) absorbed following oral administration. Peak plasma concentrations of niacin following administration of an immediate-release (Niacor) or extended-release (Niaspan) niacin preparation generally are attained within 30-60 minutes or 4-5 hours after oral administration, respectively. The bioavailability of 1 tablet containing 1 g of extended-release niacin in fixed combination with 40 mg of lovastatin (Advicor 1 g/40 mg) differs from that of 2 tablets each containing 500 mg of extended-release niacin in fixed combination with 20 mg of lovastatin (Advicor 500 mg/20 mg). ... Peak plasma concentrations of niacin and metabolites following oral administration of Niaspan extended-release tablets appear to be slightly higher in women than in men, possibly because of differences in metabolism. Limited data suggest that women may exhibit greater antilipemic response to niacin than men, possibly because of gender-specific differences in the metabolic rate or volume of distribution of the drug.</String>
            <Markup>
              <Start>0</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/Niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>121</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>178</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/Niacor</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>207</Start>
              <Length>7</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/Niaspan</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>216</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>400</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>442</Start>
              <Length>10</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/lovastatin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-53232</Extra>
            </Markup>
            <Markup>
              <Start>454</Start>
              <Length>7</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/Advicor</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-151176</Extra>
            </Markup>
            <Markup>
              <Start>547</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>589</Start>
              <Length>10</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/lovastatin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-53232</Extra>
            </Markup>
            <Markup>
              <Start>601</Start>
              <Length>7</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/Advicor</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-151176</Extra>
            </Markup>
            <Markup>
              <Start>658</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>714</Start>
              <Length>7</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/Niaspan</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>921</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
          </StringWithMarkup>
        </Value>
      </Information>
      <Information>
        <ReferenceNumber>32</ReferenceNumber>
        <Description>**PEER REVIEWED**</Description>
        <Reference>American Society of Health-System Pharmacists 2017; Drug Information 2017. Bethesda, MD. 2017, p. 1941</Reference>
        <Value>
          <StringWithMarkup>
            <String>Niacin is distributed mainly to the liver, kidney, and adipose tissue.</String>
            <Markup>
              <Start>0</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/Niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
          </StringWithMarkup>
        </Value>
      </Information>
      <Information>
        <ReferenceNumber>32</ReferenceNumber>
        <Description>**PEER REVIEWED**</Description>
        <Reference>American Society of Health-System Pharmacists 2017; Drug Information 2017. Bethesda, MD. 2017, p. 1941</Reference>
        <Value>
          <StringWithMarkup>
            <String>Niacin and its metabolites are rapidly excreted in urine. Following oral administration of single and multiple doses of an immediate-release (Niacor) or extended-release (Niaspan) niacin preparation, approximately 88 or 60-76% of the dose, respectively, was excreted in urine as unchanged drug and inactive metabolites.</String>
            <Markup>
              <Start>0</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/Niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>142</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/Niacor</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>171</Start>
              <Length>7</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/Niaspan</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>180</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
          </StringWithMarkup>
        </Value>
      </Information>
      <Information>
        <ReferenceNumber>32</ReferenceNumber>
        <Description>**PEER REVIEWED**</Description>
        <Reference>Lauring B et al; Curr Med Res Opin 25 (1): 15-22 (2009)</Reference>
        <Value>
          <StringWithMarkup>
            <String>The objective of this study was to compare pharmacokinetic parameters of niacin extended-release tablets (NER uncoated) and niacin extended-release caplet formation (NER coated). Twenty-five healthy male and female subjects were enrolled in a four-period, open-label, randomized, crossover study. Both NER uncoated and NER coated were given as 1 x 1000 mg or 2 x 500 mg tablets. Similarity of NER coated 1 x 1000 mg and NER uncoated 2 x 500 mg was declared if 90% confidence intervals for the geometric mean ratio (GMR) for nicotinuric acid (NUA) Cmax fell within the pre-specified bounds of [0.7, 1.43]. The GMRs for NUA Cmax demonstrated similarity in the pharmacokinetics of NER uncoated 2 x 500 mg, NER coated 1 x 1000 mg, and NER coated 2 x 500 mg. Although less stringent comparability bounds were prespecified for the primary pharmacokinetic endpoint (i.e., Cmax of plasma NUA), inspection of the primary comparison of interest indicated that a hypothesis with more stringent bioequivalence bounds of [0.8, 1.25] would have been satisfied. The NUA Cmax for NER uncoated 1 x 1000 mg was approximately 40% higher than that seen for the other three treatments. In contrast, total urinary excretion of niacin and its metabolites, an approximate measure of bioavailability, was similar for all four treatments. The pharmacokinetic profile of the original NER uncoated formulation dosed as 2 x 500 mg was similar to the new film-coated formulation, NER coated, dosed as 1 x 1000 mg. PubMed Abstract</String>
            <Markup>
              <Start>1484</Start>
              <Length>15</Length>
              <URL>http://www.ncbi.nlm.nih.gov/pubmed/19210135?dopt=Abstract</URL>
            </Markup>
            <Markup>
              <Start>73</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>124</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>524</Start>
              <Length>16</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/nicotinuric%20acid</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-68499</Extra>
            </Markup>
            <Markup>
              <Start>1205</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
          </StringWithMarkup>
        </Value>
      </Information>
      <Information>
        <ReferenceNumber>32</ReferenceNumber>
        <Description>**PEER REVIEWED**</Description>
        <Reference>Kumar JS et al; Am J Physiol Gastrointest Liver Physiol 305 (3): G207-13 (2013)</Reference>
        <Value>
          <StringWithMarkup>
            <String>Niacin (vitamin B3; nicotinic acid) plays an important role in maintaining redox state of cells and is obtained from endogenous and exogenous sources. The latter source has generally been assumed to be the dietary niacin, but another exogenous source that has been ignored is the niacin that is produced by the normal microflora of the large intestine. For this source of niacin to be bioavailable, it needs to be absorbed, but little is known about the ability of the large intestine to absorb niacin and the mechanism involved. Here we addressed these issues using the nontransformed human colonic epithelial NCM460 cells, native human colonic apical membrane vesicles (AMV) isolated from organ donors, and mouse colonic loops in vivo as models. Uptake of (3)H-nicotinic acid by NCM460 cells was: 1) acidic pH (but not Na+) dependent; 2) saturable (apparent Km = 2.5 +/- 0.8 uM); 3) inhibited by unlabeled nicotinic acid, nicotinamide, and probenecid; 4) neither affected by other bacterially produced monocarboxylates, monocarboxylate transport inhibitor, or by substrates of the human organic anion transporter-10; 5) affected by modulators of the intracellular protein tyrosine kinase- and Ca2+-calmodulin-regulatory pathways; and 6) adaptively regulated by extracellular nicotinate level. Uptake of nicotinic acid by human colonic AMV in vitro and by mouse colonic loops in vivo was also carrier mediated. These findings report, for the first time, that mammalian colonocytes possess a high-affinity carrier-mediated mechanism for nicotinate uptake and show that the process is affected by intracellular and extracellular factors. PubMed Abstract Full text: PMC3742858</String>
            <Markup>
              <Start>1637</Start>
              <Length>15</Length>
              <URL>http://www.ncbi.nlm.nih.gov/pubmed/23744738?dopt=Abstract</URL>
            </Markup>
            <Markup>
              <Start>1664</Start>
              <Length>10</Length>
              <URL>https://www.ncbi.nlm.nih.gov/pmc/?term=PMC3742858</URL>
            </Markup>
            <Markup>
              <Start>0</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/Niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>8</Start>
              <Length>10</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/vitamin%20B3</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>20</Start>
              <Length>14</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/nicotinic%20acid</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>214</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>280</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>372</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>495</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>763</Start>
              <Length>14</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/nicotinic%20acid</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>908</Start>
              <Length>14</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/nicotinic%20acid</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>924</Start>
              <Length>12</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/nicotinamide</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-936</Extra>
            </Markup>
            <Markup>
              <Start>942</Start>
              <Length>10</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/probenecid</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-4911</Extra>
            </Markup>
            <Markup>
              <Start>1174</Start>
              <Length>8</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/tyrosine</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-6057</Extra>
            </Markup>
            <Markup>
              <Start>1277</Start>
              <Length>10</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/nicotinate</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-937</Extra>
            </Markup>
            <Markup>
              <Start>1305</Start>
              <Length>14</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/nicotinic%20acid</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>1537</Start>
              <Length>10</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/nicotinate</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-937</Extra>
            </Markup>
          </StringWithMarkup>
        </Value>
      </Information>
      <Information>
        <ReferenceNumber>32</ReferenceNumber>
        <Description>**PEER REVIEWED**</Description>
        <Reference>Guy RH et al; J Pharm Sci 75 (10): 968-72 (1986)</Reference>
        <Value>
          <StringWithMarkup>
            <String>The percutaneous penetration of nicotinates was studied in vivo and in vitro. In vitro, the ability of (14)C labeled nicotinic acid, methyl nicotinate, ethyl nicotinate, hexyl nicotinate, or benzyl nicotinate, to penetrate through skin removed from the backs of hairless mice mounted on glass diffusion cells was evaluated. In some experiments the skin had been stripped of its stratum corneum barrier. In vivo, (14)C labeled methyl nicotinate, ethyl nicotinate, hexyl nicotinate, or benzyl nicotinate was applied to the forearm of human volunteers. The extent of absorption was determined by collecting urine samples at various times over the next 5 days and analyzing them for (14)C activity. The octanol/water partition coefficients of the compounds were determined experimentally or obtained from the literature. In vitro, 80 to 90% of the polar compounds, methyl nicotinate and ethyl nicotinate, rapidly penetrated the skin. The less polar compounds, hexyl nicotinate and benzyl nicotinate, penetrated very slowly. Nicotinate showed very little penetration, even after 50 hours. Nicotinic-acid, methyl nicotinate, and benzyl nicotinate penetrated skin with the stratum corneum removed with equal efficiency. The in-vivo data could be fit to a four compartment pharmacokinetic model consisting of the stratum corneum, viable epidermis, blood, and urine. The ratios of the rate constants in the model correlated acceptably with the partition coefficients of the compounds. /It was/ concluded that in mouse skin methyl nicotinate and ethyl nicotinate can effectively bypass the stratum corneum barrier, whereas nicotinic acid and the other compounds cannot. Skin transport is the rate limiting step in the skin absorption of these compounds. In human skin the nicotinates apparently have a higher affinity for the stratum corneum than for viable tissue. PubMed Abstract</String>
            <Markup>
              <Start>1856</Start>
              <Length>15</Length>
              <URL>http://www.ncbi.nlm.nih.gov/pubmed/3795027?dopt=Abstract</URL>
            </Markup>
            <Markup>
              <Start>117</Start>
              <Length>14</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/nicotinic%20acid</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>133</Start>
              <Length>17</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/methyl%20nicotinate</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-7151</Extra>
            </Markup>
            <Markup>
              <Start>152</Start>
              <Length>16</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/ethyl%20nicotinate</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-69188</Extra>
            </Markup>
            <Markup>
              <Start>170</Start>
              <Length>16</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/hexyl%20nicotinate</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-90202</Extra>
            </Markup>
            <Markup>
              <Start>191</Start>
              <Length>17</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/benzyl%20nicotinate</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-7191</Extra>
            </Markup>
            <Markup>
              <Start>426</Start>
              <Length>17</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/methyl%20nicotinate</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-7151</Extra>
            </Markup>
            <Markup>
              <Start>445</Start>
              <Length>16</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/ethyl%20nicotinate</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-69188</Extra>
            </Markup>
            <Markup>
              <Start>463</Start>
              <Length>16</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/hexyl%20nicotinate</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-90202</Extra>
            </Markup>
            <Markup>
              <Start>484</Start>
              <Length>17</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/benzyl%20nicotinate</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-7191</Extra>
            </Markup>
            <Markup>
              <Start>699</Start>
              <Length>7</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/octanol</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-957</Extra>
            </Markup>
            <Markup>
              <Start>707</Start>
              <Length>5</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/water</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-962</Extra>
            </Markup>
            <Markup>
              <Start>861</Start>
              <Length>17</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/methyl%20nicotinate</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-7151</Extra>
            </Markup>
            <Markup>
              <Start>883</Start>
              <Length>16</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/ethyl%20nicotinate</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-69188</Extra>
            </Markup>
            <Markup>
              <Start>956</Start>
              <Length>16</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/hexyl%20nicotinate</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-90202</Extra>
            </Markup>
            <Markup>
              <Start>977</Start>
              <Length>17</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/benzyl%20nicotinate</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-7191</Extra>
            </Markup>
            <Markup>
              <Start>1020</Start>
              <Length>10</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/Nicotinate</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-937</Extra>
            </Markup>
            <Markup>
              <Start>1084</Start>
              <Length>14</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/Nicotinic%20acid</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>1100</Start>
              <Length>17</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/methyl%20nicotinate</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-7151</Extra>
            </Markup>
            <Markup>
              <Start>1123</Start>
              <Length>17</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/benzyl%20nicotinate</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-7191</Extra>
            </Markup>
            <Markup>
              <Start>1514</Start>
              <Length>17</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/methyl%20nicotinate</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-7151</Extra>
            </Markup>
            <Markup>
              <Start>1536</Start>
              <Length>16</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/ethyl%20nicotinate</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-69188</Extra>
            </Markup>
            <Markup>
              <Start>1613</Start>
              <Length>14</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/nicotinic%20acid</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
          </StringWithMarkup>
        </Value>
      </Information>
      <Information>
        <ReferenceNumber>32</ReferenceNumber>
        <Description>**PEER REVIEWED**</Description>
        <Reference>Giachetti C et al; Arzneim Forsch 32 (11): 1433-36 (1982)</Reference>
        <Value>
          <StringWithMarkup>
            <String>Absorption, distribution and excretion data in rats and monkeys were compared for single oral doses of radiolabeled sorbinicate and nicotinic acid (niacin). ... Peak blood levels of sorbinicate were attained at 8 hr compared to 15 min for nicotinic acid. Slow excretion of sorbinicate and constant blood levels approx 10% those of nicotinic acid were observed. The organ distribution of sorbinicate is also given. Radioactive excretion patterns suggested that sorbinicate urinary excretion is 50% that of nicotinic acid, while fecal excretion of sorbinicate is several times that of nicotinic acid.</String>
            <Markup>
              <Start>116</Start>
              <Length>11</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/sorbinicate</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-3058386</Extra>
            </Markup>
            <Markup>
              <Start>132</Start>
              <Length>14</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/nicotinic%20acid</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>148</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>182</Start>
              <Length>11</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/sorbinicate</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-3058386</Extra>
            </Markup>
            <Markup>
              <Start>239</Start>
              <Length>14</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/nicotinic%20acid</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>273</Start>
              <Length>11</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/sorbinicate</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-3058386</Extra>
            </Markup>
            <Markup>
              <Start>331</Start>
              <Length>14</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/nicotinic%20acid</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>387</Start>
              <Length>11</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/sorbinicate</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-3058386</Extra>
            </Markup>
            <Markup>
              <Start>460</Start>
              <Length>11</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/sorbinicate</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-3058386</Extra>
            </Markup>
            <Markup>
              <Start>505</Start>
              <Length>14</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/nicotinic%20acid</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>546</Start>
              <Length>11</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/sorbinicate</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-3058386</Extra>
            </Markup>
            <Markup>
              <Start>583</Start>
              <Length>14</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/nicotinic%20acid</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
          </StringWithMarkup>
        </Value>
      </Information>
      <Information>
        <ReferenceNumber>32</ReferenceNumber>
        <Description>**PEER REVIEWED**</Description>
        <Reference>Organization for Economic Cooperation and Development; Screening Information Data Set for  3-Pyridinecarboxamide (Nicotinamide) CAS #: 98-92-0 p.40 (2005). Available from, as of July 23, 2018: http://www.inchem.org/pages/sids.html</Reference>
        <Value>
          <StringWithMarkup>
            <String>Niacin includes two vitamers nicotinic acid and nicotinamide. Humans are able to synthesize nicotinic acid from tryptophan. Another source for nicotinic acid is the gut flora. In humans there is no deamidation of nicotinamide to nicotinic acid in the gut. Nicotinamide is rapidly absorbed in stomach and small intestine. In plasma both the acid and the amide form are found. Erythrocytes take up the acid by a sodium dependent saturable transport system. Both the acid and the amide are able to pass the blood-brain barrier, however separate systems for uptake have been identified. Brain cells have a high affinity for nicotinamide, but not for nicotinic acid. Nicotinamide is the main substance that is transported between the different tissues as a precursor of nicotinamide adenine dinucleotide (NAD) synthesis. The liver, kidneys, brain and erythrocytes prefer nicotinic acid as a precursor for NAD synthesis, but testes and ovaries prefer nicotinamide. NAD nucleosidase cleaves NAD with nicotinamide as one of the products. This can be deamidated to form nicotinic acid (and re-converted to NAD) or methylated and released via urine. Excretion of the amide (and its metabolites) tends to be more extensive compared to the acid.</String>
            <Markup>
              <Start>0</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/Niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>29</Start>
              <Length>14</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/nicotinic%20acid</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>48</Start>
              <Length>12</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/nicotinamide</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-936</Extra>
            </Markup>
            <Markup>
              <Start>92</Start>
              <Length>14</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/nicotinic%20acid</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>112</Start>
              <Length>10</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/tryptophan</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-6305</Extra>
            </Markup>
            <Markup>
              <Start>143</Start>
              <Length>14</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/nicotinic%20acid</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>213</Start>
              <Length>12</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/nicotinamide</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-936</Extra>
            </Markup>
            <Markup>
              <Start>229</Start>
              <Length>14</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/nicotinic%20acid</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>256</Start>
              <Length>12</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/Nicotinamide</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-936</Extra>
            </Markup>
            <Markup>
              <Start>410</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/element/Sodium</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>Element-Sodium</Extra>
            </Markup>
            <Markup>
              <Start>620</Start>
              <Length>12</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/nicotinamide</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-936</Extra>
            </Markup>
            <Markup>
              <Start>646</Start>
              <Length>14</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/nicotinic%20acid</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>662</Start>
              <Length>12</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/Nicotinamide</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-936</Extra>
            </Markup>
            <Markup>
              <Start>765</Start>
              <Length>33</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/nicotinamide%20adenine%20dinucleotide</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-15938971</Extra>
            </Markup>
            <Markup>
              <Start>800</Start>
              <Length>3</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/NAD</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-5893</Extra>
            </Markup>
            <Markup>
              <Start>866</Start>
              <Length>14</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/nicotinic%20acid</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>900</Start>
              <Length>3</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/NAD</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-5893</Extra>
            </Markup>
            <Markup>
              <Start>945</Start>
              <Length>12</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/nicotinamide</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-936</Extra>
            </Markup>
            <Markup>
              <Start>959</Start>
              <Length>3</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/NAD</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-5893</Extra>
            </Markup>
            <Markup>
              <Start>984</Start>
              <Length>3</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/NAD</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-5893</Extra>
            </Markup>
            <Markup>
              <Start>993</Start>
              <Length>12</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/nicotinamide</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-936</Extra>
            </Markup>
            <Markup>
              <Start>1061</Start>
              <Length>14</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/nicotinic%20acid</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>1097</Start>
              <Length>3</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/NAD</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-5893</Extra>
            </Markup>
          </StringWithMarkup>
        </Value>
      </Information>
      <Information>
        <ReferenceNumber>32</ReferenceNumber>
        <Description>**PEER REVIEWED**</Description>
        <Reference>Cosmetic Ingredient Review (CIR) Expert Panel; Final Report of the Safety Assessment of Niacinamide and Niacin; Intl J of Toxicology 24 (Suppl 5): p.6 (2005). Available from, as og July 23, 2018: https://www.cir-safety.org/ingredients</Reference>
        <Value>
          <StringWithMarkup>
            <String>When large doses (500 mg/kg bw) of niacin or niacinamide were given by intraperitoneal injection to female Sprague-Dawley rats, the compounds were excreted largely unchanged in the urine. However, at low doses (5 mg/kg bw), N1-methylnicotinamide was the main excretory product of niacinamide. Small amounts of niacinamide and pyridone derivatives were also excreted. In case of injected niacin, about equal amounts of N1-methylnicotinamide and nicotinuric acid were excreted alone with small quantities of niacin, niacinamide, nicotinamide N-oxide, and pyridone derivatives.</String>
            <Markup>
              <Start>35</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>45</Start>
              <Length>11</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacinamide</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-936</Extra>
            </Markup>
            <Markup>
              <Start>224</Start>
              <Length>21</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/N1-methylnicotinamide</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-457</Extra>
            </Markup>
            <Markup>
              <Start>280</Start>
              <Length>11</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacinamide</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-936</Extra>
            </Markup>
            <Markup>
              <Start>310</Start>
              <Length>11</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacinamide</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-936</Extra>
            </Markup>
            <Markup>
              <Start>326</Start>
              <Length>8</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/pyridone</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-8871</Extra>
            </Markup>
            <Markup>
              <Start>387</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>418</Start>
              <Length>21</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/N1-methylnicotinamide</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-457</Extra>
            </Markup>
            <Markup>
              <Start>444</Start>
              <Length>16</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/nicotinuric%20acid</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-68499</Extra>
            </Markup>
            <Markup>
              <Start>506</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>514</Start>
              <Length>11</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacinamide</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-936</Extra>
            </Markup>
            <Markup>
              <Start>527</Start>
              <Length>20</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/nicotinamide%20N-oxide</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-72661</Extra>
            </Markup>
            <Markup>
              <Start>553</Start>
              <Length>8</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/pyridone</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-8871</Extra>
            </Markup>
          </StringWithMarkup>
        </Value>
      </Information>
    </Section>
    <Section>
      <TOCHeading>Metabolism/Metabolites</TOCHeading>
      <Description>Metabolism/Metabolites information related to the record</Description>
      <Information>
        <ReferenceNumber>17</ReferenceNumber>
        <Name>Metabolism</Name>
        <Value>
          <StringWithMarkup>
            <String>Hepatic</String>
          </StringWithMarkup>
        </Value>
      </Information>
      <Information>
        <ReferenceNumber>32</ReferenceNumber>
        <Description>**PEER REVIEWED**</Description>
        <Reference>Organization for Economic Cooperation and Development; Screening Information Data Set for  3-Pyridinecarboxamide (Nicotinamide) CAS #: 98-92-0 p.40 (2005). Available from, as of July 23, 2018: http://www.inchem.org/pages/sids.html</Reference>
        <Value>
          <StringWithMarkup>
            <String>... Nicotinamide is the main substance that is transported between the different tissues as a precursor of nicotinamide adenine dinucleotide (NAD) synthesis. The liver, kidneys, brain and erythrocytes prefer nicotinic acid as a precursor for NAD synthesis, but testes and ovaries prefer nicotinamide. NAD nucleosidase cleaves NAD with nicotinamide as one of the products. This can be deamidated to form nicotinic acid (and re-converted to NAD) or methylated and released via urine. Excretion of the amide (and its metabolites) tends to be more extensive compared to the acid.</String>
            <Markup>
              <Start>4</Start>
              <Length>12</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/Nicotinamide</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-936</Extra>
            </Markup>
            <Markup>
              <Start>107</Start>
              <Length>33</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/nicotinamide%20adenine%20dinucleotide</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-15938971</Extra>
            </Markup>
            <Markup>
              <Start>142</Start>
              <Length>3</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/NAD</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-5893</Extra>
            </Markup>
            <Markup>
              <Start>208</Start>
              <Length>14</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/nicotinic%20acid</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>242</Start>
              <Length>3</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/NAD</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-5893</Extra>
            </Markup>
            <Markup>
              <Start>287</Start>
              <Length>12</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/nicotinamide</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-936</Extra>
            </Markup>
            <Markup>
              <Start>301</Start>
              <Length>3</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/NAD</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-5893</Extra>
            </Markup>
            <Markup>
              <Start>326</Start>
              <Length>3</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/NAD</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-5893</Extra>
            </Markup>
            <Markup>
              <Start>335</Start>
              <Length>12</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/nicotinamide</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-936</Extra>
            </Markup>
            <Markup>
              <Start>403</Start>
              <Length>14</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/nicotinic%20acid</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>439</Start>
              <Length>3</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/NAD</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-5893</Extra>
            </Markup>
          </StringWithMarkup>
        </Value>
      </Information>
      <Information>
        <ReferenceNumber>32</ReferenceNumber>
        <Description>**PEER REVIEWED**</Description>
        <Reference>American Society of Health-System Pharmacists 2017; Drug Information 2017. Bethesda, MD. 2017, p. 1941</Reference>
        <Value>
          <StringWithMarkup>
            <String>Niacin is rapidly metabolized and undergoes extensive first-pass metabolism. The drug is converted to several metabolites, including nicotinuric acid (NUA), nicotinamide, and nicotinamide adenine dinucleotide (NAD). At doses used to treat hyperlipoproteinemia, the principal metabolic pathways appear to be saturable, and niacin is thought to exhibit nonlinear, dose-dependent pharmacokinetics. Nicotinamide does not appear to exert antilipemic effects; the activity of other metabolites on lipoprotein fractions currently are unknown.</String>
            <Markup>
              <Start>0</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/Niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>133</Start>
              <Length>16</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/nicotinuric%20acid</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-68499</Extra>
            </Markup>
            <Markup>
              <Start>157</Start>
              <Length>12</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/nicotinamide</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-936</Extra>
            </Markup>
            <Markup>
              <Start>175</Start>
              <Length>33</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/nicotinamide%20adenine%20dinucleotide</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-15938971</Extra>
            </Markup>
            <Markup>
              <Start>210</Start>
              <Length>3</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/NAD</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-5893</Extra>
            </Markup>
            <Markup>
              <Start>322</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>395</Start>
              <Length>12</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/Nicotinamide</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-936</Extra>
            </Markup>
          </StringWithMarkup>
        </Value>
      </Information>
      <Information>
        <ReferenceNumber>32</ReferenceNumber>
        <Description>**PEER REVIEWED**</Description>
        <Reference>Cosmetic Ingredient Review (CIR) Expert Panel; Final Report of the Safety Assessment of Niacinamide and Niacin; Intl J of Toxicology 24 (Suppl 5): p.7 (2005). Available from, as of July 23, 2018:</Reference>
        <Value>
          <StringWithMarkup>
            <String>After doses of 100 mg of niacin (total dose of 200 mg), the urinary excretion of alkalihydrolyzable niacin derivatives and of N1-methylnicotinamide increased from 6.0 to 14.6 mg and from 2.8 to 5.7 mg after 3 hr in four human subjects, respectively. Chromatographic results showed the major metabolite in the urine to be nicotinuric acid, forming 92-99% of the alkalihydrolysable derivatives. Niacinamide (1-4%) was the other metabolite. There was no free niacin in the urine except in one subject who had intense flushing of the skin soon after ingesting the niacin. In these four subjects, there was a large increase in the excretion of N1-methylnicotinamide, which varied from 6.9 to 16.6 mg/3 hr. The small rise in the tertiary nicotinyl derivatives (0.9 to 1.8 mg) was solely due to niacinamide, since no other nicotinyl compound could be detected on the paper chromatograms. Urine from undosed subjects, averaged 0.53 mg N1-methylnicotinamide for a period of 3 hr. The total content of tertiary alkali-hydrolyzable derivative of niacin ranged from 0.2 to 0.3 mg within 3 hr.</String>
            <Markup>
              <Start>25</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>100</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>126</Start>
              <Length>21</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/N1-methylnicotinamide</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-457</Extra>
            </Markup>
            <Markup>
              <Start>321</Start>
              <Length>16</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/nicotinuric%20acid</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-68499</Extra>
            </Markup>
            <Markup>
              <Start>393</Start>
              <Length>11</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/Niacinamide</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-936</Extra>
            </Markup>
            <Markup>
              <Start>456</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>560</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>639</Start>
              <Length>21</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/N1-methylnicotinamide</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-457</Extra>
            </Markup>
            <Markup>
              <Start>788</Start>
              <Length>11</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacinamide</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-936</Extra>
            </Markup>
            <Markup>
              <Start>927</Start>
              <Length>21</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/N1-methylnicotinamide</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-457</Extra>
            </Markup>
            <Markup>
              <Start>1035</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
          </StringWithMarkup>
        </Value>
      </Information>
      <Information>
        <ReferenceNumber>32</ReferenceNumber>
        <Description>**PEER REVIEWED**</Description>
        <Reference>Cosmetic Ingredient Review (CIR) Expert Panel; Final Report of the Safety Assessment of Niacinamide and Niacin; Intl J of Toxicology 24 (Suppl 5): p.8 (2005). Available from, as of July 23, 218: https://www.cir-safety.org/ingredients</Reference>
        <Value>
          <StringWithMarkup>
            <String>N1-methyl-4- pyridone-3-carboxamide is a major metabolite of niacin and niacinamide which has been found to be synthesized from N1- methylnicotinamide.</String>
            <Markup>
              <Start>0</Start>
              <Length>35</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/N1-methyl-4-pyridone-3-carboxamide</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-440810</Extra>
            </Markup>
            <Markup>
              <Start>61</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>72</Start>
              <Length>11</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacinamide</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-936</Extra>
            </Markup>
            <Markup>
              <Start>128</Start>
              <Length>22</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/N1-methylnicotinamide</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-457</Extra>
            </Markup>
          </StringWithMarkup>
        </Value>
      </Information>
      <Information>
        <ReferenceNumber>32</ReferenceNumber>
        <Description>**PEER REVIEWED**</Description>
        <Reference>Cosmetic Ingredient Review (CIR) Expert Panel; Final Report of the Safety Assessment of Niacinamide and Niacin; Intl J of Toxicology 24 (Suppl 5): p.9 (2005). Available from, as of July 23, 2018: https://www.cir-safety.org/ingredients</Reference>
        <Value>
          <StringWithMarkup>
            <String>Rats /were feed/ two diets (a low-protein maize and a synthetic casein) in separate groups (8 animals per group). The maize diet was deficient in niacin while the casein diet contained normal amounts of niacin. Urinary excretion was measured. Rats given the maize diet deficient in niacin excreted a small amount of N1-methyl-nicotinamide, niacin, and niacinamide, while those fed the normal casein diet excreted daily 0.24 mg N1-methylnicotinamide and 0.04 mg total tertiary nicotinyl compounds per rat. Both deficient and normal rats fed the casein diet excreted niacin and niacinamide in equal proportions. After dosing with 2.5 mg niacin, the major urinary excretion products in deficient rats were N1-methylnicotinamide and nicotinuric acid; in normal animals, the major urinary excretion products in descending order were N1-methylnicotinamide, nicotinuric acid, niacin, and niacinamide. Deficient and normal rats dosed with 2.5 mg niacinamide excreted N1- methylnicotinamide, niacinamide, but no nicotinuric acid.</String>
            <Markup>
              <Start>146</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>203</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>282</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>340</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>352</Start>
              <Length>11</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacinamide</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-936</Extra>
            </Markup>
            <Markup>
              <Start>427</Start>
              <Length>21</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/N1-methylnicotinamide</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-457</Extra>
            </Markup>
            <Markup>
              <Start>565</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>576</Start>
              <Length>11</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacinamide</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-936</Extra>
            </Markup>
            <Markup>
              <Start>635</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>703</Start>
              <Length>21</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/N1-methylnicotinamide</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-457</Extra>
            </Markup>
            <Markup>
              <Start>729</Start>
              <Length>16</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/nicotinuric%20acid</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-68499</Extra>
            </Markup>
            <Markup>
              <Start>828</Start>
              <Length>21</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/N1-methylnicotinamide</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-457</Extra>
            </Markup>
            <Markup>
              <Start>851</Start>
              <Length>16</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/nicotinuric%20acid</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-68499</Extra>
            </Markup>
            <Markup>
              <Start>869</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>881</Start>
              <Length>11</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacinamide</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-936</Extra>
            </Markup>
            <Markup>
              <Start>938</Start>
              <Length>11</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacinamide</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-936</Extra>
            </Markup>
            <Markup>
              <Start>959</Start>
              <Length>22</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/N1-methylnicotinamide</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-457</Extra>
            </Markup>
            <Markup>
              <Start>983</Start>
              <Length>11</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacinamide</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-936</Extra>
            </Markup>
            <Markup>
              <Start>1003</Start>
              <Length>16</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/nicotinuric%20acid</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-68499</Extra>
            </Markup>
          </StringWithMarkup>
        </Value>
      </Information>
      <Information>
        <ReferenceNumber>32</ReferenceNumber>
        <Description>**PEER REVIEWED**</Description>
        <Reference>Cosmetic Ingredient Review (CIR) Expert Panel; Final Report of the Safety Assessment of Niacinamide and Niacin; Intl J of Toxicology 24 (Suppl 5): p.8 (2005). Available from, as of July 23, 2018: https://www.cir-safety.org/ingredients</Reference>
        <Value>
          <StringWithMarkup>
            <String>Sixty-five young male Sprague-Dawley rats (about 150 g each) /were injected/ with 14(C)-carboxyl labeled niacin, urine /was collected/  and identified radiolabeled metabolites /were isolated/. N-methyl-4-pyridone-5-carboxamide /was identified/ as a major normal metabolite of niacin in the rat, along with N-methylnicotinamide, N-methyl-2-pyridone-5-carboxamide,  and nicotinamide.</String>
            <Markup>
              <Start>105</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>193</Start>
              <Length>19</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/N-methyl-4-pyridone</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-136515</Extra>
            </Markup>
            <Markup>
              <Start>276</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>306</Start>
              <Length>20</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/N-methylnicotinamide</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-64950</Extra>
            </Markup>
            <Markup>
              <Start>328</Start>
              <Length>33</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/N-methyl-2-pyridone-5-carboxamide</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-69698</Extra>
            </Markup>
            <Markup>
              <Start>368</Start>
              <Length>12</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/nicotinamide</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-936</Extra>
            </Markup>
          </StringWithMarkup>
        </Value>
      </Information>
      <Information>
        <ReferenceNumber>32</ReferenceNumber>
        <Description>**PEER REVIEWED**</Description>
        <Reference>Shibata K et al; J Nutr Sci Vitaminol (Tokyo) 60 (2): 86-93 (2014)</Reference>
        <Value>
          <StringWithMarkup>
            <String>Two compounds are known as the vitamin niacin: nicotinic acid (NiA) and nicotinamide (Nam). The physiological functions and metabolic fates of NiA and Nam are identical, but differ when pharmacological doses are administered. Our study aimed to investigate the metabolic interactions between NiA and Nam when their pharmacological doses were administered together. We measured seven major niacin catabolites, including NiA, Nam, N(1)-methylnicotinamide (MNA), N(1)-methyl-2-pyridone-5-carboxamide (2-Py), N(1)-methyl-4-pyridone-3-carboxamide (4-Py), Nam N-oxide, and nicotinuric acid (NuA). Under physiological conditions, niacin is chiefly catabolized to 4-Py via MNA. However, this was not the primary pathway when rats were fed a diet containing excess niacin. When rats were fed a diet containing excess NiA, NuA was the major catabolite, and on being fed a diet containing excess Nam, MNA was the major catabolite. When rats were fed a diet containing an excess of both NiA and Nam, MNA and NuA were the major catabolites. The metabolic fates of excess NiA and Nam did not mutually interfere. Therefore, the administration of NiA and Nam together may be better than the administration of NiA or Nam alone because different pharmacological effects are expected. PubMed Abstract</String>
            <Markup>
              <Start>1266</Start>
              <Length>15</Length>
              <URL>http://www.ncbi.nlm.nih.gov/pubmed/24975217?dopt=Abstract</URL>
            </Markup>
            <Markup>
              <Start>39</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>47</Start>
              <Length>14</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/nicotinic%20acid</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>72</Start>
              <Length>12</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/nicotinamide</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-936</Extra>
            </Markup>
            <Markup>
              <Start>389</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>429</Start>
              <Length>23</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/N%281%29-methylnicotinamide</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-457</Extra>
            </Markup>
            <Markup>
              <Start>460</Start>
              <Length>36</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/N%281%29-methyl-2-pyridone-5-carboxamide</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-69698</Extra>
            </Markup>
            <Markup>
              <Start>505</Start>
              <Length>36</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/N%281%29-methyl-4-pyridone-3-carboxamide</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-160670</Extra>
            </Markup>
            <Markup>
              <Start>567</Start>
              <Length>16</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/nicotinuric%20acid</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-68499</Extra>
            </Markup>
            <Markup>
              <Start>623</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>756</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
          </StringWithMarkup>
        </Value>
      </Information>
      <Information>
        <ReferenceNumber>32</ReferenceNumber>
        <Description>**PEER REVIEWED**</Description>
        <Reference>Mrochek JE et al; Clin Chem 22 (11): 1821-7 (1976)</Reference>
        <Value>
          <StringWithMarkup>
            <String>The identification of nicotinamide-N1-oxide as a metabolite in the urine of a schizophrenic patient prompted a study of the relative metabolism of nicotinic acid and nicotinamide in mental patients and healthy volunteers. Metabolites quantified included N1-methyl-2-pyridone-5-carboxamide, N1-methyl-4-pyridone-3-carboxamide, N1-methylnicotinamide, nicotinuric acid, and nicotinamide-N1-oxide. More of ... these metabolites evidently was excreted after nicotinamide ingestion than after nicotinic acid. At the highest doses (3000 mg/day), the relative proportions of these metabolites in the urine were changed. There were only slight difference between healthy individuals and mental patients in the quantities of metabolites excreted, and no statistically significant trends were noted. PubMed Abstract</String>
            <Markup>
              <Start>789</Start>
              <Length>15</Length>
              <URL>http://www.ncbi.nlm.nih.gov/pubmed/135660?dopt=Abstract</URL>
            </Markup>
            <Markup>
              <Start>147</Start>
              <Length>14</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/nicotinic%20acid</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>166</Start>
              <Length>12</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/nicotinamide</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-936</Extra>
            </Markup>
            <Markup>
              <Start>254</Start>
              <Length>34</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/N1-methyl-2-pyridone-5-carboxamide</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-69698</Extra>
            </Markup>
            <Markup>
              <Start>290</Start>
              <Length>34</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/N1-methyl-4-pyridone-3-carboxamide</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-440810</Extra>
            </Markup>
            <Markup>
              <Start>326</Start>
              <Length>21</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/N1-methylnicotinamide</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-457</Extra>
            </Markup>
            <Markup>
              <Start>349</Start>
              <Length>16</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/nicotinuric%20acid</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-68499</Extra>
            </Markup>
            <Markup>
              <Start>453</Start>
              <Length>12</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/nicotinamide</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-936</Extra>
            </Markup>
            <Markup>
              <Start>487</Start>
              <Length>14</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/nicotinic%20acid</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
          </StringWithMarkup>
        </Value>
      </Information>
    </Section>
    <Section>
      <TOCHeading>Biological Half-Life</TOCHeading>
      <Description>Biological Half-Life information related to the record</Description>
      <Information>
        <ReferenceNumber>17</ReferenceNumber>
        <Name>Biological Half-Life</Name>
        <Value>
          <StringWithMarkup>
            <String>20-45 minutes.</String>
          </StringWithMarkup>
        </Value>
      </Information>
      <Information>
        <ReferenceNumber>32</ReferenceNumber>
        <Description>**PEER REVIEWED**</Description>
        <Reference>Mularski RA et al; Clin Toxicol (Phila) 44 (1): 81-4 (2006)</Reference>
        <Value>
          <StringWithMarkup>
            <String>/The authors/ describe a case of massive oral niacin overdose that resulted in severe persistent hypotension without the manifestation of cutaneous flushing. ...  A 56-year-old male with a history of schizophrenia presented to the emergency department after orally ingesting 11,000 mg of niacin. ... Serum niacin levels were 8.2 ug/mL and 5.6 ug/mL at 48 and 96 hours post ingestion, respectively, giving an apparent half-life of 87 hours. ... PubMed Abstract</String>
            <Markup>
              <Start>444</Start>
              <Length>15</Length>
              <URL>http://www.ncbi.nlm.nih.gov/pubmed/16496499?dopt=Abstract</URL>
            </Markup>
            <Markup>
              <Start>46</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>288</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>306</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
          </StringWithMarkup>
        </Value>
      </Information>
      <Information>
        <ReferenceNumber>32</ReferenceNumber>
        <Description>**PEER REVIEWED**</Description>
        <Reference>Knoben, J.E. and P.O. Anderson (eds.) Handbook of Clinical Drug Data. 6th ed. Bethesda, MD: Drug Intelligence Publications, Inc. 1988., p. 502</Reference>
        <Value>
          <StringWithMarkup>
            <String>Half-life about 45 min.</String>
          </StringWithMarkup>
        </Value>
      </Information>
      <Information>
        <ReferenceNumber>32</ReferenceNumber>
        <Description>**PEER REVIEWED**</Description>
        <Reference>American Society of Health-System Pharmacists 2017; Drug Information 2017. Bethesda, MD. 2017, p. 1941</Reference>
        <Value>
          <StringWithMarkup>
            <String>The plasma half-life of niacin has been reported to range from 20-60 minutes.</String>
            <Markup>
              <Start>24</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
          </StringWithMarkup>
        </Value>
      </Information>
    </Section>
    <Section>
      <TOCHeading>Mechanism of Action</TOCHeading>
      <Description>Mechanism of Action  information related to the record</Description>
      <Information>
        <ReferenceNumber>17</ReferenceNumber>
        <Name>Mechanism of Action</Name>
        <Value>
          <StringWithMarkup>
            <String>Niacin binds to Nicotinate D-ribonucleotide phyrophsopate phosphoribosyltransferase, Nicotinic acid phosphoribosyltransferase, Nicotinate N-methyltransferase and the Niacin receptor. Niacin is the precursor to nicotinamide adenine dinucleotide (NAD) and nicotinamide adenine dinucleotide phosphate (NADP), which are vital cofactors for dozens of enzymes. The mechanism by which niacin exerts its lipid lowering effects is not entirely understood, but may involve several actions, including a decrease in esterification of hepatic triglycerides. Niacin treatment also decreases the serum levels of apolipoprotein B-100 (apo B), the major protein component of the VLDL (very low-density lipoprotein) and LDL fractions.</String>
            <Markup>
              <Start>0</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/Niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>16</Start>
              <Length>27</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/Nicotinate%20D-ribonucleotide</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-46878382</Extra>
            </Markup>
            <Markup>
              <Start>85</Start>
              <Length>14</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/Nicotinic%20acid</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>127</Start>
              <Length>10</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/Nicotinate</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-937</Extra>
            </Markup>
            <Markup>
              <Start>166</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/Niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>183</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/Niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>210</Start>
              <Length>33</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/nicotinamide%20adenine%20dinucleotide</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-15938971</Extra>
            </Markup>
            <Markup>
              <Start>245</Start>
              <Length>3</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/NAD</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-5893</Extra>
            </Markup>
            <Markup>
              <Start>254</Start>
              <Length>43</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/nicotinamide%20adenine%20dinucleotide%20phosphate</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-42609791</Extra>
            </Markup>
            <Markup>
              <Start>299</Start>
              <Length>4</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/NADP</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-2734411</Extra>
            </Markup>
            <Markup>
              <Start>378</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>545</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/Niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
          </StringWithMarkup>
        </Value>
      </Information>
      <Information>
        <ReferenceNumber>32</ReferenceNumber>
        <Description>**PEER REVIEWED**</Description>
        <Reference>Heemskerk MM et al; J Lipid Res 55 (12): 2532-40 (2014)</Reference>
        <Value>
          <StringWithMarkup>
            <String>Prolonged niacin treatment elicits beneficial effects on the plasma lipid and lipoprotein profile that is associated with a protective CVD risk profile. Acute niacin treatment inhibits nonesterified fatty acid release from adipocytes and stimulates prostaglandin release from skin Langerhans cells, but the acute effects diminish upon prolonged treatment, while the beneficial effects remain. To gain insight in the prolonged effects of niacin on lipid metabolism in adipocytes, we used a mouse model with a human-like lipoprotein metabolism and drug response [female APOE*3-Leiden.CETP (apoE3 Leiden cholesteryl ester transfer protein) mice] treated with and without niacin for 15 weeks. The gene expression profile of gonadal white adipose tissue (gWAT) from niacin-treated mice showed an upregulation of the &quot;biosynthesis of unsaturated fatty acids&quot; pathway, which was corroborated by quantitative PCR and analysis of the FA ratios in gWAT. Also, adipocytes from niacin-treated mice secreted more of the PUFA DHA ex vivo. This resulted in an increased DHA/arachidonic acid (AA) ratio in the adipocyte FA secretion profile and in plasma of niacin-treated mice. Interestingly, the DHA metabolite 19,20-dihydroxy docosapentaenoic acid (19,20-diHDPA) was increased in plasma of niacin-treated mice. Both an increased DHA/AA ratio and increased 19,20-diHDPA are indicative for an anti-inflammatory profile and may indirectly contribute to the atheroprotective lipid and lipoprotein profile associated with prolonged niacin treatment. PubMed Abstract Full text: PMC4242446</String>
            <Markup>
              <Start>1532</Start>
              <Length>15</Length>
              <URL>http://www.ncbi.nlm.nih.gov/pubmed/25320342?dopt=Abstract</URL>
            </Markup>
            <Markup>
              <Start>1559</Start>
              <Length>10</Length>
              <URL>https://www.ncbi.nlm.nih.gov/pmc/?term=PMC4242446</URL>
            </Markup>
            <Markup>
              <Start>10</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>159</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>437</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>668</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>761</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>966</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>1059</Start>
              <Length>16</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/arachidonic%20acid</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-444899</Extra>
            </Markup>
            <Markup>
              <Start>1142</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>1236</Start>
              <Length>12</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/19%2C20-diHDPA</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-16061148</Extra>
            </Markup>
            <Markup>
              <Start>1277</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>1343</Start>
              <Length>12</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/19%2C20-diHDPA</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-16061148</Extra>
            </Markup>
            <Markup>
              <Start>1514</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
          </StringWithMarkup>
        </Value>
      </Information>
      <Information>
        <ReferenceNumber>32</ReferenceNumber>
        <Description>**PEER REVIEWED**</Description>
        <Reference>Wanders D et al; PLoS One 8 (8): e71285 (2013)</Reference>
        <Value>
          <StringWithMarkup>
            <String>/The study objective was/ to determine the effects of niacin on adiponectin and markers of adipose tissue inflammation in a mouse model of obesity. Male C57BL/6 mice were placed on a control or high-fat diet (HFD) and were maintained on such diets for the duration of the study. After 6 weeks on the control or high fat diets, vehicle or niacin treatments were initiated and maintained for 5 weeks. Identical studies were conducted concurrently in HCA2 (-/-) (niacin receptor(-/-)) mice. Niacin increased serum concentrations of the anti-inflammatory adipokine, adiponectin by 21% in HFD-fed wild-type mice, but had no effect on lean wild-type or lean or HFD-fed HCA2 (-/-) mice. Niacin increased adiponectin gene and protein expression in the HFD-fed wild-type mice only. The increases in adiponectin serum concentrations, gene and protein expression occurred independently of changes in expression of PPARgamma C/EBPalpha or SREBP-1c (key transcription factors known to positively regulate adiponectin gene transcription) in the adipose tissue. Further, niacin had no effect on adipose tissue expression of ERp44, Ero1-Lalpha, or DsbA-L (key ER chaperones involved in adiponectin production and secretion). However, niacin treatment attenuated HFD-induced increases in adipose tissue gene expression of MCP-1 and IL-1beta in the wild-type HFD-fed mice. Niacin also reduced the expression of the pro-inflammatory M1 macrophage marker CD11c in HFD-fed wild-type mice. Niacin treatment attenuates obesity-induced adipose tissue inflammation through increased adiponectin and anti-inflammatory cytokine expression and reduced pro-inflammatory cytokine expression in a niacin receptor-dependent manner. PubMed Abstract Full text: PMC3742781</String>
            <Markup>
              <Start>1700</Start>
              <Length>15</Length>
              <URL>http://www.ncbi.nlm.nih.gov/pubmed/23967184?dopt=Abstract</URL>
            </Markup>
            <Markup>
              <Start>1727</Start>
              <Length>10</Length>
              <URL>https://www.ncbi.nlm.nih.gov/pmc/?term=PMC3742781</URL>
            </Markup>
            <Markup>
              <Start>54</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>338</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>460</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>488</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/Niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>680</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/Niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>1056</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>1132</Start>
              <Length>4</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/DsbA</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-29924549</Extra>
            </Markup>
            <Markup>
              <Start>1218</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>1355</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/Niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>1468</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/Niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>1666</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
          </StringWithMarkup>
        </Value>
      </Information>
      <Information>
        <ReferenceNumber>32</ReferenceNumber>
        <Description>**PEER REVIEWED**</Description>
        <Reference>Tunaru S et al; Nat Med 9 (3): 352-5 (2003)</Reference>
        <Value>
          <StringWithMarkup>
            <String>Nicotinic acid (niacin), a vitamin of the B complex, has been used for almost 50 years as a lipid-lowering drug. The pharmacological effect of nicotinic acid requires doses that are much higher than those provided by a normal diet. Its primary action is to decrease lipolysis in adipose tissue by inhibiting hormone-sensitive triglyceride lipase. This anti-lipolytic effect of nicotinic acid involves the inhibition of cyclic adenosine monophosphate (cAMP) accumulation in adipose tissue through a G(i)-protein-mediated inhibition of adenylyl cyclase. A G-protein-coupled receptor for nicotinic acid has been proposed in adipocytes. Here, we show that the orphan G-protein-coupled receptor, &quot;protein upregulated in macrophages by interferon-gamma&quot; (mouse PUMA-G, human HM74), is highly expressed in adipose tissue and is a nicotinic acid receptor. Binding of nicotinic acid to PUMA-G or HM74 results in a G(i)-mediated decrease in cAMP levels. In mice lacking PUMA-G, the nicotinic acid-induced decrease in free fatty acid (FFA) and triglyceride plasma levels was abrogated, indicating that PUMA-G mediates the anti-lipolytic and lipid-lowering effects of nicotinic acid in vivo. The identification of the nicotinic acid receptor may be useful in the development of new drugs to treat dyslipidemia. PubMed Abstract</String>
            <Markup>
              <Start>1299</Start>
              <Length>15</Length>
              <URL>http://www.ncbi.nlm.nih.gov/pubmed/12563315?dopt=Abstract</URL>
            </Markup>
            <Markup>
              <Start>0</Start>
              <Length>14</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/Nicotinic%20acid</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>16</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>143</Start>
              <Length>14</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/nicotinic%20acid</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>377</Start>
              <Length>14</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/nicotinic%20acid</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>451</Start>
              <Length>4</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/cAMP</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-6076</Extra>
            </Markup>
            <Markup>
              <Start>585</Start>
              <Length>14</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/nicotinic%20acid</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>823</Start>
              <Length>14</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/nicotinic%20acid</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>859</Start>
              <Length>14</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/nicotinic%20acid</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>931</Start>
              <Length>4</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/cAMP</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-6076</Extra>
            </Markup>
            <Markup>
              <Start>972</Start>
              <Length>14</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/nicotinic%20acid</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>1156</Start>
              <Length>14</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/nicotinic%20acid</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>1206</Start>
              <Length>14</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/nicotinic%20acid</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
          </StringWithMarkup>
        </Value>
      </Information>
    </Section>
    <Section>
      <TOCHeading>Human Metabolite Information</TOCHeading>
      <Description>Chemical metabolite information from the Human Metabolome Database (HMDB).</Description>
      <URL>http://www.hmdb.ca/</URL>
      <Section>
        <TOCHeading>Metabolite Description</TOCHeading>
        <Description>Chemical description of the compound for metabolite studies</Description>
        <Information>
          <ReferenceNumber>33</ReferenceNumber>
          <Name>Description</Name>
          <Value>
            <StringWithMarkup>
              <String>Nicotinic acid, also known as niacin or vitamin B3, is a water-soluble vitamin whose derivatives such as NADH, NAD, NAD+, and NADP play essential roles in energy metabolism in the living cell and DNA repair. The designation vitamin B3 also includes the amide form, nicotinamide or niacinamide. Severe lack of niacin causes the deficiency disease pellagra, whereas a mild deficiency slows down the metabolism decreasing cold tolerance. The recommended daily allowance of niacin is 2-12 mg a day for children, 14 mg a day for women, 16 mg a day for men, and 18 mg a day for pregnant or breast-feeding women. It is found in various animal and plant tissues and has pellagra-curative, vasodilating, and antilipemic properties. The liver can synthesize niacin from the essential amino acid tryptophan (see below), but the synthesis is extremely slow and requires vitamin B6; 60 mg of tryptophan are required to make one milligram of niacin. Bacteria in the gut may also perform the conversion but are inefficient.</String>
              <Markup>
                <Start>0</Start>
                <Length>14</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/Nicotinic%20acid</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>30</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>40</Start>
                <Length>10</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/vitamin%20B3</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>57</Start>
                <Length>5</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/water</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-962</Extra>
              </Markup>
              <Markup>
                <Start>105</Start>
                <Length>4</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/NADH</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-439153</Extra>
              </Markup>
              <Markup>
                <Start>111</Start>
                <Length>3</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/NAD</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-5893</Extra>
              </Markup>
              <Markup>
                <Start>116</Start>
                <Length>4</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/NAD%2B</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-5893</Extra>
              </Markup>
              <Markup>
                <Start>126</Start>
                <Length>4</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/NADP</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-2734411</Extra>
              </Markup>
              <Markup>
                <Start>224</Start>
                <Length>10</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/vitamin%20B3</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>265</Start>
                <Length>12</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/nicotinamide</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-936</Extra>
              </Markup>
              <Markup>
                <Start>281</Start>
                <Length>11</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacinamide</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-936</Extra>
              </Markup>
              <Markup>
                <Start>309</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>470</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>748</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>785</Start>
                <Length>10</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/tryptophan</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-6305</Extra>
              </Markup>
              <Markup>
                <Start>858</Start>
                <Length>10</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/vitamin%20B6</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>multiple-CIDs</Extra>
              </Markup>
              <Markup>
                <Start>879</Start>
                <Length>10</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/tryptophan</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-6305</Extra>
              </Markup>
              <Markup>
                <Start>928</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
            </StringWithMarkup>
          </Value>
        </Information>
      </Section>
      <Section>
        <TOCHeading>Tissue Locations</TOCHeading>
        <Description>The metabolome location in tissue</Description>
        <DisplayControls>
          <ListType>Columns</ListType>
        </DisplayControls>
        <Information>
          <ReferenceNumber>33</ReferenceNumber>
          <Name>Tissue Locations</Name>
          <Value>
            <StringWithMarkup>
              <String>Adipose Tissue</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Fibroblasts</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Intestine</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Kidney</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Liver</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Most Tissues</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Skeletal Muscle</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Skin</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Stratum Corneum</String>
            </StringWithMarkup>
          </Value>
        </Information>
      </Section>
      <Section>
        <TOCHeading>Cellular Locations</TOCHeading>
        <Description>The metabolome in Cellular Locations</Description>
        <DisplayControls>
          <ListType>Columns</ListType>
        </DisplayControls>
        <Information>
          <ReferenceNumber>33</ReferenceNumber>
          <Name>Cellular Locations</Name>
          <Value>
            <StringWithMarkup>
              <String>Cytoplasm</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Extracellular</String>
            </StringWithMarkup>
          </Value>
        </Information>
      </Section>
      <Section>
        <TOCHeading>Metabolite Pathways</TOCHeading>
        <Description>Metabolite Pathways</Description>
        <DisplayControls>
          <ListType>Columns</ListType>
        </DisplayControls>
        <Information>
          <ReferenceNumber>33</ReferenceNumber>
          <Name>Metabolite Pathways</Name>
          <Value>
            <StringWithMarkup>
              <String>Nicotinate and Nicotinamide Metabolism</String>
              <Markup>
                <Start>0</Start>
                <Length>38</Length>
                <URL>http://smpdb.ca/view/SMP00048</URL>
              </Markup>
              <Markup>
                <Start>0</Start>
                <Length>10</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/Nicotinate</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-937</Extra>
              </Markup>
              <Markup>
                <Start>15</Start>
                <Length>12</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/Nicotinamide</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-936</Extra>
              </Markup>
            </StringWithMarkup>
          </Value>
        </Information>
      </Section>
      <Section>
        <TOCHeading>Associated Disorders and Diseases</TOCHeading>
        <Description>Associated disorders, diseases and related references</Description>
        <DisplayControls>
          <CreateTable>
            <FromInformationIn>ThisSection</FromInformationIn>
            <NumberOfColumns>2</NumberOfColumns>
            <ColumnHeadings>Diseases</ColumnHeadings>
            <ColumnHeadings>References</ColumnHeadings>
            <ColumnContents>Name</ColumnContents>
            <ColumnContents>Value</ColumnContents>
          </CreateTable>
        </DisplayControls>
        <Information>
          <ReferenceNumber>33</ReferenceNumber>
          <Name>Alcoholism</Name>
          <Value>
            <StringWithMarkup>
              <String>PubMed: 182198, 15340856, 11958947, 16959481, 2779169, 9717263, 3410397, 8723414</String>
              <Markup>
                <Start>8</Start>
                <Length>6</Length>
                <URL>https://www.ncbi.nlm.nih.gov/pubmed/182198</URL>
              </Markup>
              <Markup>
                <Start>16</Start>
                <Length>8</Length>
                <URL>https://www.ncbi.nlm.nih.gov/pubmed/15340856</URL>
              </Markup>
              <Markup>
                <Start>26</Start>
                <Length>8</Length>
                <URL>https://www.ncbi.nlm.nih.gov/pubmed/11958947</URL>
              </Markup>
              <Markup>
                <Start>36</Start>
                <Length>8</Length>
                <URL>https://www.ncbi.nlm.nih.gov/pubmed/16959481</URL>
              </Markup>
              <Markup>
                <Start>46</Start>
                <Length>7</Length>
                <URL>https://www.ncbi.nlm.nih.gov/pubmed/2779169</URL>
              </Markup>
              <Markup>
                <Start>55</Start>
                <Length>7</Length>
                <URL>https://www.ncbi.nlm.nih.gov/pubmed/9717263</URL>
              </Markup>
              <Markup>
                <Start>64</Start>
                <Length>7</Length>
                <URL>https://www.ncbi.nlm.nih.gov/pubmed/3410397</URL>
              </Markup>
              <Markup>
                <Start>73</Start>
                <Length>7</Length>
                <URL>https://www.ncbi.nlm.nih.gov/pubmed/8723414</URL>
              </Markup>
            </StringWithMarkup>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>33</ReferenceNumber>
          <Name>Colorectal cancer</Name>
          <Value>
            <StringWithMarkup>
              <String>PubMed: 7482520, 19006102, 23940645, 24424155, 20156336, 19678709, 22148915, 25105552, 21773981, 25037050, 27015276, 27107423, 27275383, 28587349</String>
              <Markup>
                <Start>8</Start>
                <Length>7</Length>
                <URL>https://www.ncbi.nlm.nih.gov/pubmed/7482520</URL>
              </Markup>
              <Markup>
                <Start>17</Start>
                <Length>8</Length>
                <URL>https://www.ncbi.nlm.nih.gov/pubmed/19006102</URL>
              </Markup>
              <Markup>
                <Start>27</Start>
                <Length>8</Length>
                <URL>https://www.ncbi.nlm.nih.gov/pubmed/23940645</URL>
              </Markup>
              <Markup>
                <Start>37</Start>
                <Length>8</Length>
                <URL>https://www.ncbi.nlm.nih.gov/pubmed/24424155</URL>
              </Markup>
              <Markup>
                <Start>47</Start>
                <Length>8</Length>
                <URL>https://www.ncbi.nlm.nih.gov/pubmed/20156336</URL>
              </Markup>
              <Markup>
                <Start>57</Start>
                <Length>8</Length>
                <URL>https://www.ncbi.nlm.nih.gov/pubmed/19678709</URL>
              </Markup>
              <Markup>
                <Start>67</Start>
                <Length>8</Length>
                <URL>https://www.ncbi.nlm.nih.gov/pubmed/22148915</URL>
              </Markup>
              <Markup>
                <Start>77</Start>
                <Length>8</Length>
                <URL>https://www.ncbi.nlm.nih.gov/pubmed/25105552</URL>
              </Markup>
              <Markup>
                <Start>87</Start>
                <Length>8</Length>
                <URL>https://www.ncbi.nlm.nih.gov/pubmed/21773981</URL>
              </Markup>
              <Markup>
                <Start>97</Start>
                <Length>8</Length>
                <URL>https://www.ncbi.nlm.nih.gov/pubmed/25037050</URL>
              </Markup>
              <Markup>
                <Start>107</Start>
                <Length>8</Length>
                <URL>https://www.ncbi.nlm.nih.gov/pubmed/27015276</URL>
              </Markup>
              <Markup>
                <Start>117</Start>
                <Length>8</Length>
                <URL>https://www.ncbi.nlm.nih.gov/pubmed/27107423</URL>
              </Markup>
              <Markup>
                <Start>127</Start>
                <Length>8</Length>
                <URL>https://www.ncbi.nlm.nih.gov/pubmed/27275383</URL>
              </Markup>
              <Markup>
                <Start>137</Start>
                <Length>8</Length>
                <URL>https://www.ncbi.nlm.nih.gov/pubmed/28587349</URL>
              </Markup>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Silke Matysik, Caroline Ivanne Le Roy, Gerhard Liebisch, Sandrine Paule Claus. Metabolomics of fecal samples: A practical consideration. Trends in Food Science &amp; Technology. Vol. 57, Part B, Nov. 2016, p.244-255: http://www.sciencedirect.com/science/article/pii/S0924224416301984</String>
            </StringWithMarkup>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>33</ReferenceNumber>
          <Name>Crohn&apos;s disease</Name>
          <Value>
            <StringWithMarkup>
              <String>PubMed: 16440420, 11418788, 8723414, 19491857, 17269711, 23516449, 23867873, 24811995, 25598765, 26806034, 26848182, 27609529, 28842642</String>
              <Markup>
                <Start>8</Start>
                <Length>8</Length>
                <URL>https://www.ncbi.nlm.nih.gov/pubmed/16440420</URL>
              </Markup>
              <Markup>
                <Start>18</Start>
                <Length>8</Length>
                <URL>https://www.ncbi.nlm.nih.gov/pubmed/11418788</URL>
              </Markup>
              <Markup>
                <Start>28</Start>
                <Length>7</Length>
                <URL>https://www.ncbi.nlm.nih.gov/pubmed/8723414</URL>
              </Markup>
              <Markup>
                <Start>37</Start>
                <Length>8</Length>
                <URL>https://www.ncbi.nlm.nih.gov/pubmed/19491857</URL>
              </Markup>
              <Markup>
                <Start>47</Start>
                <Length>8</Length>
                <URL>https://www.ncbi.nlm.nih.gov/pubmed/17269711</URL>
              </Markup>
              <Markup>
                <Start>57</Start>
                <Length>8</Length>
                <URL>https://www.ncbi.nlm.nih.gov/pubmed/23516449</URL>
              </Markup>
              <Markup>
                <Start>67</Start>
                <Length>8</Length>
                <URL>https://www.ncbi.nlm.nih.gov/pubmed/23867873</URL>
              </Markup>
              <Markup>
                <Start>77</Start>
                <Length>8</Length>
                <URL>https://www.ncbi.nlm.nih.gov/pubmed/24811995</URL>
              </Markup>
              <Markup>
                <Start>87</Start>
                <Length>8</Length>
                <URL>https://www.ncbi.nlm.nih.gov/pubmed/25598765</URL>
              </Markup>
              <Markup>
                <Start>97</Start>
                <Length>8</Length>
                <URL>https://www.ncbi.nlm.nih.gov/pubmed/26806034</URL>
              </Markup>
              <Markup>
                <Start>107</Start>
                <Length>8</Length>
                <URL>https://www.ncbi.nlm.nih.gov/pubmed/26848182</URL>
              </Markup>
              <Markup>
                <Start>117</Start>
                <Length>8</Length>
                <URL>https://www.ncbi.nlm.nih.gov/pubmed/27609529</URL>
              </Markup>
              <Markup>
                <Start>127</Start>
                <Length>8</Length>
                <URL>https://www.ncbi.nlm.nih.gov/pubmed/28842642</URL>
              </Markup>
            </StringWithMarkup>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>33</ReferenceNumber>
          <Name>Ulcerative colitis</Name>
          <Value>
            <StringWithMarkup>
              <String>PubMed: 21059682, 1740537, 17269711, 17314143, 21761941, 23516449, 23867873, 24811995, 25598765, 26806034, 26848182, 27609529, 28842642</String>
              <Markup>
                <Start>8</Start>
                <Length>8</Length>
                <URL>https://www.ncbi.nlm.nih.gov/pubmed/21059682</URL>
              </Markup>
              <Markup>
                <Start>18</Start>
                <Length>7</Length>
                <URL>https://www.ncbi.nlm.nih.gov/pubmed/1740537</URL>
              </Markup>
              <Markup>
                <Start>27</Start>
                <Length>8</Length>
                <URL>https://www.ncbi.nlm.nih.gov/pubmed/17269711</URL>
              </Markup>
              <Markup>
                <Start>37</Start>
                <Length>8</Length>
                <URL>https://www.ncbi.nlm.nih.gov/pubmed/17314143</URL>
              </Markup>
              <Markup>
                <Start>47</Start>
                <Length>8</Length>
                <URL>https://www.ncbi.nlm.nih.gov/pubmed/21761941</URL>
              </Markup>
              <Markup>
                <Start>57</Start>
                <Length>8</Length>
                <URL>https://www.ncbi.nlm.nih.gov/pubmed/23516449</URL>
              </Markup>
              <Markup>
                <Start>67</Start>
                <Length>8</Length>
                <URL>https://www.ncbi.nlm.nih.gov/pubmed/23867873</URL>
              </Markup>
              <Markup>
                <Start>77</Start>
                <Length>8</Length>
                <URL>https://www.ncbi.nlm.nih.gov/pubmed/24811995</URL>
              </Markup>
              <Markup>
                <Start>87</Start>
                <Length>8</Length>
                <URL>https://www.ncbi.nlm.nih.gov/pubmed/25598765</URL>
              </Markup>
              <Markup>
                <Start>97</Start>
                <Length>8</Length>
                <URL>https://www.ncbi.nlm.nih.gov/pubmed/26806034</URL>
              </Markup>
              <Markup>
                <Start>107</Start>
                <Length>8</Length>
                <URL>https://www.ncbi.nlm.nih.gov/pubmed/26848182</URL>
              </Markup>
              <Markup>
                <Start>117</Start>
                <Length>8</Length>
                <URL>https://www.ncbi.nlm.nih.gov/pubmed/27609529</URL>
              </Markup>
              <Markup>
                <Start>127</Start>
                <Length>8</Length>
                <URL>https://www.ncbi.nlm.nih.gov/pubmed/28842642</URL>
              </Markup>
            </StringWithMarkup>
          </Value>
        </Information>
      </Section>
    </Section>
  </Section>
  <Section>
    <TOCHeading>Use and Manufacturing</TOCHeading>
    <Description>The use and manufacture of the chemical and related information</Description>
    <Section>
      <TOCHeading>Overview</TOCHeading>
      <Description>Overview</Description>
      <Information>
        <ReferenceNumber>32</ReferenceNumber>
        <Description>**PEER REVIEWED**</Description>
        <Reference>FOR MORE INFORMATION: (1) National Library of Medicine Hazardous Substances Data Bank. Available from, as of June 19, 2018: http://toxnet.nlm.nih.gov/newtoxnet/hsdb.htm (2) IARC Monographs on the Evaluation of the Carcinogenic Risk of Chemicals to Man. Available from, as of Jun 19, 2018: http://monographs.iarc.fr/ENG/Classification/index.php (3) National Toxicology Program. 2016. Report on Carcinogens, 14th ed., Research Triangle Park, NC: US Dept Health Human Serv, Public Health Serv. Available from, as of June 19, 2018: https://ntp.niehs.nih.gov/pubhealth/roc/index-1.html (4) National Library of Medicine. MedlinePlus. Available from, as of June 19, 2018: http://www.nlm.nih.gov/medlineplus/druginformation.html (5) National Library of Medicine PubMed. Available from, as of June 19, 2018: http://www.ncbi.nlm.nih.gov/pubmed (6) USEPA/IRIS Integrated Risk Information System. Available from, as of June 19, 2018: http://www.epa.gov/iris/ (7) US FDA. Everything Added to Food in the United States (EAFUS). November 2011. Nicotinic acid. Available from, as of June 19, 2018: http://www.accessdata.fda.gov/scripts/fcn/fcnNavigation.cfm?rpt=eafusListing (8) US FDA; SCOGS (Select Committee on GRAS Substances). SCOGS Opinion: Nicotinic acid. Available from, as of June 19, 2018: http://www.accessdata.fda.gov/scripts/fdcc/index.cfm?set=SCOGS</Reference>
        <Value>
          <StringWithMarkup>
            <String>IDENTIFICATION: Nicotinic acid, or niacin or vitamin B, is a colorless needle-like solid. It is odorless. It is slightly soluble in water. Nicotinic acid is present in all living cells and it is essential for normal growth and health in humans and animals. USE: Nicotinic acid is used to make other chemicals and is added to feeds and flours as a dietary supplement. It is also used as a medication. Nicotinic acid is also used in electroplating baths. EXPOSURE: Workers who use nicotinic acid may breathe in vapors or have direct skin contact. The general population may be exposed by consumption of food and administration of medications. If nicotinic acid is released to the environment, it will be broken down in air. It is not expected to be broken down by sunlight. It will not move into air from moist soil and water surfaces. It is expected to move through soil. It will be broken down by microorganisms, and is not expected to build up in fish. RISK: Nicotinic acid is a Generally Regarded As Safe (GRAS) chemical when used as indicated, and has a low risk of toxicity in humans. Skin rash and redness developed among some workers after repeated contact with nicotinic acid. Side effects have been reported in some patients taking nicotinic acid to treat medical conditions. The most common are skin effects (redness, rash, itching), stomach upset (nausea, heartburn, ulcer, vomiting), and temporary changes in liver function. Elevated blood sugar levels, decreased blood pressure, rapid heart rate, fainting, and vision problems have been reported in some patients. Permanent liver damage and gout have been reported in a few cases following large daily doses. Data on the potential for nicotinic acid to cause infertility in laboratory animals were not available. No evidence of abortion or birth defects was reported in laboratory animals following exposure to nicotinic acid during pregnancy. Tumors were not induced in laboratory animals following lifetime exposure to nicotinic acid in drinking water. The potential for nicotinic acid to cause cancer in humans has not been assessed by the U.S. EPA IRIS program, the International Agency for Research on Cancer, or the U.S. National Toxicology Program 14th Report on Carcinogens. (SRC)</String>
            <Markup>
              <Start>16</Start>
              <Length>14</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/Nicotinic%20acid</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>35</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>132</Start>
              <Length>5</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/water</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-962</Extra>
            </Markup>
            <Markup>
              <Start>139</Start>
              <Length>14</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/Nicotinic%20acid</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>262</Start>
              <Length>14</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/Nicotinic%20acid</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>400</Start>
              <Length>14</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/Nicotinic%20acid</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>479</Start>
              <Length>14</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/nicotinic%20acid</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>644</Start>
              <Length>14</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/nicotinic%20acid</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>818</Start>
              <Length>5</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/water</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-962</Extra>
            </Markup>
            <Markup>
              <Start>960</Start>
              <Length>14</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/Nicotinic%20acid</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>1168</Start>
              <Length>14</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/nicotinic%20acid</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>1240</Start>
              <Length>14</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/nicotinic%20acid</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>1697</Start>
              <Length>14</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/nicotinic%20acid</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>1873</Start>
              <Length>14</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/nicotinic%20acid</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>1983</Start>
              <Length>14</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/nicotinic%20acid</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>2010</Start>
              <Length>5</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/water</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-962</Extra>
            </Markup>
            <Markup>
              <Start>2035</Start>
              <Length>14</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/nicotinic%20acid</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
          </StringWithMarkup>
        </Value>
      </Information>
    </Section>
    <Section>
      <TOCHeading>Use Classification</TOCHeading>
      <Description>This section contains classification/categfory information from various sources</Description>
      <DisplayControls>
        <CreateTable>
          <FromInformationIn>ThisSection</FromInformationIn>
          <NumberOfColumns>2</NumberOfColumns>
          <ColumnContents>Name</ColumnContents>
          <ColumnContents>Value</ColumnContents>
        </CreateTable>
      </DisplayControls>
      <Information>
        <ReferenceNumber>25</ReferenceNumber>
        <Name>EMA Classes</Name>
        <Value>
          <StringWithMarkup>
            <String>Human, EU pediatric investigation plans</String>
          </StringWithMarkup>
        </Value>
      </Information>
      <Information>
        <ReferenceNumber>26</ReferenceNumber>
        <Name>EMA Classes</Name>
        <Value>
          <StringWithMarkup>
            <String>Human, EU pediatric investigation plans</String>
          </StringWithMarkup>
        </Value>
      </Information>
      <Information>
        <ReferenceNumber>27</ReferenceNumber>
        <Name>EMA Classes</Name>
        <Value>
          <StringWithMarkup>
            <String>Human, EU pediatric investigation plans</String>
          </StringWithMarkup>
        </Value>
      </Information>
    </Section>
    <Section>
      <TOCHeading>Uses</TOCHeading>
      <Description>This section presents the major uses of the chemical in the United States today. In addition, past uses of the chemical are summarized.</Description>
      <Information>
        <ReferenceNumber>32</ReferenceNumber>
        <Description>**PEER REVIEWED**</Description>
        <Reference>National Library of Medicine&apos;s Medical Subject Headings. Citalopram. Online file (MeSH, 2018). Available from, as of February 2, 2018: https://meshb.nlm.nih.gov/search</Reference>
        <Value>
          <StringWithMarkup>
            <String>Hypolipidemic Agents, Vasodilator Agents, Vitamin B Complex</String>
          </StringWithMarkup>
        </Value>
      </Information>
      <Information>
        <ReferenceNumber>32</ReferenceNumber>
        <Description>**PEER REVIEWED**</Description>
        <Reference>National Pesticide Information Retrieval System&apos;s Database on Nicotinic Acid (59-67-6). Available from, as of June 6, 2018: http://npirspublic.ceris.purdue.edu/ppis/</Reference>
        <Value>
          <StringWithMarkup>
            <String>For nicotinic acid (USEPA/OPP Pesticide Code: 056701) there are 0 labels match. /SRP: Not registered for current use in the U.S., but approved pesticide uses may change periodically and so federal, state and local authorities must be consulted for currently approved uses./</String>
            <Markup>
              <Start>4</Start>
              <Length>14</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/nicotinic%20acid</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
          </StringWithMarkup>
        </Value>
      </Information>
      <Information>
        <ReferenceNumber>32</ReferenceNumber>
        <Description>**PEER REVIEWED**</Description>
        <Reference>Larranaga, M.D., Lewis, R.J. Sr., Lewis, R.A.; Hawley&apos;s Condensed Chemical Dictionary 16th  Edition. John Wiley &amp; Sons, Inc. Hoboken, NJ 2016., p. 966</Reference>
        <Value>
          <StringWithMarkup>
            <String>Medicine (cholesterol-lowering agent), nutrition, feeds, enriched flours, dietary supplement</String>
            <Markup>
              <Start>10</Start>
              <Length>11</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/cholesterol</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-5997</Extra>
            </Markup>
          </StringWithMarkup>
        </Value>
      </Information>
      <Information>
        <ReferenceNumber>32</ReferenceNumber>
        <Description>**PEER REVIEWED**</Description>
        <Reference>Van Arnum SD; Niacin, Nicotinamide, and Nicotinic Acid. Kirk-Othmer Encyclopedia of Chemical Technology (1999-2018). John Wiley &amp; Sons, Inc. Online Posting Date: December 4, 2000</Reference>
        <Value>
          <StringWithMarkup>
            <String>.../Has/ been used in the enrichment of bread, flour, and other grain-derived products. Animal feed is routinely supplemented with nicotinic acid ... .</String>
            <Markup>
              <Start>131</Start>
              <Length>14</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/nicotinic%20acid</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
          </StringWithMarkup>
        </Value>
      </Information>
      <Information>
        <ReferenceNumber>32</ReferenceNumber>
        <Description>**PEER REVIEWED**</Description>
        <Reference>Ashford, R.D. Ashford&apos;s Dictionary of Industrial Chemicals. London, England: Wavelength Publications Ltd., 1994., p. 630</Reference>
        <Value>
          <StringWithMarkup>
            <String>Used as a chemical intermediate for the synthesis of azatadine; benzyl nicotinate; 2-chloronicotinic acid; etofibrate; inositol nicotinate; nicametate; nicotinyl alcohol; nifenazone; nikethamide; xanthinol nicotinate</String>
            <Markup>
              <Start>53</Start>
              <Length>9</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/azatadine</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-19861</Extra>
            </Markup>
            <Markup>
              <Start>64</Start>
              <Length>17</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/benzyl%20nicotinate</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-7191</Extra>
            </Markup>
            <Markup>
              <Start>83</Start>
              <Length>22</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/2-chloronicotinic%20acid</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-76258</Extra>
            </Markup>
            <Markup>
              <Start>107</Start>
              <Length>10</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/etofibrate</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-65777</Extra>
            </Markup>
            <Markup>
              <Start>119</Start>
              <Length>19</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/inositol%20nicotinate</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-3720</Extra>
            </Markup>
            <Markup>
              <Start>140</Start>
              <Length>10</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/nicametate</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-71650</Extra>
            </Markup>
            <Markup>
              <Start>152</Start>
              <Length>17</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/nicotinyl%20alcohol</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-7510</Extra>
            </Markup>
            <Markup>
              <Start>171</Start>
              <Length>10</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/nifenazone</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-4487</Extra>
            </Markup>
            <Markup>
              <Start>183</Start>
              <Length>11</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/nikethamide</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-5497</Extra>
            </Markup>
            <Markup>
              <Start>196</Start>
              <Length>20</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/xanthinol%20nicotinate</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-9912</Extra>
            </Markup>
          </StringWithMarkup>
        </Value>
      </Information>
      <Information>
        <ReferenceNumber>32</ReferenceNumber>
        <Description>**PEER REVIEWED**</Description>
        <Reference>Ashford, R.D. Ashford&apos;s Dictionary of Industrial Chemicals. London, England: Wavelength Publications Ltd., 1994., p. 630</Reference>
        <Value>
          <StringWithMarkup>
            <String>Electroplating bath ingredient; vasodilator/lipid reduction drug; cereal/animal feed additive</String>
          </StringWithMarkup>
        </Value>
      </Information>
      <Information>
        <ReferenceNumber>32</ReferenceNumber>
        <Description>**PEER REVIEWED**</Description>
        <Value>
          <StringWithMarkup>
            <String>MEDICATION (VET)</String>
          </StringWithMarkup>
        </Value>
      </Information>
      <Information>
        <ReferenceNumber>32</ReferenceNumber>
        <Description>**PEER REVIEWED**</Description>
        <Value>
          <StringWithMarkup>
            <String>MEDICATION</String>
          </StringWithMarkup>
        </Value>
      </Information>
      <Section>
        <TOCHeading>Industry Uses</TOCHeading>
        <Description>This section presents the information for industrial function categories</Description>
        <DisplayControls>
          <ListType>Columns</ListType>
        </DisplayControls>
        <Information>
          <ReferenceNumber>20</ReferenceNumber>
          <Reference>https://www.epa.gov/chemical-data-reporting</Reference>
          <Value>
            <StringWithMarkup>
              <String>Intermediates</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Processing Aid in Food</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Processing aid in animal feed</String>
            </StringWithMarkup>
          </Value>
        </Information>
      </Section>
      <Section>
        <TOCHeading>Consumer Uses</TOCHeading>
        <Description>This section presents the information for consumer, and commercial use information (e.g., chemical-specific product categories)</Description>
        <DisplayControls>
          <ListType>Columns</ListType>
        </DisplayControls>
        <Information>
          <ReferenceNumber>20</ReferenceNumber>
          <Reference>https://www.epa.gov/chemical-data-reporting</Reference>
          <Value>
            <StringWithMarkup>
              <String>Non-TSCA use</String>
            </StringWithMarkup>
          </Value>
        </Information>
      </Section>
    </Section>
    <Section>
      <TOCHeading>Methods of Manufacturing</TOCHeading>
      <Description>Methods of Manufacturing</Description>
      <Information>
        <ReferenceNumber>32</ReferenceNumber>
        <Description>**PEER REVIEWED**</Description>
        <Reference>Blum R; Vitamins, 11. Niacin (Nicotinic Acid and Nicotinamide). Ullmann&apos;s Encyclopedia of Industrial Chemistry 7th ed. (1999-2018). NY, NY: John Wiley &amp; Sons. Online Posting Date: April 14, 2015</Reference>
        <Value>
          <StringWithMarkup>
            <String>In an aqueous solution 5-ethyl-2-methylpyridine is oxidized to nicotinic acid in a single-tube reactor by using an excess of nitric acid. The continuous process takes place at 230-270 deg C and 6-8 MPa. Pyridine-2,5-dicarboxylic acid is formed as an intermediate, but is not stable under the reaction conditions, undergoing decarboxylation to nicotinic acid nitrate. Neutralization of the nitrate with 5-ethyl-2-methylpyridine yields nicotinic acid. Water and carbon dioxide formed in the reaction are separated from the product. The nitrogen oxide formed is oxidized with air to nitrogen dioxide and then absorbed in water to yield nitric acid, which is recycled into the process.</String>
            <Markup>
              <Start>23</Start>
              <Length>24</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/5-ethyl-2-methylpyridine</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-7728</Extra>
            </Markup>
            <Markup>
              <Start>63</Start>
              <Length>14</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/nicotinic%20acid</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>125</Start>
              <Length>11</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/nitric%20acid</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-944</Extra>
            </Markup>
            <Markup>
              <Start>203</Start>
              <Length>30</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/Pyridine-2%2C5-dicarboxylic%20acid</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-7493</Extra>
            </Markup>
            <Markup>
              <Start>389</Start>
              <Length>7</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/nitrate</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-943</Extra>
            </Markup>
            <Markup>
              <Start>402</Start>
              <Length>24</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/5-ethyl-2-methylpyridine</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-7728</Extra>
            </Markup>
            <Markup>
              <Start>434</Start>
              <Length>14</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/nicotinic%20acid</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>450</Start>
              <Length>5</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/Water</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-962</Extra>
            </Markup>
            <Markup>
              <Start>460</Start>
              <Length>14</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/carbon%20dioxide</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-280</Extra>
            </Markup>
            <Markup>
              <Start>580</Start>
              <Length>16</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/nitrogen%20dioxide</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-3032552</Extra>
            </Markup>
            <Markup>
              <Start>618</Start>
              <Length>5</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/water</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-962</Extra>
            </Markup>
            <Markup>
              <Start>633</Start>
              <Length>11</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/nitric%20acid</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-944</Extra>
            </Markup>
          </StringWithMarkup>
        </Value>
      </Information>
      <Information>
        <ReferenceNumber>32</ReferenceNumber>
        <Description>**PEER REVIEWED**</Description>
        <Reference>O&apos;Neil, M.J. (ed.). The Merck Index - An Encyclopedia of Chemicals, Drugs, and Biologicals. Cambridge, UK:  Royal Society of Chemistry, 2013., p. 1214</Reference>
        <Value>
          <StringWithMarkup>
            <String>Preparation by oxidation of alkyl beta-substituted pyridines</String>
          </StringWithMarkup>
        </Value>
      </Information>
      <Information>
        <ReferenceNumber>32</ReferenceNumber>
        <Description>**PEER REVIEWED**</Description>
        <Reference>O&apos;Neil, M.J. (ed.). The Merck Index - An Encyclopedia of Chemicals, Drugs, and Biologicals. Cambridge, UK:  Royal Society of Chemistry, 2013., p. 1214</Reference>
        <Value>
          <StringWithMarkup>
            <String>Preparation by oxidation of nicotine</String>
            <Markup>
              <Start>28</Start>
              <Length>8</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/nicotine</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-89594</Extra>
            </Markup>
          </StringWithMarkup>
        </Value>
      </Information>
      <Information>
        <ReferenceNumber>32</ReferenceNumber>
        <Description>**PEER REVIEWED**</Description>
        <Reference>Larranaga, M.D., Lewis, R.J. Sr., Lewis, R.A.; Hawley&apos;s Condensed Chemical Dictionary 16th  Edition. John Wiley &amp; Sons, Inc. Hoboken, NJ 2016., p. 966</Reference>
        <Value>
          <StringWithMarkup>
            <String>Commercial sources: Synthetic nicotinic acid is made by oxidation of nicotine, quinoline, or 2-methyl-5-ethylpyridine (from ammonia and formaldehyde or acetaldehyde).</String>
            <Markup>
              <Start>30</Start>
              <Length>14</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/nicotinic%20acid</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>69</Start>
              <Length>8</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/nicotine</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-89594</Extra>
            </Markup>
            <Markup>
              <Start>79</Start>
              <Length>9</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/quinoline</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-7047</Extra>
            </Markup>
            <Markup>
              <Start>93</Start>
              <Length>24</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/2-methyl-5-ethylpyridine</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-7728</Extra>
            </Markup>
            <Markup>
              <Start>124</Start>
              <Length>7</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/ammonia</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-222</Extra>
            </Markup>
            <Markup>
              <Start>136</Start>
              <Length>12</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/formaldehyde</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-712</Extra>
            </Markup>
            <Markup>
              <Start>152</Start>
              <Length>12</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/acetaldehyde</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-177</Extra>
            </Markup>
          </StringWithMarkup>
        </Value>
      </Information>
    </Section>
    <Section>
      <TOCHeading>Formulations/Preparations</TOCHeading>
      <Description>Formulations/Preparations</Description>
      <Information>
        <ReferenceNumber>32</ReferenceNumber>
        <Description>**PEER REVIEWED**</Description>
        <Reference>American Society of Health-System Pharmacists 2017; Drug Information 2017. Bethesda, MD. 2017, p. 1941</Reference>
        <Value>
          <StringWithMarkup>
            <String>[See Table #5216 - Niacin Preparations]</String>
            <Markup>
              <Start>0</Start>
              <Length>39</Length>
              <Type>Inline Table</Type>
              <Extra>Table #5216 - Niacin Preparations</Extra>
            </Markup>
            <Markup>
              <Start>19</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/Niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
          </StringWithMarkup>
        </Value>
      </Information>
      <Information>
        <ReferenceNumber>32</ReferenceNumber>
        <Name>Table #5216 - Niacin Preparations</Name>
        <Value>
          <Binary>
IlJvdXRlIG9mIEFkbWluaXN0cmF0aW9uIiwiRG9zYWdlIEZvcm0iLCJTdHJlbmd0aCIsIkJyYW5k
IG9yIEdlbmVyaWMgTmFtZSAoTWFudWZhY3R1cmVyKSIKIk9yYWwiLCJUYWJsZXRzIiwiNTAwIG1n
IiwiTmlhY29yIChzY29yZWQpIChVcHNoZXItU21pdGgpIgoiT3JhbCIsIlRhYmxldHMsIGV4dGVu
ZGVkLXJlbGVhc2UiLCI1MDAgbWciLCJOaWFzcGFuIChLb3MpIgoiT3JhbCIsIlRhYmxldHMsIGV4
dGVuZGVkLXJlbGVhc2UiLCI3NTAgbWciLCJOaWFzcGFuIChLb3MpIgoiT3JhbCIsIlRhYmxldHMs
IGV4dGVuZGVkLXJlbGVhc2UiLCIxMDAwIG1nIiwiTmlhc3BhbiAoS29zKSIK
</Binary>
          <MimeType>text/csv</MimeType>
        </Value>
      </Information>
      <Information>
        <ReferenceNumber>32</ReferenceNumber>
        <Description>**PEER REVIEWED**</Description>
        <Reference>American Society of Health-System Pharmacists 2017; Drug Information 2017. Bethesda, MD. 2017, p. 1941</Reference>
        <Value>
          <StringWithMarkup>
            <String>[See Table #5217 - Niacin Combination Preparations]</String>
            <Markup>
              <Start>0</Start>
              <Length>51</Length>
              <Type>Inline Table</Type>
              <Extra>Table #5217 - Niacin Combination Preparations</Extra>
            </Markup>
            <Markup>
              <Start>19</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/Niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
          </StringWithMarkup>
        </Value>
      </Information>
      <Information>
        <ReferenceNumber>32</ReferenceNumber>
        <Name>Table #5217 - Niacin Combination Preparations</Name>
        <Value>
          <Binary>
IlJvdXRlIG9mIEFkbWluaXN0cmF0aW9uIiwiRG9zYWdlIEZvcm0iLCJTdHJlbmd0aCIsIkJyYW5k
IG9yIEdlbmVyaWMgTmFtZSAoTWFudWZhY3R1cmVyKSIKIk9yYWwiLCJUYWJsZXRzLCBleHRlbmRl
ZC1yZWxlYXNlIiwiNTAwIG1nIHdpdGggTG92YXN0YXRpbiAyMCBtZyIsIkFkdmljb3IgKEFiYm90
dCkiCiJPcmFsIiwiVGFibGV0cywgZXh0ZW5kZWQtcmVsZWFzZSIsIjc1MCBtZyB3aXRoIExvdmFz
dGF0aW4gMjAgbWciLCJBZHZpY29yIChBYmJvdHQpIgoiT3JhbCIsIlRhYmxldHMsIGV4dGVuZGVk
LXJlbGVhc2UiLCIxIGcgd2l0aCBMb3Zhc3RhdGluIDIwIG1nIiwiQWR2aWNvciAoQWJib3R0KSIK
Ik9yYWwiLCJUYWJsZXRzLCBleHRlbmRlZC1yZWxlYXNlIiwiMSBnIHdpdGggTG92YXN0YXRpbiA0
MCBtZyIsIkFkdmljb3IgKEFiYm90dCkiCg==
</Binary>
          <MimeType>text/csv</MimeType>
        </Value>
      </Information>
      <Information>
        <ReferenceNumber>32</ReferenceNumber>
        <Description>**PEER REVIEWED**</Description>
        <Reference>American Society of Health-System Pharmacists 2017; Drug Information 2017. Bethesda, MD. 2017, p. 1941</Reference>
        <Value>
          <StringWithMarkup>
            <String>[See Table #5218 - Niacin Preparations]</String>
            <Markup>
              <Start>0</Start>
              <Length>39</Length>
              <Type>Inline Table</Type>
              <Extra>Table #5218 - Niacin Preparations</Extra>
            </Markup>
            <Markup>
              <Start>19</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/Niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
          </StringWithMarkup>
        </Value>
      </Information>
      <Information>
        <ReferenceNumber>32</ReferenceNumber>
        <Name>Table #5218 - Niacin Preparations</Name>
        <Value>
          <Binary>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=
</Binary>
          <MimeType>text/csv</MimeType>
        </Value>
      </Information>
      <Information>
        <ReferenceNumber>32</ReferenceNumber>
        <Description>**PEER REVIEWED**</Description>
        <Reference>Larranaga, M.D., Lewis, R.J. Sr., Lewis, R.A.; Hawley&apos;s Condensed Chemical Dictionary 16th  Edition. John Wiley &amp; Sons, Inc. Hoboken, NJ 2016., p. 966</Reference>
        <Value>
          <StringWithMarkup>
            <String>Grades: National Formulary; Food Chemical Codex; blended with soy flour (animal feeds)</String>
          </StringWithMarkup>
        </Value>
      </Information>
      <Information>
        <ReferenceNumber>32</ReferenceNumber>
        <Description>**PEER REVIEWED**</Description>
        <Reference>American Society of Health-System Pharmacists 2017; Drug Information 2017. Bethesda, MD. 2017, p. 1941</Reference>
        <Value>
          <StringWithMarkup>
            <String>Niacin is commercially available as conventional (immediate-release) and extended-release preparations and in fixed combination with lovastatin. Niacin also is available as a dietary supplement; these preparations are not FDA-labeled for management of dyslipidemias and should not be used as substitutes for prescription-only niacin preparations.</String>
            <Markup>
              <Start>0</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/Niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>133</Start>
              <Length>10</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/lovastatin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-53232</Extra>
            </Markup>
            <Markup>
              <Start>145</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/Niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>326</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
          </StringWithMarkup>
        </Value>
      </Information>
    </Section>
    <Section>
      <TOCHeading>U.S. Production</TOCHeading>
      <Description>U.S. Production</Description>
      <Information>
        <ReferenceNumber>32</ReferenceNumber>
        <Description>**PEER REVIEWED**</Description>
        <Value>
          <StringWithMarkup>
            <String>(1972) 2.49X10+9 GRAMS /NIACIN &amp; NICOTINAMIDE/</String>
            <Markup>
              <Start>24</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/NIACIN</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>33</Start>
              <Length>12</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/NICOTINAMIDE</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-936</Extra>
            </Markup>
          </StringWithMarkup>
        </Value>
      </Information>
      <Information>
        <ReferenceNumber>32</ReferenceNumber>
        <Description>**PEER REVIEWED**</Description>
        <Value>
          <StringWithMarkup>
            <String>(1975) 2.5X10+9 GRAMS /NIACIN &amp; NICOTINAMIDE/</String>
            <Markup>
              <Start>23</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/NIACIN</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>32</Start>
              <Length>12</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/NICOTINAMIDE</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-936</Extra>
            </Markup>
          </StringWithMarkup>
        </Value>
      </Information>
      <Information>
        <ReferenceNumber>32</ReferenceNumber>
        <Description>**PEER REVIEWED**</Description>
        <Reference>USEPA; 2016 Chemical Data Reporting Database. Nicotinic Acid (59-67-6). Available from, as of June 11, 2018: https://www.epa.gov/chemical-data-reporting</Reference>
        <Value>
          <StringWithMarkup>
            <String>Non-confidential 2016 Chemical Data Reporting (CDR) information on the production and use of chemicals manufactured or imported into the United States. Chemical: Nicotinic acid: [See Table #5220 - National Aggregate Production Volume (pounds)]</String>
            <Markup>
              <Start>178</Start>
              <Length>65</Length>
              <Type>Inline Table</Type>
              <Extra>Table #5220 - National Aggregate Production Volume (pounds)</Extra>
            </Markup>
            <Markup>
              <Start>162</Start>
              <Length>14</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/Nicotinic%20acid</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
          </StringWithMarkup>
        </Value>
      </Information>
      <Information>
        <ReferenceNumber>32</ReferenceNumber>
        <Name>Table #5220 - National Aggregate Production Volume (pounds)</Name>
        <Value>
          <Binary>
MjAxMSwyMDEyLDIwMTMsMjAxNCwyMDE1CiIxLDI3NywyMTgiLCJXaXRoaGVsZCIsIldpdGhoZWxk
IiwiV2l0aGhlbGQiLCJXaXRoaGVsZCIK
</Binary>
          <MimeType>text/csv</MimeType>
        </Value>
      </Information>
    </Section>
    <Section>
      <TOCHeading>Manufacturers</TOCHeading>
      <Description>Manufacturers</Description>
      <Information>
        <ReferenceNumber>32</ReferenceNumber>
        <Description>**PEER REVIEWED**</Description>
        <Reference>US EPA; Chemical Data Reporting (CDR). Non-confidential 2016 Chemical Data Reporting information on chemical production and use in the United States. Available from, as of Jun 15, 2018: https://chemview.epa.gov/chemview</Reference>
        <Value>
          <StringWithMarkup>
            <String>Nicotinic acid - Manufacture and Production Data (2016) [See Table #5219]</String>
            <Markup>
              <Start>56</Start>
              <Length>17</Length>
              <Type>Inline Table</Type>
              <Extra>Table #5219</Extra>
            </Markup>
            <Markup>
              <Start>0</Start>
              <Length>14</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/Nicotinic%20acid</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
          </StringWithMarkup>
        </Value>
      </Information>
      <Information>
        <ReferenceNumber>32</ReferenceNumber>
        <Name>Table #5219</Name>
        <Value>
          <Binary>
IkNvbXBhbnkiLCJTaXRlIiwiQWRkcmVzcyIsIjIwMTUgQWN0aXZpdHkiCiJWZXJ0ZWxsdXMgSG9s
ZGluZ3MgTExDIiwiVmVydGVsbHVzIEFncmljdWx0dXJlICYgTnV0cml0aW9uIFNwZWNpYWx0aWVz
IExMQyIsIjE1MDAgUyBUaWJicyBBdmUsIEluZGlhbmFwb2xpcywgTWFyaW9uLCBJTiwgNDYyNDE0
NTM3IiwiV2l0aGhlbGQiCiJKdWJpbGFudCBMaWZlIFNjaWVuY2VzIFVTQSBJbmMiLCJKdWJpbGlh
bnQgTGlmZSBTY2llbmNlcyBVU0EgSW5jIiwiT25lIENyb3Nzcm9hZHMgRHIsIEJlZG1pbnN0ZXIs
IFNvbWVyc2V0LCBOSiwgMDc5MjEiLCJJbXBvcnRlZCIK
</Binary>
          <MimeType>text/csv</MimeType>
        </Value>
      </Information>
      <Information>
        <ReferenceNumber>32</ReferenceNumber>
        <Description>**PEER REVIEWED**</Description>
        <Reference>Van Arnum SD; Kirk-Othmer Encyclopedia of Chemical Technology. (2005). NY, NY: John Wiley &amp; Sons; Niacin, Nicotinamide, and Nicotinic Acid. Online Posting Date: Dec 4, 2000.</Reference>
        <Value>
          <StringWithMarkup>
            <String>U.S. manufacturers of niacin and niacinamide include Nepera, Inc. ... U.S. suppliers include BASF Corporation, Hoffmann-La Roche Inc., and Rhone-Poulenc. Western European producers and suppliers include Degussa, Rhone-Poulenc, BASF, Hoffmann-La Roche, and Lonza /nicotinamide/</String>
            <Markup>
              <Start>22</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>33</Start>
              <Length>11</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacinamide</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-936</Extra>
            </Markup>
            <Markup>
              <Start>263</Start>
              <Length>12</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/nicotinamide</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-936</Extra>
            </Markup>
          </StringWithMarkup>
        </Value>
      </Information>
    </Section>
    <Section>
      <TOCHeading>General Manufacturing Information</TOCHeading>
      <Description>General Manufacturing Information</Description>
      <Information>
        <ReferenceNumber>20</ReferenceNumber>
        <Name>Industry Processing Sectors</Name>
        <Value>
          <StringWithMarkup>
            <String>Food, beverage, and tobacco product manufacturing</String>
          </StringWithMarkup>
          <StringWithMarkup>
            <String>Pharmaceutical and medicine manufacturing</String>
          </StringWithMarkup>
          <StringWithMarkup>
            <String>Used in Animal feed</String>
          </StringWithMarkup>
        </Value>
      </Information>
      <Information>
        <ReferenceNumber>20</ReferenceNumber>
        <Name>EPA TSCA Commercial Activity Status</Name>
        <Reference>https://www.epa.gov/tsca-inventory</Reference>
        <Value>
          <StringWithMarkup>
            <String>3-Pyridinecarboxylic acid: ACTIVE</String>
            <Markup>
              <Start>0</Start>
              <Length>25</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/3-Pyridinecarboxylic%20acid</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
          </StringWithMarkup>
        </Value>
      </Information>
      <Information>
        <ReferenceNumber>32</ReferenceNumber>
        <Description>**PEER REVIEWED**</Description>
        <Reference>Blum R; Vitamins, 11. Niacin (Nicotinic Acid and Nicotinamide). Ullmann&apos;s Encyclopedia of Industrial Chemistry 7th ed. (1999-2018). NY, NY: John Wiley &amp; Sons. Online Posting Date: April 14, 2015</Reference>
        <Value>
          <StringWithMarkup>
            <String>Niacin is a naturally occurring substance. Nicotinic acid is the form present in food of plant origin, whereas nicotinamide occurs in animal products.</String>
            <Markup>
              <Start>0</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/Niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>43</Start>
              <Length>14</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/Nicotinic%20acid</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>111</Start>
              <Length>12</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/nicotinamide</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-936</Extra>
            </Markup>
          </StringWithMarkup>
        </Value>
      </Information>
      <Information>
        <ReferenceNumber>32</ReferenceNumber>
        <Description>**PEER REVIEWED**</Description>
        <Reference>O&apos;Neil, M.J. (ed.). The Merck Index - An Encyclopedia of Chemicals, Drugs, and Biologicals. Cambridge, UK:  Royal Society of Chemistry, 2013., p. 1213</Reference>
        <Value>
          <StringWithMarkup>
            <String>The terms niacin, Vitamin B3, and Vitamin PP have been used to refer to both nicotinamide and nicotinic acid.</String>
            <Markup>
              <Start>10</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>18</Start>
              <Length>10</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/Vitamin%20B3</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>34</Start>
              <Length>10</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/Vitamin%20PP</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-936</Extra>
            </Markup>
            <Markup>
              <Start>77</Start>
              <Length>12</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/nicotinamide</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-936</Extra>
            </Markup>
            <Markup>
              <Start>94</Start>
              <Length>14</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/nicotinic%20acid</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
          </StringWithMarkup>
        </Value>
      </Information>
      <Information>
        <ReferenceNumber>32</ReferenceNumber>
        <Description>**PEER REVIEWED**</Description>
        <Reference>Osol, A. and J.E. Hoover, et al. (eds.). Remington&apos;s Pharmaceutical Sciences. 15th ed. Easton, Pennsylvania: Mack Publishing Co., 1975., p. 950</Reference>
        <Value>
          <StringWithMarkup>
            <String>NIACIN, MOST STABLE OF VIT, IS NOT DESTROYED BY HEATING IN ACID OR ALKALINE SOLN. IT WITHSTANDS MILD OXIDATION, &amp; RETAINS ITS BIOLOGICAL ACTIVITY DURING PROCESSING OF FOOD &amp; PREPN &amp; STORAGE OF PHARMACEUTICALS.</String>
            <Markup>
              <Start>0</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/NIACIN</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
          </StringWithMarkup>
        </Value>
      </Information>
      <Information>
        <ReferenceNumber>32</ReferenceNumber>
        <Description>**PEER REVIEWED**</Description>
        <Reference>Hardman, J.G., L.E. Limbird, P.B. Molinoff, R.W. Ruddon, A.G. Goodman (eds.). Goodman and Gilman&apos;s The Pharmacological Basis of Therapeutics. 9th ed. New York, NY: McGraw-Hill, 1996., p. 1561</Reference>
        <Value>
          <StringWithMarkup>
            <String>RECOMMENDED ALLOWANCE OF THE DIETARY ALLOWANCES COMMITTEE OF THE NATIONAL RESEARCH COUNCIL, EXPRESSED IN NICOTINIC ACID EQUIVALENTS, IS 6.6 MG/1000 KCAL.</String>
            <Markup>
              <Start>105</Start>
              <Length>14</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/NICOTINIC%20ACID</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
          </StringWithMarkup>
        </Value>
      </Information>
    </Section>
  </Section>
  <Section>
    <TOCHeading>Identification</TOCHeading>
    <Description>This section contains laboratory methods how to identify the chemical and more.</Description>
    <Section>
      <TOCHeading>Analytic Laboratory Methods</TOCHeading>
      <Description>Analytic Laboratory Methods for the sample analysis</Description>
      <Information>
        <ReferenceNumber>32</ReferenceNumber>
        <Description>**PEER REVIEWED**</Description>
        <Reference>Association of Official Analytical Chemists. Official Methods of Analysis. 15th ed. and Supplements. Washington, DC: Association of Analytical Chemists, 1990, p. V2 1055</Reference>
        <Value>
          <StringWithMarkup>
            <String>AOAC Method 975.41. Niacin and Niacinamide in cereal products. Automated method.</String>
            <Markup>
              <Start>20</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/Niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>31</Start>
              <Length>11</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/Niacinamide</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-936</Extra>
            </Markup>
          </StringWithMarkup>
        </Value>
      </Information>
      <Information>
        <ReferenceNumber>32</ReferenceNumber>
        <Description>**PEER REVIEWED**</Description>
        <Reference>Association of Official Analytical Chemists. Official Methods of Analysis. 15th ed. and Supplements. Washington, DC: Association of Analytical Chemists, 1990, p. V2 1054</Reference>
        <Value>
          <StringWithMarkup>
            <String>AOAC Method 961.14. Niacin and Niacinamide in drugs, foods, and feeds. Colorimetric method.</String>
            <Markup>
              <Start>20</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/Niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>31</Start>
              <Length>11</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/Niacinamide</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-936</Extra>
            </Markup>
          </StringWithMarkup>
        </Value>
      </Information>
      <Information>
        <ReferenceNumber>32</ReferenceNumber>
        <Description>**PEER REVIEWED**</Description>
        <Reference>Association of Official Analytical Chemists. Official Methods of Analysis. 15th ed. and Supplements. Washington, DC: Association of Analytical Chemists, 1990, p. V2 1109</Reference>
        <Value>
          <StringWithMarkup>
            <String>AOAC Method 985.34. Niacin and niacinamide (nicotinic acid and nicotinamide) in ready-to-feed milk-based infant formula. Microbiological-turbidimetric method.</String>
            <Markup>
              <Start>20</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/Niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>31</Start>
              <Length>11</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacinamide</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-936</Extra>
            </Markup>
            <Markup>
              <Start>44</Start>
              <Length>14</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/nicotinic%20acid</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>63</Start>
              <Length>12</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/nicotinamide</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-936</Extra>
            </Markup>
          </StringWithMarkup>
        </Value>
      </Information>
      <Information>
        <ReferenceNumber>32</ReferenceNumber>
        <Description>**PEER REVIEWED**</Description>
        <Reference>Association of Official Analytical Chemists. Official Methods of Analysis. 15th ed. and Supplements. Washington, DC: Association of Analytical Chemists, 1990, p. V2 1084</Reference>
        <Value>
          <StringWithMarkup>
            <String>AOAC Method 944.13. Niacin and niacinamide (nicotinic acid and nicotinamide) in vitamin preprations. Microbiological methods.</String>
            <Markup>
              <Start>20</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/Niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>31</Start>
              <Length>11</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacinamide</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-936</Extra>
            </Markup>
            <Markup>
              <Start>44</Start>
              <Length>14</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/nicotinic%20acid</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>63</Start>
              <Length>12</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/nicotinamide</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-936</Extra>
            </Markup>
          </StringWithMarkup>
        </Value>
      </Information>
      <Information>
        <ReferenceNumber>32</ReferenceNumber>
        <Description>**PEER REVIEWED**</Description>
        <Reference>U.S. Pharmacopeia. The United States Pharmacopeia, USP 30/The National Formulary, NF 25; Rockville, MD: U.S. Pharmacopeial Convention, Inc., p2745 (2007)</Reference>
        <Value>
          <StringWithMarkup>
            <String>Analyte: niacin; matrix: chemical identification; procedure: infrared absorption spectrophotometry with comparison to standards</String>
            <Markup>
              <Start>9</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
          </StringWithMarkup>
        </Value>
      </Information>
      <Information>
        <ReferenceNumber>32</ReferenceNumber>
        <Description>**PEER REVIEWED**</Description>
        <Reference>U.S. Pharmacopeia. The United States Pharmacopeia, USP 30/The National Formulary, NF 25; Rockville, MD: U.S. Pharmacopeial Convention, Inc., p2745 (2007)</Reference>
        <Value>
          <StringWithMarkup>
            <String>Analyte: niacin; matrix: chemical identification; procedure: ultraviolet absorption spectrophotometry with comparison to standards</String>
            <Markup>
              <Start>9</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
          </StringWithMarkup>
        </Value>
      </Information>
      <Information>
        <ReferenceNumber>32</ReferenceNumber>
        <Description>**PEER REVIEWED**</Description>
        <Reference>U.S. Pharmacopeia. The United States Pharmacopeia, USP 30/The National Formulary, NF 25; Rockville, MD: U.S. Pharmacopeial Convention, Inc., p2745 (2007)</Reference>
        <Value>
          <StringWithMarkup>
            <String>Analyte: niacin; matrix: chemical purity; procedure: ultraviolet absorption spectrophotometry at 262 nm with comparison to standards</String>
            <Markup>
              <Start>9</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
          </StringWithMarkup>
        </Value>
      </Information>
      <Information>
        <ReferenceNumber>32</ReferenceNumber>
        <Description>**PEER REVIEWED**</Description>
        <Reference>U.S. Pharmacopeia. The United States Pharmacopeia, USP 30/The National Formulary, NF 25; Rockville, MD: U.S. Pharmacopeial Convention, Inc., p2745 (2007)</Reference>
        <Value>
          <StringWithMarkup>
            <String>Analyte: niacin; matrix: pharmaceutical preparation (injection solution; tablet); procedure: infrared absorption spectrophotometry with comparison to standards (chemical identification)</String>
            <Markup>
              <Start>9</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
          </StringWithMarkup>
        </Value>
      </Information>
      <Information>
        <ReferenceNumber>32</ReferenceNumber>
        <Description>**PEER REVIEWED**</Description>
        <Reference>U.S. Pharmacopeia. The United States Pharmacopeia, USP 30/The National Formulary, NF 25; Rockville, MD: U.S. Pharmacopeial Convention, Inc., p2745 (2007)</Reference>
        <Value>
          <StringWithMarkup>
            <String>Analyte: niacin; matrix: pharmaceutical preparation (injection solution; tablet); procedure: ultraviolet absorption spectrophotometry with comparison to standards (chemical identification)</String>
            <Markup>
              <Start>9</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
          </StringWithMarkup>
        </Value>
      </Information>
      <Information>
        <ReferenceNumber>32</ReferenceNumber>
        <Description>**PEER REVIEWED**</Description>
        <Reference>U.S. Pharmacopeia. The United States Pharmacopeia, USP 30/The National Formulary, NF 25; Rockville, MD: U.S. Pharmacopeial Convention, Inc., p2746 (2007)</Reference>
        <Value>
          <StringWithMarkup>
            <String>Analyte: niacin; matrix: pharmaceutical preparation (tablet); procedure: retention time of the major peak of the liquid chromatogram with comparison to standards (chemical identification)</String>
            <Markup>
              <Start>9</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
          </StringWithMarkup>
        </Value>
      </Information>
      <Information>
        <ReferenceNumber>32</ReferenceNumber>
        <Description>**PEER REVIEWED**</Description>
        <Reference>U.S. Pharmacopeia. The United States Pharmacopeia, USP 30/The National Formulary, NF 25; Rockville, MD: U.S. Pharmacopeial Convention, Inc., p2746 (2007)</Reference>
        <Value>
          <StringWithMarkup>
            <String>Analyte: niacin; matrix: pharmaceutical preparation (tablet); procedure: liquid chromatography with detection at 262 nm and comparison to standards (chemical purity)</String>
            <Markup>
              <Start>9</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
          </StringWithMarkup>
        </Value>
      </Information>
      <Information>
        <ReferenceNumber>32</ReferenceNumber>
        <Description>**PEER REVIEWED**</Description>
        <Reference>Shin H et al; Food Chem 138 (2-3): 1109-15 (2013)</Reference>
        <Value>
          <StringWithMarkup>
            <String>An isotope dilution LC/mass spectrometric (ID-LC/MS) method was developed as a candidate reference method for the accurate determination of niacin in infant formula, breakfast cereals and multivitamin. After spiking nicotinamide-d(4) as an internal standard, infant formula and breakfast cereal samples were hydrolyzed under alkaline condition. Samples were then analyzed in SRM mode to detect nicotinic acid and nicotinic acid-d(4) at m/z 124--&gt;80 and 127--&gt;84, respectively. In the case of multivitamin sample that contains mainly free nicotinamide, LC/MS monitored nicotinamide and nicotinamide-d(4) at their SRM channels of m/z 123--&gt;80 and m/z 127--&gt;84, respectively, after simple extraction. The repeatability and reproducibility were tested for the validation of the developed ID/LC-MS method. Additionally, the developed analytical method was applied to determine total niacin contents in homogenized infant formula, homogenized multivitamin, and commercially available products including different types of infant formula, breakfast cereals, and multivitamin tablets. PubMed Abstract</String>
            <Markup>
              <Start>1077</Start>
              <Length>15</Length>
              <URL>http://www.ncbi.nlm.nih.gov/pubmed/23411221?dopt=Abstract</URL>
            </Markup>
            <Markup>
              <Start>140</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>394</Start>
              <Length>14</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/nicotinic%20acid</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>538</Start>
              <Length>12</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/nicotinamide</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-936</Extra>
            </Markup>
            <Markup>
              <Start>568</Start>
              <Length>12</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/nicotinamide</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-936</Extra>
            </Markup>
            <Markup>
              <Start>878</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
          </StringWithMarkup>
        </Value>
      </Information>
    </Section>
    <Section>
      <TOCHeading>Clinical Laboratory Methods</TOCHeading>
      <Description>Clinical Laboratory Methods for the sample analysis</Description>
      <Information>
        <ReferenceNumber>32</ReferenceNumber>
        <Description>**PEER REVIEWED**</Description>
        <Reference>HENGEN N ET AL; CLIN CHEM (WINSTON-SALEM, NC) 24 (10): 1740-43 (1978)</Reference>
        <Value>
          <StringWithMarkup>
            <String>HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHIC DETERMINATION OF FREE NICOTINIC ACID &amp; ITS METABOLITE, NICOTINURIC ACID, IN PLASMA &amp; URINE.</String>
            <Markup>
              <Start>62</Start>
              <Length>14</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/NICOTINIC%20ACID</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>95</Start>
              <Length>16</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/NICOTINURIC%20ACID</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-68499</Extra>
            </Markup>
          </StringWithMarkup>
        </Value>
      </Information>
      <Information>
        <ReferenceNumber>32</ReferenceNumber>
        <Description>**PEER REVIEWED**</Description>
        <Reference>ROSEBOOM H, HULSHOFF A; J CHROMATOGR 173 (1): 65-74 (1979)</Reference>
        <Value>
          <StringWithMarkup>
            <String>GAS CHROMATOGRAPHIC DETERMINATION OF ACIDIC DRUGS IN PLASMA. PubMed Abstract</String>
            <Markup>
              <Start>61</Start>
              <Length>15</Length>
              <URL>http://www.ncbi.nlm.nih.gov/pubmed/546875?dopt=Abstract</URL>
            </Markup>
          </StringWithMarkup>
        </Value>
      </Information>
    </Section>
  </Section>
  <Section>
    <TOCHeading>Safety and Hazards</TOCHeading>
    <Description>Safety and hazards information, properties, management techniques, reactivities and incompatibilities, first aid treatments, and more.</Description>
    <Section>
      <TOCHeading>Hazards Identification</TOCHeading>
      <Description>Hazards Identification includes all hazards regarding the chemical; required label elements</Description>
      <Section>
        <TOCHeading>GHS Classification</TOCHeading>
        <Description>GHS (Globally Harmonized System of Classification and Labelling of Chemicals) is a United Nations system to identify hazardous chemicals and to inform users about these hazards. GHS has been adopted by many countries around the world and is now also used as the basis for international and national transport regulations for dangerous goods. The GHS hazard statements, class categories, pictograms, signal words, and the precautionary statements can be found on the PubChem GHS page.</Description>
        <URL>https://pubchem.ncbi.nlm.nih.gov/ghs/</URL>
        <DisplayControls>
          <CreateTable>
            <FromInformationIn>ThisSection</FromInformationIn>
            <NumberOfColumns>2</NumberOfColumns>
            <ColumnContents>Name</ColumnContents>
            <ColumnContents>Value</ColumnContents>
          </CreateTable>
          <ShowAtMost>1</ShowAtMost>
        </DisplayControls>
        <Information>
          <ReferenceNumber>23</ReferenceNumber>
          <Name>Pictogram(s)</Name>
          <Value>
            <StringWithMarkup>
              <String>          </String>
              <Markup>
                <Start>0</Start>
                <Length>1</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/images/ghs/GHS07.svg</URL>
                <Type>Icon</Type>
                <Extra>Irritant</Extra>
              </Markup>
            </StringWithMarkup>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>23</ReferenceNumber>
          <Name>Signal</Name>
          <Value>
            <StringWithMarkup>
              <String>Warning</String>
              <Markup>
                <Start>0</Start>
                <Length>7</Length>
                <Type>Color</Type>
                <Extra>GHSWarning</Extra>
              </Markup>
            </StringWithMarkup>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>23</ReferenceNumber>
          <Name>GHS Hazard Statements</Name>
          <Value>
            <StringWithMarkup>
              <String>Aggregated GHS information provided by 356 companies from  10  notifications to the ECHA C&amp;L Inventory. Each notification may be associated with multiple companies.</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>H319 (86.8%): Causes serious eye irritation [Warning Serious eye damage/eye irritation]</String>
              <Markup>
                <Start>45</Start>
                <Length>7</Length>
                <Type>Color</Type>
                <Extra>GHSWarning</Extra>
              </Markup>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>H412 (12.92%): Harmful to aquatic life with long lasting effects [Hazardous to the aquatic environment, long-term hazard]</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Information may vary between notifications depending on impurities, additives, and other factors. The percentage value in parenthesis indicates the notified classification ratio from companies that provide hazard codes. Only hazard codes with percentage values above 10% are shown.</String>
            </StringWithMarkup>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>23</ReferenceNumber>
          <Name>Precautionary Statement Codes</Name>
          <Value>
            <StringWithMarkup>
              <String>P264, P273, P280, P305+P351+P338, P337+P313, and P501</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>(The corresponding statement to each P-code can be found here.)</String>
              <Markup>
                <Start>57</Start>
                <Length>4</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/ghs/#_prec</URL>
              </Markup>
            </StringWithMarkup>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>32</ReferenceNumber>
          <Name>Pictogram(s)</Name>
          <Value>
            <StringWithMarkup>
              <String>          </String>
              <Markup>
                <Start>0</Start>
                <Length>1</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/images/ghs/GHS07.svg</URL>
                <Type>Icon</Type>
                <Extra>Irritant</Extra>
              </Markup>
            </StringWithMarkup>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>32</ReferenceNumber>
          <Name>Signal</Name>
          <Value>
            <StringWithMarkup>
              <String>Warning</String>
              <Markup>
                <Start>0</Start>
                <Length>7</Length>
                <Type>Color</Type>
                <Extra>GHSWarning</Extra>
              </Markup>
            </StringWithMarkup>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>32</ReferenceNumber>
          <Name>GHS Hazard Statements</Name>
          <Value>
            <StringWithMarkup>
              <String></String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>H319: Causes serious eye irritation [Warning Serious eye damage/eye irritation]</String>
              <Markup>
                <Start>37</Start>
                <Length>7</Length>
                <Type>Color</Type>
                <Extra>GHSWarning</Extra>
              </Markup>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>H402: Harmful to aquatic life [Hazardous to the aquatic environment, acute hazard]</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String></String>
            </StringWithMarkup>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>32</ReferenceNumber>
          <Name>Precautionary Statement Codes</Name>
          <Value>
            <StringWithMarkup>
              <String>P264, P273, P280, P305+P351+P338, P337+P313, and P501</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>(The corresponding statement to each P-code can be found here.)</String>
              <Markup>
                <Start>57</Start>
                <Length>4</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/ghs/#_prec</URL>
              </Markup>
            </StringWithMarkup>
          </Value>
        </Information>
      </Section>
      <Section>
        <TOCHeading>Health Hazard</TOCHeading>
        <Description>Description of the chemical&apos;s health hazards (such as toxicity, flammability, or corrosivity).</Description>
        <Information>
          <ReferenceNumber>1</ReferenceNumber>
          <Name>Health Hazard</Name>
          <Reference>National Toxicology Program, Institute of Environmental Health Sciences, National Institutes of Health (NTP). 1992. National Toxicology Program Chemical Repository Database. Research Triangle Park, North Carolina: NTP.</Reference>
          <Value>
            <StringWithMarkup>
              <String>SYMPTOMS: Symptoms of exposure to this compound include impaired liver function, dryness of the skin, anorexia, nausea, vomiting, diarrhea, activation of peptic ulcers, hepatic disease, hyperuricemia and circulatory collapse (after rapid intravenous injection). It may cause temporary flushing and a feeling of warmth, temporary headache, itching, tingling, skin rash and allergies. It may also cause burning of the skin, face and upper trunk and elevation of serum bilirubin. Other symptoms include mild irritation of upper respiratory tract and gastrointestinal disturbances. It may cause dyspepsia, hyperpigmentation, decrease in excretion of bromosulfophthalein, increase of plasma transaminase activities, incidence of acute gouty arthritis, acanthosis nigricans, hyperglycemia, increased vasodilation and cystoid edema of the macula. It may also cause furunculosis and other skin lesions, hypotension, abdominal cramps, mild diabetes and urticaria. Other symptoms include pruritus, toxic amblyopia, jaundice and decreased glucose tolerance.  ACUTE/CHRONIC HAZARDS: This compound may cause mild irritation to the upper respiratory tract. When heated to decomposition it may emit toxic fumes of NOx. (NTP, 1992)</String>
              <Markup>
                <Start>466</Start>
                <Length>9</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/bilirubin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-5280352</Extra>
              </Markup>
              <Markup>
                <Start>646</Start>
                <Length>19</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/bromosulfophthalein</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-3533588</Extra>
              </Markup>
              <Markup>
                <Start>1028</Start>
                <Length>7</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/glucose</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-5793</Extra>
              </Markup>
            </StringWithMarkup>
          </Value>
        </Information>
      </Section>
      <Section>
        <TOCHeading>Fire Hazard</TOCHeading>
        <Description>Fire Hazard</Description>
        <Information>
          <ReferenceNumber>1</ReferenceNumber>
          <Name>Fire Hazard</Name>
          <Reference>National Toxicology Program, Institute of Environmental Health Sciences, National Institutes of Health (NTP). 1992. National Toxicology Program Chemical Repository Database. Research Triangle Park, North Carolina: NTP.</Reference>
          <Value>
            <StringWithMarkup>
              <String>Flash point data for this chemical are not available; however, it is probably combustible. (NTP, 1992)</String>
            </StringWithMarkup>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>34</ReferenceNumber>
          <Name>Fire Hazard</Name>
          <Value>
            <StringWithMarkup>
              <String>Combustible. Gives off irritating or toxic fumes (or gases) in a fire. Finely dispersed particles form explosive mixtures in air.</String>
            </StringWithMarkup>
          </Value>
        </Information>
      </Section>
    </Section>
    <Section>
      <TOCHeading>Safety and Hazard Properties</TOCHeading>
      <Description>Safety and Hazard Properties lists the chemical&apos;s safety and hazard characteristics</Description>
      <Section>
        <TOCHeading>Physical Dangers</TOCHeading>
        <Description>Physical Dangers</Description>
        <Information>
          <ReferenceNumber>34</ReferenceNumber>
          <Name>Physical Dangers</Name>
          <Value>
            <StringWithMarkup>
              <String>Dust explosion possible if in powder or granular form, mixed with air.</String>
            </StringWithMarkup>
          </Value>
        </Information>
      </Section>
      <Section>
        <TOCHeading>Explosive Limits and Potential</TOCHeading>
        <Description>Explosive Limits and Potential</Description>
        <Information>
          <ReferenceNumber>34</ReferenceNumber>
          <Name>Explosive Limits and Potential</Name>
          <Value>
            <StringWithMarkup>
              <String>Explosive limits , vol% in air: 25 - ?</String>
            </StringWithMarkup>
          </Value>
        </Information>
      </Section>
    </Section>
    <Section>
      <TOCHeading>First Aid Measures</TOCHeading>
      <Description>First-aid measures includes important symptoms/ effects, acute, delayed; required treatment.</Description>
      <Section>
        <TOCHeading>First Aid</TOCHeading>
        <Description>First Aid information</Description>
        <Information>
          <ReferenceNumber>1</ReferenceNumber>
          <Name>First Aid</Name>
          <Reference>National Toxicology Program, Institute of Environmental Health Sciences, National Institutes of Health (NTP). 1992. National Toxicology Program Chemical Repository Database. Research Triangle Park, North Carolina: NTP.</Reference>
          <Value>
            <StringWithMarkup>
              <String>EYES: First check the victim for contact lenses and remove if present. Flush victim&apos;s eyes with water or normal saline solution for 20 to 30 minutes while simultaneously calling a hospital or poison control center. Do not put any ointments, oils, or medication in the victim&apos;s eyes without specific instructions from a physician. IMMEDIATELY transport the victim after flushing eyes to a hospital even if no symptoms (such as redness or irritation) develop.  SKIN: IMMEDIATELY flood affected skin with water while removing and isolating all contaminated clothing. Gently wash all affected skin areas thoroughly with soap and water. If symptoms such as redness or irritation develop, IMMEDIATELY call a physician and be prepared to transport the victim to a hospital for treatment.  INHALATION: IMMEDIATELY leave the contaminated area; take deep breaths of fresh air. If symptoms (such as wheezing, coughing, shortness of breath, or burning in the mouth, throat, or chest) develop, call a physician and be prepared to transport the victim to a hospital. Provide proper respiratory protection to rescuers entering an unknown atmosphere. Whenever possible, Self-Contained Breathing Apparatus (SCBA) should be used; if not available, use a level of protection greater than or equal to that advised under Protective Clothing.  INGESTION: DO NOT INDUCE VOMITING. If the victim is conscious and not convulsing, give 1 or 2 glasses of water to dilute the chemical and IMMEDIATELY call a hospital or poison control center. Be prepared to transport the victim to a hospital if advised by a physician. If the victim is convulsing or unconscious, do not give anything by mouth, ensure that the victim&apos;s airway is open and lay the victim on his/her side with the head lower than the body. DO NOT INDUCE VOMITING. IMMEDIATELY transport the victim to a hospital. (NTP, 1992)</String>
              <Markup>
                <Start>96</Start>
                <Length>5</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/water</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-962</Extra>
              </Markup>
              <Markup>
                <Start>502</Start>
                <Length>5</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/water</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-962</Extra>
              </Markup>
              <Markup>
                <Start>625</Start>
                <Length>5</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/water</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-962</Extra>
              </Markup>
              <Markup>
                <Start>1427</Start>
                <Length>5</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/water</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-962</Extra>
              </Markup>
            </StringWithMarkup>
          </Value>
        </Information>
      </Section>
      <Section>
        <TOCHeading>Inhalation First Aid</TOCHeading>
        <Description>Information regarding the Inhalation First Aid</Description>
        <Information>
          <ReferenceNumber>34</ReferenceNumber>
          <Name>Inhalation First Aid</Name>
          <Value>
            <StringWithMarkup>
              <String>Fresh air, rest.</String>
            </StringWithMarkup>
          </Value>
        </Information>
      </Section>
      <Section>
        <TOCHeading>Skin First Aid</TOCHeading>
        <Description>Information regarding the Skin First Aid</Description>
        <Information>
          <ReferenceNumber>34</ReferenceNumber>
          <Name>Skin First Aid</Name>
          <Value>
            <StringWithMarkup>
              <String>Rinse skin with plenty of water or shower.</String>
              <Markup>
                <Start>26</Start>
                <Length>5</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/water</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-962</Extra>
              </Markup>
            </StringWithMarkup>
          </Value>
        </Information>
      </Section>
      <Section>
        <TOCHeading>Eye First Aid</TOCHeading>
        <Description>Eye First Aid</Description>
        <Information>
          <ReferenceNumber>34</ReferenceNumber>
          <Name>Eye First Aid</Name>
          <Value>
            <StringWithMarkup>
              <String>Rinse with plenty of water (remove contact lenses if easily possible).</String>
              <Markup>
                <Start>21</Start>
                <Length>5</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/water</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-962</Extra>
              </Markup>
            </StringWithMarkup>
          </Value>
        </Information>
      </Section>
      <Section>
        <TOCHeading>Ingestion First Aid</TOCHeading>
        <Description>Information regarding the Ingestion First Aid</Description>
        <Information>
          <ReferenceNumber>34</ReferenceNumber>
          <Name>Ingestion First Aid</Name>
          <Value>
            <StringWithMarkup>
              <String>Rinse mouth. Give one or two glasses of water to drink.</String>
              <Markup>
                <Start>40</Start>
                <Length>5</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/water</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-962</Extra>
              </Markup>
            </StringWithMarkup>
          </Value>
        </Information>
      </Section>
    </Section>
    <Section>
      <TOCHeading>Fire Fighting</TOCHeading>
      <Description>Fire Fighting information</Description>
      <Information>
        <ReferenceNumber>1</ReferenceNumber>
        <Name>Fire Fighting</Name>
        <Reference>National Toxicology Program, Institute of Environmental Health Sciences, National Institutes of Health (NTP). 1992. National Toxicology Program Chemical Repository Database. Research Triangle Park, North Carolina: NTP.</Reference>
        <Value>
          <StringWithMarkup>
            <String>Fires involving this material can be controlled with a dry chemical, carbon dioxide or Halon extinguisher. A water spray may also be used. (NTP, 1992)</String>
            <Markup>
              <Start>69</Start>
              <Length>14</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/carbon%20dioxide</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-280</Extra>
            </Markup>
            <Markup>
              <Start>87</Start>
              <Length>5</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/Halon</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-6391</Extra>
            </Markup>
            <Markup>
              <Start>109</Start>
              <Length>5</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/water</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-962</Extra>
            </Markup>
          </StringWithMarkup>
        </Value>
      </Information>
      <Information>
        <ReferenceNumber>34</ReferenceNumber>
        <Name>Fire Fighting</Name>
        <Value>
          <StringWithMarkup>
            <String>Use water spray, foam, powder, carbon dioxide.</String>
            <Markup>
              <Start>4</Start>
              <Length>5</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/water</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-962</Extra>
            </Markup>
            <Markup>
              <Start>31</Start>
              <Length>14</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/carbon%20dioxide</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-280</Extra>
            </Markup>
          </StringWithMarkup>
        </Value>
      </Information>
      <Section>
        <TOCHeading>Fire Fighting Procedures</TOCHeading>
        <Description>Fire fighting measures list suitable extinguishing techniques, equipment; chemical hazards from fire.</Description>
        <Information>
          <ReferenceNumber>32</ReferenceNumber>
          <Description>**PEER REVIEWED**</Description>
          <Reference>Sigma-Aldrich; Safety Data Sheet for Nicotinic acid. Product Number: N4126, Version 4.11 (Revision Date 09/22/2017). Available from, as of July 18, 2018: http://www.sigmaaldrich.com/safety-center.html</Reference>
          <Value>
            <StringWithMarkup>
              <String>Suitable extinguishing media: Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide.</String>
              <Markup>
                <Start>34</Start>
                <Length>5</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/water</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-962</Extra>
              </Markup>
              <Markup>
                <Start>87</Start>
                <Length>14</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/carbon%20dioxide</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-280</Extra>
              </Markup>
            </StringWithMarkup>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>32</ReferenceNumber>
          <Description>**PEER REVIEWED**</Description>
          <Reference>Sigma-Aldrich; Safety Data Sheet for Nicotinic acid. Product Number: N4126, Version 4.11 (Revision Date 09/22/2017). Available from, as of July 18, 2018: http://www.sigmaaldrich.com/safety-center.html</Reference>
          <Value>
            <StringWithMarkup>
              <String>Advice for firefighters: Wear self-contained breathing apparatus for firefighting if necessary.</String>
            </StringWithMarkup>
          </Value>
        </Information>
      </Section>
    </Section>
    <Section>
      <TOCHeading>Accidental Release Measures</TOCHeading>
      <Description>Accidental release measures lists emergency procedures; protective equipment; proper methods of containment and cleanup.</Description>
      <Section>
        <TOCHeading>Spillage Disposal</TOCHeading>
        <Description>Procedures for Spillage Disposal</Description>
        <Information>
          <ReferenceNumber>34</ReferenceNumber>
          <Name>Spillage Disposal</Name>
          <Value>
            <StringWithMarkup>
              <String>Personal protection: particulate filter respirator adapted to the airborne concentration of the substance. Do NOT let this chemical enter the environment. Sweep spilled substance into covered containers. If appropriate, moisten first to prevent dusting. Carefully collect remainder. Then store and dispose of according to local regulations.</String>
            </StringWithMarkup>
          </Value>
        </Information>
      </Section>
      <Section>
        <TOCHeading>Cleanup Methods</TOCHeading>
        <Description>Procedures for cleanup</Description>
        <Information>
          <ReferenceNumber>32</ReferenceNumber>
          <Description>**PEER REVIEWED**</Description>
          <Reference>Sigma-Aldrich; Safety Data Sheet for Nicotinic acid. Product Number: N4126, Version 4.11 (Revision Date 09/22/2017). Available from, as of July 18, 2018: http://www.sigmaaldrich.com/safety-center.html</Reference>
          <Value>
            <StringWithMarkup>
              <String>ACCIDENTAL RELEASE MEASURES: Personal precautions, protective equipment and emergency procedures: Use personal protective equipment. Avoid dust formation. Avoid breathing vapors, mist or gas. Ensure adequate ventilation. Avoid breathing dust. Environmental precautions: Prevent further leakage or spillage if safe to do so. Do not let product enter drains. Discharge into the environment must be avoided. Methods and materials for containment and cleaning up: Pick up and arrange disposal without creating dust. Sweep up and shovel. Keep in suitable, closed containers for disposal.</String>
            </StringWithMarkup>
          </Value>
        </Information>
      </Section>
      <Section>
        <TOCHeading>Disposal Methods</TOCHeading>
        <Description>Disposal Methods for this chemical</Description>
        <Information>
          <ReferenceNumber>32</ReferenceNumber>
          <Description>**PEER REVIEWED**</Description>
          <Value>
            <StringWithMarkup>
              <String>SRP: Recycle any unused portion of the material for its approved use or return it to the manufacturer or supplier. Ultimate disposal of the chemical must consider: the material&apos;s impact on air quality; potential migration in air, soil or water; effects on animal, aquatic and plant life; and conformance with environmental and public health regulations. If it is possible or reasonable use an alternative chemical product with less inherent propensity for occupational harm/injury/toxicity or environmental contamination.</String>
              <Markup>
                <Start>238</Start>
                <Length>5</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/water</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-962</Extra>
              </Markup>
            </StringWithMarkup>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>32</ReferenceNumber>
          <Description>**PEER REVIEWED**</Description>
          <Reference>Sigma-Aldrich; Safety Data Sheet for Nicotinic acid. Product Number: N4126, Version 4.11 (Revision Date 09/22/2017). Available from, as of July 18, 2018: http://www.sigmaaldrich.com/safety-center.html</Reference>
          <Value>
            <StringWithMarkup>
              <String>Product: Offer surplus and non-recyclable solutions to a licensed disposal company. Contact a licensed professional waste disposal service to dispose of this material; Contaminated packaging: Dispose of as unused product.</String>
            </StringWithMarkup>
          </Value>
        </Information>
      </Section>
      <Section>
        <TOCHeading>Preventive Measures</TOCHeading>
        <Description>Information on Preventive Measures</Description>
        <Information>
          <ReferenceNumber>32</ReferenceNumber>
          <Description>**PEER REVIEWED**</Description>
          <Reference>Sigma-Aldrich; Safety Data Sheet for Nicotinic acid. Product Number: N4126, Version 4.11 (Revision Date 09/22/2017). Available from, as of July 18, 2018: http://www.sigmaaldrich.com/safety-center.html</Reference>
          <Value>
            <StringWithMarkup>
              <String>ACCIDENTAL RELEASE MEASURES: Personal precautions, protective equipment and emergency procedures: Use personal protective equipment. Avoid dust formation. Avoid breathing vapors, mist or gas. Ensure adequate ventilation. Avoid breathing dust. Environmental precautions: Prevent further leakage or spillage if safe to do so. Do not let product enter drains. Discharge into the environment must be avoided.</String>
            </StringWithMarkup>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>32</ReferenceNumber>
          <Description>**PEER REVIEWED**</Description>
          <Reference>Sigma-Aldrich; Safety Data Sheet for Nicotinic acid. Product Number: N4126, Version 4.11 (Revision Date 09/22/2017). Available from, as of July 18, 2018: http://www.sigmaaldrich.com/safety-center.html</Reference>
          <Value>
            <StringWithMarkup>
              <String>Precautions for safe handling: Avoid contact with skin and eyes. Avoid formation of dust and aerosols. Further processing of solid materials may result in the formation of combustible dusts. The potential for combustible dust formation should be taken into consideration before additional processing occurs. Provide appropriate exhaust ventilation at places where dust is formed.</String>
            </StringWithMarkup>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>32</ReferenceNumber>
          <Description>**PEER REVIEWED**</Description>
          <Reference>Sigma-Aldrich; Safety Data Sheet for Nicotinic acid. Product Number: N4126, Version 4.11 (Revision Date 09/22/2017). Available from, as of July 18, 2018: http://www.sigmaaldrich.com/safety-center.html</Reference>
          <Value>
            <StringWithMarkup>
              <String>Appropriate engineering controls: Handle in accordance with good industrial hygiene and safety practice. Wash hands before breaks and at the end of workday.</String>
            </StringWithMarkup>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>32</ReferenceNumber>
          <Description>**PEER REVIEWED**</Description>
          <Reference>Sigma-Aldrich; Safety Data Sheet for Nicotinic acid. Product Number: N4126, Version 4.11 (Revision Date 09/22/2017). Available from, as of July 18, 2018: http://www.sigmaaldrich.com/safety-center.html</Reference>
          <Value>
            <StringWithMarkup>
              <String>Gloves must be inspected prior to use. Use proper glove removal technique (without touching glove&apos;s outer surface) to avoid skin contact with this product. Dispose of contaminated gloves after use in accordance with applicable laws and good laboratory practices. Wash and dry hands.</String>
            </StringWithMarkup>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>32</ReferenceNumber>
          <Description>**PEER REVIEWED**</Description>
          <Value>
            <StringWithMarkup>
              <String>SRP: Local exhaust ventilation should be applied wherever there is an incidence of point source emissions or dispersion of regulated contaminants in the work area. Ventilation control of the contaminant as close to its point of generation is both the most economical and safest method to minimize personnel exposure to airborne contaminants. Ensure that the local ventilation moves the contaminant away from the worker.</String>
            </StringWithMarkup>
          </Value>
        </Information>
      </Section>
    </Section>
    <Section>
      <TOCHeading>Handling and Storage</TOCHeading>
      <Description>Handling and storage lists precautions for safe handling and storage, including incompatibilities.</Description>
      <Section>
        <TOCHeading>Nonfire Spill Response</TOCHeading>
        <Description>Information for Nonfire Spill Response</Description>
        <Information>
          <ReferenceNumber>1</ReferenceNumber>
          <Name>Nonfire Spill Response</Name>
          <Reference>National Toxicology Program, Institute of Environmental Health Sciences, National Institutes of Health (NTP). 1992. National Toxicology Program Chemical Repository Database. Research Triangle Park, North Carolina: NTP.</Reference>
          <Value>
            <StringWithMarkup>
              <String>SMALL SPILLS AND LEAKAGE: If you spill this chemical, you should dampen the solid spill material with water, then transfer the dampened material to a suitable container. Use absorbent paper dampened with water to pick up any remaining material. Seal your contaminated clothing and the absorbent paper in a vapor-tight plastic bag for eventual disposal. Wash all contaminated surfaces with a soap and water solution. Do not reenter the contaminated area until the Safety Officer (or other responsible person) has verified that the area has been properly cleaned.  STORAGE PRECAUTIONS: You should store this material under ambient temperatures. (NTP, 1992)</String>
              <Markup>
                <Start>102</Start>
                <Length>5</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/water</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-962</Extra>
              </Markup>
              <Markup>
                <Start>204</Start>
                <Length>5</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/water</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-962</Extra>
              </Markup>
              <Markup>
                <Start>400</Start>
                <Length>5</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/water</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-962</Extra>
              </Markup>
            </StringWithMarkup>
          </Value>
        </Information>
      </Section>
      <Section>
        <TOCHeading>Safe Storage</TOCHeading>
        <Description>Information for Safe Storage</Description>
        <Information>
          <ReferenceNumber>34</ReferenceNumber>
          <Name>Safe Storage</Name>
          <Value>
            <StringWithMarkup>
              <String>Store in an area without drain or sewer access. Separated from strong acids, bases and oxidants.</String>
            </StringWithMarkup>
          </Value>
        </Information>
      </Section>
      <Section>
        <TOCHeading>Storage Conditions</TOCHeading>
        <Description>Information for Storage Conditions</Description>
        <Information>
          <ReferenceNumber>32</ReferenceNumber>
          <Description>**PEER REVIEWED**</Description>
          <Reference>Sigma-Aldrich; Safety Data Sheet for Nicotinic acid. Product Number: N4126, Version 4.11 (Revision Date 09/22/2017). Available from, as of July 18, 2018: http://www.sigmaaldrich.com/safety-center.html</Reference>
          <Value>
            <StringWithMarkup>
              <String>Keep container tightly closed in a dry and well-ventilated place. Light sensitive.</String>
            </StringWithMarkup>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>32</ReferenceNumber>
          <Description>**PEER REVIEWED**</Description>
          <Reference>American Society of Health-System Pharmacists 2017; Drug Information 2017. Bethesda, MD. 2017, p. 1941</Reference>
          <Value>
            <StringWithMarkup>
              <String>Niacin should be stored in well-closed, light-resistant containers at 20-25 deg C. When stored under these conditions, Niaspan extended-release and Niacor immediate-release tablets are stable for 3 and 2 years, respectively, after the date of manufacture. The fixed-combination preparation containing extended-release niacin and lovastatin (Advicor) should be stored at room temperature (20-25 deg C).</String>
              <Markup>
                <Start>0</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/Niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>119</Start>
                <Length>7</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/Niaspan</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>148</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/Niacor</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>318</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>329</Start>
                <Length>10</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/lovastatin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-53232</Extra>
              </Markup>
              <Markup>
                <Start>341</Start>
                <Length>7</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/Advicor</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-151176</Extra>
              </Markup>
            </StringWithMarkup>
          </Value>
        </Information>
      </Section>
    </Section>
    <Section>
      <TOCHeading>Exposure Control and Personal Protection</TOCHeading>
      <Description>Exposure controls and personal protection list OSHA&apos;s Permissible Exposure Limits (PELs); Threshold Limit Values (TLVs); appropriate engineering controls; personal protective equipment (PPE) and more.</Description>
      <Section>
        <TOCHeading>Inhalation Risk</TOCHeading>
        <Description>Inhalation Risk</Description>
        <Information>
          <ReferenceNumber>34</ReferenceNumber>
          <Name>Inhalation Risk</Name>
          <Value>
            <StringWithMarkup>
              <String>A nuisance-causing concentration of airborne particles can be reached quickly when dispersed, especially if powdered.</String>
            </StringWithMarkup>
          </Value>
        </Information>
      </Section>
      <Section>
        <TOCHeading>Effects of Short Term Exposure</TOCHeading>
        <Description>Effects of Short Term Exposure</Description>
        <Information>
          <ReferenceNumber>34</ReferenceNumber>
          <Name>Effects of Short Term Exposure</Name>
          <Value>
            <StringWithMarkup>
              <String>The substance is mildly irritating to the eyes.</String>
            </StringWithMarkup>
          </Value>
        </Information>
      </Section>
      <Section>
        <TOCHeading>Fire Prevention</TOCHeading>
        <Description>Fire Prevention</Description>
        <Information>
          <ReferenceNumber>34</ReferenceNumber>
          <Name>Fire Prevention</Name>
          <Value>
            <StringWithMarkup>
              <String>NO open flames. Prevent deposition of dust. Closed system, dust explosion-proof electrical equipment and lighting.</String>
            </StringWithMarkup>
          </Value>
        </Information>
      </Section>
      <Section>
        <TOCHeading>Exposure Prevention</TOCHeading>
        <Description>Exposure Prevention</Description>
        <Information>
          <ReferenceNumber>34</ReferenceNumber>
          <Name>Exposure Prevention</Name>
          <Value>
            <StringWithMarkup>
              <String>PREVENT DISPERSION OF DUST!</String>
            </StringWithMarkup>
          </Value>
        </Information>
      </Section>
      <Section>
        <TOCHeading>Inhalation Prevention</TOCHeading>
        <Description>Inhalation Prevention</Description>
        <Information>
          <ReferenceNumber>34</ReferenceNumber>
          <Name>Inhalation Prevention</Name>
          <Value>
            <StringWithMarkup>
              <String>Avoid inhalation of dust.</String>
            </StringWithMarkup>
          </Value>
        </Information>
      </Section>
      <Section>
        <TOCHeading>Skin Prevention</TOCHeading>
        <Description>Skin Prevention</Description>
        <Information>
          <ReferenceNumber>34</ReferenceNumber>
          <Name>Skin Prevention</Name>
          <Value>
            <StringWithMarkup>
              <String>Protective gloves.</String>
            </StringWithMarkup>
          </Value>
        </Information>
      </Section>
      <Section>
        <TOCHeading>Eye Prevention</TOCHeading>
        <Description>Eye Prevention</Description>
        <Information>
          <ReferenceNumber>34</ReferenceNumber>
          <Name>Eye Prevention</Name>
          <Value>
            <StringWithMarkup>
              <String>Wear safety goggles.</String>
            </StringWithMarkup>
          </Value>
        </Information>
      </Section>
      <Section>
        <TOCHeading>Ingestion Prevention</TOCHeading>
        <Description>Ingestion Prevention</Description>
        <Information>
          <ReferenceNumber>34</ReferenceNumber>
          <Name>Ingestion Prevention</Name>
          <Value>
            <StringWithMarkup>
              <String>Do not eat, drink, or smoke during work.</String>
            </StringWithMarkup>
          </Value>
        </Information>
      </Section>
      <Section>
        <TOCHeading>Protective Equipment and Clothing</TOCHeading>
        <Description>Protective Equipment and Clothing</Description>
        <Information>
          <ReferenceNumber>1</ReferenceNumber>
          <Name>Protective Equipment and Clothing</Name>
          <Reference>National Toxicology Program, Institute of Environmental Health Sciences, National Institutes of Health (NTP). 1992. National Toxicology Program Chemical Repository Database. Research Triangle Park, North Carolina: NTP.</Reference>
          <Value>
            <StringWithMarkup>
              <String>RECOMMENDED RESPIRATOR: Where the neat test chemical is weighed and diluted, wear a NIOSH-approved half face respirator equipped with an organic vapor/acid gas cartridge (specific for organic vapors, HCl, acid gas and SO2) with a dust/mist filter. (NTP, 1992)</String>
            </StringWithMarkup>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>32</ReferenceNumber>
          <Description>**PEER REVIEWED**</Description>
          <Reference>Sigma-Aldrich; Safety Data Sheet for Nicotinic acid. Product Number: N4126, Version 4.11 (Revision Date 09/22/2017). Available from, as of July 18, 2018: http://www.sigmaaldrich.com/safety-center.html</Reference>
          <Value>
            <StringWithMarkup>
              <String>Eye/face protection: Safety glasses with side-shields conforming to EN166. Use equipment for eye protection tested and approved under appropriate government standards such as NIOSH (US) or EN 166(EU).</String>
            </StringWithMarkup>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>32</ReferenceNumber>
          <Description>**PEER REVIEWED**</Description>
          <Reference>Sigma-Aldrich; Safety Data Sheet for Nicotinic acid. Product Number: N4126, Version 4.11 (Revision Date 09/22/2017). Available from, as of July 18, 2018: http://www.sigmaaldrich.com/safety-center.html</Reference>
          <Value>
            <StringWithMarkup>
              <String>Skin protection: Handle with gloves.</String>
            </StringWithMarkup>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>32</ReferenceNumber>
          <Description>**PEER REVIEWED**</Description>
          <Reference>Sigma-Aldrich; Safety Data Sheet for Nicotinic acid. Product Number: N4126, Version 4.11 (Revision Date 09/22/2017). Available from, as of July 18, 2018: http://www.sigmaaldrich.com/safety-center.html</Reference>
          <Value>
            <StringWithMarkup>
              <String>Body Protection: Impervious clothing. The type of protective equipment must be selected according to the concentration and amount of the dangerous substance at the specific workplace.</String>
            </StringWithMarkup>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>32</ReferenceNumber>
          <Description>**PEER REVIEWED**</Description>
          <Reference>Sigma-Aldrich; Safety Data Sheet for Nicotinic acid. Product Number: N4126, Version 4.11 (Revision Date 09/22/2017). Available from, as of July 18, 2018: http://www.sigmaaldrich.com/safety-center.html</Reference>
          <Value>
            <StringWithMarkup>
              <String>Respiratory protection: For nuisance exposures use type P95 (US) or type P1 (EU EN 143) particle respirator. For higher level protection use type OV/AG/P99 (US) or type ABEK-P2 (EU EN 143) respirator cartridges. Use respirators and components tested and approved under appropriate government standards such as NIOSH (US) or CEN (EU).</String>
            </StringWithMarkup>
          </Value>
        </Information>
      </Section>
    </Section>
    <Section>
      <TOCHeading>Stability and Reactivity</TOCHeading>
      <Description>Stability and reactivity lists chemical stability and possibility of hazardous reactions. (See also Stability section under the Experimental Properties if available)</Description>
      <Section>
        <TOCHeading>Air and Water Reactions</TOCHeading>
        <Description>Special alerts if the chemical reacts with air, water, or moisture.</Description>
        <Information>
          <ReferenceNumber>1</ReferenceNumber>
          <Name>Air and Water Reactions</Name>
          <Value>
            <StringWithMarkup>
              <String>Water soluble.</String>
            </StringWithMarkup>
          </Value>
        </Information>
      </Section>
      <Section>
        <TOCHeading>Reactive Group</TOCHeading>
        <Description>List of reactive groups that the chemical is assigned to, based on its known chemistry. Reactive groups are categories of chemicals that react in similar ways because their chemical structures are similar.</Description>
        <Information>
          <ReferenceNumber>1</ReferenceNumber>
          <Name>Reactive Group</Name>
          <Value>
            <StringWithMarkup>
              <String>Acids, Carboxylic</String>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Amines, Phosphines, and Pyridines</String>
            </StringWithMarkup>
          </Value>
        </Information>
      </Section>
      <Section>
        <TOCHeading>Reactivity Profile</TOCHeading>
        <Description>Generic reactivity information from CAMEO.</Description>
        <Information>
          <ReferenceNumber>1</ReferenceNumber>
          <Name>Reactivity Profile</Name>
          <Reference>National Toxicology Program, Institute of Environmental Health Sciences, National Institutes of Health (NTP). 1992. National Toxicology Program Chemical Repository Database. Research Triangle Park, North Carolina: NTP.</Reference>
          <Value>
            <StringWithMarkup>
              <String>NICOTINIC ACID is incompatible with strong oxidizers. It is also incompatible with sodium nitrite. (NTP, 1992)</String>
              <Markup>
                <Start>0</Start>
                <Length>14</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/NICOTINIC%20ACID</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>83</Start>
                <Length>14</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/sodium%20nitrite</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-23668193</Extra>
              </Markup>
            </StringWithMarkup>
          </Value>
        </Information>
      </Section>
    </Section>
    <Section>
      <TOCHeading>Regulatory Information</TOCHeading>
      <Description>Regulatory Information</Description>
      <Section>
        <TOCHeading>FDA Requirements</TOCHeading>
        <Description>FDA Requirements for the chemical&apos;s safety and hard information</Description>
        <Information>
          <ReferenceNumber>32</ReferenceNumber>
          <Description>**PEER REVIEWED**</Description>
          <Reference>21 CFR 184.1530 (USFDA); U.S. National Archives and Records Administration&apos;s Electronic Code of Federal Regulations. Available from, as of June 1, 2018: http://www.ecfr.gov</Reference>
          <Value>
            <StringWithMarkup>
              <String>Substance added directly to human food affirmed as generally recognized as safe (GRAS).</String>
            </StringWithMarkup>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>32</ReferenceNumber>
          <Description>**PEER REVIEWED**</Description>
          <Reference>21 CFR 582.5530 (USFDA); U.S. National Archives and Records Administration&apos;s Electronic Code of Federal Regulations. Available from, as of June 1, 2018: http://www.ecfr.gov</Reference>
          <Value>
            <StringWithMarkup>
              <String>Niacin used as a nutrient and/or dietary supplement in animal drugs, feeds, and related products is generally recognized as safe when used in accordance with good manufacturing or feeding practice.</String>
              <Markup>
                <Start>0</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/Niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
            </StringWithMarkup>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>32</ReferenceNumber>
          <Description>**PEER REVIEWED**</Description>
          <Reference>DHHS/FDA; Electronic Orange Book-Approved Drug Products with Therapeutic Equivalence Evaluations. Available from, as of June 12, 2018: http://www.fda.gov/cder/ob/</Reference>
          <Value>
            <StringWithMarkup>
              <String>The Approved Drug Products with Therapeutic Equivalence Evaluations identifies currently marketed prescription drug products, including niacin, approved on the basis of safety and effectiveness by FDA under sections 505 of the Federal Food, Drug, and Cosmetic Act.</String>
              <Markup>
                <Start>136</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
            </StringWithMarkup>
          </Value>
        </Information>
      </Section>
    </Section>
    <Section>
      <TOCHeading>Other Safety Information</TOCHeading>
      <Description>Other Safety Information includes the date of preparation or last revision</Description>
      <Section>
        <TOCHeading>Special Reports</TOCHeading>
        <Description>Special Reports</Description>
        <Information>
          <ReferenceNumber>32</ReferenceNumber>
          <Value>
            <StringWithMarkup>
              <String>Cosmetic Ingredient Review (CIR) Expert Panel; Final Report of the Safety Assessment of Niacinamide and Niacin; Intl J of Toxicology 24 (Suppl 5): 12 (2005)</String>
              <Markup>
                <Start>88</Start>
                <Length>11</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/Niacinamide</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-936</Extra>
              </Markup>
              <Markup>
                <Start>104</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/Niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
            </StringWithMarkup>
          </Value>
        </Information>
      </Section>
    </Section>
  </Section>
  <Section>
    <TOCHeading>Toxicity</TOCHeading>
    <Description>Toxicity information related to this record, includes routes of exposure; related symptoms, acute and chronic effects; numerical measures of toxicity.</Description>
    <Section>
      <TOCHeading>Toxicological Information</TOCHeading>
      <Description>Toxicological Information</Description>
      <Section>
        <TOCHeading>Hepatotoxicity</TOCHeading>
        <Description>This section provides a short description about the hepatotoxicity that associated with the agent, the rate of serum enzyme elevations during use, and the frequency and character of the clinically apparent liver injury associated with the medication.</Description>
        <URL>https://livertox.nlm.nih.gov/aboutus.html</URL>
        <Information>
          <ReferenceNumber>35</ReferenceNumber>
          <Name>Hepatotoxicity</Name>
          <Value>
            <StringWithMarkup>
              <String>Niacin in doses above 500 mg daily causes transient, asymptomatic elevations in serum aminotransferase levels in up to 20% of people. The elevations are rarely greater than 3 times the upper limit of the normal range and usually resolve spontaneously even with continuation of the drug. The effect is partially dose related and is more common with doses above 3 g/day. In some patients, there is an overall decrease in serum proteins synthesized by the liver and, in some instances, coagulopathy with an increase in prothrombin time and decline in serum albumin, coagulation factors and apolipoproteins. These changes resolve rapidly upon stopping therapy and may not recur with lower doses.</String>
              <Markup>
                <Start>0</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/Niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
            </StringWithMarkup>
          </Value>
        </Information>
      </Section>
      <Section>
        <TOCHeading>NIOSH Toxicity Data</TOCHeading>
        <Description>Toxicity data summary from NIOSH</Description>
        <Information>
          <ReferenceNumber>72</ReferenceNumber>
          <Name>NIOSH Toxicity Data</Name>
          <Value>
            <ExternalTableName>niosh</ExternalTableName>
          </Value>
        </Information>
      </Section>
      <Section>
        <TOCHeading>Inhalation Symptoms</TOCHeading>
        <Description>Symptoms of exposure (inhalation, skin, eyes, ingestion) routes by which the chemical can be absorbed into the body</Description>
        <Information>
          <ReferenceNumber>34</ReferenceNumber>
          <Name>Inhalation Symptoms</Name>
          <Value>
            <StringWithMarkup>
              <String>Cough.</String>
            </StringWithMarkup>
          </Value>
        </Information>
      </Section>
      <Section>
        <TOCHeading>Eye Symptoms</TOCHeading>
        <Description>Symptoms of exposure (inhalation, skin, eyes, ingestion) routes by which the chemical can be absorbed into the body</Description>
        <Information>
          <ReferenceNumber>34</ReferenceNumber>
          <Name>Eye Symptoms</Name>
          <Value>
            <StringWithMarkup>
              <String>Redness.</String>
            </StringWithMarkup>
          </Value>
        </Information>
      </Section>
      <Section>
        <TOCHeading>Ingestion Symptoms</TOCHeading>
        <Description>Symptoms of exposure (inhalation, skin, eyes, ingestion) routes by which the chemical can be absorbed into the body</Description>
        <Information>
          <ReferenceNumber>34</ReferenceNumber>
          <Name>Ingestion Symptoms</Name>
          <Value>
            <StringWithMarkup>
              <String>Flushing of the face.</String>
            </StringWithMarkup>
          </Value>
        </Information>
      </Section>
      <Section>
        <TOCHeading>Acute Effects</TOCHeading>
        <Description>The results from acute animal tests and/or acute human studies are presented in this section. Acute animal studies consist of LD50 and LC50 tests, which present the median lethal dose (or concentration) to the animals. Acute human studies usually consist of case reports from accidental poisonings or industrial accidents. These case reports often help to define the levels at which acute toxic effects are seen in humans.</Description>
        <Information>
          <ReferenceNumber>4</ReferenceNumber>
          <Value>
            <ExternalTableName>chemidplus</ExternalTableName>
            <ExternalTableNumRows>16</ExternalTableNumRows>
          </Value>
        </Information>
      </Section>
      <Section>
        <TOCHeading>Interactions</TOCHeading>
        <Description>Interactions</Description>
        <Information>
          <ReferenceNumber>32</ReferenceNumber>
          <Description>**PEER REVIEWED**</Description>
          <Reference>Kalil RS et al; Kidney Int 87 (6): 1250-7 (2015)</Reference>
          <Value>
            <StringWithMarkup>
              <String>Chronic kidney disease (CKD) in patients is strongly associated with cardiovascular morbidity and mortality, and prevalent abnormal lipid metabolism. The AIM-HIGH trial examined the benefits of adding extended-release niacin (ERN) to simvastatin in patients with established coronary heart disease. Here we conducted a post hoc analysis of the AIM-HIGH trial examining whether participants derived cardiovascular or renal benefits when stratified by renal function. Of 3414 participants, 505 had stage 3 CKD at baseline. Among the CKD subset, demographics and cardiovascular disease (CVD) risk factors were well balanced in the ERN and placebo arms. Compared with placebo, CKD participants receiving ERN had a significant decrease in triglycerides by a median of 59.0 mg/dL, and high-density lipoprotein cholesterol significantly increased by a mean of 11.3 mg/dL over a mean follow-up of 3 years. CVD events were similar between CKD participants in both arms. However, all-cause mortality was significantly higher in the ERN group (hazard ratio of 1.73). Mean change in eGFR among ERN-treated CKD participants was not significantly different between study arms. Thus, among AIM-HIGH participants with CKD, the addition of ERN to simvastatin for secondary prevention of CVD improved triglyceride and high-density lipoprotein-cholesterol concentrations but did not improve cardiovascular outcomes or kidney function, and was associated with higher all-cause mortality. PubMed Abstract Full text: PMC4449803</String>
              <Markup>
                <Start>1468</Start>
                <Length>15</Length>
                <URL>http://www.ncbi.nlm.nih.gov/pubmed/25651367?dopt=Abstract</URL>
              </Markup>
              <Markup>
                <Start>1495</Start>
                <Length>10</Length>
                <URL>https://www.ncbi.nlm.nih.gov/pmc/?term=PMC4449803</URL>
              </Markup>
              <Markup>
                <Start>218</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>234</Start>
                <Length>11</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/simvastatin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-54454</Extra>
              </Markup>
              <Markup>
                <Start>804</Start>
                <Length>11</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/cholesterol</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-5997</Extra>
              </Markup>
              <Markup>
                <Start>1230</Start>
                <Length>11</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/simvastatin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-54454</Extra>
              </Markup>
              <Markup>
                <Start>1325</Start>
                <Length>11</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/cholesterol</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-5997</Extra>
              </Markup>
            </StringWithMarkup>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>32</ReferenceNumber>
          <Description>**PEER REVIEWED**</Description>
          <Reference>American Society of Health-System Pharmacists 2017; Drug Information 2017. Bethesda, MD. 2017, p. 1940</Reference>
          <Value>
            <StringWithMarkup>
              <String>The risk of developing myopathy and rhabdomyolysis is increased in patients receiving niacin (particularly at antilipemic dosages [exceeding 1 g daily]) concomitantly with statins. ... Myopathy or rhabdomyolysis has occurred in some patients receiving certain statins concomitantly with antilipemic dosages of niacin. However, some manufacturers state that no cases of rhabdomyolysis were reported in 124 patients receiving extended-release niacin (Niaspan) concomitantly with various statins; rhabdomyolysis also was not reported in 1079 patients receiving extended-release niacin in fixed combination with lovastatin (Advicor) for up to 2 years. Other severe adverse effects, including disturbances in glycemic control requiring hospitalization, development of diabetes mellitus, adverse GI effects, myopathy, gout, rash, skin ulceration, infection, and bleeding, have been reported in patients with established cardiovascular disease following concomitant use of extended-release niacin with statin-based therapy. ... Therefore, the potential benefits (e.g., further alterations in lipid concentrations) of concomitant use of antilipemic dosages of niacin with statins should be weighed carefully against the possible risks of severe adverse effects, and caution is advised if such concomitant therapy is employed. The manufacturer of atorvastatin states that lower initial and maintenance dosages of this statin should be considered during concomitant therapy with antilipemic dosages of niacin, and patients should be carefully monitored for manifestations of muscle pain, tenderness, or weakness, particularly during the initial months of therapy and following an increase in dosage of either drug. The manufacturers of fluvastatin, pitavastatin, and pravastatin state that dosage reduction of these statins should be considered when used concomitantly with antilipemic dosages of niacin.</String>
              <Markup>
                <Start>86</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>310</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>441</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>449</Start>
                <Length>7</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/Niaspan</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>575</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>608</Start>
                <Length>10</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/lovastatin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-53232</Extra>
              </Markup>
              <Markup>
                <Start>620</Start>
                <Length>7</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/Advicor</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-151176</Extra>
              </Markup>
              <Markup>
                <Start>983</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>1152</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>1338</Start>
                <Length>12</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/atorvastatin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-60823</Extra>
              </Markup>
              <Markup>
                <Start>1492</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>1726</Start>
                <Length>11</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/fluvastatin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-446155</Extra>
              </Markup>
              <Markup>
                <Start>1739</Start>
                <Length>12</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/pitavastatin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-5282452</Extra>
              </Markup>
              <Markup>
                <Start>1757</Start>
                <Length>11</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/pravastatin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-54687</Extra>
              </Markup>
              <Markup>
                <Start>1887</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
            </StringWithMarkup>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>32</ReferenceNumber>
          <Description>**PEER REVIEWED**</Description>
          <Reference>American Society of Health-System Pharmacists 2017; Drug Information 2017. Bethesda, MD. 2017, p. 1940</Reference>
          <Value>
            <StringWithMarkup>
              <String>Concomitant use of aspirin may decrease the metabolic clearance of niacin; the clinical relevance of this interaction has not been fully elucidated.</String>
              <Markup>
                <Start>19</Start>
                <Length>7</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/aspirin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-2244</Extra>
              </Markup>
              <Markup>
                <Start>67</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
            </StringWithMarkup>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>32</ReferenceNumber>
          <Description>**PEER REVIEWED**</Description>
          <Reference>American Society of Health-System Pharmacists 2017; Drug Information 2017. Bethesda, MD. 2017, p. 1940</Reference>
          <Value>
            <StringWithMarkup>
              <String>Niacin reportedly potentiates the hypotensive effects of ganglionic blocking and vasoactive drugs, resulting in postural hypotension.</String>
              <Markup>
                <Start>0</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/Niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
            </StringWithMarkup>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>32</ReferenceNumber>
          <Description>**PEER REVIEWED**</Description>
          <Reference>American Society of Health-System Pharmacists 2017; Drug Information 2017. Bethesda, MD. 2017, p. 1940</Reference>
          <Value>
            <StringWithMarkup>
              <String>Increased prothrombin time (PT) and decreased platelet count have been reported in patients receiving niacin. Therefore, niacin should be used with caution in patients receiving concomitant anticoagulant therapy; PT and platelet count should be monitored closely in such patients.</String>
              <Markup>
                <Start>102</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>121</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
            </StringWithMarkup>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>32</ReferenceNumber>
          <Description>**PEER REVIEWED**</Description>
          <Reference>American Society of Health-System Pharmacists 2017; Drug Information 2017. Bethesda, MD. 2017, p. 1940</Reference>
          <Value>
            <StringWithMarkup>
              <String>Limited data indicate that cholestyramine or colestipol resin may decrease the bioavailability of niacin, as 10-30 or 98% of the dose of niacin binds to cholestyramine or colestipol, respectively, following concomitant administration. Therefore, some manufacturers recommend that cholestyramine or colestipol and niacin be administered at least 4-6 hours apart.</String>
              <Markup>
                <Start>27</Start>
                <Length>14</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/cholestyramine</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-70695641</Extra>
              </Markup>
              <Markup>
                <Start>45</Start>
                <Length>10</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/colestipol</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-62816</Extra>
              </Markup>
              <Markup>
                <Start>98</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>137</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>153</Start>
                <Length>14</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/cholestyramine</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-70695641</Extra>
              </Markup>
              <Markup>
                <Start>171</Start>
                <Length>10</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/colestipol</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-62816</Extra>
              </Markup>
              <Markup>
                <Start>280</Start>
                <Length>14</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/cholestyramine</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-70695641</Extra>
              </Markup>
              <Markup>
                <Start>298</Start>
                <Length>10</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/colestipol</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-62816</Extra>
              </Markup>
              <Markup>
                <Start>313</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
            </StringWithMarkup>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>32</ReferenceNumber>
          <Description>**PEER REVIEWED**</Description>
          <Reference>Parson HK et al; J Diabetes 5 (1): 59-67 (2013)</Reference>
          <Value>
            <StringWithMarkup>
              <String>Although niacin often has beneficial effects on the lipoprotein profile, flushing is an untoward effect associated with its use. Aspirin can only reduce the flushing response by 30-40%. Thus, the aim of the present study was to investigate the mechanisms of niacin-induced flushing, with and without aspirin, in normal, healthy individuals. Niacin-induced flushing was evaluated in 30 healthy individuals after oral administration of 1000 mg niacin alone or with 325 mg aspirin. Neurological, autonomic nervous system, and skin blood flow measurements (using laser Doppler on the glabrous and hairy skin of each participant) were made at various times after drug administration. In addition, the systemic release of 9alpha,11beta-prostaglandin (PG) F(2) was determined. Flushing symptoms of redness, warmth, tingling, itching, and intensity were recorded using the modified Flushing ASsessment Tool (FAST). After aspirin, the mean flushing scores for all symptoms decreased significantly; however, 36-53% of participants still had some degree of symptoms, even though aspirin completely blocked 11beta-PGF(2) synthesis. Maximum skin blood flow (MaxSkBF) in both the glabrous and hairy forearm increased significantly after niacin, but decreased significantly after aspirin only in hairy skin. Regression analysis showed that, in glabrous skin, both PGF(2) and parasympathetic activity were significant predictors of MaxSkBF after niacin, contributing 26% and 14%, respectively (total R(2) = 40%). The present study indicates, for the first time, that the parasympathetic nervous system, in addition to PGD(2), may play an important role in niacin-induced flushing. Changing the sympathetic/parasympathetic balance in favor of parasympathetic activation may be a good therapeutic target to reduce niacin-induced flushing. PubMed Abstract</String>
              <Markup>
                <Start>1821</Start>
                <Length>15</Length>
                <URL>http://www.ncbi.nlm.nih.gov/pubmed/22727040?dopt=Abstract</URL>
              </Markup>
              <Markup>
                <Start>9</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>129</Start>
                <Length>7</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/Aspirin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-2244</Extra>
              </Markup>
              <Markup>
                <Start>258</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>300</Start>
                <Length>7</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/aspirin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-2244</Extra>
              </Markup>
              <Markup>
                <Start>341</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/Niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>442</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>470</Start>
                <Length>7</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/aspirin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-2244</Extra>
              </Markup>
              <Markup>
                <Start>913</Start>
                <Length>7</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/aspirin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-2244</Extra>
              </Markup>
              <Markup>
                <Start>1068</Start>
                <Length>7</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/aspirin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-2244</Extra>
              </Markup>
              <Markup>
                <Start>1223</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>1265</Start>
                <Length>7</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/aspirin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-2244</Extra>
              </Markup>
              <Markup>
                <Start>1430</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>1640</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>1796</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
            </StringWithMarkup>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>32</ReferenceNumber>
          <Description>**PEER REVIEWED**</Description>
          <Reference>Silva de Paula E et al; J Toxicol Environ Health A 79 (4): 174-83 (2016)</Reference>
          <Value>
            <StringWithMarkup>
              <String>This study investigates the potential beneficial effects of niacin (NA; vitamin B3) supplementation in rats chronically exposed to methylmercury (MeHg). Animals were randomly assigned to one of 4 groups (n = 6): Group I, control, received distilled water by gavage; Group II, received MeHg (100 ug/kg/d) by gavage; Group III, received NA (50 mg/kg/d) in drinking water; Group IV, received MeHg (100 ug/kg/d) by gavage + NA (50 mg/kg/d) in drinking water. Biochemical parameters levels of glucose, triglycerides, total cholesterol and fractions, and enzyme activities aspartate transaminase (AST) and alanine transaminase (ALT) were determined. Further, oxidative stress markers activity of glutathione peroxidase (GPx) and catalase (CAT) activity, as well as levels of reduced glutathione (GSH), malondialdehyde (MDA), and nitric oxide, were examined, and the comet assay was performed, using blood/plasma. Hg levels were measured in blood, brain, and kidneys of animals. Our results demonstrated that NA reduced adverse effects produced by MeHg. The mechanism underlying these effects appears to be related to the intrinsic antioxidant potential of NA. Considering the beneficial effects attributed to NA following MeHg exposure and that fish are the main source of both NA and MeHg, future studies need to evaluate the potential counteractive effect of NA against the adverse consequences of MeHg exposure in fish-eating populations. PubMed Abstract</String>
              <Markup>
                <Start>1436</Start>
                <Length>15</Length>
                <URL>http://www.ncbi.nlm.nih.gov/pubmed/26914397?dopt=Abstract</URL>
              </Markup>
              <Markup>
                <Start>60</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>72</Start>
                <Length>10</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/vitamin%20B3</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>249</Start>
                <Length>5</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/water</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-962</Extra>
              </Markup>
              <Markup>
                <Start>363</Start>
                <Length>5</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/water</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-962</Extra>
              </Markup>
              <Markup>
                <Start>448</Start>
                <Length>5</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/water</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-962</Extra>
              </Markup>
              <Markup>
                <Start>488</Start>
                <Length>7</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/glucose</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-5793</Extra>
              </Markup>
              <Markup>
                <Start>518</Start>
                <Length>11</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/cholesterol</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-5997</Extra>
              </Markup>
              <Markup>
                <Start>567</Start>
                <Length>9</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/aspartate</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-5460294</Extra>
              </Markup>
              <Markup>
                <Start>600</Start>
                <Length>7</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/alanine</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-602</Extra>
              </Markup>
              <Markup>
                <Start>690</Start>
                <Length>11</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/glutathione</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-124886</Extra>
              </Markup>
              <Markup>
                <Start>790</Start>
                <Length>3</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/GSH</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-124886</Extra>
              </Markup>
              <Markup>
                <Start>796</Start>
                <Length>15</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/malondialdehyde</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-10964</Extra>
              </Markup>
              <Markup>
                <Start>823</Start>
                <Length>12</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/nitric%20oxide</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-145068</Extra>
              </Markup>
            </StringWithMarkup>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>32</ReferenceNumber>
          <Description>**PEER REVIEWED**</Description>
          <Reference>Lin F et al; Int J Mol Med 29 (4): 593-600 (2012)</Reference>
          <Value>
            <StringWithMarkup>
              <String>Niacin and its related derivatives have been shown to have effects on cellular activities. However, the molecular mechanism of its reduced immunosuppressive effects and photoprotective effects remains unclear. In this study, we investigated the molecular mechanism of the photoprotective effect of niacin in ultraviolet (UV)-irradiated human skin keratinocytes (HaCaT cells). We found that niacin effectively suppressed the UV-induced cell death and cell apoptosis of HaCaT cells. Existing data have shown that protein kinase B (AKT) activation is involved in the cell survival process. Yet, the potential mechanism of niacin in protection against UV-induced skin damage has thus far not fully been eluvidated. We observed that niacin pretreatment enhances UV induced activation of AKT (Ser473 phosphorylation) as well as that of the downstream signal mechanistic target of rapamycin (mTOR; S6 and 4E-BP1 phosphorylation). The phosphoinositide-3-kinase (PI3K)/AKT inhibitor, LY294002, and the mTOR inhibitor, rapamycin, largely neutralized the protective effects of niacin, suggesting that AKT and downstream signaling mTOR/S6 activation are necessary for the niacin-induced protective effects against UV-induced cell death and cell apoptosis. Collectively, our data suggest that niacin may be utilized to prevent UV-induced skin damage and provide a novel mechanism of its photoprotective effects against the UV radiation of sunlight by modulating both AKT and downstream mTOR signaling pathways. PubMed Abstract Full text: PMC3577345</String>
              <Markup>
                <Start>1498</Start>
                <Length>15</Length>
                <URL>http://www.ncbi.nlm.nih.gov/pubmed/22246168?dopt=Abstract</URL>
              </Markup>
              <Markup>
                <Start>1525</Start>
                <Length>10</Length>
                <URL>https://www.ncbi.nlm.nih.gov/pmc/?term=PMC3577345</URL>
              </Markup>
              <Markup>
                <Start>0</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/Niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>298</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>390</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>619</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>728</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>874</Start>
                <Length>9</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/rapamycin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-5284616</Extra>
              </Markup>
              <Markup>
                <Start>975</Start>
                <Length>8</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/LY294002</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-3973</Extra>
              </Markup>
              <Markup>
                <Start>1009</Start>
                <Length>9</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/rapamycin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-5284616</Extra>
              </Markup>
              <Markup>
                <Start>1066</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>1160</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>1280</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
            </StringWithMarkup>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>32</ReferenceNumber>
          <Description>**PEER REVIEWED**</Description>
          <Reference>Lai E et al; Clin Pharmacol Ther 81 (6): 849-57 (2007)</Reference>
          <Value>
            <StringWithMarkup>
              <String>Niacin (nicotinic acid) reduces cardiovascular events in patients with dyslipidemia. However, symptoms associated with niacin-induced vasodilation (e.g., flushing) have limited its use. Laropiprant is a selective antagonist of the prostaglandin D(2) receptor subtype 1 (DP1), which may mediate niacin-induced vasodilation. The aim of this proof-of-concept study was to evaluate the effects of laropiprant (vs placebo) on niacin-induced cutaneous vasodilation. Coadministration of laropiprant 30, 100, and 300 mg with extended-release (ER) niacin significantly lowered flushing symptom scores (by approximately 50% or more) and also significantly reduced malar skin blood flow measured by laser Doppler perfusion imaging. Laropiprant was effective after multiple doses in reducing symptoms of flushing and attenuating the increased malar skin blood flow induced by ER niacin. In conclusion, the DP1 receptor antagonist laropiprant was effective in suppressing both subjective and objective manifestations of niacin-induced vasodilation. PubMed Abstract</String>
              <Markup>
                <Start>1036</Start>
                <Length>15</Length>
                <URL>http://www.ncbi.nlm.nih.gov/pubmed/17392721?dopt=Abstract</URL>
              </Markup>
              <Markup>
                <Start>0</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/Niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>8</Start>
                <Length>14</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/nicotinic%20acid</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>119</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>186</Start>
                <Length>11</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/Laropiprant</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-9867642</Extra>
              </Markup>
              <Markup>
                <Start>294</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>393</Start>
                <Length>11</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/laropiprant</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-9867642</Extra>
              </Markup>
              <Markup>
                <Start>421</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>480</Start>
                <Length>11</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/laropiprant</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-9867642</Extra>
              </Markup>
              <Markup>
                <Start>539</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>721</Start>
                <Length>11</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/Laropiprant</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-9867642</Extra>
              </Markup>
              <Markup>
                <Start>867</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>918</Start>
                <Length>11</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/laropiprant</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-9867642</Extra>
              </Markup>
              <Markup>
                <Start>1007</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
            </StringWithMarkup>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>32</ReferenceNumber>
          <Description>**PEER REVIEWED**</Description>
          <Reference>Maccubbin DL et al; Am J Cardiol 110 (6): 817-22 (2012)</Reference>
          <Value>
            <StringWithMarkup>
              <String>Extended-release niacin (ERN) improves multiple lipid parameters but is underused owing to niacin-induced flushing (NIF). Laropiprant (LRPT) reduces NIF; however, its effects on chronic flushing (&gt;6 months) have not been studied. We examined whether after 20 weeks of treatment with ERN/LRPT, patients who continued ERN/LRPT would experience less NIF than patients who stopped LRPT and continued ERN alone. A total of 1,152 dyslipidemic patients were randomized 2:2:1 to group 1, ERN/LRPT 1 g/20 mg/day from 0 to 4 weeks and then ERN/LRPT 2 g/40 mg/day from 5 to 32 weeks; group 2, ERN/LRPT 1 g/20 mg/day from 0 to 4 weeks, ERN/LRPT 2 g/40 mg/day from 5 to 20 weeks, and then ERN 2 g/day without LRPT from 21 to 32 weeks; or group 3, placebo for the entire study. The end points included the number of days each week with a moderate or greater Global Flushing Severity Score (GFSS) &gt;/=4 (primary end point) and the percentage of patients with a maximum GFSS of &gt;/=4 (secondary end point) during the postwithdrawal period (weeks 21 to 32). ERN/LRPT produced significantly less NIF than ERN alone during the postwithdrawal period, as measured by the number of days each week with a GFSS of &gt;/=4 (p &lt;0.001) and the percentage of patients with a maximum GFSS of &gt;/=4 (p &lt;0.001; ERN/LRPT 19.6%; ERN 48.9%; placebo 9.2%). Compared with ERN alone, ERN/LRPT produced fewer drug-related adverse experiences during the postwithdrawal period. After 20 weeks of stable maintenance therapy, dyslipidemic patients treated continuously with ERN/LRPT experienced less NIF than did patients who had had LRPT withdrawn and had continued with ERN alone. In conclusion, the results of our study support the long-term efficacy of ERN/LRPT in reducing NIF symptoms. PubMed Abstract</String>
              <Markup>
                <Start>1744</Start>
                <Length>15</Length>
                <URL>http://www.ncbi.nlm.nih.gov/pubmed/22683042?dopt=Abstract</URL>
              </Markup>
              <Markup>
                <Start>17</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>91</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>122</Start>
                <Length>11</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/Laropiprant</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-9867642</Extra>
              </Markup>
            </StringWithMarkup>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>32</ReferenceNumber>
          <Description>**PEER REVIEWED**</Description>
          <Reference>Moriarty PM et al; J Clin Lipidol 7 (2): 140-6 (2013)</Reference>
          <Value>
            <StringWithMarkup>
              <String>Niacin, or vitamin B3, when used in high doses can significantly improve the levels of all major lipoproteins. Despite these benefits, the use of niacin is greatly limited secondary to benign yet bothersome cutaneous flushing primarily involving the face and upper extremities. Pretreatment with aspirin or other prostaglandin inhibitors has demonstrated significant reductions in niacin-induced flushing (NIF), but other treatment options are needed. Clinical and anecdotal evidence suggests the ingestion of pectin-containing fruits (eg, apple) mitigates NIF; however, clinical trials evaluating this are nonexistent. /The study objective was to determine whether/ pretreatment with encapsulated apple pectin would limit the incidence, severity, time of initiation, and duration of NIF. We enrolled 100 niacin-naive subjects (n = 25 per group) and preteated them in a double-blind manner with apple pectin, apple pectin + aspirin, aspirin, or placebo, followed by a one-time 1000 mg dose of niacin extended-release (niacin ER). Subjects then assessed major flushing parameters hourly for the next 6 hours with a validated visual analog scale. Apple pectin and aspirin each significantly lowered the duration of NIF and produced nonsignificant but positive improvements in all other major flushing parameters compared with placebo. Apple pectin may potentially be an alternative to aspirin for the prevention of NIF. Larger trials are needed to further evaluate the benefit of pectin on NIF. PubMed Abstract</String>
              <Markup>
                <Start>1493</Start>
                <Length>15</Length>
                <URL>http://www.ncbi.nlm.nih.gov/pubmed/23415433?dopt=Abstract</URL>
              </Markup>
              <Markup>
                <Start>0</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/Niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>11</Start>
                <Length>10</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/vitamin%20B3</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>146</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>296</Start>
                <Length>7</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/aspirin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-2244</Extra>
              </Markup>
              <Markup>
                <Start>381</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>510</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/pectin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-441476</Extra>
              </Markup>
              <Markup>
                <Start>704</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/pectin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-441476</Extra>
              </Markup>
              <Markup>
                <Start>805</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>901</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/pectin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-441476</Extra>
              </Markup>
              <Markup>
                <Start>915</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/pectin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-441476</Extra>
              </Markup>
              <Markup>
                <Start>924</Start>
                <Length>7</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/aspirin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-2244</Extra>
              </Markup>
              <Markup>
                <Start>933</Start>
                <Length>7</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/aspirin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-2244</Extra>
              </Markup>
              <Markup>
                <Start>993</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>1018</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>1151</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/pectin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-441476</Extra>
              </Markup>
              <Markup>
                <Start>1162</Start>
                <Length>7</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/aspirin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-2244</Extra>
              </Markup>
              <Markup>
                <Start>1339</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/pectin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-441476</Extra>
              </Markup>
              <Markup>
                <Start>1383</Start>
                <Length>7</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/aspirin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-2244</Extra>
              </Markup>
              <Markup>
                <Start>1478</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/pectin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-441476</Extra>
              </Markup>
            </StringWithMarkup>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>32</ReferenceNumber>
          <Description>**PEER REVIEWED**</Description>
          <Reference>Cupo MA, Donaldson WE; J Nutr 118 (1): 107-13 (1988)</Reference>
          <Value>
            <StringWithMarkup>
              <String>Interactions of lead and niacin were studied in growing broiler chicks fed one of four experimental diets from day-old to 3 wk of age. The diets were a low niacin basal diet, the basal diet supplemented with 40 mg of niacin/kg (control), the basal diet supplemented with 2000 mg lead/kg, as lead acetate (low niacin + lead) and the basal diet supplemented with both niacin and lead (control + lead). Growth and feed efficiency were reduced significantly by lead. The lead-associated growth depression was less severe in chicks fed the low niacin diet as indicated by a significant lead X niacin interaction. ... The data indicate that tryptophan and serotonin metabolism were altered by lead treatment, whereas niacin was without effect. The interaction of lead and niacin on growth does not appear to be related to alterations of serotonin metabolism in the central nervous system. PubMed Abstract</String>
              <Markup>
                <Start>883</Start>
                <Length>15</Length>
                <URL>http://www.ncbi.nlm.nih.gov/pubmed/3335932?dopt=Abstract</URL>
              </Markup>
              <Markup>
                <Start>25</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>156</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>217</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>291</Start>
                <Length>12</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/lead%20acetate</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-9317</Extra>
              </Markup>
              <Markup>
                <Start>309</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>366</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>539</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>588</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>635</Start>
                <Length>10</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/tryptophan</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-6305</Extra>
              </Markup>
              <Markup>
                <Start>650</Start>
                <Length>9</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/serotonin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-5202</Extra>
              </Markup>
              <Markup>
                <Start>711</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>766</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>831</Start>
                <Length>9</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/serotonin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-5202</Extra>
              </Markup>
            </StringWithMarkup>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>32</ReferenceNumber>
          <Description>**PEER REVIEWED**</Description>
          <Reference>Shafer RB et al; Eur J Nucl Med 8 (1): 12-4 (1983)</Reference>
          <Value>
            <StringWithMarkup>
              <String>Hepatic injury has been associated with nicotinic acid treatment of schizophrenia and hypercholesterolemia. This association was implicated when the liver and biliary tract were not visualized after 99mTc-HIDA in a patient taking 3 g daily of nicotinic acid. We studied hepatic transport of 99mTc-PIPIDA both in vitro in isolated hepatocytes and in vivo in rabbits pretreated with nicotinic acid to further examine this association. Nicotinic acid increased uptake of PIPIDA by isolated hepatocytes and 7 days of nicotinic acid treatment in rabbits produced no abnormalities in hepatic uptake, gallbladder visualization, or biliary excretion of PIPIDA. It was concluded that nicotinic acid does not have an inhibitory effect on uptake of biliary imaging agents and actually may be useful in enhancing hepatic imaging in patients with reduced liver funciton. PubMed Abstract</String>
              <Markup>
                <Start>858</Start>
                <Length>15</Length>
                <URL>http://www.ncbi.nlm.nih.gov/pubmed/6832182?dopt=Abstract</URL>
              </Markup>
              <Markup>
                <Start>40</Start>
                <Length>14</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/nicotinic%20acid</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>199</Start>
                <Length>10</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/99mTc-HIDA</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-450484</Extra>
              </Markup>
              <Markup>
                <Start>243</Start>
                <Length>14</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/nicotinic%20acid</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>381</Start>
                <Length>14</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/nicotinic%20acid</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>433</Start>
                <Length>14</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/Nicotinic%20acid</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>513</Start>
                <Length>14</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/nicotinic%20acid</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>675</Start>
                <Length>14</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/nicotinic%20acid</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
            </StringWithMarkup>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>32</ReferenceNumber>
          <Description>**PEER REVIEWED**</Description>
          <Reference>Whelan AM et al; ASHP Midyear Clin Meeting 25 (Dec): PSPG-51 (1990)</Reference>
          <Value>
            <StringWithMarkup>
              <String>Nicotinic acid is one of the first line agents recommended for the treatment of hyperlipidemias. Although this drug is effective and safe for long term use, bothersome cutaneous reactions (flushing, feeling of warmth, itching, and tingling) often limit patient acceptability and tolerability. Animal and human studies have indicated that the flushing reaction is prostaglandin mediated. This prompted the National Cholesterol Education Program to recommend giving aspirin or another nonsteroidal anti-inflammatory drug prior to a dose of niacin. Lack of scientific data supporting this recommendation, however, lead to this randomized, double-blind, placebo controlled study evaluating the influence of 80 mg aspirin and 325 mg aspirin on reducing these cutaneous reactions. Thirty-one healthy subjects enrolled in the study. Any subjects with known hypersensitivities or contraindications to any of the study drugs or lactose were excluded from the study. Patients were randomized into one of four treatment regimens (placebo/placebo, 80 mg aspirin/500 mg niacin, 325 mg aspirin/500 mg niacin, placebo/500 mg niacin). Subjects received each treatment regimen on four separate visits which were at least 24 hours apart. Intensity and tolerability of flushing, warmth, itching and tingling were evaluated by an intensity rating scale and visual analog scale. Statistical analysis indicate that 325 mg aspirin is better than the 80 mg aspirin in decreasing the intolerability to the niacin. Further analysis showed that aspirin had an effect on reducing the discomfort of warmth and flushing but not itching or tingling. These results indicate that the National Cholesterol Education Program Recommendations should be followed.</String>
              <Markup>
                <Start>0</Start>
                <Length>14</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/Nicotinic%20acid</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>414</Start>
                <Length>11</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/Cholesterol</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-5997</Extra>
              </Markup>
              <Markup>
                <Start>464</Start>
                <Length>7</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/aspirin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-2244</Extra>
              </Markup>
              <Markup>
                <Start>538</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>709</Start>
                <Length>7</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/aspirin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-2244</Extra>
              </Markup>
              <Markup>
                <Start>728</Start>
                <Length>7</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/aspirin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-2244</Extra>
              </Markup>
              <Markup>
                <Start>919</Start>
                <Length>7</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/lactose</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-440995</Extra>
              </Markup>
              <Markup>
                <Start>1042</Start>
                <Length>7</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/aspirin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-2244</Extra>
              </Markup>
              <Markup>
                <Start>1057</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>1072</Start>
                <Length>7</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/aspirin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-2244</Extra>
              </Markup>
              <Markup>
                <Start>1087</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>1110</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>1400</Start>
                <Length>7</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/aspirin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-2244</Extra>
              </Markup>
              <Markup>
                <Start>1433</Start>
                <Length>7</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/aspirin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-2244</Extra>
              </Markup>
              <Markup>
                <Start>1481</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>1518</Start>
                <Length>7</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/aspirin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-2244</Extra>
              </Markup>
              <Markup>
                <Start>1660</Start>
                <Length>11</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/Cholesterol</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-5997</Extra>
              </Markup>
            </StringWithMarkup>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>32</ReferenceNumber>
          <Description>**PEER REVIEWED**</Description>
          <Reference>Vannucchi H, Moreno FS; Am J Clin Nutr 50 (2): 364-69 (1989)</Reference>
          <Value>
            <StringWithMarkup>
              <String>The effect of zinc supplementation on the metabolism of tryptophan conversion to niacin was studied in 14 alcoholic patients with pellagra and in 7 male control subjects aged 21-45 years. The pellagrins received chemically defined diets based on crystalline amino acids through an enteral tube for 7 days. Patients were divided into two groups (A and B), both receiving a diet from which tryptophan, zinc and niacin were excluded. Patients in group B, however, received 220 mg zinc sulfate orally. Upon admission the pellagra patients had low plasma zinc levels and low urinary excretion values of N-methylnicotinamide and N-methyl-2-pyridone-5-carboxamide in relation to the control subjects (p&lt; 0.01). During the experimental period there was an increase in plasma zinc levels (p&lt; 0.005) and in urinary N-methylnicotinamide (p&lt; 0.05) and N-methyl-2-pyridone-5-carboxamide (p&lt; 0.05) excretion in the patients receiving zinc supplementation (group B). These results suggest that zinc interacts with niacin metabolism in alcoholic patients with pellagra through a probable mediation by vitamin B-6. PubMed Abstract</String>
              <Markup>
                <Start>1098</Start>
                <Length>15</Length>
                <URL>http://www.ncbi.nlm.nih.gov/pubmed/2526999?dopt=Abstract</URL>
              </Markup>
              <Markup>
                <Start>14</Start>
                <Length>4</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/element/Zinc</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>Element-Zinc</Extra>
              </Markup>
              <Markup>
                <Start>56</Start>
                <Length>10</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/tryptophan</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-6305</Extra>
              </Markup>
              <Markup>
                <Start>81</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>388</Start>
                <Length>10</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/tryptophan</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-6305</Extra>
              </Markup>
              <Markup>
                <Start>400</Start>
                <Length>4</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/element/Zinc</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>Element-Zinc</Extra>
              </Markup>
              <Markup>
                <Start>409</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>477</Start>
                <Length>12</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/zinc%20sulfate</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-24424</Extra>
              </Markup>
              <Markup>
                <Start>550</Start>
                <Length>4</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/element/Zinc</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>Element-Zinc</Extra>
              </Markup>
              <Markup>
                <Start>598</Start>
                <Length>20</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/N-methylnicotinamide</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-64950</Extra>
              </Markup>
              <Markup>
                <Start>623</Start>
                <Length>33</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/N-methyl-2-pyridone-5-carboxamide</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-69698</Extra>
              </Markup>
            </StringWithMarkup>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>32</ReferenceNumber>
          <Description>**PEER REVIEWED**</Description>
          <Reference>Urgerg M, Zemel MB; Metabolism 36 (9): 896-99 (1987)</Reference>
          <Value>
            <StringWithMarkup>
              <String>Impaired glucose tolerance results from chromium restriction in animals, and chromium supplementation improves glucose tolerances in diabetic animals. These effects are presumably due to the role of chromium in glucose tolerance factor, a complex of chromium and nicotinic acid believed to facilitate insulin binding. Humans, however, do not uniformly respond to chromium supplementation. The present study was designed to evaluate the possibility that the failure results from inadequate levels of dietary nicotinic acid to serve as substrate for glucose tolerance factor synthesis. Sixteen healthy elderly volunteers were divided into three groups and given either 200 ug chromium, 100 mg nicotinic acid, or 200 ug chromium + 100 mg nicotinic acid daily for 28 days and evaluated on days 0 and 28. Fasting glucoses and glucose tolerance were unaffected by either chromium or nicotinic acid alone. In contrast, the combined chromium-nicotinic acid supplement caused 15% decrease in a glucose area integrated total (p&lt; 0.025) and a 7% decrease in fasting glucose. None of the treatments exerted any effect on fasting or one-hour insulin levels. Thus, these data suggest that the inability to respond to chromium supplementation may result from suboptimal levels of dietary nicotinic acid. PubMed Abstract</String>
              <Markup>
                <Start>1289</Start>
                <Length>15</Length>
                <URL>http://www.ncbi.nlm.nih.gov/pubmed/3626867?dopt=Abstract</URL>
              </Markup>
              <Markup>
                <Start>9</Start>
                <Length>7</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/glucose</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-5793</Extra>
              </Markup>
              <Markup>
                <Start>40</Start>
                <Length>8</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/element/Chromium</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>Element-Chromium</Extra>
              </Markup>
              <Markup>
                <Start>77</Start>
                <Length>8</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/element/Chromium</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>Element-Chromium</Extra>
              </Markup>
              <Markup>
                <Start>111</Start>
                <Length>7</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/glucose</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-5793</Extra>
              </Markup>
              <Markup>
                <Start>199</Start>
                <Length>8</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/element/Chromium</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>Element-Chromium</Extra>
              </Markup>
              <Markup>
                <Start>211</Start>
                <Length>7</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/glucose</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-5793</Extra>
              </Markup>
              <Markup>
                <Start>250</Start>
                <Length>8</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/element/Chromium</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>Element-Chromium</Extra>
              </Markup>
              <Markup>
                <Start>263</Start>
                <Length>14</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/nicotinic%20acid</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>363</Start>
                <Length>8</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/element/Chromium</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>Element-Chromium</Extra>
              </Markup>
              <Markup>
                <Start>507</Start>
                <Length>14</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/nicotinic%20acid</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>548</Start>
                <Length>7</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/glucose</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-5793</Extra>
              </Markup>
              <Markup>
                <Start>674</Start>
                <Length>8</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/element/Chromium</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>Element-Chromium</Extra>
              </Markup>
              <Markup>
                <Start>691</Start>
                <Length>14</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/nicotinic%20acid</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>717</Start>
                <Length>8</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/element/Chromium</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>Element-Chromium</Extra>
              </Markup>
              <Markup>
                <Start>735</Start>
                <Length>14</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/nicotinic%20acid</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>821</Start>
                <Length>7</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/glucose</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-5793</Extra>
              </Markup>
              <Markup>
                <Start>865</Start>
                <Length>8</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/element/Chromium</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>Element-Chromium</Extra>
              </Markup>
              <Markup>
                <Start>877</Start>
                <Length>14</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/nicotinic%20acid</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>925</Start>
                <Length>8</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/element/Chromium</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>Element-Chromium</Extra>
              </Markup>
              <Markup>
                <Start>934</Start>
                <Length>14</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/nicotinic%20acid</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>985</Start>
                <Length>7</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/glucose</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-5793</Extra>
              </Markup>
            </StringWithMarkup>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>32</ReferenceNumber>
          <Description>**PEER REVIEWED**</Description>
          <Reference>Reaven GM et al; Diabetes 37 (1): 28-32 (1988)</Reference>
          <Value>
            <StringWithMarkup>
              <String>In this study the effect of two drugs (etomoxir and nicotinic acid) on plasma glucose, free-fatty acid, and triglyceride concentrations was determined in rats with streptozocin-induced diabetes. The two compounds modify free-fatty acid metabolism by different mechanisms, etomoxir (ethyl-2-(6-(4-chlorophenoxyl)-hexyl)oxirane-2-carboxylate) by inhibiting hepatic fatty acid oxidation, and nicotinic acid by inhibiting lipolysis in adipose tissue. Diabetes was induced in male Sprague-Dawley rats, weighing approximately 400 g, by streptozocin injection (30 mg/kg iv), and the metabolic effects of the two drugs were studied 7-10 days later. The acute administration of either etomoxir or nicotinic acid lowered plasma glucose concentrations in diabetic rats by approximately 150 mg/dL (p&lt;0.001) in 4 hr. However, the two drugs differed dramatically in their effects on plasma free-fatty acid and triglyceride concentrations. Specifically, etomoxir produced striking increases in plasma free-fatty acid and triglyceride concentrations, whereas nicotinic acid administration caused a marked decrease. However, when nicotinic acid was given in conjunction with etomoxir, nicotinic acid prevented the increase in plasma free-fatty acid and triglyceride concentration seen with etomoxir; the combination of nicotinic acid and etomoxir approximately doubled the decrease in plasma glucose concentration produced by nicotinic acid or etomoxir when given alone. Because plasma insulin concentrations did not change in response to either drug, whether administered singly or in combination, these metabolic effects do not result from a change in insulin secretion. These results suggest that modulation of free-fatty acid metabolism at the level of the adipocyte or the liver can have dramatic effects on carbohydrate and lipid metabolism. PubMed Abstract</String>
              <Markup>
                <Start>1831</Start>
                <Length>15</Length>
                <URL>http://www.ncbi.nlm.nih.gov/pubmed/3275556?dopt=Abstract</URL>
              </Markup>
              <Markup>
                <Start>39</Start>
                <Length>8</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/etomoxir</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-123823</Extra>
              </Markup>
              <Markup>
                <Start>52</Start>
                <Length>14</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/nicotinic%20acid</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>78</Start>
                <Length>7</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/glucose</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-5793</Extra>
              </Markup>
              <Markup>
                <Start>164</Start>
                <Length>12</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/streptozocin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-29327</Extra>
              </Markup>
              <Markup>
                <Start>272</Start>
                <Length>8</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/etomoxir</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-123823</Extra>
              </Markup>
              <Markup>
                <Start>389</Start>
                <Length>14</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/nicotinic%20acid</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>530</Start>
                <Length>12</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/streptozocin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-29327</Extra>
              </Markup>
              <Markup>
                <Start>676</Start>
                <Length>8</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/etomoxir</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-123823</Extra>
              </Markup>
              <Markup>
                <Start>688</Start>
                <Length>14</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/nicotinic%20acid</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>718</Start>
                <Length>7</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/glucose</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-5793</Extra>
              </Markup>
            </StringWithMarkup>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>32</ReferenceNumber>
          <Description>**PEER REVIEWED**</Description>
          <Reference>Brown OR et al; Science 212 (4502): 1510-12 (1981)</Reference>
          <Value>
            <StringWithMarkup>
              <String>The effect of niacin on the toxicity of paraquat was investigated in rats. Paraquat was given to rats in two doses at 30 mg/kg 24 hr apart. Another group of rats received ip 500 mg/kg niacin every 24 hr for 5 days beginning with the first two doses of paraquat. Other groups of rats received in addition to niacin, thiamine at 100 mg/kg. Weight, behavior, liver niacin content, and liver nicotinamide adenine dinucleotide content were determined. Animals that received paraquat only began to die approx 30 hr after treatment, and 50% death of animals occurred by 60 hr. Animals receiving both paraquat and niacin began to die 36 hr after treatment and 50% death of animals occurred at approx 120 hr after treatment. Thiamine and niacin combinations produced no significant difference from those administered niacin alone. All animals had respiratory distress but those given niacin or the combination of niacin and thiamine had less distress than those not given vitamins. Vitamin treatment resulted in smaller weight loss than those not treated with vitamins. Niacin therapy maintained liver niacin and nicotanamide adenine dinucleotide levels and these levels were significantly lowered in animals that died from treatment with paraquat alone. Altogether prevention of respiratory distress, entire prevention of weight loss, or elimination of all deaths was not achieved by niacin treatment of paraquat administered rats. /It was/ concluded that damage by other mechanisms may also occur in the lung and this is not mitigated by niacin. PubMed Abstract</String>
              <Markup>
                <Start>1539</Start>
                <Length>15</Length>
                <URL>http://www.ncbi.nlm.nih.gov/pubmed/7233236?dopt=Abstract</URL>
              </Markup>
              <Markup>
                <Start>14</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>40</Start>
                <Length>8</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/paraquat</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-15939</Extra>
              </Markup>
              <Markup>
                <Start>75</Start>
                <Length>8</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/Paraquat</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-15939</Extra>
              </Markup>
              <Markup>
                <Start>184</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>252</Start>
                <Length>8</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/paraquat</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-15939</Extra>
              </Markup>
              <Markup>
                <Start>307</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>315</Start>
                <Length>8</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/thiamine</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-1130</Extra>
              </Markup>
              <Markup>
                <Start>362</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>388</Start>
                <Length>33</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/nicotinamide%20adenine%20dinucleotide</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-15938971</Extra>
              </Markup>
              <Markup>
                <Start>469</Start>
                <Length>8</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/paraquat</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-15939</Extra>
              </Markup>
              <Markup>
                <Start>593</Start>
                <Length>8</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/paraquat</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-15939</Extra>
              </Markup>
              <Markup>
                <Start>606</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>716</Start>
                <Length>8</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/Thiamine</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-1130</Extra>
              </Markup>
              <Markup>
                <Start>729</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>808</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>875</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>904</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>915</Start>
                <Length>8</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/thiamine</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-1130</Extra>
              </Markup>
              <Markup>
                <Start>1061</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/Niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>1093</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>1117</Start>
                <Length>7</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/adenine</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-190</Extra>
              </Markup>
              <Markup>
                <Start>1230</Start>
                <Length>8</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/paraquat</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-15939</Extra>
              </Markup>
              <Markup>
                <Start>1376</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>1396</Start>
                <Length>8</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/paraquat</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-15939</Extra>
              </Markup>
              <Markup>
                <Start>1531</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
            </StringWithMarkup>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>32</ReferenceNumber>
          <Description>**PEER REVIEWED**</Description>
          <Reference>Wronska-Nofer T et al; Medicina del Lavoro 64 (1-2): 13-9 (1973)</Reference>
          <Value>
            <StringWithMarkup>
              <String>The effect of carbon-disulfide (CS2) on excretion of of nicotinamide and nicotinic-acid metabolites was assessed in Wistar-rats. Carbon-14 (C-14) labeled nicotinic-acid or nicotinamide were administered by intraperitoneal injection to rats exposed to CS2 vapors at concentrations of 1.5 to 1.8 milligrams per liter (mg/L) 5 hours per day, 6 days per week, for 6 months. Metabolites were determined in urine of treated and untreated CS2 exposed rates. Radioactivity was determined for total and individual metabolites in urine of treated rats. Metabolites were separated identified. Rats were intoxicated with CS2 for 3 days or 6 months, killed, and the nicotinamide demethylation determined in liver homogenates. In CS2 exposed rats, daily excretion of N-methylnicotinamide was increased 126 percent. Total nicotinic-acid excretion rose slightly. After C-14 labeled compounds were administered, total radioactivity was higher in CS2 exposed rats given either compound. Rats given C-14-nicotinamide and exposed to CS2 had increased excretion of nicotinamide, pyridone, and N-methylnicotinamide. Those given C-14-nicotinic-acid had increased excretion of pyridone, nicotinic-acid, nicotinuric-acid, and N-methylnicotinamide. In liver homogenates, the activity of nicotinamide-methyltransferase was 43 percent higher in rats exposed to CS2 for 6 months, with the trend already apparent at 3 days. The authors conclude that the metabolism of nicotinamide and nicotinic-acid is accelerated in the course of CS2 poisoning. PubMed Abstract</String>
              <Markup>
                <Start>1517</Start>
                <Length>15</Length>
                <URL>http://www.ncbi.nlm.nih.gov/pubmed/4275347?dopt=Abstract</URL>
              </Markup>
              <Markup>
                <Start>14</Start>
                <Length>16</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/carbon-disulfide</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-6348</Extra>
              </Markup>
              <Markup>
                <Start>56</Start>
                <Length>12</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/nicotinamide</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-936</Extra>
              </Markup>
              <Markup>
                <Start>73</Start>
                <Length>14</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/nicotinic%20acid</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>129</Start>
                <Length>9</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/Carbon-14</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-26873</Extra>
              </Markup>
              <Markup>
                <Start>154</Start>
                <Length>14</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/nicotinic%20acid</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>172</Start>
                <Length>12</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/nicotinamide</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-936</Extra>
              </Markup>
              <Markup>
                <Start>653</Start>
                <Length>12</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/nicotinamide</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-936</Extra>
              </Markup>
              <Markup>
                <Start>753</Start>
                <Length>20</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/N-methylnicotinamide</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-64950</Extra>
              </Markup>
              <Markup>
                <Start>807</Start>
                <Length>14</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/nicotinic%20acid</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>1044</Start>
                <Length>12</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/nicotinamide</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-936</Extra>
              </Markup>
              <Markup>
                <Start>1058</Start>
                <Length>8</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/pyridone</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-8871</Extra>
              </Markup>
              <Markup>
                <Start>1072</Start>
                <Length>20</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/N-methylnicotinamide</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-64950</Extra>
              </Markup>
              <Markup>
                <Start>1153</Start>
                <Length>8</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/pyridone</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-8871</Extra>
              </Markup>
              <Markup>
                <Start>1163</Start>
                <Length>14</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/nicotinic%20acid</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>1179</Start>
                <Length>16</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/nicotinuric%20acid</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-68499</Extra>
              </Markup>
              <Markup>
                <Start>1201</Start>
                <Length>20</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/N-methylnicotinamide</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-64950</Extra>
              </Markup>
              <Markup>
                <Start>1261</Start>
                <Length>12</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/nicotinamide</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-936</Extra>
              </Markup>
              <Markup>
                <Start>1438</Start>
                <Length>12</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/nicotinamide</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-936</Extra>
              </Markup>
              <Markup>
                <Start>1455</Start>
                <Length>14</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/nicotinic%20acid</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
            </StringWithMarkup>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>32</ReferenceNumber>
          <Description>**PEER REVIEWED**</Description>
          <Reference>Ballantyne CM et al; Arch Intern Med 163 (5): 553-64 (2003)</Reference>
          <Value>
            <StringWithMarkup>
              <String>Emerging data suggest that the 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins) offer important benefits for the large population of individuals at high risk for coronary heart disease. This population encompasses a sizable portion of individuals who are also at high risk for drug-drug interactions due to their need for multiple medications. In general, statins are associated with a very small risk for myopathy (which may progress to fatal or nonfatal rhabdomyolysis); however, the potential for drug-drug interactions is known to increase this risk in specific high-risk groups. The incidence of myopathy associated with statin therapy is dose related and is increased when statins are used in combination with agents that share common metabolic pathways. Of particular concern is the potential for interactions with other lipid-lowering agents such as fibrates and niacin (nicotinic acid), which may be used in patients with mixed lipidemia, and with immunosuppressive agents, such as cyclosporine, which are commonly used in patients after transplantation. Clinicians should be alert to the potential for drug-drug interactions to minimize the risk of myopathy during long-term statin therapy in patients at high risk for coronary heart disease. PubMed Abstract</String>
              <Markup>
                <Start>1283</Start>
                <Length>15</Length>
                <URL>http://www.ncbi.nlm.nih.gov/pubmed/12622602?dopt=Abstract</URL>
              </Markup>
              <Markup>
                <Start>31</Start>
                <Length>37</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/3-hydroxy-3-methylglutaryl-coenzyme%20A</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-5288565</Extra>
              </Markup>
              <Markup>
                <Start>70</Start>
                <Length>7</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/HMG-CoA</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-445127</Extra>
              </Markup>
              <Markup>
                <Start>901</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>909</Start>
                <Length>14</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/nicotinic%20acid</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>1021</Start>
                <Length>12</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/cyclosporine</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-5280754</Extra>
              </Markup>
            </StringWithMarkup>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>32</ReferenceNumber>
          <Description>**PEER REVIEWED**</Description>
          <Reference>Li Q et al; Alcohol Clin Exp Res 38 (7): 1982-92 (2014)</Reference>
          <Value>
            <StringWithMarkup>
              <String>Alcohol abuse frequently causes niacin deficiency in association with the development of alcoholic liver disease. The objective of the present study was to determine whether dietary nicotinic acid (NA) deficiency exaggerates and whether dietary NA supplementation alleviates alcohol-induced fatty liver. Male Sprague-Dawley rats were pair-fed with 4 isocaloric liquid diets: control, ethanol (EtOH), EtOH with dietary NA deficiency, and EtOH with dietary NA supplementation, respectively, for 8 weeks. The control and EtOH diets contained normal levels of NA (7.5 mg/l). Dietary NA deficiency (0 mg NA/L) was achieved by removing NA from the vitamin mix, while NA was added to the liquid diet at 750 mg/L for dietary NA supplementation. Chronic EtOH feeding induced significant lipid accumulation in the liver, which was not worsened by dietary NA deficiency, but was ameliorated by dietary NA supplementation. Liver total NAD, NAD(+), and NADH levels were remarkably higher in the NA supplemented group than the NA deficient or EtOH alone groups. Dietary NA supplementation to EtOH-fed rats increased the protein levels of hepatic cytochrome P450 4A1 (CYP4A1) and acyl-coenzyme A oxidase 1 without affecting their mRNA levels. Interestingly, we found dietary NA supplementation reduced the ubiquitination level of CYP4A1. In addition, hepatic fatty acid synthase expression was reduced, while the serum beta-hydroxybutyrate and adiponectin concentrations were significantly elevated by dietary NA supplementation. Moreover, dietary NA supplementation modulated EtOH-perturbed liver and serum metabolite profiles. These results demonstrate that alcoholic fatty liver was not exaggerated by dietary NA deficiency, but was ameliorated by dietary NA supplementation. Increased hepatic fatty acid oxidation and decreased hepatic de novo lipogenesis contribute to the effects of dietary NA supplementation. PubMed Abstract Full text: PMC5742865</String>
              <Markup>
                <Start>1902</Start>
                <Length>15</Length>
                <URL>http://www.ncbi.nlm.nih.gov/pubmed/24848081?dopt=Abstract</URL>
              </Markup>
              <Markup>
                <Start>1929</Start>
                <Length>10</Length>
                <URL>https://www.ncbi.nlm.nih.gov/pmc/?term=PMC5742865</URL>
              </Markup>
              <Markup>
                <Start>32</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>182</Start>
                <Length>14</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/nicotinic%20acid</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>384</Start>
                <Length>7</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/ethanol</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-702</Extra>
              </Markup>
              <Markup>
                <Start>923</Start>
                <Length>3</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/NAD</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-5893</Extra>
              </Markup>
              <Markup>
                <Start>928</Start>
                <Length>3</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/NAD</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-5893</Extra>
              </Markup>
              <Markup>
                <Start>940</Start>
                <Length>4</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/NADH</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-439153</Extra>
              </Markup>
              <Markup>
                <Start>1404</Start>
                <Length>20</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/beta-hydroxybutyrate</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-3541112</Extra>
              </Markup>
            </StringWithMarkup>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>32</ReferenceNumber>
          <Description>**PEER REVIEWED**</Description>
          <Reference>Kuhnast S et al; PLoS One 8 (6): e66467 (2013)</Reference>
          <Value>
            <StringWithMarkup>
              <String>Niacin potently lowers triglycerides, mildly decreases LDL-cholesterol, and largely increases HDL-cholesterol. Despite evidence for an atheroprotective effect of niacin from previous small clinical studies, the large outcome trials, AIM-HIGH and HPS2-THRIVE did not reveal additional beneficial effects of niacin (alone or in combination with laropiprant) on top of statin treatment. We aimed to address this apparent discrepancy by investigating the effects of niacin without and with simvastatin on atherosclerosis development and determine the underlying mechanisms, in APOE*3Leiden.CETP mice, a model for familial dysbetalipoproteinemia (FD). Mice were fed a western-type diet containing cholesterol without or with niacin (120 mg/kg/day), simvastatin (36 mg/kg/day) or their combination for 18 weeks. Similarly as in FD patients, niacin reduced total cholesterol by -39% and triglycerides by -50%, (both P&lt;0.001). Simvastatin and the combination reduced total cholesterol (-30%; -55%, P&lt;0.001) where the combination revealed a greater reduction compared to simvastatin (-36%, P&lt;0.001). Niacin decreased total cholesterol and triglycerides primarily by increasing VLDL clearance. Niacin increased HDL-cholesterol (+28%, P&lt;0.01) and mildly increased reverse cholesterol transport. All treatments reduced monocyte adhesion to the endothelium (-46%; -47%, P&lt;0.01; -53%, P&lt;0.001), atherosclerotic lesion area (-78%; -49%, P&lt;0.01; -87%, P&lt;0.001) and severity. Compared to simvastatin, the combination increased plaque stability index [(SMC+collagen)/macrophages] (3-fold, P&lt;0.01). Niacin and the combination reduced T cells in the aortic root (-71%, P&lt;0.01; -81%, P&lt;0.001). Lesion area was strongly predicted by nonHDL-cholesterol (R(2)=0.69, P&lt;0.001) and to a much lesser extent by HDL-cholesterol (R(2)=0.20, P&lt;0.001). Niacin decreases atherosclerosis development mainly by reducing nonHDL-cholesterol with modest HDL-cholesterol-raising and additional anti-inflammatory effects. The additive effect of niacin on top of simvastatin is mostly dependent on its nonHDL-cholesterol-lowering capacities. These data suggest that clinical beneficial effects of niacin are largely dependent on its ability to lower LDL-cholesterol on top of concomitant lipid-lowering therapy. PubMed Abstract Full text: PMC3686722</String>
              <Markup>
                <Start>2270</Start>
                <Length>15</Length>
                <URL>http://www.ncbi.nlm.nih.gov/pubmed/23840481?dopt=Abstract</URL>
              </Markup>
              <Markup>
                <Start>2297</Start>
                <Length>10</Length>
                <URL>https://www.ncbi.nlm.nih.gov/pmc/?term=PMC3686722</URL>
              </Markup>
              <Markup>
                <Start>0</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/Niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>59</Start>
                <Length>11</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/cholesterol</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-5997</Extra>
              </Markup>
              <Markup>
                <Start>98</Start>
                <Length>11</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/cholesterol</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-5997</Extra>
              </Markup>
              <Markup>
                <Start>162</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>306</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>343</Start>
                <Length>11</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/laropiprant</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-9867642</Extra>
              </Markup>
              <Markup>
                <Start>462</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>486</Start>
                <Length>11</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/simvastatin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-54454</Extra>
              </Markup>
              <Markup>
                <Start>692</Start>
                <Length>11</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/cholesterol</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-5997</Extra>
              </Markup>
              <Markup>
                <Start>720</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>744</Start>
                <Length>11</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/simvastatin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-54454</Extra>
              </Markup>
              <Markup>
                <Start>835</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>856</Start>
                <Length>11</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/cholesterol</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-5997</Extra>
              </Markup>
            </StringWithMarkup>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>32</ReferenceNumber>
          <Description>**PEER REVIEWED**</Description>
          <Reference>Le NA et al; J Am Heart Assoc 2 (4): e000037 (2013)</Reference>
          <Value>
            <StringWithMarkup>
              <String>Combination therapy with ezetimibe/simvastatin (E/S) and extended-release niacin (N) has been reported to be safe and efficacious in concomitantly reducing low-density lipoprotein cholesterol and increasing high-density lipoprotein cholesterol in hyperlipidemic patients at high risk for atherosclerotic cardiovascular events. This analysis evaluated the effect of E/S coadministered with N on low-density lipoprotein particle number (LDL-P) and high-density lipoprotein particle number (HDL-P) as assessed by nuclear magnetic resonance (NMR) spectroscopy in patients with type IIa or IIb hyperlipidemia. This was an analysis of a previously reported 24-week randomized, double-blind study in type IIa/IIb hyperlipidemic patients randomized to treatment with E/S (10/20 mg/day)+N (titrated to 2 g/day) or N (titrated to 2 g/day) or E/S (10/20 mg/day). Samples from a subset of patients (577 of 1220) were available for post hoc analysis of LDL-P and HDL-P by NMR spectroscopy. Increases in HDL-P (+16.2%) and decreases in LDL-P (-47.7%) were significantly greater with E/S+N compared with N (+9.8% for HDL-P and -21.5% for LDL-P) and E/S (+12.8% for HDL-P and -36.8% for LDL-P). In tertile analyses, those with the lowest baseline HDL-P had the greatest percent increase in HDL-P (N, 18.4/7.9/2.1; E/S, 19.3/12.2/5.3; and E/S+N, 26.9/13.8/6.9; all P&lt;0.001). Individuals in the highest tertile of LDL-P had the greatest percent reduction in LDL-P (N, 18.3/23.1/24.6; E/S, 29.7/38.3/41.8; and E/S+N, 44.3/49.0/50.5; all P&lt;0.001). These results suggest that E/S+N improves lipoprotein particle number, consistent with its lipid-modifying benefits in type IIa or IIb hyperlipidemia patients and may exert the greatest effect in those with high LDL-P and low HDL-P at baseline. PubMed Abstract Full text: PMC3828803</String>
              <Markup>
                <Start>1773</Start>
                <Length>15</Length>
                <URL>http://www.ncbi.nlm.nih.gov/pubmed/23926117?dopt=Abstract</URL>
              </Markup>
              <Markup>
                <Start>1800</Start>
                <Length>10</Length>
                <URL>https://www.ncbi.nlm.nih.gov/pmc/?term=PMC3828803</URL>
              </Markup>
              <Markup>
                <Start>25</Start>
                <Length>21</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/ezetimibe%2Fsimvastatin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-9832423</Extra>
              </Markup>
              <Markup>
                <Start>74</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>180</Start>
                <Length>11</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/cholesterol</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-5997</Extra>
              </Markup>
              <Markup>
                <Start>232</Start>
                <Length>11</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/cholesterol</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-5997</Extra>
              </Markup>
            </StringWithMarkup>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>32</ReferenceNumber>
          <Description>**PEER REVIEWED**</Description>
          <Reference>Kolovou GD et al; Methods Find Exp Clin Pharmacol 27 (1): 17-23 (2005)</Reference>
          <Value>
            <StringWithMarkup>
              <String>The effects of co-administration of nicotinic acid (NA) and alcohol (Alc) on liver function in male Wistar rats were evaluated. The rats were randomized into five groups: (i) Olive oil (Oil), (ii) Alc+Oil, (iii) NA+Oil, (iv) NA+Alc+Oil, and (v) Controls (fed only normal rat chow). Alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (AP), total cholesterol and triglycerides (TG) were measured. Liver histopathology was also assessed. The Alc+Oil group had higher TG levels compared with the NA+Alc+Oil group and all other groups, as well. NA+Oil group had higher levels of AP compared with Alc+Oil and Oil groups. The NA+Oil group had higher ALT levels compared with the Oil group. The Oil group had lower ALT levels compared with the control group. The Alc+Oil group had higher AST levels compared with the NA+Alc+Oil group, as well as with all other groups. Liver histopathology was within the normal range. A moderate amount of Alc daily together with NA is safe in rats. The NA and Alc co-administration reduces the TG and AST levels in rats, compared with the administration of Alc alone. PubMed Abstract</String>
              <Markup>
                <Start>1131</Start>
                <Length>15</Length>
                <URL>http://www.ncbi.nlm.nih.gov/pubmed/15834455?dopt=Abstract</URL>
              </Markup>
              <Markup>
                <Start>36</Start>
                <Length>14</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/nicotinic%20acid</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>282</Start>
                <Length>7</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/Alanine</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-602</Extra>
              </Markup>
              <Markup>
                <Start>314</Start>
                <Length>9</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/aspartate</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-5460294</Extra>
              </Markup>
              <Markup>
                <Start>381</Start>
                <Length>11</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/cholesterol</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-5997</Extra>
              </Markup>
            </StringWithMarkup>
          </Value>
        </Information>
      </Section>
      <Section>
        <TOCHeading>Toxicity Summary</TOCHeading>
        <Description>Toxicity Summary</Description>
        <Information>
          <ReferenceNumber>17</ReferenceNumber>
          <Name>Toxicity</Name>
          <Value>
            <StringWithMarkup>
              <String>Nicotinic acid can cause vasodilation of cutaneous blood vessels resulting in increased blood flow, principally in the face, neck and chest. This produces the niacin- or nicotinic acid-flush. The niacin-flush is thought to be mediated via the prostaglandin prostacyclin. Histamine may also play a role in the niacin-flush. Flushing is the adverse reaction first observed after intake of a large dose of nicotinic acid, and the most bothersome one. LD50 7000 mg/kg (Rat)</String>
              <Markup>
                <Start>450</Start>
                <Length>2</Length>
                <Type>Subscript</Type>
              </Markup>
              <Markup>
                <Start>0</Start>
                <Length>14</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/Nicotinic%20acid</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>159</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>170</Start>
                <Length>14</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/nicotinic%20acid</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>196</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>257</Start>
                <Length>12</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/prostacyclin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-24868263</Extra>
              </Markup>
              <Markup>
                <Start>271</Start>
                <Length>9</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/Histamine</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-774</Extra>
              </Markup>
              <Markup>
                <Start>309</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>403</Start>
                <Length>14</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/nicotinic%20acid</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
            </StringWithMarkup>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>32</ReferenceNumber>
          <Description>**PEER REVIEWED**</Description>
          <Value>
            <StringWithMarkup>
              <String>IDENTIFICATION AND USE: Nicotinic acid (Niacin) is a solid. It is a part of the vitamin B complex. Niacin and niacinamide (also known as nicotinamide) are similarly effective as a vitamin because they can be converted into each other within the organism. The blanket term vitamin B(3) is used for both. Niacinamide is a component of important coenzymes involved in hydrogen transfer. Niacin is used in medicine as a cholesterol-lowering agent, nutrition, feeds, enriched flours, and as a dietary supplement. It is also an electroplating bath ingredient. HUMAN STUDIES: A deficiency of this vitamin causes pellagra, a disease characterized by dermatitis, diarrhea, and dementia that is endemic today in parts of India and China, and may result in death in severe cases. Niacin deficiency is rare in the United States but may still be seen in alcoholics, dietary cultists, and patients with malabsorption syndrome. In single doses of 50 mg niacin, intense flushing and pruritus have been reported. When the practice of giving niacin in doses ranging upward to 30 g or more a day was advocated, more serious toxicity was noted. These effects included intense flushing and unbearable pruritus, skin rash, heartburn, nausea and vomiting, diarrhea, ulcer activation, abnormal liver function, hypotension, tachycardia, fainting, hyperglycemia, hyperbilirubinemia and jaundice, dermatoses, hyperuricemia, elevated serum enzymes, and hyperkeratosis of the skin. A greater incidence of atrial fibrillation and other cardiac arrhythmias is seen in persons taking niacin. One of the most significant adverse reactions of niacin is the hepatotoxicity seen in dosages exceeding 3 g/day. Sensitivity to the skin flush effect of niacin is reduced in a portion of patients with schizophrenia. As a precursor of pyridine nucleotides (nicotinamide adenine dinucleotide (NAD) and nicotinamide adenine dinucleotide phosphate (NADP), niacin participates in the function of numerous enzymatic pathways, which are critical for normal cell metabolism, involving, for example redox reactions and those that consume NAD. ANIMAL STUDIES: Niacin administered to mice for a lifetime as a 1% solution in drinking water was not carcinogenic. A decreased growth rate in male rats fed diets containing 10% casein and large amounts of niacin daily was reported. A slight decrease in growth rate was noted at the 2% level with niacin, but not at 1%. Fatty liver formation was noted at both niacin feeding levels. Niacin administration to pregnant rats during the period of organogenesis at oral doses up to 200 mg/kg/day was without adverse effects. At 1000 mg/kg/day maternal body weight gain, placental and fetal weights were slightly depressed. Niacin deficiency causes dramatic genomic instability in bone marrow cells in an in vivo rat model. The end result is seen in the increased incidence of sister chromatid exchanges, micronuclei, chromosomal aberrations and the eventual development of nitrosourea-induced leukemias. Pigs deficient in niacin have inflammatory lesions of the digestive tract and exhibit diarrhea, weight loss, rough skin and coat, and dermatitis on the ears. Niacin deficiency in poultry is characterized by severe metabolic disorders in the skin and digestive organs. An Ames test using Salmonella typhimurium strains TA92, TA1535, TA100, TA1537, TA94 and TA98, with and without metabolic activation, and a chromosome aberration test using a Chinese hamster fibroblast cell line were carried out on niacin. Niacin tested negative at maximum concentrations of 10 mg/plate and 2 mg/mL, respectively.</String>
              <Markup>
                <Start>24</Start>
                <Length>14</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/Nicotinic%20acid</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>40</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/Niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>99</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/Niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>110</Start>
                <Length>11</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacinamide</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-936</Extra>
              </Markup>
              <Markup>
                <Start>137</Start>
                <Length>12</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/nicotinamide</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-936</Extra>
              </Markup>
              <Markup>
                <Start>303</Start>
                <Length>11</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/Niacinamide</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-936</Extra>
              </Markup>
              <Markup>
                <Start>365</Start>
                <Length>8</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/element/Hydrogen</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>Element-Hydrogen</Extra>
              </Markup>
              <Markup>
                <Start>384</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/Niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>416</Start>
                <Length>11</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/cholesterol</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-5997</Extra>
              </Markup>
              <Markup>
                <Start>769</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/Niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>938</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>1024</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>1552</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>1609</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>1713</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>1816</Start>
                <Length>33</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/nicotinamide%20adenine%20dinucleotide</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-15938971</Extra>
              </Markup>
              <Markup>
                <Start>1851</Start>
                <Length>3</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/NAD</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-5893</Extra>
              </Markup>
              <Markup>
                <Start>1860</Start>
                <Length>43</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/nicotinamide%20adenine%20dinucleotide%20phosphate</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-42609791</Extra>
              </Markup>
              <Markup>
                <Start>1905</Start>
                <Length>4</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/NADP</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-2734411</Extra>
              </Markup>
              <Markup>
                <Start>1912</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>2089</Start>
                <Length>3</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/NAD</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-5893</Extra>
              </Markup>
              <Markup>
                <Start>2110</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/Niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>2182</Start>
                <Length>5</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/water</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-962</Extra>
              </Markup>
              <Markup>
                <Start>2300</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>2391</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>2454</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>2477</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/Niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>2712</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/Niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>2962</Start>
                <Length>11</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/nitrosourea</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-105035</Extra>
              </Markup>
              <Markup>
                <Start>3011</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>3151</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/Niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>3492</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>3500</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/Niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
            </StringWithMarkup>
          </Value>
        </Information>
      </Section>
      <Section>
        <TOCHeading>Antidote and Emergency Treatment</TOCHeading>
        <Description>Antidote and Emergency Treatment</Description>
        <Information>
          <ReferenceNumber>32</ReferenceNumber>
          <Description>**PEER REVIEWED**</Description>
          <Reference>Currance, P.L. Clements, B., Bronstein, A.C. (Eds).; Emergency Care For Hazardous Materials Exposure. 3rd revised edition, Elsevier Mosby, St. Louis, MO 2007, p. 160</Reference>
          <Value>
            <StringWithMarkup>
              <String>/SRP:/ Immediate first aid: Ensure that adequate decontamination has been carried out. If patient is not breathing, start artificial respiration, preferably with a demand valve resuscitator, bag-valve-mask device, or pocket mask, as trained. Perform CPR if necessary. Immediately flush contaminated eyes with gently flowing water. Do not induce vomiting. If vomiting occurs, lean patient forward or place on left side (head-down position, if possible) to maintain an open airway and prevent aspiration. Keep patient quiet and maintain normal body temperature. Obtain medical attention. /Poisons A and B/</String>
              <Markup>
                <Start>324</Start>
                <Length>5</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/water</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-962</Extra>
              </Markup>
            </StringWithMarkup>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>32</ReferenceNumber>
          <Description>**PEER REVIEWED**</Description>
          <Reference>Currance, P.L. Clements, B., Bronstein, A.C. (Eds).; Emergency Care For Hazardous Materials Exposure. 3rd revised edition, Elsevier Mosby, St. Louis, MO 2007, p. 160</Reference>
          <Value>
            <StringWithMarkup>
              <String>/SRP:/ Basic treatment: Establish a patent airway (oropharyngeal or nasopharyngeal airway, if needed). Suction if necessary. Watch for signs of respiratory insufficiency and assist ventilations if needed. Administer oxygen by nonrebreather mask at 10 to 15 L/min. Monitor for pulmonary edema and treat if necessary ... . Monitor for shock and treat if necessary ... . Anticipate seizures and treat if necessary ... . For eye contamination, flush eyes immediately with water. Irrigate each eye continuously with 0.9% saline (NS) during transport ... . Do not use emetics. For ingestion, rinse mouth and administer 5 mL/kg up to 200 mL of water for dilution if the patient can swallow, has a strong gag reflex, and does not drool ... . Cover skin burns with dry sterile dressings after decontamination ... . /Poisons A and B/</String>
              <Markup>
                <Start>216</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/element/Oxygen</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>Element-Oxygen</Extra>
              </Markup>
              <Markup>
                <Start>468</Start>
                <Length>5</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/water</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-962</Extra>
              </Markup>
              <Markup>
                <Start>637</Start>
                <Length>5</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/water</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-962</Extra>
              </Markup>
            </StringWithMarkup>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>32</ReferenceNumber>
          <Description>**PEER REVIEWED**</Description>
          <Reference>Currance, P.L. Clements, B., Bronstein, A.C. (Eds).; Emergency Care For Hazardous Materials Exposure. 3rd revised edition, Elsevier Mosby, St. Louis, MO 2007, p. 160-1</Reference>
          <Value>
            <StringWithMarkup>
              <String>/SRP:/ Advanced treatment: Consider orotracheal or nasotracheal intubation for airway control in the patient who is unconscious, has severe pulmonary edema, or is in severe respiratory distress. Positive-pressure ventilation techniques with a bag valve mask device may be beneficial. Consider drug therapy for pulmonary edema ... . Consider administering a beta agonist such as albuterol for severe bronchospasm ... . Monitor cardiac rhythm and treat arrhythmias as necessary ... . Start IV administration of D5W TKO /SRP: &quot;To keep open&quot;, minimal flow rate/. Use 0.9% saline (NS) or lactated Ringer&apos;s (LR) if signs of hypovolemia are present. For hypotension with signs of hypovolemia, administer fluid cautiously. Watch for signs of fluid overload ... . Treat seizures with diazepam (Valium) or lorazepam (Ativan) ... . Use proparacaine hydrochloride to assist eye irrigation ... . /Poisons A and B/</String>
              <Markup>
                <Start>378</Start>
                <Length>9</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/albuterol</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-2083</Extra>
              </Markup>
              <Markup>
                <Start>775</Start>
                <Length>8</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/diazepam</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-3016</Extra>
              </Markup>
              <Markup>
                <Start>785</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/Valium</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-3016</Extra>
              </Markup>
              <Markup>
                <Start>796</Start>
                <Length>9</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/lorazepam</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-3958</Extra>
              </Markup>
              <Markup>
                <Start>807</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/Ativan</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-3958</Extra>
              </Markup>
              <Markup>
                <Start>825</Start>
                <Length>26</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/proparacaine%20hydrochloride</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-517321</Extra>
              </Markup>
            </StringWithMarkup>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>32</ReferenceNumber>
          <Description>**PEER REVIEWED**</Description>
          <Reference>Dart, R.C. (ed). Medical Toxicology. Third Edition, Lippincott Williams &amp; Wilkins. Philadelphia, PA. 2004., p. 1023</Reference>
          <Value>
            <StringWithMarkup>
              <String>Immediate withdrawal of niacin is the primary treatment in acute toxicity. Symptoms should resolve over several hours without sequelae. Aspirin or nonsteroidal antiinflammatory drugs can be used for symptoms. For chronic toxicity treatment, niacin should be stopped and attention given to presenting symptoms and findings. Patients with significant hepatotoxicity may require intensive care monitoring and supportive care until liver function recovers. ... Treatment of rhabdomyolysis includes monitoring of renal function, urinary alkalinization, and maintenance of urinary output.</String>
              <Markup>
                <Start>24</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>136</Start>
                <Length>7</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/Aspirin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-2244</Extra>
              </Markup>
              <Markup>
                <Start>241</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
            </StringWithMarkup>
          </Value>
        </Information>
      </Section>
      <Section>
        <TOCHeading>Human Toxicity Excerpts</TOCHeading>
        <Description>Human Toxicity Excerpts</Description>
        <Information>
          <ReferenceNumber>32</ReferenceNumber>
          <Description>**PEER REVIEWED**</Description>
          <Reference>Odetti P et al; Pharmatherapeutica 4 (1): 21-4 (1984)</Reference>
          <Value>
            <StringWithMarkup>
              <String>/HUMAN EXPOSURE STUDIES/ Twelve hypercholesterolaemic patients, with or without hypertriglyceridemia, were treated sequentially with 600 mg nicotinic acid alone per day and 300 mg nicotinic acid plus 60,000 U retinol and 140 mg tocopherols per day, each treatment being given for 30 days in random order sequence. Plasma concentrations of lipid fractions were determined before the start of the study and at the end of each treatment period. Both treatments resulted in a significant decrease in total cholesterol and low-density lipoprotein cholesterol; high-density lipoprotein cholesterol showed a small but significant increase and plasma triglycerides presented a variable behavior pattern of change. The difference between the hypolipidemic effect of nicotinic acid alone and the lower dose given with Vitamins A and E was small but the combination seemed to be more effective. No side-effects were reported with either treatment. PubMed Abstract</String>
              <Markup>
                <Start>937</Start>
                <Length>15</Length>
                <URL>http://www.ncbi.nlm.nih.gov/pubmed/6390462?dopt=Abstract</URL>
              </Markup>
              <Markup>
                <Start>140</Start>
                <Length>14</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/nicotinic%20acid</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>180</Start>
                <Length>14</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/nicotinic%20acid</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>209</Start>
                <Length>7</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/retinol</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-445354</Extra>
              </Markup>
              <Markup>
                <Start>502</Start>
                <Length>11</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/cholesterol</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-5997</Extra>
              </Markup>
              <Markup>
                <Start>542</Start>
                <Length>11</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/cholesterol</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-5997</Extra>
              </Markup>
              <Markup>
                <Start>580</Start>
                <Length>11</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/cholesterol</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-5997</Extra>
              </Markup>
              <Markup>
                <Start>757</Start>
                <Length>14</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/nicotinic%20acid</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
            </StringWithMarkup>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>32</ReferenceNumber>
          <Description>**PEER REVIEWED**</Description>
          <Reference>Souza SA et al; Hawaii Med J 69 (5): 122-5 (2010)</Reference>
          <Value>
            <StringWithMarkup>
              <String>/HUMAN EXPOSURE STUDIES/ /The study objective was/ to determine the safety and tolerability of extended release niacin (ERN) in HIV-infected patients. This was a pilot, open-label, 36 week study evaluating the safety and tolerability of ERN in HIV-infected patients with hypertriglyceridemia. Subjects with cardiovascular disease, diabetes or liver disease were excluded. Subjects with persistent elevation of triglyceride (TG) &gt; 200 after 8 weeks on American Heart Association Step One and Two Diets were started on ERN 500 mg once daily, with continuation of the diet and exercise recommendations until the end of the study. ERN was increased by 500 mg every 4 weeks, to a maximum of 1500 mg/day, depending on subject tolerability. Safety and tolerability of ERN were assessed. Ten subjects enrolled received ERN. Dose titration and maintenance to 1500 mg/day were achieved in all 10 subjects. No subject required dose adjustment. Mild flushing was experienced in 8 subjects. Asymptomatic hypophosphotemia was noted in 4 subjects; all resolved with oral phosphate supplementation. Median TG was reduced by 254 mg/dL (p &lt; 0.05). Non-significant changes were noted in liver enzymes, HDL, LDL, and total cholesterol. Fasting insulin and glucose levels did not change with treatment. In this pilot study ERN was well-tolerated and resulted in reduction of TG. Although the results of this study are promising, the study is limited in the small number of subjects. Further investigation is warranted. PubMed Abstract Full text: PMC3111654</String>
              <Markup>
                <Start>1498</Start>
                <Length>15</Length>
                <URL>http://www.ncbi.nlm.nih.gov/pubmed/20533755?dopt=Abstract</URL>
              </Markup>
              <Markup>
                <Start>1525</Start>
                <Length>10</Length>
                <URL>https://www.ncbi.nlm.nih.gov/pmc/?term=PMC3111654</URL>
              </Markup>
              <Markup>
                <Start>112</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>1056</Start>
                <Length>9</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/phosphate</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-1061</Extra>
              </Markup>
            </StringWithMarkup>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>32</ReferenceNumber>
          <Description>**PEER REVIEWED**</Description>
          <Reference>AIM-HIGH Investigators et al; N Engl J Med 365 (24): 2255-67 (2011)</Reference>
          <Value>
            <StringWithMarkup>
              <String>/HUMAN EXPOSURE STUDIES/ In patients with established cardiovascular disease, residual cardiovascular risk persists despite the achievement of target low-density lipoprotein (LDL) cholesterol levels with statin therapy. It is unclear whether extended-release niacin added to simvastatin to raise low levels of high-density lipoprotein (HDL) cholesterol is superior to simvastatin alone in reducing such residual risk. We randomly assigned eligible patients to receive extended-release niacin, 1500 to 2000 mg per day, or matching placebo. All patients received simvastatin, 40 to 80 mg per day, plus ezetimibe, 10 mg per day, if needed, to maintain an LDL cholesterol level of 40 to 80 mg per deciliter (1.03 to 2.07 mmol per liter). The primary end point was the first event of the composite of death from coronary heart disease, nonfatal myocardial infarction, ischemic stroke, hospitalization for an acute coronary syndrome, or symptom-driven coronary or cerebral revascularization. A total of 3414 patients were randomly assigned to receive niacin (1718) or placebo (1696). The trial was stopped after a mean follow-up period of 3 years owing to a lack of efficacy. At 2 years, niacin therapy had significantly increased the median HDL cholesterol level from 35 mg per deciliter (0.91 mmol per liter) to 42 mg per deciliter (1.08 mmol per liter), lowered the triglyceride level from 164 mg per deciliter (1.85 mmol per liter) to 122 mg per deciliter (1.38 mmol per liter), and lowered the LDL cholesterol level from 74 mg per deciliter (1.91 mmol per liter) to 62 mg per deciliter (1.60 mmol per liter). The primary end point occurred in 282 patients in the niacin group (16.4%) and in 274 patients in the placebo group (16.2%) (hazard ratio, 1.02; 95% confidence interval, 0.87 to 1.21; P=0.79 by the log-rank test). Among patients with atherosclerotic cardiovascular disease and LDL cholesterol levels of less than 70 mg per deciliter (1.81 mmol per liter), there was no incremental clinical benefit from the addition of niacin to statin therapy during a 36-month follow-up period, despite significant improvements in HDL cholesterol and triglyceride levels. PubMed Abstract</String>
              <Markup>
                <Start>2165</Start>
                <Length>15</Length>
                <URL>http://www.ncbi.nlm.nih.gov/pubmed/22085343?dopt=Abstract</URL>
              </Markup>
              <Markup>
                <Start>180</Start>
                <Length>11</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/cholesterol</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-5997</Extra>
              </Markup>
              <Markup>
                <Start>259</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>275</Start>
                <Length>11</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/simvastatin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-54454</Extra>
              </Markup>
              <Markup>
                <Start>341</Start>
                <Length>11</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/cholesterol</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-5997</Extra>
              </Markup>
              <Markup>
                <Start>368</Start>
                <Length>11</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/simvastatin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-54454</Extra>
              </Markup>
              <Markup>
                <Start>485</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>561</Start>
                <Length>11</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/simvastatin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-54454</Extra>
              </Markup>
              <Markup>
                <Start>600</Start>
                <Length>9</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/ezetimibe</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-150311</Extra>
              </Markup>
              <Markup>
                <Start>656</Start>
                <Length>11</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/cholesterol</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-5997</Extra>
              </Markup>
              <Markup>
                <Start>1045</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>1182</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>1240</Start>
                <Length>11</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/cholesterol</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-5997</Extra>
              </Markup>
              <Markup>
                <Start>1497</Start>
                <Length>11</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/cholesterol</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-5997</Extra>
              </Markup>
              <Markup>
                <Start>1662</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>1889</Start>
                <Length>11</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/cholesterol</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-5997</Extra>
              </Markup>
              <Markup>
                <Start>2027</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>2128</Start>
                <Length>11</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/cholesterol</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-5997</Extra>
              </Markup>
            </StringWithMarkup>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>32</ReferenceNumber>
          <Description>**PEER REVIEWED**</Description>
          <Reference>Parson HK et al; J Diabetes 5 (1): 59-67 (2013)</Reference>
          <Value>
            <StringWithMarkup>
              <String>/HUMAN EXPOSURE STUDIES/ Although niacin often has beneficial effects on the lipoprotein profile, flushing is an untoward effect associated with its use. Aspirin can only reduce the flushing response by 30-40%. Thus, the aim of the present study was to investigate the mechanisms of niacin-induced flushing, with and without aspirin, in normal, healthy individuals. Niacin-induced flushing was evaluated in 30 healthy individuals after oral administration of 1000 mg niacin alone or with 325 mg aspirin. Neurological, autonomic nervous system, and skin blood flow measurements (using laser Doppler on the glabrous and hairy skin of each participant) were made at various times after drug administration. In addition, the systemic release of 9alpha,11beta-prostaglandin (PG) F(2) was determined. Flushing symptoms of redness, warmth, tingling, itching, and intensity were recorded using the modified Flushing ASsessment Tool (FAST). After aspirin, the mean flushing scores for all symptoms decreased significantly; however, 36-53% of participants still had some degree of symptoms, even though aspirin completely blocked 11beta-PGF(2) synthesis. Maximum skin blood flow (MaxSkBF) in both the glabrous and hairy forearm increased significantly after niacin, but decreased significantly after aspirin only in hairy skin. Regression analysis showed that, in glabrous skin, both PGF(2) and parasympathetic activity were significant predictors of MaxSkBF after niacin, contributing 26% and 14%, respectively (total R(2) = 40%). The present study indicates, for the first time, that the parasympathetic nervous system, in addition to PGD(2), may play an important role in niacin-induced flushing. Changing the sympathetic/parasympathetic balance in favor of parasympathetic activation may be a good therapeutic target to reduce niacin-induced flushing. PubMed Abstract</String>
              <Markup>
                <Start>1846</Start>
                <Length>15</Length>
                <URL>http://www.ncbi.nlm.nih.gov/pubmed/22727040?dopt=Abstract</URL>
              </Markup>
              <Markup>
                <Start>34</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>154</Start>
                <Length>7</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/Aspirin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-2244</Extra>
              </Markup>
              <Markup>
                <Start>283</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>325</Start>
                <Length>7</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/aspirin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-2244</Extra>
              </Markup>
              <Markup>
                <Start>366</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/Niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>467</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>495</Start>
                <Length>7</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/aspirin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-2244</Extra>
              </Markup>
              <Markup>
                <Start>938</Start>
                <Length>7</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/aspirin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-2244</Extra>
              </Markup>
              <Markup>
                <Start>1093</Start>
                <Length>7</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/aspirin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-2244</Extra>
              </Markup>
              <Markup>
                <Start>1248</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>1290</Start>
                <Length>7</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/aspirin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-2244</Extra>
              </Markup>
              <Markup>
                <Start>1455</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>1665</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>1821</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
            </StringWithMarkup>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>32</ReferenceNumber>
          <Description>**PEER REVIEWED**</Description>
          <Reference>Garg A, Grundy SM; JAMA 264 (Aug 8): 723-26 (1990)</Reference>
          <Value>
            <StringWithMarkup>
              <String>/HUMAN EXPOSURE STUDIES/ Recently, nicotinic acid has been recommended as a first-line hypolipidemic drug. To determine the effectiveness of nicotinic acid in dyslipidemic patients with non-insulin-dependent diabetes mellitus, 13 patients were treated in a randomized crossover trial. Patients received either nicotinic acid (1.5 g three times daily) or no therapy (control period) for 8 weeks each. Compared with the control period, nicotinic acid therapy reduced the plasma total cholesterol level by 24%, plasma triglyceride level by 45%, very-low-density lipoprotein cholesterol level by 58%, and low-density lipoprotein cholesterol level by 15%, and it increased the high-density lipoprotein cholesterol level by 34%. However, nicotinic acid therapy resulted in the deterioration of glycemic control, as evidenced by a 16% increase in mean plasma glucose concentrations, a 21% increase in glycosylated hemoglobin levels, and the induction of marked glycosuria in some patients. Furthermore, a consistent increase in plasma uric acid levels was observed. Therefore, despite improvement in lipid and lipoprotein concentrations, because of worsening hyperglycemia and the development of hyperuricemia, nicotinic acid must be used with caution in patients with non-insulin-dependent diabetes mellitus with dyslipidemia. We suggest that the drug not be used as a first-line hypolipidemic drug in patients with non-insulin-dependent diabetes mellitus. PubMed Abstract</String>
              <Markup>
                <Start>1451</Start>
                <Length>15</Length>
                <URL>http://www.ncbi.nlm.nih.gov/pubmed/2374275?dopt=Abstract</URL>
              </Markup>
              <Markup>
                <Start>35</Start>
                <Length>14</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/nicotinic%20acid</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>141</Start>
                <Length>14</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/nicotinic%20acid</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>310</Start>
                <Length>14</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/nicotinic%20acid</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>434</Start>
                <Length>14</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/nicotinic%20acid</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>482</Start>
                <Length>11</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/cholesterol</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-5997</Extra>
              </Markup>
              <Markup>
                <Start>571</Start>
                <Length>11</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/cholesterol</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-5997</Extra>
              </Markup>
              <Markup>
                <Start>625</Start>
                <Length>11</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/cholesterol</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-5997</Extra>
              </Markup>
              <Markup>
                <Start>697</Start>
                <Length>11</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/cholesterol</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-5997</Extra>
              </Markup>
              <Markup>
                <Start>732</Start>
                <Length>14</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/nicotinic%20acid</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>852</Start>
                <Length>7</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/glucose</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-5793</Extra>
              </Markup>
              <Markup>
                <Start>1028</Start>
                <Length>9</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/uric%20acid</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-1175</Extra>
              </Markup>
              <Markup>
                <Start>1204</Start>
                <Length>14</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/nicotinic%20acid</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
            </StringWithMarkup>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>32</ReferenceNumber>
          <Description>**PEER REVIEWED**</Description>
          <Reference>Gossel, T.A., J.D. Bricker. Principles of Clinical Toxicology. 3rd ed. New York, NY: Raven Press, Ltd., 1994., p. 410</Reference>
          <Value>
            <StringWithMarkup>
              <String>/SIGNS AND SYMPTOMS/ In single doses of 50 mg niacin, intense flushing and pruritus have been reported. When the practice of giving niacin in doses ranging upward to 30 g or more a day was advocated, more serious toxicity was noted. These effects included intense flushing and unbearable pruritus, skin rash, heartburn, nausea and vomiting, diarrhea, ulcer activation, abnormal liver function, hypotension, tachycardia, fainting, hyperglycemia, hyperbilirubinemia and jaundice, dermatoses, hyperuricemia, elevated serum enzymes, and hyperkeratosis of the skin. A greater incidence of artial fibrillation and other cardiac arrhythmias is seen in persons taking niacin.</String>
              <Markup>
                <Start>46</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>132</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>660</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
            </StringWithMarkup>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>32</ReferenceNumber>
          <Description>**PEER REVIEWED**</Description>
          <Reference>Rahman W et al; J Fr Ophtalmol 36 (2): e33-6 (2013)</Reference>
          <Value>
            <StringWithMarkup>
              <String>/CASE REPORTS/ We describe the case of a healthy 67-year-old Caucasian female who developed a rare, reversible case of cystoid maculopathy without late leak on fluorescein angiogram. She presented initially with a 5-year history of bilateral, variable central scotomata. The visual acuities were 6/6, while foveal reflexes were abnormal. Fluorescein angiogram showed no leakage; however, optical coherence tomography (OCT) revealed cystic spaces in the fovea of both eyes. The patient had been taking niacin supplements averaging 100 mg daily for 30 years. Niacin was discontinued, and 7 months later, her symptoms and OCT results improved. Although niacin-induced maculopathy is uncommon, the clinician should enquire about possible niacin supplementation in any patient with cystoid macular edema in the absence of late leakage on fluorescein angiography. We describe a new reason for niacin maculopathy due to chronic low dose niacin supplementation and a slower pattern of visual recovery than that previously suggested in the literature. PubMed Abstract</String>
              <Markup>
                <Start>1043</Start>
                <Length>15</Length>
                <URL>http://www.ncbi.nlm.nih.gov/pubmed/23218599?dopt=Abstract</URL>
              </Markup>
              <Markup>
                <Start>160</Start>
                <Length>11</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/fluorescein</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-16850</Extra>
              </Markup>
              <Markup>
                <Start>338</Start>
                <Length>11</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/Fluorescein</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-16850</Extra>
              </Markup>
              <Markup>
                <Start>501</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>557</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/Niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>650</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>734</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>833</Start>
                <Length>11</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/fluorescein</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-16850</Extra>
              </Markup>
              <Markup>
                <Start>887</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>930</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
            </StringWithMarkup>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>32</ReferenceNumber>
          <Description>**PEER REVIEWED**</Description>
          <Reference>Daul AM, Beuhler MC; J Emerg Med 41 (3): e65-8 (2011)</Reference>
          <Value>
            <StringWithMarkup>
              <String>/CASE REPORTS/ Niacin, a well-established agent for treating dyslipidemia, has been promoted on the Internet as a method for passing urine drug screening, although there are no data to support its use for this purpose. In a handful of cases, this practice has resulted in serious niacin toxicity. The aim of this article is to describe a unique clinical presentation of niacin toxicity. A 23-year-old previously healthy man presented to an Emergency Department with altered mental status, fever, acute renal failure, microangiopathic hemolytic anemia, thrombocytopenia, and coagulopathy. It was revealed that he had taken approximately 22.5 g of sustained-release niacin over the preceding 48 hr in an attempt to pass a pre-employment urine drug screen. After a complicated hospital course that included mechanical ventilation for respiratory failure and hemodialysis for acute renal failure, the patient made a full recovery and was discharged 10 days after his initial presentation. After a massive niacin overdose, the young man in this case presented with a complex clinical picture that mimicked concurrent thrombotic thrombocytopenic purpura and disseminated intravascular coagulation. Although this patient was fortunate to make a full recovery, the case highlights the potential for multi-system toxicity with niacin overdose, and the potential for harm posed by medical misinformation on the Internet. PubMed Abstract</String>
              <Markup>
                <Start>1411</Start>
                <Length>15</Length>
                <URL>http://www.ncbi.nlm.nih.gov/pubmed/20138459?dopt=Abstract</URL>
              </Markup>
              <Markup>
                <Start>15</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/Niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>280</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>370</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>664</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>1001</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>1318</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
            </StringWithMarkup>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>32</ReferenceNumber>
          <Description>**PEER REVIEWED**</Description>
          <Reference>Tittler EH et al; Ophthalmic Surg Lasers Imaging 39 (4): 341-2 (2008)</Reference>
          <Value>
            <StringWithMarkup>
              <String>/CASE REPORTS/ The intraocular pressure of a 73-year-old man with a history of primary open-angle glaucoma had been approximately 21 and 17 mm Hg in the right and left eyes, respectively, while taking latanoprost 0.005% and dorzolamide hydrochloride 2%. When taking 500 mg of oral niacin (also known as vitamin B3 or nicotinic acid), his intraocular pressure increased to 37 and 27 mm Hg in the right and left eyes, respectively, on one occasion. On reexamination, the intraocular pressure had increased to 28 and 23 mm Hg in the right and left eyes, respectively. Each time the niacin was stopped, the intraocular pressure decreased to the original levels. PubMed Abstract</String>
              <Markup>
                <Start>658</Start>
                <Length>15</Length>
                <URL>http://www.ncbi.nlm.nih.gov/pubmed/18717445?dopt=Abstract</URL>
              </Markup>
              <Markup>
                <Start>201</Start>
                <Length>11</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/latanoprost</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-5311221</Extra>
              </Markup>
              <Markup>
                <Start>224</Start>
                <Length>25</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/dorzolamide%20hydrochloride</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-6918132</Extra>
              </Markup>
              <Markup>
                <Start>281</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>303</Start>
                <Length>10</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/vitamin%20B3</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>317</Start>
                <Length>14</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/nicotinic%20acid</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>579</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
            </StringWithMarkup>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>32</ReferenceNumber>
          <Description>**PEER REVIEWED**</Description>
          <Reference>Bassan M et al; Heart Lung 41 (1): 95-8 (2012)</Reference>
          <Value>
            <StringWithMarkup>
              <String>/CASE REPORTS/ Niacin is currently a favored drug for increasing high-density lipoprotein, especially in patients with ischemic heart disease or at high risk of developing it. In addition, niacin further decreases low-density lipoprotein in statin-treated patients and has been shown to reduce morbidity and mortality. Among the available niacin preparations, crystalline, immediate-release niacin is the most effective for increasing high-density lipoprotein and is relatively free of hepatic toxicity. We present the case of a patient who had an excellent clinical and laboratory response to 3 g daily of immediate-release niacin, but who later developed clinical hepatitis when he inadvertently switched to the same dose of slow-release niacin. We encourage the use of niacin in general, immediate-release niacin in particular, and caution that niacin is a drug and not a dietary supplement. We also present practical steps for starting niacin, including close patient contact and support, and beginning with a therapeutic dose of 2 g per day right from the start. PubMed Abstract</String>
              <Markup>
                <Start>1068</Start>
                <Length>15</Length>
                <URL>http://www.ncbi.nlm.nih.gov/pubmed/21414665?dopt=Abstract</URL>
              </Markup>
              <Markup>
                <Start>15</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/Niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>189</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>339</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>391</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>625</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>740</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>772</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>809</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>848</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>940</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
            </StringWithMarkup>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>32</ReferenceNumber>
          <Description>**PEER REVIEWED**</Description>
          <Reference>Ali EH et al; W V Med J 109 (1): 12-4 (2013)</Reference>
          <Value>
            <StringWithMarkup>
              <String>/CASE REPORTS/ Niacin is an effective lipid-lowering agent which occasionally may cause hepatic failure. Liver enzymes are periodically tested during niacin therapy to assess for hepatic injury. We report a case of suppressed synthesis of hepatically derived coagulation factors and other liver proteins in a patient on niacin with no elevation of hepatic aminotransferases. The protein abnormalities reversed rapidly on discontinuation of niacin. It appears that niacin can cause occult liver injury without frank aminotransferase elevations, and may portend severe hepatotoxicity. Periodic assessment of prothrombin time should be considered in addition to aminotransferase levels to screen for liver injury. We believe this is the first reported case of occult hepatic injury due to extended release niacin, presenting as coagulopathy. PubMed Abstract</String>
              <Markup>
                <Start>839</Start>
                <Length>15</Length>
                <URL>http://www.ncbi.nlm.nih.gov/pubmed/23413541?dopt=Abstract</URL>
              </Markup>
              <Markup>
                <Start>15</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/Niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>150</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>320</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>440</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>464</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>803</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
            </StringWithMarkup>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>32</ReferenceNumber>
          <Description>**PEER REVIEWED**</Description>
          <Reference>Mularski RA et al; Clin Toxicol (Phila) 44 (1): 81-4 (2006)</Reference>
          <Value>
            <StringWithMarkup>
              <String>/CASE REPORTS/ /The authors/ describe a case of massive oral niacin overdose that resulted in severe persistent hypotension without the manifestation of cutaneous flushing. ...  A 56-year-old male with a history of schizophrenia presented to the emergency department after orally ingesting 11,000 mg of niacin. The patient cited an Internet resource that recommended high-dose niacin for therapy of schizophrenia as the reason for his ingestion. He stopped his psychiatric medications several weeks prior to his niacin overdose. At presentation, the patient was alert and normothermic. His pulse was 68 beats per minute and his blood pressure was initially 92/41 mm Hg. Hypotension with a blood pressure of 58/40 developed over the next few hours and persisted despite intravenous infusion of over 4 liters of normal saline. The physical exam was otherwise unremarkable, specifically without signs of an allergic reaction or cutaneous flushing. He required intravenous dopamine infusion for 12 hours to support a mean arterial blood pressure greater than 60 mm Hg. Evaluation for other etiologies of hypotension was unrevealing. Serum niacin levels were 8.2 ug/mL and 5.6 ug/mL at 48 and 96 hours post ingestion, respectively, giving an apparent half-life of 87 hours. Massive overdose of niacin appears to be capable of causing severe, persistent hypotension in the absence of cutaneous flushing. ... PubMed Abstract</String>
              <Markup>
                <Start>1402</Start>
                <Length>15</Length>
                <URL>http://www.ncbi.nlm.nih.gov/pubmed/16496499?dopt=Abstract</URL>
              </Markup>
              <Markup>
                <Start>61</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>303</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>377</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>512</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>969</Start>
                <Length>8</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/dopamine</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-681</Extra>
              </Markup>
              <Markup>
                <Start>1135</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>1289</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
            </StringWithMarkup>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>32</ReferenceNumber>
          <Description>**PEER REVIEWED**</Description>
          <Reference>Etchason JA et al; Mayo Clin Proc 66 (1): 23-8 (1991)</Reference>
          <Value>
            <StringWithMarkup>
              <String>/CASE REPORTS/ Hepatitis developed in five patients who were taking low dosages (3 g/day or less) of time-release niacin. In four of the five patients, clinical symptoms of hepatitis developed after the medication had been taken for a relatively short time (2 days to 7 weeks). This manifestation of hepatotoxicity seems to differ from that previously reported in association with use of crystalline niacin, which occurred with high dosage and prolonged usage of the medication. ... PubMed Abstract</String>
              <Markup>
                <Start>483</Start>
                <Length>15</Length>
                <URL>http://www.ncbi.nlm.nih.gov/pubmed/1988755?dopt=Abstract</URL>
              </Markup>
              <Markup>
                <Start>114</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>400</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
            </StringWithMarkup>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>32</ReferenceNumber>
          <Description>**PEER REVIEWED**</Description>
          <Reference>Alisky JM; Nutr Neurosci 8 (5-6): 327-9 (2005)</Reference>
          <Value>
            <StringWithMarkup>
              <String>/CASE REPORTS/ A patient with Parkinson&apos;s disease taking levodopa/carbidopa, selegiline, buproprion, aspirin and niacin had decreased rigidity and bradykinesia when his niacin dose was steadily escalated for treatment of high triglycerides, but ultimately the patient could not tolerate niacin because of severe nightmares and skin rash. ... PubMed Abstract</String>
              <Markup>
                <Start>342</Start>
                <Length>15</Length>
                <URL>http://www.ncbi.nlm.nih.gov/pubmed/16669604?dopt=Abstract</URL>
              </Markup>
              <Markup>
                <Start>57</Start>
                <Length>8</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/levodopa</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-6047</Extra>
              </Markup>
              <Markup>
                <Start>66</Start>
                <Length>9</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/carbidopa</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-34359</Extra>
              </Markup>
              <Markup>
                <Start>77</Start>
                <Length>10</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/selegiline</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-26757</Extra>
              </Markup>
              <Markup>
                <Start>89</Start>
                <Length>10</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/bupropion</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-444</Extra>
              </Markup>
              <Markup>
                <Start>101</Start>
                <Length>7</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/aspirin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-2244</Extra>
              </Markup>
              <Markup>
                <Start>113</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>169</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>287</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
            </StringWithMarkup>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>32</ReferenceNumber>
          <Description>**PEER REVIEWED**</Description>
          <Reference>Clementz GL, Holmes AW; J Clin Gastroenterol 9 (5): 582-4 (1987)</Reference>
          <Value>
            <StringWithMarkup>
              <String>/CASE REPORTS/ A 46-year-old man began taking nicotinic acid, 3 g daily, for hypercholesterolemia. A month later, he developed clinical and biochemical evidence of modest hepatocellular injury, and therapy was stopped. It was restarted 6 weeks later, and 10 weeks after that, the patient presented with fulminant hepatic failure, which resolved rapidly after cessation of nicotinic acid therapy. ... PubMed Abstract</String>
              <Markup>
                <Start>400</Start>
                <Length>15</Length>
                <URL>http://www.ncbi.nlm.nih.gov/pubmed/3680913?dopt=Abstract</URL>
              </Markup>
              <Markup>
                <Start>46</Start>
                <Length>14</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/nicotinic%20acid</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>372</Start>
                <Length>14</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/nicotinic%20acid</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
            </StringWithMarkup>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>32</ReferenceNumber>
          <Description>**PEER REVIEWED**</Description>
          <Reference>Mullin GE et al; Ann Intern Med 111: 253-55 (1989)</Reference>
          <Value>
            <StringWithMarkup>
              <String>/CASE REPORTS/ A case of a 44 yr old man with hypercholesterolemia who experienced hepatic failure attributed to switching from regular niacin (nicotinic acid), 6 g/day (which he had been taking for over one yr), to controlled release niacin, 6 g/day, is presented. The patient was hospitalized with fulminant hepatic failure and had a successful liver transplantation. ...</String>
              <Markup>
                <Start>136</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>144</Start>
                <Length>14</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/nicotinic%20acid</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>235</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
            </StringWithMarkup>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>32</ReferenceNumber>
          <Description>**PEER REVIEWED**</Description>
          <Reference>Lang JR; ASHP Midyear Clin Meeting 24: 257 (1989)</Reference>
          <Value>
            <StringWithMarkup>
              <String>/CASE REPORTS/ One of the most significant adverse reactions of nicotinic acid (niacin) is the hepatotoxicity seen in dosages exceeding 3 g/day. In this report a 36 year old male was being followed for type IIa hyperlipoproteinemia and was put on a low fat, low cholesterol diet, cholestyramine resin, and quick-release nicotinic acid at 1.5 g/day. Because of side effects, the patient was switched to a sustained-release product and the dosage was gradually increased to 3 g/day. After six weeks of therapy, the patient began feeling lethargic, weak, and complained of flu-like symptoms. Laboratory values revealed a serum glutamic-oxaloacetic transaminase of 173 IU and a serum glutamate pyruvate transaminase of 465 IU. The sustained-release product was suspected as the cause, and the patient was re-challenged with quick-release nicotinic acid at 3 g/day. There were no apparent adverse reactions after six months of therapy. Nicotinic acid is being promoted as a medication free from serious adverse reactions and is available over-the-counter in tablets as large as 750 mg. From this report it is apparent that high dose nicotinic acid is not free from serious adverse reactions. Hepatoxicity has been associated with the sustained-release nicotinic acid formulations, and the time course of this report supports that nicotinic acid should not be considered an innocuous over-the-counter drug, and should only be administered in large doses cautiously with liver enzymes monitored accordingly.</String>
              <Markup>
                <Start>64</Start>
                <Length>14</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/nicotinic%20acid</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>80</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>262</Start>
                <Length>11</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/cholesterol</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-5997</Extra>
              </Markup>
              <Markup>
                <Start>320</Start>
                <Length>14</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/nicotinic%20acid</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>680</Start>
                <Length>9</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/glutamate</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-4525487</Extra>
              </Markup>
              <Markup>
                <Start>690</Start>
                <Length>8</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/pyruvate</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-107735</Extra>
              </Markup>
              <Markup>
                <Start>834</Start>
                <Length>14</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/nicotinic%20acid</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>931</Start>
                <Length>14</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/Nicotinic%20acid</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>1128</Start>
                <Length>14</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/nicotinic%20acid</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>1247</Start>
                <Length>14</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/nicotinic%20acid</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>1325</Start>
                <Length>14</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/nicotinic%20acid</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
            </StringWithMarkup>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>32</ReferenceNumber>
          <Description>**PEER REVIEWED**</Description>
          <Reference>Paolini JF et al; Int J Clin Pract 62 (6): 896-904 (2008)</Reference>
          <Value>
            <StringWithMarkup>
              <String>/EPIDEMIOLOGY STUDIES/ Niacin is underutilized because of flushing. Lack of a quantitative tool to assess niacin-induced flushing has precluded the objective evaluation of flushing associated with extended-release (ER) niacin formulations. We developed the Flushing Symptom Questionnaire((c)) (FSQ), a quantitative tool to assess patient-reported flushing, and assessed its ability to characterize ER niacin-induced flushing. This study focused on the responses to one question in the FSQ, the Global Flushing Severity Score (GFSS), reported on a 0-10 scale (none = 0, mild = 1-3, moderate = 4-6, severe = 7-9 and extreme = 10) to assess flushing during ER niacin initiation (week 1) and maintenance (weeks 2-8). Flushing severity with ER niacin was greatest during week 1 and remained greater than placebo for the study duration. During weeks 2-8, 40% of patients on ER niacin vs. 8% of those on placebo had &gt; 1 day/week with &apos;moderate or greater&apos; GFSS. In conclusion, the GFSS component of the FSQ was a sensitive and responsive quantitative measure of ER niacin-induced flushing that will aid in the objective comparison of novel strategies intended to improve tolerability and adherence to niacin, an agent proven to reduce cardiovascular risk. PubMed Abstract Full text: PMC2408654</String>
              <Markup>
                <Start>1249</Start>
                <Length>15</Length>
                <URL>http://www.ncbi.nlm.nih.gov/pubmed/18410350?dopt=Abstract</URL>
              </Markup>
              <Markup>
                <Start>1276</Start>
                <Length>10</Length>
                <URL>https://www.ncbi.nlm.nih.gov/pmc/?term=PMC2408654</URL>
              </Markup>
              <Markup>
                <Start>23</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/Niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>106</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>219</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>401</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>657</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>739</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>871</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>1058</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>1194</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
            </StringWithMarkup>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>32</ReferenceNumber>
          <Description>**PEER REVIEWED**</Description>
          <Reference>Kalil RS et al; Kidney Int 87 (6): 1250-7 (2015)</Reference>
          <Value>
            <StringWithMarkup>
              <String>/EPIDEMIOLOGY STUDIES/ Chronic kidney disease (CKD) in patients is strongly associated with cardiovascular morbidity and mortality, and prevalent abnormal lipid metabolism. The AIM-HIGH trial examined the benefits of adding extended-release niacin (ERN) to simvastatin in patients with established coronary heart disease. Here we conducted a post hoc analysis of the AIM-HIGH trial examining whether participants derived cardiovascular or renal benefits when stratified by renal function. Of 3414 participants, 505 had stage 3 CKD at baseline. Among the CKD subset, demographics and cardiovascular disease (CVD) risk factors were well balanced in the ERN and placebo arms. Compared with placebo, CKD participants receiving ERN had a significant decrease in triglycerides by a median of 59.0 mg/dL, and high-density lipoprotein cholesterol significantly increased by a mean of 11.3 mg/dL over a mean follow-up of 3 years. CVD events were similar between CKD participants in both arms. However, all-cause mortality was significantly higher in the ERN group (hazard ratio of 1.73). Mean change in eGFR among ERN-treated CKD participants was not significantly different between study arms. Thus, among AIM-HIGH participants with CKD, the addition of ERN to simvastatin for secondary prevention of CVD improved triglyceride and high-density lipoprotein-cholesterol concentrations but did not improve cardiovascular outcomes or kidney function, and was associated with higher all-cause mortality. PubMed Abstract Full text: PMC4449803</String>
              <Markup>
                <Start>1491</Start>
                <Length>15</Length>
                <URL>http://www.ncbi.nlm.nih.gov/pubmed/25651367?dopt=Abstract</URL>
              </Markup>
              <Markup>
                <Start>1518</Start>
                <Length>10</Length>
                <URL>https://www.ncbi.nlm.nih.gov/pmc/?term=PMC4449803</URL>
              </Markup>
              <Markup>
                <Start>241</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>257</Start>
                <Length>11</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/simvastatin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-54454</Extra>
              </Markup>
              <Markup>
                <Start>827</Start>
                <Length>11</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/cholesterol</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-5997</Extra>
              </Markup>
              <Markup>
                <Start>1253</Start>
                <Length>11</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/simvastatin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-54454</Extra>
              </Markup>
              <Markup>
                <Start>1348</Start>
                <Length>11</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/cholesterol</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-5997</Extra>
              </Markup>
            </StringWithMarkup>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>32</ReferenceNumber>
          <Description>**PEER REVIEWED**</Description>
          <Reference>Maccubbin D et al; Clin J Am Soc Nephrol 5 (4): 582-9 (2010)</Reference>
          <Value>
            <StringWithMarkup>
              <String>/EPIDEMIOLOGY STUDIES/ Niacin administration lowers the marked hyperphosphatemia that is characteristic of renal failure. We examined whether niacin administration also reduces serum phosphorus concentrations in patients who have dyslipidemia and are free of advanced renal disease. We performed a post hoc data analysis of serum phosphorus concentrations that had been determined serially (at baseline and weeks 4, 8, 12, 18, and 24) among 1547 patients who had dyslipidemia and were randomly assigned in a 3:2:1 ratio to treatment with extended release niacin (ERN; 1 g/d for 4 weeks and dose advanced to 2 g/d for 20 weeks) combined with the selective prostaglandin D2 receptor subtype 1 inhibitor laropiprant (L; n = 761), ERN alone (n = 518), or placebo (n = 268). Repeated measures analysis revealed that ERN-L treatment resulted in a net mean (95% confidence interval) serum phosphorus change comparing ERN-L with placebo treatment of -0.13 mmol/L (-0.15 to -0.13 mmol/L; -0.41 mg/dL [-0.46 to -0.37 mg/dL]). These results were consistent across the subgroups defined by estimated GFR of &lt;60 or &gt; or =60 mL/min per 1.73 sq m a serum phosphorus of &gt;1.13 mmol/L (3.5 mg/dL) versus &lt; or =1.13 mmol/L (3.5 mg/dL), the presence of clinical diabetes, or concomitant statin use. We have provided definitive evidence that once-daily ERN-L treatment causes a sustained 0.13-mmol/L (0.4-mg/dL) reduction in serum phosphorus concentrations, approximately 10% from baseline, which is unaffected by estimated GFR ranging from 30 to &gt; or =90 mL/min per 1.73 sq m (i.e., stages 1 through 3 chronic kidney disease). PubMed Abstract Full text: PMC2849700</String>
              <Markup>
                <Start>1607</Start>
                <Length>15</Length>
                <URL>http://www.ncbi.nlm.nih.gov/pubmed/20299362?dopt=Abstract</URL>
              </Markup>
              <Markup>
                <Start>1634</Start>
                <Length>10</Length>
                <URL>https://www.ncbi.nlm.nih.gov/pmc/?term=PMC2849700</URL>
              </Markup>
              <Markup>
                <Start>23</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/Niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>142</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>183</Start>
                <Length>10</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/element/Phosphorus</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>Element-Phosphorus</Extra>
              </Markup>
              <Markup>
                <Start>330</Start>
                <Length>10</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/element/Phosphorus</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>Element-Phosphorus</Extra>
              </Markup>
              <Markup>
                <Start>555</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>655</Start>
                <Length>16</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/prostaglandin%20D2</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-448457</Extra>
              </Markup>
              <Markup>
                <Start>701</Start>
                <Length>11</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/laropiprant</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-9867642</Extra>
              </Markup>
              <Markup>
                <Start>882</Start>
                <Length>10</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/element/Phosphorus</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>Element-Phosphorus</Extra>
              </Markup>
              <Markup>
                <Start>1140</Start>
                <Length>10</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/element/Phosphorus</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>Element-Phosphorus</Extra>
              </Markup>
            </StringWithMarkup>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>32</ReferenceNumber>
          <Description>**PEER REVIEWED**</Description>
          <Reference>Teo KK et al; Stroke 44 (10): 2688-93 (2013)</Reference>
          <Value>
            <StringWithMarkup>
              <String>/EPIDEMIOLOGY STUDIES/ In Atherothrombosis Intervention in Metabolic Syndrome with low HDL/High Triglycerides: Impact on Global Health Outcomes (AIM-HIGH) trial, addition of extended-release niacin (ERN) to simvastatin in participants with established cardiovascular disease, low high-density lipoprotein cholesterol, and high triglycerides had no incremental benefit, despite increases in high-density lipoprotein cholesterol. Preliminary analysis based on incomplete end point adjudication suggested increased ischemic stroke risk among participants randomized to ERN. This final analysis was conducted after complete AIM-HIGH event ascertainment to further explore potential relationship between niacin therapy and ischemic stroke risk. There was no group difference in trial primary composite end point at a mean 36-month follow-up among 3414 patients (85% men; mean age, 64 +/- 9 years) randomized to simvastatin plus ERN (1500-2000 mg/d) versus simvastatin plus matching placebo. In the intention-to-treat analysis, there were 50 fatal or nonfatal ischemic strokes: 18 (1.06%) in placebo arm versus 32 (1.86%) in ERN arm (hazard ratio [HR], 1.78 [95% confidence interval {CI}, 1.00-3.17; P=0.050). Multivariate analysis showed independent associations between ischemic stroke risk and &gt;65 years of age (HR, 3.58; 95% CI, 1.82-7.05; P=0.0002), history of stroke/transient ischemic attack/carotid disease (HR, 2.18; 95% CI, 1.23-3.88; P=0.0079), elevated baseline Lp(a) (HR, 2.80; 95% CI, 1.25-6.27 comparing the middle with the lowest tertile; HR, 2.31; 95% CI, 1.002-5.30 comparing the highest with the lowest tertile; overall P=0.042) but a nonsignificant association with ERN (HR, 1.74; 95% CI, 0.97-3.11; P=0.063). Although there were numerically more ischemic strokes with addition of ERN to simvastatin that reached nominal significance, the number was small, and multivariable analysis accounting for known risk factors did not support a significant association between niacin and ischemic stroke risk. PubMed Abstract Full text: PMC4886540</String>
              <Markup>
                <Start>2015</Start>
                <Length>15</Length>
                <URL>http://www.ncbi.nlm.nih.gov/pubmed/23881958?dopt=Abstract</URL>
              </Markup>
              <Markup>
                <Start>2042</Start>
                <Length>10</Length>
                <URL>https://www.ncbi.nlm.nih.gov/pmc/?term=PMC4886540</URL>
              </Markup>
              <Markup>
                <Start>191</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>207</Start>
                <Length>11</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/simvastatin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-54454</Extra>
              </Markup>
              <Markup>
                <Start>305</Start>
                <Length>11</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/cholesterol</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-5997</Extra>
              </Markup>
              <Markup>
                <Start>415</Start>
                <Length>11</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/cholesterol</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-5997</Extra>
              </Markup>
              <Markup>
                <Start>699</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>906</Start>
                <Length>11</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/simvastatin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-54454</Extra>
              </Markup>
              <Markup>
                <Start>951</Start>
                <Length>11</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/simvastatin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-54454</Extra>
              </Markup>
              <Markup>
                <Start>1802</Start>
                <Length>11</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/simvastatin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-54454</Extra>
              </Markup>
              <Markup>
                <Start>1982</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
            </StringWithMarkup>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>32</ReferenceNumber>
          <Description>**PEER REVIEWED**</Description>
          <Reference>Verdoia M et al; Nutr Metab Cardiovasc Dis 25 (1): 9-23 (2015)</Reference>
          <Value>
            <StringWithMarkup>
              <String>/EPIDEMIOLOGY STUDIES/ High density lipoproteins (HDL) have been addressed as a potential strategy for cardiovascular prevention, with great controversies on pharmacological approaches for HDL-elevation. Our aim was to compare HDL-rising treatment with niacin or CETP-inhibitors with optimal medical therapy in cardiovascular outcome. Randomized trials were searched. Primary endpoint was cardiovascular death, secondary were: non fatal myocardial infarction; coronary revascularization; cerebrovascular accidents and safety endpoints. As many as 18 randomized trials, for a total of 69,515 patients, were included. HDL-modifiers did not reduce cardiovascular mortality (2.3% vs 3.4%; OR [95%CI] = 0.96 [0.87-1.05], p = 0.37, phet = 0.58), with no benefit from niacin/CETP inhibitors according to patients&apos; risk profile (beta [95%CI] = -0.14 [-0.29 to 0.02], p = 0.09) or the amount of HDL increase (beta [95%CI] = 0.014 [-0.008 to 0.04], p = 0.21). Niacin but not CETP-I reduced myocardial infarction and coronary revascularization, but higher rate of SAE occurred with HDL-modifiers (OR [95%CI] = 1.24 [1.18-1.31], p &lt; 0.00001, phet = 0.02), in particular new onset of diabetes with niacin and worsening of hypertension with CETP-inhibitors. Niacin and CETP inhibitors do not influence cardiovascular mortality. Significant benefits in MI and coronary revascularization were observed with niacin, despite the higher occurrence of diabetes. PubMed Abstract</String>
              <Markup>
                <Start>1442</Start>
                <Length>15</Length>
                <URL>http://www.ncbi.nlm.nih.gov/pubmed/25439661?dopt=Abstract</URL>
              </Markup>
              <Markup>
                <Start>253</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>761</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>950</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/Niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
            </StringWithMarkup>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>32</ReferenceNumber>
          <Description>**PEER REVIEWED**</Description>
          <Reference>McKenney J et al; J Clin Lipidol 9 (3): 313-25 (2015)</Reference>
          <Value>
            <StringWithMarkup>
              <String>/EPIDEMIOLOGY STUDIES/ The Heart Protection Study 2-Treatment of HDL to Reduce the Incidence of Vascular Events (HPS2-THRIVE) showed that adding extended-release niacin-laropiprant (ERN-LRPT) to statin provided no incremental cardiovascular benefit vs placebo (PBO). ERN-LRPT was also associated with an excess of serious adverse experiences (AEs), some of which were unexpected (infections and bleeding). These findings led to the withdrawal of ERN-LRPT from all markets. We examined the safety profile of ERN-LRPT vs the comparators ERN alone and statins in the ERN-LRPT development program to assess whether similar safety signals were observed to those seen in HPS-THRIVE and whether these might be attributed to ERN or LRPT. Postrandomization safety data from 12 clinical studies, 12 to 52 weeks in duration and involving 11,310 patients, were analyzed across 3 treatments: (1) ERN-LRPT; (2) ERN-NSP (ERN, Merck &amp; Co, Inc or Niaspan [NSP], Abbott Laboratories); and (3) statin-PBO (statin or PBO). The safety profiles of ERN-LRPT and ERN-NSP were similar, except for less flushing with ERN-LRPT. Nonflushing AEs reported more frequently with ERN-LRPT or ERN-NSP than with statin-PBO were mostly nonserious and typical of niacin (nausea, diarrhea, and increased blood glucose). There was no evidence for an increased risk of serious AEs related to diabetes, muscle, infection, or bleeding. Pooled data from 11,310 patients revealed that, except for reduced flushing, the safety profile of ERN-LRPT was similar to that of ERN-NSP; LRPT did not appear to adversely affect the side-effect profile of ERN. The inability to replicate the unexpected AE findings in HPS2-THRIVE could be because of the smaller sample size and substantially shorter duration of these studies. PubMed Abstract</String>
              <Markup>
                <Start>1772</Start>
                <Length>15</Length>
                <URL>http://www.ncbi.nlm.nih.gov/pubmed/26073389?dopt=Abstract</URL>
              </Markup>
              <Markup>
                <Start>162</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>169</Start>
                <Length>11</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/laropiprant</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-9867642</Extra>
              </Markup>
              <Markup>
                <Start>930</Start>
                <Length>7</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/Niaspan</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>1226</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>1272</Start>
                <Length>7</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/glucose</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-5793</Extra>
              </Markup>
            </StringWithMarkup>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>32</ReferenceNumber>
          <Description>**PEER REVIEWED**</Description>
          <Reference>Rhodes T et al; Int J Clin Pract 67 (12): 1238-46. (2013)</Reference>
          <Value>
            <StringWithMarkup>
              <String>/EPIDEMIOLOGY STUDIES/ Niacin has lipid-modifying efficacy and cardiovascular benefit, but is underutilized because of niacin-induced flushing (NIF). This real-world, prospective, observational study characterized the severity and impact of NIF symptoms among participants who were newly prescribed extended-release (ER) niacin. Participants were surveyed daily during week 1 of therapy, at weeks 5, 9, 13, and at months 7, 10 and 13. Surveys included the Flushing Symptom Questionnaire (FSQ), which includes the Global Flushing Severity Score (GFSS) question, the Flushing Impact Questionnaire (FIQ) and the Treatment Satisfaction Questionnaire for Medication (TSQM). Overall, 306 participants were enrolled. During week 1, 30.0% of participants reported a maximum GFSS &gt;/= 4 (moderate or greater). Mean FIQ domain scores increased with increasing flushing severity, primarily driven by the Irritation/Frustration domain. By week 13, only 2.5% of participants had attained a 2 g ER niacin dose. By month 13, 43.5% (n = 133) had discontinued ER niacin. At discontinuation, only 3.1% of participants had attained the 2 g dose. Over half of the participants who discontinued experienced flushing symptoms: 82% reported moderate to extreme flushing (GFSS &gt;/= 4), and 68% reported severe to extreme flushing (GFSS &gt;/= 7). Participants who discontinued and had flushing side effects reported high degrees of impact in the FIQ Irritation/Frustration domain, and high dissatisfaction as a result of side effects, as measured by the TSQM. In a real-world setting, NIF side effects were bothersome and had an impact on the continuation of therapy. PubMed Abstract</String>
              <Markup>
                <Start>1639</Start>
                <Length>15</Length>
                <URL>http://www.ncbi.nlm.nih.gov/pubmed/24102896?dopt=Abstract</URL>
              </Markup>
              <Markup>
                <Start>23</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/Niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>119</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>321</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>983</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>1045</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
            </StringWithMarkup>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>32</ReferenceNumber>
          <Description>**PEER REVIEWED**</Description>
          <Reference>HPS2-THRIVE Collaborative Group et al; N Engl J Med 371 (3): 203-12 (2014)</Reference>
          <Value>
            <StringWithMarkup>
              <String>/EPIDEMIOLOGY STUDIES/ Patients with evidence of vascular disease are at increased risk for subsequent vascular events despite effective use of statins to lower the low-density lipoprotein (LDL) cholesterol level. Niacin lowers the LDL cholesterol level and raises the high-density lipoprotein (HDL) cholesterol level, but its clinical efficacy and safety are uncertain. After a prerandomization run-in phase to standardize the background statin-based LDL cholesterol-lowering therapy and to establish participants&apos; ability to take extended-release niacin without clinically significant adverse effects, we randomly assigned 25,673 adults with vascular disease to receive 2 g of extended-release niacin and 40 mg of laropiprant or a matching placebo daily. The primary outcome was the first major vascular event (nonfatal myocardial infarction, death from coronary causes, stroke, or arterial revascularization). During a median follow-up period of 3.9 years, participants who were assigned to extended-release niacin-laropiprant had an LDL cholesterol level that was an average of 10 mg per deciliter (0.25 mmol per liter as measured in the central laboratory) lower and an HDL cholesterol level that was an average of 6 mg per deciliter (0.16 mmol per liter) higher than the levels in those assigned to placebo. Assignment to niacin-laropiprant, as compared with assignment to placebo, had no significant effect on the incidence of major vascular events (13.2% and 13.7% of participants with an event, respectively; rate ratio, 0.96; 95% confidence interval [CI], 0.90 to 1.03; P=0.29). Niacin-laropiprant was associated with an increased incidence of disturbances in diabetes control that were considered to be serious (absolute excess as compared with placebo, 3.7 percentage points; P&lt;0.001) and with an increased incidence of diabetes diagnoses (absolute excess, 1.3 percentage points; P&lt;0.001), as well as increases in serious adverse events associated with the gastrointestinal system (absolute excess, 1.0 percentage point; P&lt;0.001), musculoskeletal system (absolute excess, 0.7 percentage points; P&lt;0.001), skin (absolute excess, 0.3 percentage points; P=0.003), and unexpectedly, infection (absolute excess, 1.4 percentage points; P&lt;0.001) and bleeding (absolute excess, 0.7 percentage points; P&lt;0.001). Among participants with atherosclerotic vascular disease, the addition of extended-release niacin-laropiprant to statin-based LDL cholesterol-lowering therapy did not significantly reduce the risk of major vascular events but did increase the risk of serious adverse events. PubMed Abstract</String>
              <Markup>
                <Start>2590</Start>
                <Length>15</Length>
                <URL>http://www.ncbi.nlm.nih.gov/pubmed/25014686?dopt=Abstract</URL>
              </Markup>
              <Markup>
                <Start>195</Start>
                <Length>11</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/cholesterol</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-5997</Extra>
              </Markup>
              <Markup>
                <Start>214</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/Niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>236</Start>
                <Length>11</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/cholesterol</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-5997</Extra>
              </Markup>
              <Markup>
                <Start>300</Start>
                <Length>11</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/cholesterol</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-5997</Extra>
              </Markup>
              <Markup>
                <Start>456</Start>
                <Length>11</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/cholesterol</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-5997</Extra>
              </Markup>
              <Markup>
                <Start>549</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>696</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>716</Start>
                <Length>11</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/laropiprant</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-9867642</Extra>
              </Markup>
              <Markup>
                <Start>1011</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>1018</Start>
                <Length>11</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/laropiprant</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-9867642</Extra>
              </Markup>
              <Markup>
                <Start>1041</Start>
                <Length>11</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/cholesterol</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-5997</Extra>
              </Markup>
              <Markup>
                <Start>1179</Start>
                <Length>11</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/cholesterol</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-5997</Extra>
              </Markup>
              <Markup>
                <Start>1328</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>1335</Start>
                <Length>11</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/laropiprant</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-9867642</Extra>
              </Markup>
              <Markup>
                <Start>1589</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/Niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>1596</Start>
                <Length>11</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/laropiprant</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-9867642</Extra>
              </Markup>
            </StringWithMarkup>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>32</ReferenceNumber>
          <Description>**PEER REVIEWED**</Description>
          <Reference>Zhang LH et al; J Lipid Res 53 (5): 941-50 (2012)</Reference>
          <Value>
            <StringWithMarkup>
              <String>/ALTERNATIVE and IN VITRO TESTS/ The lipidation of apoA-I in liver greatly influences HDL biogenesis and plasma HDL levels by stabilizing the secreted apoA-I. Niacin is the most effective lipid-regulating agent clinically available to raise HDL. This study was undertaken to identify regulatory mechanisms of niacin action in hepatic lipidation of apoA-I, a critical event involved in HDL biogenesis. In cultured human hepatocytes (HepG2), niacin increased: association of apoA-I with phospholipids and cholesterol by 46% and 23% respectively, formation of lipid-poor single apoA-I molecule-containing particles up to ~2.4-fold, and pre beta 1 and alpha migrating HDL particles. Niacin dose-dependently stimulated the cell efflux of phospholipid and cholesterol and increased transcription of ABCA1 gene and ABCA1 protein. Mutated DR4, a binding site for nuclear factor liver X receptor alpha (LXR alpha) in the ABCA1 promoter, abolished niacin stimulatory effect. Further, knocking down LXR alpha or ABCA1 by RNA interference eliminated niacin-stimulated apoA-I lipidation. Niacin treatment did not change apoA-I gene expression. The present data indicate that niacin increases apoA-I lipidation by enhancing lipid efflux through a DR4-dependent transcription of ABCA1 gene in HepG2 cells. A stimulatory role of niacin in early hepatic formation of HDL particles suggests a new mechanism that contributes to niacin action to increase the stability of newly synthesized circulating HDL. PubMed Abstract Full text: PMC3329393</String>
              <Markup>
                <Start>1487</Start>
                <Length>15</Length>
                <URL>http://www.ncbi.nlm.nih.gov/pubmed/22389325?dopt=Abstract</URL>
              </Markup>
              <Markup>
                <Start>1514</Start>
                <Length>10</Length>
                <URL>https://www.ncbi.nlm.nih.gov/pmc/?term=PMC3329393</URL>
              </Markup>
              <Markup>
                <Start>159</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/Niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>309</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>440</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>503</Start>
                <Length>11</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/cholesterol</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-5997</Extra>
              </Markup>
              <Markup>
                <Start>679</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/Niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>750</Start>
                <Length>11</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/cholesterol</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-5997</Extra>
              </Markup>
              <Markup>
                <Start>938</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>1038</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>1075</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/Niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>1162</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>1313</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>1409</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
            </StringWithMarkup>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>32</ReferenceNumber>
          <Description>**PEER REVIEWED**</Description>
          <Reference>Sun H et al; PLoS One 9 (11): e112310 (2014)</Reference>
          <Value>
            <StringWithMarkup>
              <String>/ALTERNATIVE and IN VITRO TESTS/ Niacin has been demonstrated to activate a PI3K/Akt signaling cascade to prevent brain damage after stroke and UV-induced skin damage; however, the underlying molecular mechanisms for hydroxycarboxylic acid receptor 2 (HCA2)-induced Akt activation remain to be elucidated. Using CHO-K1 cells stably expressing HCA2 and A431 cells, a human epidermoid cell line with high levels of endogenous expression of functional HCA2 receptors, we first demonstrated that niacin induced a robust Akt phosphorylation at both Thr308 and Ser473 in a time-dependent fashion, with a maximal activation at 5 min and a subsequent reduction to baseline by 30 min through HCA2, and that the activation was significantly blocked by pertussis toxin. The HCA2-mediated activation of Akt was also significantly inhibited by the protein kinase C (PKC) inhibitors GF109203x and Go6983 in both cell lines, by the PDGFR-selective inhibitor tyrphostin A9 in CHO-HCA2 cells and by the matrix metalloproteinases (MMP) inhibitor GM6001 and EGFR-specific inhibitor AG1478 in A431 cells. These results suggest that the PKC pathway and PDGFR/EGFR transactivation pathway play important roles in HCA2-mediated Akt activation. Further investigation indicated that phosphoinositide 3-kinase (PI3K) and the G-beta-gamma subunit were likely to play an essential role in HCA2-induced Akt activation. Moreover, Immunobloting analyses using an antibody that recognizes p70S6K1 phosphorylated at Thr389 showed that niacin evoked p70S6K1 activation via the PI3K/Akt pathway. The results of our study provide new insight into the signaling pathways involved in HCA2 activation. PubMed Abstract Full text: PMC4223033</String>
              <Markup>
                <Start>1663</Start>
                <Length>15</Length>
                <URL>http://www.ncbi.nlm.nih.gov/pubmed/25375133?dopt=Abstract</URL>
              </Markup>
              <Markup>
                <Start>1690</Start>
                <Length>10</Length>
                <URL>https://www.ncbi.nlm.nih.gov/pmc/?term=PMC4223033</URL>
              </Markup>
              <Markup>
                <Start>33</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/Niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>217</Start>
                <Length>22</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/hydroxycarboxylic%20acid</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-767</Extra>
              </Markup>
              <Markup>
                <Start>492</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>869</Start>
                <Length>9</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/GF109203x</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-2396</Extra>
              </Markup>
              <Markup>
                <Start>883</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/Go6983</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-3499</Extra>
              </Markup>
              <Markup>
                <Start>943</Start>
                <Length>13</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/tyrphostin%20A9</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-5614</Extra>
              </Markup>
              <Markup>
                <Start>1028</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/GM6001</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-132519</Extra>
              </Markup>
              <Markup>
                <Start>1063</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/AG1478</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-2051</Extra>
              </Markup>
              <Markup>
                <Start>1502</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
            </StringWithMarkup>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>32</ReferenceNumber>
          <Description>**PEER REVIEWED**</Description>
          <Reference>Wu BJ et al; Circulation 125 (1): 150-8 (2012)</Reference>
          <Value>
            <StringWithMarkup>
              <String>/ALTERNATIVE and IN VITRO TESTS/ Heme oxygenase-1 (HO-1) is a cytoprotective protein whose expression is consistently associated with therapeutic benefits in a number of pathological conditions such as atherosclerotic vascular disease and inflammation. Niacin is a pleiotropic drug that slows the progression of coronary artery disease and increases serum levels of the HO-1 enzymatic product bilirubin. This study asks if the cardioprotective properties of niacin involve the induction of HO-1. PubMed Abstract</String>
              <Markup>
                <Start>496</Start>
                <Length>15</Length>
                <URL>http://www.ncbi.nlm.nih.gov/pubmed/22095827?dopt=Abstract</URL>
              </Markup>
              <Markup>
                <Start>253</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/Niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>393</Start>
                <Length>9</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/bilirubin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-5280352</Extra>
              </Markup>
              <Markup>
                <Start>458</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
            </StringWithMarkup>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>32</ReferenceNumber>
          <Description>**PEER REVIEWED**</Description>
          <Reference>Ganji SH et al; Atherosclerosis 235 (2): 554-61 (2014)</Reference>
          <Value>
            <StringWithMarkup>
              <String>/ALTERNATIVE and IN VITRO TESTS/ Leukocyte myeloperoxidase (MPO) is a major player in the pathogenesis of various chronic diseases including atherosclerosis. This study proposes the novel concept that niacin, through reactive oxygen species (ROS)-mediated signaling, decreases neutrophil MPO release and its activity, protects apolipoprotein-AI (apo-AI) modification and improves high-density lipoprotein (HDL) function. Human blood leukocytes and leukocytic cell line HL-60 cells were treated with niacin, and stimulated with phorbol myristate acetate (PMA). Cellular and released MPO activity in the medium was measured by assessing chlorination of MPO-specific substrate. MPO protein release in the medium and apo-AI degradation was measured by Western blot analysis. Monocyte adhesion to human aortic primary endothelial cells was measured to assess biological function of HDL/apo-AI. PMA significantly increased leukocyte MPO activity in both intracellular extract and medium. Niacin (0.25-0.5 mM) decreased PMA-induced MPO activity (cellular and released in the media). Niacin also decreased MPO protein mass in the medium without affecting its mRNA expression. Increased NADPH oxidase and ROS production by PMA were also significantly inhibited by niacin. Studies with specific inhibitors suggest that ROS-dependent Src and p38MAP kinase mediate decreased MPO activity by niacin. Niacin blocked apo-AI degradation, and apo-AI from niacin treated cells decreased monocyte adhesion to aortic endothelial cells. These findings identify niacin as a potent inhibitor of leukocyte MPO release and MPO-mediated formation of dysfunctional HDL. Niacin and niacin-related chemical entities may form important therapeutic agents for MPO-mediated inflammatory diseases. PubMed Abstract</String>
              <Markup>
                <Start>1765</Start>
                <Length>15</Length>
                <URL>http://www.ncbi.nlm.nih.gov/pubmed/24956528?dopt=Abstract</URL>
              </Markup>
              <Markup>
                <Start>201</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>499</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>527</Start>
                <Length>25</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/phorbol%20myristate%20acetate</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-4792</Extra>
              </Markup>
              <Markup>
                <Start>982</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/Niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>1076</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/Niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>1178</Start>
                <Length>5</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/NADPH</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-5884</Extra>
              </Markup>
              <Markup>
                <Start>1255</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>1379</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>1387</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/Niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>1438</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>1540</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>1643</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/Niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>1654</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
            </StringWithMarkup>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>32</ReferenceNumber>
          <Description>**PEER REVIEWED**</Description>
          <Reference>Niu N et al; Zhonghua Er Ke Za Zhi 51 (11): 825-30 (2013)</Reference>
          <Value>
            <StringWithMarkup>
              <String>/ALTERNATIVE and IN VITRO TESTS/ /The study objective was/ to examine the effects of niacin on lysophosphatidylcholine (LPC)-induced intercellular adhesion molecule-1 (ICAM-1), and gained insight to the mechanisms. Human umbilical vein endothelial cell line was cultured using Medium 200 medium in incubator at 37 deg C and 5% CO2 condition. Experimental groups: (1) the negative control group: medium; (2) LPC different time groups: the medium added with 20 umol/L final concentration of LPC, were cultured for 10 min and 8 hr, 24 hr; (3) LPC+ p38-mitogen-activated protein kinase (p38MAPK) inhibitor (SB203580) group:the medium added with 10 umol/L p38MAPK inhibitor (SB203580) was cultured for 1 hr, then human umbilical vein endothelial cells (HUVECs) added with the LPC were cultured for 10 min, 8 hr and 24 hr.(4) LPC+different niacin dose group:after separately adding with 0.25, 0.5, 1 mmol/L niacin, the cells were cultured for 18 hr, then HUVECs added with the LPC were cultured for 10 min, 8 hr and 24 hr. Cell concentration in each group was 5 x 10(5)/mL, inoculated in 6-well plates, each well 1 mL. Detected by Western blot analysis of pp38MAPK, ICAM-1 protein content, real-time quantitative PCR to detect endothelial cell ICAM-1 mRNA expression, cell immunofluorescence to detect LPC-induced ICAM-1 protein expression. In LPC 24 hr group, the expression of ICAM-1 protein was significantly increased 0.786 +/- 0.02, the LPC+niacin group, ICAM-1 protein levels (0.487 +/- 0.015) was significantly lower than the LPC 24 hr group (P &lt; 0.01), in LPC+SB203580 intervention group, ICAM-1 protein levels (0.461 +/- 0.011) was significantly lower than that of the LPC 24 hr group (P &lt; 0.01), but did not reach the level of the control group. Adding LPC to culture for 10 min, phosphorylation of p38MAPK (pp38MAPK) reached its peak (0.47 +/- 0.02), niacin could reduce the pp38MAPK (0.07 +/- 0.02), SB203580 could also reduce its activity (0.11 +/- 0.02). Adding LPC to culture for 8 h, ICAM-1 mRNA expression (8.16 +/- 0.15) compared with the control group (1.00 +/- 0.02) had a significant increase (t = 24.34, P &lt; 0.01). Compared with the LPC 8 hr, niacin reduced LPC-induced ICAM-1 mRNA expression (3.85 +/- 0.14), and showed a dose-dependent manner (F = 8.06, P &lt; 0.01), while SB203580 could not effectively reduce the ICAM-1 mRNA (8.09 +/- 0.11). Niacin prevented LPC-induced endothelial dysfunction by reducing expression of ICAM-1. These mechanisms appeared to be at least partly mediated by suppression of the pp38MAPK in endothelial cells. These pleiotropic effects of niacin may potentially contribute to the beneficial effects of risk reduction for atherosclerotic disease. PubMed Abstract</String>
              <Markup>
                <Start>2693</Start>
                <Length>15</Length>
                <URL>http://www.ncbi.nlm.nih.gov/pubmed/24484556?dopt=Abstract</URL>
              </Markup>
              <Markup>
                <Start>85</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>603</Start>
                <Length>8</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/SB203580</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-176155</Extra>
              </Markup>
              <Markup>
                <Start>670</Start>
                <Length>8</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/SB203580</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-176155</Extra>
              </Markup>
              <Markup>
                <Start>834</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>901</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>1440</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
            </StringWithMarkup>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>32</ReferenceNumber>
          <Description>**PEER REVIEWED**</Description>
          <Reference>Babcock MJ et al; J Clin Lipidol 5 (2): 114-9 (2011)</Reference>
          <Value>
            <StringWithMarkup>
              <String>/OTHER TOXICITY INFORMATION/ Niacin is suboptimally used in patients because it causes flushing and erythema. These side effects have been attributed to release of the vasodilating prostaglandin D2, generated in a reaction catalyzed by cyclooxygenase-1. Aspirin reduces but does not completely eliminate these side effects. Because some patients are resistant to its antiplatelet effects, we hypothesized that patients with persistent niacin-induced erythema might be aspirin resistant. Platelet function studies (via the use of a whole-blood platelet function aggregometer with end points of aspirin reaction unit [ARUs] and P2Y12 reaction units [PRUs]) were performed on 32 healthy, drug-free subjects before and after 324 mg of aspirin. A niacin skin test with the use of topical methylnicotinate was also performed before and after the administration of aspirin. Responses to methyl nicotinate were assessed by a reaction score and by counting the time to first visible redness (TTR). All subjects had an expected decrease in arachidonic acid induced platelet response (ARU 642.8 +/- 47.20 before to 431.5 +/- 41.1 after aspirin, P &lt; 0.0001) without a significant change in the PRU. The reaction score and TTR were prolonged by aspirin at methylnicotinate concentrations &gt;/= 0.001 M. Although no subject had aspirin resistance (defined as ARU &gt; 550), there was considerable variability in skin responses with erythema elicited in all subjects at the greatest concentrations. There was no difference in the ARU for subjects with TTR values above and below the mean, indicating that aspirin resistance does not explain the variation in skin responses to a topical niacin derivative. Aspirin resistance is unlikely to be a significant contributor to the persistent erythema and flushing in niacin-treated patients. PubMed Abstract</String>
              <Markup>
                <Start>1816</Start>
                <Length>15</Length>
                <URL>http://www.ncbi.nlm.nih.gov/pubmed/21392725?dopt=Abstract</URL>
              </Markup>
              <Markup>
                <Start>29</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/Niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>181</Start>
                <Length>16</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/prostaglandin%20D2</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-448457</Extra>
              </Markup>
              <Markup>
                <Start>254</Start>
                <Length>7</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/Aspirin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-2244</Extra>
              </Markup>
              <Markup>
                <Start>435</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>468</Start>
                <Length>7</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/aspirin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-2244</Extra>
              </Markup>
              <Markup>
                <Start>593</Start>
                <Length>7</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/aspirin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-2244</Extra>
              </Markup>
              <Markup>
                <Start>731</Start>
                <Length>7</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/aspirin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-2244</Extra>
              </Markup>
              <Markup>
                <Start>742</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>783</Start>
                <Length>16</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/methylnicotinate</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-7151</Extra>
              </Markup>
              <Markup>
                <Start>858</Start>
                <Length>7</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/aspirin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-2244</Extra>
              </Markup>
              <Markup>
                <Start>880</Start>
                <Length>17</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/methyl%20nicotinate</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-7151</Extra>
              </Markup>
              <Markup>
                <Start>1030</Start>
                <Length>16</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/arachidonic%20acid</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-444899</Extra>
              </Markup>
              <Markup>
                <Start>1125</Start>
                <Length>7</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/aspirin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-2244</Extra>
              </Markup>
              <Markup>
                <Start>1312</Start>
                <Length>7</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/aspirin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-2244</Extra>
              </Markup>
              <Markup>
                <Start>1585</Start>
                <Length>7</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/aspirin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-2244</Extra>
              </Markup>
              <Markup>
                <Start>1666</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>1685</Start>
                <Length>7</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/Aspirin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-2244</Extra>
              </Markup>
              <Markup>
                <Start>1791</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
            </StringWithMarkup>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>32</ReferenceNumber>
          <Description>**PEER REVIEWED**</Description>
          <Reference>Berger GE et al; PLoS One 11 (2): e0148429 (2016)</Reference>
          <Value>
            <StringWithMarkup>
              <String>/OTHER TOXICITY INFORMATION/ Most studies provide evidence that the skin flush response to nicotinic acid (niacin) stimulation is impaired in schizophrenia. However, only little is known about niacin sensitivity in the ultra-high risk (UHR) phase of psychotic disorders. We compared visual ratings of niacin sensitivity between adolescents at UHR for psychosis according to the one year transition outcome (UHR-T n = 11; UHR-NT n = 55) with healthy controls (HC n = 25) and first episode schizophrenia patients (FEP n = 25) treated with atypical antipsychotics. Contrary to our hypothesis niacin sensitivity of the entire UHR group was not attenuated, but significantly increased compared to the HC group, whereas no difference could be found between the UHR-T and UHR-NT groups. As expected, niacin sensitivity of FEP was attenuated compared to HC group. In UHR individuals niacin sensitivity was inversely correlated with omega-6 and -9 fatty acids (FA), but positively correlated with phospholipase A2 (inPLA2) activity, a marker of membrane lipid repair/remodeling. Increased niacin sensitivity in UHR states likely indicates an impaired balance of eicosanoids and omega-6/-9 FA at a membrane level. Our findings suggest that the emergence of psychosis is associated with an increased mobilization of eicosanoids prior to the transition to psychosis possibly reflecting a &quot;pro-inflammatory state&quot;, whereas thereafter eicosanoid mobilization seems to be attenuated. Potential treatment implications for the UHR state should be further investigated. PubMed Abstract Full text: PMC4764507</String>
              <Markup>
                <Start>1552</Start>
                <Length>15</Length>
                <URL>http://www.ncbi.nlm.nih.gov/pubmed/26894921?dopt=Abstract</URL>
              </Markup>
              <Markup>
                <Start>1579</Start>
                <Length>10</Length>
                <URL>https://www.ncbi.nlm.nih.gov/pmc/?term=PMC4764507</URL>
              </Markup>
              <Markup>
                <Start>91</Start>
                <Length>14</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/nicotinic%20acid</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>107</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>193</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>301</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>589</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>793</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>875</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>1080</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
            </StringWithMarkup>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>32</ReferenceNumber>
          <Description>**PEER REVIEWED**</Description>
          <Reference>American Society of Health-System Pharmacists 2017; Drug Information 2017. Bethesda, MD. 2017, p. 1940</Reference>
          <Value>
            <StringWithMarkup>
              <String>/OTHER TOXICITY INFORMATION/ ... Niacin has no effect on cholesterol synthesis or fecal excretion of fats, sterols, or bile acids.</String>
              <Markup>
                <Start>33</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/Niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>57</Start>
                <Length>11</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/cholesterol</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-5997</Extra>
              </Markup>
            </StringWithMarkup>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>32</ReferenceNumber>
          <Description>**PEER REVIEWED**</Description>
          <Reference>Ma L et al; Sci Rep 5: 8906 (2015)</Reference>
          <Value>
            <StringWithMarkup>
              <String>/OTHER TOXICITY INFORMATION/ Nicotinic acid (NA, a.k.a. vitamin B3 or niacin) can reduce blood cholesterol and low-density lipoproteins whereas increase high-density lipoproteins. However, when NA is used to treat dyslipidemias, it causes a strong side effect of cutaneous vasodilation, commonly called flushing. A recent study showed that NA may cause flushing by lowering activation threshold temperature of the heat-sensitive capsaicin receptor TRPV1 ion channel, leading to its activation at body temperature. The finding calls into question whether NA might also interact with the homologous heat-sensitive TRPV2-4 channels, particularly given that TRPV3 and TRPV4 are abundantly expressed in keratinocytes of the skin where much of the flushing response occurs. We found that NA indeed potentiated TRPV3 while inhibited TRPV2 and TRPV4. Consistent with these gating effects, NA lowered the heat-activation threshold of TRPV3 but elevated that of TRPV4. We further found that activity of TRPV1 was substantially prolonged by extracellular NA, which may further enhance the direct activation effect. Consistent with the broad gating effect on TRPV1-4 channels, evidence from the present study hints that NA may share the same activation pathway as 2-aminoethoxydiphenyl borate (2-APB), a common agonist for these TRPV channels. These findings shed new light on the molecular mechanism underlying NA regulation of TRPV channels. PubMed Abstract Full text: PMC4894441</String>
              <Markup>
                <Start>1432</Start>
                <Length>15</Length>
                <URL>http://www.ncbi.nlm.nih.gov/pubmed/25752528?dopt=Abstract</URL>
              </Markup>
              <Markup>
                <Start>1459</Start>
                <Length>10</Length>
                <URL>https://www.ncbi.nlm.nih.gov/pmc/?term=PMC4894441</URL>
              </Markup>
              <Markup>
                <Start>29</Start>
                <Length>14</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/Nicotinic%20acid</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>56</Start>
                <Length>10</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/vitamin%20B3</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>70</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>95</Start>
                <Length>11</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/cholesterol</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-5997</Extra>
              </Markup>
              <Markup>
                <Start>429</Start>
                <Length>9</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/capsaicin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-1548943</Extra>
              </Markup>
              <Markup>
                <Start>1252</Start>
                <Length>28</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/2-aminoethoxydiphenyl%20borate</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-1598</Extra>
              </Markup>
              <Markup>
                <Start>1282</Start>
                <Length>5</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/2-APB</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-1598</Extra>
              </Markup>
            </StringWithMarkup>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>32</ReferenceNumber>
          <Description>**PEER REVIEWED**</Description>
          <Reference>Sainio EL, Sainio P; Toxicol Appl Pharmacol 102 (2): 251-58 (1990)</Reference>
          <Value>
            <StringWithMarkup>
              <String>/OTHER TOXICITY INFORMATION/ Tryptophan is one of the strongest activators of tryptophan 2,3-dioxygenase, the rate-limiting enzyme in the pathway which degraded tryptophan. One of the metabolites thus formed is nicotinic acid, widely administered as a drug (often at high doses) and a vitamin. This study determined whether nicotinic acid also has a potency to activate tryptophan 2,3-dioxygenase and, if so, by what mechanism, whether changes in plasma tryptophan result, and if such activation is permanent. The results showed that nicotinic acid activated the enzyme almost as strongly as tryptophan. The results confirmed the activation to be of the &quot;substrate&quot; type, ie, at least partly due to increased tryptophan concentrations in the liver. In repeated nicotinic acid administration plasma tryptophan levels did not diminish, despite the high activation of tryptophan 2,3-dioxgenase (high flux of tryptophan through the kynurenine pathway). However, the activation disappeared after 11 days of treatment. The powerful and sustained activation of tryptophan 2,3-dioxygenase by nicotinic acid may at least partly explain some of its side effects, such as glucose intolerance. However, mental disturbance as a side effect of diminished brain levels of tryptophan is not supported by these findings. PubMed Abstract</String>
              <Markup>
                <Start>1304</Start>
                <Length>15</Length>
                <URL>http://www.ncbi.nlm.nih.gov/pubmed/2300969?dopt=Abstract</URL>
              </Markup>
              <Markup>
                <Start>29</Start>
                <Length>10</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/Tryptophan</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-6305</Extra>
              </Markup>
              <Markup>
                <Start>78</Start>
                <Length>10</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/tryptophan</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-6305</Extra>
              </Markup>
              <Markup>
                <Start>161</Start>
                <Length>10</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/tryptophan</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-6305</Extra>
              </Markup>
              <Markup>
                <Start>211</Start>
                <Length>14</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/nicotinic%20acid</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>324</Start>
                <Length>14</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/nicotinic%20acid</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>370</Start>
                <Length>10</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/tryptophan</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-6305</Extra>
              </Markup>
              <Markup>
                <Start>454</Start>
                <Length>10</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/tryptophan</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-6305</Extra>
              </Markup>
              <Markup>
                <Start>534</Start>
                <Length>14</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/nicotinic%20acid</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>592</Start>
                <Length>10</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/tryptophan</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-6305</Extra>
              </Markup>
              <Markup>
                <Start>709</Start>
                <Length>10</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/tryptophan</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-6305</Extra>
              </Markup>
              <Markup>
                <Start>761</Start>
                <Length>14</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/nicotinic%20acid</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>798</Start>
                <Length>10</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/tryptophan</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-6305</Extra>
              </Markup>
              <Markup>
                <Start>865</Start>
                <Length>10</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/tryptophan</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-6305</Extra>
              </Markup>
              <Markup>
                <Start>905</Start>
                <Length>10</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/tryptophan</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-6305</Extra>
              </Markup>
              <Markup>
                <Start>928</Start>
                <Length>10</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/kynurenine</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-846</Extra>
              </Markup>
              <Markup>
                <Start>1054</Start>
                <Length>10</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/tryptophan</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-6305</Extra>
              </Markup>
              <Markup>
                <Start>1084</Start>
                <Length>14</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/nicotinic%20acid</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>1161</Start>
                <Length>7</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/glucose</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-5793</Extra>
              </Markup>
              <Markup>
                <Start>1257</Start>
                <Length>10</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/tryptophan</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-6305</Extra>
              </Markup>
            </StringWithMarkup>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>32</ReferenceNumber>
          <Description>**PEER REVIEWED**</Description>
          <Reference>Soudijn W et al; Med Res Rev 27 (3): 417-33 (2007)</Reference>
          <Value>
            <StringWithMarkup>
              <String>/OTHER TOXICITY INFORMATION/ ... G protein-coupled receptor (HM74A or GPR109A). Responds to both nicotinic acid and the ketone body beta-hydroxybutyrate, the latter thought to be the more probable endogenous ligand for HM74A. In this review, we will discuss the pharmacology and medicinal chemistry of this receptor subtype and a related one (HM74 or GPR109B) /is discussed/. ... Mutagenesis experiments have provided clues regarding the ligand binding site; in particular, an arginine residue in transmembrane domain 3 of the receptor seems to recognize the acidic moiety present in nicotinic acid and related substances. HM74A has also been linked to one of the major side effects of nicotinic acid, that is, flushing, since this receptor subtype also occurs in skin immune cells. It is not known yet whether HM74 is also present on these cells. Since nicotinic acid is one of the few available medicines that raise high-density lipoprotein (HDL; &quot;good cholesterol&quot;) levels, HM74A and HM74 appear promising targets for future pharmacotherapy. PubMed Abstract</String>
              <Markup>
                <Start>1045</Start>
                <Length>15</Length>
                <URL>http://www.ncbi.nlm.nih.gov/pubmed/17238156?dopt=Abstract</URL>
              </Markup>
              <Markup>
                <Start>97</Start>
                <Length>14</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/nicotinic%20acid</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>132</Start>
                <Length>20</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/beta-hydroxybutyrate</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-3541112</Extra>
              </Markup>
              <Markup>
                <Start>477</Start>
                <Length>8</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/arginine</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-6322</Extra>
              </Markup>
              <Markup>
                <Start>584</Start>
                <Length>14</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/nicotinic%20acid</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>686</Start>
                <Length>14</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/nicotinic%20acid</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>854</Start>
                <Length>14</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/nicotinic%20acid</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>955</Start>
                <Length>11</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/cholesterol</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-5997</Extra>
              </Markup>
            </StringWithMarkup>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>32</ReferenceNumber>
          <Description>**PEER REVIEWED**</Description>
          <Reference>American Society of Health-System Pharmacists 2017; Drug Information 2017. Bethesda, MD. 2017, p. 1940</Reference>
          <Value>
            <StringWithMarkup>
              <String>/OTHER TOXICITY INFORMATION/ Niacin reportedly potentiates the hypotensive effects of ganglionic blocking and vasoactive drugs, resulting in postural hypotension.</String>
              <Markup>
                <Start>29</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/Niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
            </StringWithMarkup>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>32</ReferenceNumber>
          <Description>**PEER REVIEWED**</Description>
          <Reference>Messamore E; Schizophr Res 137 (1-3): 180-4 (2012)</Reference>
          <Value>
            <StringWithMarkup>
              <String>/OTHER TOXICITY INFORMATION/ Sensitivity to the skin flush effect of niacin is reduced in a portion of patients with schizophrenia. Though this peripheral physiological abnormality has been widely replicated, its relevance to neuropsychiatric manifestations of the illness has been unclear. The goal of this study was to determine if the niacin response abnormality in schizophrenia is associated with functional impairment. Following psychiatric assessment, a Global Assessment of Functioning (GAF) score was assigned to each of 40 volunteers with schizophrenia. For each subject, the blood flow responses to several concentrations of topical methylnicotinate were recorded. Blood flow was measured objectively, using laser Doppler flowmetry. From the dose-response data, EC(50) values were derived. GAF scores were assigned without knowledge of the participants&apos; niacin response data. There was a significant negative correlation between GAF scores and EC(50) values for methylnicotinate (Pearson r=-0.42; p=0.007). Reduced niacin sensitivity is associated with greater functional impairment among patients with schizophrenia. ... PubMed Abstract</String>
              <Markup>
                <Start>1133</Start>
                <Length>15</Length>
                <URL>http://www.ncbi.nlm.nih.gov/pubmed/22445461?dopt=Abstract</URL>
              </Markup>
              <Markup>
                <Start>69</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>338</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>644</Start>
                <Length>16</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/methylnicotinate</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-7151</Extra>
              </Markup>
              <Markup>
                <Start>865</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>973</Start>
                <Length>16</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/methylnicotinate</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-7151</Extra>
              </Markup>
              <Markup>
                <Start>1026</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
            </StringWithMarkup>
          </Value>
        </Information>
      </Section>
      <Section>
        <TOCHeading>Non-Human Toxicity Excerpts</TOCHeading>
        <Description>Non-Human Toxicity Excerpts</Description>
        <Information>
          <ReferenceNumber>32</ReferenceNumber>
          <Description>**PEER REVIEWED**</Description>
          <Reference>Heemskerk MM et al; J Lipid Res 55 (12): 2532-40 (2014)</Reference>
          <Value>
            <StringWithMarkup>
              <String>/LABORATORY ANIMALS: Subchronic or Prechronic Exposure/ Prolonged niacin treatment elicits beneficial effects on the plasma lipid and lipoprotein profile that is associated with a protective CVD risk profile. Acute niacin treatment inhibits nonesterified fatty acid release from adipocytes and stimulates prostaglandin release from skin Langerhans cells, but the acute effects diminish upon prolonged treatment, while the beneficial effects remain. To gain insight in the prolonged effects of niacin on lipid metabolism in adipocytes, we used a mouse model with a human-like lipoprotein metabolism and drug response [female APOE*3-Leiden.CETP (apoE3 Leiden cholesteryl ester transfer protein) mice] treated with and without niacin for 15 weeks. The gene expression profile of gonadal white adipose tissue (gWAT) from niacin-treated mice showed an upregulation of the &quot;biosynthesis of unsaturated fatty acids&quot; pathway, which was corroborated by quantitative PCR and analysis of the FA ratios in gWAT. Also, adipocytes from niacin-treated mice secreted more of the PUFA DHA ex vivo. This resulted in an increased DHA/arachidonic acid (AA) ratio in the adipocyte FA secretion profile and in plasma of niacin-treated mice. Interestingly, the DHA metabolite 19,20-dihydroxy docosapentaenoic acid (19,20-diHDPA) was increased in plasma of niacin-treated mice. Both an increased DHA/AA ratio and increased 19,20-diHDPA are indicative for an anti-inflammatory profile and may indirectly contribute to the atheroprotective lipid and lipoprotein profile associated with prolonged niacin treatment. PubMed Abstract Full text: PMC4242446</String>
              <Markup>
                <Start>1588</Start>
                <Length>15</Length>
                <URL>http://www.ncbi.nlm.nih.gov/pubmed/25320342?dopt=Abstract</URL>
              </Markup>
              <Markup>
                <Start>1615</Start>
                <Length>10</Length>
                <URL>https://www.ncbi.nlm.nih.gov/pmc/?term=PMC4242446</URL>
              </Markup>
              <Markup>
                <Start>66</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>215</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>493</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>724</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>817</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>1022</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>1115</Start>
                <Length>16</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/arachidonic%20acid</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-444899</Extra>
              </Markup>
              <Markup>
                <Start>1198</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>1292</Start>
                <Length>12</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/19%2C20-diHDPA</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-16061148</Extra>
              </Markup>
              <Markup>
                <Start>1333</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>1399</Start>
                <Length>12</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/19%2C20-diHDPA</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-16061148</Extra>
              </Markup>
              <Markup>
                <Start>1570</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
            </StringWithMarkup>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>32</ReferenceNumber>
          <Description>**PEER REVIEWED**</Description>
          <Reference>Wanders D et al; PLoS One 8 (8): e71285 (2013)</Reference>
          <Value>
            <StringWithMarkup>
              <String>/LABORATORY ANIMALS: Subchronic or Prechronic Exposure/ /The study objective was/ to determine the effects of niacin on adiponectin and markers of adipose tissue inflammation in a mouse model of obesity. Male C57BL/6 mice were placed on a control or high-fat diet (HFD) and were maintained on such diets for the duration of the study. After 6 weeks on the control or high fat diets, vehicle or niacin treatments were initiated and maintained for 5 weeks. Identical studies were conducted concurrently in HCA2 (-/-) (niacin receptor(-/-)) mice. Niacin increased serum concentrations of the anti-inflammatory adipokine, adiponectin by 21% in HFD-fed wild-type mice, but had no effect on lean wild-type or lean or HFD-fed HCA2 (-/-) mice. Niacin increased adiponectin gene and protein expression in the HFD-fed wild-type mice only. The increases in adiponectin serum concentrations, gene and protein expression occurred independently of changes in expression of PPARgamma C/EBPalpha or SREBP-1c (key transcription factors known to positively regulate adiponectin gene transcription) in the adipose tissue. Further, niacin had no effect on adipose tissue expression of ERp44, Ero1-Lalpha, or DsbA-L (key ER chaperones involved in adiponectin production and secretion). However, niacin treatment attenuated HFD-induced increases in adipose tissue gene expression of MCP-1 and IL-1beta in the wild-type HFD-fed mice. Niacin also reduced the expression of the pro-inflammatory M1 macrophage marker CD11c in HFD-fed wild-type mice. Niacin treatment attenuates obesity-induced adipose tissue inflammation through increased adiponectin and anti-inflammatory cytokine expression and reduced pro-inflammatory cytokine expression in a niacin receptor-dependent manner. PubMed Abstract Full text: PMC3742781</String>
              <Markup>
                <Start>1756</Start>
                <Length>15</Length>
                <URL>http://www.ncbi.nlm.nih.gov/pubmed/23967184?dopt=Abstract</URL>
              </Markup>
              <Markup>
                <Start>1783</Start>
                <Length>10</Length>
                <URL>https://www.ncbi.nlm.nih.gov/pmc/?term=PMC3742781</URL>
              </Markup>
              <Markup>
                <Start>110</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>394</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>516</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>544</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/Niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>736</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/Niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>1112</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>1188</Start>
                <Length>4</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/DsbA</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-29924549</Extra>
              </Markup>
              <Markup>
                <Start>1274</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>1411</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/Niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>1524</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/Niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>1722</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
            </StringWithMarkup>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>32</ReferenceNumber>
          <Description>**PEER REVIEWED**</Description>
          <Reference>Khan M et al; Acta Vet Scand 55: 85 (2013)</Reference>
          <Value>
            <StringWithMarkup>
              <String>/LABORATORY ANIMALS: Subchronic or Prechronic Exposure/ It was recently shown that niacin supplementation counteracts the obesity-induced muscle fiber transition from oxidative type I to glycolytic type II and increases the number of type I fibers in skeletal muscle of obese Zucker rats. These effects were likely mediated by the induction of key regulators of fiber transition, PPARdelta (encoded by PPARD), PGC-1alpha (encoded by PPARGC1A) and PGC-1beta (encoded by PPARGC1B), leading to type II to type I fiber transition and upregulation of genes involved in oxidative metabolism. The aim of the present study was to investigate whether niacin administration also influences fiber distribution and the metabolic phenotype of different muscles [M. longissimus dorsi (LD), M. semimembranosus (SM), M. semitendinosus (ST)] in sheep as a model for ruminants. For this purpose, 16 male, 11 wk old Rhoen sheep were randomly allocated to two groups of 8 sheep each administered either no (control group) or 1 g niacin per day (niacin group) for 4 wk. After 4 wk, the percentage number of type I fibers in LD, SM and ST muscles was greater in the niacin group, whereas the percentage number of type II fibers was less in niacin group than in the control group (P&lt;0.05). The mRNA levels of PPARGC1A, PPARGC1B, and PPARD and the relative mRNA levels of genes involved in mitochondrial fatty acid uptake (CPT1B, SLC25A20), tricarboxylic acid cycle (SDHA), mitochondrial respiratory chain (COX5A, COX6A1), and angiogenesis (VEGFA) in LD, SM and ST muscles were greater (P&lt;0.05) or tended to be greater (P&lt;0.15) in the niacin group than in the control group. The study shows that niacin supplementation induces muscle fiber transition from type II to type I, and thereby an oxidative metabolic phenotype of skeletal muscle in sheep as a model for ruminants. The enhanced capacity of skeletal muscle to utilize fatty acids in ruminants might be particularly useful during metabolic states in which fatty acids are excessively mobilized from adipose tissue, such as during the early lactating period in high producing cows. PubMed Abstract Full text: PMC4176759</String>
              <Markup>
                <Start>2114</Start>
                <Length>15</Length>
                <URL>http://www.ncbi.nlm.nih.gov/pubmed/24267720?dopt=Abstract</URL>
              </Markup>
              <Markup>
                <Start>2141</Start>
                <Length>10</Length>
                <URL>https://www.ncbi.nlm.nih.gov/pmc/?term=PMC4176759</URL>
              </Markup>
              <Markup>
                <Start>83</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>642</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>1009</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>1025</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>1144</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>1218</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
            </StringWithMarkup>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>32</ReferenceNumber>
          <Description>**PEER REVIEWED**</Description>
          <Reference>Wu BJ et al; Circulation 125 (1): 150-8 (2012)</Reference>
          <Value>
            <StringWithMarkup>
              <String>/LABORATORY ANIMALS: Subchronic or Prechronic Exposure/ Heme oxygenase-1 (HO-1) is a cytoprotective protein whose expression is consistently associated with therapeutic benefits in a number of pathological conditions such as atherosclerotic vascular disease and inflammation. Niacin is a pleiotropic drug that slows the progression of coronary artery disease and increases serum levels of the HO-1 enzymatic product bilirubin. This study asks if the cardioprotective properties of niacin involve the induction of HO-1. New Zealand White rabbits received chow or chow supplemented with 0.6% (wt/wt) niacin for 2 weeks. Acute vascular inflammation was induced in the animals by placing a nonocclusive silastic collar around the left common carotid artery. At 24 hours after collar implantation, serum bilirubin and vascular, liver, and spleen HO-1 messenger RNA levels were significantly increased. Vascular inflammation was decreased in the niacin-supplemented animals compared with control. Treatment of the animals with tin protoporphyrin-IX, a global HO inhibitor, or HO-1 small interfering RNA to knock down carotid artery HO-1 attenuated the ability of niacin to inhibit vascular inflammation. Treatment of cultured human coronary artery endothelial cells with niacin increased HO-1 expression by activating the nuclear factor-E2-related factor 2/p38 mitogen-activated protein kinase signaling pathway and inhibiting tumor necrosis factor alpha-induced endothelial inflammation. The antiinflammatory effects of niacin in human coronary artery endothelial cells were mimicked by bilirubin and abolished by incubation with tin protoporphyrin-IX and knock down of nuclear factor-E2-related factor 2. Niacin activates HO-1 in vivo and in vitro. Induction of HO-1 may be partly responsible for the vascular protective properties of niacin. PubMed Abstract</String>
              <Markup>
                <Start>1839</Start>
                <Length>15</Length>
                <URL>http://www.ncbi.nlm.nih.gov/pubmed/22095827?dopt=Abstract</URL>
              </Markup>
              <Markup>
                <Start>276</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/Niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>416</Start>
                <Length>9</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/bilirubin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-5280352</Extra>
              </Markup>
              <Markup>
                <Start>481</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>598</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>799</Start>
                <Length>9</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/bilirubin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-5280352</Extra>
              </Markup>
              <Markup>
                <Start>940</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>1021</Start>
                <Length>3</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/element/Tin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>Element-Tin</Extra>
              </Markup>
              <Markup>
                <Start>1025</Start>
                <Length>17</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/protoporphyrin-IX</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-4971</Extra>
              </Markup>
              <Markup>
                <Start>1157</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>1265</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>1515</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>1582</Start>
                <Length>9</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/bilirubin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-5280352</Extra>
              </Markup>
              <Markup>
                <Start>1625</Start>
                <Length>3</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/element/Tin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>Element-Tin</Extra>
              </Markup>
              <Markup>
                <Start>1629</Start>
                <Length>17</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/protoporphyrin-IX</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-4971</Extra>
              </Markup>
              <Markup>
                <Start>1701</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/Niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>1831</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
            </StringWithMarkup>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>32</ReferenceNumber>
          <Description>**PEER REVIEWED**</Description>
          <Reference>Heemskerk MM et al; Am J Physiol Endocrinol Metab 306 (7): E808-13 (2014)</Reference>
          <Value>
            <StringWithMarkup>
              <String>/LABORATORY ANIMALS: Subchronic or Prechronic Exposure/ The lipid-lowering effect of niacin has been attributed to the inhibition of cAMP production in adipocytes, thereby inhibiting intracellular lipolysis and release of nonesterified fatty acids (NEFA) to the circulation. However, long-term niacin treatment leads to a normalization of plasma NEFA levels and induces insulin resistance, for which the underlying mechanisms are poorly understood. The current study addressed the effects of long-term niacin treatment on insulin-mediated inhibition of adipocyte lipolysis and focused on the regulation of cAMP levels. APOE*3-Leiden.CETP transgenic mice treated with niacin for 15 wk were subjected to an insulin tolerance test and showed whole body insulin resistance. Similarly, adipocytes isolated from niacin-treated mice were insulin resistant and, interestingly, exhibited an increased response to cAMP stimulation by 8Br-cAMP, beta1- and beta2-adrenergic stimulation. Gene expression analysis of the insulin and beta-adrenergic pathways in adipose tissue indicated that all genes were downregulated, including the gene encoding the cAMP-degrading enzyme phosphodiesterase 3B (PDE3B). In line with this, we showed that insulin induced a lower PDE3B response in adipocytes isolated from niacin-treated mice. Inhibiting PDE3B with cilostazol increased lipolytic responsiveness to cAMP stimulation in adipocytes. These data show that long-term niacin treatment leads to a downregulation of PDE3B in adipocytes, which could explain part of the observed insulin resistance and the increased responsiveness to cAMP stimulation. PubMed Abstract Full text: PMC3962609</String>
              <Markup>
                <Start>1628</Start>
                <Length>15</Length>
                <URL>http://www.ncbi.nlm.nih.gov/pubmed/24473440?dopt=Abstract</URL>
              </Markup>
              <Markup>
                <Start>1655</Start>
                <Length>10</Length>
                <URL>https://www.ncbi.nlm.nih.gov/pmc/?term=PMC3962609</URL>
              </Markup>
              <Markup>
                <Start>85</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>133</Start>
                <Length>4</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/cAMP</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-6076</Extra>
              </Markup>
              <Markup>
                <Start>294</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>502</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>606</Start>
                <Length>4</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/cAMP</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-6076</Extra>
              </Markup>
              <Markup>
                <Start>667</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>806</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>904</Start>
                <Length>4</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/cAMP</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-6076</Extra>
              </Markup>
              <Markup>
                <Start>928</Start>
                <Length>4</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/cAMP</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-6076</Extra>
              </Markup>
              <Markup>
                <Start>1139</Start>
                <Length>4</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/cAMP</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-6076</Extra>
              </Markup>
              <Markup>
                <Start>1292</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>1335</Start>
                <Length>10</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/cilostazol</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-2754</Extra>
              </Markup>
              <Markup>
                <Start>1384</Start>
                <Length>4</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/cAMP</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-6076</Extra>
              </Markup>
              <Markup>
                <Start>1447</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>1610</Start>
                <Length>4</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/cAMP</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-6076</Extra>
              </Markup>
            </StringWithMarkup>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>32</ReferenceNumber>
          <Description>**PEER REVIEWED**</Description>
          <Reference>Li Z et al; Biochem Pharmacol 84 (6): 821-9 (2012)</Reference>
          <Value>
            <StringWithMarkup>
              <String>/LABORATORY ANIMALS: Subchronic or Prechronic Exposure/ The anti-dyslipidemic drug niacin has recently been shown to reduce the hepatic expression and plasma levels of cholesteryl ester transfer protein (CETP). Since liver macrophages contribute to hepatic CETP expression, we investigated the role of macrophages in the CETP-lowering effect of niacin in mice. In vitro studies showed that niacin does not directly attenuate CETP expression in macrophages. Treatment of normolipidemic human CETP transgenic mice, fed a Western-type diet with niacin for 4 weeks, significantly reduced the hepatic cholesterol concentration (-20%), hepatic CETP gene expression (-20%), and plasma CETP mass (-30%). Concomitantly, niacin decreased the hepatic expression of CD68 (-44%) and ABCG1 (-32%), both of which are specific markers for the hepatic macrophage content. The decrease in hepatic CETP expression was significantly correlated with the reduction of hepatic macrophage markers. Furthermore, niacin attenuated atherogenic diet-induced inflammation in liver, as evident from decreased expression of TNF-alpha (-43%). Niacin similarly decreased the macrophage markers and absolute macrophage content in hyperlipidemic APOE*3-Leiden.CETP transgenic mice on a Western-type diet. In conclusion, niacin decreases hepatic CETP expression and plasma CETP mass by attenuating liver inflammation and macrophage content in response to its primary lipid-lowering effect, rather than by attenuating the macrophage CETP expression level. PubMed Abstract</String>
              <Markup>
                <Start>1519</Start>
                <Length>15</Length>
                <URL>http://www.ncbi.nlm.nih.gov/pubmed/22750059?dopt=Abstract</URL>
              </Markup>
              <Markup>
                <Start>83</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>345</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>390</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>542</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>596</Start>
                <Length>11</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/cholesterol</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-5997</Extra>
              </Markup>
              <Markup>
                <Start>711</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>987</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>1111</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/Niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>1285</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
            </StringWithMarkup>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>32</ReferenceNumber>
          <Description>**PEER REVIEWED**</Description>
          <Reference>Cosmetic Ingredient Review (CIR) Expert Panel; Final Report of the Safety Assessment of Niacinamide and Niacin; Intl J of Toxicology 24 (Suppl 5): p.12 (2005). Available from, as of July 23, 2018: https://www.cir-safety.org/ingredients</Reference>
          <Value>
            <StringWithMarkup>
              <String>/LABORATORY ANIMALS: Subchronic or Prechronic Exposure/ A decreased growth rate in male Vanderbilt strain rats fed diets containing 10% casein and large amounts of niacin or niacinamide daily /was reported/. The rats weighed 48 to 54 g at the onset of the study and received diets containing 1% or 2% (1.0 or 2.0 g/kg bw) niacinamide or niacin for 30 or 40 days. Each feeding group consisted of six rats and most experiments were repeated three times. Growth rate was decreased to a greater degree with niacinamide than with niacin. A slight decrease in growth rate was noted at the 2% level with niacin, but not at 1%. Fatty liver formation was noted at both niacin feeding levels. Almost complete growth inhibition occurred in animals fed 1% niacinamide.</String>
              <Markup>
                <Start>164</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>174</Start>
                <Length>11</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacinamide</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-936</Extra>
              </Markup>
              <Markup>
                <Start>322</Start>
                <Length>11</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacinamide</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-936</Extra>
              </Markup>
              <Markup>
                <Start>337</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>503</Start>
                <Length>11</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacinamide</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-936</Extra>
              </Markup>
              <Markup>
                <Start>525</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>597</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>660</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>744</Start>
                <Length>11</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacinamide</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-936</Extra>
              </Markup>
            </StringWithMarkup>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>32</ReferenceNumber>
          <Description>**PEER REVIEWED**</Description>
          <Reference>American Society of Health-System Pharmacists 2017; Drug Information 2017. Bethesda, MD. 2017, p. 1939</Reference>
          <Value>
            <StringWithMarkup>
              <String>/LABORATORY ANIMALS: Chronic Exposure or Carcinogenicity/ Niacin administered to mice for a lifetime as a 1% solution in drinking water was not carcinogenic. The mice in this study received approximately 6-8 times the human dose of 3 g daily as determined on a mg/sq m basis.</String>
              <Markup>
                <Start>58</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/Niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>130</Start>
                <Length>5</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/water</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-962</Extra>
              </Markup>
            </StringWithMarkup>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>32</ReferenceNumber>
          <Description>**PEER REVIEWED**</Description>
          <Reference>Kwong AM et al; Nutr Cancer 63 (6): 950-9 (2011)</Reference>
          <Value>
            <StringWithMarkup>
              <String>/LABORATORY ANIMALS: Chronic Exposure or Carcinogenicity: Initiation-Promotion/ High doses of niacin (nicotinic acid) used to treat dyslipidemias cause flushing, due to high levels of prostaglandin D(2) (PGD(2)). GPR109A, a G-protein coupled receptor, triggers the flushing in the skin. In addition to boosting PGD(2), niacin binding to GPR109A activates the entire prostanoid cascade. We found that GPR109A occurs throughout the gastrointestinal tract. Mice that alternated between a 1% niacin diet and a control diet had higher urinary prostaglandin E(2) (PGE(2)) metabolite levels when on niacin (2.8-fold increase; 95% confidence interval, 1.8-3.9). PGE(2) promotes tumors in the intestines, whereas PGD(2) may have an opposite effect, on the basis of our report showing that transgenic hematopoietic prostaglandin D synthase suppresses intestinal adenomas in Apc(Min/+) mice. To determine if either tumor growth or tumor suppression prevails, we fed Apc(Min/+) mice a 1% niacin diet and assessed tumor development. A 1% niacin diet did not affect the number of tumors scored histologically in Apc(Min/+) mice at 14 wk (33 mice on niacin, 33 controls). Although niacin stimulates production of various prostaglandins, our results support an interpretation that very high intakes of niacin are safe in relation to intestinal tumors in this model. PubMed Abstract Full text: PMC3224853</String>
              <Markup>
                <Start>1350</Start>
                <Length>15</Length>
                <URL>http://www.ncbi.nlm.nih.gov/pubmed/21774590?dopt=Abstract</URL>
              </Markup>
              <Markup>
                <Start>1377</Start>
                <Length>10</Length>
                <URL>https://www.ncbi.nlm.nih.gov/pmc/?term=PMC3224853</URL>
              </Markup>
              <Markup>
                <Start>94</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>102</Start>
                <Length>14</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/nicotinic%20acid</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>319</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>488</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>538</Start>
                <Length>18</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/prostaglandin%20E%282%29</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-5280360</Extra>
              </Markup>
              <Markup>
                <Start>592</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>976</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>1025</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>1135</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>1166</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>1286</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
            </StringWithMarkup>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>32</ReferenceNumber>
          <Description>**PEER REVIEWED**</Description>
          <Reference>Organization for Economic Cooperation and Development; Screening Information Data Set for Nicotinic Acid, CAS # 59-67-6 p.292 (1995). Available from, as of July 23, 2018: http://www.inchem.org/pages/sids.html</Reference>
          <Value>
            <StringWithMarkup>
              <String>/LABORATORY ANIMALS: Developmental or Reproductive Toxicity/ Test substance /nicotinic acid in aqueous methylcellulose 0.5% (w/v)/ was given in oral gavage at dose levels of 40, 200 or 1000 mg/kg/day to groups of 22 pregnant rats from day 6 to day 15 of gestation. On day 20 of gestation, all animals were killed and the uterine contents were examined. Under the test conditions nicotinic acid in oral administration to pregnant rats during the period of organogenesis at doses up to 200 mg/kg/day was without adverse effects. At 1000 mg/kg/day maternal body weight gain, placental and fetal weights were slightly depressed. No effect on survival, on litter size nor morphological changes upon &quot;in utero&quot; development were observed</String>
              <Markup>
                <Start>77</Start>
                <Length>14</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/nicotinic%20acid</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>103</Start>
                <Length>15</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/methylcellulose</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-6850753</Extra>
              </Markup>
              <Markup>
                <Start>379</Start>
                <Length>14</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/nicotinic%20acid</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
            </StringWithMarkup>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>32</ReferenceNumber>
          <Description>**PEER REVIEWED**</Description>
          <Reference>Chen L et al; Mol Cell Endocrinol 404: 56-66 (2015)</Reference>
          <Value>
            <StringWithMarkup>
              <String>/ENDOCRINE MODULATION/ The widely used lipid-lowering drug niacin is reported to induce hyperglycemia during chronic and high-dose treatments, but the mechanism is poorly understood. Recently, the niacin receptor [G-protein-coupled receptor, (GPR) 109a], has been localized to islet cells while its potential role therein remains unclear. We, therefore, aimed at investigating how GPR109a regulates islet beta-cell function and its downstream signaling using high-fat diet-induced obese mice and INS-1E beta cells. Eight-week niacin treatment elevated blood glucose concentration in obese mice with increased areas under the curve at oral glucose and intraperitoneal insulin tolerance tests. Additionally, niacin treatment significantly decreased glucose-stimulated insulin secretion (GSIS) but induced peroxisome proliferator-activated receptor gamma (Pparg) and GPR109a expression in isolated pancreatic islets; concomitantly, reactive oxygen species (ROS) were transiently increased, with decreases in GSIS, intracellular cyclic adenosine monophosphate (cAMP) accumulation and mitochondrial membrane potential (delta-psi-m), but with increased expression of uncoupling protein 2 (Ucp2), Pparg and Gpr109a in INS-1E cells. Corroborating these findings, the decreases in GSIS, delta-psi-m and cAMP production and increases in ROS, Pparg and GPR109a expression were abolished in INS-1E cells by GPR109a knockdown. Our data indicate that niacin-induced pancreatic islet dysfunction is probably modulated through activation of the islet beta-cell GPR109a-induced ROS-PPARgamma-UCP2 pathways. PubMed Abstract</String>
              <Markup>
                <Start>1590</Start>
                <Length>15</Length>
                <URL>http://www.ncbi.nlm.nih.gov/pubmed/25622782?dopt=Abstract</URL>
              </Markup>
              <Markup>
                <Start>59</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>197</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>526</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>558</Start>
                <Length>7</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/glucose</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-5793</Extra>
              </Markup>
              <Markup>
                <Start>639</Start>
                <Length>7</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/glucose</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-5793</Extra>
              </Markup>
              <Markup>
                <Start>706</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>747</Start>
                <Length>7</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/glucose</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-5793</Extra>
              </Markup>
              <Markup>
                <Start>1057</Start>
                <Length>4</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/cAMP</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-6076</Extra>
              </Markup>
              <Markup>
                <Start>1294</Start>
                <Length>4</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/cAMP</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-6076</Extra>
              </Markup>
              <Markup>
                <Start>1437</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
            </StringWithMarkup>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>32</ReferenceNumber>
          <Description>**PEER REVIEWED**</Description>
          <Reference>Cosmetic Ingredient Review (CIR) Expert Panel; Final Report of the Safety Assessment of Niacinamide and Niacin; Intl J of Toxicology 24 (Suppl 5): p.15 (2005). Available from, as of July 23, 2018: https://www.cir-safety.org/ingredients</Reference>
          <Value>
            <StringWithMarkup>
              <String>/GENOTOXICITY/ Niacinamide and niacin were tested at 5, 0.5, 0.05, 0.005, and 0.0005% w/w or v/v in Saccharomyces cerevisiae, strain D4 and Salmonella typhimurium strains TA 1535, 1537, 1538, 98, and 100 with and without metabolic activation. Liver homogenates were prepared from the following mammalian species: ICR random bred adult male mice, Sprague-Dawley adult male rats, and Macaca mulatta adult male monkeys. The positive controls used in direct and activation assays were: methylnitrosoguanidine, ethylmethanesulfonate, 2-nitrofluourene, quinacrine mustard, dimethylnitrosamine, 2-acetylaminofluorene, 8-aminoquinoline, 2-aminoanthracene. Neither niacinamide nor niacin exhibited mutagenic activity in any of the assays used in these studies.</String>
              <Markup>
                <Start>15</Start>
                <Length>11</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/Niacinamide</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-936</Extra>
              </Markup>
              <Markup>
                <Start>31</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>482</Start>
                <Length>22</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/methylnitrosoguanidine</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-104963</Extra>
              </Markup>
              <Markup>
                <Start>547</Start>
                <Length>18</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/quinacrine%20mustard</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-20193</Extra>
              </Markup>
              <Markup>
                <Start>567</Start>
                <Length>19</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/dimethylnitrosamine</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-6124</Extra>
              </Markup>
              <Markup>
                <Start>588</Start>
                <Length>21</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/2-acetylaminofluorene</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-5897</Extra>
              </Markup>
              <Markup>
                <Start>611</Start>
                <Length>16</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/8-aminoquinoline</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-11359</Extra>
              </Markup>
              <Markup>
                <Start>629</Start>
                <Length>17</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/2-aminoanthracene</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-11937</Extra>
              </Markup>
              <Markup>
                <Start>656</Start>
                <Length>11</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacinamide</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-936</Extra>
              </Markup>
              <Markup>
                <Start>672</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
            </StringWithMarkup>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>32</ReferenceNumber>
          <Description>**PEER REVIEWED**</Description>
          <Reference>Cosmetic Ingredient Review (CIR) Expert Panel; Final Report of the Safety Assessment of Niacinamide and Niacin; Intl J of Toxicology 24 (Suppl 5): p.16 (2005). Available from, as of July 23, 2018: https://www.cir-safety.org/ingredients</Reference>
          <Value>
            <StringWithMarkup>
              <String>/GENOTOXICITY/ An Ames test using Salmonella typhimurium strains TA92, TA1535, TA100, TA1537, TA94 and TA98, with and without metabolic activation, and a chromosome aberration test using a Chinese hamster fibroblast cell line were carried out on both niacin and niacinamide. At a maximum dose of 50 mg/plate and 2 mg/mL, niacinamide was negative in both the Ames and chromosome test, respectively. In the Ames and chromosome test, niacin tested negative at maximum concentrations of 10 mg/plate and 2 mg/mL, respectively.</String>
              <Markup>
                <Start>251</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>262</Start>
                <Length>11</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacinamide</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-936</Extra>
              </Markup>
              <Markup>
                <Start>321</Start>
                <Length>11</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacinamide</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-936</Extra>
              </Markup>
              <Markup>
                <Start>431</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
            </StringWithMarkup>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>32</ReferenceNumber>
          <Description>**PEER REVIEWED**</Description>
          <Reference>Sun H et al; PLoS One 9 (11): e112310 (2014)</Reference>
          <Value>
            <StringWithMarkup>
              <String>/ALTERNATIVE and IN VITRO TESTS/ Niacin has been demonstrated to activate a PI3K/Akt signaling cascade to prevent brain damage after stroke and UV-induced skin damage; however, the underlying molecular mechanisms for hydroxycarboxylic acid receptor 2 (HCA2)-induced Akt activation remain to be elucidated. Using CHO-K1 cells stably expressing HCA2 and A431 cells, a human epidermoid cell line with high levels of endogenous expression of functional HCA2 receptors, we first demonstrated that niacin induced a robust Akt phosphorylation at both Thr308 and Ser473 in a time-dependent fashion, with a maximal activation at 5 min and a subsequent reduction to baseline by 30 min through HCA2, and that the activation was significantly blocked by pertussis toxin. The HCA2-mediated activation of Akt was also significantly inhibited by the protein kinase C (PKC) inhibitors GF109203x and Go6983 in both cell lines, by the PDGFR-selective inhibitor tyrphostin A9 in CHO-HCA2 cells and by the matrix metalloproteinases (MMP) inhibitor GM6001 and EGFR-specific inhibitor AG1478 in A431 cells. These results suggest that the PKC pathway and PDGFR/EGFR transactivation pathway play important roles in HCA2-mediated Akt activation. Further investigation indicated that phosphoinositide 3-kinase (PI3K) and the G-beta-gamma subunit were likely to play an essential role in HCA2-induced Akt activation. Moreover, Immunobloting analyses using an antibody that recognizes p70S6K1 phosphorylated at Thr389 showed that niacin evoked p70S6K1 activation via the PI3K/Akt pathway. The results of our study provide new insight into the signaling pathways involved in HCA2 activation. PubMed Abstract Full text: PMC4223033</String>
              <Markup>
                <Start>1663</Start>
                <Length>15</Length>
                <URL>http://www.ncbi.nlm.nih.gov/pubmed/25375133?dopt=Abstract</URL>
              </Markup>
              <Markup>
                <Start>1690</Start>
                <Length>10</Length>
                <URL>https://www.ncbi.nlm.nih.gov/pmc/?term=PMC4223033</URL>
              </Markup>
              <Markup>
                <Start>33</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/Niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>217</Start>
                <Length>22</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/hydroxycarboxylic%20acid</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-767</Extra>
              </Markup>
              <Markup>
                <Start>492</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>869</Start>
                <Length>9</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/GF109203x</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-2396</Extra>
              </Markup>
              <Markup>
                <Start>883</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/Go6983</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-3499</Extra>
              </Markup>
              <Markup>
                <Start>943</Start>
                <Length>13</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/tyrphostin%20A9</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-5614</Extra>
              </Markup>
              <Markup>
                <Start>1028</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/GM6001</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-132519</Extra>
              </Markup>
              <Markup>
                <Start>1063</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/AG1478</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-2051</Extra>
              </Markup>
              <Markup>
                <Start>1502</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
            </StringWithMarkup>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>32</ReferenceNumber>
          <Description>**PEER REVIEWED**</Description>
          <Reference>Rungruang S et al; J Dairy Sci 97 (8): 5023-34 (2014)</Reference>
          <Value>
            <StringWithMarkup>
              <String>/VETERINARY STUDIES/ Twenty-four multiparous high-producing dairy cows (40.0+/-1.4 kg/d) were used in a factorial design to evaluate effects of 2 environments [thermoneutral (TN) and heat stress (HS)] and a dose range of dietary rumen-protected niacin (RPN; 0, 4, 8, or 12 g/d) on body temperature, sweating rate, feed intake, water intake, production parameters, and blood niacin concentrations. Temperature-humidity index values during TN never exceeded 68 (stress threshold), whereas temperature-humidity index values during HS were above 68 for 24 hr/d. The HS environment increased hair coat and skin, rectal, and vaginal temperatures; respiration rate; skin and hair coat evaporative heat loss; and water intake and decreased DMI (3.5 kg/d), milk yield (4.1 kg/d), 4% fat-corrected milk (2.7 kg/d), and milk protein yield (181.7 g/d). Sweating rate increased during HS (12.7 g/sq m per hr) compared with TN, but this increase was only 10% of that reported in summer-acclimated cattle. Niacin supplementation did not affect sweating rate, dry-matter intake, or milk yield in either environment. Rumen-protected niacin increased plasma and milk niacin concentrations in a linear manner. Heat stress reduced niacin concentration in whole blood (7.86 vs. 6.89 ug/mL) but not in milk. Reduced blood niacin concentration was partially corrected by dietary RPN. An interaction existed between dietary RPN and environment; dietary RPN linearly increased water intake in both environments, but the increase was greater during HS conditions. Increasing dietary RPN did not influence skin temperatures. During TN, supplementing 12 g/d of RPN increased hair coat (unshaved skin; 30.3 vs. 31.3 deg C at 1600 hr) but not shaved skin (32.8 vs. 32.9 deg C at 1600 hr) temperature when compared with 0 g/d at all time points, whereas the maximum temperature (18 deg C) of the room was lower than skin temperature. These data suggest that dietary RPN increased water intake during both TN and HS and hair coat temperature during TN; however, core body temperature was unaffected. Thus, encapsulated niacin did not improve thermotolerance of winter-acclimated lactating dairy cows exposed to moderate thermal stress in Arizona. PubMed Abstract</String>
              <Markup>
                <Start>2215</Start>
                <Length>15</Length>
                <URL>http://www.ncbi.nlm.nih.gov/pubmed/24881789?dopt=Abstract</URL>
              </Markup>
              <Markup>
                <Start>245</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>327</Start>
                <Length>5</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/water</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-962</Extra>
              </Markup>
              <Markup>
                <Start>374</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>705</Start>
                <Length>5</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/water</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-962</Extra>
              </Markup>
              <Markup>
                <Start>991</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/Niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>1116</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>1149</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>1211</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>1300</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>1452</Start>
                <Length>5</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/water</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-962</Extra>
              </Markup>
              <Markup>
                <Start>1949</Start>
                <Length>5</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/water</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-962</Extra>
              </Markup>
              <Markup>
                <Start>2087</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
            </StringWithMarkup>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>32</ReferenceNumber>
          <Description>**PEER REVIEWED**</Description>
          <Reference>Loholter M et al; Arch Anim Nutr 67 (3): 202-18 (2013)</Reference>
          <Value>
            <StringWithMarkup>
              <String>/VETERINARY STUDIES/ The objective of this study was to investigate the effects of niacin and dietary concentrate proportion on body temperature, ruminal pH and milk production of dairy cows. In a 2 x 2 factorial design, 20 primiparous Holstein cows (179 +/- 12 days in milk) were assigned to four dietary treatments aimed to receive either 0 or 24 g niacin and 30% (low) or 60% (high) concentrate with the rest being a partial mixed ration (PMR) composed of 60% corn and 40% grass silage (on dry matter basis). Ambient temperature and relative humidity were determined and combined by the calculation of temperature humidity index. Respiration rates, rectal, skin and subcutaneous temperatures were measured. Milk production and composition were determined. Ruminal pH and temperature were recorded at a frequency of 5 min using wireless devices for continuous intra-ruminal measurement (boluses). pH values were corrected for pH sensor drift. The climatic conditions varied considerably but temporarily indicated mild heat stress. Niacin did not affect skin, rectal and subcutaneous temperatures but tended to increase respiration rates. High concentrate reduced skin temperatures at rump, thigh and neck by 0.1-0.3 deg C. Due to the technical disturbances, not all bolus data could be subjected to statistical evaluation. However, both niacin and high concentrate influenced mean ruminal pH. High concentrate increased the time spent with a pH below 5.6 and ruminal temperatures (0.2-0.3 deg C). Niacin and high concentrate enhanced milk, protein and lactose yield but reduced milk fat and protein content. Milk fat yield was slightly reduced by high concentrate but increased due to niacin supplementation. In conclusion, niacin did not affect body temperature but stimulated milk performance. High concentrate partially influenced body temperatures and had beneficial effects on milk production. PubMed Abstract</String>
              <Markup>
                <Start>1901</Start>
                <Length>15</Length>
                <URL>http://www.ncbi.nlm.nih.gov/pubmed/23742643?dopt=Abstract</URL>
              </Markup>
              <Markup>
                <Start>83</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>351</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>1033</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/Niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>1339</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>1499</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/Niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>1554</Start>
                <Length>7</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/lactose</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-440995</Extra>
              </Markup>
              <Markup>
                <Start>1687</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>1726</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
            </StringWithMarkup>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>32</ReferenceNumber>
          <Description>**PEER REVIEWED**</Description>
          <Reference>Lauring B et al; Sci Transl Med 4 (148): 148ra115 (2012)</Reference>
          <Value>
            <StringWithMarkup>
              <String>/OTHER TOXICITY INFORMATION/ Nicotinic acid (niacin) induces beneficial changes in serum lipoproteins and has been associated with beneficial cardiovascular effects. Niacin reduces low-density lipoprotein, increases high-density lipoprotein, and decreases triglycerides. It is well established that activation of the seven-transmembrane G(i)-coupled receptor GPR109A on Langerhans cells results in release of prostaglandin D2, which mediates the well-known flushing side effect of niacin. Niacin activation of GPR109A on adipocytes also mediates the transient reduction of plasma free fatty acid (FFA) levels characteristic of niacin, which has been long hypothesized to be the mechanism underlying the changes in the serum lipid profile. We tested this &quot;FFA hypothesis&quot; and the hypothesis that niacin lipid efficacy is mediated via GPR109A by dosing mice lacking GPR109A with niacin and testing two novel, full GPR109A agonists, MK-1903 and SCH900271, in three human clinical trials. In mice, the absence of GPR109A had no effect on niacin&apos;s lipid efficacy despite complete abrogation of the anti-lipolytic effect. Both MK-1903 and SCH900271 lowered FFAs acutely in humans; however, neither had the expected effects on serum lipids. Chronic FFA suppression was not sustainable via GPR109A agonism with niacin, MK-1903, or SCH900271. We conclude that the GPR109A receptor does not mediate niacin&apos;s lipid efficacy, challenging the long-standing FFA hypothesis. PubMed Abstract</String>
              <Markup>
                <Start>1460</Start>
                <Length>15</Length>
                <URL>http://www.ncbi.nlm.nih.gov/pubmed/22914621?dopt=Abstract</URL>
              </Markup>
              <Markup>
                <Start>29</Start>
                <Length>14</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/Nicotinic%20acid</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>45</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>166</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/Niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>409</Start>
                <Length>16</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/prostaglandin%20D2</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-448457</Extra>
              </Markup>
              <Markup>
                <Start>481</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>489</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/Niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>627</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>795</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>877</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>930</Start>
                <Length>7</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/MK-1903</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-49763030</Extra>
              </Markup>
              <Markup>
                <Start>942</Start>
                <Length>9</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/SCH900271</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-56950369</Extra>
              </Markup>
              <Markup>
                <Start>1034</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>1121</Start>
                <Length>7</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/MK-1903</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-49763030</Extra>
              </Markup>
              <Markup>
                <Start>1133</Start>
                <Length>9</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/SCH900271</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-56950369</Extra>
              </Markup>
              <Markup>
                <Start>1303</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>1311</Start>
                <Length>7</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/MK-1903</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-49763030</Extra>
              </Markup>
              <Markup>
                <Start>1323</Start>
                <Length>9</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/SCH900271</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-56950369</Extra>
              </Markup>
              <Markup>
                <Start>1389</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
            </StringWithMarkup>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>32</ReferenceNumber>
          <Description>**PEER REVIEWED**</Description>
          <Reference>Clifton HL et al; J Cardiovasc Pharmacol 65 (2): 184-91 (2015)</Reference>
          <Value>
            <StringWithMarkup>
              <String>/OTHER TOXICITY INFORMATION/ Niacin is effective in treating dyslipidemias but causes cutaneous vasodilation or flushing, a side effect that limits its clinical use. Blocking prostaglandins in humans reduces but does not consistently eliminate flushing, indicating additional mechanisms may contribute to flushing. The transient receptor potential vanilloid 1 (TRPV1) channel, when activated, causes cutaneous vasodilation and undergoes tachyphylaxis similar to that seen with niacin. Using a murine model, early phase niacin-induced flushing was examined and TRPV1 channel involvement demonstrated using pharmacologic blockade, desensitization, and genetic knockouts (TRPV1 KO). The TRPV1 antagonist AMG9810 reduced the magnitude of the initial and secondary peaks and the rapidity of the vasodilatory response (slope). TRPV1 desensitization by chronic capsaicin reduced the initial peak and slope. TRPV1 KO mice had a lower initial peak, secondary peak, and slope compared with wild-type mice. Chronic niacin reduced the initial peak, secondary peak, and slope in wild-type mice but had no effect in knockout mice. Furthermore, chronic niacin diminished the response to capsaicin in wild-type mice. Overall, these data demonstrate an important role for TRPV1 channels in niacin-induced flushing, both in the acute response and with chronic administration. That niacin-induced flushing is a complex cascade of events, which should inform pharmacological intervention against this side effect. PubMed Abstract Full text: PMC5797728</String>
              <Markup>
                <Start>1494</Start>
                <Length>15</Length>
                <URL>http://www.ncbi.nlm.nih.gov/pubmed/25387247?dopt=Abstract</URL>
              </Markup>
              <Markup>
                <Start>1521</Start>
                <Length>10</Length>
                <URL>https://www.ncbi.nlm.nih.gov/pmc/?term=PMC5797728</URL>
              </Markup>
              <Markup>
                <Start>29</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/Niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>477</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>519</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>701</Start>
                <Length>7</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/AMG9810</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-680502</Extra>
              </Markup>
              <Markup>
                <Start>854</Start>
                <Length>9</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/capsaicin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-1548943</Extra>
              </Markup>
              <Markup>
                <Start>1004</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>1138</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>1172</Start>
                <Length>9</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/capsaicin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-1548943</Extra>
              </Markup>
              <Markup>
                <Start>1273</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>1363</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
            </StringWithMarkup>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>32</ReferenceNumber>
          <Description>**PEER REVIEWED**</Description>
          <Reference>Zhou E et al; Int Immunopharmacol 23 (1): 121-6 (2014)</Reference>
          <Value>
            <StringWithMarkup>
              <String>/OTHER TOXICITY INFORMATION/ Niacin has been reported to have potent anti-inflammatory effects in LPS-induced acute lung injury. However, the molecular mechanism of niacin has not been fully understood. The aim of the present study was to investigate the effects of niacin on the production of pro-inflammatory cytokines TNF-alpha, IL-6 and IL-1beta in LPS-induced mouse alveolar macrophages and explore its underlying mechanism. Mouse alveolar macrophages were incubated in the presence or absence of various concentrations of niacin (1, 10, 100 umol/L) 1 hr before LPS (1 ug/mL) challenge. The results showed that niacin reduced the levels of TNF-alpha, IL-6 and IL-1beta in LPS-challenged alveolar macrophages. Furthermore, NF-kappaB activation was inhibited by niacin through blocking the phosphorylation of NF-kappaB p65 and IkappaBalpha. In addition, silencing HCA2 abrogated the effect of niacin on the production of pro-inflammatory cytokines. These findings suggested that niacin attenuated the LPS-induced pro-inflammatory cytokines possibly mediated by HCA2 in LPS-challenged alveolar macrophages. PubMed Abstract</String>
              <Markup>
                <Start>1109</Start>
                <Length>15</Length>
                <URL>http://www.ncbi.nlm.nih.gov/pubmed/25038318?dopt=Abstract</URL>
              </Markup>
              <Markup>
                <Start>29</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/Niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>165</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>266</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>528</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>616</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>765</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>896</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>982</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
            </StringWithMarkup>
          </Value>
        </Information>
      </Section>
      <Section>
        <TOCHeading>Non-Human Toxicity Values</TOCHeading>
        <Description>Non-Human Toxicity Values</Description>
        <Information>
          <ReferenceNumber>32</ReferenceNumber>
          <Description>**PEER REVIEWED**</Description>
          <Reference>O&apos;Neil, M.J. (ed.). The Merck Index - An Encyclopedia of Chemicals, Drugs, and Biologicals. Cambridge, UK:  Royal Society of Chemistry, 2013., p. 1215</Reference>
          <Value>
            <StringWithMarkup>
              <String>LD50 Rat sc 5 g/kg</String>
            </StringWithMarkup>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>32</ReferenceNumber>
          <Description>**PEER REVIEWED**</Description>
          <Reference>Lewis, R.J. Sr. (ed) Sax&apos;s Dangerous Properties of Industrial Materials. 11th Edition. Wiley-Interscience, Wiley &amp; Sons, Inc. Hoboken, NJ. 2004., p. 2622</Reference>
          <Value>
            <StringWithMarkup>
              <String>LD50 Rat oral 7000 mg/kg</String>
            </StringWithMarkup>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>32</ReferenceNumber>
          <Description>**PEER REVIEWED**</Description>
          <Reference>Lewis, R.J. Sr. (ed) Sax&apos;s Dangerous Properties of Industrial Materials. 11th Edition. Wiley-Interscience, Wiley &amp; Sons, Inc. Hoboken, NJ. 2004., p. 2622</Reference>
          <Value>
            <StringWithMarkup>
              <String>LD50 Rat ip 730 mg/kg</String>
            </StringWithMarkup>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>32</ReferenceNumber>
          <Description>**PEER REVIEWED**</Description>
          <Reference>Lewis, R.J. Sr. (ed) Sax&apos;s Dangerous Properties of Industrial Materials. 11th Edition. Wiley-Interscience, Wiley &amp; Sons, Inc. Hoboken, NJ. 2004., p. 2622</Reference>
          <Value>
            <StringWithMarkup>
              <String>LD50 Mouse oral 3720 mg/kg</String>
            </StringWithMarkup>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>32</ReferenceNumber>
          <Description>**PEER REVIEWED**</Description>
          <Reference>Lewis, R.J. Sr. (ed) Sax&apos;s Dangerous Properties of Industrial Materials. 11th Edition. Wiley-Interscience, Wiley &amp; Sons, Inc. Hoboken, NJ. 2004., p. 2622</Reference>
          <Value>
            <StringWithMarkup>
              <String>LD50 Mouse ip 358 mg/kg</String>
            </StringWithMarkup>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>32</ReferenceNumber>
          <Description>**PEER REVIEWED**</Description>
          <Reference>Lewis, R.J. Sr. (ed) Sax&apos;s Dangerous Properties of Industrial Materials. 11th Edition. Wiley-Interscience, Wiley &amp; Sons, Inc. Hoboken, NJ. 2004., p. 2622</Reference>
          <Value>
            <StringWithMarkup>
              <String>LD50 Mouse sc 3500 mg/kg</String>
            </StringWithMarkup>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>32</ReferenceNumber>
          <Description>**PEER REVIEWED**</Description>
          <Reference>Lewis, R.J. Sr. (ed) Sax&apos;s Dangerous Properties of Industrial Materials. 11th Edition. Wiley-Interscience, Wiley &amp; Sons, Inc. Hoboken, NJ. 2004., p. 2623</Reference>
          <Value>
            <StringWithMarkup>
              <String>LD50 Mouse iv 5000 mg/kg</String>
            </StringWithMarkup>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>32</ReferenceNumber>
          <Description>**PEER REVIEWED**</Description>
          <Reference>Lewis, R.J. Sr. (ed) Sax&apos;s Dangerous Properties of Industrial Materials. 11th Edition. Wiley-Interscience, Wiley &amp; Sons, Inc. Hoboken, NJ. 2004., p. 2623</Reference>
          <Value>
            <StringWithMarkup>
              <String>LD50 Rabbit oral 4550 mg/kg</String>
            </StringWithMarkup>
          </Value>
        </Information>
      </Section>
      <Section>
        <TOCHeading>Ecotoxicity Values</TOCHeading>
        <Description>Ecotoxicity Values</Description>
        <Information>
          <ReferenceNumber>32</ReferenceNumber>
          <Description>**PEER REVIEWED**</Description>
          <Reference>Organization for Economic Cooperation and Development; Screening Information Data Set for  Nicotinic Acid, CAS # 59-67-6 p.35 (1995). Available from, as of June 19, 2018: http://www.inchem.org/pages/sids.html</Reference>
          <Value>
            <StringWithMarkup>
              <String>LD50; Species: Coturnix coturnix (Quail) oral &gt; 1000 mg/kg</String>
            </StringWithMarkup>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>32</ReferenceNumber>
          <Description>**PEER REVIEWED**</Description>
          <Reference>Organization for Economic Cooperation and Development; Screening Information Data Set for  Nicotinic Acid, CAS # 59-67-6 p.35 (1995). Available from, as of June 19, 2018: http://www.inchem.org/pages/sids.html</Reference>
          <Value>
            <StringWithMarkup>
              <String>EC50; Species: Daphnia magna (Water flea); Concentration: 77 mg/L for 48 hr; Effect: immobilization /Conditions of bioassay not specified in source examined/</String>
              <Markup>
                <Start>30</Start>
                <Length>5</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/Water</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-962</Extra>
              </Markup>
            </StringWithMarkup>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>32</ReferenceNumber>
          <Description>**PEER REVIEWED**</Description>
          <Reference>Organization for Economic Cooperation and Development; Screening Information Data Set for  Nicotinic Acid, CAS # 59-67-6 p.35 (1995). Available from, as of June 19, 2018: http://www.inchem.org/pages/sids.html</Reference>
          <Value>
            <StringWithMarkup>
              <String>EC50; Species: Scenedesmus subspicatus (Green algae); Concentration: 89.93 mg/L for 72 hr; Effect: Growth inhibition /Conditions of bioassay not specified in source examined/</String>
            </StringWithMarkup>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>32</ReferenceNumber>
          <Description>**PEER REVIEWED**</Description>
          <Reference>Organization for Economic Cooperation and Development; Screening Information Data Set for  Nicotinic Acid, CAS # 59-67-6 p.35 (1995). Available from, as of June 19, 2018: http://www.inchem.org/pages/sids.html</Reference>
          <Value>
            <StringWithMarkup>
              <String>LC50; Species: Salmo trutta (Brown trout); Conditions: static; Concentration: 520 mg/L for 96 hr /Technical material, 99.8%/</String>
            </StringWithMarkup>
          </Value>
        </Information>
      </Section>
      <Section>
        <TOCHeading>Ongoing Test Status</TOCHeading>
        <Description>Ongoing Test Status</Description>
        <Information>
          <ReferenceNumber>32</ReferenceNumber>
          <Reference>HPS2-THRIVE Collaborative Group et al; N Engl J Med 371 (3): 203-12 (2014)</Reference>
          <Value>
            <StringWithMarkup>
              <String>Patients with evidence of vascular disease are at increased risk for subsequent vascular events despite effective use of statins to lower the low-density lipoprotein (LDL) cholesterol level. Niacin lowers the LDL cholesterol level and raises the high-density lipoprotein (HDL) cholesterol level, but its clinical efficacy and safety are uncertain. After a prerandomization run-in phase to standardize the background statin-based LDL cholesterol-lowering therapy and to establish participants&apos; ability to take extended-release niacin without clinically significant adverse effects, we randomly assigned 25,673 adults with vascular disease to receive 2 g of extended-release niacin and 40 mg of laropiprant or a matching placebo daily. The primary outcome was the first major vascular event (nonfatal myocardial infarction, death from coronary causes, stroke, or arterial revascularization). During a median follow-up period of 3.9 years, participants who were assigned to extended-release niacin-laropiprant had an LDL cholesterol level that was an average of 10 mg per deciliter (0.25 mmol per liter as measured in the central laboratory) lower and an HDL cholesterol level that was an average of 6 mg per deciliter (0.16 mmol per liter) higher than the levels in those assigned to placebo. Assignment to niacin-laropiprant, as compared with assignment to placebo, had no significant effect on the incidence of major vascular events (13.2% and 13.7% of participants with an event, respectively; rate ratio, 0.96; 95% confidence interval [CI], 0.90 to 1.03; P=0.29). Niacin-laropiprant was associated with an increased incidence of disturbances in diabetes control that were considered to be serious (absolute excess as compared with placebo, 3.7 percentage points; P&lt;0.001) and with an increased incidence of diabetes diagnoses (absolute excess, 1.3 percentage points; P&lt;0.001), as well as increases in serious adverse events associated with the gastrointestinal system (absolute excess, 1.0 percentage point; P&lt;0.001), musculoskeletal system (absolute excess, 0.7 percentage points; P&lt;0.001), skin (absolute excess, 0.3 percentage points; P=0.003), and unexpectedly, infection (absolute excess, 1.4 percentage points; P&lt;0.001) and bleeding (absolute excess, 0.7 percentage points; P&lt;0.001). Among participants with atherosclerotic vascular disease, the addition of extended-release niacin-laropiprant to statin-based LDL cholesterol-lowering therapy did not significantly reduce the risk of major vascular events but did increase the risk of serious adverse events. PubMed Abstract</String>
              <Markup>
                <Start>2567</Start>
                <Length>15</Length>
                <URL>http://www.ncbi.nlm.nih.gov/pubmed/25014686?dopt=Abstract</URL>
              </Markup>
              <Markup>
                <Start>172</Start>
                <Length>11</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/cholesterol</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-5997</Extra>
              </Markup>
              <Markup>
                <Start>191</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/Niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>213</Start>
                <Length>11</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/cholesterol</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-5997</Extra>
              </Markup>
              <Markup>
                <Start>277</Start>
                <Length>11</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/cholesterol</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-5997</Extra>
              </Markup>
              <Markup>
                <Start>433</Start>
                <Length>11</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/cholesterol</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-5997</Extra>
              </Markup>
              <Markup>
                <Start>526</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>673</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>693</Start>
                <Length>11</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/laropiprant</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-9867642</Extra>
              </Markup>
              <Markup>
                <Start>988</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>995</Start>
                <Length>11</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/laropiprant</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-9867642</Extra>
              </Markup>
              <Markup>
                <Start>1018</Start>
                <Length>11</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/cholesterol</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-5997</Extra>
              </Markup>
              <Markup>
                <Start>1156</Start>
                <Length>11</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/cholesterol</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-5997</Extra>
              </Markup>
              <Markup>
                <Start>1305</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>1312</Start>
                <Length>11</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/laropiprant</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-9867642</Extra>
              </Markup>
              <Markup>
                <Start>1566</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/Niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>1573</Start>
                <Length>11</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/laropiprant</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-9867642</Extra>
              </Markup>
            </StringWithMarkup>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>32</ReferenceNumber>
          <Reference>USEPA; ICSS Dashboard Application; Available from, as of August 9, 2018: http://actor.epa.gov/dashboard/</Reference>
          <Value>
            <StringWithMarkup>
              <String>EPA has released the Interactive Chemical Safety for Sustainability (iCSS) Dashboard. The iCSS Dashboard provides an interactive tool to explore rapid, automated (or in vitro high-throughput) chemical screening data generated by the Toxicity Forecaster (ToxCast) project and the federal Toxicity Testing in the 21st century (Tox21) collaboration. /The title compound was tested by ToxCast and/or Tox21 assays/</String>
            </StringWithMarkup>
          </Value>
        </Information>
      </Section>
      <Section>
        <TOCHeading>Populations at Special Risk</TOCHeading>
        <Description>Populations at Special Risk</Description>
        <Information>
          <ReferenceNumber>32</ReferenceNumber>
          <Description>**PEER REVIEWED**</Description>
          <Reference>American Society of Health-System Pharmacists 2017; Drug Information 2017. Bethesda, MD. 2017, p. 1937</Reference>
          <Value>
            <StringWithMarkup>
              <String>Niacin, alone or in fixed combination with lovastatin, should be used with caution in patients with renal or hepatic impairment. In addition, the drug also should be used with caution in patients who consume substantial amounts of alcohol and/or who have a history of liver disease; such patients should be closely monitored. Use of niacin is contraindicated in patients with active liver disease or unexplained, persistent increases in serum aminotransferase concentrations.</String>
              <Markup>
                <Start>0</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/Niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>43</Start>
                <Length>10</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/lovastatin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-53232</Extra>
              </Markup>
              <Markup>
                <Start>333</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
            </StringWithMarkup>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>32</ReferenceNumber>
          <Description>**PEER REVIEWED**</Description>
          <Reference>American Society of Health-System Pharmacists 2017; Drug Information 2017. Bethesda, MD. 2017, p. 1939</Reference>
          <Value>
            <StringWithMarkup>
              <String>Decreased glucose tolerance has been reported in patients receiving niacin in controlled clinical trials. Therefore, the manufacturers and many clinicians suggest that patients with (or those at risk of developing) diabetes mellitus be observed closely. The ACC/AHA cholesterol management guideline recommends that fasting blood glucose concentrations or glycosylated hemoglobin (hemoglobin A1c, HbA1c) be obtained before initiation of therapy, following an increase in niacin dosage, and periodically (e.g., every 6 months) thereafter. If niacin is used in diabetic or potentially diabetic patients, dosages of niacin and/or antidiabetic agents should be adjusted appropriately. Niacin should be discontinued if hyperglycemia persists.</String>
              <Markup>
                <Start>10</Start>
                <Length>7</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/glucose</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-5793</Extra>
              </Markup>
              <Markup>
                <Start>68</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>266</Start>
                <Length>11</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/cholesterol</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-5997</Extra>
              </Markup>
              <Markup>
                <Start>329</Start>
                <Length>7</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/glucose</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-5793</Extra>
              </Markup>
              <Markup>
                <Start>470</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>540</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>612</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>680</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/Niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
            </StringWithMarkup>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>32</ReferenceNumber>
          <Description>**PEER REVIEWED**</Description>
          <Reference>American Society of Health-System Pharmacists 2017; Drug Information 2017. Bethesda, MD. 2017, p. 1939</Reference>
          <Value>
            <StringWithMarkup>
              <String>Since data in patients with renal or hepatic impairment currently are lacking, the manufacturers state that niacin should be used with caution in these patients.</String>
              <Markup>
                <Start>108</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
            </StringWithMarkup>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>32</ReferenceNumber>
          <Description>**PEER REVIEWED**</Description>
          <Reference>American Society of Health-System Pharmacists 2017; Drug Information 2017. Bethesda, MD. 2017, p. 1939</Reference>
          <Value>
            <StringWithMarkup>
              <String>Niacin should be used with caution in patients with unstable angina, acute myocardial infarction (MI), or coronary heart disease (CHD), particularly when these patients also are receiving vasoactive drugs such as nitrates, calcium-channel blockers, or adrenergic blocking agents.</String>
              <Markup>
                <Start>0</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/Niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>223</Start>
                <Length>7</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/element/Calcium</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>Element-Calcium</Extra>
              </Markup>
            </StringWithMarkup>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>32</ReferenceNumber>
          <Description>**PEER REVIEWED**</Description>
          <Reference>American Society of Health-System Pharmacists 2017; Drug Information 2017. Bethesda, MD. 2017, p. 1939</Reference>
          <Value>
            <StringWithMarkup>
              <String>Because hyperuricemia has been reported with niacin therapy, the drug should be used with caution in patients predisposed to gout.</String>
              <Markup>
                <Start>45</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
            </StringWithMarkup>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>32</ReferenceNumber>
          <Description>**PEER REVIEWED**</Description>
          <Reference>American Society of Health-System Pharmacists 2017; Drug Information 2017. Bethesda, MD. 2017, p. 1940</Reference>
          <Value>
            <StringWithMarkup>
              <String>Because the risk of myopathy appears to be increased among Chinese versus non-Chinese patients receiving simvastatin (40 mg daily) concomitantly with preparations containing antilipemic dosages of niacin, the manufacturer of simvastatin states that caution is advised when Chinese patients receive simvastatin dosages exceeding 20 mg daily concomitantly with preparations containing antilipemic dosages of niacin; concomitant use of simvastatin 80 mg daily with preparations containing antilipemic dosages of niacin should be avoided in these patients.</String>
              <Markup>
                <Start>105</Start>
                <Length>11</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/simvastatin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-54454</Extra>
              </Markup>
              <Markup>
                <Start>197</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>225</Start>
                <Length>11</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/simvastatin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-54454</Extra>
              </Markup>
              <Markup>
                <Start>298</Start>
                <Length>11</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/simvastatin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-54454</Extra>
              </Markup>
              <Markup>
                <Start>406</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>433</Start>
                <Length>11</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/simvastatin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-54454</Extra>
              </Markup>
              <Markup>
                <Start>509</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
            </StringWithMarkup>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>32</ReferenceNumber>
          <Description>**PEER REVIEWED**</Description>
          <Reference>American Society of Health-System Pharmacists 2017; Drug Information 2017. Bethesda, MD. 2017</Reference>
          <Value>
            <StringWithMarkup>
              <String>Large doses of niacin should be used with caution in patients with coronary artery disease, since an increased incidence of atrial and other cardiac arrhythmias has been reported in one study in patients who received the drug to lower serum lipid concentrations.</String>
              <Markup>
                <Start>15</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
            </StringWithMarkup>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>32</ReferenceNumber>
          <Description>**PEER REVIEWED**</Description>
          <Reference>American Society of Health-System Pharmacists 2017; Drug Information 2017. Bethesda, MD. 2017</Reference>
          <Value>
            <StringWithMarkup>
              <String>Large doses of niacin or niacinamide should be administered with caution to patients with gallbladder disease or a history of jaundice or liver disease, diabetes mellitus, gout, peptic ulcer, or allergy.  Niacin and niacinamide are contraindicated in patients with liver disease, active peptic ulcer, or hypersensitivity to the drugs. Niacin is also contraindicated in patients with arterial hemorrhaging or severe hypotension.</String>
              <Markup>
                <Start>15</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>25</Start>
                <Length>11</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacinamide</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-936</Extra>
              </Markup>
              <Markup>
                <Start>205</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/Niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>216</Start>
                <Length>11</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacinamide</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-936</Extra>
              </Markup>
              <Markup>
                <Start>335</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/Niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
            </StringWithMarkup>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>32</ReferenceNumber>
          <Description>**PEER REVIEWED**</Description>
          <Reference>Berger GE et al; PLoS One 11 (2): e0148429 (2016)</Reference>
          <Value>
            <StringWithMarkup>
              <String>Most studies provide evidence that the skin flush response to nicotinic acid (niacin) stimulation is impaired in schizophrenia. However, only little is known about niacin sensitivity in the ultra-high risk (UHR) phase of psychotic disorders. We compared visual ratings of niacin sensitivity between adolescents at UHR for psychosis according to the one year transition outcome (UHR-T n = 11; UHR-NT n = 55) with healthy controls (HC n = 25) and first episode schizophrenia patients (FEP n = 25) treated with atypical antipsychotics. Contrary to our hypothesis niacin sensitivity of the entire UHR group was not attenuated, but significantly increased compared to the HC group, whereas no difference could be found between the UHR-T and UHR-NT groups. As expected, niacin sensitivity of FEP was attenuated compared to HC group. In UHR individuals niacin sensitivity was inversely correlated with omega-6 and -9 fatty acids (FA), but positively correlated with phospholipase A2 (inPLA2) activity, a marker of membrane lipid repair/remodeling. Increased niacin sensitivity in UHR states likely indicates an impaired balance of eicosanoids and omega-6/-9 FA at a membrane level. Our findings suggest that the emergence of psychosis is associated with an increased mobilization of eicosanoids prior to the transition to psychosis possibly reflecting a &quot;pro-inflammatory state&quot;, whereas thereafter eicosanoid mobilization seems to be attenuated. Potential treatment implications for the UHR state should be further investigated. PubMed Abstract Full text: PMC4764507</String>
              <Markup>
                <Start>1523</Start>
                <Length>15</Length>
                <URL>http://www.ncbi.nlm.nih.gov/pubmed/26894921?dopt=Abstract</URL>
              </Markup>
              <Markup>
                <Start>1550</Start>
                <Length>10</Length>
                <URL>https://www.ncbi.nlm.nih.gov/pmc/?term=PMC4764507</URL>
              </Markup>
              <Markup>
                <Start>62</Start>
                <Length>14</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/nicotinic%20acid</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>78</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>164</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>272</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>560</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>764</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>846</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>1051</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
            </StringWithMarkup>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>32</ReferenceNumber>
          <Description>**PEER REVIEWED**</Description>
          <Reference>Garg A, Grundy SM; JAMA 264 (Aug 8): 723-26 (1990)</Reference>
          <Value>
            <StringWithMarkup>
              <String>... Niacin must be used with caution in patients with non-insulin dependent diabetes mellitus with dyslipidemia. PubMed Abstract</String>
              <Markup>
                <Start>113</Start>
                <Length>15</Length>
                <URL>http://www.ncbi.nlm.nih.gov/pubmed/2374275?dopt=Abstract</URL>
              </Markup>
              <Markup>
                <Start>4</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/Niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
            </StringWithMarkup>
          </Value>
        </Information>
      </Section>
    </Section>
    <Section>
      <TOCHeading>Ecological Information</TOCHeading>
      <Description>Ecological Information</Description>
      <Section>
        <TOCHeading>ICSC Environmental Data</TOCHeading>
        <Description>ICSC Environmental Data</Description>
        <Information>
          <ReferenceNumber>34</ReferenceNumber>
          <Name>ICSC Environmental Data</Name>
          <Value>
            <StringWithMarkup>
              <String>The substance is harmful to aquatic organisms.</String>
            </StringWithMarkup>
          </Value>
        </Information>
      </Section>
      <Section>
        <TOCHeading>Environmental Fate/Exposure Summary</TOCHeading>
        <Description>Environmental Fate/Exposure Summary</Description>
        <Information>
          <ReferenceNumber>32</ReferenceNumber>
          <Description>**PEER REVIEWED**</Description>
          <Value>
            <StringWithMarkup>
              <String>Nicotinic acid&apos;s production and use as a chemical intermediate, in feeds and enriched flours, dietary supplement, medication and as an electroplating bath ingredient may result in its release to the environment through various waste streams. Minute amounts of nicotinic acid are present in all living cells; greater amounts are found in liver, adrenal glands, milk, alfalfa, legumes and corn. If released to air, an estimated vapor pressure of 9.4X10-5 mm Hg at 25 deg C indicates nicotinic acid will exist in both the vapor and particulate phases in the atmosphere. Vapor-phase nicotinic acid will be degraded in the atmosphere by reaction with photochemically-produced hydroxyl radicals; the half-life for this reaction in air is estimated to be 22 days. Particulate-phase nicotinic acid will be removed from the atmosphere by wet or dry deposition. Nicotinic acid absorbs UV light at wavelength 263 nm and, therefore, is not expected to be susceptible to direct photolysis since sunlight consists of wavelengths above 290 nm. If released to soil, nicotinic acid is expected to have very high mobility based upon an estimated Koc of 8. The pKa of nicotinic acid is 4.75, indicating that this compound will exist almost entirely in the anion form in the environment and anions generally do not adsorb more strongly to soils containing organic carbon and clay than their neutral counterparts. In aqueous, aerobic soil suspensions, nicotinic acid was completely degraded after 2 to 4 days of incubation, suggesting that biodegadation may be an important environmental fate process in soil and water. If released into water, nicotinic acid is not expected to adsorb to suspended solids and sediment based upon the estimated Koc. A pKa of 4.75 indicates nicotinic acid will exist almost entirely in the anion form at pH values of 5 to 9 and, therefore, volatilization from water surfaces is not expected to be an important fate process. An estimated BCF of 3 suggests the potential for bioconcentration in aquatic organisms is low. Hydrolysis is not expected to be an important environmental fate process since this compound lacks functional groups that hydrolyze under environmental conditions. Occupational exposure to nicotinic acid may occur through inhalation and dermal contact with this compound at workplaces where nicotinic acid is produced or used. Monitoring data indicate that the general population may be exposed to nicotinic acid via ingestion of food and smoking cigarettes. Exposure to nicotinic acid will also occur by direct medical treatment. (SRC)</String>
              <Markup>
                <Start>0</Start>
                <Length>14</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/Nicotinic%20acid</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>260</Start>
                <Length>14</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/nicotinic%20acid</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>481</Start>
                <Length>14</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/nicotinic%20acid</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>579</Start>
                <Length>14</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/nicotinic%20acid</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>671</Start>
                <Length>8</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/hydroxyl</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-961</Extra>
              </Markup>
              <Markup>
                <Start>775</Start>
                <Length>14</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/nicotinic%20acid</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>852</Start>
                <Length>14</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/Nicotinic%20acid</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>1050</Start>
                <Length>14</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/nicotinic%20acid</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>1149</Start>
                <Length>14</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/nicotinic%20acid</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>1344</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/element/Carbon</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>Element-Carbon</Extra>
              </Markup>
              <Markup>
                <Start>1431</Start>
                <Length>14</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/nicotinic%20acid</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>1592</Start>
                <Length>5</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/water</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-962</Extra>
              </Markup>
              <Markup>
                <Start>1616</Start>
                <Length>5</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/water</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-962</Extra>
              </Markup>
              <Markup>
                <Start>1623</Start>
                <Length>14</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/nicotinic%20acid</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>1751</Start>
                <Length>14</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/nicotinic%20acid</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>1870</Start>
                <Length>5</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/water</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-962</Extra>
              </Markup>
              <Markup>
                <Start>2218</Start>
                <Length>14</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/nicotinic%20acid</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>2320</Start>
                <Length>14</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/nicotinic%20acid</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>2427</Start>
                <Length>14</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/nicotinic%20acid</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>2500</Start>
                <Length>14</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/nicotinic%20acid</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
            </StringWithMarkup>
          </Value>
        </Information>
      </Section>
      <Section>
        <TOCHeading>Natural Pollution Sources</TOCHeading>
        <Description>Natural Pollution Sources</Description>
        <Information>
          <ReferenceNumber>32</ReferenceNumber>
          <Description>**PEER REVIEWED**</Description>
          <Reference>(1) O&apos;Neil MJ, ed; The Merck Index. 15th ed., Cambridge, UK: Royal Society of Chemistry, p. 1214 (2013) (2) Larranaga MD et al, eds; Hawley&apos;s Condensed Chemical Dictionary 16th ed., Hoboken, NJ: John Wiley &amp; Sons, Inc., p. 966 (2016) (3) Dr. Duke&apos;s Phytochemical and Ethnobotanical Databases. Nicotinic Acid. Available from, as of June 18, 2018: https://phytochem.nal.usda.gov/phytochem/search</Reference>
          <Value>
            <StringWithMarkup>
              <String>Nicotinic acid is widely distributed in nature and is the precursor to coenzymes NAD (nicotinamide adenine dinucleotide) and NADP (nicotinamide adenine dinucleotide phosphate)(1). An antipellagra vitamin, it is essential to many animals for growth and health. In humans, niacin is believed necessary, along with other vitamins, for the prevention and cure of pellagra. It functions in protein and carbohydrate metabolism. As a component of two important enzymes, coenzymes I and II, it functions in glycolysis and tissue respiration(2). The compound occurs naturally in many plants(3).</String>
              <Markup>
                <Start>0</Start>
                <Length>14</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/Nicotinic%20acid</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>81</Start>
                <Length>3</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/NAD</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-5893</Extra>
              </Markup>
              <Markup>
                <Start>86</Start>
                <Length>33</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/nicotinamide%20adenine%20dinucleotide</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-15938971</Extra>
              </Markup>
              <Markup>
                <Start>125</Start>
                <Length>4</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/NADP</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-2734411</Extra>
              </Markup>
              <Markup>
                <Start>131</Start>
                <Length>43</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/nicotinamide%20adenine%20dinucleotide%20phosphate</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-42609791</Extra>
              </Markup>
              <Markup>
                <Start>183</Start>
                <Length>20</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/antipellagra%20vitamin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>271</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
            </StringWithMarkup>
          </Value>
        </Information>
      </Section>
      <Section>
        <TOCHeading>Artificial Pollution Sources</TOCHeading>
        <Description>Artificial Sources</Description>
        <Information>
          <ReferenceNumber>32</ReferenceNumber>
          <Description>**PEER REVIEWED**</Description>
          <Reference>(1) Larranaga MD et al, eds; Hawley&apos;s Condensed Chemical Dictionary 16th ed., Hoboken, NJ: John Wiley &amp; Sons, Inc., p. 966 (2016) (2) van Arnum S; Niacin, Nicotinamide and Nicotinic Acid. Kirk-Othmer Encyclopedia of Chemical Technology. (1999-2018). New York, NY: John Wiley &amp; Sons. Online Posting Date: 4 Dec 2000</Reference>
          <Value>
            <StringWithMarkup>
              <String>Nicotinic acid&apos;s production and use as a chemical intermediate, in feeds and enriched flours, dietary supplement, medication(1,2) and as an electroplating bath ingredient(2) may result in its release to the environment through various waste streams(SRC).</String>
              <Markup>
                <Start>0</Start>
                <Length>14</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/Nicotinic%20acid</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
            </StringWithMarkup>
          </Value>
        </Information>
      </Section>
      <Section>
        <TOCHeading>Environmental Fate</TOCHeading>
        <Description>Environmental Fate</Description>
        <Information>
          <ReferenceNumber>32</ReferenceNumber>
          <Description>**PEER REVIEWED**</Description>
          <Reference>(1) Swann RL et al; Res Rev 85: 17-28 (1983) (2) US EPA; Estimation Program Interface (EPI) Suite. Ver. 4.11. Nov, 2012. Available from, as of June 18, 2018: http://www2.epa.gov/tsca-screening-tools (3) Dean JA; Lange&apos;s Handbook of Chemistry 13th ed. NY: McGraw-Hill Book Co. p. 5-39 (1985) (4) Doucette WJ; pp. 141-188 in Handbook of Property Estimation Methods for Chemicals. Boethling RS, Mackay D, eds. Boca Raton, FL: Lewis Publ (2000) (5) Naik MN et al; Soil Biol Biochem 4: 313-23 (1972)</Reference>
          <Value>
            <StringWithMarkup>
              <String>TERRESTRIAL FATE: Based on a classification scheme(1), an estimated Koc value of 8(SRC), determined from a structure estimation method(2), indicates that nicotinic acid is expected to have very high mobility in soil(SRC). The pKa of nicotinic acid is 4.75(3), indicating that this compound will exist almost entirely in the anion form in the environment and anions generally do not adsorb more strongly to soils containing organic carbon and clay than their neutral counterparts(4). Nicotinic acid is not expected to volatilize from dry soil surfaces(SRC) based upon an estimated vapor pressure of 9.4X10-5 mm Hg at 25 deg C(SRC), determined from a fragment constant method(2). In aqueous, aerobic soil suspensions, nicotinic acid was completely degraded after 2 to 4 days of incubation(5), suggesting that biodegradation may be an important environmental fate process in soil(SRC).</String>
              <Markup>
                <Start>154</Start>
                <Length>14</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/nicotinic%20acid</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>233</Start>
                <Length>14</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/nicotinic%20acid</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>431</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/element/Carbon</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>Element-Carbon</Extra>
              </Markup>
              <Markup>
                <Start>483</Start>
                <Length>14</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/Nicotinic%20acid</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>716</Start>
                <Length>14</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/nicotinic%20acid</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
            </StringWithMarkup>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>32</ReferenceNumber>
          <Description>**PEER REVIEWED**</Description>
          <Reference>(1) Swann RL et al; Res Rev 85: 17-28 (1983) (2) US EPA; Estimation Program Interface (EPI) Suite. Ver. 4.11. Nov, 2012. Available from, as of June 18, 2018: http://www2.epa.gov/tsca-screening-tools (3) Dean JA; Lange&apos;s Handbook of Chemistry 13th ed. NY: McGraw-Hill Book Co. p. 5-39 (1985) (4) Franke C et al; Chemosphere 29: 1501-14 (1994) (5) Sangster J; LOGKOW Databank. Sangster Res. Lab., Montreal Quebec, Canada (1993) (6) Naik MN et al; Soil Biol Biochem 4: 313-23 (1972)</Reference>
          <Value>
            <StringWithMarkup>
              <String>AQUATIC FATE: Based on a classification scheme(1), an estimated Koc value of 8(SRC), determined from a structure estimation method(2), indicates that nicotinic acid is not expected to adsorb to suspended solids and sediment(SRC). A pKa of 4.75(3) indicates nicotinic acid will exist almost entirely in the anion form at pH values of 5 to 9 and, therefore, volatilization from water surfaces is not expected to be an important fate process(SRC). According to a classification scheme(4), an estimated BCF of 3(SRC), from its log Kow of 0.36(5) and a regression-derived equation(2), suggests the potential for bioconcentration in aquatic organisms is low(SRC).  In aqueous, aerobic soil suspensions, nicotinic acid was completely degraded after 2 to 4 days of incubation(6), suggesting that biodegradation may be an important environmental fate process in water(SRC).</String>
              <Markup>
                <Start>150</Start>
                <Length>14</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/nicotinic%20acid</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>257</Start>
                <Length>14</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/nicotinic%20acid</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>376</Start>
                <Length>5</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/water</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-962</Extra>
              </Markup>
              <Markup>
                <Start>697</Start>
                <Length>14</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/nicotinic%20acid</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>853</Start>
                <Length>5</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/water</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-962</Extra>
              </Markup>
            </StringWithMarkup>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>32</ReferenceNumber>
          <Description>**PEER REVIEWED**</Description>
          <Reference>(1) Bidleman TF; Environ Sci Technol 22: 361-367 (1988) (2) US EPA; Estimation Program Interface (EPI) Suite. Ver. 4.11. Nov, 2012. Available from, as of June 18, 2018: http://www2.epa.gov/tsca-screening-tools (3) Atkinson R; Environ Toxicol Chem 7: 435-62 (1988) (4) O&apos;Neil MJ, ed; The Merck Index. Cambridge, UK: Royal Society of Chemistry, p. 1214 (2013)</Reference>
          <Value>
            <StringWithMarkup>
              <String>ATMOSPHERIC FATE: According to a model of gas/particle partitioning of semivolatile organic compounds in the atmosphere(1), nicotinic acid, which has an estimated vapor pressure of 9.4X10-5 mm Hg at 25 deg C(SRC), determined from a fragment constant method(2), will exist in both the vapor and particulate phases in the ambient atmosphere. Vapor-phase nicotinic acid is degraded in the atmosphere by reaction with photochemically-produced hydroxyl radicals(SRC); the half-life for this reaction in air is estimated to be 22 days(SRC), calculated from its rate constant of 1.72X10-13 cu cm/molecule-sec at 25 deg C(3). Particulate-phase nicotinic acid may be removed from the air by wet and dry deposition(SRC). Nicotinic acid absorbs UV light at wavelength 263 nm(4) and, therefore, is not expected to be susceptible to direct photolysis since sunlight consists of wavelengths above 290 nm(SRC).</String>
              <Markup>
                <Start>124</Start>
                <Length>14</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/nicotinic%20acid</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>352</Start>
                <Length>14</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/nicotinic%20acid</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>439</Start>
                <Length>8</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/hydroxyl</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-961</Extra>
              </Markup>
              <Markup>
                <Start>636</Start>
                <Length>14</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/nicotinic%20acid</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>711</Start>
                <Length>14</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/Nicotinic%20acid</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
            </StringWithMarkup>
          </Value>
        </Information>
      </Section>
      <Section>
        <TOCHeading>Environmental Biodegradation</TOCHeading>
        <Description>Environmental Biodegradation</Description>
        <Information>
          <ReferenceNumber>32</ReferenceNumber>
          <Description>**PEER REVIEWED**</Description>
          <Reference>(1) Naik MN et al; Soil Biol Biochem 4: 313-23 (1972) (2) Sims GK, Sommers LE; J Environ Qual 14: 580-4 (1985) (3) Pitter P, Simanova J; Sb Vys Sk Chem-Technol Praze, (Oddil) F: Technol Vody Prostredi 22: 93-113 (1978)</Reference>
          <Value>
            <StringWithMarkup>
              <String>AEROBIC: In aqueous, aerobic soil suspensions containing mineral salts and a fertile garden soil inoculum, nicotinic acid was completely degraded after 2 to 4 days of incubation(1). In aqueous, aerobic soil suspensions containing a silt loam soil inoculum, nicotinic acid was degraded 16.1% after 1 day, 99.9% after 2 days, and 100% after 4 days of incubation(2). Nicotinic acid was readily biodegraded in screening tests using an activated sludge inoculum(3).</String>
              <Markup>
                <Start>107</Start>
                <Length>14</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/nicotinic%20acid</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>257</Start>
                <Length>14</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/nicotinic%20acid</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>364</Start>
                <Length>14</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/Nicotinic%20acid</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
            </StringWithMarkup>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>32</ReferenceNumber>
          <Description>**PEER REVIEWED**</Description>
          <Reference>(1) Naik MN et al; Soil Biol Biochem 4: 313-23 (1972) (2) Adrian NR, Suflita JM; Environ Toxicol Chem 13: 1551-57 (1994)</Reference>
          <Value>
            <StringWithMarkup>
              <String>ANAEROBIC: In aqueous, anaerobic soil suspensions containing mineral salts and a fertile garden soil inoculum, nicotinic acid was completely degraded after 8 to 17 days of incubation(1). In anaerobic aquifer slurries, nicotinic acid was completely biodegraded after incubation for one year reaching 74% of the potential methane production from this process(2).</String>
              <Markup>
                <Start>111</Start>
                <Length>14</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/nicotinic%20acid</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>218</Start>
                <Length>14</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/nicotinic%20acid</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>320</Start>
                <Length>7</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/methane</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-297</Extra>
              </Markup>
            </StringWithMarkup>
          </Value>
        </Information>
      </Section>
      <Section>
        <TOCHeading>Environmental Abiotic Degradation</TOCHeading>
        <Description>Environmental Abiotic Degradation</Description>
        <Information>
          <ReferenceNumber>32</ReferenceNumber>
          <Description>**PEER REVIEWED**</Description>
          <Reference>(1) Atkinson R; Environ Toxicol Chem 7: 435-62 (1988) (2) Meylan WM, Howard PH; Chemosphere 26: 2293-99 (1993) (3) Lyman WJ et al; Handbook of Chemical Property Estimation Methods. Washington, DC: Amer Chem Soc pp. 7-4, 7-5, 8-12 (1990) (4) Buxton GV et al; J Phys Chem Ref Data 17: 513-882 (1988) (5) Mill T et al; Sci 207: 886-7 (1980) (6) Rajasekhar N et al; Bull Environ Contam Toxicol 65: 375-82 (2000) (7) O&apos;Neil MJ, ed; The Merck Index. Cambridge, UK: Royal Society of Chemistry, p. 1214 (2013)</Reference>
          <Value>
            <StringWithMarkup>
              <String>The rate constant for the vapor-phase reaction of nicotinic acid with photochemically-produced hydroxyl radicals has been estimated as 1.7X10-13 cu cm/molecule-sec at 25 deg C(2). This corresponds to an atmospheric half-life of about 22 days at an atmospheric concentration of 5X10+5 hydroxyl radicals per cu cm(1). Nicotinic acid is not expected to undergo hydrolysis in the environment due to the lack of functional groups that hydrolyze under environmental conditions(3). The rate constant for the reaction between photochemically produced hydroxyl radicals in water and nicotinic acid is 2.6X10+8 L/mole-sec(4). Assuming that the concentration of hydroxyl radicals in brightly sunlit natural water is 1X10-17 M(5), the half-life would be about 8.45 years in continuous (24 hr/day) sunlight(SRC). Nicotinic acid absorbs UV light at wavelength 263 nm(6,7) and, therefore, is not expected to be susceptible to direct photolysis since sunlight consists of wavelengths above 290 nm(SRC).</String>
              <Markup>
                <Start>50</Start>
                <Length>14</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/nicotinic%20acid</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>95</Start>
                <Length>8</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/hydroxyl</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-961</Extra>
              </Markup>
              <Markup>
                <Start>284</Start>
                <Length>8</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/hydroxyl</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-961</Extra>
              </Markup>
              <Markup>
                <Start>316</Start>
                <Length>14</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/Nicotinic%20acid</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>543</Start>
                <Length>8</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/hydroxyl</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-961</Extra>
              </Markup>
              <Markup>
                <Start>564</Start>
                <Length>5</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/water</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-962</Extra>
              </Markup>
              <Markup>
                <Start>574</Start>
                <Length>14</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/nicotinic%20acid</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>651</Start>
                <Length>8</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/hydroxyl</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-961</Extra>
              </Markup>
              <Markup>
                <Start>696</Start>
                <Length>5</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/water</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-962</Extra>
              </Markup>
              <Markup>
                <Start>800</Start>
                <Length>14</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/Nicotinic%20acid</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
            </StringWithMarkup>
          </Value>
        </Information>
      </Section>
      <Section>
        <TOCHeading>Environmental Bioconcentration</TOCHeading>
        <Description>Environmental Bioconcentration</Description>
        <Information>
          <ReferenceNumber>32</ReferenceNumber>
          <Description>**PEER REVIEWED**</Description>
          <Reference>(1) Sangster J; LOGKOW Databank. Sangster Res. Lab., Montreal Quebec, Canada (1993) (2) US EPA; Estimation Program Interface (EPI) Suite. Ver. 4.11. Nov, 2012. Available from, as of June 18, 2018: http://www2.epa.gov/tsca-screening-tools (3) Franke C et al; Chemosphere 29: 1501-14 (1994)</Reference>
          <Value>
            <StringWithMarkup>
              <String>An estimated BCF of 3 was calculated in fish for nicotinic acid(SRC), using a log Kow of 0.36(1) and a regression-derived equation(2). According to a classification scheme(3), this BCF suggests the potential for bioconcentration in aquatic organisms is low(SRC).</String>
              <Markup>
                <Start>49</Start>
                <Length>14</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/nicotinic%20acid</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
            </StringWithMarkup>
          </Value>
        </Information>
      </Section>
      <Section>
        <TOCHeading>Soil Adsorption/Mobility</TOCHeading>
        <Description>Soil Adsorption/Mobility</Description>
        <Information>
          <ReferenceNumber>32</ReferenceNumber>
          <Description>**PEER REVIEWED**</Description>
          <Reference>(1) US EPA; Estimation Program Interface (EPI) Suite. Ver. 4.11. Nov, 2012. Available from, as of June 18, 2018: http://www2.epa.gov/tsca-screening-tools (2) Swann RL et al; Res Rev 85: 17-28 (1983) (3) Dean JA; Lange&apos;s Handbook of Chemistry 13th ed. NY: McGraw-Hill Book Co. p. 5-39 (1985) (4) Doucette WJ; pp. 141-188 in Handbook of Property Estimation Methods for Chemicals. Boethling RS, Mackay D, eds. Boca Raton, FL: Lewis Publ (2000)</Reference>
          <Value>
            <StringWithMarkup>
              <String>Using a structure estimation method based on molecular connectivity indices(1), the Koc of nicotinic acid can be estimated to be 8(SRC). According to a classification scheme(2), this estimated Koc value suggests that nicotinic acid is expected to have very high mobility in soil. The pKa of nicotinic acid is 4.75(3), indicating that this compound will exist almost entirely in the anion form in the environment and anions generally do not adsorb more strongly to soils containing organic carbon and clay than their neutral counterparts(4).</String>
              <Markup>
                <Start>91</Start>
                <Length>14</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/nicotinic%20acid</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>217</Start>
                <Length>14</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/nicotinic%20acid</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>291</Start>
                <Length>14</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/nicotinic%20acid</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>489</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/element/Carbon</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>Element-Carbon</Extra>
              </Markup>
            </StringWithMarkup>
          </Value>
        </Information>
      </Section>
      <Section>
        <TOCHeading>Volatilization from Water/Soil</TOCHeading>
        <Description>Volatilization from Water/Soil</Description>
        <Information>
          <ReferenceNumber>32</ReferenceNumber>
          <Description>**PEER REVIEWED**</Description>
          <Reference>(1) Dean JA; Lange&apos;s Handbook of Chemistry 13th ed. NY: McGraw-Hill Book Co. p. 5-39 (1985) (2) US EPA; Estimation Program Interface (EPI) Suite. Ver. 4.11. Nov, 2012. Available from, as of June 18, 2018: http://www2.epa.gov/tsca-screening-tools</Reference>
          <Value>
            <StringWithMarkup>
              <String>A pKa of 4.75(1) indicates nicotinic acid will exist almost entirely in the anion form at pH values of 5 to 9 and, therefore, volatilization from water surfaces is not expected to be an important fate process(SRC). Nicotinic acid is not expected to volatilize from dry soil surfaces(SRC) based upon a an estimated vapor pressure of 9.4X10-5 mm Hg(SRC), determined from a fragment constant method(2).</String>
              <Markup>
                <Start>27</Start>
                <Length>14</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/nicotinic%20acid</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>146</Start>
                <Length>5</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/water</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-962</Extra>
              </Markup>
              <Markup>
                <Start>215</Start>
                <Length>14</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/Nicotinic%20acid</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
            </StringWithMarkup>
          </Value>
        </Information>
      </Section>
      <Section>
        <TOCHeading>Effluent Concentrations</TOCHeading>
        <Description>Effluent Concentrations</Description>
        <Information>
          <ReferenceNumber>32</ReferenceNumber>
          <Description>**PEER REVIEWED**</Description>
          <Reference>(1) Leenheer JA et al; Environ Sci Technol 16: 714-23 (1982)</Reference>
          <Value>
            <StringWithMarkup>
              <String>Oil-shale process retort water contained nicotinic acid at 0.5 mg/L(1).</String>
              <Markup>
                <Start>25</Start>
                <Length>5</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/water</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-962</Extra>
              </Markup>
              <Markup>
                <Start>41</Start>
                <Length>14</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/nicotinic%20acid</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
            </StringWithMarkup>
          </Value>
        </Information>
      </Section>
      <Section>
        <TOCHeading>Food Survey Values</TOCHeading>
        <Description>Food Survey Values</Description>
        <Information>
          <ReferenceNumber>32</ReferenceNumber>
          <Description>**PEER REVIEWED**</Description>
          <Reference>(1) O&apos;Neil MJ, ed; The Merck Index. 15th ed., Cambridge, UK: Royal Society of Chemistry, p. 1214 (2013) (2) van Arnum S; Niacin, Nicotinamide and Nicotinic Acid. Kirk-Othmer Encyclopedia of Chemical Technology. (1999-2018). New York, NY: John Wiley &amp; Sons. Online Posting Date: 4 Dec 2000 (3) Young CT; Nuts. Kirk-Othmer Encyclopedia of Chemical Technology. (1999-2018). New York, NY: John Wiley &amp; Sons. Online Posting Date: 15 Sept 2007</Reference>
          <Value>
            <StringWithMarkup>
              <String>Substantial amounts of nicotinic acid are found in fish, yeast and ceral grains(1). The compound is especially concentrated in brewer&apos;s yeast, wheat germ and liver(2). The average cup of coffee contains between 1-2 mg nicotinic acid, depending on roasting conditions(2). The nicotinic acid content of several nuts has been reported (in mg/kg) as follows: chestnut, 200; hazel nut, 600; almond, 1600; and sunflower seed, 5000(3).</String>
              <Markup>
                <Start>23</Start>
                <Length>14</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/nicotinic%20acid</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>218</Start>
                <Length>14</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/nicotinic%20acid</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>275</Start>
                <Length>14</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/nicotinic%20acid</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
            </StringWithMarkup>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>32</ReferenceNumber>
          <Description>**PEER REVIEWED**</Description>
          <Reference>(1) van Arnum SD; Niacin, Nicotinamide, and Nicotinic Acid. Kirk-Othmer Encyclopedia of Chemical Technology. (1999-2018). New York, NY: John Wiley &amp; Sons. Online Posting Date: 4 Dec 2000</Reference>
          <Value>
            <StringWithMarkup>
              <String>Nicotinic Acid and Nicotinamide (Vitamin B3) Foodstuff Content(1).  [See Table #5224]</String>
              <Markup>
                <Start>68</Start>
                <Length>17</Length>
                <Type>Inline Table</Type>
                <Extra>Table #5224</Extra>
              </Markup>
              <Markup>
                <Start>0</Start>
                <Length>14</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/Nicotinic%20Acid</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>19</Start>
                <Length>12</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/Nicotinamide</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-936</Extra>
              </Markup>
              <Markup>
                <Start>33</Start>
                <Length>10</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/Vitamin%20B3</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
            </StringWithMarkup>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>32</ReferenceNumber>
          <Name>Table #5224</Name>
          <Value>
            <Binary>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==
</Binary>
            <MimeType>text/csv</MimeType>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>32</ReferenceNumber>
          <Description>**PEER REVIEWED**</Description>
          <Reference>(1) van Arnum SD; Niacin, Nicotinamide, and Nicotinic Acid. Kirk-Othmer Encyclopedia of Chemical Technology. (1999-2018). New York, NY: John Wiley &amp; Sons. Online Posting Date: 4 Dec 2000</Reference>
          <Value>
            <StringWithMarkup>
              <String>Nicotinic Acid and Nicotinamide (Vitamin B3) in Coffee(1).  [See Table #5225]</String>
              <Markup>
                <Start>60</Start>
                <Length>17</Length>
                <Type>Inline Table</Type>
                <Extra>Table #5225</Extra>
              </Markup>
              <Markup>
                <Start>0</Start>
                <Length>14</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/Nicotinic%20Acid</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>19</Start>
                <Length>12</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/Nicotinamide</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-936</Extra>
              </Markup>
              <Markup>
                <Start>33</Start>
                <Length>10</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/Vitamin%20B3</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
            </StringWithMarkup>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>32</ReferenceNumber>
          <Name>Table #5225</Name>
          <Value>
            <Binary>
IkZvb2QgaXRlbSIsIlBvdGVudGlhbCwgbWcva2ciCiJHcmVlbiIsMjAKIk1lZGl1bSByb2FzdGVk
IiwiODAtMTUwIgoiRGFyayBSb2FzdGVkIiwiPD0gNTAwIgo=
</Binary>
            <MimeType>text/csv</MimeType>
          </Value>
        </Information>
      </Section>
      <Section>
        <TOCHeading>Plant Concentrations</TOCHeading>
        <Description>Plant Concentrations</Description>
        <Information>
          <ReferenceNumber>32</ReferenceNumber>
          <Description>**PEER REVIEWED**</Description>
          <Reference>(1) Dr. Duke&apos;s Phytochemical and Ethnobotanical Databases. Nicotinic Acid. Available from, as of June 18, 2018: https://phytochem.nal.usda.gov/phytochem/search</Reference>
          <Value>
            <StringWithMarkup>
              <String>Nicotinic acid occurrence in plants(1). [See Table #5226 - 13 of 33 plants listed]</String>
              <Markup>
                <Start>40</Start>
                <Length>42</Length>
                <Type>Inline Table</Type>
                <Extra>Table #5226 - 13 of 33 plants listed</Extra>
              </Markup>
              <Markup>
                <Start>0</Start>
                <Length>14</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/Nicotinic%20acid</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
            </StringWithMarkup>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>32</ReferenceNumber>
          <Name>Table #5226 - 13 of 33 plants listed</Name>
          <Value>
            <Binary>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</Binary>
            <MimeType>text/csv</MimeType>
          </Value>
        </Information>
      </Section>
      <Section>
        <TOCHeading>Milk Concentrations</TOCHeading>
        <Description>Milk Concentrations</Description>
        <Information>
          <ReferenceNumber>32</ReferenceNumber>
          <Description>**PEER REVIEWED**</Description>
          <Reference>(1) Hall CW; Milk and Milk Products. Kirk-Othmer Encyclopedia of Chemical Technology. (1999-2018). New York, NY: John Wiley &amp; Sons. Online Posting Date: 14 Sept 2007</Reference>
          <Value>
            <StringWithMarkup>
              <String>Nicotinic acid has been reported in the milk of various mammals (in mg/L) as follows: cow, 0.85; goat, 1.87; sheep, 4.27; horse, 0.58; human, 1.47; pig, 8.35; whale, 20.40(1).</String>
              <Markup>
                <Start>0</Start>
                <Length>14</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/Nicotinic%20acid</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
            </StringWithMarkup>
          </Value>
        </Information>
      </Section>
      <Section>
        <TOCHeading>Other Environmental Concentrations</TOCHeading>
        <Description>Other Environmental Concentrations</Description>
        <Information>
          <ReferenceNumber>32</ReferenceNumber>
          <Description>**PEER REVIEWED**</Description>
          <Reference>(1) Rodgman A, Perfetti TA; The Chemical Components of Tobacco and Tobacco Smoke. Boca Raton, FL: CRC Press p. 360 (2009)</Reference>
          <Value>
            <StringWithMarkup>
              <String>Nicotinic acid is a component of tobacco and tobacco smoke(1).</String>
              <Markup>
                <Start>0</Start>
                <Length>14</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/Nicotinic%20acid</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
            </StringWithMarkup>
          </Value>
        </Information>
      </Section>
      <Section>
        <TOCHeading>Probable Routes of Human Exposure</TOCHeading>
        <Description>Probable Routes of Human Exposure</Description>
        <Information>
          <ReferenceNumber>32</ReferenceNumber>
          <Description>**PEER REVIEWED**</Description>
          <Reference>(1) US EPA; Chemical Data Reporting (CDR). Non-confidential 2016 Chemical Data Reporting information on chemical production and use in the United States. Available from, as of Jun 5, 2018: http://www.epa.gov/chemical-data-reporting</Reference>
          <Value>
            <StringWithMarkup>
              <String>According to the 2016 TSCA Inventory Update Reporting data, 2 reporting facilities estimate the number of persons reasonably likely to be exposed during the manufacturing, processing, or use of nicotinic acid in the United States may be as low as 10 workers and as high as 500 workers per plant; the data may be greatly underestimated due to confidential business information (CBI) or unknown values(1).</String>
              <Markup>
                <Start>22</Start>
                <Length>4</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/TSCA</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-110408</Extra>
              </Markup>
              <Markup>
                <Start>194</Start>
                <Length>14</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/nicotinic%20acid</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
            </StringWithMarkup>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>32</ReferenceNumber>
          <Description>**PEER REVIEWED**</Description>
          <Reference>(1) CDC; International Chemical Safety Cards (ICSC) 2012. Atlanta, GA: Centers for Disease Prevention &amp; Control. National Institute for Occupational Safety &amp; Health (NIOSH). Ed Info Div. Available from, as of June 18, 2018: http://www.cdc.gov/niosh/ipcs/default.html</Reference>
          <Value>
            <StringWithMarkup>
              <String>NIOSH (NOES Survey 1981-1983) has statistically estimated that 61,057 workers (26,152 of these are female) are potentially exposed to nicotinic acid in the US(1). Occupational exposure to nicotinic acid may occur through inhalation and dermal contact with this compound at workplaces where nicotinic acid is produced or used(SRC). Monitoring data indicate that the general population may be exposed to nicotinic acid via ingestion of food and smoking cigarettes. Exposure to nicotinic acid will also occur by direct medical treatment(SRC).</String>
              <Markup>
                <Start>134</Start>
                <Length>14</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/nicotinic%20acid</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>188</Start>
                <Length>14</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/nicotinic%20acid</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>290</Start>
                <Length>14</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/nicotinic%20acid</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>402</Start>
                <Length>14</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/nicotinic%20acid</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>475</Start>
                <Length>14</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/nicotinic%20acid</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
            </StringWithMarkup>
          </Value>
        </Information>
      </Section>
      <Section>
        <TOCHeading>Body Burden</TOCHeading>
        <Description>Body Burdens</Description>
        <Information>
          <ReferenceNumber>32</ReferenceNumber>
          <Description>**PEER REVIEWED**</Description>
          <Reference>(1) O&apos;Neil MJ, ed; The Merck Index. 15th ed., Cambridge, UK: Royal Society of Chemistry, p. 1214 (2013) (2) Larranaga MD et al, eds; Hawley&apos;s Condensed Chemical Dictionary 16th ed., Hoboken, NJ: John Wiley &amp; Sons, Inc., p. 966 (2016) (3) Hall CW; Milk and Milk Products. Kirk-Othmer Encyclopedia of Chemical Technology. (1999-2018). New York, NY: John Wiley &amp; Sons. Online Posting Date: 14 Sept 2007</Reference>
          <Value>
            <StringWithMarkup>
              <String>Nicotinic acid is widely distributed in nature and is the precursor to coenzymes NAD (nicotinamide adenine dinucleotide) and NADP (nicotinamide adenine dinucleotide phosphate)(1). An antipellagra vitamin, it is essential to many animals for growth and health. In humans, niacin is believed necessary, along with other vitamins, for the prevention and cure of pellagra. It functions in protein and carbohydrate metabolism. As a component of two important enzymes, coenzymes I and II, it functions in glycolysis and tissue respiration(2). Nicotinic acid has been reported in humans at 1.47 mg/L(3).</String>
              <Markup>
                <Start>0</Start>
                <Length>14</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/Nicotinic%20acid</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>81</Start>
                <Length>3</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/NAD</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-5893</Extra>
              </Markup>
              <Markup>
                <Start>86</Start>
                <Length>33</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/nicotinamide%20adenine%20dinucleotide</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-15938971</Extra>
              </Markup>
              <Markup>
                <Start>125</Start>
                <Length>4</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/NADP</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-2734411</Extra>
              </Markup>
              <Markup>
                <Start>131</Start>
                <Length>43</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/nicotinamide%20adenine%20dinucleotide%20phosphate</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-42609791</Extra>
              </Markup>
              <Markup>
                <Start>183</Start>
                <Length>20</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/antipellagra%20vitamin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>271</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>537</Start>
                <Length>14</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/Nicotinic%20acid</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
            </StringWithMarkup>
          </Value>
        </Information>
      </Section>
    </Section>
  </Section>
  <Section>
    <TOCHeading>Literature</TOCHeading>
    <Description>Literature citation references mainly refers to regular publications such as journal articles, etc.</Description>
    <URL>https://pubchemdocs.ncbi.nlm.nih.gov/literature</URL>
    <Section>
      <TOCHeading>Depositor Provided PubMed Citations</TOCHeading>
      <Description>This section displays a concatenated list of all PubMed records that have been cited by the depositors of all PubChem Substance records that contain the same chemical structure as the compound.</Description>
      <Information>
        <ReferenceNumber>77</ReferenceNumber>
        <Name>Depositor Provided PubMed Citations</Name>
        <URL>https://www.ncbi.nlm.nih.gov/sites/entrez?LinkName=pccompound_pubmed&amp;db=pccompound&amp;cmd=Link&amp;from_uid=938</URL>
        <Value>
          <ExternalTableName>collection=pubmed&amp;pmidsrcs=xref</ExternalTableName>
          <ExternalTableNumRows>3663</ExternalTableNumRows>
        </Value>
      </Information>
    </Section>
    <Section>
      <TOCHeading>NLM Curated PubMed Citations</TOCHeading>
      <Description>The &quot;NLM Curated PubMed Citations&quot; section links to all PubMed records that are tagged with the same MeSH term that has been associated with a particular compound.</Description>
      <Information>
        <ReferenceNumber>77</ReferenceNumber>
        <URL>https://www.ncbi.nlm.nih.gov/sites/entrez?LinkName=pccompound_pubmed_mesh&amp;db=pccompound&amp;cmd=Link&amp;from_uid=938</URL>
        <Value>
          <Boolean>true</Boolean>
        </Value>
      </Information>
    </Section>
    <Section>
      <TOCHeading>Synthesis References</TOCHeading>
      <Description>References that are related to the preparation and synthesis reaction.</Description>
      <Information>
        <ReferenceNumber>17</ReferenceNumber>
        <Name>Synthesis Reference</Name>
        <Value>
          <StringWithMarkup>
            <String>Joseph E. Toomey, Jr., &quot;Electrochemical synthesis of niacin and other N-heterocyclic compounds.&quot; U.S. Patent US5002641, issued 1914.</String>
            <Markup>
              <Start>53</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
          </StringWithMarkup>
        </Value>
      </Information>
      <Information>
        <ReferenceNumber>33</ReferenceNumber>
        <Name>Synthesis References</Name>
        <Value>
          <StringWithMarkup>
            <String>McElvain, S. M.; Goese, M. A. Preparation of nicotinic acid from pyridine. Journal of the American Chemical Society (1941), 63 2283-4.</String>
            <Markup>
              <Start>45</Start>
              <Length>14</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/nicotinic%20acid</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>65</Start>
              <Length>8</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/pyridine</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-1049</Extra>
            </Markup>
          </StringWithMarkup>
        </Value>
      </Information>
    </Section>
    <Section>
      <TOCHeading>General References</TOCHeading>
      <Description>General References</Description>
      <DisplayControls>
        <ListType>Numbered</ListType>
      </DisplayControls>
      <Information>
        <ReferenceNumber>17</ReferenceNumber>
        <Name>General References</Name>
        <Value>
          <StringWithMarkup>
            <String>Gopal E, Fei YJ, Miyauchi S, Zhuang L, Prasad PD, Ganapathy V: Sodium-coupled and electrogenic transport of B-complex vitamin nicotinic acid by slc5a8, a member of the Na/glucose co-transporter gene family. Biochem J. 2005 May 15;388(Pt 1):309-16. [PMID: 15651982]</String>
            <Markup>
              <Start>249</Start>
              <Length>14</Length>
              <URL>https://www.ncbi.nlm.nih.gov/pubmed/15651982</URL>
            </Markup>
            <Markup>
              <Start>63</Start>
              <Length>6</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/element/Sodium</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>Element-Sodium</Extra>
            </Markup>
            <Markup>
              <Start>126</Start>
              <Length>14</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/nicotinic%20acid</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-938</Extra>
            </Markup>
            <Markup>
              <Start>171</Start>
              <Length>7</Length>
              <URL>https://pubchem.ncbi.nlm.nih.gov/compound/glucose</URL>
              <Type>PubChem Internal Link</Type>
              <Extra>CID-5793</Extra>
            </Markup>
          </StringWithMarkup>
        </Value>
      </Information>
    </Section>
    <Section>
      <TOCHeading>Metabolite References</TOCHeading>
      <Description>General metabolite literature references, from the Human Metabolome Database (HMDB) or other sources</Description>
      <Information>
        <ReferenceNumber>33</ReferenceNumber>
        <Name>General References from the Human Metabolome Database</Name>
        <Value>
          <ExternalTableName>hmdb</ExternalTableName>
          <ExternalTableNumRows>17</ExternalTableNumRows>
        </Value>
      </Information>
    </Section>
    <Section>
      <TOCHeading>Springer Nature References</TOCHeading>
      <Description>Literature references related to scientific contents from Springer Nature journals and books. These references have been ranked automatically by an algorithm which calculates the relevance for each substance in a Springer Nature document. It is based on: 1. the TF-IDF, adapted to chemical structures, 2. location information in the text (e.g. title, abstract, keywords), and 3. the document size.  Springer Nature aims to provide only high qualitative and relevant content but references of lower relevance aren&apos;t withheld as they might contain also very useful information</Description>
      <URL>https://group.springernature.com/gp/group/aboutus</URL>
      <Information>
        <ReferenceNumber>71</ReferenceNumber>
        <Name>Springer Nature References</Name>
        <Value>
          <ExternalTableName>springernature</ExternalTableName>
        </Value>
      </Information>
    </Section>
    <Section>
      <TOCHeading>Thieme References</TOCHeading>
      <Description>Literature references related to scientific contents from Thieme Chemistry journals and books.  The Thieme Chemistry content within this section is provided under a CC-BY-NC-ND 4.0 license (https://creativecommons.org/licenses/by-nc-nd/4.0/), unless otherwise stated.</Description>
      <URL>https://www.thieme.de/en/thieme-chemistry/home-51399.htm</URL>
      <Information>
        <ReferenceNumber>73</ReferenceNumber>
        <Name>Thieme References</Name>
        <Value>
          <ExternalTableName>ThiemeChemistry</ExternalTableName>
        </Value>
      </Information>
    </Section>
    <Section>
      <TOCHeading>Chemical Co-Occurrences in Literature</TOCHeading>
      <Description>Chemical co-occurrences in literature highlight chemicals that are found mentioned together in scientific articles.  This may suggest an important relationship exists between the two chemicals.  The lists of chemicals are ordered by count of publications with co-occurrences.  The publications are prioritized such that the most relevant mentions appear at the top.  Please note that this content is generated by text-mining algorithms (i.e., it is not human curated).  It is possible that the algorithms get fooled such that a co-occurrence may be happenstance or a casual mention.</Description>
      <URL>https://pubchemdocs.ncbi.nlm.nih.gov/knowledge_panels</URL>
      <Information>
        <ReferenceNumber>77</ReferenceNumber>
        <Name>Co-Occurrence Panel</Name>
        <Value>
          <StringWithMarkup>
            <String>ChemicalNeighbor</String>
          </StringWithMarkup>
          <StringWithMarkup>
            <String>Chemical</String>
          </StringWithMarkup>
          <StringWithMarkup>
            <String>ChemicalName_1</String>
          </StringWithMarkup>
          <StringWithMarkup>
            <String>ChemicalName_2</String>
          </StringWithMarkup>
          <StringWithMarkup>
            <String>SUMMARY_URL.cid</String>
          </StringWithMarkup>
          <StringWithMarkup>
            <String>CID</String>
          </StringWithMarkup>
          <StringWithMarkup>
            <String>CID</String>
          </StringWithMarkup>
        </Value>
      </Information>
    </Section>
    <Section>
      <TOCHeading>Chemical-Disease Co-Occurrences in Literature</TOCHeading>
      <Description>Chemical-disease co-occurrences in literature highlight chemical-disease pairs that are found mentioned together in scientific articles.  This may suggest an important relationship exists between the two.  The lists of diseases are ordered by count of publications with co-occurrences.  The publications are prioritized such that the most relevant mentions appear at the top.  Please note that this content is generated by text-mining algorithms (i.e., it is not human curated).  It is possible that the algorithms get fooled such that a co-occurrence may be happenstance or a casual mention.</Description>
      <URL>https://pubchemdocs.ncbi.nlm.nih.gov/knowledge_panels</URL>
      <Information>
        <ReferenceNumber>77</ReferenceNumber>
        <Name>Co-Occurrence Panel</Name>
        <Value>
          <StringWithMarkup>
            <String>ChemicalDiseaseNeighbor</String>
          </StringWithMarkup>
          <StringWithMarkup>
            <String>Disease</String>
          </StringWithMarkup>
          <StringWithMarkup>
            <String>ChemicalName</String>
          </StringWithMarkup>
          <StringWithMarkup>
            <String>DiseaseName</String>
          </StringWithMarkup>
          <StringWithMarkup>
            <String>https://meshb.nlm.nih.gov/record/ui?ui=</String>
          </StringWithMarkup>
          <StringWithMarkup>
            <String>CID</String>
          </StringWithMarkup>
          <StringWithMarkup>
            <String>MeSH</String>
          </StringWithMarkup>
        </Value>
      </Information>
    </Section>
    <Section>
      <TOCHeading>Chemical-Gene Co-Occurrences in Literature</TOCHeading>
      <Description>Chemical-gene co-occurrences in literature highlight chemical-gene pairs that are found mentioned together in scientific articles.  This may suggest an important relationship exists between the two.  The lists of genes are ordered by count of publications with co-occurrences.  The publications are prioritized such that the most relevant mentions appear at the top.  Please note that this content is generated by text-mining algorithms (i.e., it is not human curated).  It is possible that the algorithms get fooled such that a co-occurrence may be happenstance or a casual mention.</Description>
      <URL>https://pubchemdocs.ncbi.nlm.nih.gov/knowledge_panels</URL>
      <Information>
        <ReferenceNumber>77</ReferenceNumber>
        <Name>Co-Occurrence Panel</Name>
        <Value>
          <StringWithMarkup>
            <String>ChemicalGeneProteinNeighbor</String>
          </StringWithMarkup>
          <StringWithMarkup>
            <String>Gene</String>
          </StringWithMarkup>
          <StringWithMarkup>
            <String>ChemicalName</String>
          </StringWithMarkup>
          <StringWithMarkup>
            <String>GeneProteinName</String>
          </StringWithMarkup>
          <StringWithMarkup>
            <String>SUMMARY_URL.geneid</String>
          </StringWithMarkup>
          <StringWithMarkup>
            <String>CID</String>
          </StringWithMarkup>
          <StringWithMarkup>
            <String>GeneID</String>
          </StringWithMarkup>
        </Value>
      </Information>
    </Section>
  </Section>
  <Section>
    <TOCHeading>Patents</TOCHeading>
    <Description>A PubChem summary page displays Patent information when available for the given molecule.</Description>
    <URL>https://pubchemdocs.ncbi.nlm.nih.gov/patents</URL>
    <DisplayControls>
      <ListType>Columns</ListType>
    </DisplayControls>
    <Information>
      <ReferenceNumber>17</ReferenceNumber>
      <Name>Patents</Name>
      <Value>
        <StringWithMarkup>
          <String>US6129930</String>
          <Markup>
            <Start>0</Start>
            <Length>9</Length>
            <URL>https://pubchem.ncbi.nlm.nih.gov/patent/US6129930</URL>
          </Markup>
        </StringWithMarkup>
        <StringWithMarkup>
          <String>CA2283159</String>
        </StringWithMarkup>
        <StringWithMarkup>
          <String>CA2298549</String>
        </StringWithMarkup>
        <StringWithMarkup>
          <String>US6080428</String>
          <Markup>
            <Start>0</Start>
            <Length>9</Length>
            <URL>https://pubchem.ncbi.nlm.nih.gov/patent/US6080428</URL>
          </Markup>
        </StringWithMarkup>
        <StringWithMarkup>
          <String>US6469035</String>
          <Markup>
            <Start>0</Start>
            <Length>9</Length>
            <URL>https://pubchem.ncbi.nlm.nih.gov/patent/US6469035</URL>
          </Markup>
        </StringWithMarkup>
      </Value>
    </Information>
    <Section>
      <TOCHeading>Depositor-Supplied Patent Identifiers</TOCHeading>
      <Description>Patent identifiers and more information provided by depositors in form of a widget.</Description>
      <Information>
        <ReferenceNumber>77</ReferenceNumber>
        <Value>
          <ExternalTableName>patent</ExternalTableName>
        </Value>
      </Information>
    </Section>
  </Section>
  <Section>
    <TOCHeading>Biomolecular Interactions and Pathways</TOCHeading>
    <Description>A PubChem summary page displays biomolecular interactions and pathways information when available for the given record.</Description>
    <Section>
      <TOCHeading>Protein Bound 3-D Structures</TOCHeading>
      <Description>Protein Bound 3-D Structures (from Structure) - links to experimentally resolved 3D structures that contain biomolecules bound to the small molecule.</Description>
      <Information>
        <ReferenceNumber>51</ReferenceNumber>
        <Value>
          <ExternalTableName>pdb</ExternalTableName>
        </Value>
      </Information>
      <Information>
        <ReferenceNumber>77</ReferenceNumber>
        <URL>https://www.ncbi.nlm.nih.gov/structure?cmd=Link&amp;LinkName=pccompound_structure&amp;from_uid=938</URL>
        <Value>
          <StringWithMarkup>
            <String>View 32 proteins in NCBI Structure</String>
          </StringWithMarkup>
        </Value>
      </Information>
    </Section>
    <Section>
      <TOCHeading>Biosystems and Pathways</TOCHeading>
      <Description>Biosystems and Pathways (from BioSystems) - biological systems, such as pathways, that include the small molecule as a component.</Description>
      <Information>
        <ReferenceNumber>77</ReferenceNumber>
        <Value>
          <ExternalTableName>biosystem</ExternalTableName>
        </Value>
      </Information>
    </Section>
    <Section>
      <TOCHeading>DrugBank Interactions</TOCHeading>
      <DisplayControls>
        <CreateTable>
          <FromInformationIn>Subsections</FromInformationIn>
          <NumberOfColumns>2</NumberOfColumns>
          <ColumnContents>Name</ColumnContents>
          <ColumnContents>Value</ColumnContents>
        </CreateTable>
        <ListType>Numbered</ListType>
        <ShowAtMost>1</ShowAtMost>
      </DisplayControls>
      <Section>
        <TOCHeading>Target</TOCHeading>
        <Description>A protein, macromolecule, nucleic acid, or small molecule to which a given drug binds, resulting in an alteration of the normal function of the bound molecule and a desirable therapeutic effect. Drug targets are most commonly proteins such as enzymes, ion channels, and receptors.</Description>
        <Information>
          <ReferenceNumber>7</ReferenceNumber>
          <Name>Target</Name>
          <URL>http://www.drugbank.ca/biodb/bio_entities/BE0000836</URL>
          <Value>
            <StringWithMarkup>
              <String>Hydroxycarboxylic acid receptor 3</String>
              <Markup>
                <Start>0</Start>
                <Length>22</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/Hydroxycarboxylic%20acid</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-767</Extra>
              </Markup>
            </StringWithMarkup>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>8</ReferenceNumber>
          <Name>Target</Name>
          <URL>http://www.drugbank.ca/biodb/bio_entities/BE0000635</URL>
          <Value>
            <StringWithMarkup>
              <String>Hydroxycarboxylic acid receptor 2</String>
              <Markup>
                <Start>0</Start>
                <Length>22</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/Hydroxycarboxylic%20acid</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-767</Extra>
              </Markup>
            </StringWithMarkup>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>9</ReferenceNumber>
          <Name>Target</Name>
          <URL>http://www.drugbank.ca/biodb/bio_entities/BE0000526</URL>
          <Value>
            <StringWithMarkup>
              <String>Nicotinate-nucleotide pyrophosphorylase [carboxylating]</String>
              <Markup>
                <Start>0</Start>
                <Length>10</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/Nicotinate</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-937</Extra>
              </Markup>
            </StringWithMarkup>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>10</ReferenceNumber>
          <Name>Target</Name>
          <URL>http://www.drugbank.ca/biodb/bio_entities/BE0000783</URL>
          <Value>
            <StringWithMarkup>
              <String>Nicotinamide N-methyltransferase</String>
              <Markup>
                <Start>0</Start>
                <Length>12</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/Nicotinamide</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-936</Extra>
              </Markup>
            </StringWithMarkup>
          </Value>
        </Information>
      </Section>
      <Section>
        <TOCHeading>Enzyme</TOCHeading>
        <Description>A protein which catalyzes chemical reactions involving the a given drug (substrate).</Description>
        <Information>
          <ReferenceNumber>11</ReferenceNumber>
          <Name>Enzyme</Name>
          <URL>http://www.drugbank.ca/biodb/bio_entities/BE0002363</URL>
          <Value>
            <StringWithMarkup>
              <String>Cytochrome P450 2D6</String>
            </StringWithMarkup>
          </Value>
        </Information>
      </Section>
      <Section>
        <TOCHeading>Transporter</TOCHeading>
        <Description>A membrane bound protein which shuttles ions, small molecules or macromolecules across membranes, into cells or out of cells.</Description>
        <Information>
          <ReferenceNumber>12</ReferenceNumber>
          <Name>Transporter</Name>
          <URL>http://www.drugbank.ca/biodb/bio_entities/BE0000106</URL>
          <Value>
            <StringWithMarkup>
              <String>Solute carrier family 22 member 5</String>
            </StringWithMarkup>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>13</ReferenceNumber>
          <Name>Transporter</Name>
          <URL>http://www.drugbank.ca/biodb/bio_entities/BE0001042</URL>
          <Value>
            <StringWithMarkup>
              <String>Solute carrier organic anion transporter family member 2B1</String>
            </StringWithMarkup>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>14</ReferenceNumber>
          <Name>Transporter</Name>
          <URL>http://www.drugbank.ca/biodb/bio_entities/BE0000669</URL>
          <Value>
            <StringWithMarkup>
              <String>Monocarboxylate transporter 1</String>
            </StringWithMarkup>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>15</ReferenceNumber>
          <Name>Transporter</Name>
          <URL>http://www.drugbank.ca/biodb/bio_entities/BE0004708</URL>
          <Value>
            <StringWithMarkup>
              <String>Sodium-coupled monocarboxylate transporter 1</String>
              <Markup>
                <Start>0</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/element/Sodium</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>Element-Sodium</Extra>
              </Markup>
            </StringWithMarkup>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>16</ReferenceNumber>
          <Name>Transporter</Name>
          <URL>http://www.drugbank.ca/biodb/bio_entities/BE0000449</URL>
          <Value>
            <StringWithMarkup>
              <String>Monocarboxylate transporter 4</String>
            </StringWithMarkup>
          </Value>
        </Information>
      </Section>
      <Section>
        <TOCHeading>Action</TOCHeading>
        <Description>Action</Description>
        <Information>
          <ReferenceNumber>7</ReferenceNumber>
          <Name>Action</Name>
          <Value>
            <StringWithMarkup>
              <String>agonist</String>
            </StringWithMarkup>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>8</ReferenceNumber>
          <Name>Action</Name>
          <Value>
            <StringWithMarkup>
              <String>agonist</String>
            </StringWithMarkup>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>9</ReferenceNumber>
          <Name>Action</Name>
          <Value>
            <StringWithMarkup>
              <String>binder</String>
            </StringWithMarkup>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>10</ReferenceNumber>
          <Name>Action</Name>
          <Value>
            <StringWithMarkup>
              <String>binder</String>
            </StringWithMarkup>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>11</ReferenceNumber>
          <Name>Action</Name>
          <Value>
            <StringWithMarkup>
              <String>inhibitor</String>
            </StringWithMarkup>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>12</ReferenceNumber>
          <Name>Action</Name>
          <Value>
            <StringWithMarkup>
              <String>inhibitor</String>
            </StringWithMarkup>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>13</ReferenceNumber>
          <Name>Action</Name>
          <Value>
            <StringWithMarkup>
              <String>inhibitor</String>
            </StringWithMarkup>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>14</ReferenceNumber>
          <Name>Action</Name>
          <Value>
            <StringWithMarkup>
              <String>substrate</String>
            </StringWithMarkup>
          </Value>
        </Information>
      </Section>
      <Section>
        <TOCHeading>PubChem Protein Target</TOCHeading>
        <Description>Mapped protein target in PubChem</Description>
        <Information>
          <ReferenceNumber>7</ReferenceNumber>
          <Name>PubChem Protein Target</Name>
          <URL>https://pubchem.ncbi.nlm.nih.gov/protein/P49019</URL>
          <Value>
            <StringWithMarkup>
              <String>P49019</String>
            </StringWithMarkup>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>8</ReferenceNumber>
          <Name>PubChem Protein Target</Name>
          <URL>https://pubchem.ncbi.nlm.nih.gov/protein/Q8TDS4</URL>
          <Value>
            <StringWithMarkup>
              <String>Q8TDS4</String>
            </StringWithMarkup>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>10</ReferenceNumber>
          <Name>PubChem Protein Target</Name>
          <URL>https://pubchem.ncbi.nlm.nih.gov/protein/P40261</URL>
          <Value>
            <StringWithMarkup>
              <String>P40261</String>
            </StringWithMarkup>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>11</ReferenceNumber>
          <Name>PubChem Protein Target</Name>
          <URL>https://pubchem.ncbi.nlm.nih.gov/protein/P10635</URL>
          <Value>
            <StringWithMarkup>
              <String>P10635</String>
            </StringWithMarkup>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>12</ReferenceNumber>
          <Name>PubChem Protein Target</Name>
          <URL>https://pubchem.ncbi.nlm.nih.gov/protein/O76082</URL>
          <Value>
            <StringWithMarkup>
              <String>O76082</String>
            </StringWithMarkup>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>13</ReferenceNumber>
          <Name>PubChem Protein Target</Name>
          <URL>https://pubchem.ncbi.nlm.nih.gov/protein/O94956</URL>
          <Value>
            <StringWithMarkup>
              <String>O94956</String>
            </StringWithMarkup>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>14</ReferenceNumber>
          <Name>PubChem Protein Target</Name>
          <URL>https://pubchem.ncbi.nlm.nih.gov/protein/P53985</URL>
          <Value>
            <StringWithMarkup>
              <String>P53985</String>
            </StringWithMarkup>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>16</ReferenceNumber>
          <Name>PubChem Protein Target</Name>
          <URL>https://pubchem.ncbi.nlm.nih.gov/protein/O15427</URL>
          <Value>
            <StringWithMarkup>
              <String>O15427</String>
            </StringWithMarkup>
          </Value>
        </Information>
      </Section>
      <Section>
        <TOCHeading>PubChem Gene Target</TOCHeading>
        <Description>Mapped gene target in PubChem</Description>
        <Information>
          <ReferenceNumber>7</ReferenceNumber>
          <Name>PubChem Gene Target</Name>
          <URL>https://pubchem.ncbi.nlm.nih.gov/gene/8843</URL>
          <Value>
            <StringWithMarkup>
              <String>HCAR3</String>
            </StringWithMarkup>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>8</ReferenceNumber>
          <Name>PubChem Gene Target</Name>
          <URL>https://pubchem.ncbi.nlm.nih.gov/gene/338442</URL>
          <Value>
            <StringWithMarkup>
              <String>HCAR2</String>
            </StringWithMarkup>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>9</ReferenceNumber>
          <Name>PubChem Gene Target</Name>
          <URL>https://pubchem.ncbi.nlm.nih.gov/gene/23475</URL>
          <Value>
            <StringWithMarkup>
              <String>QPRT</String>
            </StringWithMarkup>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>10</ReferenceNumber>
          <Name>PubChem Gene Target</Name>
          <URL>https://pubchem.ncbi.nlm.nih.gov/gene/4837</URL>
          <Value>
            <StringWithMarkup>
              <String>NNMT</String>
            </StringWithMarkup>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>11</ReferenceNumber>
          <Name>PubChem Gene Target</Name>
          <URL>https://pubchem.ncbi.nlm.nih.gov/gene/1565</URL>
          <Value>
            <StringWithMarkup>
              <String>CYP2D6</String>
            </StringWithMarkup>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>12</ReferenceNumber>
          <Name>PubChem Gene Target</Name>
          <URL>https://pubchem.ncbi.nlm.nih.gov/gene/6584</URL>
          <Value>
            <StringWithMarkup>
              <String>SLC22A5</String>
            </StringWithMarkup>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>13</ReferenceNumber>
          <Name>PubChem Gene Target</Name>
          <URL>https://pubchem.ncbi.nlm.nih.gov/gene/11309</URL>
          <Value>
            <StringWithMarkup>
              <String>SLCO2B1</String>
            </StringWithMarkup>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>14</ReferenceNumber>
          <Name>PubChem Gene Target</Name>
          <URL>https://pubchem.ncbi.nlm.nih.gov/gene/6566</URL>
          <Value>
            <StringWithMarkup>
              <String>SLC16A1</String>
            </StringWithMarkup>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>15</ReferenceNumber>
          <Name>PubChem Gene Target</Name>
          <URL>https://pubchem.ncbi.nlm.nih.gov/gene/160728</URL>
          <Value>
            <StringWithMarkup>
              <String>SLC5A8</String>
            </StringWithMarkup>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>16</ReferenceNumber>
          <Name>PubChem Gene Target</Name>
          <URL>https://pubchem.ncbi.nlm.nih.gov/gene/9123</URL>
          <Value>
            <StringWithMarkup>
              <String>SLC16A3</String>
            </StringWithMarkup>
          </Value>
        </Information>
      </Section>
      <Section>
        <TOCHeading>General Function</TOCHeading>
        <Description>Short 3-4 word summary of the primary functions</Description>
        <Information>
          <ReferenceNumber>7</ReferenceNumber>
          <Name>General Function</Name>
          <Value>
            <StringWithMarkup>
              <String>G-protein coupled receptor activity</String>
            </StringWithMarkup>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>8</ReferenceNumber>
          <Name>General Function</Name>
          <Value>
            <StringWithMarkup>
              <String>Nicotinic acid receptor activity</String>
              <Markup>
                <Start>0</Start>
                <Length>14</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/Nicotinic%20acid</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
            </StringWithMarkup>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>9</ReferenceNumber>
          <Name>General Function</Name>
          <Value>
            <StringWithMarkup>
              <String>Protein homodimerization activity</String>
            </StringWithMarkup>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>10</ReferenceNumber>
          <Name>General Function</Name>
          <Value>
            <StringWithMarkup>
              <String>Nicotinamide n-methyltransferase activity</String>
              <Markup>
                <Start>0</Start>
                <Length>12</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/Nicotinamide</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-936</Extra>
              </Markup>
            </StringWithMarkup>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>11</ReferenceNumber>
          <Name>General Function</Name>
          <Value>
            <StringWithMarkup>
              <String>Steroid hydroxylase activity</String>
            </StringWithMarkup>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>12</ReferenceNumber>
          <Name>General Function</Name>
          <Value>
            <StringWithMarkup>
              <String>Symporter activity</String>
            </StringWithMarkup>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>13</ReferenceNumber>
          <Name>General Function</Name>
          <Value>
            <StringWithMarkup>
              <String>Sodium-independent organic anion transmembrane transporter activity</String>
              <Markup>
                <Start>0</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/element/Sodium</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>Element-Sodium</Extra>
              </Markup>
            </StringWithMarkup>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>14</ReferenceNumber>
          <Name>General Function</Name>
          <Value>
            <StringWithMarkup>
              <String>Symporter activity</String>
            </StringWithMarkup>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>15</ReferenceNumber>
          <Name>General Function</Name>
          <Value>
            <StringWithMarkup>
              <String>Symporter activity</String>
            </StringWithMarkup>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>16</ReferenceNumber>
          <Name>General Function</Name>
          <Value>
            <StringWithMarkup>
              <String>Symporter activity</String>
            </StringWithMarkup>
          </Value>
        </Information>
      </Section>
      <Section>
        <TOCHeading>Specific Function</TOCHeading>
        <Description>Detailed 30-40 word summary of the specific functions</Description>
        <Information>
          <ReferenceNumber>7</ReferenceNumber>
          <Name>Specific Function</Name>
          <Value>
            <StringWithMarkup>
              <String>Receptor for 3-OH-octanoid acid mediates a negative feedback regulation of adipocyte lipolysis to counteract prolipolytic influences under conditions of physiological or pathological increases in beta-oxidation rates. Acts as a low affinity receptor for nicotinic acid. This pharmacological effect requires nicotinic acid doses that are much higher than those provided by a normal diet.</String>
              <Markup>
                <Start>254</Start>
                <Length>14</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/nicotinic%20acid</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>307</Start>
                <Length>14</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/nicotinic%20acid</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
            </StringWithMarkup>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>8</ReferenceNumber>
          <Name>Specific Function</Name>
          <Value>
            <StringWithMarkup>
              <String>Acts as a high affinity receptor for both nicotinic acid (also known as niacin) and (D)-beta-hydroxybutyrate and mediates increased adiponectin secretion and decreased lipolysis through G(i)-protein-mediated inhibition of adenylyl cyclase. This pharmacological effect requires nicotinic acid doses that are much higher than those provided by a normal diet. Mediates nicotinic acid-induced apoptosis in mature neutrophils. Receptor activation by nicotinic acid results in reduced cAMP levels which may affect activity of cAMP-dependent protein kinase A and phosphorylation of target proteins, leading to neutrophil apoptosis. The rank order of potency for the displacement of nicotinic acid binding is 5-methyl pyrazole-3-carboxylic acid = pyridine-3-acetic acid &gt; acifran &gt; 5-methyl nicotinic acid = acipimox &gt;&gt; nicotinuric acid = nicotinamide.</String>
              <Markup>
                <Start>42</Start>
                <Length>14</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/nicotinic%20acid</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>72</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>277</Start>
                <Length>14</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/nicotinic%20acid</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>366</Start>
                <Length>14</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/nicotinic%20acid</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>445</Start>
                <Length>14</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/nicotinic%20acid</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>479</Start>
                <Length>4</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/cAMP</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-6076</Extra>
              </Markup>
              <Markup>
                <Start>520</Start>
                <Length>4</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/cAMP</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-6076</Extra>
              </Markup>
              <Markup>
                <Start>675</Start>
                <Length>14</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/nicotinic%20acid</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>701</Start>
                <Length>35</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/5-methyl-pyrazole-3-carboxylic%20acid</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-9822</Extra>
              </Markup>
              <Markup>
                <Start>739</Start>
                <Length>22</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/pyridine-3-acetic%20acid</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-108</Extra>
              </Markup>
              <Markup>
                <Start>764</Start>
                <Length>7</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/acifran</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-51576</Extra>
              </Markup>
              <Markup>
                <Start>774</Start>
                <Length>23</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/5-methyl-nicotinic%20acid</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-256208</Extra>
              </Markup>
              <Markup>
                <Start>800</Start>
                <Length>8</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/acipimox</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-5310993</Extra>
              </Markup>
              <Markup>
                <Start>812</Start>
                <Length>16</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/nicotinuric%20acid</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-68499</Extra>
              </Markup>
              <Markup>
                <Start>831</Start>
                <Length>12</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/nicotinamide</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-936</Extra>
              </Markup>
            </StringWithMarkup>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>9</ReferenceNumber>
          <Name>Specific Function</Name>
          <Value>
            <StringWithMarkup>
              <String>Involved in the catabolism of quinolinic acid (QA).</String>
              <Markup>
                <Start>30</Start>
                <Length>15</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/quinolinic%20acid</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-1066</Extra>
              </Markup>
            </StringWithMarkup>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>10</ReferenceNumber>
          <Name>Specific Function</Name>
          <Value>
            <StringWithMarkup>
              <String>Catalyzes the N-methylation of nicotinamide and other pyridines to form pyridinium ions. This activity is important for biotransformation of many drugs and xenobiotic compounds.</String>
              <Markup>
                <Start>31</Start>
                <Length>12</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/nicotinamide</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-936</Extra>
              </Markup>
              <Markup>
                <Start>72</Start>
                <Length>10</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/pyridinium</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-4989215</Extra>
              </Markup>
            </StringWithMarkup>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>11</ReferenceNumber>
          <Name>Specific Function</Name>
          <Value>
            <StringWithMarkup>
              <String>Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.</String>
            </StringWithMarkup>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>12</ReferenceNumber>
          <Name>Specific Function</Name>
          <Value>
            <StringWithMarkup>
              <String>Sodium-ion dependent, high affinity carnitine transporter. Involved in the active cellular uptake of carnitine. Transports one sodium ion with one molecule of carnitine. Also transports organic cations such as tetraethylammonium (TEA) without the involvement of sodium. Also relative uptake activity ratio of carnitine to TEA is 11.3.</String>
              <Markup>
                <Start>0</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/element/Sodium</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>Element-Sodium</Extra>
              </Markup>
              <Markup>
                <Start>36</Start>
                <Length>9</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/carnitine</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-288</Extra>
              </Markup>
              <Markup>
                <Start>101</Start>
                <Length>9</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/carnitine</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-288</Extra>
              </Markup>
              <Markup>
                <Start>127</Start>
                <Length>10</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/sodium%20ion</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-923</Extra>
              </Markup>
              <Markup>
                <Start>159</Start>
                <Length>9</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/carnitine</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-288</Extra>
              </Markup>
              <Markup>
                <Start>210</Start>
                <Length>18</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/tetraethylammonium</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-5413</Extra>
              </Markup>
              <Markup>
                <Start>262</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/element/Sodium</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>Element-Sodium</Extra>
              </Markup>
              <Markup>
                <Start>309</Start>
                <Length>9</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/carnitine</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-288</Extra>
              </Markup>
            </StringWithMarkup>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>13</ReferenceNumber>
          <Name>Specific Function</Name>
          <Value>
            <StringWithMarkup>
              <String>Mediates the Na(+)-independent transport of organic anions such as taurocholate, the prostaglandins PGD2, PGE1, PGE2, leukotriene C4, thromboxane B2 and iloprost.</String>
              <Markup>
                <Start>67</Start>
                <Length>12</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/taurocholate</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-6675</Extra>
              </Markup>
              <Markup>
                <Start>100</Start>
                <Length>4</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/PGD2</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-448457</Extra>
              </Markup>
              <Markup>
                <Start>106</Start>
                <Length>4</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/PGE1</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-5280723</Extra>
              </Markup>
              <Markup>
                <Start>112</Start>
                <Length>4</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/PGE2</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-5280360</Extra>
              </Markup>
              <Markup>
                <Start>118</Start>
                <Length>14</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/leukotriene%20C4</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-5280493</Extra>
              </Markup>
              <Markup>
                <Start>134</Start>
                <Length>14</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/thromboxane%20B2</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-5283137</Extra>
              </Markup>
              <Markup>
                <Start>153</Start>
                <Length>8</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/iloprost</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-5311181</Extra>
              </Markup>
            </StringWithMarkup>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>14</ReferenceNumber>
          <Name>Specific Function</Name>
          <Value>
            <StringWithMarkup>
              <String>Proton-coupled monocarboxylate transporter. Catalyzes the rapid transport across the plasma membrane of many monocarboxylates such as lactate, pyruvate, branched-chain oxo acids derived from leucine, valine and isoleucine, and the ketone bodies acetoacetate, beta-hydroxybutyrate and acetate. Depending on the tissue and on cicumstances, mediates the import or export of lactic acid and ketone bodies. Required for normal nutrient assimilation, increase of white adipose tissue and body weight gain when on a high-fat diet. Plays a role in cellular responses to a high-fat diet by modulating the cellular levels of lactate and pyruvate, small molecules that contribute to the regulation of central metabolic pathways and insulin secretion, with concomitant effects on plasma insulin levels and blood glucose homeostasis.</String>
              <Markup>
                <Start>134</Start>
                <Length>7</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/lactate</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-91435</Extra>
              </Markup>
              <Markup>
                <Start>143</Start>
                <Length>8</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/pyruvate</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-107735</Extra>
              </Markup>
              <Markup>
                <Start>191</Start>
                <Length>7</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/leucine</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-6106</Extra>
              </Markup>
              <Markup>
                <Start>200</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/valine</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-6287</Extra>
              </Markup>
              <Markup>
                <Start>211</Start>
                <Length>10</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/isoleucine</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-791</Extra>
              </Markup>
              <Markup>
                <Start>245</Start>
                <Length>12</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/acetoacetate</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-6971017</Extra>
              </Markup>
              <Markup>
                <Start>259</Start>
                <Length>20</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/beta-hydroxybutyrate</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-3541112</Extra>
              </Markup>
              <Markup>
                <Start>284</Start>
                <Length>7</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/acetate</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-175</Extra>
              </Markup>
              <Markup>
                <Start>371</Start>
                <Length>11</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/lactic%20acid</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-612</Extra>
              </Markup>
              <Markup>
                <Start>615</Start>
                <Length>7</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/lactate</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-91435</Extra>
              </Markup>
              <Markup>
                <Start>627</Start>
                <Length>8</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/pyruvate</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-107735</Extra>
              </Markup>
              <Markup>
                <Start>800</Start>
                <Length>7</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/glucose</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-5793</Extra>
              </Markup>
            </StringWithMarkup>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>15</ReferenceNumber>
          <Name>Specific Function</Name>
          <Value>
            <StringWithMarkup>
              <String>Acts as an electrogenic sodium (Na(+)) and chloride (Cl-)-dependent sodium-coupled solute transporter, including transport of monocarboxylates (short-chain fatty acids including L-lactate, D-lactate, pyruvate, acetate, propionate, valerate and butyrate), lactate, mocarboxylate drugs (nicotinate, benzoate, salicylate and 5-aminosalicylate) and ketone bodies (beta-D-hydroxybutyrate, acetoacetate and alpha-ketoisocaproate), with a Na(+):substrate stoichiometry of between 4:1 and 2:1. Catalyzes passive carrier mediated diffusion of iodide. Mediates iodide transport from the thyrocyte into the colloid lumen through the apical membrane. May be responsible for the absorption of D-lactate and monocarboxylate drugs from the intestinal tract. Acts as a tumor suppressor, suppressing colony formation in colon cancer, prostate cancer and glioma cell lines. May play a critical role in the entry of L-lactate and ketone bodies into neurons by a process driven by an electrochemical Na(+) gradient and hence contribute to the maintenance of the energy status and function of neurons.</String>
              <Markup>
                <Start>24</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/element/Sodium</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>Element-Sodium</Extra>
              </Markup>
              <Markup>
                <Start>43</Start>
                <Length>8</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/chloride</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-18413378</Extra>
              </Markup>
              <Markup>
                <Start>68</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/element/Sodium</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>Element-Sodium</Extra>
              </Markup>
              <Markup>
                <Start>178</Start>
                <Length>9</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/L-lactate</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-5460161</Extra>
              </Markup>
              <Markup>
                <Start>189</Start>
                <Length>9</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/D-lactate</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>multiple-CIDs</Extra>
              </Markup>
              <Markup>
                <Start>200</Start>
                <Length>8</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/pyruvate</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-107735</Extra>
              </Markup>
              <Markup>
                <Start>210</Start>
                <Length>7</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/acetate</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-175</Extra>
              </Markup>
              <Markup>
                <Start>219</Start>
                <Length>10</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/propionate</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-104745</Extra>
              </Markup>
              <Markup>
                <Start>231</Start>
                <Length>8</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/valerate</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-114781</Extra>
              </Markup>
              <Markup>
                <Start>244</Start>
                <Length>8</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/butyrate</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-104775</Extra>
              </Markup>
              <Markup>
                <Start>255</Start>
                <Length>7</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/lactate</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-91435</Extra>
              </Markup>
              <Markup>
                <Start>285</Start>
                <Length>10</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/nicotinate</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-937</Extra>
              </Markup>
              <Markup>
                <Start>297</Start>
                <Length>8</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/benzoate</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-242</Extra>
              </Markup>
              <Markup>
                <Start>307</Start>
                <Length>10</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/salicylate</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-54675850</Extra>
              </Markup>
              <Markup>
                <Start>322</Start>
                <Length>17</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/5-aminosalicylate</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-54675840</Extra>
              </Markup>
              <Markup>
                <Start>384</Start>
                <Length>12</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/acetoacetate</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-6971017</Extra>
              </Markup>
              <Markup>
                <Start>401</Start>
                <Length>21</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/alpha-ketoisocaproate</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-70</Extra>
              </Markup>
              <Markup>
                <Start>534</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/iodide</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-3021261</Extra>
              </Markup>
              <Markup>
                <Start>551</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/iodide</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-3021261</Extra>
              </Markup>
              <Markup>
                <Start>680</Start>
                <Length>9</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/D-lactate</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>multiple-CIDs</Extra>
              </Markup>
              <Markup>
                <Start>897</Start>
                <Length>9</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/L-lactate</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-5460161</Extra>
              </Markup>
            </StringWithMarkup>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>16</ReferenceNumber>
          <Name>Specific Function</Name>
          <Value>
            <StringWithMarkup>
              <String>Proton-linked monocarboxylate transporter. Catalyzes the rapid transport across the plasma membrane of many monocarboxylates such as lactate, pyruvate, branched-chain oxo acids derived from leucine, valine and isoleucine, and the ketone bodies acetoacetate, beta-hydroxybutyrate and acetate (By similarity).</String>
              <Markup>
                <Start>133</Start>
                <Length>7</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/lactate</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-91435</Extra>
              </Markup>
              <Markup>
                <Start>142</Start>
                <Length>8</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/pyruvate</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-107735</Extra>
              </Markup>
              <Markup>
                <Start>190</Start>
                <Length>7</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/leucine</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-6106</Extra>
              </Markup>
              <Markup>
                <Start>199</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/valine</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-6287</Extra>
              </Markup>
              <Markup>
                <Start>210</Start>
                <Length>10</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/isoleucine</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-791</Extra>
              </Markup>
              <Markup>
                <Start>244</Start>
                <Length>12</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/acetoacetate</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-6971017</Extra>
              </Markup>
              <Markup>
                <Start>258</Start>
                <Length>20</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/beta-hydroxybutyrate</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-3541112</Extra>
              </Markup>
              <Markup>
                <Start>283</Start>
                <Length>7</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/acetate</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-175</Extra>
              </Markup>
            </StringWithMarkup>
          </Value>
        </Information>
      </Section>
      <Section>
        <TOCHeading>Interaction References</TOCHeading>
        <Description>Interaction References</Description>
        <Information>
          <ReferenceNumber>7</ReferenceNumber>
          <Name>References</Name>
          <Value>
            <StringWithMarkup>
              <String>Tunaru S, Kero J, Schaub A, Wufka C, Blaukat A, Pfeffer K, Offermanns S: PUMA-G and HM74 are receptors for nicotinic acid and mediate its anti-lipolytic effect. Nat Med. 2003 Mar;9(3):352-5. Epub 2003 Feb 3. [PMID: 12563315]</String>
              <Markup>
                <Start>209</Start>
                <Length>14</Length>
                <URL>https://www.ncbi.nlm.nih.gov/pubmed/12563315</URL>
              </Markup>
              <Markup>
                <Start>107</Start>
                <Length>14</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/nicotinic%20acid</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Taggart AK, Kero J, Gan X, Cai TQ, Cheng K, Ippolito M, Ren N, Kaplan R, Wu K, Wu TJ, Jin L, Liaw C, Chen R, Richman J, Connolly D, Offermanns S, Wright SD, Waters MG: (D)-beta-Hydroxybutyrate inhibits adipocyte lipolysis via the nicotinic acid receptor PUMA-G. J Biol Chem. 2005 Jul 22;280(29):26649-52. Epub 2005 Jun 1. [PMID: 15929991]</String>
              <Markup>
                <Start>323</Start>
                <Length>14</Length>
                <URL>https://www.ncbi.nlm.nih.gov/pubmed/15929991</URL>
              </Markup>
              <Markup>
                <Start>230</Start>
                <Length>14</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/nicotinic%20acid</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Zhang Y, Schmidt RJ, Foxworthy P, Emkey R, Oler JK, Large TH, Wang H, Su EW, Mosior MK, Eacho PI, Cao G: Niacin mediates lipolysis in adipose tissue through its G-protein coupled receptor HM74A. Biochem Biophys Res Commun. 2005 Aug 26;334(2):729-32. [PMID: 16018973]</String>
              <Markup>
                <Start>251</Start>
                <Length>14</Length>
                <URL>https://www.ncbi.nlm.nih.gov/pubmed/16018973</URL>
              </Markup>
              <Markup>
                <Start>105</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/Niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Tunaru S, Lattig J, Kero J, Krause G, Offermanns S: Characterization of determinants of ligand binding to the nicotinic acid receptor GPR109A (HM74A/PUMA-G). Mol Pharmacol. 2005 Nov;68(5):1271-80. Epub 2005 Aug 11. [PMID: 16099840]</String>
              <Markup>
                <Start>216</Start>
                <Length>14</Length>
                <URL>https://www.ncbi.nlm.nih.gov/pubmed/16099840</URL>
              </Markup>
              <Markup>
                <Start>110</Start>
                <Length>14</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/nicotinic%20acid</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Benyo Z, Gille A, Kero J, Csiky M, Suchankova MC, Nusing RM, Moers A, Pfeffer K, Offermanns S: GPR109A (PUMA-G/HM74A) mediates nicotinic acid-induced flushing. J Clin Invest. 2005 Dec;115(12):3634-40. [PMID: 16322797]</String>
              <Markup>
                <Start>202</Start>
                <Length>14</Length>
                <URL>https://www.ncbi.nlm.nih.gov/pubmed/16322797</URL>
              </Markup>
              <Markup>
                <Start>127</Start>
                <Length>14</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/nicotinic%20acid</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Wise A, Foord SM, Fraser NJ, Barnes AA, Elshourbagy N, Eilert M, Ignar DM, Murdock PR, Steplewski K, Green A, Brown AJ, Dowell SJ, Szekeres PG, Hassall DG, Marshall FH, Wilson S, Pike NB: Molecular identification of high and low affinity receptors for nicotinic acid. J Biol Chem. 2003 Mar 14;278(11):9869-74. Epub 2003 Jan 9. [PMID: 12522134]</String>
              <Markup>
                <Start>328</Start>
                <Length>14</Length>
                <URL>https://www.ncbi.nlm.nih.gov/pubmed/12522134</URL>
              </Markup>
              <Markup>
                <Start>252</Start>
                <Length>14</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/nicotinic%20acid</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
            </StringWithMarkup>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>8</ReferenceNumber>
          <Name>References</Name>
          <Value>
            <StringWithMarkup>
              <String>Wise A, Foord SM, Fraser NJ, Barnes AA, Elshourbagy N, Eilert M, Ignar DM, Murdock PR, Steplewski K, Green A, Brown AJ, Dowell SJ, Szekeres PG, Hassall DG, Marshall FH, Wilson S, Pike NB: Molecular identification of high and low affinity receptors for nicotinic acid. J Biol Chem. 2003 Mar 14;278(11):9869-74. Epub 2003 Jan 9. [PMID: 12522134]</String>
              <Markup>
                <Start>328</Start>
                <Length>14</Length>
                <URL>https://www.ncbi.nlm.nih.gov/pubmed/12522134</URL>
              </Markup>
              <Markup>
                <Start>252</Start>
                <Length>14</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/nicotinic%20acid</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Soga T, Kamohara M, Takasaki J, Matsumoto S, Saito T, Ohishi T, Hiyama H, Matsuo A, Matsushime H, Furuichi K: Molecular identification of nicotinic acid receptor. Biochem Biophys Res Commun. 2003 Mar 28;303(1):364-9. [PMID: 12646212]</String>
              <Markup>
                <Start>218</Start>
                <Length>14</Length>
                <URL>https://www.ncbi.nlm.nih.gov/pubmed/12646212</URL>
              </Markup>
              <Markup>
                <Start>138</Start>
                <Length>14</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/nicotinic%20acid</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Zellner C, Pullinger CR, Aouizerat BE, Frost PH, Kwok PY, Malloy MJ, Kane JP: Variations in human HM74 (GPR109B) and HM74A (GPR109A) niacin receptors. Hum Mutat. 2005 Jan;25(1):18-21. [PMID: 15580557]</String>
              <Markup>
                <Start>185</Start>
                <Length>14</Length>
                <URL>https://www.ncbi.nlm.nih.gov/pubmed/15580557</URL>
              </Markup>
              <Markup>
                <Start>133</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Zhang Y, Schmidt RJ, Foxworthy P, Emkey R, Oler JK, Large TH, Wang H, Su EW, Mosior MK, Eacho PI, Cao G: Niacin mediates lipolysis in adipose tissue through its G-protein coupled receptor HM74A. Biochem Biophys Res Commun. 2005 Aug 26;334(2):729-32. [PMID: 16018973]</String>
              <Markup>
                <Start>251</Start>
                <Length>14</Length>
                <URL>https://www.ncbi.nlm.nih.gov/pubmed/16018973</URL>
              </Markup>
              <Markup>
                <Start>105</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/Niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Tunaru S, Lattig J, Kero J, Krause G, Offermanns S: Characterization of determinants of ligand binding to the nicotinic acid receptor GPR109A (HM74A/PUMA-G). Mol Pharmacol. 2005 Nov;68(5):1271-80. Epub 2005 Aug 11. [PMID: 16099840]</String>
              <Markup>
                <Start>216</Start>
                <Length>14</Length>
                <URL>https://www.ncbi.nlm.nih.gov/pubmed/16099840</URL>
              </Markup>
              <Markup>
                <Start>110</Start>
                <Length>14</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/nicotinic%20acid</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
            </StringWithMarkup>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>9</ReferenceNumber>
          <Name>References</Name>
          <Value>
            <StringWithMarkup>
              <String>Fukuwatari T, Morikawa Y, Hayakawa F, Sugimoto E, Shibata K: Influence of adenine-induced renal failure on tryptophan-niacin metabolism in rats. Biosci Biotechnol Biochem. 2001 Oct;65(10):2154-61. [PMID: 11758903]</String>
              <Markup>
                <Start>198</Start>
                <Length>14</Length>
                <URL>https://www.ncbi.nlm.nih.gov/pubmed/11758903</URL>
              </Markup>
              <Markup>
                <Start>74</Start>
                <Length>7</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/adenine</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-190</Extra>
              </Markup>
              <Markup>
                <Start>107</Start>
                <Length>10</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/tryptophan</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-6305</Extra>
              </Markup>
              <Markup>
                <Start>118</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/niacin</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Shin DH, Oganesyan N, Jancarik J, Yokota H, Kim R, Kim SH: Crystal structure of a nicotinate phosphoribosyltransferase from Thermoplasma acidophilum. J Biol Chem. 2005 May 6;280(18):18326-35. Epub 2005 Mar 6. [PMID: 15753098]</String>
              <Markup>
                <Start>210</Start>
                <Length>14</Length>
                <URL>https://www.ncbi.nlm.nih.gov/pubmed/15753098</URL>
              </Markup>
              <Markup>
                <Start>82</Start>
                <Length>10</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/nicotinate</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-937</Extra>
              </Markup>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Zheng XQ, Hayashibe E, Ashihara H: Changes in trigonelline (N-methylnicotinic acid) content and nicotinic acid metabolism during germination of mungbean (Phaseolus aureus) seeds. J Exp Bot. 2005 Jun;56(416):1615-23. Epub 2005 Apr 18. [PMID: 15837705]</String>
              <Markup>
                <Start>235</Start>
                <Length>14</Length>
                <URL>https://www.ncbi.nlm.nih.gov/pubmed/15837705</URL>
              </Markup>
              <Markup>
                <Start>46</Start>
                <Length>12</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/trigonelline</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-5570</Extra>
              </Markup>
              <Markup>
                <Start>60</Start>
                <Length>22</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/N-methylnicotinic%20acid</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-5571</Extra>
              </Markup>
              <Markup>
                <Start>96</Start>
                <Length>14</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/nicotinic%20acid</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
            </StringWithMarkup>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>10</ReferenceNumber>
          <Name>References</Name>
          <Value>
            <StringWithMarkup>
              <String>Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PMID: 17139284]</String>
              <Markup>
                <Start>119</Start>
                <Length>14</Length>
                <URL>https://www.ncbi.nlm.nih.gov/pubmed/17139284</URL>
              </Markup>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PMID: 17016423]</String>
              <Markup>
                <Start>139</Start>
                <Length>14</Length>
                <URL>https://www.ncbi.nlm.nih.gov/pubmed/17016423</URL>
              </Markup>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Riederer M, Erwa W, Zimmermann R, Frank S, Zechner R: Adipose tissue as a source of nicotinamide N-methyltransferase and homocysteine. Atherosclerosis. 2009 Jun;204(2):412-7. doi: 10.1016/j.atherosclerosis.2008.09.015. Epub 2008 Sep 27. [PMID: 18996527]</String>
              <Markup>
                <Start>238</Start>
                <Length>14</Length>
                <URL>https://www.ncbi.nlm.nih.gov/pubmed/18996527</URL>
              </Markup>
              <Markup>
                <Start>84</Start>
                <Length>12</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/nicotinamide</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-936</Extra>
              </Markup>
              <Markup>
                <Start>121</Start>
                <Length>12</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/homocysteine</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>multiple-CIDs</Extra>
              </Markup>
            </StringWithMarkup>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>11</ReferenceNumber>
          <Name>References</Name>
          <Value>
            <StringWithMarkup>
              <String>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970.  Epub 2009 Nov 24. [PMID: 19934256]</String>
              <Markup>
                <Start>336</Start>
                <Length>14</Length>
                <URL>https://www.ncbi.nlm.nih.gov/pubmed/19934256</URL>
              </Markup>
            </StringWithMarkup>
            <StringWithMarkup>
              <String>Gaudineau C, Auclair K: Inhibition of human P450 enzymes by nicotinic acid and nicotinamide. Biochem Biophys Res Commun. 2004 May 7;317(3):950-6. doi: 10.1016/j.bbrc.2004.03.137. [PMID: 15081432]</String>
              <Markup>
                <Start>180</Start>
                <Length>14</Length>
                <URL>https://www.ncbi.nlm.nih.gov/pubmed/15081432</URL>
              </Markup>
              <Markup>
                <Start>60</Start>
                <Length>14</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/nicotinic%20acid</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>79</Start>
                <Length>12</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/nicotinamide</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-936</Extra>
              </Markup>
            </StringWithMarkup>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>12</ReferenceNumber>
          <Name>References</Name>
          <Value>
            <StringWithMarkup>
              <String>Ohashi R, Tamai I, Yabuuchi H, Nezu JI, Oku A, Sai Y, Shimane M, Tsuji A: Na(+)-dependent carnitine transport by organic cation transporter (OCTN2): its pharmacological and toxicological relevance. J Pharmacol Exp Ther. 1999 Nov;291(2):778-84. [PMID: 10525100]</String>
              <Markup>
                <Start>245</Start>
                <Length>14</Length>
                <URL>https://www.ncbi.nlm.nih.gov/pubmed/10525100</URL>
              </Markup>
              <Markup>
                <Start>90</Start>
                <Length>9</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/carnitine</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-288</Extra>
              </Markup>
            </StringWithMarkup>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>13</ReferenceNumber>
          <Name>References</Name>
          <Value>
            <StringWithMarkup>
              <String>Kobayashi D, Nozawa T, Imai K, Nezu J, Tsuji A, Tamai I: Involvement of human organic anion transporting polypeptide OATP-B (SLC21A9) in pH-dependent transport across intestinal apical membrane. J Pharmacol Exp Ther. 2003 Aug;306(2):703-8. Epub 2003 Apr 30. [PMID: 12724351]</String>
              <Markup>
                <Start>259</Start>
                <Length>14</Length>
                <URL>https://www.ncbi.nlm.nih.gov/pubmed/12724351</URL>
              </Markup>
              <Markup>
                <Start>117</Start>
                <Length>4</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/OATP</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>multiple-CIDs</Extra>
              </Markup>
            </StringWithMarkup>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>14</ReferenceNumber>
          <Name>References</Name>
          <Value>
            <StringWithMarkup>
              <String>Tamai I, Sai Y, Ono A, Kido Y, Yabuuchi H, Takanaga H, Satoh E, Ogihara T, Amano O, Izeki S, Tsuji A: Immunohistochemical and functional characterization of pH-dependent intestinal absorption of weak organic acids by the monocarboxylic acid transporter MCT1. J Pharm Pharmacol. 1999 Oct;51(10):1113-21. [PMID: 10579682]</String>
              <Markup>
                <Start>304</Start>
                <Length>14</Length>
                <URL>https://www.ncbi.nlm.nih.gov/pubmed/10579682</URL>
              </Markup>
            </StringWithMarkup>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>15</ReferenceNumber>
          <Name>References</Name>
          <Value>
            <StringWithMarkup>
              <String>Gopal E, Fei YJ, Miyauchi S, Zhuang L, Prasad PD, Ganapathy V: Sodium-coupled and electrogenic transport of B-complex vitamin nicotinic acid by slc5a8, a member of the Na/glucose co-transporter gene family. Biochem J. 2005 May 15;388(Pt 1):309-16. [PMID: 15651982]</String>
              <Markup>
                <Start>249</Start>
                <Length>14</Length>
                <URL>https://www.ncbi.nlm.nih.gov/pubmed/15651982</URL>
              </Markup>
              <Markup>
                <Start>63</Start>
                <Length>6</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/element/Sodium</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>Element-Sodium</Extra>
              </Markup>
              <Markup>
                <Start>126</Start>
                <Length>14</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/nicotinic%20acid</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-938</Extra>
              </Markup>
              <Markup>
                <Start>171</Start>
                <Length>7</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/glucose</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-5793</Extra>
              </Markup>
            </StringWithMarkup>
          </Value>
        </Information>
        <Information>
          <ReferenceNumber>16</ReferenceNumber>
          <Name>References</Name>
          <Value>
            <StringWithMarkup>
              <String>Shimada A, Nakagawa Y, Morishige H, Yamamoto A, Fujita T: Functional characteristics of H+ -dependent nicotinate transport in primary cultures of astrocytes from rat cerebral cortex. Neurosci Lett. 2006 Jan 16;392(3):207-12. Epub 2005 Oct 5. [PMID: 16213084]</String>
              <Markup>
                <Start>243</Start>
                <Length>14</Length>
                <URL>https://www.ncbi.nlm.nih.gov/pubmed/16213084</URL>
              </Markup>
              <Markup>
                <Start>102</Start>
                <Length>10</Length>
                <URL>https://pubchem.ncbi.nlm.nih.gov/compound/nicotinate</URL>
                <Type>PubChem Internal Link</Type>
                <Extra>CID-937</Extra>
              </Markup>
            </StringWithMarkup>
          </Value>
        </Information>
      </Section>
    </Section>
  </Section>
  <Section>
    <TOCHeading>Biological Test Results</TOCHeading>
    <Description>A PubChem substance or compound summary page displays biological test results from the PubChem BioAssay database, if/as available, for the chemical structure currently displayed. (Note that you can embed biological test results displays within your own web pages, for a PubChem Compound or Substance of interest, by using theBioActivity Widget.)</Description>
    <URL>https://pubchemdocs.ncbi.nlm.nih.gov/bioassays</URL>
    <Section>
      <TOCHeading>BioAssay Results</TOCHeading>
      <Description>BioActivity information showed in tabular widget.</Description>
      <Information>
        <ReferenceNumber>77</ReferenceNumber>
        <Value>
          <ExternalTableName>bioactivity</ExternalTableName>
        </Value>
      </Information>
    </Section>
  </Section>
  <Section>
    <TOCHeading>Classification</TOCHeading>
    <Description>Classification systems from MeSH, ChEBI, Kegg, etc.</Description>
    <URL>https://pubchem.ncbi.nlm.nih.gov/classification</URL>
    <Section>
      <TOCHeading>Ontologies</TOCHeading>
      <Description>Ontologies</Description>
      <Section>
        <TOCHeading>MeSH Tree</TOCHeading>
        <Description>MeSH tree</Description>
        <Information>
          <ReferenceNumber>78</ReferenceNumber>
          <Name>HID</Name>
          <URL>https://pubchem.ncbi.nlm.nih.gov/classification/#hid=1</URL>
          <Value>
            <Number>1</Number>
          </Value>
        </Information>
      </Section>
      <Section>
        <TOCHeading>ChEBI Ontology</TOCHeading>
        <Description>ChEBI Ontology tree</Description>
        <Information>
          <ReferenceNumber>79</ReferenceNumber>
          <Name>HID</Name>
          <URL>https://pubchem.ncbi.nlm.nih.gov/classification/#hid=2</URL>
          <Value>
            <Number>2</Number>
          </Value>
        </Information>
      </Section>
      <Section>
        <TOCHeading>KEGG: Metabolite</TOCHeading>
        <Description>KEGG : Metabolite tree</Description>
        <Information>
          <ReferenceNumber>80</ReferenceNumber>
          <Name>HID</Name>
          <URL>https://pubchem.ncbi.nlm.nih.gov/classification/#hid=3</URL>
          <Value>
            <Number>3</Number>
          </Value>
        </Information>
      </Section>
      <Section>
        <TOCHeading>KEGG: Phytochemical Compounds</TOCHeading>
        <Description>KEGG : Phytochemical Compounds tree</Description>
        <Information>
          <ReferenceNumber>81</ReferenceNumber>
          <Name>HID</Name>
          <URL>https://pubchem.ncbi.nlm.nih.gov/classification/#hid=5</URL>
          <Value>
            <Number>5</Number>
          </Value>
        </Information>
      </Section>
      <Section>
        <TOCHeading>KEGG: Drug</TOCHeading>
        <Description>KEGG : Drug tree</Description>
        <Information>
          <ReferenceNumber>82</ReferenceNumber>
          <Name>HID</Name>
          <URL>https://pubchem.ncbi.nlm.nih.gov/classification/#hid=14</URL>
          <Value>
            <Number>14</Number>
          </Value>
        </Information>
      </Section>
      <Section>
        <TOCHeading>KEGG: USP</TOCHeading>
        <Description>KEGG : USP tree</Description>
        <Information>
          <ReferenceNumber>83</ReferenceNumber>
          <Name>HID</Name>
          <URL>https://pubchem.ncbi.nlm.nih.gov/classification/#hid=15</URL>
          <Value>
            <Number>15</Number>
          </Value>
        </Information>
      </Section>
      <Section>
        <TOCHeading>KEGG: ATC</TOCHeading>
        <Description>KEGG : ATC tree</Description>
        <Information>
          <ReferenceNumber>84</ReferenceNumber>
          <Name>HID</Name>
          <URL>https://pubchem.ncbi.nlm.nih.gov/classification/#hid=16</URL>
          <Value>
            <Number>16</Number>
          </Value>
        </Information>
      </Section>
      <Section>
        <TOCHeading>KEGG: JP15</TOCHeading>
        <Description>KEGG : JP15 tree</Description>
        <Information>
          <ReferenceNumber>85</ReferenceNumber>
          <Name>HID</Name>
          <URL>https://pubchem.ncbi.nlm.nih.gov/classification/#hid=23</URL>
          <Value>
            <Number>23</Number>
          </Value>
        </Information>
      </Section>
      <Section>
        <TOCHeading>KEGG: Risk Category of Japanese OTC Drugs</TOCHeading>
        <Description>KEGG : Risk Category of Japanese OTC Drugs tree</Description>
        <Information>
          <ReferenceNumber>86</ReferenceNumber>
          <Name>HID</Name>
          <URL>https://pubchem.ncbi.nlm.nih.gov/classification/#hid=24</URL>
          <Value>
            <Number>24</Number>
          </Value>
        </Information>
      </Section>
      <Section>
        <TOCHeading>KEGG: Animal Drugs</TOCHeading>
        <Description>KEGG : Animal Drugs tree</Description>
        <Information>
          <ReferenceNumber>87</ReferenceNumber>
          <Name>HID</Name>
          <URL>https://pubchem.ncbi.nlm.nih.gov/classification/#hid=28</URL>
          <Value>
            <Number>28</Number>
          </Value>
        </Information>
      </Section>
      <Section>
        <TOCHeading>KEGG: Drug Classes</TOCHeading>
        <Description>KEGG : Drug Classes tree</Description>
        <Information>
          <ReferenceNumber>96</ReferenceNumber>
          <Name>HID</Name>
          <URL>https://pubchem.ncbi.nlm.nih.gov/classification/#hid=96</URL>
          <Value>
            <Number>96</Number>
          </Value>
        </Information>
      </Section>
      <Section>
        <TOCHeading>WHO ATC Classification System</TOCHeading>
        <Description>The Anatomical Therapeutic Chemical (ATC) Classification System is used for the classification of drugs. This pharmaceutical coding system divides drugs into different groups according to the organ or system on which they act and/or their therapeutic and chemical characteristics. Each bottom-level ATC code stands for a pharmaceutically used substance, or a combination of substances, in a single indication (or use). This means that one drug can have more than one code: acetylsalicylic acid (aspirin), for example, has A01AD05 as a drug for local oral treatment, B01AC06 as a platelet inhibitor, and N02BA01 as an analgesic and antipyretic. On the other hand, several different brands share the same code if they have the same active substance and indications.</Description>
        <URL>http://www.whocc.no/atc/</URL>
        <Information>
          <ReferenceNumber>90</ReferenceNumber>
          <Name>HID</Name>
          <URL>https://pubchem.ncbi.nlm.nih.gov/classification/#hid=79</URL>
          <Value>
            <Number>79</Number>
          </Value>
        </Information>
      </Section>
      <Section>
        <TOCHeading>FDA Pharm Classes</TOCHeading>
        <Description>FDA Pharm Classes tree</Description>
        <Information>
          <ReferenceNumber>89</ReferenceNumber>
          <Name>HID</Name>
          <URL>https://pubchem.ncbi.nlm.nih.gov/classification/#hid=78</URL>
          <Value>
            <Number>78</Number>
          </Value>
        </Information>
      </Section>
      <Section>
        <TOCHeading>WIPO IPC</TOCHeading>
        <Description>WIPO IPC tree</Description>
        <Information>
          <ReferenceNumber>88</ReferenceNumber>
          <Name>HID</Name>
          <URL>https://pubchem.ncbi.nlm.nih.gov/classification/#hid=58</URL>
          <Value>
            <Number>58</Number>
          </Value>
        </Information>
      </Section>
      <Section>
        <TOCHeading>ChemIDplus</TOCHeading>
        <Description>ChemIDplus tree</Description>
        <Information>
          <ReferenceNumber>92</ReferenceNumber>
          <Name>HID</Name>
          <URL>https://pubchem.ncbi.nlm.nih.gov/classification/#hid=84</URL>
          <Value>
            <Number>84</Number>
          </Value>
        </Information>
      </Section>
      <Section>
        <TOCHeading>CAMEO Chemicals</TOCHeading>
        <Description>CAMEO Chemical Reactivity Classification</Description>
        <Information>
          <ReferenceNumber>93</ReferenceNumber>
          <Name>HID</Name>
          <URL>https://pubchem.ncbi.nlm.nih.gov/classification/#hid=86</URL>
          <Value>
            <Number>86</Number>
          </Value>
        </Information>
      </Section>
      <Section>
        <TOCHeading>Guide to PHARMACOLOGY Target Classification</TOCHeading>
        <Description>Protein classification from the IUPHAR/BPS Guide to PHARMACOLOGY.</Description>
        <URL>http://guidetopharmacology.org/targets.jsp</URL>
        <Information>
          <ReferenceNumber>95</ReferenceNumber>
          <Name>HID</Name>
          <URL>https://pubchem.ncbi.nlm.nih.gov/classification/#hid=92</URL>
          <Value>
            <Number>92</Number>
          </Value>
        </Information>
      </Section>
      <Section>
        <TOCHeading>ChEMBL Target Tree</TOCHeading>
        <Description>Protein target tree from ChEMBL</Description>
        <URL>https://www.ebi.ac.uk/chembl/target/browser</URL>
        <Information>
          <ReferenceNumber>94</ReferenceNumber>
          <Name>HID</Name>
          <URL>https://pubchem.ncbi.nlm.nih.gov/classification/#hid=87</URL>
          <Value>
            <Number>87</Number>
          </Value>
        </Information>
      </Section>
      <Section>
        <TOCHeading>UN GHS Classification</TOCHeading>
        <Description>The United Nations&apos; Globally Harmonised System of Classification and Labelling of Chemicals (GHS) provides a harmonised basis for globally uniform physical, environmental, and health and safety information on hazardous chemical substances and mixtures.</Description>
        <Information>
          <ReferenceNumber>91</ReferenceNumber>
          <Name>HID</Name>
          <URL>https://pubchem.ncbi.nlm.nih.gov/classification/#hid=83</URL>
          <Value>
            <Number>83</Number>
          </Value>
        </Information>
      </Section>
    </Section>
  </Section>
  <Reference>
    <ReferenceNumber>1</ReferenceNumber>
    <SourceName>CAMEO Chemicals</SourceName>
    <SourceID>20737</SourceID>
    <Name>NICOTINIC ACID</Name>
    <URL>https://cameochemicals.noaa.gov/chemical/20737</URL>
    <ANID>759810</ANID>
  </Reference>
  <Reference>
    <ReferenceNumber>20</ReferenceNumber>
    <SourceName>EPA Chemicals under the TSCA</SourceName>
    <SourceID>59-67-6</SourceID>
    <Name>3-Pyridinecarboxylic acid</Name>
    <Description>EPA Chemicals under the Toxic Substances Control Act (TSCA) collection contains information on chemicals and their regulation under TSCA, including non-confidential content from the TSCA Chemical Substance Inventory, Acute Exposure Guideline Levels (AEGLs), and Chemical Data Reporting.</Description>
    <URL>https://www.epa.gov/chemicals-under-tsca</URL>
    <ANID>2131787</ANID>
  </Reference>
  <Reference>
    <ReferenceNumber>33</ReferenceNumber>
    <SourceName>Human Metabolome Database (HMDB)</SourceName>
    <SourceID>HMDB0001488</SourceID>
    <Name>Nicotinic acid</Name>
    <Description>The Human Metabolome Database (HMDB) is a freely available electronic database containing detailed information about small molecule metabolites found in the human body.</Description>
    <URL>http://www.hmdb.ca/metabolites/HMDB0001488</URL>
    <ANID>2143308</ANID>
  </Reference>
  <Reference>
    <ReferenceNumber>34</ReferenceNumber>
    <SourceName>ILO International Chemical Safety Cards (ICSC)</SourceName>
    <SourceID>1702</SourceID>
    <Name>NICOTINIC ACID</Name>
    <Description>International Chemical Safety Cards (ICSC) are data sheets intended to provide essential safety and health information on chemicals in a clear and concise way.</Description>
    <URL>http://www.ilo.org/dyn/icsc/showcard.display?p_version=2&amp;p_card_id=1702</URL>
    <ANID>2261493</ANID>
  </Reference>
  <Reference>
    <ReferenceNumber>2</ReferenceNumber>
    <SourceName>ChEBI</SourceName>
    <SourceID>CHEBI:OBO:938</SourceID>
    <Name>Nicotinic acid</Name>
    <URL>http://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:15940</URL>
    <ANID>2478723</ANID>
  </Reference>
  <Reference>
    <ReferenceNumber>17</ReferenceNumber>
    <SourceName>DrugBank</SourceName>
    <SourceID>DB00627</SourceID>
    <Name>Niacin</Name>
    <URL>http://www.drugbank.ca/drugs/DB00627</URL>
    <ANID>3604554</ANID>
  </Reference>
  <Reference>
    <ReferenceNumber>30</ReferenceNumber>
    <SourceName>FDA Pharm Classes</SourceName>
    <SourceID>2679MF687A</SourceID>
    <Name>NIACIN</Name>
    <Description>FDA Pharmacologic class is a group of active moieties that share scientifically documented properties and is defined on the basis of any combination of attributes of the active moiety. Read more at https://www.fda.gov/forindustry/datastandards/structuredproductlabeling/ucm162549.htm</Description>
    <URL>https://www.accessdata.fda.gov/spl/data/5ebd3d3b-9a5e-4c13-850d-9147fff333c6/5ebd3d3b-9a5e-4c13-850d-9147fff333c6.xml</URL>
    <ANID>6490031</ANID>
  </Reference>
  <Reference>
    <ReferenceNumber>35</ReferenceNumber>
    <SourceName>LiverTox</SourceName>
    <SourceID>Niacin</SourceID>
    <Name>Niacin</Name>
    <Description>LIVERTOX provides up-to-date, accurate, and easily accessed information on the diagnosis, cause, frequency, patterns, and management of liver injury attributable to prescription and nonprescription medications, herbals and dietary supplements. Read more: https://livertox.nlm.nih.gov/</Description>
    <URL>https://livertox.nlm.nih.gov/Niacin.htm</URL>
    <IsToxnet>true</IsToxnet>
    <ANID>2262209</ANID>
  </Reference>
  <Reference>
    <ReferenceNumber>41</ReferenceNumber>
    <SourceName>NCIt</SourceName>
    <SourceID>C689_3316</SourceID>
    <Name>Niacin</Name>
    <Description>NCI Thesaurus (NCIt) provides reference terminology for many systems. It covers vocabulary for clinical care, translational and basic research, and public information and administrative activities.</Description>
    <URL>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;ns=NCI_Thesaurus&amp;code=C689</URL>
    <ANID>7686435</ANID>
  </Reference>
  <Reference>
    <ReferenceNumber>32</ReferenceNumber>
    <SourceName>HSDB</SourceName>
    <SourceID>3134</SourceID>
    <Name>Nicotinic acid</Name>
    <Description>Nicotinic acid (pyridine-3-carboxylic acid) is a form of Vitamin B3 found in yeast, meats, milk, eggs, cereal grains, and green vegetables.  It can be produced in the body from tryptophan, which is found in most protein-containing foods.  Nicotinic acid should not be confused with niacinamide, inositol nicotinate, or trytophan.  Vitamin B3 is Niacin (a name coined from &quot;nicotinic acid vitamin&quot;) and has fundamental biological roles as part of reduction/oxidation coenzymes involved in energy metabolism, amino acid metabolism, and detoxification reactions for drugs and other substances.  Niacin comes in several forms: (1) nicotinic acid, (2) nicotinamide (nicotinic acid amide), and (3) other derivatives (e.g., inositol hexanicotinate) that exhibit biological activity.  There are other derivatives may be converted to nicotinic acid or may contain nicotinic acid, nicotinamide, or their releasable moieties; whether these compounds should be referred to as niacin depends on the biological effects that are attributed to them, the interpretation of the evidence for the rates of uptake and metabolism, and the release of the chemical components (bioavailability) that produce biological effects similar to the primary forms of niacin.</Description>
    <URL>https://toxnet.nlm.nih.gov/cgi-bin/sis/search/r?dbs+hsdb:@term+@rn+@rel+59-67-6</URL>
    <IsToxnet>true</IsToxnet>
    <ANID>2302</ANID>
  </Reference>
  <Reference>
    <ReferenceNumber>21</ReferenceNumber>
    <SourceName>EPA DSSTox</SourceName>
    <SourceID>DTXSID1020932</SourceID>
    <Name>Nicotinic acid</Name>
    <Description>DSSTox provides a high quality public chemistry resource for supporting improved predictive toxicology.</Description>
    <URL>https://comptox.epa.gov/dashboard/DTXSID1020932</URL>
    <ANID>1149376</ANID>
  </Reference>
  <Reference>
    <ReferenceNumber>52</ReferenceNumber>
    <SourceName>Sanford-Burnham Center for Chemical Genomics</SourceName>
    <SourceID>SID8139875</SourceID>
    <Name>SID8139875</Name>
    <Description>Aqueous solubility in buffer at pH 7.4</Description>
    <URL>https://pubchem.ncbi.nlm.nih.gov/bioassay/1996#section=Data-Table</URL>
    <ANID>694636</ANID>
  </Reference>
  <Reference>
    <ReferenceNumber>3</ReferenceNumber>
    <SourceName>ChemIDplus</SourceName>
    <SourceID>0000059676</SourceID>
    <Name>Niacin [USP]</Name>
    <URL>https://chem.nlm.nih.gov/chemidplus/sid/0000059676</URL>
    <IsToxnet>true</IsToxnet>
    <ANID>762279</ANID>
  </Reference>
  <Reference>
    <ReferenceNumber>18</ReferenceNumber>
    <SourceName>DTP/NCI</SourceName>
    <SourceID>NSC 757241</SourceID>
    <Name>niacin</Name>
    <Description>The NCI Development Therapeutics Program (DTP) provides services and resources to the academic and private-sector research communities worldwide to facilitate the discovery and development of new cancer therapeutic agents.</Description>
    <URL>https://dtp.cancer.gov/dtpstandard/servlet/dwindex?searchtype=NSC&amp;outputformat=html&amp;searchlist=757241</URL>
    <ANID>6608639</ANID>
  </Reference>
  <Reference>
    <ReferenceNumber>19</ReferenceNumber>
    <SourceName>DTP/NCI</SourceName>
    <SourceID>NSC 169454</SourceID>
    <Name>nicotinic acid</Name>
    <Description>The NCI Development Therapeutics Program (DTP) provides services and resources to the academic and private-sector research communities worldwide to facilitate the discovery and development of new cancer therapeutic agents.</Description>
    <URL>https://dtp.cancer.gov/dtpstandard/servlet/dwindex?searchtype=NSC&amp;outputformat=html&amp;searchlist=169454</URL>
    <ANID>6752332</ANID>
  </Reference>
  <Reference>
    <ReferenceNumber>24</ReferenceNumber>
    <SourceName>European Chemicals Agency (ECHA)</SourceName>
    <SourceID>200-441-0</SourceID>
    <Name>Nicotinic acid</Name>
    <Description>The European Chemicals Agency (ECHA) is an agency of the European Union which is the driving force among regulatory authorities in implementing the EU&apos;s groundbreaking chemicals legislation for the benefit of human health and the environment as well as for innovation and competitiveness.</Description>
    <URL>https://echa.europa.eu/substance-information/-/substanceinfo/100.000.401</URL>
    <ANID>1977116</ANID>
  </Reference>
  <Reference>
    <ReferenceNumber>72</ReferenceNumber>
    <SourceName>The National Institute for Occupational Safety and Health (NIOSH)</SourceName>
    <SourceID>QT0525000</SourceID>
    <Name>Nicotinic acid</Name>
    <Description>The NIOSH Pocket Guide to Chemical Hazards is intended as a source of general industrial hygiene information on several hundred chemicals/classes for workers, employers, and occupational health professionals. Read more at: https://www.cdc.gov/niosh/npg/default.html</Description>
    <URL>https://www.cdc.gov/niosh-rtecs/QT802C8.html</URL>
    <ANID>2268185</ANID>
  </Reference>
  <Reference>
    <ReferenceNumber>4</ReferenceNumber>
    <SourceName>ChemIDplus</SourceName>
    <SourceID>r_938</SourceID>
    <Description>The toxicity data was from the legacy RTECS data set in ChemIDplus.</Description>
    <URL>https://chem.nlm.nih.gov/chemidplus/sid/0000059676</URL>
    <IsToxnet>true</IsToxnet>
    <ANID>3741027</ANID>
  </Reference>
  <Reference>
    <ReferenceNumber>5</ReferenceNumber>
    <SourceName>ClinicalTrials.gov</SourceName>
    <SourceID>cid938</SourceID>
    <Name>Niacin</Name>
    <URL>https://clinicaltrials.gov/</URL>
    <ANID>5186521</ANID>
  </Reference>
  <Reference>
    <ReferenceNumber>6</ReferenceNumber>
    <SourceName>DailyMed</SourceName>
    <SourceID>NIACIN</SourceID>
    <Name>NIACIN</Name>
    <Description>DailyMed provides trustworthy information about marketed drugs in the United States. DailyMed is the official provider of FDA label information (package inserts).</Description>
    <URL>https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&amp;query=NIACIN</URL>
    <ANID>2127338</ANID>
  </Reference>
  <Reference>
    <ReferenceNumber>7</ReferenceNumber>
    <SourceName>DrugBank</SourceName>
    <SourceID>DB00627 interaction #1</SourceID>
    <URL>http://www.drugbank.ca/drugs/DB00627#targets</URL>
    <ANID>3604544</ANID>
  </Reference>
  <Reference>
    <ReferenceNumber>8</ReferenceNumber>
    <SourceName>DrugBank</SourceName>
    <SourceID>DB00627 interaction #2</SourceID>
    <URL>http://www.drugbank.ca/drugs/DB00627#targets</URL>
    <ANID>3604545</ANID>
  </Reference>
  <Reference>
    <ReferenceNumber>9</ReferenceNumber>
    <SourceName>DrugBank</SourceName>
    <SourceID>DB00627 interaction #3</SourceID>
    <URL>http://www.drugbank.ca/drugs/DB00627#targets</URL>
    <ANID>3604546</ANID>
  </Reference>
  <Reference>
    <ReferenceNumber>10</ReferenceNumber>
    <SourceName>DrugBank</SourceName>
    <SourceID>DB00627 interaction #4</SourceID>
    <URL>http://www.drugbank.ca/drugs/DB00627#targets</URL>
    <ANID>3604547</ANID>
  </Reference>
  <Reference>
    <ReferenceNumber>11</ReferenceNumber>
    <SourceName>DrugBank</SourceName>
    <SourceID>DB00627 interaction #5</SourceID>
    <URL>http://www.drugbank.ca/drugs/DB00627#enzymes</URL>
    <ANID>3604548</ANID>
  </Reference>
  <Reference>
    <ReferenceNumber>12</ReferenceNumber>
    <SourceName>DrugBank</SourceName>
    <SourceID>DB00627 interaction #6</SourceID>
    <URL>http://www.drugbank.ca/drugs/DB00627#transporters</URL>
    <ANID>3604549</ANID>
  </Reference>
  <Reference>
    <ReferenceNumber>13</ReferenceNumber>
    <SourceName>DrugBank</SourceName>
    <SourceID>DB00627 interaction #7</SourceID>
    <URL>http://www.drugbank.ca/drugs/DB00627#transporters</URL>
    <ANID>3604550</ANID>
  </Reference>
  <Reference>
    <ReferenceNumber>14</ReferenceNumber>
    <SourceName>DrugBank</SourceName>
    <SourceID>DB00627 interaction #8</SourceID>
    <URL>http://www.drugbank.ca/drugs/DB00627#transporters</URL>
    <ANID>3604551</ANID>
  </Reference>
  <Reference>
    <ReferenceNumber>16</ReferenceNumber>
    <SourceName>DrugBank</SourceName>
    <SourceID>DB00627 interaction #10</SourceID>
    <URL>http://www.drugbank.ca/drugs/DB00627#transporters</URL>
    <ANID>3604553</ANID>
  </Reference>
  <Reference>
    <ReferenceNumber>15</ReferenceNumber>
    <SourceName>DrugBank</SourceName>
    <SourceID>DB00627 interaction #9</SourceID>
    <URL>http://www.drugbank.ca/drugs/DB00627#transporters</URL>
    <ANID>3604552</ANID>
  </Reference>
  <Reference>
    <ReferenceNumber>25</ReferenceNumber>
    <SourceName>European Medicines Agency (EMA)</SourceName>
    <SourceID>P/72/2008</SourceID>
    <Name>Nicotinic acid, simvastatin and laropiprant</Name>
    <Description>The European Medicines Agency (EMA) presents information on regulatory topics of the medicinal product lifecycle in EU countries.</Description>
    <URL>https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/nicotinic-acid-simvastatin-laropiprant-1</URL>
    <ANID>5130912</ANID>
  </Reference>
  <Reference>
    <ReferenceNumber>26</ReferenceNumber>
    <SourceName>European Medicines Agency (EMA)</SourceName>
    <SourceID>P/71/2008</SourceID>
    <Name>Nicotinic acid, simvastatin and laropiprant</Name>
    <Description>The European Medicines Agency (EMA) presents information on regulatory topics of the medicinal product lifecycle in EU countries.</Description>
    <URL>https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/nicotinic-acid-simvastatin-laropiprant</URL>
    <ANID>5131386</ANID>
  </Reference>
  <Reference>
    <ReferenceNumber>27</ReferenceNumber>
    <SourceName>European Medicines Agency (EMA)</SourceName>
    <SourceID>P/70/2008</SourceID>
    <Name>Nicotinic acid, simvastatin and laropiprant</Name>
    <Description>The European Medicines Agency (EMA) presents information on regulatory topics of the medicinal product lifecycle in EU countries.</Description>
    <URL>https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/nicotinic-acid-simvastatin-laropiprant-0</URL>
    <ANID>5131623</ANID>
  </Reference>
  <Reference>
    <ReferenceNumber>22</ReferenceNumber>
    <SourceName>EU Clinical Trials Register</SourceName>
    <SourceID>cid938</SourceID>
    <URL>https://www.clinicaltrialsregister.eu/</URL>
    <ANID>6478948</ANID>
  </Reference>
  <Reference>
    <ReferenceNumber>23</ReferenceNumber>
    <SourceName>European Chemicals Agency (ECHA)</SourceName>
    <SourceID>111679</SourceID>
    <Name>Nicotinic acid</Name>
    <Description>The information provided here is aggregated from the &quot;Notified classification and labelling&quot; from ECHA&apos;s C&amp;L Inventory. Read more: https://echa.europa.eu/information-on-chemicals/cl-inventory-database</Description>
    <URL>https://echa.europa.eu/information-on-chemicals/cl-inventory-database/-/discli/details/111679</URL>
    <ANID>1883895</ANID>
  </Reference>
  <Reference>
    <ReferenceNumber>28</ReferenceNumber>
    <SourceName>FDA Center for Food Safety and Applied Nutrition (CFSAN)</SourceName>
    <SourceID>e_2707</SourceID>
    <Name>NIACIN</Name>
    <Description>The Substances Added to Food (formerly EAFUS) inventory contains approximately 4,000 substances, and includes information on food additives, color additives, Generally Recognized As Safe (GRAS) and prior-sanctioned substances.&#x9;https://www.accessdata.fda.gov/scripts/fdcc/?set=FoodSubstances</Description>
    <URL>https://www.accessdata.fda.gov/scripts/fdcc/?set=FoodSubstances&amp;id=NIACIN</URL>
    <ANID>6477634</ANID>
  </Reference>
  <Reference>
    <ReferenceNumber>29</ReferenceNumber>
    <SourceName>FDA Orange Book</SourceName>
    <SourceID>org_938</SourceID>
    <Description>The publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the List, commonly known as the Orange Book), identifies drug products approved on the basis of safety and effectiveness by the Food and Drug Administration (FDA) under the Federal Food, Drug, and Cosmetic Act (the Act).</Description>
    <URL>https://www.fda.gov/Drugs/InformationOnDrugs/ucm129662.htm</URL>
    <ANID>396809</ANID>
  </Reference>
  <Reference>
    <ReferenceNumber>31</ReferenceNumber>
    <SourceName>FDA/SPL Indexing Data</SourceName>
    <SourceID>2679MF687A</SourceID>
    <Name>2679MF687A</Name>
    <Description>The UNique Ingredient Identifier (UNII) is an alphanumeric substance identifier from the joint FDA/USP Substance Registration System (SRS).</Description>
    <URL>https://www.fda.gov/ForIndustry/DataStandards/SubstanceRegistrationSystem-UniqueIngredientIdentifierUNII/</URL>
    <ANID>5792565</ANID>
  </Reference>
  <Reference>
    <ReferenceNumber>50</ReferenceNumber>
    <SourceName>NMRShiftDB</SourceName>
    <SourceID>20027733</SourceID>
    <Description>NMRShiftDB(2) is a NMR database (web database) for organic structures and their nuclear magnetic resonance (nmr) spectra. It allows for spectrum prediction (13C, 1H and other nuclei) as well as for searching spectra, structures and other properties. http://nmrshiftdb.nmr.uni-koeln.de/</Description>
    <URL>https://pubchem.ncbi.nlm.nih.gov/substance/839469</URL>
    <ANID>6436703</ANID>
  </Reference>
  <Reference>
    <ReferenceNumber>36</ReferenceNumber>
    <SourceName>MassBank of North America (MoNA)</SourceName>
    <SourceID>FiehnHILIC000611</SourceID>
    <Name>Nicotinic acid</Name>
    <Description>MassBank of North America (MoNA) is a metadata-centric, auto-curating repository designed for efficient storage and querying of mass spectral records. CLick the link above to see all spectral information from this compound.</Description>
    <URL>http://mona.fiehnlab.ucdavis.edu/spectra/browse?inchikey=PVNIIMVLHYAWGP-UHFFFAOYSA-N</URL>
    <ANID>3412666</ANID>
  </Reference>
  <Reference>
    <ReferenceNumber>37</ReferenceNumber>
    <SourceName>MassBank of North America (MoNA)</SourceName>
    <SourceID>MoNA003051</SourceID>
    <Name>Nicotinic acid; CE10; PVNIIMVLHYAWGP-UHFFFAOYSA-N</Name>
    <Description>MassBank of North America (MoNA) is a metadata-centric, auto-curating repository designed for efficient storage and querying of mass spectral records. CLick the link above to see all spectral information from this compound.</Description>
    <URL>http://mona.fiehnlab.ucdavis.edu/spectra/browse?inchikey=PVNIIMVLHYAWGP-UHFFFAOYSA-N</URL>
    <ANID>7676788</ANID>
  </Reference>
  <Reference>
    <ReferenceNumber>38</ReferenceNumber>
    <SourceName>MassBank of North America (MoNA)</SourceName>
    <SourceID>MoNA003052</SourceID>
    <Name>Nicotinic acid; CE20; PVNIIMVLHYAWGP-UHFFFAOYSA-N</Name>
    <Description>MassBank of North America (MoNA) is a metadata-centric, auto-curating repository designed for efficient storage and querying of mass spectral records. CLick the link above to see all spectral information from this compound.</Description>
    <URL>http://mona.fiehnlab.ucdavis.edu/spectra/browse?inchikey=PVNIIMVLHYAWGP-UHFFFAOYSA-N</URL>
    <ANID>7676789</ANID>
  </Reference>
  <Reference>
    <ReferenceNumber>39</ReferenceNumber>
    <SourceName>MassBank of North America (MoNA)</SourceName>
    <SourceID>MoNA003053</SourceID>
    <Name>Nicotinic acid; CE30; PVNIIMVLHYAWGP-UHFFFAOYSA-N</Name>
    <Description>MassBank of North America (MoNA) is a metadata-centric, auto-curating repository designed for efficient storage and querying of mass spectral records. CLick the link above to see all spectral information from this compound.</Description>
    <URL>http://mona.fiehnlab.ucdavis.edu/spectra/browse?inchikey=PVNIIMVLHYAWGP-UHFFFAOYSA-N</URL>
    <ANID>7676790</ANID>
  </Reference>
  <Reference>
    <ReferenceNumber>40</ReferenceNumber>
    <SourceName>MassBank of North America (MoNA)</SourceName>
    <SourceID>MoNA003054</SourceID>
    <Name>Nicotinic acid; CE40; PVNIIMVLHYAWGP-UHFFFAOYSA-N</Name>
    <Description>MassBank of North America (MoNA) is a metadata-centric, auto-curating repository designed for efficient storage and querying of mass spectral records. CLick the link above to see all spectral information from this compound.</Description>
    <URL>http://mona.fiehnlab.ucdavis.edu/spectra/browse?inchikey=PVNIIMVLHYAWGP-UHFFFAOYSA-N</URL>
    <ANID>7676791</ANID>
  </Reference>
  <Reference>
    <ReferenceNumber>53</ReferenceNumber>
    <SourceName>SpectraBase</SourceName>
    <SourceID>Asz28UwMTPG</SourceID>
    <Name></Name>
    <URL>https://spectrabase.com/spectrum/Asz28UwMTPG</URL>
    <ANID>4975081</ANID>
  </Reference>
  <Reference>
    <ReferenceNumber>56</ReferenceNumber>
    <SourceName>SpectraBase</SourceName>
    <SourceID>4pPSBsn6fDW</SourceID>
    <Name></Name>
    <URL>https://spectrabase.com/spectrum/4pPSBsn6fDW</URL>
    <ANID>4975084</ANID>
  </Reference>
  <Reference>
    <ReferenceNumber>55</ReferenceNumber>
    <SourceName>SpectraBase</SourceName>
    <SourceID>5lXbMRxggfO</SourceID>
    <Name></Name>
    <URL>https://spectrabase.com/spectrum/5lXbMRxggfO</URL>
    <ANID>4975083</ANID>
  </Reference>
  <Reference>
    <ReferenceNumber>57</ReferenceNumber>
    <SourceName>SpectraBase</SourceName>
    <SourceID>2lFSfwK1NW1</SourceID>
    <Name></Name>
    <URL>https://spectrabase.com/spectrum/2lFSfwK1NW1</URL>
    <ANID>4975085</ANID>
  </Reference>
  <Reference>
    <ReferenceNumber>68</ReferenceNumber>
    <SourceName>SpectraBase</SourceName>
    <SourceID>Fmfuqd2wBn7</SourceID>
    <Name></Name>
    <URL>https://spectrabase.com/spectrum/Fmfuqd2wBn7</URL>
    <ANID>4975096</ANID>
  </Reference>
  <Reference>
    <ReferenceNumber>69</ReferenceNumber>
    <SourceName>SpectraBase</SourceName>
    <SourceID>KtJDzp9xTk2</SourceID>
    <Name></Name>
    <URL>https://spectrabase.com/spectrum/KtJDzp9xTk2</URL>
    <ANID>4975097</ANID>
  </Reference>
  <Reference>
    <ReferenceNumber>70</ReferenceNumber>
    <SourceName>SpectraBase</SourceName>
    <SourceID>AX2TKE0S8e2</SourceID>
    <Name></Name>
    <URL>https://spectrabase.com/spectrum/AX2TKE0S8e2</URL>
    <ANID>4975098</ANID>
  </Reference>
  <Reference>
    <ReferenceNumber>48</ReferenceNumber>
    <SourceName>NIST</SourceName>
    <SourceID>MS-MS #1 for PVNIIMVLHYAWGP-UHFFFAOYSA-N</SourceID>
    <Name>Nicotinic acid</Name>
    <URL>http://www.nist.gov/srd/nist1a.cfm</URL>
    <ANID>287055</ANID>
  </Reference>
  <Reference>
    <ReferenceNumber>43</ReferenceNumber>
    <SourceName>NIST</SourceName>
    <SourceID>GC-MS #1 for PVNIIMVLHYAWGP-UHFFFAOYSA-N</SourceID>
    <Name>Niacin</Name>
    <URL>http://www.nist.gov/srd/nist1a.cfm</URL>
    <ANID>112097</ANID>
  </Reference>
  <Reference>
    <ReferenceNumber>44</ReferenceNumber>
    <SourceName>NIST</SourceName>
    <SourceID>GC-MS #2 for PVNIIMVLHYAWGP-UHFFFAOYSA-N</SourceID>
    <Name>Niacin</Name>
    <URL>http://www.nist.gov/srd/nist1a.cfm</URL>
    <ANID>267348</ANID>
  </Reference>
  <Reference>
    <ReferenceNumber>45</ReferenceNumber>
    <SourceName>NIST</SourceName>
    <SourceID>GC-MS #3 for PVNIIMVLHYAWGP-UHFFFAOYSA-N</SourceID>
    <Name>Niacin</Name>
    <URL>http://www.nist.gov/srd/nist1a.cfm</URL>
    <ANID>267427</ANID>
  </Reference>
  <Reference>
    <ReferenceNumber>46</ReferenceNumber>
    <SourceName>NIST</SourceName>
    <SourceID>GC-MS #4 for PVNIIMVLHYAWGP-UHFFFAOYSA-N</SourceID>
    <Name>Niacin</Name>
    <URL>http://www.nist.gov/srd/nist1a.cfm</URL>
    <ANID>267428</ANID>
  </Reference>
  <Reference>
    <ReferenceNumber>47</ReferenceNumber>
    <SourceName>NIST</SourceName>
    <SourceID>GC-MS #5 for PVNIIMVLHYAWGP-UHFFFAOYSA-N</SourceID>
    <Name>Niacin</Name>
    <URL>http://www.nist.gov/srd/nist1a.cfm</URL>
    <ANID>267429</ANID>
  </Reference>
  <Reference>
    <ReferenceNumber>75</ReferenceNumber>
    <SourceName>Wikipedia</SourceName>
    <SourceID>wlNiacin</SourceID>
    <Name>niacin</Name>
    <Description>Chemical information link to Wikipedia.</Description>
    <URL>https://en.wikipedia.org/wiki/Niacin</URL>
    <ANID>2288410</ANID>
  </Reference>
  <Reference>
    <ReferenceNumber>42</ReferenceNumber>
    <SourceName>NIPH Clinical Trials Search of Japan</SourceName>
    <SourceID>cid938</SourceID>
    <URL>https://rctportal.niph.go.jp/en/</URL>
    <ANID>6486609</ANID>
  </Reference>
  <Reference>
    <ReferenceNumber>49</ReferenceNumber>
    <SourceName>NIST</SourceName>
    <SourceID>RI for PVNIIMVLHYAWGP-UHFFFAOYSA-N</SourceID>
    <Name>Niacin</Name>
    <URL>http://www.nist.gov/srd/nist1a.cfm</URL>
    <ANID>304150</ANID>
  </Reference>
  <Reference>
    <ReferenceNumber>51</ReferenceNumber>
    <SourceName>PDB</SourceName>
    <SourceID>NIO</SourceID>
    <URL>http://www.rcsb.org/ligand/NIO</URL>
    <ANID>637231</ANID>
  </Reference>
  <Reference>
    <ReferenceNumber>54</ReferenceNumber>
    <SourceName>SpectraBase</SourceName>
    <SourceID>BkKtRe7AAEX</SourceID>
    <Name></Name>
    <URL>https://spectrabase.com/spectrum/BkKtRe7AAEX</URL>
    <ANID>4975082</ANID>
  </Reference>
  <Reference>
    <ReferenceNumber>58</ReferenceNumber>
    <SourceName>SpectraBase</SourceName>
    <SourceID>5YFtP9lfmIT</SourceID>
    <Name></Name>
    <URL>https://spectrabase.com/spectrum/5YFtP9lfmIT</URL>
    <ANID>4975086</ANID>
  </Reference>
  <Reference>
    <ReferenceNumber>59</ReferenceNumber>
    <SourceName>SpectraBase</SourceName>
    <SourceID>FH3fYG9Mp3R</SourceID>
    <Name></Name>
    <URL>https://spectrabase.com/spectrum/FH3fYG9Mp3R</URL>
    <ANID>4975087</ANID>
  </Reference>
  <Reference>
    <ReferenceNumber>60</ReferenceNumber>
    <SourceName>SpectraBase</SourceName>
    <SourceID>CZoaeS2tVAc</SourceID>
    <Name></Name>
    <URL>https://spectrabase.com/spectrum/CZoaeS2tVAc</URL>
    <ANID>4975088</ANID>
  </Reference>
  <Reference>
    <ReferenceNumber>61</ReferenceNumber>
    <SourceName>SpectraBase</SourceName>
    <SourceID>D9KI1cPezdt</SourceID>
    <Name></Name>
    <URL>https://spectrabase.com/spectrum/D9KI1cPezdt</URL>
    <ANID>4975089</ANID>
  </Reference>
  <Reference>
    <ReferenceNumber>62</ReferenceNumber>
    <SourceName>SpectraBase</SourceName>
    <SourceID>GHMJC1lPBOh</SourceID>
    <Name></Name>
    <URL>https://spectrabase.com/spectrum/GHMJC1lPBOh</URL>
    <ANID>4975090</ANID>
  </Reference>
  <Reference>
    <ReferenceNumber>63</ReferenceNumber>
    <SourceName>SpectraBase</SourceName>
    <SourceID>2mpWyETltKW</SourceID>
    <Name></Name>
    <URL>https://spectrabase.com/spectrum/2mpWyETltKW</URL>
    <ANID>4975091</ANID>
  </Reference>
  <Reference>
    <ReferenceNumber>64</ReferenceNumber>
    <SourceName>SpectraBase</SourceName>
    <SourceID>F5JN1HlmoE3</SourceID>
    <Name></Name>
    <URL>https://spectrabase.com/spectrum/F5JN1HlmoE3</URL>
    <ANID>4975092</ANID>
  </Reference>
  <Reference>
    <ReferenceNumber>65</ReferenceNumber>
    <SourceName>SpectraBase</SourceName>
    <SourceID>L92EDJNff43</SourceID>
    <Name></Name>
    <URL>https://spectrabase.com/spectrum/L92EDJNff43</URL>
    <ANID>4975093</ANID>
  </Reference>
  <Reference>
    <ReferenceNumber>66</ReferenceNumber>
    <SourceName>SpectraBase</SourceName>
    <SourceID>CrzRcEWgKJG</SourceID>
    <Name></Name>
    <URL>https://spectrabase.com/spectrum/CrzRcEWgKJG</URL>
    <ANID>4975094</ANID>
  </Reference>
  <Reference>
    <ReferenceNumber>67</ReferenceNumber>
    <SourceName>SpectraBase</SourceName>
    <SourceID>2fOTglO1ij3</SourceID>
    <Name></Name>
    <URL>https://spectrabase.com/spectrum/2fOTglO1ij3</URL>
    <ANID>4975095</ANID>
  </Reference>
  <Reference>
    <ReferenceNumber>71</ReferenceNumber>
    <SourceName>Springer Nature</SourceName>
    <SourceID>9042359-137517366</SourceID>
    <Description>Literature references related to scientific contents from Springer Nature journals and books. Read more: https://link.springer.com/</Description>
    <ANID>3846428</ANID>
  </Reference>
  <Reference>
    <ReferenceNumber>73</ReferenceNumber>
    <SourceName>Thieme Chemistry</SourceName>
    <SourceID>9042359-137517366</SourceID>
    <Description>Literature references related to scientific contents from Thieme journals and books. Read more: http://www.thieme-chemistry.com</Description>
    <ANID>3843632</ANID>
  </Reference>
  <Reference>
    <ReferenceNumber>74</ReferenceNumber>
    <SourceName>WHO ATC</SourceName>
    <SourceID>4188</SourceID>
    <URL>https://www.whocc.no/atc/</URL>
    <ANID>7681714</ANID>
  </Reference>
  <Reference>
    <ReferenceNumber>76</ReferenceNumber>
    <SourceName>MeSH</SourceName>
    <SourceID>68009525</SourceID>
    <Name>Niacin</Name>
    <URL>https://www.ncbi.nlm.nih.gov/mesh/68009525</URL>
  </Reference>
  <Reference>
    <ReferenceNumber>77</ReferenceNumber>
    <SourceName>PubChem</SourceName>
    <SourceID>PubChem</SourceID>
    <Description>Data deposited in or computed by PubChem</Description>
    <URL>https://pubchem.ncbi.nlm.nih.gov</URL>
  </Reference>
  <Reference>
    <ReferenceNumber>78</ReferenceNumber>
    <SourceName>MeSH</SourceName>
    <SourceID>DescTree</SourceID>
    <Name>MeSH Tree</Name>
    <Description>MeSH (Medical Subject Headings) is the NLM controlled vocabulary thesaurus used for indexing articles for PubMed.</Description>
    <URL>http://www.nlm.nih.gov/mesh/meshhome.html</URL>
  </Reference>
  <Reference>
    <ReferenceNumber>79</ReferenceNumber>
    <SourceName>ChEBI</SourceName>
    <SourceID>OBO</SourceID>
    <Name>ChEBI Ontology</Name>
    <Description>The ChEBI Ontology is a structured classification of the entities contained within ChEBI.</Description>
    <URL>http://www.ebi.ac.uk/chebi/userManualForward.do#ChEBI%20Ontology</URL>
  </Reference>
  <Reference>
    <ReferenceNumber>80</ReferenceNumber>
    <SourceName>KEGG</SourceName>
    <SourceID>br08001</SourceID>
    <Name>Compounds with biological roles</Name>
    <URL>http://www.genome.jp/kegg-bin/get_htext?br08001.keg</URL>
  </Reference>
  <Reference>
    <ReferenceNumber>81</ReferenceNumber>
    <SourceName>KEGG</SourceName>
    <SourceID>br08003</SourceID>
    <Name>Phytochemical compounds</Name>
    <URL>http://www.genome.jp/kegg-bin/get_htext?br08003.keg</URL>
  </Reference>
  <Reference>
    <ReferenceNumber>82</ReferenceNumber>
    <SourceName>KEGG</SourceName>
    <SourceID>br08301</SourceID>
    <Name>Therapeutic category of drugs in Japan</Name>
    <URL>http://www.genome.jp/kegg-bin/get_htext?br08301.keg</URL>
  </Reference>
  <Reference>
    <ReferenceNumber>83</ReferenceNumber>
    <SourceName>KEGG</SourceName>
    <SourceID>br08302</SourceID>
    <Name>USP drug classification</Name>
    <URL>http://www.genome.jp/kegg-bin/get_htext?br08302.keg</URL>
  </Reference>
  <Reference>
    <ReferenceNumber>84</ReferenceNumber>
    <SourceName>KEGG</SourceName>
    <SourceID>br08303</SourceID>
    <Name>Anatomical Therapeutic Chemical (ATC) classification</Name>
    <URL>http://www.genome.jp/kegg-bin/get_htext?br08303.keg</URL>
  </Reference>
  <Reference>
    <ReferenceNumber>85</ReferenceNumber>
    <SourceName>KEGG</SourceName>
    <SourceID>br08311</SourceID>
    <Name>Drugs listed in the Japanese Pharmacopoeia</Name>
    <URL>http://www.genome.jp/kegg-bin/get_htext?br08311.keg</URL>
  </Reference>
  <Reference>
    <ReferenceNumber>86</ReferenceNumber>
    <SourceName>KEGG</SourceName>
    <SourceID>br08312</SourceID>
    <Name>Risk category of Japanese OTC drugs</Name>
    <URL>http://www.genome.jp/kegg-bin/get_htext?br08312.keg</URL>
  </Reference>
  <Reference>
    <ReferenceNumber>87</ReferenceNumber>
    <SourceName>KEGG</SourceName>
    <SourceID>br08331</SourceID>
    <Name>Animal drugs in Japan</Name>
    <URL>http://www.genome.jp/kegg-bin/get_htext?br08331.keg</URL>
  </Reference>
  <Reference>
    <ReferenceNumber>88</ReferenceNumber>
    <SourceName>WIPO</SourceName>
    <SourceID>IPC</SourceID>
    <Name>International Patent Classification</Name>
    <Description>The World Intellectual Property Organization (WIPO) International Patent Classification (IPC), established by the Strasbourg Agreement 1971, provides for a hierarchical system of language independent symbols for the classification of patents and utility models according to the different areas of technology to which they pertain.</Description>
    <URL>http://www.wipo.int/classifications/ipc/</URL>
  </Reference>
  <Reference>
    <ReferenceNumber>89</ReferenceNumber>
    <SourceName>FDA Pharm Classes</SourceName>
    <SourceID>FDA_pharm_tree</SourceID>
    <Name>FDA Pharmacological Classification</Name>
    <Description>FDA published a final rule that amended the requirements for the content and format of approved labeling (prescribing information) for human prescription drug and biological products in January 2006.</Description>
    <URL>https://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/ucm162549.htm</URL>
  </Reference>
  <Reference>
    <ReferenceNumber>90</ReferenceNumber>
    <SourceName>WHO ATC</SourceName>
    <SourceID>ATCTree</SourceID>
    <Name>ATC Code</Name>
    <Description>In the World Health Organization (WHO) Anatomical Therapeutic Chemical (ATC) classification system, the active substances are divided into different groups according to the organ or system on which they act and their therapeutic, pharmacological and chemical properties.</Description>
    <URL>https://www.whocc.no/atc_ddd_index/</URL>
  </Reference>
  <Reference>
    <ReferenceNumber>91</ReferenceNumber>
    <SourceName>UN Globally Harmonized System of Classification and Labelling of Chemicals (GHS)</SourceName>
    <SourceID>UN_GHS_tree</SourceID>
    <Name>GHS Classification Tree</Name>
    <Description>The United Nations&apos; Globally Harmonised System of Classification and Labelling of Chemicals (GHS) provides a harmonised basis for globally uniform physical, environmental, and health and safety information on hazardous chemical substances and mixtures. It sets up criteria for the classification of chemicals for physical-chemical, health, and environmental hazards of chemical substances and mixtures and sets up standardised hazard information to facilitate global trade of chemicals.</Description>
    <URL>http://www.unece.org/trans/danger/publi/ghs/ghs_welcome_e.html</URL>
  </Reference>
  <Reference>
    <ReferenceNumber>92</ReferenceNumber>
    <SourceName>ChemIDplus</SourceName>
    <SourceID>ChemIDplus_tree</SourceID>
    <Name>ChemIDplus Chemical Information Classification</Name>
    <Description>ChemIDplus is a TOXNET (TOXicology Data NETwork) databases that contain chemicals and drugs related information. It is managed by the Toxicology and Environmental Health Information Program (TEHIP) in the Division of Specialized Information Services (SIS) of the National Library of Medicine (NLM).</Description>
    <URL>https://chem.sis.nlm.nih.gov/chemidplus/</URL>
    <IsToxnet>true</IsToxnet>
  </Reference>
  <Reference>
    <ReferenceNumber>93</ReferenceNumber>
    <SourceName>CAMEO Chemicals</SourceName>
    <SourceID>CameoReactivityTree</SourceID>
    <Name>CAMEO Chemical Reactivity Classification</Name>
    <Description>CAMEO Chemical Reactivity Classification was created based on the reactive groups.</Description>
    <URL>https://cameochemicals.noaa.gov/browse/react</URL>
  </Reference>
  <Reference>
    <ReferenceNumber>94</ReferenceNumber>
    <SourceName>ChEMBL</SourceName>
    <SourceID>Target Tree</SourceID>
    <Name>Target Tree</Name>
    <Description>The ChEMBL Protein Target Tree is a structured classification of the protein target entities contained with the ChEMBL resource.</Description>
    <URL>https://www.ebi.ac.uk/chembl/target/browser</URL>
  </Reference>
  <Reference>
    <ReferenceNumber>95</ReferenceNumber>
    <SourceName>IUPHAR/BPS Guide to PHARMACOLOGY</SourceName>
    <SourceID>Target Classification</SourceID>
    <Name>Target Classification</Name>
    <Description>An expert-driven guide to pharmacological targets and the substances that act on them</Description>
    <URL>http://www.guidetopharmacology.org/</URL>
  </Reference>
  <Reference>
    <ReferenceNumber>96</ReferenceNumber>
    <SourceName>KEGG</SourceName>
    <SourceID>br08330</SourceID>
    <Name>Drug Classes</Name>
    <URL>http://www.genome.jp/kegg-bin/get_htext?br08330.keg</URL>
  </Reference>
  <Reference>
    <ReferenceNumber>97</ReferenceNumber>
    <SourceName>MeSH</SourceName>
    <SourceID>68014665</SourceID>
    <Name>Vasodilator Agents</Name>
    <URL>https://www.ncbi.nlm.nih.gov/mesh/68014665</URL>
  </Reference>
  <Reference>
    <ReferenceNumber>98</ReferenceNumber>
    <SourceName>MeSH</SourceName>
    <SourceID>68000960</SourceID>
    <Name>Hypolipidemic Agents</Name>
    <URL>https://www.ncbi.nlm.nih.gov/mesh/68000960</URL>
  </Reference>
  <Reference>
    <ReferenceNumber>99</ReferenceNumber>
    <SourceName>MeSH</SourceName>
    <SourceID>68014803</SourceID>
    <Name>Vitamin B Complex</Name>
    <URL>https://www.ncbi.nlm.nih.gov/mesh/68014803</URL>
  </Reference>
  <Reference>
    <ReferenceNumber>100</ReferenceNumber>
    <SourceName>NCBI</SourceName>
    <SourceID>LinkOut</SourceID>
    <Description>LinkOut is a service that allows one to link directly from NCBI databases to a wide range of information and services beyond NCBI systems.</Description>
    <URL>https://www.ncbi.nlm.nih.gov/projects/linkout</URL>
  </Reference>
</Record>
